<SEC-DOCUMENT>0001493152-24-010822.txt : 20240321
<SEC-HEADER>0001493152-24-010822.hdr.sgml : 20240321
<ACCEPTANCE-DATETIME>20240321172848
ACCESSION NUMBER:		0001493152-24-010822
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240321
DATE AS OF CHANGE:		20240321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shuttle Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001757499
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41488
		FILM NUMBER:		24772458

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE
		STREET 2:		SUITE 260
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		(240) 403-4212

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE
		STREET 2:		SUITE 260
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:SHPH="http://shuttlepharma.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_SHPH_shuttlepharma.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001757499 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06E_TradingDays_0_utr%2D%2DD -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001757499</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0063" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0066" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0078" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl0100" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0102" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ConvertibleNotePayableCurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2022-12-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0121" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0132" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl0133" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:FinanceFee" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0222" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0366" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0377" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0429" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="xdx2ixbrl0440" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:AccruedInterestSettledWithCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DebtSecuritiesGainLoss" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfAccruedInterest" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:CommonStockIssuedForDividendPayable" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:InitialRecognitionOfRightOfUseAssetAndLiability" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0715" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="xdx2ixbrl0760" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl0768" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0975" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl0977" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_custom_AcceleratedFeatureMember" id="xdx2ixbrl1122" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_custom_AcceleratedFeatureMember" id="xdx2ixbrl1126" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1128" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1130" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1167" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:ShortfallOfStockCompensationExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1182" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1185" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1188" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="xdx2ixbrl1195" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeferredTaxAssetsbasedCompensation" contextRef="AsOf2022-12-31" id="xdx2ixbrl1205" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeferredTaxAssetsLeaseLiabilities" contextRef="AsOf2022-12-31" id="xdx2ixbrl1211" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFairMarketValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl1217" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2022-12-31" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFiniteLivedAssets" contextRef="AsOf2022-12-31" id="xdx2ixbrl1223" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2022-12-31" id="xdx2ixbrl1226" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1234" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1235" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1261" unitRef="Pure" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="shph-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CommonStockToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-122016-08-12_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-12</xbrli:startDate>
        <xbrli:endDate>2016-08-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16_custom_NewLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16_custom_NewLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-152023-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-15</xbrli:startDate>
        <xbrli:endDate>2023-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-01_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-212021-06-21_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-21</xbrli:startDate>
        <xbrli:endDate>2021-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-06-30_custom_OfficersSpouseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-092023-01-11_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-09</xbrli:startDate>
        <xbrli:endDate>2023-01-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31_custom_AltoConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_AyrtonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:AyrtonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember14624828">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:AyrtonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_WarrantMember14624859">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember14624875">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_NotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_NotesPayableRelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableRelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AcceleratedFeatureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AcceleratedFeatureMember14626328">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TCGGreenChemIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TCGGreenChemIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_FederalTaxableIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:FederalTaxableIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_StateTaxableIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:StateTaxableIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TaxYear2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TaxYear2017Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-312023-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-31</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-07</xbrli:startDate>
        <xbrli:endDate>2024-02-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001757499</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-08</xbrli:startDate>
        <xbrli:endDate>2024-03-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="TradingDays">
      <xbrli:measure>utr:D</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000979" toRefs="Footnote001012"/>
  <ix:relationship fromRefs="Fact000981" toRefs="Footnote001012"/>
  <ix:relationship fromRefs="Fact000983" toRefs="Footnote001012"/>
  <ix:relationship fromRefs="Fact000985" toRefs="Footnote001021"/>
  <ix:relationship fromRefs="Fact000987" toRefs="Footnote001021"/>
  <ix:relationship fromRefs="Fact001092" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001093" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001094" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001095" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001096" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001097" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001098" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001099" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001100" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001102" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001104" toRefs="Footnote001105 Footnote001116"/>
  <ix:relationship fromRefs="Fact001106" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001107" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001108" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001109" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001110" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001111" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001113" toRefs="Footnote001116"/>
  <ix:relationship fromRefs="Fact001115" toRefs="Footnote001116"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90D_edei--DocumentType_c20230101__20231231_zzCCzQ7iYvV2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span id="xdx_909_edei--DocumentAnnualReport_c20230101__20231231_zxSjA4MJFCxb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20230101__20231231_zrdllOz63XR2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_90D_edei--CurrentFiscalYearEndDate_c20230101__20231231_z1LMzjBmQCTd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90C_edei--DocumentFiscalYearFocus_c20230101__20231231_zz07oZUSFZE2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><span id="xdx_906_edei--DocumentTransitionReport_c20230101__20231231_zF7ukWkH9Lyj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from ______________ to ______________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <span id="xdx_90F_edei--EntityFileNumber_c20230101__20231231_zLd0ZjfEANK2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000018" name="dei:EntityFileNumber">001-41488</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityRegistrantName_c20230101__20231231_zG04gWwr1Vn2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000019" name="dei:EntityRegistrantName">Shuttle
Pharmaceuticals Holdings, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20230101__20231231_zZOaTsH76Tnd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20230101__20231231_zl3bajXC6n8a"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">82-5089826</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation
    or organization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230101__20231231_zVVyPG7PPl93"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">401
Professional Drive</ix:nonNumeric></span>,&#160;<span id="xdx_90A_edei--EntityAddressAddressLine2_c20230101__20231231_zy2FULQQQ0Fi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 260</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20230101__20231231_zfQf5CBT2x38"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Gaithersburg</ix:nonNumeric></span>,&#160;<span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230101__20231231_znsDUVkqQBCc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000025" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric></span>&#160;<span id="xdx_90C_edei--EntityAddressPostalZipCode_c20230101__20231231_zJlaM3l0Psha"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">20879</ix:nonNumeric></span>
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--CityAreaCode_c20230101__20231231_z7lkQmFnssn2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000027" name="dei:CityAreaCode">(240)</ix:nonNumeric></span>
<span id="xdx_90F_edei--LocalPhoneNumber_c20230101__20231231_zNoPAehqrLc1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000028" name="dei:LocalPhoneNumber">403-4212</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--Security12bTitle_c20230101__20231231_zyi5yqxLCh81"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000029" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--TradingSymbol_c20230101__20231231_zgkO1lsIs09g"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000030" name="dei:TradingSymbol">SHPH</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
    <span id="xdx_90E_edei--SecurityExchangeName_c20230101__20231231_zAvfCmVSt726"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to section 12(g) of the Act: NONE</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_901_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zhdcZ53ayhud"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_90D_edei--EntityVoluntaryFilers_c20230101__20231231_zfumFCVXTAw1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_907_edei--EntityCurrentReportingStatus_c20230101__20231231_zoTUGvA5Wqd4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20230101__20231231_zo2c8daiR9Q2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20230101__20231231_zMwN3qF3Npnj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntitySmallBusiness_c20230101__20231231_zm64WjTUlq7j"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20230101__20231231_zxcqIF9AAtsk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_90A_edei--EntityExTransitionPeriod_c20230101__20231231_zPDUUsJgajqb"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_90C_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zSDtudlrSXIc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_903_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_zLqU2aaGRoak"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000041" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span id="xdx_903_edei--DocumentFinStmtRestatementRecoveryAnalysisFlag_c20230101__20231231_zTvKrqYkiung"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:DocumentFinStmtRestatementRecoveryAnalysisFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <span id="xdx_907_edei--EntityShellCompany_dbF_c20230101__20231231_zDY6QFQrGiR7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
aggregate market value of the registrant&#8217;s common stock, par value $0.00001 per share, held by non-affiliates of the registrant,
as computed by reference to the June 30, 2023 closing price reported by Nasdaq, was approximately $<span id="xdx_90B_edei--EntityPublicFloat_iI_pid_c20230630_zaRtAfFnMr61"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">11,712,797</ix:nonFraction><span style="background-color: white"></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares outstanding of the registrant&#8217;s common stock on March 20, 2024, was <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_pid_c20240320_zYyhk3Fjuclh"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-03-20" id="Fact000045" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,794,893</ix:nonFraction></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    No.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ds_001">PART I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_003">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1C. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_006">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ds_009">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_011">[Reserved]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_014">Financial Statements and Supplementary Data</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_015">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_016">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_017">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_018">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ds_019">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_020">Directors, Executive Officers and Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_021">Executive Compensation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_023">Certain Relationships and Related Transactions, and Director Independence</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_024">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ds_025">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_026">Exhibit and Financial Statement Schedules</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ds_027">Form 10&#8211;K Summary</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#ds_028">SIGNATURES</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD
LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (including the section regarding Management&#8217;s Discussion and Analysis and Results of Operations, the
&#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements
are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Although we believe
that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future
financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels
of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. All statements other than statements of historical facts contained in this
Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221;
&#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221;
&#8220;project,&#8221; &#8220;continue,&#8221; &#8220;potential,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other
comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and INDs,
    NDAs other regulatory submissions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expected dependence on third party collaborators for developing, obtaining regulatory approval for and commercializing product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    receipt and timing of any milestone payments or royalties under any research collaboration and license agreement we enter into;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to identify and develop product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    or a collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    rate and degree of market acceptance of any approved products candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commercialization of any approved product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain additional collaborations and retain commercial rights for our product candidates subject to collaborations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    implementation of our business model and strategic plans for our business, technologies and product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates of our expenses, ongoing losses, future revenue and capital requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funds for our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain intellectual property protection for our technologies and product candidates and our ability to operate
    our business without infringing the intellectual property rights of others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third parties to conduct our preclinical studies or any future clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reliance on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research
    and development, preclinical and clinical trial drug supplies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified key management and technical personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    use of net proceeds received by us from our initial public offering, or IPO, or any subsequent private placement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding the time during which we will be an emerging growth company under the JOBS Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    financial performance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    relating to our competitors or our industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not place undue reliance on forward-looking statements, because they involve known and unknown risks, uncertainties, and other
factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results
to differ materially from current expectations include, among other things, those listed in the reports we filed with the Securities
and Exchange Commission (the &#8220;SEC&#8221;). Actual events or results may vary significantly from those implied or projected by the
forward-looking statements due to these risk factors. No forward-looking statement is a guarantee of future performance. You should read
this Annual Report, the documents that we reference in this Annual Report and the documentation we have filed as exhibits thereto with
the SEC, with the understanding that our actual future results and circumstances may be materially different from what we expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, the terms &#8220;the Company,&#8221; &#8220;Shuttle Pharma,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
and &#8220;our&#8221; in this Annual Report refer to Shuttle Pharmaceuticals Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_002"></span>Item
1. Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers.
Our goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy
(&#8220;RT&#8221;) is one of the most effective modalities for treating cancers. We are developing a pipeline of products designed to
address the limitations of the current cancer therapies as well as to extend to the new applications of RT. We believe that our product
candidates will enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current
standard of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates include Ropidoxuridine, Extended Bio-availability Ropidoxuridine (IPdR/TPI), and a platform of HDAC inhibitors (SP-1-161,
SP-2-225 and SP-1-303). In December 2023, we submitted an Investigational New Drug (&#8220;IND&#8221;) application with the U.S. Food
and Drug Administration (&#8220;FDA&#8221;) to support the next phase of development of Ropidoxuridine. In January 2024, we received
the &#8216;Safe to Proceed&#8217; letter from the FDA for our IND application for the Phase II study of Ropidoxuridine (IPdR) as a radiation
sensitizing agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt
of the letter allows us to commence the Phase II study of Ropidoxuridine (IPdR). We have applied for and received FDA approval of Orphan
designation for Ropidoxuridine and RT for treating brain cancer (glioblastoma). We believe our management team&#8217;s expertise in radiation
therapy, combined modality cancer treatment and immuno-oncology will help drive the development and, if approved, the commercialization
of these potentially curative therapies for patients with aggressive cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncology has gone through transformative technological innovation over the last several years to better define tumors, allow improved
shaping of radiation delivery and support dose escalation with shorter courses of treatment. Furthermore, achieving higher dose distributions
within tumor volumes has reached a practical plateau, since cancers are frequently integrated with or surrounded by more sensitive normal
tissues and further dose escalation increases risks of tissue necrosis. To increase cancer cures at maximally tolerated radiation doses,
pharmacological and biological modifications of cells are needed to sensitize cancers, protect normal tissues, and stimulate the immune
system to react against antigens produced by irradiated, damaged cancer cells. Drugs that show sensitizing properties, or the ability
to make cancer cells more sensitive to radiation, offer a solution to this problem. Currently, such drugs are chemotherapy agents used
off-label, and many have inherent toxicities since they were designed for direct cancer treatments and not for sensitization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our products with the goal of addressing the unmet need in cancer treatment for a commercially marketable radiation response
modifier solution that leads to greater sensitivity of cancer cells to ionizing radiation therapy. The goal of our products is to increase
the therapeutic index for patients receiving radiation and to decrease radiation-related toxicities in patients with solid tumors. Our
products operate across three areas related to the treatment of cancer with RT:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sensitization
    of growing cancer cells, rendering them more susceptible to the effects of radiation therapy.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the DNA damage response pathway to kill cancer cells and protect adjacent normal cells.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Activation
    of the immune system to kill any remaining cells after RT.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology allows for the creation of an inventory of products for radiation sensitizing, immune modulation, and protection
of healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing a pipeline of small molecule radiation sensitizers and immune response regulating drugs. Our most advanced product
candidate is Ropidoxuridine, an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties in preclinical
studies. In addition, we have a pipeline of complimentary product candidates that we are developing to address a host of solid tumor
cancer indications. Our pipeline is represented in the diagram below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_001.jpg" alt="A diagram of a medical procedure&#10;&#10;Description automatically generated with medium confidence" style="height: 295px; width: 624px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timeline
for clinical phase (Ropidoxuridine) and pre-clinical phase (HDAC inhibitors) pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lead product candidates include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    (IPdR)</span></b> is our lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and
    sarcomas. Phase I clinical trial results supported by Shuttle Pharma and the NCI (CTEP) were reported in the medical journal, Clinical
    Cancer Research, in July 2019, by our SBIR subcontractor. Eighteen patients completed dose escalations to 1,800 mg/day for 30 days,
    establishing the maximum tolerated dose (MTD) of 1,200 mg/day in combination with RT. Four partial responses, nine stable disease
    and one progressive disease in target lesions were reported. Four patients did not have measurable disease and, as a result, were
    not evaluable. These Phase I trial results demonstrate oral bioavailability and an MTD of 1,200 mg per day for 28 days for use in
    combination with radiation for Phase II clinical trials that we propose to perform in brain tumors and in sarcomas. The brain tumor,
    glioblastoma multiforme (GB) is eligible for orphan disease designations. Shuttle Pharma has advanced drug manufacture and formulation
    and prepared a clinical protocol of a &#8220;Phase 2 Single-Arm Study of IPdR as a Radiation Sensitizing Agent During Radiotherapy
    in Patients with Newly Diagnosed IDH-Wildtype MGMT Unmethylated Glioblastoma Multiforme.&#8221; In December 2023, we submitted an
    IND application with the FDA to support the next phase of development of Ropidoxuridine. In January 2024, we received the &#8216;Safe
    to Proceed&#8217; letter from the FDA for our IND application for the Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing
    agent during radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of
    the letter allows us to commence the Phase II study of Ropidoxuridine (IPdR).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Ropidoxuridine
    and Tipiracil (IPdR/TPI)</span></b> is a new combination formulation demonstrating extended bioavailability after oral administration
    in an animal model system. The IPdR/TPI formulation will undergo preclinical development for use as a radiation sensitizer of rectal
    cancers after the Phase II brain tumor clinical trial has been initiated.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-161
    </span></b>is Shuttle Pharma&#8217;s pre-clinical candidate lead HDAC inhibitor, radiation sensitizing candidate product. This pan HDAC
    inhibitor initiates the mutated in ataxia-telangiectasia (ATM) response pathway. Using rational drug design, we discovered dual function
    molecules, HDAC inhibitors and ATM activators capable of sensitizing cancer cells to radiation and protecting normal cells. The drug
    candidate may serve as a direct chemotherapeutic agent or as radiation sensitizers for treating cancers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225
    </span></b>is Shuttle Pharma&#8217;s pre-clinical class IIb selective HDAC inhibitor that selectively affects histone deacetylase HDAC6.
    SP-2-225 has effects on the regulation of the immune system. The interactions of RT with the immune response for cancer treatment
    are of great current interest, offering insight into potential mechanisms for primary site and metastatic cancer treatment. For this
    reason, Shuttle Pharma has selected SP-2-225 as the candidate lead HDAC inhibitor for preclinical development. We have contracted
    with investigators at Georgetown University to perform preclinical studies of immune activation after radiation therapy in an animal
    tumor model. Requests for proposals for advancing drug manufacture and IND-enabling studies have been submitted and are under review
    to enable drug development to a Phase I clinical trial in 2024. With the introduction of check-point inhibitors, CAR-T therapies
    and personalized medicine in cancer, regulation of the immune response following RT is of significant clinical and commercial interest.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
    </span></b>is Shuttle Pharma&#8217;s pre-clinical selective Class I HDAC inhibitor that preferentially affects histone deacetylases
    HDAC1 and HDAC3 members of the class I HDAC family of enzymes. SP-1-303 data show direct cellular toxicity in ER positive breast
    cancer cells. Furthermore, SP-1-303 increases PD-L1 expression. A manuscript reporting completed preclinical in vitro studies is
    in preparation. We plan to seek collaborations to complete SP-1-303 pre-clinical development in 2024.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Approach</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have established a leadership position in radiation sensitizer discovery and development. Over approximately seven years
of research, we have identified two clinical phase product candidates and discovered new pre-clinical molecules using our proprietary
platform technologies to increase the therapeutic index for patients receiving radiation for treatment of solid tumors. Our development
strategy has four key pillars: (1) to improve the efficacy of RT by demonstrating improved disease-free survival rates in patients who
undergo radiation therapy, (2) reduce the amount of radiation needed for a favorable tumor response, thereby limiting the potential for
radiation related toxicities to healthy cells, (3) decrease the extent of surgery needed to remove cancers and improve quality of life,
and (4) leverage our next generation technologies to create drugs that regulate the immune response assisting immune checkpoint and CAR-T
therapies and other personalized medicines targeting cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
propose to perform Phase I and Phase II clinical trials to advance our clinical product candidates. In addition, candidate HDAC inhibitor
molecules will be tested in animal models, and IND-enabling studies will be performed to prepare for Phase I clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have been awarded three SBIR contracts from the NIH to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    IPdR as a radiation sensitizer for the treatment of gastro-intestinal cancers, in combination with radiation therapy. This funding
    provided partial support for the Phase I clinical trial of Ropidoxuridine and RT.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    prostate cancer cell cultures from African-American men, with donor matched normal prostate cells, establishing 50 pairs for accelerating
    research to reduce prostate cancer health disparities in African-American men. This project was funded under &#8220;Moonshot&#8221;
    designation and Shuttle Pharma is eligible to submit an application for additional SBIR (Phase IIb) funding to establish the infrastructure
    required to expand and distribute cells for research purposes. Cells from African-American patients are distributed to investigators
    who are conducting health disparities research.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Develop
    predictive biomarkers for determining outcomes for prostate cancer patients following treatment with SBRT. This SBIR-funded project
    was completed on March 15, 2022 and Shuttle Pharma is eligible to apply for additional funding through the SBIR (Phase IIb) mechanism
    The Phase IIb SBIR grant mechanism is designed to de-risk clinical validation to develop the predictive biomarkers to commercialization.
    Shuttle Pharma has licensed the intellectual property for the prostate cancer predictive biomarker test from Georgetown University
    and will seek additional investment from the public market to advance clinical development through its Shuttle Diagnostics entity.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
three SBIR funded projects have been completed. The Company is eligible to apply for SBIR Phase IIb funding to &#8220;bridge&#8221; the
funding gap should Shuttle Pharma elect to advance the &#8220;Moonshot&#8221; health disparities or the predictive biomarker project.
The NIH SBIR program is designed to encourage small businesses to engage in Federal Research/Research and Development (&#8220;R/R&amp;D&#8221;)
that has the potential for commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to maintain and build upon our leadership position in radiation sensitization. We plan to develop Ropidoxuridine and the HDAC6
inhibitor (SP-2-225) and, if approved by the FDA, commercialize our product candidates for the treatment of cancers. While this process
may require years to complete, we believe achieving this goal could result in new radiation sensitizer and immunotherapy products. Key
elements of our strategy include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalize
    on Ropidoxuridine as an orally available, small molecule radiation sensitizer. </b>To date, there is one drug (Cetuximab, a monoclonal
    antibody) approved by the FDA specifically as a radiation sensitizer. If we are successful in developing Ropidoxuridine and obtaining
    FDA approval, a small molecule sensitizer would then be enabled for clinical applications for radiation sensitization indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expand
    our leadership position within radiation sensitizers</b>. In addition to our traditional radiation sensitizers, we plan to advance
    our near-term pipeline to include radiation sensitizers for proton therapy. Proton Therapy is growing worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates</b>. We have built our current product
    pipeline through in-house discovery, development, partnerships with leading academic institutions and through in-licensing. We will
    continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other biotechnology
    companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability of clinical
    success, including programs beyond our target franchise areas and current technology footprint.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Invest
    in our HDAC platform technology and maximize its utility across cancer therapies</b>. We are initially applying the platform to develop
    drugs for cancer radiation sensitization, normal tissue radiation protection and post radiation immune stimulation. Based on the
    data we have obtained thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform
    technology, as well.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enter
    into collaborations to realize the full potential of our platform</b>. The breadth of our HDAC technology platform enables other
    therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our
    platform to maximize applications for cancer treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Radiation
Therapy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radiation
Oncologists use Radiation Therapy (RT) to treat cancers that cannot be completely removed by surgery but have not yet spread to distant
sites within the body. RT has been a mainstay for the treatment of cancer malignancies for more than half a century. The combination
treatment of radiation therapy and chemotherapy has involved the use of cytotoxic drugs, targeted biologic agents and targeted external
beam radiation to increase the destruction of tumor cells and cure or delay cancer progression. The low number of drugs and biologic
agents under investigation as radiation sensitizing agents highlights an unmet need for new approaches and agents that provide greater
effectiveness, increased quality and better tolerability for patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
&#8220;chemo-radiation&#8221; treatments are established in cancers of the head and neck, esophagus, lung, stomach, breast, brain, pancreas,
rectum and uterine cervix. The ideal radiation sensitizer would reach the tumor in adequate concentrations and act selectively in the
tumor, as compared to surrounding normal tissues. It would have predictable pharmacokinetics for timing with radiation therapy and could
be administered with every radiation treatment approach. The ideal radiation sensitizer would have minimal toxicity or manageable enhancement
of radiation toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. market for radiation sensitizing agents is experiencing dynamic growth through development of new radiation technology, the introduction
of new agents, growth in the number of diagnosed patients in a variety of cancers and changes in treatment patterns. New agents have
been introduced, including bevacizumab (Avastin&#174;, Roche), panitumumab (Vectibix&#174;, Amgen), temozolomide (Temodar&#174;, Merck)
and cetuximab (Erbitux&#174;, Eli Lilly/Imclone), with potential as radiation sensitizing agents (though all but cetuximab are used off
label); and all are recommended by the NCCN&#174; (National Comprehensive Cancer Network) in clinical practice guidelines for use in combination
with established therapies such as FOLFOX (leucovorin, 5-FU, oxaliplatin), CapeOX (capecitabine, oxaliplatin) and FOLFIRI (leucovorin,
5-FU, irinotecan).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
growth in the number of patients with cancers is being driven by an aging population and improved diagnostic tools. According to the
National Cancer Institute (NCI), more than half (~50 - 60%) of all cancer patients undergo some type of radiotherapy during the course
of their treatment. Confirming the patient estimate from the NCI, the American Society for Therapeutic Radiology and Oncology (ASTRO)
factsheet states approximately 67% of approximately 1.25 million cancer patients are treated with radiation therapy annually, either
one or more times. In addition, in a study published by the Journal of Clinical Oncology in 2016, it is estimated that the number of
cancer patients needing radiation therapy will increase by 22% in the next 10 years. (<i>See &#8220;The Future of Radiation Oncology
in the United States From 2010 to 2020: Will Supply Keep Pace With Demand?&#8221; Benjamin D. Smith, Bruce G. Haffty, Lynn D. Wilson,
Grace L. Smith, Akshar N. Patel, and Thomas A. Buchholz Journal of Clinical Oncology 2010 28:35, 5160-5165).</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
American Society of Clinical Oncology (ASCO) estimates more than 80% of cancers in the U.S. occur in people in the age group of 50 and
above with over 60% of cancers occurring in those 65 and over. (<i>See</i>, 2018 Clinical Cancer Advances Report, American College of
Clinical Oncology, 2018). For example, according to the American Cancer Society (ACS), more than 90% of colorectal cancer patients are
individuals aged 50 years and older, with approximately 40% of all cases occurring in patients aged 75 years and over. The Colon Cancer
Alliance estimates that 90% of new cases and 95% of deaths from colorectal cancers occur in people aged 50 or older. Also, the U.S. Census
estimates that the age group of 65-84 will grow by 23% within the next five years, indicating a likely increase in the overall number
of cancer patients in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below details the number of cancers estimated in the United States in 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated
New Cancer Cases in the U.S.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="9" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Male</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="9" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Female</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">299,010</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;310,720</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lung
    &amp; bronchus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,310</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lung
    &amp; bronchus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,270</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colon
    &amp; rectum</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81,540</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colon
    &amp; rectum</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71,270</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Urinary
    bladder</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,330</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Uterine
    corpus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,880</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melanoma
    of the skin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59,170</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melanoma
    of the skin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,470</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kidney
    &amp; renal pelvis</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,380</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thyroid</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,520</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Hodgkin
    lymphoma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44,590</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Hodgkin
    lymphoma</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,030</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral
    cavity &amp; pharynx</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,510</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kidney
    &amp; renal pelvis</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;29,230</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leukemia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,450</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreas</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,910</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreas</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,530</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leukemia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26,320</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    sites</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>983,160</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    sites</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>934,870</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACS
Facts &amp; Figures, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. estimated incidence, deaths and five-year survival rate of cancer patients responsive to radiation therapy is significant (ACS Facts
&amp; Figures, 2024). The top cancers responsive to radiation are shown, based on the number of newly diagnosed patients. The incidence
rates for some cancers are increasing by approximately 1-2% per year in the U.S. The number of newly diagnosed patients is significant
and growing due to the aging of the population and improved diagnostic techniques.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cancers listed above illustrate the opportunity presented for radiation sensitizers. Of note is the low five-year survival of pancreas,
brain, lung and esophagus cancers&#8212;all are candidates for Shuttle Pharma&#8217;s pipeline of radiation sensitizing compounds. Cancers
with low survival rates are of interest since they show a high unmet need for new therapeutics and an opportunity for Shuttle Pharma
to gain significant uptake of their pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
that present challenges and may restrict growth in the radiation sensitizer market include the safety and tolerability of many of the
newer agents with radiation sensitizing properties; a regulatory environment that engenders greater levels of scrutiny of clinical practice
issues; the high cost of newer agents; and the changing (and more restrictive) reimbursement environment in radiation oncology through
CMS (Center for Medicare and Medicaid Services) and private payors. These factors may negatively impact the potential for growth in the
U.S. market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the drugs used &#8220;off-label&#8221; as radiation sensitizers currently require close scrutiny of their potential for side effects
that can affect the safety and tolerability of their use with patients. All of the current agents carry significant potential for side
effects that can affect patients&#8217; therapies and quality of life. Radiation sensitizing agents can cause both acute and chronic
side effects in patients. Side effects can vary from person to person depending on age, sex, type of cancer, dose given per day, total
dose given, and the patient&#8217;s general medical condition. Some common side effects of currently used radiation sensitizers include
leukopenia, skin damage, hair loss, fatigue, bladder problems, nausea, fibrosis, memory loss, infertility, and enhanced risk of developing
a second cancer, which may arise as a result of the patient&#8217;s weakened immune system due to cytotoxic drugs used in treatment or
when newer biologic agents cause the over-production of specific cytokines or proteins, which can lead to developing secondary cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past five years, the FDA has taken an increasingly conservative approach to the approval of new agents for oncology treatment. There
is greater scrutiny of results from clinical trials regarding progression free survival, overall survival, and safety and tolerability
of new agents. Restrictions such as black box warnings and REMS (Risk Evaluation and Migration Strategies) are being applied to more
new products over the past five years compared to the previous five years. These restrictions require physicians to be more careful in
evaluating the use of newer agents and newer diagnostic tools to select the most appropriate patients for newer approved agents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the new agents are molecularly targeted therapies that are biologic in their development and manufacturing. The cost of the newer
agents can be significant. For example, the cost for Avastin for one treatment course as a radiation sensitizer is estimated at $9,000-12,000
according to one Key Opinion Leader in the U.S. (Carl Schmidt, Consultant, Shuttle Pharmaceuticals Holdings, Inc., Business Plan 2018).
Recently, a CAR-T gene therapy from Novartis was launched with a yearly cost of $475,000. Further, as many private payors scrutinize
the cost and appropriate use of newer drugs, they require physicians to provide justification through prior authorization requests, use
of step therapy and guidelines that delay treatment, increase administrative costs and limit the therapeutic choices for physicians and
hospitals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
payors for radiation oncology therapies such as CMS have instituted reimbursement reductions that potentially affect the overall cost
of therapy and can limit the acceptance of newer agents. With CMS announced reductions in reimbursement for radiation oncology, there
is increased pressure to find a more potent radiation sensitizer agent with reduced side effects, and greater cost-effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Escalating
healthcare spending is adding pressure on government and commercial payors to contain drug costs. While the oncology space is arguably
not as tightly managed by payors as other therapeutic areas, utilization management of costly cancer therapeutics has become an increasing
priority for U.S. payors, especially with the advent of biologics. Payors (and market access agencies in the EU) will most often restrict
high-cost drugs, drugs with limited or no survival benefits, and drugs deemed to be at high risk for widespread off-label use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
efforts at cost containment by insurers (which often require patients to first be prescribed lower cost drugs to determine effectiveness
prior to allowing for reimbursements for more expensive (or less cost effective) drugs), payors are also looking toward implementing
clinical pathways as a way to maintain or improve health outcomes while lowering costs. Clinical pathways are designed to address the
limitations of prior authorization and of reduced fee schedules, offering more durable cost containment to payors. These pathways may
lead to cost savings by encouraging the use of generics, streamlining treatment choices, and reducing side effects while maintaining
outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Engineered
Radiation Sensitizers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market for radiation sensitizers in selected cancer types is defined by the need to improve local-regional tumor control. Treatment regimens
have been developed to address patient needs for tumor control and quality of life. Since the initial applications of Ropidoxuridine
and selective HDAC inhibitors are as adjuncts to the standard of care for the treatment of radiation responsive cancers, the unmet needs
of the market lie in the potential for the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in efficacy of radiation treatments as determined by overall survival, progression free survival and response rates in comparison
    to currently used &#8220;off-label&#8221; sensitizer drugs.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    in radiation doses needed to affect a positive clinical response for the patient.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction
    in the surgical extent that is needed to remove residual cancer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improvement
    in quality-of-life outcomes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
sources have estimated that more than 800,000 patients in the U.S. are treated with radiation therapy for their cancers. According to
the American Cancer Society, about 50% are treated for curative purposes and the balance for palliative care. The market opportunity
for radiation sensitizers lies with the 400,000 patients treated for curative purposes. The number of patients being treated with RT
is expected to grow by more than 22% over the next five years. Based on a rough estimate of a course of radiation sensitizing brand drug
therapy (off label at this time) of $12,000 per patient&#8212;the market size would exceed $4.0 billion. This would represent about 4%
of the annual cost of cancer care in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past two decades, developments in the field of oncology have resulted in an increase in the number of clinical trials of marketed
products that exhibit radiation sensitizing properties. The following are a few examples of recently approved products that exhibit radiation
sensitizing properties: topotecan (Hycamtin&#174;) was approved for ovarian and small-cell lung cancer and also in cervical cancer when
used in combination with cisplatin. Irinotecan (Camptosar&#174;) is used for metastatic colorectal carcinoma, trastuzumab (Hercepetin&#174;)
for breast cancer, and gefitinib (Iressa&#174;) for locally advanced non-small-cell lung cancer. However, the claims on radiation sensitization
are anecdotal in the scientific literature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, clinical trials are in progress to develop novel molecules (such as poly (ADP-ribose) polymerase (PARP) inhibitors (such as
Lynparza (olaparib)), histone deacetylase (HDAC) inhibitors (such Zolinza&#174; (vorinostat) and heat-shock protein 90 (hsp90) inhibitors
with potential to increase the therapeutic use of compounds with radiation sensitizing properties for other cancers. Several drugs with
radiation sensitizing properties are currently in Phase III clinical trials, such as nimorazole (for head and neck cancer), motexafin
gadolinium (for brain metastases), and cisplatin (for cervical cancer); though none are likely to apply for a radiosensitizing claim
with the FDA since the radiosensitizing element in their clinical trials are not primary endpoints. While additional drugs with radiation
sensitizing properties are expected to be launched in the future, thereby driving the radiation sensitizers market further, to date,
there is no indication that any drug in development is expected to be approved specifically as a radiation sensitizer.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive environment for &#8220;off-label&#8221; radiation sensitizers for solid tumor cancers is anticipated to become predominantly
generic. Avastin, Erbitux, Camptosar and Xeloda have or will lose patent protection in the next three years. Newer products under investigation
or approved, such as Vectibix&#174; (panitumumab) from Amgen will be promoted as having radiation sensitizing properties, along with indications
for treatment for specific cancers. The high cost of these new therapies coupled with limited efficacy compared to current standard of
care will be constrained by both public and private payors. Other new agents are in development but will face similar challenges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that new products launching into the cancer market with anecdotal claims for use as radiation sensitizers with improved effectiveness,
quality and tolerability will initially be limited in their growth until they have been added to established clinical pathways and guidelines.
If their effectiveness, quality and tolerability are demonstrated clinically, as determined by the FDA, it is anticipated the National
Comprehensive Cancer Network (NCCN), the leading authority in oncology drug evaluation for treatment guidelines, would issue a recommendation
and addition to standard of care within approximately six to twelve months after launch. An NCCN recommendation would positively impact
the growth potential for a new product entering the market. Also, payors, both public and private, would add the new product to their
approved drug lists and provide reimbursement giving providers incentive to use the product as neoadjuvant and adjuvant therapy to standard
of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
with many cancer therapies, side effects can often have a distinct impact on quality of life and influence the potential for market growth.
Patients increasingly have a stronger voice in the decision-making process for the appropriate therapies and costs to treat their cancers.
As payors are increasingly placing more of the financial burden of the cost of therapy directly on patients, patients are voicing their
opinions to their physicians and payors which have a direct effect on which products are selected. Many of the current therapies have
significant side effects:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
insurers are expected to have more restrictive formularies and medical benefits in which patients will be expected to carry more of the
burden of the cost of drugs. Also, it is anticipated that increased application of third party developed treatment guidelines, such as
those from the NCCN (National Comprehensive Cancer Network), are expected to be used by private payors to limit the access to products
for specific conditions through prior authorizations and implementation of step therapy or increased out of pocket cost approaches. As
many of the current drugs used as radiation sensitizers are expensive and not approved for use as radiation sensitizers (thus, such treatment
is &#8220;off label&#8221;), and as many of the products in clinical trials are expected to be at the current or higher price levels,
new products that may be specifically approved for an indication as the only approved product as a radiation sensitizer will have increased
consideration for reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CMS
is increasingly moving many patients to private insurance through Medicare Advantage and ACOs. Medicare Advantage plans are capitation
HMO and PPO plans offered through private insurers to Medicare patients. ACOs are being developed to increase quality of care for their
patients. Most of the new ACOs are initially positioned for Medicare patients with over 400 approved by CMS. Several studies from the
Center for Health Strategies, 2017, Journal of American Medical Association, 2018 and the Brookings Institute, 2015 estimated that almost
1000 ACOs for Medicare and non-Medicare patient populations would be approved by CMS or developed by a variety of healthcare entities
to begin operating under the ACA in 2017. We expect the growth in ACOs to continue, regardless of any changes that may be made to the
ACA going forward. In early 2017, Health Affairs, a magazine tracking ACOs, estimated that over 22 million patients are enrolled in Medicare
and private ACOs. To address the quality of care measures designated by CMS and to gain additional incentives, use of clinical pathways
or treatment guidelines is anticipated to be increasingly instituted to manage patient care. The impact on the uptake of new products
in this environment can be profound if the new product is first in class and is included in national guidelines from organizations such
as the NCCN and/or approval by the regional CMS contracting groups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">ROPIDOXURIDINE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
halogenated thymidine (TdR) analogs, bromodeoxyuridine (BUdR) and iododeoxyuridine (IUdR), are a class of pyrimidine analogs that have
been recognized as potent radiosensitizing agents since the early 1960s. (<i>See</i> Kinsella TJ. An Approach to the Radiosensitization
of Human Tumors. <i>Cancer J Sci Am.</i> Jul-Aug 1996:2(4); 184-193). Their cellular uptake and metabolism are dependent on the TdR salvage
pathway where they are initially phosphorylated to the monophosphate derivative by the rate-limiting enzyme, thymidine kinase (TK). (<i>See
</i>Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. <i>J Clin Oncol, </i>Sep 10 2007; 25(26):4043-4050). After sequential phosphorylation
to triphosphates, they are then used in DNA replication, in competition with deoxythymidine triphosphate (dTTP), by DNA polymerase. DNA
incorporation is a prerequisite for radiosensitization of human tumors by the halogenated TdR analogs, and the extent of radiosensitization
correlates directly with the percentage TdR replacement in DNA. (<i>See </i>Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD.
The Dependence of Halogenated Pyrimidine Incorporation and Radiosensitization on the Duration of Drug Exposure. <i>International Journal
of radiation oncology, biology, physics.</i> Jun 1990; 18(6);1393-1398). The molecular mechanisms of radiosensitization are most likely
the result of increased susceptibility of TdR analog-substituted DNA to the generation of highly reactive uracil free radicals by ionizing
radiation (IR), which may also damage unsubstituted complementary-strand DNA. Repair of IR damage may also be reduced by pre-IR exposure
to these analogs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rationale for using Ropidoxuridine as a radiation sensitizer is based on prior clinical studies with the active metabolite IUdR; identified
in NIH laboratories as a potent radiation sensitizer. Ropidoxuridine is an orally available prodrug of IUdR. In the body, Ropidoxuridine
is metabolized in the liver into IUdR. IUdR is incorporated into the DNA of actively growing cells and when cells are exposed to ionizing
radiation, DNA strand breaks are generated, resulting in more cell death and radiation sensitization. (<i>See</i> Gurkan E, Schupp JE,
Aziz MA, Kinsella TJ, Loparo KA. Probabilistic modeling of DNA mismatch repair effects on cell cycle dynamics and iododeoxyuridine-DNA
incorporation. Cancer Res. Nov 15 2007; 67(22):10993-11000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
of the clinical efficacy data were obtained from NIH supported studies performed with IUdR, the active metabolite of Ropidoxuridine.
However, IUdR requires constant infusion over six weeks of therapy which creates a significant compliance issue for patients. Ropidoxuridine
can be given as a capsule for oral administration, resulting in greater ease of medication delivery and potentially improved compliance
and fewer complications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last 20 years, there has been renewed interest in these halogenated TdR analogs as experimental radiation sensitizers in selected
cancer patient groups. These analogs are rapidly metabolized in both rodents and humans, principally with cleavage of deoxyribose and
subsequent dehalogenation by hepatic and extrahepatic metabolism, when given as a bolus infusion with a plasma half-life of &lt;5 min.
Consequently, prolonged continuous or repeated intermittent drug infusions over several weeks before and during irradiation are necessary,
based on in vivo human tumor kinetics, to maximize the proportion of tumor cells that incorporate these analogs into DNA during the S
phase of the cell cycle. (<i>See</i> Fowler JF, Kinsella TJ. The Limiting Radiosensitization of Tumors by S-phase Sensitizers. <i>Br
J Cancer</i>. 1996;74 (Suppl)(27):294-296). Phase I and Phase II trials using prolonged continuous or repeated intermittent intravenous
infusions of BUdR or IUdR before and during radiation therapy (RT) have focused principally on patients with high-grade brain tumors.
These clinically radiation resistant tumors can have a rapid proliferation rate (potential tumor doubling times of 5&#8211;15 days) and
are surrounded by non-proliferating normal brain tissues that show little to no DNA incorporation of the TdR analogs. As such, high-grade
brain tumors are ideal targets for this approach to radiation sensitization. In Phase I/Phase II clinical trials, prolonged survival
outcomes were observed compared to RT alone in patients with anaplastic astrocytomas and in patients with glioblastoma multiforme IUdR
continuous IV infusion (1000 mg/m<sup>2</sup>/ day/ 14 days), Total 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994;
30(3):583-90.) A therapeutic gain in clinical radiation sensitization using these halogenated TdR analogs was proposed for other types
of poorly responsive (radiation resistant) cancers, including locally advanced cervical cancer, head and neck cancers, unresectable hepatic
metastases from colorectal cancers, and locally advanced sarcomas, based on the results of other Phase I/Phase II clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Target
Indication: Glioblastoma, Sarcomas and Rectal Cancers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
completion of the Phase I clinical trial of Ropidoxuridine and RT in advanced GI cancers, we proposed to perform Phase II efficacy clinical
trials in brain tumors (glioblastoma), soft tissue sarcomas, and rectal cancers. Glioblastoma multiforme is a deadly malignancy of the
brain with no known cure. Radiation therapy provides delay of disease progression and is standard of care following surgical resection
or biopsy. Radiation therapy is combined with Temodar, a drug that has shown activity (~ four months survival benefit) in treating brain
tumors. Preliminary data using radiation therapy in combination with IUdR resulted in a delay of disease progression of up to six months.
We propose to test IPdR in combination with radiation therapy in the Phase II clinical trial. Similarly, delay in disease progression
has been observed following treatment of sarcomas by the combination of IUdR and RT. Based on the Phase I data of our clinical trial
we know that therapeutic levels of IUdR are reached by administering the orally available prodrug, IPdR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase I results of the clinical trial supported by an SBIR contract to Shuttle Pharma and a sub-contract to the Brown University Oncology
Group (BrUOG) at the LifeSpan/Rhode Island Hospital were reported by the subcontractor at the 30th EORTC-NCI-AACR Symposium in November
2018 and in the medical journal, Clinical Cancer Research, in 2019. Eighteen patients completed dose escalation to 1800 mg/day for 30
days, establishing the maximum tolerated dose (MTD) of 1,200 mg/day in combination with RT. Therapeutic blood levels of IUdR were achieved.
Four patients were scored as partial responses, nine patients had stable disease and one patient progressed in the target lesions. These
data support advancing IPdR and RT to clinical trials for the FDA to determine efficacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key to driving the Ropidoxuridine product forward is the development of a clinical plan with aggressive timelines and support within
the radiation oncology community to participate in clinical trials with the appropriate patients to ensure a comprehensive NDA dossier
for each product. Initially, the plan is focused on the Phase I and Phase II clinical trials. Upon completion of Phase II studies, we
will determine whether to extend the Phase II study to a randomized Phase II, or to perform a randomized Phase III clinical trial. Such
determination will be based on results of the initial clinical trials and the end of a Phase II meeting with the FDA. Shuttle Pharmaceuticals
requested and received FDA orphan drug status for Ropidoxuridine as a clinical radiation sensitizer for treatment of glioblastoma and
pre-operative treatment of soft tissue sarcomas. As a result, the application for &#8220;orphan&#8221; designation for Ropidoxuridine
with RT for glioblastoma has been approved. The application for sarcomas, however, was not approved and will require addressing certain
FDA comments and resubmission. The IPdR/TPI formulation clinical plan will focus on resectable stage II and III rectal cancer patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical plan for Ropidoxuridine development as implemented to date, includes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMP
    manufacture and formulation of 24 kg of Ropidoxuridine for use in clinical trials has been completed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IND for a Phase II clinical trial of Ropidoxuridine and RT in glioblastoma has been approved for the study to proceed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    contract research organizations (CRO), Theradex Oncology has been engaged to assist in the performance the Phase II clinical trial.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
    of the Phase II clinical trial in glioblastomas to determine appropriate dosing, effectiveness and tolerability of the treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data obtained from the NIH/NCI SBIR funded Phase I clinical trial supported efforts to raise capital to enable performing the Phase II
clinical trials of Ropidoxuridine. We aim to conduct and complete the Phase II clinical trial so that we may present data to the FDA
for its determination of efficacy. We believe this will support our efforts to raise the additional required capital to complete Phase
II and to fund the Phase III clinical trials and seek FDA approval of an NDA with &#8220;orphan&#8221; designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical plan for the IPdR/TPI formulation will focus on resectable Stage II and Stage III rectal cancer patients and on recurrent glioblastoma
treated with proton therapy. Nonetheless, we cannot guarantee the successful completion of any of these trials. Our inability to meet
any of the aforementioned milestones in the Phase II or Phase III clinical trials will cause us to be unable to proceed with our present
efforts and will likely cause us to be unable to raise additional funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
HDAC Small Molecule Delivery Platform</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the founding of Shuttle Pharma, our discovery research and development efforts have been focused on our small molecule technology delivery
platform which uses HDAC inhibitors, designed to target cancer cells, while protecting healthy tissue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HDACs
are a class of enzymes that regulate gene expression through chemical modification of histones and non-histone proteins. Increased HDAC
activity leads to a more condensed chromatin (which is a protein complex consisting of DNA and other proteins), decreased gene expression
and loss of key gene products, including tumor suppressor gene function. Inhibition of HDAC activity leads to a more open chromatin and
increased expression of the key gene products. This chromatin modification underlies the epigenetic cellular regulatory system and is
an area of intense investigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development efforts to date have focused on the discovery of novel, dual functional molecules for potential use in cancer
treatment as radiation sensitizers of cancers, protectors of normal tissues, and activators of the immune responses to antigens expressed
by irradiated cancer cells. To date, we have produced three candidate molecules:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161,
    a candidate lead of compounds demonstrating activation of the &#8220;ATM&#8221; gene product (mutated in Ataxia-Telangiectasia).
    Ataxia-Telangiectasia is a human genetic disease characterized by neurological, immunological and radiobiological clinical features.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225,
    a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. HDAC6 is a molecule integral to the presentation
    of antigens by macrophages to T-lymphocytes.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-303
    is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-161
</span>- A Dual Functional Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-1-161
is an HDAC inhibitor of the hydroxamate chemical class of compounds and an ATM activator of the indole chemical class. HDACs modify histones
and non-histone proteins, which are key components of the chromatin structure, gene expression regulation, and cell growth. HDAC inhibitors
inhibit cell proliferation, angiogenesis and immunity. Eighteen human HDACs have been identified, subdivided into four classes based
on sequence and functional homology. In cancer cells, HDAC activity silences tumor suppressor genes important for cell growth regulation
and to chromosomal instability. Abnormal HDAC activity is also associated with tumor cell growth, invasion, metastasis and resistance
to therapy. Therefore, inhibitors of HDACs have emerged as anti-cancer agents for cancer therapy. Vorinostat and romidepsin have been
approved by the FDA for treatment of patients with relapsed or refractory T-cell lymphomas. In addition, panobinostat received FDA approval
for treatment of recurrent multiple myeloma in combination with bortezomib and dexamethasone.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 inhibited the activity of pan-HDACs and activated the ATM gene product. ATM is a critical protein for the
activation of the cell stress response for cellular recovery from radiation exposure in normal cells, but not in cancer cells. ATM activates
the P53 protein, referred to as the &#8220;guardian of the genome,&#8221; and serves as a tumor suppressor critical for normal cell function
and activation of programmed cell death in cancer cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preclinical studies, SP-1-161 protected normal breast epithelial cells (184A1) following exposure to ionizing radiation while increasing
sensitivity of breast cancer cells (MCF7). SP-1-161 provides this dual function in a single molecule and this molecule is differentiated
from other HDAC inhibitors by treatment of cancers while protecting normal cells. (<i>See</i> Grindrod S, Brown M, Jung M. &#8220;Development
of dual Function Small Molecules as Therapeutic Agents for Cancer Research,&#8221; Poster presentation #A178, American Association of
Cancer Research Oct 2017).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-2-225</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SP-2-225
is a selective HDAC inhibitor that affects histone deacetylase (HDAC6) and is a member of the class IIb HDAC family. Class II HDACs play
important roles in cancer motility, invasion, neurological diseases, and immune checkpoint. HDAC6 inhibition has been most extensively
studied for its role in the treatment of hematological cancers. HDAC6 is unique among HDAC enzymes in having two active catalytic domains
and a unique physiological function. In addition to the modification of histones, HDAC6 targets specific substrates including &#945;-tubulin
and HSP90, and are involved in protein trafficking and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging
class of pharmaceuticals due to the involvement of HDAC6 in pathways related to neurodegenerative diseases, cancer and immunology. Specifically,
its potential to affect regulation of the immune system and enhance the immune response in cancer is of great interest. With the introduction
of check-point inhibitors, CAR-T therapies and personalized medicine in cancer, regulation of the immune response to this therapy is
of significant clinical and commercial interest. (See Noonepalle SKR, Grindrod S, Aghdam N, Li X, Gracia-Hernandez M, Zevallos-Delgado
C, Jung M, Villagra A, Dritschilo A. Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition. Mol Cancer Ther. 2023
Dec 1;22(12):1376-1389. doi: 10.1158/1535-7163.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selective
inhibition of HCAC6 reduces dose limiting side effects associated with non-selective HDAC inhibitors. Selective HDAC6 inhibitors may
be combined with other cytotoxic agents. Shuttle&#8217;s discovery of selective HDAC inhibitors has yielded several HDAC6 selective candidate
molecules including SP-2-225. HDAC6 inhibitors are under investigation for roles in the treatment of diseases such as multiple myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">SP-1-303
</span>- Target Indication: Breast Cancer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Histone
deacetylase inhibitors sensitize cancers to the effects of radiation, protect normal tissues from radiation injury and activate the immune
system. SP-1-303 is a selective Class I HDAC inhibitor that inhibits HDAC1, 3 and 6 and has direct cellular toxicity in ER positive breast
cancer cells. Furthermore, SP-1-303 increases the PD-L1 expression level in a time-dependent manner, support combination of SP-1-303
with an immune checkpoint blocker to enhance the therapeutic benefits. We are currently conducting preclinical efficacy studies of these
molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development
Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HDAC inhibitor platform of candidate molecules will require pre-clinical evaluation, completion of IND-enabling studies and the lead
drug candidates will be tested in Phase I clinical trials for pharmacokinetics and MTD determination. We have three lead candidates for
potential development for the treatment of solid tumors, including breast cancer, lung cancer and multiple myeloma.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of Phase I and Phase II clinical trials will determine further drug development and Shuttle will seek to establish collaborative
partnerships with other pharmaceutical companies to complete pre-clinical and clinical development, drug manufacturing and marketing
of our product candidates. In the event we are unsuccessful in completing our clinical trials at any stage, or in the event we obtain
negative results, we will likely be unable to raise additional funding related to our HDAC studies or will have to change direction of
our research efforts regarding the HDAC inhibitor platform of candidate molecules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Manufacturing Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no manufacturing facilities that are owned or operated by us. We have performed laboratory scale synthesis and testing in our research
laboratories in Gaithersburg, Maryland. GMP synthesis of API, drug formulation and human dosage preparation will be performed under contracts
with third-party manufacturers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategic
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed important strategic agreements with academic institutions for access to resources such as intellectual property, core
facilities and contracting relationships. In addition, we have established an agreement with Propagenix for intellectual property in-licensing.
Our current and ongoing relationships include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Georgetown
    University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    for the SBIR supported African American prostate cancer patient health disparities project (completed). The conditional reprogramming
    of cells (CRC) technology was invented at Georgetown University and Georgetown University owns the intellectual property. Propagenix
    holds the license for the intellectual property for the CRC technology from Georgetown University. The intellectual property for
    cells derived from African American patients under the Georgetown University subcontract belong to Shuttle Pharmaceuticals, Inc.
    based on our sub-licensing agreement with Propagenix.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    for the SBIR supported metabolomic predictive biomarker project (completed). The metabolomic biomarker intellectual property belongs
    to Georgetown University and Shuttle Pharma holds an exclusive option to license the intellectual property. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive
    licensing agreement with Georgetown University pursuant to which Georgetown University agreed to license the intellectual property
    known as &#8220;Predictive Biomarkers for Adverse Effects of Radiation Therapy&#8221; (U.S. Patent Application No. 17/476,184, filed
    on September 15, 2021) (the &#8220;Patent Rights&#8221;), which was developed by Dr. Anatoly Dritschilo, the Company&#8217;s Chief
    Executive Officer, Dr. Scott Grindrod, the Company&#8217;s Principal Scientist, and Drs. Amrita Cheema and Yaoxiang Li, employees
    of Georgetown. The Patent Rights will be available for the Company&#8217;s use worldwide. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
    Pharma entered into a research agreement (the &#8220;Research Agreement&#8221;) with Georgetown University for testing small molecule
    radiation sensitizers and immune activation candidates discovered and developed by Shuttle Pharma in cell-based and animal xenograft
    models. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    conjunction with the Research Agreement, Shuttle Pharma also entered into a material transfer agreement (the &#8220;MTA&#8221;),
    dated March 21, 2023, with Georgetown University. Under the MTA, Shuttle Pharma agreed to transfer research quantities of candidate
    drug molecules to Georgetown University, which materials will be used by Georgetown University solely to carry out additional research
    for Shuttle Pharma and which materials shall at all times remain the property of Shuttle Pharma. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brown
    University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sub-contractor
    of the SBIR supported Phase I clinical trial of IPdR and RT (completed).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">University
    of Virginia</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    collaboration to develop heavy oxygen molecules for proton radiation sensitizer applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">George
    Washington University</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    transfer agreement for testing HDAC inhibitor effects in immune model systems</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    material transfer agreement that protects our HDAC inhibitor intellectual property is with George Washington University, transferring
    drugs for research purposes and sharing authorship on publications. There is no transfer of funds related to such activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Propagenix,
    Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    agreement for &#8220;conditional re-programmed cell&#8221; (CRC) technology. The cells established by Shuttle Pharma scientists at
    Georgetown University belong to us, based on the sublicense from Propagenix, Inc. An up-front licensing fee of $25,000 was paid to
    Propagenix. No other future milestone or royalty payments owed related to the Propagenix agreement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition
&#8220;Off-Label&#8221; Use</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt="A table with different colored text&#10;&#10;Description automatically generated with medium confidence" style="height: 301px; width: 604px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
with radiation sensitizing properties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are advancing a clinical stage product candidate, Ropidoxuridine, that we believe will target cancer cells while protecting healthy tissue
when used in conjunction with RT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ropidoxuridine</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ropidoxuridine,
an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties, is our lead &#8220;clinical phase&#8221;
product candidate. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and become more sensitive to the
effects of RT. We have received an SBIR contract from the NIH to fund a Phase I clinical trial in collaboration with Brown University
at the Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in patients with advanced gastrointestinal cancers. In
connection with the trial, NCI approved the Phase I clinical protocol and provided drug and clinical data management support to Rhode
Island Hospital. The Phase I clinical trial has been completed and the results support advancing Ropidoxuridine to Phase II clinical
trials of brain tumors, sarcomas and other tumors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provide data from reported clinical trials of Iododeoxyuridine and RT therapy in brain cancers (glioblastoma multiforme)
and high-grade sarcomas. Our primary strategy for Ropidoxuridine and RT therapy is to provide oral drug delivery to effect radiation
sensitization of cancers and validate effectiveness in glioblastoma and sarcoma, potential &#8220;Orphan&#8221; indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brain
Cancer Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Efficacy
compared to historical RT-alone controls for treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
high-grade primary brain tumors (RTOG*, NCI** trials)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_003.jpg" alt="" style="height: 186px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR
    continuous IV infusion (1000 mg/m2/ day/ 14 days), Total of 39 patients (F. Sullivan, et al. Int J Radiat Oncol Biol Phys. 1994;
    30(3):583-90)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IUdR
    continuous IV infusion (2000 mg/m2/ 4 day infusion/ 6 week treatment), Total of 21 patients (R. Urtasun, et al. Int J Radiat Oncol
    Biol Phys. 1996;36(5):1163-7.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sarcoma
Treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Efficacy
compared to historical RT-alone controls for treatment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
high-grade sarcomas (University of Michigan*** trials)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_004.jpg" alt="" style="height: 186px; width: 576px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16
    patients were treated with continuous infusion (1000-1600 mg/m2/day) plus RT (J.M. Robertson, et al. Int J Radiat Oncol Biol Phys.
    1995; 31(1):87-92).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our primary product candidate, we are developing and planning to develop other cancer radiation sensitizers and radiation
protectors, which target protecting normal tissue during the administration of RT, and other products utilizing our HDAC small molecule
technology platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SBIR
Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
SBIR Program</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Small Business Innovation Research program, as developed by Congress under the Small Business Innovation Development Act of 1982, is
designed to encourage domestic small businesses to engage in Federal Research/Research and Development (&#8220;R/R&amp;D&#8221;) that
has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their technological
potential and provides the incentive to profit from its commercialization. Some of the SBIR&#8217;s program goals include stimulating
technological innovation, meeting Federal research and development needs and encouraging participation in innovation and entrepreneurship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SBIR program is a three-phase program. Phase 1 is to establish the technical merit and commercial potential of the proposed R/R&amp;D
efforts. Phase 2 is to continue the R/R&amp;D efforts initiated in Phase 1 and funding is based on the results achieved in Phase 1. Phase
3 allows for the small business to pursue commercialization objectives resulting from the Phase 1 and 2 R/R&amp;D activities. In addition,
companies that have successfully completed Phases I and II are also eligible to apply for Phase IIb funding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the SBIR contract to fund our Phase I clinical study on Ropidoxuridine in combination with RT for treatment of advanced gastrointestinal
cancers, we have also received awards of SBIR contracts from the NIH to address prostate cancer health disparities and prostate cancer
radiation biomarker development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, all SBIR contracts received by the Company have been completed. The Company submitted a final report
for SBIR contract # 75N81018C00031 on March 28, 2022. The following summary of terms for the three Phase II SBIR contracts is provided
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Summary
of SBIR Contracts</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contract #261201400013C: Phase I ($191,971) and Phase II ($1,428,117) for Clinical Development of IPdR for Radiosensitization, dates
    September 19, 2014 through August 3, 2017. Subcontract to Brown University/LifeSpan Rhode Island Hospital. No related intellectual
    property.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contracts # HHSN261201600038C; Phase I ($224,687) and #261201800016C: Cell-Based Models for Prostate Cancer Health Disparity Research
    - Moonshot Project (Phase II), award amount $1,484,350, dates September 19, 2016 through September 16, 2021. Subcontract to Georgetown
    University. Intellectual property consists of cell cultures and is property of Shuttle Pharmaceuticals, Inc. via licensing agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBIR
    contracts #HHSN261201600027C ($299,502) and #75N81018C00031: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation
    Late Effects, award amount $1,903,015, dates September 16, 2019 through March 15, 2022. Subcontract to Georgetown University. Intellectual
    property is owned by subcontractor Georgetown University with option to license to Shuttle Pharmaceuticals, Inc.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer Studies to Address Health Disparities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate
cancer health disparities studies have shown that African American men are at higher risk for developing prostate cancer, as well as
at higher risk of cancer specific death rates as compared to Caucasian American men. The causes of disparities have been attributed to
socioeconomic differences, environmental exposures and biological factors. Most disparities studies have been population based, in part,
due to the lack of relevant in vitro and in vivo models to support biological studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharma has been awarded Phase I and II SBIR contracts entitled &#8220;Cell-based models for prostate cancer health disparity research&#8221;
to develop African American prostate cancer cell lines with donor matched normal prostate epithelial cell lines from African American
men.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercialization of the prostate cells will require additional support through the SBIR funding mechanism. Companies that have completed
Phase I and II SBIR awards are eligible to apply for Phase IIb SBIR funding. These awards are intended to de-risk a project by providing
up to $4 million of matching funding for product development to commercialization. We intend to apply for such government funding to
advance laboratory facilities and to expand the availability of the cell cultures. We did not raise capital through our IPO for the health
disparities project. Should we not be successful with SBIR IIb funding, we will pause and may have to terminate this project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Prostate
Cancer Biomarker Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
treated for prostate cancer may experience treatment related late effects that adversely affect quality of life and may prove life-threatening.
Shuttle Pharma has been awarded a Phase I SBIR contract entitled &#8220;Predictive biomarkers for prostate cancer patient sensitivity
for radiation late effects&#8221; to determine the technical and commercial feasibility of a biomarker panel predictive of radiation
mediated late effects in patients treated for prostate cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
collaboration with Georgetown University, patients treated with SBRT for prostate cancers were analyzed for urinary and rectal symptoms
and their blood was analyzed by mass spectroscopy for predictive biomarkers. The discovery and validation of metabolite panels to serve
as a predictive biomarker of patient outcomes following radiation therapy and supports future development and commercialization of a
diagnostic product through a Phase 2 SBIR effort.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development to commercialization of the metabolite predictive biomarker panel requires additional support through the SBIR funding mechanism.
We will be eligible to apply for Phase IIb SBIR funding the next round of solicitation. A Phase IIb will help de-risk the project by
providing up to $4 million of matching funds for performing the clinical validation trial for product development to commercialization.
We intend to apply for such government funding to advance this project. We also intend to raise capital through the public market for
predictive biomarker development through the Shuttle Diagnostics entity. We do not intend to use the funds raised through our IPO for
the health disparities project. Should we not be successful for SBIR IIb funding, we will terminate this project.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative
Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to enter into selective collaborative arrangements to further develop our drug candidates in the future, at present we have
not entered into any collaborative arrangements with third parties to develop our drug candidates as we are still completing clinical
trials and, as a result, there can be no assurance that we will be able to do so on commercially reasonable terms or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
invest significant amounts of funds in research and development. Our research and development expenses before contract reimbursements
were $3,517,093 and $1,360,167 for the fiscal years ended December 31, 2023 and 2022 respectively. After reimbursements for contracts
of $0 and $211,455 for the fiscal years ended December 31, 2023 and 2022, net research and development expenses were $3,517,093 and $1,148,712,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are seeking multifaceted protection for our intellectual property that includes licenses, confidentiality and non-disclosure agreements,
copyrights, patents, trademarks and common law rights, such as trade secrets. We enter into confidentiality and proprietary rights agreements
with our employees, consultants, collaborators, subcontractors and other third parties and generally control access to our documentation
and proprietary information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, we have filed five patent applications with the USPTO with respect to various aspects of our HDAC
small molecule delivery platform and Ropidoxuridine, our lead product candidate. The following is the status of the patent applications
Shuttle has filed to date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Shuttle Pharma&#8217;s Intellectual Property Portfolio</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_005.jpg" alt="" style="height: 369px; width: 670px"/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan,
Lewis &amp; Bockius LLP prepared patent applications related to Ropidoxuridine (IPdR) and HDAC inhibitors, and, in the fourth quarter
of 2018, found no freedom to operate (FTO) issue for Ropidoxuridine used as radiosensitizer and used with tipiracil, and HDAC inhibitors
SP-1-161 and SP-2-225.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategy around protection of our proprietary technology, including any innovations and improvements, is to obtain worldwide patent coverage
with a focus on jurisdictions that represent significant global pharmaceutical markets. Generally, patents have a term of twenty years
from the earliest priority date, assuming that all maintenance fees are paid, no portion of the patent has been terminally disclaimed
and the patent has not been invalidated. In certain jurisdictions, and in certain circumstances, patent terms can be extended or shortened.
We are obtaining worldwide patent protection for at least novel molecules, composition of matter, pharmaceutical formulations, methods
of use, including treatment of disease, methods of manufacture and other novel uses for the inventive molecules originating from our
research and development efforts. We continuously assess whether it is strategically more favorable to maintain confidentiality for the
&#8220;know-how&#8221; regarding a novel invention rather than pursue patent protection. For each patent application that is filed we
strategically tailor our claims in accordance with the existing patent landscape around a particular technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
can be no assurance that an issued patent will remain valid and enforceable in a court of law through the entire patent term. Should
the validity of a patent be challenged, the legal process associated with defending the patent can be costly and time consuming. Issued
patents can be subject to oppositions, interferences and other third-party challenges that can result in the revocation of the patent
limit patent claims such that patent coverage lacks sufficient breadth to protect subject matter that is commercially relevant. Competitors
may be able to circumvent our patents. Development and commercialization of pharmaceutical products can be subject to substantial delays
and it is possible that at the time of commercialization any patent covering the product has expired or will be in force for only a short
period of time following commercialization. We cannot predict with any certainty if any third-party U.S. or foreign patent rights or
other proprietary rights will be deemed infringed by the use of our technology. Nor can we predict with certainty which, if any, of these
rights will or may be asserted against us by third parties. Should we need to defend ourselves and our partners against any such claims,
substantial costs may be incurred. Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief,
which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad and could result
in the award of substantial damages. In the event of a claim of infringement, we or our partners may be required to obtain one or more
licenses from a third party. There can be no assurance that we can obtain a license on a reasonable basis should we deem it necessary
to obtain rights to an alternative technology that meets our needs. The failure to obtain a license may have a material adverse effect
on our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secret protection for our confidential and proprietary information. No assurance can be given that we can meaningfully
protect our trade secrets on a continuing basis. Others may independently develop substantially equivalent confidential and proprietary
information or otherwise gain access to our trade secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who
receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships.
These agreements provide that all confidential information developed or made known to these individuals during the course of the individual&#8217;s
relationship with the company is to be kept confidential and is not to be disclosed to third parties except in specific circumstances.
The agreements provide that all inventions conceived by an employee will be the property of our company. There can be no assurance, however,
that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use
or disclosure of such information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend in part on our ability to obtain and maintain patent protection, preserve trade secrets, prevent third parties from
infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others, both in the U.S. and other
territories worldwide.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
and Supply</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently own or operate manufacturing facilities for the production of preclinical, clinical or commercial quantities of any
of our product candidates. We currently use a number of our suppliers for the raw materials and formulation to meet the preclinical and
any clinical requirements of our product candidates. We do not have a long-term agreement with any of these parties and we believe alternative
sources of supply exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to enter into collaborations for the manufacture of our product candidates, with our collaborators assuming responsibility for
such manufacturing. Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements,
which govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. Any
collaborator or third-party contract manufacturer we use would need to be compliant with cGMP. cGMP is a regulatory standard for the
production of pharmaceuticals that will be used in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sales
and Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current focus is on the development of our existing portfolio, the completion of clinical trials and, if and where appropriate, the registration
of our product candidates. We currently do not have marketing, sales and distribution capabilities. If we receive marketing and commercialization
approval for any of our product candidates, we intend to market the product either directly or through collaborations, strategic alliances
and distribution agreements with third parties. The ultimate implementation of our strategy for realizing the financial value of our
product candidates is dependent on the results of clinical trials for our product candidates, the availability of funds and the ability
to negotiate acceptable commercial terms with third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Annual Report, we have eight full-time employees, including our five executive officers, and three engaged in research
and development. We consider our relationship with our employees to be good.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Financings &#8211; Our IPO and Post-2022 Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 2, 2022, we closed on our IPO of 1,225,888 units (each a &#8220;Unit,&#8221; and collectively, the &#8220;Units&#8221;), with
each Unit consisting of one share of the Company&#8217;s common stock and one warrant to purchase one share of common stock, at a public
offering price of $8.125 per Unit. Our IPO, which was underwritten by Boustead Securities, LLC (&#8220;Boustead&#8221;), resulted in
gross proceeds of $9,960,430, before deducting underwriting discounts and commissions. On September 29, 2022, Boustead exercised its
overallotment option, purchasing an additional 183,883 Units, resulting in gross proceeds of $1,494,041, before deducting underwriter
commissions and discounts. As a result, our IPO raised a total of $11,454,474, before deducting underwriting discounts, commissions and
related IPO expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master Fund, SPC &#8211;
Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to the Investor a $4.3
million convertible note (the &#8220;Convertible Note&#8221;) and warrant (the &#8220;Warrant&#8221;) to purchase 1,018,079 shares of
common stock of the Company, in exchange for gross proceeds of $4.0 million (the &#8220;Investment Amount&#8221;). The Convertible Note
amortizes on a monthly basis and the Company can make such monthly amortization payments in cash or, subject to certain equity conditions,
in registered shares of common stock or a combination thereof. For equity repayment, the Convertible Note is convertible into shares
of common stock at price per share equal to the lower of (i) $2.35 (ii) 90% of the three lowest daily VWAPs of the 15 trading days prior
to the payment date or (iii) 90% of the VWAP of the trading day prior to payment date. The Convertible Note is repayable over 26 months
and bears interest at the rate of 5% per annum. The Warrant is exercisable for four years from the date of closing and is exercisable
at $2.35 per share. In the event the Investor exercises the Warrant in full, such exercise would result in additional gross proceeds
to the Company of approximately $2.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2023, we entered into an amendment agreement (the &#8220;Amendment Agreement&#8221;) to the SPA. Under the Amendment Agreement,
the Company and the Investor amended the transaction documents as follows: (i) amended and restated Section 2 of the Warrant so as to
remove a provision that would have potentially required an adjustment to the number of warrant shares exercisable under the Warrant,
(ii) stipulated that the Company would obtain majority shareholder approval to issue up to an additional $10 million in convertible notes
(the &#8220;Subsequent Notes&#8221;) and warrants (the &#8220;Subsequent Warrants&#8221;) equal to 42.5% of the outstanding principal
value of the Subsequent Notes, which Subsequent Note and Subsequent Warrant would be sold to the Investor on substantially the same terms
as the existing Convertible Note and Warrant (each as amended by the Amendment Agreement) and upon conversion and/or exercise would cause
the potential issuance of in excess of 19.9% of the Company&#8217;s issued and outstanding stock, (iii) that, upon obtaining majority
stockholder approval, the Company would file a Schedule 14C related to such potential issuance of the shares of common stock related
to the potential sale of the Subsequent Notes and Subsequent Warrants to the Investor within 30 calendar days of entry into the Amendment
Agreement, and (iv) stipulated that the Investor would release $1,500,000 in cash collateral to the Company, with $1,000,000 to be released
to the Company immediately upon singing of the Amendment Agreement and $500,000 to be released upon the Company&#8217;s filing of the
Schedule 14C. The Company obtained majority stockholder consent to the potential sale of the Subsequent Notes and Subsequent Warrants
to the Investor in advance of entry into the Amendment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2023, we entered into amendment no. 1 (&#8220;Amendment No. 1&#8221;) to the Amendment Agreement dated May 11, 2023, for purposes
of amending the terms of the SPA. Under Amendment No. 1 to the Amendment Agreement, the Company and the Investor agreed as follows: (i)
that Section 15(q) to the Convertible Note, which required the Company to hold the Cash Collateral in a Controlled Account Agreement
(as defined in the Convertible Note), would no longer be applicable, (ii) that the Investor would stipulate the release to the Company
of the remaining Cash Collateral totaling $2,924,000 (thus releasing the full amount of the Cash Collateral to the Company), and (iii)
that, should the Investor exercise its option to purchase the Subsequent Notes and Subsequent Warrants, that such Subsequent Notes would
omit Section 15(q) and that the Company would not be required to maintain any controlled accounts or otherwise be subject to any controlled
account agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_003"></span>Item
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our securities involves a high degree of risk. You should carefully consider all of the risks described below, together
with the other information contained in this Annual Report on Form 10-K, including our financial statements and related notes elsewhere,
before making a decision to invest in our securities. If any of the following events occur, our business, financial condition and operating
results may be materially adversely affected. In that event, the trading price of our securities could decline, and you could lose all
or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risks described under the heading &#8220;Risk Factors&#8221; beginning on page 25 of this Annual Report on Form 10-K may cause us not
to realize the full benefits of our strengths and/or may cause us to be unable to successfully execute all or part of our strategy. Some
of the more significant challenges we face include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt">Our ability to continue as a going concern in the near term is dependent
upon us successfully raising additional equity or debt financing to fund our operations.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates,
    all of which are in the early stages of development.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    currently have no source of product sales revenue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    face competition from entities that have developed or may develop product candidates for our target disease indications, including
    companies developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies
    develop technologies or product candidates more rapidly than we do or their technologies, including delivery technologies, are more
    effective, our ability to develop and commercialize product candidates may be adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or
    commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
    affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
    of our product candidates may be adversely affected.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or our licensors, or any future collaborators or a strategic partners may become subject to third party claims or litigation alleging
    infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need
    to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming,
    delay or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights
    at risk.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform
    initiatives, thereby harming our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal
    spending.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the
    product candidate, our ability to market and derive revenue from the product candidates could be compromised.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stock price is presently trading below $1.00 and, while Nasdaq has granted us until August 26, 2024 to regain compliance, there
    is no guarantee that we will regain compliance without effectuating a reverse stock split.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    stock price may be volatile, and purchasers of our common stock could incur substantial losses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25pt; text-align: justify; text-indent: -0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading
    opinion regarding our stock, our stock price and trading volume could decline. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK
FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>An
investment in our common stock involves a high degree of risk. You should carefully consider the following risk factors and all the other
information in this Annual Report before you decide to buy our common stock. If any of the following risks related to our business actually
occurs, our business, financial condition, operating results, and prospects would be adversely affected. The market price of our common
stock could decline due to any of these risks and uncertainties related to our business, or related to an investment in our common stock,
and you may lose part or all of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business, Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business; <b><i>our ability to continue as a going concern is dependent upon our
ability to successfully conduct clinical trials, bring a drug candidate to commercialization, generate revenues, and to raise additional
equity or debt financing to fund our operations.</i></b></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and had a net loss of
approximately $6.6 million and no revenues for the year ended December 31, 2023, with working capital of approximately $4.6 million as
of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and certain cash
payment requirements. These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering of common stock, generating net proceeds of approximately $10.0
million. Additionally, in January 2023, the Company entered into a securities purchase agreement with an institutional investor
through which the Company sold a convertible note with a principal value of $4.3 million, along with a four-year warrant to purchase
1,018,079 shares of common stock, exercisable at $2.35 per share, providing the Company with approximately $3.6 million in net
proceeds. To date, the warrant has not yet been exercised. However, the Company&#8217;s existing cash resources, marketable
securities and the cash received from the Company&#8217;s initial public offering and convertible note offering are not expected to
provide sufficient funds to support the Company&#8217;s operations and clinical trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital raise has supported operations leading up to the manufacture of drug product and FDA approval of the IND for the Phase II
clinical trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the company agreed to an expansion
of the clinical trial, necessitating additional capital expenditures to complete the trial. Management intends to initiate a rights
offering for $4.5 million and has submitted SBIR applications for non-dilutive NIH funding for our pre-clinical project. The ability
of the Company to continue as a going concern is dependent upon our ability to successfully conduct clinical trials, bring a drug
candidate to commercialization, generate revenues, and to raise additional equity or debt financing to fund our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success is primarily dependent on the successful development, regulatory approval and commercialization of our product candidates, all
of which are in the early stages of development.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have one clinical stage product candidate in the early stages of development. Ropidoxuridine has undergone an SBIR funded Phase
I clinical trial at Lifespan/Rhode Island Hospital. We also have an HDAC inhibitor small molecule platform. The three lead drug candidate
molecules are in preclinical phases of development. None of our product candidates have gained marketing approval for sale in the United
States or any other country, and we cannot guarantee that we will ever have marketable products. To date, we have invested substantially
all of our efforts and financial resources in the research and development and commercial planning for our current product candidate
and our HDAC small molecule delivery platform. Our near-term prospects, including our ability to finance our Company and generate revenue,
as well as our future growth, will depend heavily on the development, marketing approval and commercialization of our product candidates.
The clinical and commercial success of product candidates will depend on a number of factors, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">building
    on favorable results from our Phase I clinical trial for IPdR and proceeding to Phase II and Phase III clinical trials, which may
    be slower or cost more than we currently anticipate;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to demonstrate safety and efficacy of our product candidates, which are ongoing determinations that are solely within the
    authority of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">even
    if our clinical trials are completed, there can be no assurance that the FDA will agree that we have satisfactorily demonstrated
    safety or efficacy or that the FDA will not raise new issues regarding the design of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are required by the FDA to conduct additional clinical trials to support the approval of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance by the FDA of our proposed parameters for regulatory approval, including our proposed indication, endpoints and endpoint
    measurement tools relating to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    incidence, duration and severity of adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timely receipt of necessary marketing approvals from the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we are able to secure collaborations for completing the development and, if approved, commercialization of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our and our potential collaborators&#8217; marketing, sales and distribution strategy and operations of product
    candidates that are approved;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    success in educating physicians and patients about the benefits, administration and use of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our third-party manufacturers and potential collaborators to manufacture clinical trial and commercial supplies of our
    product candidates to remain in good standing with regulatory bodies, and to develop, validate and maintain commercially viable manufacturing
    processes that are compliant with current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to commercialize our product candidates, if approved for marketing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to enforce our intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to avoid third-party patent interference or patent infringement claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our product candidates as safe and effective by patients and the medical community; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    continued acceptable quality profile of our product candidates following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Many
of the above-listed risk factors are beyond our control. Accordingly, we cannot assure you that we will ever be able to generate
revenue through the sale of our product candidates. Any one of these factors or other factors discussed in this Annual Report could
affect our ability to commercialize product candidates, which could impact our ability to earn sufficient revenues to transition
from a developmental stage company and continue our business. If we do not obtain marketing approval of and commercialization of our
product candidates, or are significantly delayed in doing so, our business will be materially harmed. We have a limited operating
history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the
foreseeable future and may never achieve or maintain profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company, preparing to commence Phase II clinical trials of our lead drug candidate, with a limited operating history upon which you can evaluate our business and prospects.
Specialty pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We do not
currently have any product candidates in advanced clinical trials or approved for sale, and we continue to incur significant research
and development and general and administrative expenses related to our operations. In addition, we have limited experience and have not
yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and
rapidly evolving fields, particularly in the specialty pharmaceutical industry. We have not generated any revenue and have incurred losses
in each year since our founding in December 2012. Our accumulated deficit as of December 31, 2023 was $15.5 million. We expect to continue
to incur significant losses for the foreseeable future. Even if we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no source of product sales revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet completed clinical trials and thus do not yet have commercial sales of our products and have not yet not generated any
revenues from commercial sales of our product candidates. Our ability to generate product revenue depends upon our ability to
develop and commercialize products, including any of our current product candidates or other product candidates that we may develop,
in-license or acquire in the future. We do not anticipate generating revenue from the sale of products for the foreseeable future.
Our ability to generate future product revenue from our current or future product candidates also depends on a number of additional
factors, including our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete
    research and clinical development of current and future product candidates, either directly or through collaborative relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of
    bulk drug substances and drug products to maintain that supply;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    regulatory approval from relevant regulatory authorities in jurisdictions where we intend to market our product candidates, either
    directly or through collaborative relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launch
    and commercialize future product candidates for which we obtain marketing approval, if any, through collaborative partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    coverage and adequate product reimbursement from third-party payors, including government payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieve
    market acceptance for our products, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish,
    maintain and protect our intellectual property rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract,
    hire and retain qualified personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, because of the numerous risks and uncertainties associated with clinical product development, including that our product candidates
may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount
of any potential future product sales revenues. Our expenses also could increase beyond expectations if we decide to or are required
by the FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate.
Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with
launching and commercializing these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market may not be receptive to our product candidates based on our novel therapeutic modality, and we may not generate any future revenue
from the sale or licensing of product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such
as whether the product can be sold at a competitive cost and otherwise accepted in the market. The product candidates that we are developing
are based on new delivery platform therapeutic approaches (there currently is no drug which has FDA approval for indications of radiation
sensitization). Market participants with significant influence over acceptance of new treatments, such as physicians and third-party
payors, may not accept our delivery platform, and we may not be able to convince the medical community and third-party payors to accept
and use, or to provide favorable reimbursement for, any product candidates developed by us. Market acceptance of our product candidates
will depend on, among other factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of our receipt of any marketing and commercialization approvals;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terms
    of any approvals and the countries in which approvals are obtained;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    and efficacy of our product candidates, which are determinations solely within the authority of the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any adverse side effects associated with our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warnings
    contained in any labeling approved by the FDA or other regulatory authority;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
    and ease of administration of our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success
    of our physician education programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of adequate government and third-party payor reimbursement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    of our products, particularly as compared to alternative treatments; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of alternative effective products for indications our product candidates are intended to treat.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will require substantial additional financing in order to obtain marketing approval of our product candidates and commercialize our product
candidates; a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce
or terminate our product development, other operations or commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, substantially all of our resources have been dedicated to the preclinical and clinical development of our HDAC small molecule
delivery platform and our initial product candidate, Ropidoxuridine. Our capital needs to date have been met by contributions from existing
stockholders, as well as through private offerings and IPO of our securities and our SBIR contracts. We believe that we will continue
to expend substantial resources for the foreseeable future on the completion of clinical development and regulatory preparedness of our
product candidates, preparations for a commercial launch of our product candidates, if approved, and development of any other current
or future product candidates we may choose to further develop. These expenditures will include costs associated with research and development,
conducting preclinical studies and clinical trials, obtaining marketing approvals, and, if we are not able to enter into planned collaborations,
manufacturing and supply as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may
arise. Because the outcome of any drug development process is highly uncertain, we cannot reasonably estimate the actual amounts necessary
to complete the development and commercialization of our current product candidates, if approved, or future product candidates, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the proceeds we received in our IPO and subsequent $4.0 million follow on convertible note offering, for which we
received net proceeds of $3.6 million, along with our existing capital resources, will not be sufficient to fund our operations
through March 2025 without additional capital infusion. We anticipate we will need to seek additional funding through
public or private equity or debt financings or other sources, such as through a rights offering, strategic collaborations or grants
and contracts. Such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or
other restrictions that may adversely affect our business. In addition, we may seek additional capital due to favorable market
conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements depend on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, results and costs of researching and developing our current product candidates, future product candidates and conducting
    preclinical and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including
    securing collaborative ventures for completing development of, securing marketing approval for and ultimately marketing, selling
    and distributing our product candidates, if approved or building a corporate infrastructure if we have to undertake these activities
    directly;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and characteristics of any additional product candidates we may develop or acquire;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability or other lawsuits related to our products or commenced against us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs
    and the outcome of such litigation; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and amount of sales of, or royalties on, any future approved products, if any.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us
on a timely basis, we may be required to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate preclinical studies, clinical trials or other development activities for our current product candidates
    or future product candidates, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our research and development activities; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay,
    limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize
    our current or future product candidates.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Raising
additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of public and private equity offerings, debt financings, strategic collaborations and
alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive
covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual
property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional
funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable
rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable
and/or unstable global market and economic conditions, including those caused by the ongoing conflict between the Ukraine and Russia
and the ongoing COVID-19 pandemic, could have serious adverse consequences on our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions as a result of the ongoing
conflict between the Ukraine and Russia and challenges arising from the ongoing COVID-19 pandemic, including severely diminished liquidity
and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in
inflation rates and uncertainty about economic stability. Our results of operations could be adversely affected by the general conditions
of the global economy and the global financial markets. In addition, any such volatility and disruptions may have adverse consequences
on us or the third parties upon whom we rely. For example, in 2008, the global financial crisis caused extreme volatility and disruptions
in the capital and credit markets and the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international
markets. Inflation rates, particularly in the United States, have increased recently to levels not seen in years. Increased inflation
may result in increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit
or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest
rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and
volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks, which may
impact our ability to raise additional capital in the future. The March 2023 failure of Silicon Valley Bank, the pressure such failure
has placed on other mid-sized banks, and its potential near- and long-term effects on the biotechnology industry and its participants
such as our vendors, suppliers and investors, may also adversely affect our operations and stock price. In addition, U.S. and global
markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict
between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length
and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including
significant volatility in commodity prices, credit and capital markets, as well as supply chain disruptions. Various of Russia&#8217;s
actions have led to sanctions and other penalties being levied by the United States, Australia, the European Union, and other countries,
as well as other public and private actors and companies, against Russia and certain other geographic areas, including agreement to remove
certain Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system and restrictions
on imports of Russian oil, liquified natural gas and coal. Additional potential sanctions and penalties have also been proposed and/or
threatened. Russian military actions and the resulting sanctions could disrupt or otherwise adversely impact our operations and the operations
of third parties upon which we rely, as well as the global economy and financial markets, and lead to instability and lack of liquidity
in capital markets, potentially making it more difficult for us to obtain additional funds. Related sanctions, export controls or other
actions that may be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption
of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with
which we conduct business. A severe or prolonged economic downturn, inflationary environment, rising interest rates, or political unrest
could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional
capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in
supply disruption, or cause our customers to delay making payments for our services. The extent and duration of the military action,
sanctions, and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify
the impact of other risks described in this Annual Report on Form 10-K and the documents incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates are in the early stages of development and may fail in development or suffer delays that materially adversely affect
their commercial viability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no products on the market and all of our product candidates are in the early stages of development. Our ability to achieve and sustain
profitability depends on obtaining regulatory approvals, including IRB approval, for and commercializing our product candidates, either
alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or one
of our collaborators must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of
our product candidates, the final determination of which rests solely in the authority of the FDA. Preclinical testing and clinical trials
are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. The start or end of
a clinical study is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial
administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of
a comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient
enrollment or difficulties in retaining trial participants can result in increased costs, longer development times or termination of
a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients
who are suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient
enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial,
the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical
sites and the availability of effective treatments for the relevant disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product
candidates is high due to scientific feasibility, lack of quality and effectiveness, changing standards of medical care and other variables.
The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be obtained
in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects participating in such trials are being
exposed to unacceptable health risks or adverse side effects. We may not have the financial resources to continue development of, or
to enter into collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent
regulatory approval of, or our ability to commercialize, product candidates, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading
    to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
    and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar
    to our product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in submitting an Investigational New Drug application (&#8220;IND&#8221;) or delays or failure in obtaining the necessary approvals
    from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
    imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in enrolling research subjects in clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
    drop-out rates of research subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
    than anticipated clinical trial costs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
    effectiveness of our product candidates during clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
    FDA or other regulatory agency inspection and review of a clinical trial site;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations
    in a timely manner, or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around
    clinical testing generally or with respect to our technology in particular; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
    interpretations of data by the FDA and similar foreign regulatory agencies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
third parties on which we depend to conduct our preclinical studies, or any future clinical trials, do not perform as contractually required,
fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with materially
adverse effects on our business, financial condition, results of operations and prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are relying on third party collaborators to conduct our efficacy clinical trials for Ropidoxuridine and plan to rely on third party clinical
investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor preclinical studies
of our product candidates and will do the same for any clinical trials. Because we plan to largely rely on third parties and do not have
the ability to conduct preclinical studies or clinical trials independently, we have less control over the timing, quality and other
aspects of preclinical studies and clinical trials than we would if we conducted them on our own. These investigators, CROs, and consultants
are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third
parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources
from our programs. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies
or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry
out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or
meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we are responsible
for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan
and protocols for the trial. The FDA requires clinical trials to be conducted in accordance with good clinical practices, including for
conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are
credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on
third parties that we do not control does not relieve us of these responsibilities and requirements. Any such event could have a material
adverse effect on our business, financial condition, results of operations and/or prospects.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
we rely on third party manufacturing and supply partners, our supply of research and development, preclinical and clinical development
materials may become limited or interrupted or may not be of satisfactory quantity or quality.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on third party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development,
preclinical and clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials.
There can be no assurance that our supply of research and development, preclinical and clinical development drugs and other materials
will not be limited, interrupted, restricted in certain geographic regions or of satisfactory quality or continue to be available at
acceptable prices. In particular, any replacement of any drug product formulation manufacturer we may use could require significant effort
and expertise in the event there are a limited number of qualified replacements for a particular product candidate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers
must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards, such as Current Good Manufacturing Practice (or CGMP). In the event that any of our suppliers
or manufacturers fail to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise,
or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the
materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third
party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture
our product candidates may be unique or proprietary to the original manufacturer, and we may have difficulty, or there may be contractual
restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist.
These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have
another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required
to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations
and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product
candidates in a timely manner or within budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to rely on third party manufacturers if we receive regulatory approval for any product candidate. To the extent that
we have existing or future manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.
If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms,
we may not be able to fully develop and commercialize our product candidates. Our or a third party&#8217;s failure to execute on our
manufacturing requirements could adversely affect our business in a number of ways, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to initiate or continue clinical trials of product candidates under development;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of the cooperation of a collaborator;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
    our product candidates to additional inspections by regulatory authorities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
    to cease distribution or to recall batches of our product candidates; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unsuccessful in engaging in strategic transactions which could adversely affect our ability to develop and commercialize product
candidates, impact our cash position, increase our expense and present significant distractions to our management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases and out- or
in- licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter
into additional collaborations, including with major biotechnology or pharmaceutical companies to complete development and marketing
of our product candidates, if approved. The competition for collaborators is intense, and the negotiation process is time-consuming and
complex. Any proposed collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new or existing
collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not
meet expectations or the collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require
us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation
challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including
exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage
a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances
of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs,
write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration
or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or
customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired
business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature
described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material adverse effect
on our business, results of operations, financial condition and prospects. Conversely, any failure to enter into any collaboration or
other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product
candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face competition from entities that have developed or may develop product candidates for our target disease indications, including companies
developing novel treatments and technology platforms based on modalities and technology similar to ours. If these companies develop technologies
or product candidates more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability
to develop and commercialize product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as with universities and other research institutions which are developing new technology.
Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates.
Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments
that enter the market. We believe that a significant number of products are currently under development, and may become commercially
available in the future, for the treatment of conditions for which we may try to develop product candidates.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience
than we have. If we obtain approval for any product candidate, we will face competition based on many different factors, including the
quality and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept
relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of
manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present
superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than
any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense
of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact
our level of expertise and our ability to execute our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success largely depends on the continued service of certain key management and other specialized personnel, including Anatoly Dritschilo,
M.D., our Chief Executive Officer, Mira Jung, Ph.D., our Chief Scientific Officer, Michael Vander Hoek, our Chief Financial Officer and
Vice President Operations and Regulatory, and Peter Dritschilo, our President and Chief Operating Officer. The loss of one or more members
of our management team or other key employees or advisors could delay our research and development programs and materially harm our business,
financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry
make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel
because of the highly technical nature of our product candidates and technologies and the specialized nature of the regulatory approval
process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their
employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members
or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified
scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental
regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions,
government entities and other organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our product candidates advance into Phase II and Phase III clinical trials, we may experience difficulties in managing our growth and
expanding our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development,
regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we
expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to manage
our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting
systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient
or timely manner and may discover deficiencies in existing systems and controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our product candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution
capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable
to commercialize any such future products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved, we plan
to enter into collaborations with third parties to sell, market and distribute our products. In the alternative, we would have to develop
internal sales, marketing and distribution capabilities to commercialize any approved product, which would be expensive and time-consuming,
or, as is more likely, enter into collaborations with third parties to perform these services. If we rely on third parties with sales,
marketing and distribution capabilities to market our products or decide to co-promote products with collaborators, we will need to establish
and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter
into such arrangements on acceptable terms, if, at all. In entering into third-party marketing or distribution arrangements, any revenue
we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate
sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we decide to market our
products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with
technical expertise and supporting distribution, administration and compliance capabilities. If we are not able to commercialize any
product approved in the future, either on our own or through third parties, our business, financial condition, results of operations
and prospects could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization
approvals we may receive and subject us to other penalties that could materially harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we receive marketing and commercialization approval of a product candidate, there can be no assurance we will not be subject to future
or continuing regulatory review, including in relation to adverse patient experiences with the product and clinical results that are
reported after a product is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval.
The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and
to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of
the product from the market. The FDA also has the authority to require a risk evaluation and mitigation strategies (&#8220;REMS&#8221;)
plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. The manufacturer
and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA
and other regulatory agencies, including for continued compliance with CGMP requirements. The discovery of any new or previously unknown
problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer
or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over
compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to
regulatory requirements and continuing regulatory review. If we or our collaborators, manufacturers or service providers fail to comply
with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or
they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA to approve pending applications
or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit
the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material
effect on our business, financial condition, results of operations or prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products,
such claims could result in an FDA investigation of the quality and effectiveness of our products, our manufacturing processes and facilities
or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications
for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may
also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s
time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently
have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior
to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential
liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable
to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a
material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance
with regulatory standards and requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraud, other misconduct or illegal
activity. Misconduct by these parties could include intentional failures to comply with FDA regulations, provide accurate information
to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations,
report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business
arrangements in the healthcare industry are subject to extensive laws and regulations, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. While we make an effort to maintain strict work processes and oversight
of our employees, contractors and consultants, any misconduct could expose us to liability through the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Furthermore, it is not
always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective
in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits
stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant fines or other sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of cyber security measures, our internal computer systems and those of our CROs and other contractors and consultants
are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. Such events could cause interruptions of our operations. For example, the loss of preclinical data or data from any future
clinical trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly
increase our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be
delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, our proprietary
business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers,
clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of
this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable
to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced
any such material security breach to date, any such breach could compromise our network, or the networks of our CROs or other third-party
service providers, and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure
or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information,
regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in our products and our ability to
conduct clinical trials, which could adversely affect our business and reputation and lead to delays in gaining regulatory approvals
for our drugs. Although we maintain business interruption insurance coverage, our insurance might not cover all losses from any future
breaches of our systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
of our information technology systems could significantly disrupt the operation of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business increasingly depends on the use of information technologies, which means that certain key areas such as research and development,
production and sales are to a large extent dependent on our information systems or those of third-party providers. Our ability to execute
our business plan and to comply with regulatory requirements with respect to data control and data integrity, depends, in part, on the
continued and uninterrupted performance of our information technology systems, or IT systems and the IT systems supplied by third-party
service providers. These systems are vulnerable to damage from a variety of sources, including telecommunications or network failures,
malicious human acts and natural disasters. Moreover, despite network security and backup measures, some of our servers are potentially
vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures
we and our third-party service providers have taken to prevent unanticipated problems that could affect our IT systems, sustained or
repeated system failures or problems arising during the upgrade of any of our IT systems that interrupt our ability to generate and maintain
data, and in particular to operate our proprietary technology platform, could adversely affect our ability to operate our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various
flammable and toxic chemicals in our facilities in Gaithersburg, Maryland that are required for our research, development and manufacturing
activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal
of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Gaithersburg facilities
comply with the relevant guidelines of Gaithersburg, the State of Maryland and the Occupational Safety and Health Administration of the
U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the
standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated.
If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental,
health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens
and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs
and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide
adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may
be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and
local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and
substantial fines or penalties if we violate any of these laws or regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
information technology systems could face serious disruptions that could adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection
to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of
our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners
and delays in our research and development work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change
our compensation policies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
methods and policies for pharmaceutical companies, including policies governing revenue recognition, research and development and related
expenses and accounting for stock-based compensation are subject to review, interpretation and guidance from relevant accounting authorities,
including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate or otherwise
change or revise our financial statements, including those contained in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization
of our product candidates may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses
of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods
for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from
infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. As of the date of this
Annual Report, we have filed 6 patent applications with the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) with respect to
various aspects of our HDAC inhibitor small molecule delivery platforms and Ropidoxuridine, our lead product candidate. However, we may
not be able to apply for patents on certain aspects of our product candidates or delivery technologies in a timely fashion or at all.
To date, four U.S. patents and eighteen European patents have been granted. There is no guarantee that any of our pending patent applications
will result in issued or granted patents, that any of our issued, granted or licensed patents will not later be found to be invalid or
unenforceable or that any issued, granted or licensed patents will include claims that are sufficiently broad to cover our product candidates
or delivery technologies or to provide meaningful protection from our competitors. Moreover, the patent position of specialty pharmaceutical
companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary
rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates
are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate
our proprietary rights, it may materially and adversely impact our position in the market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
requirements during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or
patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors
might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent
offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding
patentable subject matter or the scope of claims allowable in pharmaceutical patents. As such, we do not know the degree of future protection
that we will have on our proprietary products and technology. While we will endeavor to try to protect our product candidates with intellectual
property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may decide for business reasons to no longer pursue or to abandon certain intellectual property rights in the U.S. or elsewhere, including
due to non-cooperation of inventors or owners of such intellectual property, prior art, or scope of protection, or for other reasons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, nullification or
derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which
time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted
period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the
allowed or granted claims altogether. In addition, there can be no assurance that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are
    not covered by the claims of the patents that we own or license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to make the inventions covered by each of our issued patents
    and pending patent applications that we own or license;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    or our licensors, collaborators or any future collaborators are the first to file patent applications covering certain aspects of
    our inventions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual
    property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    third party may not challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable and infringed;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may develop additional proprietary technologies that are patentable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents of others will not have an adverse effect on our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then
    use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
intend to license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain,
maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive
position and business prospects may be adversely affected. We may not be able to protect our intellectual property rights throughout
the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions
where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared
to the U.S. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents
or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities
in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce
patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals.
This could make it difficult for us to prevent the infringement of patents or marketing of competing products in violation of our proprietary
rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
cost and divert our efforts and attention from other aspects of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally file a provisional patent application first (a priority filing) at the USPTO. A U.S. utility application and international
application under the Patent Cooperation Treaty (PCT) are usually filed within twelve months after the priority filing. Based on the
PCT filing, national and regional patent applications may be filed in the European Union, Japan, Australia and Canada and other countries.
We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In
addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national
or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused
by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes
of patent protection may be granted on the same product candidate or technology. The laws of some jurisdictions do not protect intellectual
property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting
and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded
from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights
may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing
laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability
of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which
could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with
respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business
and results of operations may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our licensors, or any future collaborators or a strategic partners may become subject to third party claims or litigation alleging
infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to
resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay
or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights at risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors, or any future collaborators or strategic partners may be subject to third-party claims for infringement or misappropriation
of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold
harmless our licensors or collaborator for damages arising from intellectual property infringement by us. If we or our licensors, or
any future collaborators or strategic partners are found to infringe a third-party patent or other intellectual property rights, we could
be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our
licensors, collaborators or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which
may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive,
which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a
required license, we or our collaborator, or any future collaborator, may be unable to effectively market product candidates based on
our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue
sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce
our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating
to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s
attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because
they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant
could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity
or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements,
for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution.
The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to
the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose
at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology.
Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights
also will not protect our technology if competitors design around our protected technology without legally infringing our patents or
other intellectual property rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could
be costly or not available on commercially reasonable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products
or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop
or commercialize products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual
property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially
reasonable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be
able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms
acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented
from or experience substantial delays in marketing our products. If we fail in any such dispute, in addition to being forced to pay damages,
we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We
might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property
rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could
lose intellectual property rights that are necessary for developing and protecting our product candidates and delivery technologies or
we could lose certain rights to grant sublicenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding,
milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach
any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages
and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell
products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our
licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless
of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine
the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant.
The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we aim to
develop and commercialize, if any. Therefore, even if we are able to develop and commercialize products, we may be unable to achieve
or maintain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to seeking patent protection for certain aspects of our product candidates and delivery technologies, we also consider trade
secrets, including confidential and unpatented know-how important to the maintenance of our competitive position. We protect trade secrets
and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have
access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,
consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with
our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us. Despite these efforts,
any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not
be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time- consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain
foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained
or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete
with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would
be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217;
or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we
may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have
inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may
be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to
commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful
in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based
on our trademarks and trade names, we may not be able to effectively compete and our business may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation and Product Approvals</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development,
manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing,
marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are
required to be completed in the U.S. and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other
regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the product
candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval
by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement
of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign
counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from
preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit
or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example,
from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials
and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations,
guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular
product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations
on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority
to require a Risk Evaluation and Mitigation Strategy (REMS) plan as part of an NDA or biologics license application (BLA) or after approval,
which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing
to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use
criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market
for the product and affect reimbursement by third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be
subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and our collaborators are subject to federal, state, and foreign healthcare laws and regulations pertaining to fraud and abuse and patients&#8217;
rights. These laws and regulations include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing
    remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing
    or ordering of an item or service, for which payment may be made under a federal healthcare program such as Medicare or Medicaid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal false claims law, which prohibits, among other things, individuals or entities from knowingly presenting or causing
    to be presented, claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and
    which may apply to us by virtue of statements and representations made to customers or third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal Health Insurance Portability and Accountability Act (HIPAA) and Health Information Technology for Economic and Clinical
    Health (HITECH) Act, which prohibit executing a scheme to defraud healthcare programs, impose requirements relating to the privacy,
    security, and transmission of individually identifiable health information, and require notification to affected individuals and
    regulatory authorities of certain breaches of security of individually identifiable health information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Open Payments regulations under the National Physician Payment Transparency Program have been issued under the Patient Protection
    and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, and will require that manufacturers
    of pharmaceutical and biological drugs covered by Medicare, Medicaid, and Children&#8217;s Health Insurance Programs report all consulting
    fees, travel reimbursements, research grants, and other payments or gifts with values over $10 made to physicians and teaching hospitals;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws applicable to commercial
    insurers and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to
    patient data privacy and security.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties,
monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion
from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid,
any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and
prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected
violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of
our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations
may be costly to us in terms of money, time, and resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our collaborators, manufacturers or service providers fail to comply with applicable federal, state, or foreign laws or regulations,
we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and
could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory inspection findings;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, marketing our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on, or prohibitions against, importation or exportation of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    of review or refusal to approve pending applications or supplements to approved applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from participation in government-funded healthcare programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusion
    from eligibility for the award of government contracts for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of product approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    and criminal penalties and fines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives,
thereby harming our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some countries
require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing
or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing
governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently
in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result,
we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial
launch of the product and negatively impact the revenues we are able to generate from the sale of the product in that country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any products also will depend in part on the extent to which reimbursement for these products and related treatments
will be available from government health administration authorities, private health insurers and other organizations. Even if we succeed
in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any
products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of
development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly,
the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring
that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts
reimbursed for pharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement provided
for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current product candidates will need to be administered under the supervision of a physician on an outpatient basis. Under currently
applicable U.S. law, certain drugs that are not usually self-administered (including injectable drugs) may be eligible for coverage under
the Medicare Part B program if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are incident to a physician&#8217;s services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to
    accepted standards of medical practice; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">they
    have been approved by the FDA and meet other requirements of the statute.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the purposes for which
the drug is approved by the FDA. Moreover, eligibility for coverage does not imply that any drug will be reimbursed in all cases or at
a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if
applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed
for lower- cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary
constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded
and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on
our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the efforts of governments and third-party payors to contain or reduce the cost of healthcare and legislative and regulatory
proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and
biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare
markets have been proposed in recent years, and such efforts have expanded substantially in recent years. These developments have included
prescription drug benefit legislation that was enacted and took effect in January 2006, healthcare reform legislation enacted by certain
states, and Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act
(the &#8220;ACA&#8221;), a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending and enhance remedies against fraud and abuse. The ACA also contains provisions that will affect companies in the pharmaceutical
industry and other healthcare related industries by imposing additional costs and changes to business practices. Provisions affecting
pharmaceutical companies include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandatory
    rebates for drugs sold into the Medicaid program have been increased, and the rebate requirement has been extended to drugs used
    in risk-based Medicaid managed care plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    340B Drug Pricing Program under the Public Health Services Act has been extended to require mandatory discounts for drug products
    sold to certain critical access hospitals, cancer hospitals and other covered entities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly
    referred to as the &#8220;Donut Hole&#8221;; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pharmaceutical
    companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#8217;s market share
    of prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans
    Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion of the total federal
    health program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we cannot predict what healthcare reform initiatives may be adopted in the future. Further federal and state legislative and regulatory
developments are likely, and we expect ongoing initiatives in the U.S. to increase pressure on drug pricing. Such reforms could have
an adverse effect on anticipated revenues from product candidates that we may develop and for which we may obtain regulatory approval
and may affect our overall financial condition and ability to develop product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to obtain services, reimbursement or funding from the federal government may be impacted by possible reductions in federal spending.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
federal government agencies currently face potentially significant spending reductions. Under the Budget Control Act of 2011, the failure
of Congress to enact deficit reduction measures of at least $1.2 trillion for the years 2013 through 2021 triggered automatic cuts to
most federal programs. These cuts would include aggregate reductions to Medicare payments to providers of up to two percent per fiscal
year, starting in 2013. Under the American Taxpayer Relief Act of 2012, which was enacted on January 1, 2013, the imposition of these
automatic cuts was delayed until March 1, 2013. Certain of these automatic cuts have been implemented. The full impact on our business
of these automatic cuts is uncertain. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of
relevant agencies, such as the FDA or the NIH to continue to function at current levels. Amounts allocated to federal grants and contracts
may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research
and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may
develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of our product candidates receives marketing approval and we or others later identify undesirable side effects caused by the product
candidate, our ability to market and derive revenue from the product candidates could be compromised.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that any of our product candidates receive regulatory approval and we or others identify undesirable side effects caused by
one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and
materially and adversely affect our results of operations and business:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval of the product or seize the product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall the product or change the way the product is administered to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
    thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may become less competitive; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with the continued listing requirements of the Nasdaq Stock Market, it could result in our common stock being delisted,
which could adversely affect the market price and liquidity of our securities and could have other adverse effects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2023, we received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)
stating that for the 30 consecutive business day period <span style="background-color: white">between July 20, 2023 to August 30, 2023
</span>the Company&#8217;s common stock had failed to maintain a minimum closing bid price of $1.00 per share, as required for continued
listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;). Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial period of 180 calendar days, <span style="background-color: white">or
until February 27, 2024</span> (the &#8220;Compliance Period&#8221;), to regain compliance with the Minimum Bid Price Requirement. To
regain compliance, the closing bid price of the Company&#8217;s common stock must meet or exceed $1.00 per share for a minimum of 10
consecutive trading days, unless such period is extended by Nasdaq. As the Company had not regained compliance with the Minimum Bid Price
Requirement by <span style="background-color: white">February 27, 2024</span>, the Company requested and was granted an additional 180-day
period to regain compliance (the &#8220;Additional Compliance Period&#8221;). To qualify, the Company was required to meet the continued
listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with
the exception of the Minimum Bid Price Requirement, and we would need to provide written notice of our intention to cure the bid price
deficiency during the second compliance period, by effecting a reverse stock split, if necessary. Nasdaq staff determined that the Company
is eligible for an additional 180 calendar day period, or until August 26, 2024, to regain compliance (1 Listing Rule 5810(c)(3)(A)).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company believes that it can either regain compliance organically through market forces or, if necessary, by effectuating a reverse stock
split prior to the end of the Additional Compliance Period. However, if the Company cannot regain compliance with the Minimum Bid Price
Requirement during the Additional Compliance Period, Nasdaq will provide the Company with notice that our common stock will be subject
to delisting. At that time, the Company may appeal Nasdaq&#8217;s delisting determination to a Nasdaq Hearings Panel. While Nasdaq&#8217;s
notice to the Company of noncompliance has no immediate effect on the listing of our common stock and our common stock will continue
to be listed on The Nasdaq Capital Market under the symbol &#8220;SHPH,&#8221; there can be no assurance that we will regain compliance
with the Minimum Bid Price Requirement or maintain compliance with any of the other Nasdaq continued listing requirements. We will continue
to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the
Minimum Bid Price Requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
financial covenants of the convertible note could result in default and could have a material adverse effect on our liquidity. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our ability to settle debt on the convertible note through cash or issuing shares of common stock, we may be required to repay the convertible
note and interest thereon in cash if we do not meet certain equity conditions, including but not limited to volume or price failure on
each trading day during the equity conditions measuring period, authorized shares failure, or occurrence of default as defined in the
note. Events that could trigger a default include failure to pay the note holder any amount, bankruptcy, insolvency, or violation of
the Cash Burn Covenant. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>While our Company&#8217;s management is working to improve our internal
controls and procedures, at present management has determined that our
internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to
misinformation being disseminated to the public.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f)
under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), internal control over financial reporting is
a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board
of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those
policies and procedures that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain
    to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
    generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with
    authorizations of management and/or directors of the Company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s
    assets that could have a material effect on the financial statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to include a report of management on the effectiveness of our internal control over financial reporting. We expect to incur
additional expenses and diversion of management&#8217;s time as a result of performing the system and process evaluation, testing and
remediation required in order to comply with the management certification requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently, we
do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging
outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies
that we may not be able to timely remediate. If we cannot provide reliable financial reports or prevent fraud, our business and operating
results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock,
if a market ever develops, could drop significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Jobs Act has reduced the information that we are required to disclose.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Jobs Act, the information that we will be required to disclose has been reduced in a number of ways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company that had gross revenues of less than $1.0 billion during the Company&#8217;s last fiscal year, the Company is an &#8220;emerging
growth company,&#8221; as defined in the Jobs Act (an &#8220;EGC&#8221;). We will retain that status until the earliest of (a) the last
day of the fiscal year which we have total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth
in the Jobs Act) or more; (b) the last day of the fiscal year of following the fifth anniversary of the date of the first sale of the
common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;);
(c) the date on which we have, during the previous three year period, issued more than $1,000,000,000 in non-convertible debt; or (d)
the date on which we are deemed to be a &#8220;large accelerated filer,&#8221; as defined in Rule 12b-2 under the Exchange Act or any
successor thereto. As an EGC, the Company is relieved from the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company is excluded from Section 404(b) of Sarbanes-Oxley Act (&#8220;Sarbanes-Oxley&#8221;), which otherwise would have required
    the Company&#8217;s auditors to attest to and report on the Company&#8217;s internal control over financial reporting. The JOBS Act
    also amended Section 103(a)(3) of Sarbanes-Oxley to provide that (i) any new rules adopted by the PCAOB requiring mandatory audit
    firm rotation or changes to the auditor&#8217;s report to include auditor discussion and analysis (in the event the PCAOB adopts
    an auditor rotation requirement) will not apply to an audit of an EGC; and (ii) any other future rules adopted by the PCAOB will
    not apply to the Company&#8217;s audits unless the SEC determines otherwise.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Jobs Act amended Section 7(a) of the Securities Act to provide that the Company need not present more than two years of audited financial
    statements in an initial public offering registration statement and in any other registration statement, need not present selected
    financial data pursuant to Item 301 of Regulation S-K for any period prior to the earliest audited period presented in connection
    with such initial public offering. In addition, the Company is not required to comply with any new or revised financial accounting
    standard until such date as a private company (i.e., a company that is not an &#8220;issuer&#8221; as defined by Section 2(a) of
    Sarbanes-Oxley) is required to comply with such new or revised accounting standard. Corresponding changes have been made to the Exchange
    Act, which relates to periodic reporting requirements, which would be applicable if the Company were required to comply with them.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    long as we are an EGC, we may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative disclosure
    regarding executive compensation, by disclosing the more limited information required of a &#8220;smaller reporting company.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Jobs Act will also exempt us from the following additional compensation-related disclosure provisions that were imposed on U.S. public
    companies pursuant to the Dodd-Frank Act: (i) the advisory vote on executive compensation required by Section 14A(a) of the Exchange
    Act; (ii) the requirements of Section 14A(b) of the Exchange Act relating to stockholders advisory votes on &#8220;golden parachute&#8221;
    compensation; (iii) the requirements of Section 14(i) of the Exchange Act as to disclosure relating to the relationship between executive
    compensation and our financial performance; and (iv) the requirement of Section 953(b)(1) of the Dodd-Frank Act, which requires disclosure
    as to the relationship between the compensation of our chief executive officer and median employee pay.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may be volatile, and purchasers of our common stock could incur substantial losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
commencement of trading on Nasdaq Stock Market LLC or Nasdaq, on August 29, 2022, our stock price has been extremely volatile, having
traded as high as $126.26 and as low as $0.42. As a result of this volatility, investors may not be able to sell their common stock at
or above the price when they purchased our common stock. The market price for our common stock may be influenced by many factors, including
the other risks described in this section of this Annual Report entitled &#8220;Risk Factors&#8221; and the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of preclinical and clinical studies of our product candidates, or those of our competitors, our existing collaborator or any future
    collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introductions
    and announcements of new products by us, our commercialization partners, or our competitors, and the timing of these introductions
    or announcements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization
    partners;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent
    protection for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions in the pharmaceutical and biotechnology sectors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>






























































<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other
    comparable companies or our industry generally;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to
    the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in the valuation of companies perceived by investors to be comparable to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcement
    and expectation of additional financing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of our common stock by us or our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    concentrated ownership of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">terrorist
    acts, acts of war or periods of widespread civil unrest;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters and other calamities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, industry and market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets in general, and the markets for pharmaceutical stocks, in particular, have experienced extreme volatility
that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm
the market price of our common stock, regardless of our operating performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
future issuance of equity or of debt securities that are convertible into common stock will dilute our share capital.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements.
To the extent that additional capital is raised through the issuance of shares or other securities convertible into shares of our common
stock, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception that such
sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future
offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the
availability of common stock for future sales will have on the trading price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to maintain applicable listing requirements, Nasdaq may delist our common stock from trading, in which case the liquidity and
market price of our common stock could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will be able to meet the continued listing standards of Nasdaq in the future. If we fail to comply with the
applicable listing standards and Nasdaq delists our common stock, we and our stockholders could face significant material adverse consequences,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited availability of market quotations for shares of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    liquidity for our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that our common stock is &#8220;penny stock,&#8221; which would require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for shares of
    our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of news about us and analyst coverage of us; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the
sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because our common stock is listed on Nasdaq,
such securities will be deemed covered securities. Although the states will be preempted from regulating the sale of our securities,
the federal statute does allow states to investigate companies if there is a suspicion of fraud and, if there is a finding of fraudulent
activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed
on Nasdaq, our securities would not be covered securities and we would be subject to regulations in each state in which we offer our
securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
our management has broad discretion over the use of the net proceeds we received from our IPO and follow-on offering, you may not agree
with how we use them and the proceeds may not be invested successfully.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds to us from our IPO and follow-on offering to fund preclinical and clinical trials of product candidates,
Ropidoxuridine and new formulations of Ropidoxuridine with Tipiracil, O-18 containing molecules for proton radiation sensitization, continued
HDAC technology platform development, working capital and general corporate purposes, including the costs of operating as a public company,
as well as potential acquisition or in-licensing activities. Therefore, our management has broad discretion as to the use of the IPO
proceeds and proceeds from our subsequent private placement. Accordingly, you will be relying on the judgment of our management with
regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether
the proceeds are being used appropriately. It is possible that the proceeds will be invested in a way that does not yield a favorable,
or any, return for our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion
regarding our stock, our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about
us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few
securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted. In the event we
obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding
us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet
the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to
publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading
volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
board of directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to
holders of our common stock and such issuance could potentially adversely affect stockholders&#8217; voting power and perpetuate their
control over us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, allows us to issue shares of preferred stock without any vote or further action by
our stockholders. Our board of directors has the authority to fix and determine the relative rights and preferences of any preferred
stock. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the
preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders
of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of shares of our common
stock. These rights and preferences could negatively affect the holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
ability of our executive officers and directors, who are our principal stockholders, to control our business may limit or eliminate the
ability of minority stockholders to influence corporate affairs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers and directors, who are our principal stockholders, own approximately 39.6% of our issued and outstanding common stock.
Accordingly, they may be able to effectively control the election of directors, as well as all other matters requiring stockholder approval.
The interests of our principal stockholders may differ from the interests of other stockholders with respect to the issuance of shares,
business transactions with or sales to other companies, selection of other directors and other business decisions. The minority stockholders
have no way of overriding decisions made by our principal stockholders. This level of control may also have an adverse impact on the
market value of our shares because our principal stockholders may institute or undertake transactions, policies or programs that result
in losses and may not take any steps to increase our visibility in the financial community and/or may sell sufficient numbers of shares
to significantly decrease our price per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for indemnification of officers and directors at the expense
of the Company and limit their liability that may result in a major cost to us and hurt the interests of our stockholders because corporate
resources may be expended for the benefit of officers and/or directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, provide for the indemnification of our officers and directors. We have
been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public
policy as expressed in the Securities Act and is therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Incorporation, as amended to date, provides that disputes must be resolved in the Court of Chancery of the State of Delaware,
except for cases brought under the Securities Act or Exchange Act. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation, as amended to date, provides that the Court of Chancery in the State of Delaware will be the exclusive
forum for dispute resolution for certain enumerated actions, excluding any actions brought under the Securities Act or Exchange Act,
or unless the Company consents in writing to an alternative jurisdiction. This exclusive forum selection clause may cause inconvenience
of our stockholders or other stakeholders, should they need to bring suit against the Company for an action other than one arising under
the Securities Act or Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to pay cash dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable
future. The future payment of dividends on our common stock directly depends upon our future earnings, capital requirements, financial
requirements and other factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common
stock, return on your investment, if any, will depend solely on an increase, if any, in the market value of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
in our amended and restated certificate of incorporation, as amended, and bylaws, as amended, as well as Delaware law, might discourage,
delay or prevent a change of control of our company or changes in our management and, therefore, depress the market price of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Incorporation and Bylaws, each as amended to date, and bylaws contain provisions that could depress the market price of
our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the
stockholders of our company may deem advantageous. These provisions, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit
    the board of directors to establish the number of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that directors may only be removed &#8220;for cause&#8221; and only with the approval of 66 2/3 percent of our stockholders;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    super-majority voting to amend some provisions in our Certificate of Incorporation and Bylaws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights
    plan (also known as a &#8220;poison pill&#8221;);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eliminate
    the ability of our stockholders to call special meetings of stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibit
    stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that the board of directors is expressly authorized to make, alter or repeal our bylaws; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon
    by stockholders at annual stockholder meetings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company. Section
203 imposes certain restrictions on merger, business combinations and other transactions between us and holders of 15% or more of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_004"></span>Item
1B. Unresolved Staff Comments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_005"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risk
Management and Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established policies and processes for assessing, identifying, and managing material risks from cybersecurity threats, and have integrated
these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats,
including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on
the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conduct risk assessments at least annually to identify cybersecurity threats. These risk assessments include identifying reasonably
foreseeable potential internal and external risks, the likelihood of occurrence and any potential damage that could result from such
risks, and the sufficiency of existing policies, procedures, systems, controls and other safeguards we have put in place to manage
such risks. Our risk management process also encompasses cybersecurity risks associated with the use of our major third-party
vendors and service providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
these risk assessments, we design, implement, and maintain reasonable safeguards to minimize the identified risks; reasonably
address any identified gaps in existing safeguards; update existing safeguards as necessary; and monitor the effectiveness of our
safeguards. We believe we have allocated adequate resources related to our cybersecurity risk management processes and have
designated our Chief Financial Officer with the responsibility of managing the cybersecurity risk assessment and mitigation
process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of our overall risk management program, we provide required training to employees in high risk areas on cybersecurity and have
distributed standard operating procedures to all employees subsequent to this filing. For additional information regarding whether any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to
materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item
1A, &#8220;Risk Factors,&#8221; in this annual report on Form 10-K , including the risk factors entitled <i>&#8220;Our internal
computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result
in a material disruption of our product development programs,&#8221; &#8220;Our proprietary information, or that of our customers,
suppliers and business partners, may be lost or we may suffer security breaches,&#8221; and &#8220;Failure of our information
technology systems could significantly disrupt the operation of our business.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Governance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">One of the key functions of our Board of Directors is informed oversight of our risk management process, including
risks arising from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure,
and our executive officers are responsible for the day-to-day management of the material risks we face. Our Board of Directors administers
its cybersecurity risk oversight function directly as a whole, and we recently established a Cybersecurity Committee of the Board of
Directors (the &#8220;Cybersecurity Committee&#8221;) to further enhance our cybersecurity oversight. Members of the Cybersecurity Committee
are appointed by, and serve at the discretion of, the Board. The Cybersecurity Committee consists of two Board members, both of whom
are independent.<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Financial Officer is primarily responsible for assessing and managing material risks from cybersecurity threats on a day to day basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_006"></span>Item
2. Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
corporate headquarters are presently located in 401 Professional Drive,
Suite 260, Gaithersburg, Maryland 20879 where we lease approximately 2,109 square feet of office and laboratory space (together, the &#8220;Laboratory
Space&#8221;), which includes shared access to office space and reception services. Our research and development activities are performed
in the Laboratory Space. We entered into a lease for the new Laboratory Space on June 1, 2023, and the lease has an initial term of 5.25
years and an option to extend for an additional three years, with a monthly rent of $7,206 per month, subject to increase at the rate
of 3% per year. All of such space is leased from a non-affiliated third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the above facilities are adequate for our current needs and have sufficient laboratory space to house additional scientists
as we grow.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_007"></span>Item
3. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no legal proceedings pending or threatened against us. We are not presently party to any pending or other threatened legal
proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results,
although from time to time, we may become involved in legal proceedings in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_008"></span>Item
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_009"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_010"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock commenced trading on the Nasdaq Capital Market, under the symbol &#8220;SHPH&#8221; on August 29, 2022. Prior to that time,
our common stock was not traded on any exchange or quoted on any over the counter market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2024, we had 55 holders of record of our common stock and 16,794,893 shares of common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid any dividends on our common stock since inception and we currently expect that, in the foreseeable future, all earnings
(if any) will be retained for the development of our business and no dividends will be declared or paid on our common stock. Any future
dividends on our common stock will be subject to the discretion of our board of directors and will depend upon, among other things, our
earnings (if any), operating results, financial condition and capital requirements, general business conditions and other pertinent facts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has designated and authorized the issuance of up to 10,000 shares of Series A Convertible preferred stock, par value
$0.00001 per share (the &#8220;Series A Convertible Preferred Stock&#8221;), of which there were 1,212.5 shares issued, all of which
were converted into 336,810 shares of or common stock and 336,810 warrants to purchase common stock upon closing of our IPO on September
2, 2022. The Series A Convertible Preferred Stock had a stated value of $1,000 per share, was entitled to receive a dividend at the rate
of 8.5% per annum, which dividend was cumulative and was payable at our option in shares of common stock or cash upon the date of conversion
or redemption, as so determined by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, the Company accrued $71,009 for the 8.5% cumulative dividends on the Series A Convertible Preferred
Stock and $103,062 for the year ended December 31, 2021, for a total of $402,068 and $331,059 respectively, all of which was paid in
the form of 100,517 shares of our common stock following completion of our IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past three years, we effected the following transactions in reliance upon exemptions from registration under the Securities Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, in conjunction with entering into two loan agreements for a total of $500,000, which were repayable at the time
of our IPO, we issued warrants to purchase a total of 500,000 shares of our common stock, exercisable at $1.00 per share. Such
warrants were sold to two accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities Act.
Boustead Securities LLC acted as placement agent but waived its cash compensation related to such offering and, to date, has
received no warrant compensation related to the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2022 and March 11, 2022, the Company sold to certain accredited investors $365,000 and $224,985, respectively, in 6% convertible
notes (the &#8220;Notes&#8221;), which bore 6% interest, were repayable three years from the date of issuance, and converted automatically
into shares of common stock or, in the event that units were sold in the offering, units, at a conversion price of $4.00 per unit upon
closing of our IPO. Such notes were sold to accredited investors pursuant to an exemption from registration under Rule 506(b) of the
Securities Act. Boustead Securities LLC acted as placement agent and received compensation of (i) $36,500 in cash and warrants to purchase
10% of the total number of shares issuable upon conversion of the Convertible Notes, exercisable at the conversion price of the Convertible
Notes for the February offering and (ii) $22,750 in cash and warrants to purchase 10% of the total number of shares issuable upon conversion
of the Convertible Notes, exercisable at the conversion price of the Convertible Notes for the March offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
March 30, 2022, the Company issued a total of 1,678 shares (839 shares on a post-reverse split basis) of common stock (the &#8220;Issuance&#8221;)
to some 23 existing shareholders in satisfaction of certain interest that had accrued as the result of an inaccurate conversion of convertible
notes in our 2018 share exchange. The Issuance satisfied in full all interest owed or otherwise accruing as the result of the inaccurate
conversion. Such issuance was made in accordance with Rule 506(b) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, in conjunction with entering into three loan agreements for a total of $125,000, which were repayable following consummation
of our IPO, we issued warrants to purchase a total of 50,000 shares of our common stock, exercisable at $2.50 per share. Such warrants
were sold to three accredited investors pursuant to an exemption from registration under Rule 506(b) of the Securities Act. Boustead
Securities LLC acted as placement agent and received warrants to purchase 5,000 shares of common stock exercisable at $2.50 per share,
equal to 10% of the value of the note offering, and $12,500 in cash compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above disclosures do not include 678,180 shares granted pursuant to the Shuttle Pharmaceuticals
Holdings, Inc. 2018 Equity Incentive Plan, which were issued to certain employees, directors and consultants, and vest on a periodic
basis in accordance with the grant agreements between such individuals and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_011"></span>Item
6. [Reserved]</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_012"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following Management&#8217;s Discussion and Analysis should be read in conjunction with our financial statements and the related notes
thereto included elsewhere in this Annual Report. The Management&#8217;s Discussion and Analysis contains forward-looking statements
that involve risks and uncertainties, such as statements of our plans, objectives, expectations, and intentions. Any statements that
are not statements of historical fact are forward-looking statements. When used, the words &#8220;believe,&#8221; &#8220;plan,&#8221;
&#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; and the like, and/or
future-tense or conditional constructions (&#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; etc.), or
similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and
uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements
in this Annual Report. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking
statements as a result of several factors including, but not limited to, those noted under &#8220;Risk Factors&#8221; in this Annual
Report. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this
Annual Report, except as required by U.S. federal securities laws.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founded
by Georgetown University Medical School faculty members, Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage
pharmaceutical company leveraging our proprietary technology to develop novel therapies that are designed to cure cancer. Originally
formed as Shuttle Pharmaceuticals, LLC in 2012, our goal is to extend the benefits of cancer treatments by leveraging insights into cancer
therapy with surgery, radiation therapy, chemotherapy and immunotherapy. While there are several therapies being developed with the goal
of curing cancer, one of the most effective and proven approaches to this is radiation therapy (RT). We are developing a pipeline of
products designed to address the limitations of the current standard of cancer therapies. We believe that our product candidates will
enable us to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations
to date have focused on continuing our research and development efforts to advance Ropidoxuridine clinical testing and improved drug
formulation, to advance HDAC6 inhibitor (SP-2-225) preclinical development and explore new SBIR contract work on predictive biomarkers
of radiation response, as well as prostate cell lines for health disparities research. We received Small Business Innovation Research
(&#8220;SBIR&#8221;) contract funding from the National Institutes of Health (&#8220;NIH&#8221;) for the aforementioned projects. The
clinical development of Ropidoxuridine has shown drug bioavailability and a maximum tolerated dose has been established for use in Phase
II clinical trials. TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), with whom we have contracted for process research, development
and cGMP compliant manufacture of IPdR, has successfully completed the manufacturing campaign for the active pharmaceutical ingredient
(API) of Ropidoxuridine for use in the Company&#8217;s upcoming Phase II clinical trial in brain cancer patients undergoing radiation
therapy. Shuttle also worked with University of Iowa Pharmaceuticals to develop the formulation, produce the capsules, and which have
been shipped to Contract Research Organization (CRO) Theradex Oncology for distribution to clinical trial sites. Both activities have
now been completed. In addition, Shuttle received approval from the FDA to begin the clinical trial. The FDA made recommendations to
expand the clinical trial and the company agreed with the recommendation. With this change incorporated into the revised protocol, the
Company believes it remains on track to commence its Phase II clinical study in the second quarter of 2024. The radiation biomarker project
and the health disparities project have been completed and the company is following up with plans for clinical validation and potential
commercialization. Changes in operational, administrative, legal and professional expenses related to our operations are set forth in
more detail in the discussion below.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the year ended December 31, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the results of our operations:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Research and development, net of contract expense reimbursements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">3,517,093</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">1,148,712</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">2,368,381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">206</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,046,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">538,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">508,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,328,435</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">866,770</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">461,665</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">53</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating expenses and loss of operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,892,382</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,554,278</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,338,104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">131</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,825</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(52,010</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,484,193</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(917,879</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,566,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,245</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,245</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,216,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,122,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,257</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,568</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss on settlement of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(477,221</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(477,221</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(328,687</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,007</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(73,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(100</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(700,341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(474,170</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(226,171</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,592,723</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,028,448</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,564,275</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development, net of contract expense reimbursements.</i> Total research and development (&#8220;R&amp;D&#8221;) expense was $3.5
million for the year ended December 31, 2023, as compared to $1.1 million for the year ended December 31, 2022, which included R&amp;D
expense reimbursements of $0 and $211,455, respectively. The increase of $2.4 million, or 206%, is primarily related to the Company increasing
R&amp;D spending as a result of having received funding from the Company&#8217;s initial public offering in the third quarter of fiscal
2022 and, the convertible note issued during the period ended March 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
compensation related expenses were $1.5 million in the year ended December 31, 2023 as compared to $0.8 million in the year ended
December 31, 2022. Compensation related expenses, excluding reimbursements, for the year ended December 31, 2023 was 43% as a
percent of R&amp;D expense, representing a decrease from the 59% of total R&amp;D incurred in the year ended December 31, 2022. Subcontract work, excluding reimbursements, made up 52% of total R&amp;D expenses in the year ended December 31,
2023 and 35% of total R&amp;D expenses during the year ended December 31, 2022.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses. </i>General and Administrative expenses in the year ended December 31, 2023 increased by $0.5 million, or
94%, from $0.5 million in the year ended December 31, 2022 to $1.0 million in the year ended December 31, 2023. The increase in general
and administrative expenses was primarily due to increases in insurance expenses of $0.1 million, compensation of $0.2 million and advertising
costs of $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Legal
and Professional Expenses</i>. During the year ended December 31, 2023, legal and professional expenses increased by $0.5 million or
53%. The increase in legal and professional fees was primarily due to increases in our expenses related to our public filing requirements,
contracts and financing related work.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Income (expense)</i> Other expense was $0.7 million for the year ended December 31, 2023, which mainly consisted of $2.5 million in
interest expense on convertible notes, loss on settlement of convertible debt of $0.5 million, and offset by a gain on change in
fair value of derivative liabilities of $2.2 million. Other expense was $0.5 million for the year ended December 31, 2022, which
mainly consisted of $0.9 million in interest expense on convertible notes, offset by a gain on change in warrant liability of $94.0
thousand and a $0.3 million gain on settlement of accounts payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and had a net loss of
$6.6 million and no revenues during the year ended December 31, 2023 and working capital of approximately $4.6 million as of December
31, 2023. In addition, the convertible notes payable outstanding at December 31, 2023 includes covenants and certain cash payment requirements.
These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date
that these financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering of common stock, generating net proceeds of $10.0 million. Additionally,
in January 2023, the Company entered into a securities purchase agreement with an institutional investor through which the Company sold
a convertible note with a principal value of $4.3 million, along with a four-year warrant to purchase 1,018,079 shares of common stock,
exercisable at $2.35 per share, providing the Company with $3.6 million in net proceeds. To date, the warrant has not yet been exercised.
However, the Company&#8217;s existing cash resources, marketable securities and the cash received from the equity offering and convertible
note are not expected to provide sufficient funds to carry out the Company&#8217;s operations and clinical trials through the next twelve
months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital raise has supported operations leading up to the manufacture of drug product and FDA approval of the IND for the Phase II clinical
trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the company agreed to an expansion of the clinical
trial, necessitating additional capital to complete the trial. Management intends to initiate a rights offering for $4.5 million and has submitted
SBIR applications for non-dilutive NIH funding for pre-clinical project. The ability of the Company to continue as a going concern is
dependent upon our ability to successfully conduct clinical trials, bring a drug candidate to commercialization to generate revenues,
and to raise additional equity or debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements do not include any adjustments to reflect the future effects on the recoverability and classification
of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheet Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Current assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,593,005</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,578,351</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,985,346</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">(35</td><td style="width: 1%; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,042,237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">975,676</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,561</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Working capital</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,550,768</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,602,675</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,051,907</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(40</td><td style="padding-bottom: 2.5pt; text-align: left">%)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, total current assets were $5.6 million and total current liabilities were $1.0 million, resulting in working
capital of $4.6 million. As of December 31, 2022, total current assets were $8.6 million and total current liabilities were $1.0
million, resulting in a working capital of $7.6 million. The Company&#8217;s current assets as of December 31, 2023 primarily
resulted from $3.6 million in net cash received from the issuance of a convertible note payable, offset by $0.8 million repaid for
related party notes ($685,473 in principal and $98,135 of accrued interest), and $0.4 million repaid in cash for a convertible note
($334,444 in principal and $59,846 in accrued interest). In addition, we continued progress on our R&amp;D programs during the year
ended December 31, 2023 that resulted in increased cash expenditures. The increase in current liabilities is primarily due to the
current portion of the $4.3 million convertible note which is $0.7 million of convertible note payable and accrued interest, an
increase in accounts payable of $0.2 million, offset by the reduction of $0.8 million in related party notes payable and accrued
interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: left">Cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,581,147</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,710,454</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(2,870,693</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">106</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,829,723</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,829,723</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,570,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,622,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,052,825</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76</td><td style="text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash on hand</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,576,416</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,417,203</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(5,840,787</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(69</td><td style="text-align: left">%)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated positive cash flows from operating activities. For the year ended December 31, 2023, net cash flows used
in operating activities was $5.6 million, primarily consisting of a net loss of $6.6 million, increased by a gain on change in derivative
liabilities of $2.2 million, offset by amortization of debt discount of $2.1 million, loss on settlement of convertible debt of $0.5
million, accrued interest settled with common stock of $0.3 million, stock-based compensation of $0.2 million and further reduced by
a net change in operating assets and liabilities of $0.2 million. For the year ended December 31, 2022, net cash flows used in operating
activities was $2.7 million, primarily consisting of a net loss of $3.0 million increased by a gain on change in derivative liability
of $94.0 thousand, a gain on settlement of accounts payable of $0.3 million, a net change in in operating assets and liabilities of $0.5
million, amortization of debt discount of $0.9 million, and stock-based
compensation of $0.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, we invested in trading marketable securities for $2,998,572 and received $187,895 in proceeds from
disposition of marketable securities and purchased $19,046 of equipment. For the year ended December 31, 2022, we had no investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows from Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2023, we received net proceeds of $3,590,000 from the sale and issuance of convertible notes payable and
warrants and repaid $334,444 in convertible notes and $685,473 in related party notes payable. For the year ended December 31, 2022,
we received $10,022,193 from the issuance of shares of common stock and exercise of warrants and $600,715 from the issuance of
convertible notes and warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, we entered into the SPA with the Investor, pursuant to which the Company sold to the Investor a $4.3 million convertible note (the &#8220;Convertible Note&#8221;) and warrant
(the &#8220;Warrant&#8221;) to purchase 1,018,079 shares of common stock of the Company, in exchange for gross proceeds of $4.0 million Investment
Amount. The Convertible Note amortizes on a monthly basis and the Company can make such monthly amortization payments in cash or, subject
to certain equity conditions, in registered shares of common stock or a combination thereof. For equity repayment, the Convertible Note
is convertible into shares of common stock at price per share equal to the lower of (i) $2.35 (ii) 90% of the three lowest daily VWAPs
of the 15 trading days prior to the payment date or (iii) 90% of the VWAP of the trading day prior to payment date. The Convertible Note
is repayable over 26 months and bears interest at the rate of 5% per annum. The Warrant is exercisable for four years from the date of
closing and is exercisable at $2.35 per share. In the event the Investor exercises the Warrant in full, such exercise would result in
additional gross proceeds to the Company of approximately $2.4 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10, 2023, we entered into the Amendment Agreement to the SPA. Under the Amendment Agreement, the Company and the Investor amended
the transaction documents as follows: (i) amended and restated Section 2 of the Warrant so as to remove a provision that would have potentially
required an adjustment to the number of warrant shares exercisable under the Warrant, (ii) stipulated that the Company would obtain majority
shareholder approval to issue up to an additional $10 million Subsequent Notes and Subsequent Warrants equal to 42.5% of the outstanding
principal value of the Subsequent Notes, which Subsequent Note and Subsequent Warrant would be sold to the Investor on substantially
the same terms as the existing Convertible Note and Warrant (each as amended by the Amendment Agreement) and upon conversion and/or exercise
would cause the potential issuance of in excess of 19.9% of the Company&#8217;s issued and outstanding stock, (iii) that, upon obtaining
majority stockholder approval, the Company would file a Schedule 14C related to such potential issuance of the shares of common stock
related to the potential sale of the Subsequent Notes and Subsequent Warrants to the Investor within 30 calendar days of entry into the
Amendment Agreement, and (iv) stipulated that the Investor would release $1,500,000 in cash collateral to the Company, with $1,000,000
to be released to the Company immediately upon singing of the Amendment Agreement and $500,000 to be released upon the Company&#8217;s
filing of the Schedule 14C. The Company obtained majority stockholder consent to the potential sale of the Subsequent Notes and Subsequent
Warrants to the Investor in advance of entry into the Amendment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2023, we entered into the Amendment to the Amendment Agreement dated May 11, 2023, for purposes of amending the terms of the
SPA. Under the Amendment to the Amendment Agreement, the Company and the Investor agreed as follows: (i) that Section 15(q) to the Convertible
Note, which required the Company to hold the Cash Collateral in a Controlled Account Agreement (as defined in the Convertible Note),
would no longer be applicable, (ii) that the Investor would stipulate the release to the Company of the remaining Cash Collateral totaling
$2,924,000 (thus releasing the full amount of the Cash Collateral to the Company), and (iii) that, should the Investor exercise its option
to purchase the Subsequent Notes and Subsequent Warrants, that such Subsequent Notes would omit Section 15(q) and that the Company would
not be required to maintain any controlled accounts or otherwise be subject to any controlled account agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared
in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). The preparation of these financial
statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting
periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting
policies are described in more detail in the notes to our financial statements included elsewhere in this registration statement, we
believe that the following accounting policies are critical to understanding our historical and future performance, as these policies
relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most critical accounting policies and estimates relate to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development Expenses</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value of Derivative Financial Instruments</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Measurement of Equity-Based Warrants</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are expensed as incurred and, prior to our initial public offering in September 2022, have historically been
offset by contract receivable payments from an NIH SBIR contract that has supported our scientific research. This is stated in the consolidated
financial statements as research and development, net of contract expense reimbursements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
Value of Financial Instruments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded
at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements
of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities are
evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our derivative financial instruments classified as a liability, the Company uses a Monte Carlo valuation model to value the
derivative instruments at inception and on subsequent valuation dates. The model requires the use of simulations that are weighted
based on significant unobservable inputs including the average volatility of a population set and probabilities assigned. Each
simulation is based on the range of inputs in a scenario with the mean of the output on each simulation calculated as an average.
The Monte Carlo simulation uses an implied VWAP for valuation. The implied VWAP was backsolved by setting the summation of the parts
(e.g., derivatives and debt without derivatives) equal to the cash proceeds, and is updated each period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of Monte Carlo valuation models require key inputs, some of which are based on estimates and judgements by management and/or external
consultants. Any change to these key inputs could produce significantly higher or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial
Measurement of Equity-Based Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as equity, the derivative instrument is initially recorded at
its fair value and recorded to additional paid in capital. The classification of derivative instruments, including whether such instruments
should be recorded as equity, is evaluated at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our derivative financial instruments classified as equity, the Company used a Black Scholes valuation model, to calculate the fair value
on issuance date, without revaluation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of Black Scholes valuation model requires the input of highly subjective assumptions, including the expected price volatility, that
is based on an analysis of the historical volatility of the common stock of a group of comparable entities. Any change to
these inputs could produce significantly higher or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_013"></span>Item
7A. Quantitative and Qualitative Disclosures About Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &#8220;smaller reporting company,&#8221; this item is not required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_014"></span>Item
8. Financial Statements and Supplementary Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index
to Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_001">Report
of Independent Registered Public Accounting Firm &#8211; FORVIS,
LLP (PCAOB ID <span id="xdx_90A_edei--AuditorFirmId_c20230101__20231231_zvB4dV7JbcXh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000046" name="dei:AuditorFirmId">686</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#c_001">Report
of Independent Registered Public Accounting Firm &#8211; BF Borgers CPA PC (PCAOB ID 5041)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_002">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_003">Consolidated Statements of Operations and Comprehensive Income (Loss) for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_004">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_005">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ps_006">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders, Board of Directors, and Audit Committee of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Consolidated Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheet of Shuttle Pharmaceuticals Holdings, Inc. and subsidiaries (the &#8220;Company&#8221;)
as of December 31, 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for
the year ended December 31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31,
2023, and the results of its operations and its cash flows for the year ended December&#160;31,&#160;2023, in conformity with accounting
principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note&#160;1
to the financial statements, the Company has suffered recurring losses and negative cash flows from operations since inception. These
conditions, along with other matters as set forth in Note 1, raise substantial doubt about the Company&#8217;s ability to continue as
a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>/s/
<span id="xdx_90E_edei--AuditorName_c20230101__20231231_zLUXU5mNL3K6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000047" name="dei:AuditorName">FORVIS, LLP</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--AuditorLocation_c20230101__20231231_zOK9C9x8G6C7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000048" name="dei:AuditorLocation">Atlanta,
GA</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
21, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 62; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="o_001"></span><b><span id="c_001"></span>Report
of Independent Registered Public Accounting Firm</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the shareholders and the board of directors of Shuttle Pharmaceuticals Holdings, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Shuttle Pharmaceuticals Holdings, Inc. (the &#8220;Company&#8221;) as of
December 31, 2022, the related statements of operations, stockholders&#8217; equity (deficit), and cash flows for the years then ended,
and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations
and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
BF Borgers CPA PC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BF
Borgers CPA PC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Served
as Auditor from 2021</span> until March 21, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
CO</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
15, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_002"></span>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_znWgYAa3sFCh" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zYI93zUE6UCj" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zHdRA1h16i8g" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsAbstract_iB_zf0IV4Om33r4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_zHlhnUOqlXYi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzB8u_zv2kB7AhCRBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PrepaidExpenseCurrent_i02I_maACzB8u_zCNcxAJbuPH7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--MarketableSecuritiesCurrent_i02I_maACzB8u_zNEUuULOiCGc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0063">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestReceivableCurrent_i02I_maACzB8u_zbRflCKz3EPg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accrued interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,901</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0066">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrent_i02TI_mtACzB8u_maAzqfs_z4HEOK2XAiv1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,593,005</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,578,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzqfs_zWkdI7P5m9h2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net of accumulated depreciation of $<span id="xdx_90E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20231231_z32QUfUZjb31" title="Property and equipment, accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,685</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20221231_zbzkEIgrmXod" title="Property and equipment, accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,875</ix:nonFraction></span> respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,592</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherAssetsNoncurrent_i01I_maAzqfs_zZ2MswkH7b2k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0078">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2022-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzqfs_zcRb0Cnxxeg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,904</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Assets_i01TI_mtAzqfs_zAPLl3KZn6Ab" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,951,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,653,545</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_ztSII40MoIjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzI7y_zT8aNat5qTh3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="Fact000094" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzI7y_zf5iYfuvKEr7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued expenses related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzI7y_zIudUtEabUM5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0100">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzI7y_zpZthUykce8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0102">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzI7y_ziutAh8gZay2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ConvertibleNotePayableCurrent_i02I_maLCzI7y_zU6DYFO0Gr8g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:ConvertibleNotePayableCurrent" contextRef="AsOf2023-12-31" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">595,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0109">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzI7y_zWkJtgvi8Y36" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,479</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzI7y_maLzbRb_z1w7FHGElHJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,042,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,676</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ConvertibleLongTermNotesPayable_i01I_maLzbRb_zCJY5Z61X9r1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable non-current, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2023-12-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,089</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_maLzbRb_zMnRdu16Mbuf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0121">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzbRb_zJAwb1ICgDPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">304,127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0124">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i01TI_mtLzbRb_maLASEzn8f_zmj68R5EhLq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,895,965</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact000127" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,676</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockValue_i01I_maSEzDiQ_zmGHWPrC9Ome" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Series A Convertible Preferred Stock, $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z4NQxenxPwdc" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20221231_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreference_iI_c20231231_zT7cuaqUs6L9" title="Preferred stock, liquidation preference per share"><span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreference_c20221231_pdd" title="Preferred stock, liquidation preference per share"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2023-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="AsOf2022-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></ix:nonFraction></span></span> per share liquidation value; <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zpWEvZOi9l1j" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20221231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20231231_zHaxcabFV2e5" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20221231_zzR4TLaxRKq7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000149" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0132">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0133">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CommonStockValue_i01I_maSEzDiQ_z6mRuGeVa2kl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zcWOuc1gmdud" title="Common stock, par value"><span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20221231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zF6EcHCKoRk5" title="Common stock, shares authorized"><span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20231231_z7gm5uhEzSr5" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_ztMWrnDwoaN1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,069,320</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20221231_zpJLVmpI0BMa" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zSTUMafdaLmf" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,603,129</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AdditionalPaidInCapital_i01I_maSEzDiQ_zC2eJJSrAXPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,543,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,572,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEzDiQ_zSfTFlK3SNl7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,487,612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,894,889</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquity_i01TI_mtSEzDiQ_maLASEzn8f_zvoX9qOZGus1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtLASEzn8f_zT37Ir3InSVj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,951,736</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,653,545</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_003"></span>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zBVl3uV1Rbyl" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20230101__20231231_zrv6BGk0ccg6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231_zceGXZUEjF46" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--Revenues_maOILzYeb_zwhnuJ1gPIHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0183">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpensesAbstract_iB_z2cUZg4k5ape" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEz7FA_zwMqnbc2Ltah" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Research and development, net of contract expense reimbursements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,517,093</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,148,712</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEz7FA_z2nWHKMGk1d5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,854</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,796</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LegalFees_i01_maOEz7FA_z2tPopNoIM1k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Legal and professional</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-01to2023-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,328,435</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2022-01-012022-12-31" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">866,770</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_mtOEz7FA_msOILzYeb_zF7ISxZPRTBg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,892,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,554,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_mtOILzYeb_maILFCOzJ4p_zaPi3UnXmuL4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,892,382</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,554,278</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zT9ciliBxqC2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSmhrMrUZGP4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember" id="Fact000206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,825</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,010</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_i01N_di_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_msNIEzPbK_z3z5VgCzRRE6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000209" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484,193</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">917,879</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--InvestmentIncomeInterest_i01_maNIEzPbK_zAXZxrQMA86l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FinanceFee_i01N_di_msNIEzPbK_zr62LARC3m7k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Finance fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:FinanceFee" contextRef="From2023-01-01to2023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,245</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maNIEzPbK_z37JGfZ7Kst1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-01to2023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,216,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GainLossOnSaleOfInvestments_i01_maNIEzPbK_z5xfOVxONos6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Gain on sale of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0222">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i01_maNIEzPbK_zcCBjVAl0WDb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-01to2023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LossOnSettlementOfConvertibleDebt_i01N_di_msNIEzPbK_z64uobv9iati" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loss on settlement of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0228">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzPbK_z92QPJ7DGWDd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0230">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--GainOnForgivenessOfNotePayable_i01_maNIEzPbK_zJGik1XFcDMg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Gain on forgiveness of Paycheck Protection Program note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0233">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2022-01-012022-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_maILFCOzJ4p_mtNIEzPbK_zm6b1AYfHorl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">700,341</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">474,170</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzJ4p_maNILATzvmv_zWWyxVvfrP59" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockDividendsIncomeStatementImpact_iN_di_msNILATzvmv_zqdk56XTV1ul" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Dividend on Series A Preferred Stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0242">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="From2022-01-012022-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_maCINOTz8Dh_mtNILATzvmv_zR7NnOjEEWuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,099,457</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_zKKW8soJ6uN7" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zO1zse5RtAbb" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000248" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,919,484</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zYzr2lEX6C09" title="Weighted average common shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zOorQLB3DzKe" title="Weighted average common shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,351,046</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share - basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_z37SEIaUUDBl" title="Net loss per shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zcjKYypHfFZc" title="Net loss per shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_pid_c20220101__20221231_z6APBnenuoVb" title="Net loss per shares - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20221231_zqxAjcR9sP9g" title="Net loss per shares - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.29</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_004"></span>Consolidated
Statements of Changes in Stockholders&#8217; Equity</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_114_zrUYJHOgBu4f" summary="xdx: Statement - Consolidated Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zdOatB04gZk2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zQJUUWTxUGk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvGnlwzOHjCc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--CommonStockToBeIssuedMember_zOaauK3Y2gn8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zeRCLvb68jBh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B1_zPr0wOJ6tCS6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="6" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Series A Preferred Stock</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional Paid in</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Common Stock to be</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total<br/>
Stockholders&#8217; Equity</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> Issued</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> (Deficit)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_435_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z0jcT0L45kF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 28%; font-weight: bold">Balance - December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHAzEkWmGr4h" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,213</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjy38xSKz2r8" title="Beginning balance, shares" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,312,152</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,150,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,795,432</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,628,132</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zruY3da15mTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUd5E29azNH4" title="Common stock issued for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000282" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,008,081</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0279">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,008,095</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zE60JBtcyiYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants exercised for cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bCl2nO7K31" title="Warrants exercised for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,084</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0288">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="Fact000289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zyxlJBHgxbwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued for financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2022-01-012022-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,241</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zZlslDTl20kd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for conversion of convertible debt and accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgvoYpqoPnzf" title="Common stock issued for conversion of convertible debt and accrued interest, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">148,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">604,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,340</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueOther_zTQoTcoXHy02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued for exercise of warrants with settlement of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8OCBjGgY1Hh" title="Common stock issued for exercise of warrants with settlement of notes payable, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000316" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">857,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000311" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,467</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2022-01-012022-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zqTNAGZ5X0o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj8zmD7UwyJk" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zkUh77keXtX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000329" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,956</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,956</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DividendsPreferredStock_iN_di_z8KlWIr2v6Cj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividends on Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,009</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueDividendReinvestmentPlan_zfcPbcrW5k5c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common shares issued for dividends on and conversion of Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbAtF877gPa3" title="Common shares issued for dividends on and conversion of Series A preferred stock, shares" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,213</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zg3YwuDAIa2h" title="Common shares issued for dividends on and conversion of Series A preferred stock, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">437,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan" contextRef="From2022-01-012022-12-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_z12LJtXPsx37" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43E_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zJBdAfiKMtm8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold">Balance - December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zxsq3CvOnQxg" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0359">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zH7MuEco01D5" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,603,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,572,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,894,889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_432_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zjdl5JvWGRpj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Beginning balance, value</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zhAJxUb7E1sk" title="Beginning balance, shares" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkfpFfNO2LQ1" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,603,129</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000372" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,572,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000374" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,894,889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000375" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,677,869</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_zYZmEizy6Jpc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants issued for financing costs, net of issuance fees of $<span id="xdx_90B_ecustom--WarrantsIssuanceFees_c20230101__20231231_zOEXjPjVp7Sa" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-01to2023-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_zkCq6Eo5O9td" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for conversion of accrued interest and principal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBzdPEe7gZTk" title="Common stock issued for conversion of accrued interest and principal, shares" style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000391" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,697,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" contextRef="From2023-01-01to2023-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,697,849</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zMhLGTg2UZa3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock issued for restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF6jk3FWPFBe" title="Common stock issued for restricted stock units, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,195</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000400" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z9F3ueC0iqOf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000410" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-01-01to2023-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zzfJgXW1WlNe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000420" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zwydoEGSNAj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zo5Y8G5b89Je" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zs0J6UcSp3Q9" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000431" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,069,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000423" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,543,222</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,487,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000427" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zGpANciOpIW4" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending
    balance, value</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKJOk9jGBGl7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zymPvLlWPq64" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,069,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000434" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000435" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,543,222</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000437" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,487,612</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,055,771</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_005"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_112_zRetpg4Fljn4" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230101__20231231_z6hfjjQLG4ye" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220101__20221231_zbJctKaNJaQ7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zqtB7SM7dMZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_maNCPBUzR4E_zeUNxl9uTEmk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,592,723</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,028,448</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zEkJ4fE7GZih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Depreciation_i02_maNCPBUzR4E_znvuJZze9vvi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000454" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueOfDerivativeLiability_i02N_di_msNCPBUzR4E_zlDH0hXqohc2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:ChangeInFairValueOfDerivativeLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000456" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,216,488</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:ChangeInFairValueOfDerivativeLiability" contextRef="From2022-01-012022-12-31" id="Fact000457" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maNCPBUzR4E_zMhcZy5ykgPh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and finance fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-01-01to2023-12-31" id="Fact000459" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,123,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-01-012022-12-31" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">885,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--GainLossOnSaleOfInvestments_i02N_di_msNCPBUzR4E_zm1HeSxu1BUk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfInvestments" contextRef="From2023-01-01to2023-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_i02N_di_msNCPBUzR4E_zWx9FX5BZHF1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-01to2023-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,568</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedInterestSettledWithCommonStock_i02_maNCPBUzR4E_zS7o6Blw74ya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accrued interest settled with common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:AccruedInterestSettledWithCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,927</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossOnSettlementOfConvertibleDebt_i02_maNCPBUzR4E_zS3VVbSbXb35" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss on settlement of convertible debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzR4E_zw1dn8mkwTl9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on settlement of accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328,687</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--GainOnForgivenessOfNotePayable_i02N_di_msNCPBUzR4E_z8vqUsbV9iR1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gain on forgiveness of Paycheck Protection Program note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0477">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:GainOnForgivenessOfNotePayable" contextRef="From2022-01-012022-12-31" id="Fact000478" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,007</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DebtSecuritiesGainLoss_i02N_di_msNCPBUzR4E_ze3e8SwYEBM7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Gain on interest relief on conversion of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtSecuritiesGainLoss" contextRef="From2022-01-012022-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,625</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ShareBasedCompensation_i02_maNCPBUzR4E_zl2xhPJuJaXi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,956</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zZsDGeESBSx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i02N_di_msNCPBUzR4E_zWOmDwG1ocx8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2023-01-01to2023-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,901</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzR4E_z8PeoBaPeZRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-12-31" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">156,282</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i02_maNCPBUzR4E_zEGsYi8Fsu33" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000496" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">382,881</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInDueToRelatedPartiesCurrent_i02_maNCPBUzR4E_zoImVke8iQob" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable and accrued expenses - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2023-01-01to2023-12-31" id="Fact000498" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,054</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="From2022-01-012022-12-31" id="Fact000499" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_maNCPBUzR4E_zorEnQQBm9i6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2023-01-01to2023-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,453</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2022-01-012022-12-31" id="Fact000502" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,177</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--IncreaseDecreaseInAccruedInterestPayableRelatedParties_i02_maNCPBUzR4E_zSGpp2plW9w8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accrued interest payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties" contextRef="From2023-01-01to2023-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties" contextRef="From2022-01-012022-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i02N_di_msNCPBUzR4E_z56G97Ey3fxh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,480</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maNCPBUzR4E_zu6SNLZOQ647" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Change in operating lease asset and liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000510" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,001</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzR4E_maCCERCzJ2h_zDbdjgyc75Xe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000513" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,581,147</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000514" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,710,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zAXQWjoPNm41" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PaymentsToAcquireMarketableSecurities_i01N_di_msNCPBUznlu_zDTufd0BPpya" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Investment in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="From2023-01-01to2023-12-31" id="Fact000519" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,998,572</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_i01_maNCPBUznlu_z5F4GPiYf026" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from disposition of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-01-01to2023-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,895</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUznlu_zDrpRud8plk4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Purchase of equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUznlu_maCCERCzJ2h_zYKzebV9MeB4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,829,723</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zPdtHq0PExqg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_i01_maNCPBUzd4R_zConKrDb2l07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common shares and exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,022,193</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzd4R_zUR0nVCV3WV3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from note payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-12-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_msNCPBUzd4R_zWdqB54eujX4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Repayment of note payable-related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzd4R_zxZG3Bsn2M33" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Proceeds from convertible notes payable and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,935,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzd4R_zIgUlprSY3N8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Payment for finance costs related to convertible note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msNCPBUzd4R_z5iiRu7ZPva6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Payment of convertible note payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzJ2h_mtNCPBUzd4R_zkZwHEifex6l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000552" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,570,083</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,622,908</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzJ2h_zxMh6n5OluRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" id="Fact000555" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,840,787</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000556" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,912,454</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zoY11yhg0CTk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000559" format="ixt:numdotdecimal" decimals="0" unitRef="USD">504,749</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z42Y7BF0oBu9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000562" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zCGaJR3YqbT9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InterestPaidNet_i01_zmOUGOT1Byo" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" id="Fact000567" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,807</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,201</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaid_i01_zfLtAKhsDMzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxesPaid_i01_zC0b8RRuD9y9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Supplemental non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--CommonStockIssuedForConversionOfAccruedInterest_i01_zY8nVZy55ryf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for conversion of accrued interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForConversionOfAccruedInterest" contextRef="From2022-01-012022-12-31" id="Fact000577" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--CommonStockIssuedForSettlementOfDebt_i01_zCj8BeFL9G65" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for settlement of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForSettlementOfDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000579" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,697,849</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForSettlementOfDebt" contextRef="From2022-01-012022-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_i01_zCJs4aRljjVf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for exercise of warrants with settlement of notes payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact000583" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CommonStockIssuedForDividendPayable_i01_zpZ0tO6p7mJj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Common stock issued for dividend payable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:CommonStockIssuedForDividendPayable" contextRef="From2022-01-012022-12-31" id="Fact000586" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantsIssuedForFinancingFees_i01_zA364NLcz7Ib" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Warrants issued for financing fees, net of issuance fees of $<span id="xdx_908_ecustom--WarrantsIssuanceFees_c20230101__20231231_zoJtfd4WZLu8" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2023-01-01to2023-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span> and $<span id="xdx_909_ecustom--WarrantsIssuanceFees_c20220101__20221231_zpOFiEnEPDf6" title="Warranst of issuance fees"><ix:nonFraction name="SHPH:WarrantsIssuanceFees" contextRef="From2022-01-012022-12-31" id="Fact000593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2023-01-01to2023-12-31" id="Fact000588" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,816</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:WarrantsIssuedForFinancingFees" contextRef="From2022-01-012022-12-31" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">412,241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--InitialRecognitionOfRightOfUseAssetAndLiability_i01_z6N2QvOprUPj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Initial recognition of right of use asset and liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:InitialRecognitionOfRightOfUseAssetAndLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,556</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
accompanying notes are an integral part of these consolidated financial statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shuttle
Pharmaceuticals Holdings, Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ps_006"></span>Notes
to Consolidated Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000598" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLSnJOFJjx87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82A_zNQTfjOQsJoh">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuWYMCwBa1l" title="Conversion of stock, shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,000,000</ix:nonFraction></span> shares of common
stock in exchange for <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrFlg9kE6KXj" title="Sale of stock membership percentage"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#8220;Company&#8221;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract provided
by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#8217;s initial public offering, the Company
has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay
or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and has a net loss of
approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zvDIDv0jCj34" title="Net income loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000604" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">6.6</ix:nonFraction></span> million and no revenues for the year ended December 31, 2023 and working capital of approximately $<span id="xdx_90D_ecustom--WorkingCapital_iN_pn5n6_di_c20230101__20231231_zpMi8peYTBP7" title="Working capital"><ix:nonFraction name="SHPH:WorkingCapital" contextRef="From2023-01-01to2023-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">4.6</ix:nonFraction></span> million as
of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and certain cash
payment requirements. These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering of common stock, generating net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220901__20220930_zR49qYY8Cmnl" title="Proceeds from issuance or sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2022-09-012022-09-30" id="Fact000608" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span>
million. Additionally, in January 2023, the Company entered into a securities purchase agreement with an institutional investor
through which the Company sold a convertible note with a principal value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLz2DBKNXBw9" title="Debt instrument, face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000610" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span>
million, along with a four-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zl355kJKiw01" title="Four year warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000612" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,018,079</ix:nonFraction></span>
shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUpMqMf0Hl09" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span>
per share, providing the Company with approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zObOWFtvk5K9" title="Net proceeds from warrants"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000616" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.6</ix:nonFraction></span>
million in net proceeds. To date, the warrant has not yet been exercised. However, the Company&#8217;s existing cash resources,
marketable securities and the cash received from the equity offering and convertible note are not expected to provide sufficient
funds to carry out the Company&#8217;s operations and clinical trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital raise has supported operations leading up to the manufacture of drug product and FDA approval of the IND for the Phase II clinical
trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the company agreed to an expansion of the clinical
trial, necessitating additional capital to complete the trial. Management intends to initiate a rights offering for $<span id="xdx_90C_eus-gaap--PartnersCapital_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVMpPjuScNs2" title="Initiated a capital offering"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember" id="Fact000618" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.5</ix:nonFraction></span> million and has submitted
SBIR applications for non-dilutive NIH funding for pre-clinical project. The ability of the Company to continue as a going concern is
dependent upon its ability to successfully conduct clinical trials, bring a drug candidate to commercialization to generate revenues,
and to raise additional equity or debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements do not include any adjustments to reflect the future effects on the recoverability and
classification of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000620" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_ztutohW0DxZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82D_zF1DC2RbvP0b">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000622" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zN9JmHykJAle">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000624" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zXzky5zRn35g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000626" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000628" name="SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock"><p id="xdx_84C_ecustom--CorrectionOfPriorPeriodErrorsPolicyTextBlock_zUNM6DMxDWG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zmSLE9UXGTZ4">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expense in accordance with ASC 730. As a <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">result,
c</span>ertain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the
materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting
Bulletin No. 99, &#8220;Materiality,&#8221; (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the
Company concluded that these error corrections in its <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations</span> are not material to any previously presented financial statements based upon overall considerations
of both quantitative and qualitative factors. The corrections had no impact on the</span> Consolidated <span style="background-color: white">Balance
Sheet, </span> Consolidated Statements of Cash Flows, or Consolidated Statement of Changes in Stockholders&#8217; <span style="background-color: white">Equity,
to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per
share, or working capital. The quarterly
corrections for 2023 include $<span id="xdx_902_eus-gaap--PriorPeriodReclassificationAdjustment_c20230101__20230331_zFakzIKd6fI5" title="Quarterly reclassifications"><ix:nonFraction name="us-gaap:PriorPeriodReclassificationAdjustment" contextRef="From2023-01-012023-03-31" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,007</ix:nonFraction></span>
(March 31), $<span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230401__20230630_zjgd06Zv936i" title="Quarterly reclassifications"><ix:nonFraction name="us-gaap:PriorPeriodReclassificationAdjustment" contextRef="From2023-04-012023-06-30" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,708</ix:nonFraction></span>
(June 30), and $<span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230701__20230930_z6t87eTcNI8l" title="Quarterly reclassifications"><ix:nonFraction name="us-gaap:PriorPeriodReclassificationAdjustment" contextRef="From2023-07-012023-09-30" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,129</ix:nonFraction></span>
(September 30). Accordingly, the Company corrected the previously reported immaterial errors for the years ended December 31, 2023
and 2022 in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000636" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of corrections reflecting the prior period impact to the Company&#8217;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zAUbI2M0uK5l" style="display: none">Schedule of the Error Correction</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As Corrected <br/>
December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">General and administrative expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact000638" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,978</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" id="Fact000639" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339,818</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000640" format="ixt:numdotdecimal" decimals="0" unitRef="USD">538,796</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,488,530</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" id="Fact000643" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">339,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000644" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,148,712</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact000646" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,687,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-01-012022-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,687,508</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zyP3t9CJDzV" style="margin-top: 0; margin-bottom: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000650" name="us-gaap:UseOfEstimates"><p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the
accompanying consolidated financial statements for the valuation of derivatives and initial measurement of equity-based
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000652" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zJkXkj4AZTy2">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000654" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000656" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,550,098</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2022-12-31" id="Fact000657" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,411,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000659" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026,318</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,005,825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,576,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,417,203</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" id="Fact000665" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2023-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,849,000</ix:nonFraction></span>. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000669" name="us-gaap:MarketableSecuritiesPolicy"><p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zcIP2rrvmXK8">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2023-12-31" id="Fact000671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></span>. During the year ended December 31, 2023, the Company recognized interest income of $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2023-01-01to2023-12-31" id="Fact000673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,855</ix:nonFraction></span>,
realized gains of $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" contextRef="From2023-01-01to2023-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,970</ix:nonFraction></span>, and unrealized gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,568</ix:nonFraction></span>. The were <span id="xdx_90E_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zVNP7VA0iPmh" title="Marketable securities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0679">no</span></span> marketable securities during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000681" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqfmU6VxYX7j">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000683" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">December 31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember" id="Fact000690" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeAssetsCurrent" contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember" id="Fact000693" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="Fact000695" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact000698" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,887,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_WarrantMember" id="Fact000708" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember" id="Fact000713" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact000717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000720" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUfQ5IhZAVZ7">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine if an arrangement is a lease at inception. <span style="background-color: white">Operating leases are included in operating
lease right-of-use asset (&#8220;ROU&#8221;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with a lease term of 12 months or less at inception are not recorded on our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">balance </span>sheets <span style="background-color: white">and are expensed on a straight-line
basis over the lease term in our statement of operations. </span>We have lease agreements with lease and non-lease components, which
are generally accounted for separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#8220;incremental borrowing rate&#8221; or &#8220;IBR&#8221;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000722" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zhMEboul1fnf">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000724" name="SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Furniture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000726" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000728" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000730" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000732" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYSObLAWFqrd">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For
our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception
and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded
as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated
balance sheet sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000734" name="SHPH:ConvertibleNotePolicyTextBlock"><p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zIShPO1DVFMg">Convertible
Note</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments
if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000736" name="SHPH:WarrantsPolicyTextBlock"><p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_860_zbFQsfTI6WN7">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;)
and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether
the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000738" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMKVdyEG0BI7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000740" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z4CSzyso8ih9">Stock-Based Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost for stock awards, which include restricted stock units (&#8220;RSUs&#8221;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000742" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z01OOEEOeht9">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#8217; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$<span id="xdx_901_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE8MCOpDGG97" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000744" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyagly3uGnx8" title="Share based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact000746" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $<span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20231231_zQBcV79W2Tl3" title="Research and development, net of contract expense reimbursements"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20220101__20221231_z6jSzaNLWoj" title="Research and development, net of contract expense reimbursements"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="0" unitRef="USD">211,455</ix:nonFraction></span> in Research and development, net of contract expense reimbursements, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000752" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zjUxdX9ZNGFl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000754" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwbvAlIY1l46">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all
entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share
computation. In the accompanying consolidated financial statements, basic loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by
the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to
reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and
warrants unless the result would be antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#8220;treasury
stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#8220;if-converted
method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000756" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">959,513</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000762" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,446,155</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" id="Fact000764" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,810</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000766" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,855</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-12-31" id="Fact000770" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,603,523</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,810</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000774" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zSWNCgOEheR1">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not expect the adoption of this standard to
have any material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.</p>

</ix:nonNumeric><p id="xdx_85E_zQNfopfWoCN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000776" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z08OzEyKAwJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82E_zYhGzQEhHDX1">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had two lease agreements during the year which allowed for the use of laboratory facilities. <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zEya2wAH9aKc" title="Lessee, operating lease, description"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000778" name="us-gaap:LesseeOperatingLeaseDescription">The first was for a monthly payment
of $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20231231_z4j16dhXCej9" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-01-01to2023-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span>, with a security deposit of $<span id="xdx_90A_eus-gaap--Deposits_iI_c20231231_zO8e4gkFsUJk" title="Deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,480</ix:nonFraction></span> held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019</ix:nonNumeric></span> and ended on <span id="xdx_90D_eus-gaap--LeaseExpirationDate1_c20230101__20231231_zI0l5Mds2Am4" title="Lease expiration date"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000784" name="us-gaap:LeaseExpirationDate1">October 31, 2023</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2023, the Company entered into a new lease agreement for new office and laboratory space, with base rent of $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zzwRNVzOdczf" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember" id="Fact000786" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,206</ix:nonFraction></span> per month
for a period of 64 months, which increases at the rate of <span id="xdx_903_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIt1JZKcThLk" title="Rent variable rate"><ix:nonFraction name="SHPH:RentVariableRate1" contextRef="AsOf2023-02-16_custom_NewLeaseAgreementMember" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% per year, that <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zj1i3ww8Qve3"><ix:nonNumeric contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember" id="Fact000789" name="us-gaap:LesseeOperatingLeaseDescription">commenced June 1, 2023</ix:nonNumeric></span>. The new lease included a six-month
50% rent abatement upon commencement. Additional common area maintenance (&#8220;CAM&#8221;) fees are charged monthly and revised annually.
The estimated monthly CAM fees are $<span id="xdx_908_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230215__20230216_zd0rmLCuEgvl" title="Estimated monthly common area maintenance cost"><ix:nonFraction name="SHPH:EstimatedMonthlyCommonAreaMaintenanceCost" contextRef="From2023-02-152023-02-16" id="Fact000791" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,300</ix:nonFraction></span> per month for the first year of the lease, which are being expensed as incurred. An irrevocable
letter of credit (&#8220;LOC&#8221;) for the security deposit of $<span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20230216_zE3n7U3fwQok" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2023-02-16" id="Fact000793" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,234</ix:nonFraction></span> and base rent of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20230215__20230216_zETIouZ8QDv6" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2023-02-152023-02-16" id="Fact000795" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,891</ix:nonFraction></span>, including 50% abatement, and $<span id="xdx_909_ecustom--CommonAreaMaintenanceCost_c20230215__20230216_zRiqEIIYf8j8" title="Common area maintenance cost"><ix:nonFraction name="SHPH:CommonAreaMaintenanceCost" contextRef="From2023-02-152023-02-16" id="Fact000797" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,315</ix:nonFraction></span>
of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC,
and the expiry date of the LOC is February 15, 2024. Subsequent to December 31, 2023, the LOC was renewed with an updated expiry date
of March 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000799" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the right-of use asset and lease information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z3chxPAugTvb" style="display: none">Schedule of Right-of Use Asset and Lease Information About Operating Lease</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact000801" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,022</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,175</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sublease income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2023-01-01to2023-12-31" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,819</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SubleaseIncome" contextRef="From2022-01-012022-12-31" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-01to2023-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,425</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2022-01-012022-12-31" id="Fact000811" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,105</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-01to2023-12-31" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-01-012022-12-31" id="Fact000817" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000819" format="ixt:numdotdecimal" decimals="0" unitRef="USD">365,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term &#8212; operating leases (year)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_ziMEmd9Mt5Sc" title="Weighted-average remaining lease term - operating leases (year)" style="text-align: right"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" id="Fact000822" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.67</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" title="Weighted-average remaining lease term - operating leases (year)" style="text-align: right"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" id="Fact000824" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">0.80</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate &#8212; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zQzuTkcat7T6" title="Weighted-average discount rate - operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" id="Fact000826" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.48</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zFmXEc2OJ102" title="Weighted-average discount rate - operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" id="Fact000828" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zAskMv6Jd9Ib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000830" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFdDGFDXJUZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zww5HoyzAXBk" style="display: none">Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Years ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzDPt_zsoBHIDG7oh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact000832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">91,502</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzDPt_z7eQTs5MmjR1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" id="Fact000834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,247</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzDPt_zKCgLvy8lLQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" id="Fact000836" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzDPt_zDNVsoZEHARd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2023-12-31" id="Fact000838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,986</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzDPt_zKj9Z36cUNyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2023-12-31" id="Fact000840" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzDPt_zB0xrbyBjUZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31" id="Fact000842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">451,044</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31" id="Fact000844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,438</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact000846" format="ixt:numdotdecimal" decimals="0" unitRef="USD">356,606</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zGZjjGq7mVc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000848" name="SHPH:NotesPayableRelatedPartyDisclosureTextBlock"><p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zd061yowJNd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_825_zH1XaP0tjrW5">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z3NgxGTYg4V9"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" id="Fact000849" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426,243</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWqcEUtfPTu6"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity date of <span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zfFRy9Sub3Hc"><ix:nonNumeric contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember" format="ixt:datemonthdayyearen" id="Fact000851" name="us-gaap:RelatedPartyTransactionDate">December 31, 2021</ix:nonNumeric></span>; and (ii) a single loan
owed to an officer of the Company in the principal amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z9TMMPLJqMKk"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember" id="Fact000852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,229</ix:nonFraction></span>, bearing interest at the rate of <span id="xdx_90A_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zerWcgbpUGVj"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum, with a maturity
date of December 31, 2021. <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211231_zfxw96gGmmth"><ix:nonNumeric contextRef="From2021-12-012021-12-31" id="Fact000854" name="us-gaap:DebtInstrumentMaturityDateDescription">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zTHYCCtmQ77h"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" id="Fact000855" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span> (principal) with
an interest rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z7JDA19McyJa"><ix:nonFraction name="us-gaap:RelatedPartyTransactionRate" contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember" id="Fact000856" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.5</ix:nonFraction></span>% per annum due June 21, 2022. In July of 2022, the loan was extended to June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023 principal payments of $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zSYaCBxemUD8"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember" id="Fact000857" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,473</ix:nonFraction></span> and interest of $<span id="xdx_902_eus-gaap--InterestPaidNet_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zffNQmXite2e"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember" id="Fact000858" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,968</ix:nonFraction></span> were paid. As of December 31, 2023, there were <span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_do_c20230101__20231231_z5bCjpTtB4u2" title="Increase accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-01to2023-12-31" id="Fact000860" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> outstanding
principal or interest balances for these related party notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000862" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_z2GEya6C7Gm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5&#8211; <span><span id="xdx_821_z4YyPFusOaGd">Convertible Notes</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alto
Opportunity Master Fund, SPC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master Fund,
SPC &#8211; Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to the Investor
a $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1qYaf3PFxbb" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,300,000</ix:nonFraction></span> convertible note (the &#8220;Alto Convertible Note&#8221;) and warrant (the &#8220;Warrant&#8221;) to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSUnRPFxSwvf" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,018,079</ix:nonFraction></span>
shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z64P6QuvGP1l" title="Warrants exerciable shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000868" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span> per share, in exchange for gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230109__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXyVfotWMQH3" title="Proceeds from convertible note payable"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-092023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000870" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,935,000</ix:nonFraction></span> million (the &#8220;Investment Amount&#8221;)
(See Note 7). The Company determined that the Warrant contains a net cash settlement feature at inception and categorized the Warrant
as a liability in the accompanying consolidated financial statements. The Alto Convertible Note matures on March 11, 2025, but may be
extended at the option of the noteholder. The Alto Convertible Note amortizes on a monthly basis and the Company can make such monthly
amortization payments in cash or, subject to certain equity conditions, in registered shares of common stock or a combination thereof.
Installments may be deferred by the noteholder, resulting in a variable interest rate. However, the effective interest rate is approximately
<span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYihioEmX1N1" title="Effective interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">346</ix:nonFraction></span>% based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment,
<span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20230109__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zaxJ1y0qhQBi" title="Debt description"><ix:nonNumeric contextRef="From2023-01-092023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000874" name="us-gaap:DebtInstrumentDescription">the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment
date. The noteholder may convert at any time at a fixed price of $2.35 per share.</ix:nonNumeric></span> The noteholder has an acceleration of installment amount
conversion option (the &#8220;Acceleration Option&#8221;), whereby the noteholder, with certain share percentage limitations, can convert
to common stock any outstanding installment amount at an amount equal to the installment amount plus five times (5x) the installment
amount at any time. The Company has determined the Acceleration Option is an embedded derivative within the host instrument and has bifurcated
it from the host instrument and recorded it as a derivative liability valued at $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zw9FmdP2k1rj" title="Derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span>, using a Monte Carlo simulation model (Note
7). The Convertible Note is repayable over 26 months and bears interest at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIDfdUAlNQL7" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum. Additionally, the note contains
certain redemption options and &#8220;Make Whole&#8221; provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the &#8220;Security
Agreement&#8221;), an intellectual property security agreement (the &#8220;IP Security Agreement&#8221;) and a subsidiary guaranty (the
&#8220;Subsidiary Guaranty&#8221;). The security agreements and guaranty allow, among other things, for the Investor to have a security
interest in and place a lien on all of the Company&#8217;s assets and intellectual property until such time as the Alto Convertible Note
is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the &#8220;Springing
DACA&#8221;), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume
control of the Company&#8217;s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such,
in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and
pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing
DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller
banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing
DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor
agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing
DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20231231_zhjUClDQimI" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2023-12-31" id="Fact000880" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span>
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Warrant, excluding the Springing
DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an opportunity to participate
in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company expects that such subsequent convertible notes and warrants would be issued on substantially similar
terms as the January 11, 2023 initial agreement, as amended, thus providing the Company the opportunity to negotiate certain aspects of
the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_ziS9eEQtuv1f" title="Payment for placement agent"><ix:nonFraction name="SHPH:PaymentForPlacementAgent" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></span> cash compensation and a warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zAqlkvNNaDpd" title="Warrants to purchase common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000884" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,266</ix:nonFraction></span> shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zojy77XppzIe" title="Warrants exerciable shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span> per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPC674AVJKXc" title="Expected years"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember" format="ixt-sec:durwordsen" id="Fact000888" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span>, volatility of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znMOWfqPGjYf" title="Warrants and rights outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">110</ix:nonFraction></span>%, a risk-free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zILXwC7DhWBl"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact000891" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.53</ix:nonFraction></span>% for a value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zEonjOrQ2ZU" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000893" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,543</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated the finance costs related to the Boustead placement agent fee of $<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z1qEjzidygn" title="Payment for placement agent"><ix:nonFraction name="SHPH:PaymentForPlacementAgent" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000895" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,000</ix:nonFraction></span>, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $<span id="xdx_902_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGBEljeJa0Nb" title="Allocation of financing costs"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">232,027</ix:nonFraction></span> to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmNk8FczQ6Wh" title="Warrant derivative liability"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,245</ix:nonFraction></span> to the warrant derivative liability component,
expensed as a finance fee, and $<span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zSUixncCkJS1" title="Equity warrant as reduction in additional paid in capital"><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,727</ix:nonFraction></span> to the equity warrant as a reduction in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated to the debt component of the note an original discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMx5hPAesnIi" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact000903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>, legal fees of $<span id="xdx_90D_eus-gaap--LegalFees_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zLBOZ1MJKbi8" title="Legal fees"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,000</ix:nonFraction></span>, $<span id="xdx_900_ecustom--InterestFeeAmount_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zqJJyHoHEi83" title="Interest fee"><ix:nonFraction name="SHPH:InterestFeeAmount" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact000907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,000</ix:nonFraction></span> for additional
interest fees on day one added to note principal, $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zayR1vJlE2s9" title="Debt principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact000909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></span> for the accelerated conversion feature, and $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxa2TC77bmFd" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact000911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,288,543</ix:nonFraction></span> for the fair value
of warrants, resulting in an additional $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_znnI28Rtm2fb" title="Interest expense debt"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember" id="Fact000913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,310,543</ix:nonFraction></span> debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded interest expense of $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_znhWETUYiYQb"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,484,193</ix:nonFraction></span>, which included amortization of debt discount as
interest expense of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20230101__20231231_zpTyEbkt4Xac"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,123,049</ix:nonFraction></span>. During the year ended December 31, 2023, the Company settled $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJLs4MfXiOZ5" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,700</ix:nonFraction></span> of principal and settled $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIH04jwIMOkl" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,927</ix:nonFraction></span>
of accrued interest, which settlements were made in the form of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z61rjBMkQSyb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000920" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,996</ix:nonFraction></span> shares of common stock during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the outstanding principal for the convertible note was $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20231231_zSRsEaMmQVQd"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31" id="Fact000921" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,254,856</ix:nonFraction></span> and the debt discount remaining was $<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20231231_zLkKrYZw6Y46"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,523,768</ix:nonFraction></span>,
with a net convertible note carrying value of $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20231231_z90vWvRx7oy1" title="Convertible note payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">731,088</ix:nonFraction></span>, which represents the current and non-current portions of the convertible note
as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000926" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRCb1RVFvgkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_825_zr458jZvyJC5">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231_zZds9nkiSPPl" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-01to2023-12-31" id="Fact000928" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,380,996</ix:nonFraction></span>
    shares of common stock to settle $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRAn1fkxWHy9" title="Debt, principal"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,925,700</ix:nonFraction></span> of principal and $<span id="xdx_90B_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jBXJnIxDLa" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,927</ix:nonFraction></span> of interest on a Convertible Note and incurred $<span id="xdx_908_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMO1eJwiZXi" title="Loss on settlement of convertible debt"><ix:nonFraction name="SHPH:LossOnSettlementOfConvertibleDebt" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,221</ix:nonFraction></span> of
    loss on settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z96iryR5Kbn2" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,195</ix:nonFraction></span>
    shares of common stock issued for vesting of restricted stock units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20220101__20221231_zEEdlwiuK3mi" title="Common stock issued for conversion of convertible debt, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact000938" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">839</ix:nonFraction></span>
    shares of common stock for conversion of $<span id="xdx_90F_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20220101__20221231_zCR0LvynQrpk" title="Accrued interest settled with common stock"><ix:nonFraction name="SHPH:AccruedInterestValueToIssueShares" contextRef="From2022-01-012022-12-31" id="Fact000940" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,340</ix:nonFraction></span>
    of accrued interest and <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesSettlementOfNotesPayable_c20220101__20221231_zi3imVIifs4j"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesSettlementOfNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact000941" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,500</ix:nonFraction></span> shares of common stock upon settlement of notes payable for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20221231_z32bqH7a2h3f" title="Number of shares of common stock upon settlement of notes payable"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact000943" format="ixt:numdotdecimal" decimals="0" unitRef="USD">588,524</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--CommonStockVestingOfRestrictedStockUnit_c20220101__20221231_zTGhXRDb9rbf" title="Common stock vesting of restricted stock unit"><ix:nonFraction name="SHPH:CommonStockVestingOfRestrictedStockUnit" contextRef="From2022-01-012022-12-31" id="Fact000945" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,989</ix:nonFraction></span>
    shares of common stock upon vesting of restricted stock units.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjeceiAKMQN6" title="Common stock issued for cash, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000947" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></span>
    shares of common stock upon completion of the Company&#8217;s initial public offering for $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231_zReQhA0jXBO1" title="Common stock issued for cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" id="Fact000949" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,008,095</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_znddZycuNdzi" title="Number of shares of common stock issued for exercise of warrants"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,409,771</ix:nonFraction></span> shares of common stock upon completion of the Company&#8217;s initial public offering for exercise of warrants
$<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20220101__20221231_zxa59QQ9BSid" title="Exercise of warrants, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="Fact000953" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,098</ix:nonFraction></span>.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20220101__20221231_zaISTewlGzo4" title="Common stock issued for exercise of warrants, shares"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesExerciseOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">857,780</ix:nonFraction></span>
    shares of common stock upon exercise of warrants to settle notes payable for $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueWarrantsNotesPayable_c20220101__20221231_zPRvRgJIApw3" title="Common stock issued for exercise of warrants notes payable, value"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueWarrantsNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact000957" format="ixt:numdotdecimal" decimals="0" unitRef="USD">576,476</ix:nonFraction></span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredShares_pp0p0_c20220101__20221231_zMXs1V3yATd" title="Number shares issued for conversion of note, shares"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfPreferredShares" contextRef="From2022-01-012022-12-31" id="Fact000959" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">336,810</ix:nonFraction></span>
    shares of common stock upon conversion of preferred shares and <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesConversionOfDividends_pp0p0_c20220101__20221231_zeGN8oiBf77k" title="Number shares issued for conversion dividends payable, shares"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodSharesConversionOfDividends" contextRef="From2022-01-012022-12-31" id="Fact000961" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">100,517</ix:nonFraction></span> to settle dividends payable for $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueDividendsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxo9SNpEoe9d" title="Common stock issued for dividends payable"><ix:nonFraction name="SHPH:StockIssuedDuringPeriodValueDividendsPayable" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">402,068</ix:nonFraction></span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zam6FgbDoIvd" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember" id="Fact000965" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,266</ix:nonFraction></span> shares of common stock, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_ziFSekf5Pqm7" title="Exercisable price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span> per share (Note 5). In addition, Alto was granted warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zxfR1IUHlnT6" title="Number of warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,018,079</ix:nonFraction></span> shares of common stock, at an
exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zCr58QMvgMwh" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31" id="Fact000971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span> per share (Note 5, 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000973" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zQPSvyFjdRPc" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (years)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" title="Number of Warrants Outstanding, Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" title="Number of Warrants Outstanding, Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,641,354</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted Average Life (Years), Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember" format="ixt-sec:duryear" id="Fact000983" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">4.75</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_z96MJfoqmzQl" title="Number of Warrants Outstanding, Beginning Balance" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_AyrtonMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,284,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_zAb8nlxLZFrd" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_AyrtonMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" title="Number of Warrants Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000989" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">356,810</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted Average Life (Years), Outstanding Beginning"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember14624828" format="ixt-sec:duryear" id="Fact000993" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.79</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted - Boustead</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" title="Number of Warrants Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact000995" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,266</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted Average Life (Years), Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember" format="ixt-sec:duryear" id="Fact000999" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">5.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Granted - Ayrton</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" title="Number of Warrants Outstanding, Beginning Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember" id="Fact001001" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,018,079</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember" id="Fact001003" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted Average Life (Years), Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember" format="ixt-sec:duryear" id="Fact001005" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">4.00</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" title="Number of Warrants Outstanding, Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_WarrantMember14624859" id="Fact001007" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,446,155</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_WarrantMember14624859" id="Fact001009" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.74</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted Average Life (Years), Outstanding Ending"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember14624875" format="ixt-sec:duryear" id="Fact001011" name="SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">2.77</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001012" xml:lang="en-US">Granted
    warrants include those granted on conversion of Notes Payable - <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe" title="Number of shares warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_NotesPayableMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">677,500</ix:nonFraction></span>, Notes Payable &#8211; Related Parties &#8211; <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk" title="Number of shares warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_NotesPayableRelatedPartiesMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span>, Series
    A Preferred Shares - <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g" title="Converted shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">336,810</ix:nonFraction></span> and issued during the IPO - <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact001020" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,607,044</ix:nonFraction></span>.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zV5jmENmows3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote001021" xml:lang="en-US">Includes
    <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6" title="Warrants exercised" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember" id="Fact001023" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,273</ix:nonFraction></span> warrants exercised on a cashless basis for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj" title="Number of shares issued" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember" id="Fact001025" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,280</ix:nonFraction></span> shares of common stock.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_z33AkX1pnRpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of the warrants as of December 31, 2023 is $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20231231_zC4txtN2nCP9" title="Aggregate intrinsic value of warrants"><ix:nonFraction name="SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="Fact001027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. All of the outstanding warrants are exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s
compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zVWYrlzZ5Oq9" title="Common stock reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact001029" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000,000</ix:nonFraction></span> shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zZqAzrExO8Pf" title="Share granted under equity incentive plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember" id="Fact001031" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,180</ix:nonFraction></span> shares have been granted under the 2018 Equity Incentive Plan, of which <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231_zdTmHNQqbfgf" title="Number of shares vested under plan"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-01-01to2023-12-31" id="Fact001033" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">480,325</ix:nonFraction></span> shares have vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant restricted stock units (&#8220;RSU&#8221;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, pursuant to agreements with directors, officers and consultants, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zFnLLrAAZDzd" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">259,326</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zYkx69bvfJxg" title="Restricted stock award granted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,587</ix:nonFraction></span> RSUs
with a value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zce9Kpju1tFj" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352,400</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zxRxNN5a4Rs8" title="Restricted stock award granted value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> were granted, respectively. Compensation expense for the vesting RSUs were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td>&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Recognized in general and administrative expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">115,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170,663</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recognized in research and development expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,293</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">403,956</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEzBhMNnlrN8" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,550</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5mtOdUbbZX" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,111</ix:nonFraction></span>, respectively, of unrecognized stock-based compensation expense
related to unvested RSUs, which is expected to be recognized over a weighted-average period of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuwnfeYO91d" title="Weighted Average Life (Years), Outstanding Ending"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453" format="ixt-sec:duryear" id="Fact001047" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.06</ix:nonNumeric></span> years
and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSrNXYP6sZG7" title="Weighted Average Life (Years), Outstanding Ending"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468" format="ixt-sec:duryear" id="Fact001049" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">1.83</ix:nonNumeric></span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001051" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zXV9pKVawChd" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding, December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" title="Number of RSUs, Outstanding, Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">63,686</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.87</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" title="Number of Stock Option Outstanding, Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" title="Weighted Average Exercise Price, Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.81</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" title="Number of RSUs, Outstanding, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.06</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" title="Number of Stock Option Outstanding, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">259,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.36</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" title="Number of RSUs, Vested" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">160,744</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" title="Weighted Average Grant Date Fair Value Per RSU, Vested" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" title="Number of RSUs, Outstanding, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001073" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">197,855</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001075" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A5_zV6HtUCMIcil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001077" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zM0LnaDFnXNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82A_z4aTbusRJlK5">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Assumptions Used in Accounting for Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_z11cwYracUa3" title="Number of shares warrant to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-01-31" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,018,079</ix:nonFraction></span>
shares of common stock, with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zIh20NrCUX41" title="Exercise price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-01-31" id="Fact001081" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span>
per share, valued at inception at $<span id="xdx_90C_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20230131_zRPJuOGDR5kl" title="Warrants price"><ix:nonFraction name="SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" contextRef="AsOf2023-01-31" id="Fact001083" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">1,189,000</ix:nonFraction></span>
and as of December 31, 2023, at $<span id="xdx_90F_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20231231_zGXfDYMNMqJ7" title="Warrants price"><ix:nonFraction name="SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" contextRef="AsOf2023-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="INF" unitRef="USD">410,660</ix:nonFraction></span>. The Company determined our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy
the classification as equity instruments due to the existence of a certain net cash settlement provision that is not within the sole
control of the Company. In addition, there are certain down round provisions that could reduce the exercise price if the Company
issues securities at lower prices in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined our derivative liability from the noteholder&#8217;s Acceleration Option for the Alto Convertible Note is not clearly
and closely related to the host and should be thus accounted for as a bifurcated derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023, and for each reporting period. Key inputs for the simulation are summarized below. The Monte Carlo simulation
uses an implied VWAP for each valuation date. The implied VWAP was backsolved by setting the summation of the parts (e.g., derivatives
and debt without derivatives) equal to the cash proceeds. The simulation was then iterated and manipulated to solve for the implied share
price, which was approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TLyu8dorpa" title="Share price"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact001087" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.58</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (or an approximate <span id="xdx_902_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjE6Jw38fbK2" title="Derivative discount percentage"><ix:nonFraction name="SHPH:DerivativeDiscountPercentage" contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember" id="Fact001089" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount to the quoted market VWAP on January 11, 2023). Additionally, the Company estimates probability for various specific scenarios
impacting the warrant valuation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001091" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 80%">Annualized volatility</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zozFDVZAFK4e"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">77.51</ix:nonFraction></span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0Ggii4jslye"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001093" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">92.33</ix:nonFraction></span>%</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zoMIQofY4K5a"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.01</ix:nonFraction></span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zwCcxH7FeOC5"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001095" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.23</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Quoted VWAP*</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_fKg_____zo7lD17gzxV2"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember_srt_MinimumMember" id="Fact001096" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.59</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z4L0sAqFUTj8"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember" id="Fact001097" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.35</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zrouVaColRqk"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember" id="Fact001098" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span>% - <span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zfcKKc9EOvb2"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember" id="Fact001099" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">25</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmkmMVae8hSk"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">17</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9SRrpNLzopk" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001102" name="us-gaap:DebtInstrumentTerm">0.53</ix:nonNumeric></span> - <span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zhXNFkwkLBCb" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001104" name="us-gaap:DebtInstrumentTerm">3.03</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0F_z2LWif3ShStb">*</i></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F14_zMHZ22vWVnw6"><ix:footnote id="Footnote001105" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 50,000 iterations</ix:footnote></i></span></td></tr>
</table>


<p style="margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Annualized volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____ze5I3bDWN1aj"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">34.23</ix:nonFraction></span>% - <span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLIohlVjEEf3"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember" id="Fact001107" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">59.15</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zCGZKKlOO9g1"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.68</ix:nonFraction></span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsa6ppLFMsB4"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember" id="Fact001109" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.60</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Quoted VWAP*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">$<span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zYkXA6Tza4Ek"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.59</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zQDqXgqjbjIj"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember" id="Fact001111" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">17</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zSr9igPhn80d" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001113" name="us-gaap:DebtInstrumentTerm">0</ix:nonNumeric></span> - <span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLp7YOcr570g" title="Time period (years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001115" name="us-gaap:DebtInstrumentTerm">1.2</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F09_zHTgwsedsgfj">*</i></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F18_zw6xhmmh8TEf"><ix:footnote id="Footnote001116" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 50,000 iterations</ix:footnote></i></span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A5_z9FqO83Hz1gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001118" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zHuN5mIWCcld" style="display: none">Schedule of Derivative Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accelerated Feature</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance - December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdBqZ4p6AuHc" title="Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zyX1n8IWdRLe" title="Beginning balance" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvHA7ssNPFdl" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zJnad48mTEA" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zipNXTFL6L3k" title="Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfiv9Plk69a" title="Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Addition of new derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoUz8eWIMtrb" title="Addition of new derivatives recognized as debt discounts" style="text-align: right"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,189,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_za5rszMeX5Sj" title="Addition of new derivatives recognized as debt discounts" style="text-align: right"><ix:nonFraction name="SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts" contextRef="From2023-01-012023-12-31_custom_AcceleratedFeatureMember" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjV2cxH2Bmf9" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">778,340</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zD45NbyyDdH3" title="Gain on change in fair value of the derivative" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:DerivativeGainLossOnDerivativeWarrants" contextRef="From2023-01-012023-12-31_custom_AcceleratedFeatureMember" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3L6mkfzMUpd" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_znqHQDi2fG6g" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember14626328" id="Fact001142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,852</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<!-- Field: Split-Segment; Name: 001 -->
</ix:nonNumeric><p id="xdx_8AA_zjykzB9b6bda" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001144" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zysAiD3uWv96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_821_zqKZNps5qm1a">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. The Company paid TCG GreenChem $<span id="xdx_909_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20221231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zs0HwiZEVXj3" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2022-01-012022-12-31_custom_TCGGreenChemIncMember" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450,000</ix:nonFraction></span> during the year ended December
31, 2022 and a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20230101__20231231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zEZHhc9Bky7j" title="Payments to invoices in research and development"><ix:nonFraction name="SHPH:PaymentsToInvoicesInResearchAndDevelopment" contextRef="From2023-01-012023-12-31_custom_TCGGreenChemIncMember" id="Fact001148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,096,370</ix:nonFraction></span> during the year ended December 31, 2023, completing the contract.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001150" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zIzNnGyFJnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_82A_zYL3mUjUjp33">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no income tax expense or benefit for the years ended December 31, 2023 and 2022, since the Company has a full valuation allowance
for the net operating loss carryforwards in these periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination
by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated
based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain
tax positions to be reported for the tax years 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) amended IRC Section 174 to require capitalization of all research and development
(&#8220;R&amp;D&#8221;) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over
five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. For
tax reporting purposes, the Company capitalized $<span id="xdx_90F_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20231231_zXvHn7wdQpqg" title="Research and development expenses"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2023-12-31" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,517,485</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20221231_zCI5g925C8v7" title="Research and development expenses"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="AsOf2022-12-31" id="Fact001154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,488,530</ix:nonFraction></span> of R&amp;D expenses incurred as of December 31, 2023 and
2022, respectively.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001156" name="SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z2tRzaeOyVg3" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zjwy0KWXJK1e" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zSaqbByehmf1" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001160" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,384,472</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001161" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">635,974</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact001163" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">452,682</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact001164" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">249,847</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-01-01to2023-12-31" id="Fact001166" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,710</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msITEBzspy_zIbOgxRjiMF1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">R &amp; D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2023-01-01to2023-12-31" id="Fact001169" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">240,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31" id="Fact001170" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,975</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationProvisionAdjustments" contextRef="From2023-01-01to2023-12-31" id="Fact001172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">286,015</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationProvisionAdjustments" contextRef="From2022-01-012022-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,214</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_maITEBzspy_zKjunr4YTXDa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" contextRef="From2023-01-01to2023-12-31" id="Fact001175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">203,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" contextRef="From2022-01-012022-12-31" id="Fact001176" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,355</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,535,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">924,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shortfall of stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:ShortfallOfStockCompensationExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2023-01-01to2023-12-31" id="Fact001184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zdVsqCFpXlch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001190" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zPU61r3hFOe7" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,727,566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact001193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,173,451</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact001196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,801</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangibles (includes Section 174 capitalization)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-12-31" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,197,938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2022-12-31" id="Fact001199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,644</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact001201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">423,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2022-12-31" id="Fact001202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,229</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsbasedCompensation" contextRef="AsOf2023-12-31" id="Fact001204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,251</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest &amp; other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact001207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,140</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2022-12-31" id="Fact001208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease asset/(liability)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLeaseLiabilities" contextRef="AsOf2023-12-31" id="Fact001210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact001213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,429,136</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" id="Fact001214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,841,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Deferred tax Liabilities:</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Change in fair market value of securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFairMarketValue" contextRef="AsOf2023-12-31" id="Fact001216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,943</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2023-12-31" id="Fact001219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,544</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="SHPH:DeferredTaxLiabilitiesFiniteLivedAssets" contextRef="AsOf2023-12-31" id="Fact001222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact001225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="AsOf2023-12-31" id="Fact001228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,375,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" contextRef="AsOf2022-12-31" id="Fact001229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,841,698</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,375,903</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,841,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zrwMVAPp8x91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001237" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zI3yIfzm5n7c" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zfaXBlkgHcyk" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_z5Nl7grKpMZf" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001240" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact001242" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.9</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.3</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001246" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">R&amp;D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2023-01-01to2023-12-31" id="Fact001248" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="From2022-01-012022-12-31" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.8</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="From2023-01-01to2023-12-31" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">4.3</ix:nonFraction></td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="From2022-01-012022-12-31" id="Fact001252" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.2</ix:nonFraction></td><td style="text-align: left">%)</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maDEF_zt6yAr9oJKm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="From2023-01-01to2023-12-31" id="Fact001254" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">3.1</ix:nonFraction></td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="From2022-01-012022-12-31" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.7</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">23.2</ix:nonFraction></td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001258" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">30.5</ix:nonFraction></td><td style="text-align: left">%)</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shortfall of stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001260" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.6</ix:nonFraction></td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-01-01to2023-12-31" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-01-012022-12-31" id="Fact001264" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="Fact001266" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_ziTYp8KTsYlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalTaxableIncomeMember_zrG81Ug3Peyl" title="Net operatiing loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_FederalTaxableIncomeMember" id="Fact001269" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span>
million and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateTaxableIncomeMember_zXVNaHVK7E06" title="Net operatiing loss"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_StateTaxableIncomeMember" id="Fact001271" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.9</ix:nonFraction></span> million of net operating losses (&#8220;NOL&#8221;) carried forward to offset federal and state taxable income, if
any, in the future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making
this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax
asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be
realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">NOLs created prior to 2018 could
be carried back two years and carried forward <span id="xdx_90E_ecustom--DeferredTaxAssetsOperatingLossCarriedForward_dtY_c20230101__20231231_ztKkx6mJrK2h" title="Carried forward"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001273" name="SHPH:DeferredTaxAssetsOperatingLossCarriedForward">20</ix:nonNumeric></span> years. As amended by the Tax Cuts and Jobs Act of 2017 (TCJA), NOLs created after 2017
can no longer be carried back and are instead carried forward indefinitely. The Company has $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2016Member_zzagpmkbLOni" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_TaxYear2016Member" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,813</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2017Member_zflhOv8qsPn8" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31_us-gaap_TaxYear2017Member" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238,380</ix:nonFraction></span> of federal NOL carryforwards
from 2016 and 2017, respectively, which begin to expire in 2036. The Company has an additional $<span id="xdx_90B_eus-gaap--CurrentFederalTaxExpenseBenefit_c20230101__20231231_zxleUUsZJnK3" title="Federal income tax"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,036,599</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20230101__20231231_z3VTmnAMCrMh" title="state income tax"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-01to2023-12-31" id="Fact001281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,933,889</ix:nonFraction></span> of federal and
state NOLs created after 2017, respectively, which can be carried forward indefinitely. The NOLs can be used to offset future income limited
to the lesser of the NOL or <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_pid_dp_uPure_c20230101__20231231_zA745rNSZcVk" title="Future taxable income"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" contextRef="From2023-01-01to2023-12-31" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the year&#8217;s taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of December 31, 2023, the Company has $<span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_zyM9U2Dualt9" title="Federal Research and Development"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="From2023-01-01to2023-12-31" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD">360,715</ix:nonFraction></span>
of federal Research and Development (R&amp;D) tax credits. These can be carried forward <span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_dtY_c20230101__20231231_zE0Rx6zu1dBh" title="Carried forward"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001287" name="SHPH:DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome">20</ix:nonNumeric></span> years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $<span id="xdx_900_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zgHvq6C4B1f" title="R&amp;D tax credits"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact001289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,000</ix:nonFraction></span> of state R&amp;D tax credits which can be carried forward seven years.
These begin to expire in 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001291" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zvLsbfAmqZ93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_824_zs2tFHK7qGtg">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued
and determined that the following items are required to be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Bid Price Requirement Extension Granted until August 26, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 7.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2023, after the Company&#8217;s common stock had traded below $<span id="xdx_906_eus-gaap--SharePrice_iI_c20230831_zMaOM7ZhXbF7" title="Common stock trading price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-08-31" id="Fact001293" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uTradingDays_c20230831__20230831_zm1qjoOyB6m9"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="From2023-08-312023-08-31" id="Fact001294" format="ixt:numdotdecimal" decimals="INF" unitRef="TradingDays">30</ix:nonFraction></span> consecutive trading
days, the Company received notice from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that it was not in compliance with Nasdaq Listing
Rule 5550(a)(2) (the &#8220;Bid Price Requirement&#8221;). In
accordance with Nasdaq Rules, the Company was provided with an initial period of 180 calendar days, or until February 27, 2024, to regain
compliance with the Bid Price Requirement. On February 19, 2024, the Company submitted a plan of compliance to Nasdaq seeking an additional
180-day grace period to regain compliance with the Bid Price Requirement. On February 29, 2024, the Company received formal approval
from Nasdaq granting it an additional 180 days, or until August 26, 2024, to regain compliance &#8211; whether organically through market forces or by effectuating a reverse stock split,
should such action be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Approval to Proceed with Phase II study of Ropidoxuridine (IPdR)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing
that the Company had received the &#8220;Safe to Proceed&#8221; letter from the U.S. Food and Drug Administration for the Company&#8217;s
investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence
the Phase II study and, as a result, the Company is currently finalizing site enrollment with &#8220;first patient, first dose&#8221;
expected in the coming months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase
agreement (the &#8220;Purchase Agreement&#8221;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed
to commit to purchasing from the Company $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJDnbJVClHRk" title="Sale of stock consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact001296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>
of units from the Company, with each Unit consisting of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp4MPskJvYJi" title="Share based compensation arrangement by share based payment award description"><ix:nonNumeric contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact001298" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $2.35
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.</ix:nonNumeric></span> Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90% of the VWAP of SHPH common
stock for the five trading days immediately preceding closing. The parties entered into the Purchase Agreement in anticipation of
the Company commencing a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which the Company intends to offer a total
of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHARLaNGNfl" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact001300" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span>
Units to existing stockholders, which includes the $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEVUQW1Y2LFg" title="Sale of stock consideration received per transaction"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember" id="Fact001302" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>
Units being sold to SRO LLC, an entity which is owned by Keith Moore, CEO of Boustead Securities, LLC
(&#8220;BSL&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement allows SRO LLC up to 60 days to raise the initial $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeJXcEGJ6F95" title="Escrow deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span>, which funds will be placed in escrow with Sutter Securities,
Inc. (&#8220;SSI&#8221;), an affiliate of BSL, pursuant to the terms of an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI
on February 7, 2024 (the &#8220;Escrow Agreement&#8221;). The funds will remain in escrow up until closing on the Rights Offering. In
addition, in the event the Company fails to raise a full $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zAbw8U4vQqh" title="Right offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,500,000</ix:nonFraction></span> in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant
to which it would have the right to purchase any remaining Units not purchased by existing SHPH stockholders in the Rights Offering,
up to an additional $<span id="xdx_905_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLidexbeXPOd" title="Escrow deposit"><ix:nonFraction name="SHPH:AdditionalEscrowDeposit" contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250,000</ix:nonFraction></span> (the &#8220;Back-up Contingency&#8221;). <span id="xdx_902_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKBB7lm2dIQ" title="Initial public offering description"><ix:nonNumeric contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember" id="Fact001310" name="SHPH:InitialPublicOfferingDescription">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#8217;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Stock Awarded to Chief Financial Officer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2024, the CFO was awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zrFoglyhoPx1" title="Restricted stock units"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember" id="Fact001312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
restricted stock units (&#8220;RSUs&#8221;), with a value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zz0X64iPXAvj" title="Restricted stock value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember" id="Fact001314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,840</ix:nonFraction></span>, with such RSUs vesting in full as of the date of issuance.
Each RSU represents the right to receive one share of SHPH common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><p id="xdx_816_zkSyRzHVGiPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_015"></span>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company&#8217;s audit committee selected FORVIS, LLP (the &#8220;New Accountant&#8221;) to serve as the Company&#8217;s
independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for
the year ending December 31, 2023. As a result, the audit committee determined that BF Borgers CPA PC (the &#8220;Former Accountant&#8221;)
would no longer serve as the Company&#8217;s independent registered public accounting firm, effective as of March 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2023, the Company filed a Current Report on Form 8-K (the &#8220;Form 8-K&#8221;) with the SEC disclosing the changes in its
certifying accountant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed in the Form 8-K, the Former Accountant&#8217;s audit report on our financial statements for the years ended December 31, 2021
and 2022 contained no adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting
principles, except that the audit report on the financial statements of the Company for the year ended December 31, 2021 contained an
uncertainty about the Company&#8217;s ability to continue as a going concern (the &#8220;Going Concern Opinion&#8221;). The Former Auditor&#8217;s
Going Concern Opinion was resolved following the Company&#8217;s completion of its approximately $11.4 million initial public offering
in September 2022 and subsequent $4.0 million private placement in January 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2022 and 2021 and through the date of the Form 8-K, the Company had no &#8220;disagreements&#8221; (as defined
in Regulation S-K, Item 304(a)(1)(iv) and the related instructions) with the Former Accountant on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction
of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no reportable events for the years ended December 31, 2022 or 2021 and through the date of the Form 8-K, there were no reportable
events as defined in item 304(a)(1)(v) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
also disclosed in the Form 8-K, prior to retaining the New Accountant, the Company did not consult with the New Accountant regarding
either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit
opinion that might be rendered on the Company&#8217;s financial statements; or (ii) any matter that was the subject of a &#8220;disagreement&#8221;
or a &#8220;reportable event&#8221; (as those terms are defined in Item 304(a)(1)(iv) and (a)(1)(v) of Regulation S-K, respectively).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2023, the Company provided the Former Accountant with the disclosures contained in the Form 8-K disclosing the dismissal of
the Former Accountant and requested in writing that the Former Accountant furnish the Company with a letter addressed to the SEC stating
whether or not they agree with such disclosures. The Former Accountant&#8217;s response was filed as Exhibit 16.1 to the Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_016"></span>Item
9A. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Evaluation
of Disclosure Controls and Procedures </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
controls and procedures (as defined in Exchange Act Rule 15d-15(e)) are designed with the objective of ensuring that information required
to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized, and reported within
the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures are also designed with the objective
of ensuring that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief
Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, our management carried out an evaluation of the effectiveness of the design and operation of our disclosure controls
and procedures. Such evaluation was carried out under the supervision of our Chief Executive Officer with the participation of our President
and Chief Operating Officer, our Chief Financial Officer, and our third party financial service provider. Based on this evaluation, management
concluded that our disclosure controls and procedures were, and continues to be, ineffective as of December 31, 2023. Based on the foregoing,
our management concluded that our internal controls over the following financial reporting areas to be material weaknesses: </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">Our written accounting policies and documentation of management&#8217;s contemplation of the accounting treatment and implications over significant unusual transactions, including complex accounting associated with debt and equity transactions, was limited and resulted in ineffective monitoring of financial reporting,</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">Due to our size and stage of development, segregation of all conflicting duties may not always be possible and may not be economically feasible. During the year, we lacked sufficient review procedures and segregation
of duties such that a proper review had not been performed by someone other than preparer, including manual journal entries, and that
process documentation is lacking for review and monitoring controls over financial statements close process and financial reporting.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">As a result of the Company&#8217;s evolution since the date of our initial
formation, when we were focused on NIH SBIR research contracts with related costing allocation allowances until when we completed our
IPO and continued our development process, management has lacked a formal process to identify and properly classify operating expenses
as Research and Development (&#8220;R&amp;D&#8221;).</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">We identified findings related to overall information technology general
controls (&#8220;ITGCs&#8221;) including issues with access and segregation of duties for systems supporting the Company&#8217;s internal
control processes and controls.</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has been no change in the Company&#8217;s internal control over financial reporting during the three months
ended December 31, 2023 that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control
over financial reporting. Management
will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing
basis and are committed to taking further action and implementing additional improvements as necessary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_017"></span>Item
9B. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_018"></span>Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Options: NewSection; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_019"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_020"></span>Item
10. Directors, Executive Officers and Corporate Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors and executive officers and their respective ages and titles are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 56%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position(s)
    and Office(s) Held</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the board of directors and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer, VP for Operations and Regulatory</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Dritschilo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Operating Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mira
    Jung, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyvin
    Rich, M.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Clinical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton
    Brown, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Richards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (1)(2)(3)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Schafer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (2)(3)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    H. Senanayake, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (1)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bette
    Jacobs, Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
    Director (1)(3)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Audit Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Compensation Committee</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member
    of the Nominating and Corporate Governance Committee</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a description of the background and business experience of our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anatoly
Dritschilo, </b>M.D. Dr. Dritschilo is a co-founder of the Company and has served as Chief Executive Officer and Chairman of the Board
of Directors since the Company&#8217;s formation in December 2012. Dr. Dritschilo is a radiation oncologist by training and has held
multiple leadership positions in health care. At Georgetown University Medical School in Washington, D.C., he served principally as Department
Chair from 1980 to 2022; Chief of Radiation Oncology at MedStar-Georgetown University Hospital from 2005 to 2022; Medical Director of
Georgetown University Hospital from 1994 to 1997; and Interim Director of the NCI-funded Lombardi Comprehensive Cancer Center from 2005
to 2007. He has also served on the boards of directors of MedStar-Georgetown University Hospital, the National Capital Rehabilitation
Hospital, and the MedStar Health Research Institute. Previously, he was a founding director of Oncomed, Inc. and a member of the board
of directors of Neopharm, Inc. His 250+ scientific publications and 12 issued patents have earned him election as a Fellow of the National
Academy of Inventors. Dr. Dritschilo holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania,
a medical degree from the College of Medicine of New Jersey and residency training from the Harvard Joint Center for Radiation Therapy.
His qualifications support his service as our Chief Executive Officer and Chairman of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Michael
P. Vander Hoek</b> serves as the Company&#8217;s Chief Financial Officer, a position he was appointed to in August 2019, and Vice President,
Operations and Regulatory, a position he has held since 2019. From November 2019 until April 2021, Mr. Vander Hoek served as Director,
Finance and Business Development at Georgetown Lombardi Comprehensive Cancer Center (&#8220;LCCC&#8221;), where he directed a new five-year
$221.9 million institutional commitment for cancer center research under a new NCI-approved cancer consortium arrangement and recruited
scientists to fulfill strategic objectives with senior leaders to improve cancer research and treatment. From 2007 until November 2019,
Mr. Vander Hoek served as Associate Director, Administration, at Georgetown&#8217;s LCCC, where he was responsible for direct administrative
operations for more than 400 faculty and staff in the department of oncology, radiation medicine, pathology and biostatistics, bioinformatics
and biomathematics, including managing $216.9 million in institutional commitments to LCCC from Medstar Health, John Theurer Cancer Center
(&#8220;JTCC&#8221;), and Georgetown University. and implementing an enterprise-wide clinical trial management system for Georgetown
University and Medstar Health. From 2004 until 2007, Mr. Vander Hoek served as Chief Financial Officer at Georgetown&#8217;s LCCC. During
his time at Georgetown, Mr. Vander Hoek negotiated a series of 12 research integration agreements between LCCC and the JTCC that resulted
in the approval of an NCI recognized Consortium in 2019. From 2001 until 2004, Mr. Vander Hoek served as Vice-Chair, Planning and Administration,
at MedStar Georgetown University Hospital, where he was responsible for managing administrative and financial operations for some 440
staff, physicians, residents and fellows in the departments of Medicine and Neurology. From 1996 until 2001, Mr. Vander Hoek served as
Senior Associate Administrator, Finance and Information Systems, for the Department of Medicine, Georgetown University Medical Center,
where he designed and managed the faculty compensation system, while managing the finances and information systems for the department.
His financial management experience in publicly held companies includes Director of Managed Care Reimbursement for Critical Care America
from 1990 to 1993 and Regional Controller for Laboratory Corporation of America (LabCorp) from 1993 to 1996. His responsibilities at
both companies included extensive financial management related to mergers, acquisitions, and start-up operations. Mr. Vander Hoek holds
a Master&#8217;s in Health Services Administration from The George Washington University and a Bachelor of Arts in Biology and Psychology
from Hope College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 82; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peter
Dritschilo </b>has served as our President and Chief Operating Officer since Shuttle was formed in December 2012. He also served as our
Chief Financial Officer until 2019. Mr. Dritschilo has more than 25 years of business management experience in medical services and cancer
treatment. He has held administrative positions with Medstar-Rad America from 2001 to 2005, Georgetown University 2005 to 2006, Prince
William Hospital and the Fauquier Hospital Cancer Center 2006 to 2011 and Inova Health System&#8217;s Schar Cancer Institute from 2011
to 2018. In 2014, Mr. Dritschilo filed for Chapter 7 bankruptcy protection due to the failure of a personal business venture. Mr. Dritschilo
graduated from Georgetown University and received his MBA from the George Washington University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mira
Jung, Ph.D.</b>, a co-founder of our company, has served as our Chief Scientific Officer for Biology since December 2012, and was a member
of our board of directors from our formation in December 2012 until 2019. Since 2004, Dr. Jung has served as Professor of Radiation Medicine
and Microbiology at Georgetown University Medical School. With over 30 years of experience in molecular radiation biology research, she
is an expert in mechanisms of radiation resistance and on the roles of HDAC inhibitors in modifying the radiation response. Dr. Jung&#8217;s
research has been funded by NIH and the DOD leading to 100+ publications and nine patents granted by the USPTO, including the first reports
of HDAC inhibitor drug classes modifying cancer cell radiation resistance and protecting normal tissues from radiation damage. Dr. Jung
holds an MA degree and a PhD in Microbiology and Molecular Virology from the University of Kansas, Lawrence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tyvin
A. Rich, M.D.</b> serves as our company&#8217;s Chief Medical Officer and is responsible for the clinical development of novel radiation
sensitizers. Since 2010, Dr. Rich has served as a Staff Radiation Oncologist at the Hampton University Proton Therapy Institute in Hampton
Virginia and Professor Emeritus at University of Virginia Health Sciences Center, Department of Radiation Oncology. From 1995 until 2010,
Dr. Rich was a Professor and Chairman of the Department of Therapeutic Radiology and Oncology at the University of Virginia Health Sciences
Center. Prior to that, from 1984 through 1995, Dr. Rich was a Professor of Radiotherapy and Director of Clinics in the Department of
Radiotherapy of the University of Texas M. D. Anderson Cancer Center. He has served as the protocol chair for RTOG clinical trials that
advanced the use of chemoradiation for the treatment of rectal and pancreatic cancers. He is an expert in the applications of infusional
5-Fluorouracil for chemoradiation therapy of gastro-intestinal cancers and has authored more than 200 scientific articles, reviews and
book chapters. Dr. Rich received his undergraduate degree at Rutgers University, his medical degree at the University of Virginia, and
completed residencies in internal medicine at Georgetown University Medical Center and radiation therapy at Massachusetts General Hospital,
Harvard Medical School.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Milton
Brown, M.D., Ph.D., FNAI. </b>Dr. Brown is a co-founder of our Company, previously served as our Chief Scientific Officer for Chemistry,
and has served a member of our Board of Directors since the Company&#8217;s formation in December 2012. Since August 2022, Dr. Brown
has also served as Vice Dean of Research, Professor of Internal Medicine and the Prudence and Louis Ryan endowed chair in translational
research at Eastern Virginia Medical School. Previously, he was Director of the Center for Drug Discovery at the George Mason University
from 2020 to 2022 and Director of the Inova Center for Drug Discovery and Development from 2016 to 2020. Dr. Brown was a founder of Rivanna
Pharmaceuticals in 2004 and co-founder, Chairman and CEO of Trocar Pharma in 2020, both of which are Virginia-based biopharmaceutical
companies engaged in the discovery and development of novel small molecule therapeutics for the treatment of neurological, oncological,
and infectious diseases. Dr. Brown has also served as Director of the Drug Discovery Center at Georgetown University Medical School from
2012 to 2016 and principal investigator of the NIH/NCI funded Chemical Diversity Center from 2010 to 2015. Dr. Brown brings to Shuttle
Pharma 25 years of experience in drug discovery with over 100 publications and 67 issued patents, including discovery of novel HDAC inhibitors.
Dr. Brown was a 2015 recipient of the Percy Julian Award by the National Organization of Black Chemists and Chemical Engineers for significant
contributions in pure and/or applied research in science. He has served on government committees including the NIH Experimental Therapeutics
Study Section, the NIH Drug Discovery and Molecular Pharmacology Study Section and was a scientific counselor to the U.S. Secretary of
Health. Dr. Brown holds a Ph.D. in synthetic chemistry from the University of Alabama, and an M.D. from the University of Virginia. He
is an elected fellow of the National Academy of Inventors (FNAI). His extensive experience and expertise in drug discovery makes him
uniquely qualified to guide the company&#8217;s drug discovery program as a member of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 83; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Steven
Richards. </b>Mr. Richards was appointed to be a member of our Board of Directors in 2019. He is CEO and Founder of Endurance Media,
a media finance company based in Santa Monica, California, that launched in 2014 with a strategic alliance with eOne Entertainment and
a mandate to produce and finance commercially driven feature films. From 2006 to 2014, Mr. Richards served as Co-President and Chief
Operating Officer of Silver Pictures where he oversaw all business activities and managed a team of more than 20 people responsible for
film development, production, and financial information. From 2000 to 2006, he served as Chief Financial Officer at Silver Pictures and
from 1995 to 2000 as Vice President, Finance, at Silver Pictures. Mr. Richards holds an MBA in Finance from UCLA, a BBA in accounting
from Temple University, and holds his CPA license. We believe his experience as a chief financial officer and his knowledge of accounting
will assist in providing guidance and oversight to our Board of Directors as we grow our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joshua
Schafer. </b>Mr. Schafer was appointed to be a member of our Board of Directors in 2019. From January 2023 until present, Mr. Schafer
has been serving as the Chief Commercial Officer, and EVP Business Development at Zevra Therapeutics, a rare disease company. From November
2022 until January 2023, Mr. Schafer was interim CEO and Chair of the board of directors at PHARNEXT, an entity he has served on the
board of directors since July 2020. From December 2020 until November 2022, Mr. Schafer served as Senior Vice President and General Manager,
Autoimmune and Rare Disease Business for Mallinckrodt Pharmaceuticals Incorporated. In addition, he served as Chief Strategy and Business
Development Officer from September 2019 until December 2020, and from 2015 to September 2019 he was SCP of Business Development and General
Manager of International Operations at Mallinckrodt Pharmaceuticals. From 2009 until 2015, he served as Vice President and Oncology Therapeutic
Area Head at Astellas Pharmaceuticals Incorporated, where he was responsible for building the company&#8217;s global oncology franchise.
From 2000 until 2009, Mr. Schafer served in positions of increasing seniority at Takeda Pharmaceuticals North America, including Manager
and Senior Manager, New Product and New Business Development; Senior Product Manager, Gastrointestinal Marketing; and Director, Oncology
and Renal Marketing and Commercial Development. He began working in the healthcare and pharmaceutical industry in 1998 and has served
in various positions including management consulting at Accenture (formerly Anderson Consulting), G.D. Searle &amp; Co. (later acquired
by Pfizer) and Cognia Corporation. He received his Bachelor of Arts in Biology and German at the University of Notre Dame, his MS in
Biotechnology from Northwestern University and his MBA from Northwestern University. We believe Mr. Schafer&#8217;s extensive experience
in pharmaceutical strategy, marketing and business development will assist our Board of Directors&#8217; oversight role as we build and
develop our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chris
H. Senanayake, Ph.D.</b> Dr. Senanayake was appointed to be a member of the Company&#8217;s Board of Directors in 2021. In 2019, Dr.
Senanayake founded TCG GreenChem, Inc., a U.S. subsidiary of TCG Lifesciences Pvt. Ltd., a leading global Contract Research and Manufacturing
Services (CRAMS) company in the area of drug discovery, development and commercialization, where he serves as chief executive officer.
Dr. Senanayake has more than 30 years of pharmaceutical industry experience, making him an invaluable asset to Shuttle Pharma&#8217;s
mission as the Company advances its pharmaceutical candidates in clinical trials. He has held positions of Senior Scientist at Dow Chemical,
and Research Fellow at Merck &amp; Co, Inc. (from 1990 to 1996), Director and Executive Director of Process Research at Sepracor, Inc.
(1996 to 2002), Director of Chemical Development and Vice President of Chemical Development for Boehringer Ingelheim Pharmaceuticals,
Inc. In 2018, he was appointed as the CEO of Asta GreenChem, Inc in Richmond VA and Astatech (Chengdu) Biopharmaceuticals Corp. in China.
He has a record of leading and delivering high complexity APIs for manufacturing. Dr. Senanayake participated in development activities
of many drugs, including multi-billion-dollar blockbuster drugs, such as Crixivan, Lunesta, Jardiance, Formotorol, Desvenlafaxine and
other drug candidates. He is co-author of 425 scientific publications and is co-inventor of more than 150 patents. Dr. Senanayake received
his Ph.D. in synthetic organic chemistry at Wayne State University, where he developed the total synthesis of complex natural products
and completed the first total synthesis of grosshemin in the guaianolide family. In his postdoctoral fellowship, he conducted total synthesis
of polyol systems such as amphotericin B, compactin and C-nucleosides. We believe Dr. Senanayake&#8217;s detailed and in-depth experience
as an executive and developer of pharmaceuticals will enable him to provide value to us by introducing potential joint venture partners,
as well as enhancing our oversight through his in-depth understanding of and experience in the pharmaceuticals industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 84; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bette
Jacobs, Ph.D.</b> Dr. Jacobs was appointed to be a member of the Company&#8217;s Board of Directors in October 2022. Dr. Jacobs is an
experienced researcher, administrator, and businesswoman currently serving as a professor in the department of health systems administration
at Georgetown University and as a distinguished scholar at the O&#8217;Neill Institute for National and Global Health Law. Dr. Jacobs
holds her Ph.D. from the University of Texas and is noted for her groundbreaking transdisciplinary and cross-sector work in systems design.
As a voting member of the Cherokee Nation, she has lifetime involvement in equity programs and has testified before Congress. In addition
to serving on several start-up boards, Dr. Jacobs founded the National Coalition of Ethnic Minority Nurse Associations funded by the
NIH National Institute of General Medical Sciences. Prior to her current role at Georgetown, she served as dean at the Georgetown School
of Nursing and Health Studies, vice president for Honda of America Manufacturing, associate director of applied research at UAB Civitan
International Research Center and acting dean of graduate studies and research at California State University. She has been a fellow
and visiting professor at the University of Oxford and an academic guest scholar and lecturer at several acclaimed universities worldwide.
Her wealth of experience in research, administration and serving on boards coupled with her unique background and perspectives makes
her ideally suited to serving as a member of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Scientific
Advisory Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Theodore
L. Phillips, M.D.</b> has served as the Chair of our Scientific Advisory Committee since 2018. He held the position of Chief Medical
Officer and Clinical Director at Shuttle Pharmaceuticals from 2014 until 2018. Dr. Phillips&#8217; distinguished career has included
positions of Chair of the Department of Radiation Oncology (from1978 to 1998) and Associate Director (from 1996 to 1999) of the UCSF
Cancer Center at the University of California at San Francisco. He is highly experienced in radiation oncology clinical trials of hypoxic
radiation sensitizers. Dr. Phillips served as the principal investigator of the SBIR contract for the Phase I clinical trial of Ropidoxuridine.
He previously served as Associate Director of the Northern California Oncology Group from 1983-1990, president of the American Society
of Therapeutic Radiation Oncologists from 1984 to 1985 and is an elected member of the Institute of Medicine of the National Academy
of Science. Dr. Phillips holds a BS degree from Dickinson College in Carlisle, Pennsylvania and a MD from the University of Pennsylvania.
He provides advice to the leadership team to help design and implement clinical trials of radiation therapy and radiation response modifying
drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ralph
R. Weichselbaum, M.D. </b>has served as Scientific Advisor to Shuttle Pharmaceuticals for translational research for the discovery and
development of radiation response modifiers since 2013. Dr. Weichselbaum is the Daniel K. Ludwig Professor and Chairman of the Department
of Radiation and Cellular Oncology, the University of Chicago, a position he has held since 1985. He is also an elected member of the
Institute of Medicine, National Academy of Sciences. He has devoted his career to translational research in cancer with combined radiotherapy
and chemotherapy. Dr. Weichselbaum and his colleagues conceived &#8220;genetic radiotherapy&#8221; and developed viral constructs for
use in clinical tumor radiation sensitization. These were commercialized as TNFerade (GenVec, Inc.) and tested in a Phase I clinical
trial in prostate cancer and a Phase III clinical trial for pancreatic cancer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.
Martin Brown, Ph.D.</b> has served as a Scientific Advisor to Shuttle Pharmaceuticals for translational research for the development
of hypoxic radiation sensitizers since 2017. Dr. Brown received his Ph.D.in Cancer Biology from Oxford University in 1968 and was Director
of the Division of Radiation and Cancer Biology at Stanford University from 1984 to 2004. He is an expert in the radiation biology of
hypoxia in cancers and has more than 300 peer-reviewed published articles. He has received awards in recognition of his work, including
the Gold Medal, American Society for Therapeutic Radiology and Oncology (1999, the Failla Memorial Award, Radiation Research Society
(2000), the Weiss Medal, Association for Radiation Research (2001) and the Henry S. Kaplan Distinguished Scientist Award, International
Association for Radiation Research (2007). He developed etanidazole, a hypoxic radiation sensitizer, and tirapazamine, a hypoxic cytotoxic
drug, from bench to clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alejandro
Villagra, Ph.D.</b> has served as a Scientific Advisor to Shuttle Pharmaceuticals with expertise in cellular signaling pathways, epigenetics
and immunology since 2017. Dr. Villagra received his Ph.D. in Molecular Biology from the University of Concepcion, in Chile in 2004 and
completed post-graduate training at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida in Molecular Immunology
in 2009, in the Laboratory of Eduardo Sotomayor, MD. He joined the faculty of the Moffitt Cancer Center and Research Institute, as a
research scientist from 2009 through 2015 and advanced to Assistant Professor of Oncologic Sciences. He became an Assistant Professor
in the Department of Biochemistry and Molecular Medicine at the George Washington University (GWU) School of Medicine and Health Sciences
in 2015, as a member of the GWU Cancer Center. His research is focused on molecular and cellular roles of histone deacetylases (HDACs)
in tumor immunology and as adjuvants for immunotherapy of cancers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joseph
Armstrong, III, Ph.D.</b> joined as a Scientific Advisor to Shuttle Pharmaceuticals in 2021, He received his Ph.D. from the University
of Colorado in 1988, completed his post-doctoral work at the University of Virginia at Charlottesville and holds the position of Chief
Operating Officer at and Global Head of Business Development TCG GreenChem, Inc. He provides industry experience in chemistry, drug development
and process research, having previously held positions at Merck &amp; Co. Inc. in Rahway, N.J and in the U.K. for two pharmaceutical
companies in the areas of Pharmaceutical Research and Development. His primary areas of focus have been in the design and implementation
of efficient synthesis of drug candidates amenable to large scale production. Dr. Armstrong led the development team that designed, developed
and implemented the manufacturing process for the new treatment for Type II diabetes, Januvia TM. His team was awarded the Solvias Prize
in 2004 (Basel, Switzerland), the IChemE Aztra-Zeneca Award for Green Chemistry and Engineering in 2005 (London, England), Dr. Armstrong
has more than 40 publications and holds 10 patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Anatoly Dritschilo and Peter Dritschilo are father and son. There are no other family relationships among our directors and executive
officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Involvement
in Certain Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past ten years, other than Peter Dritschilo, our President, who filed for personal bankruptcy under Chapter 7 of the U.S.
Bankruptcy Code in 2014, no director, executive officer, promoter, or control person of the Company has been involved in the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent
    or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general
    partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive
    officer at or within two years before the time of such filing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations
    and other minor offenses);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of any order, judgment, or decree, not subsequently reversed, suspended, or vacated, of any court of competent
    jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acting
    as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage
    transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the
    foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee
    of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice
    in connection with such activity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging
    in any type of business practice; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging
    in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal
    or State securities laws or Federal commodities laws;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any Federal or State
    authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described
    in paragraph (f)(3)(i) below, or to be associated with persons engaged in any such activity;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State
    securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended,
    or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated
    any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not
    been subsequently reversed, suspended, or vacated;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not
    subsequently reversed, suspended, or vacated, relating to an alleged violation of:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    Federal or State securities or commodities law or regulation; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent
    injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal
    or prohibition order; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
    person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
    organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section
    1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that
    has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is responsible for overseeing the Company&#8217;s business consistent with its fiduciary duty to the stockholders.
This significant responsibility requires highly skilled individuals with various qualities, attributes and professional experience. There
are general requirements for service on the board of directors that are applicable to directors and there are other skills and experience
that should be represented on the board of directors as a whole but not necessarily by each director. Our Corporate Governance and Nominating
Committee, detailed below, considers the qualifications of director candidates individually and in the broader context of the board of
directors&#8217; overall composition and the Company&#8217;s current and future needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of Office</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our directors are elected to one-year terms to hold office until the next annual meeting of our stockholders and until a successor
is appointed and qualified, or until their removal, resignation, or death. Executive officers serve at the pleasure of the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to qualify for continued listing on Nasdaq, our board of directors must consist of a majority of &#8220;independent&#8221; directors,
as defined under Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. At present, four of the six directors serving
on our board of directors qualify as &#8220;independent.&#8221; Our independent directors consist of Messrs. Richards and Schafer, Dr.
Senanayake and Dr. Jacobs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 87; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has established three committees consisting of an audit committee, a compensation committee, and a nominating and
corporate governance committee. The members of each committee qualify as &#8220;independent&#8221; as defined under Nasdaq listing standards
and Rule 10A-3(b)(1). Moreover, at least one member of the audit committee qualifies as an &#8220;audit committee financial expert&#8221;
as the term is defined under Nasdaq listing standards and applicable rules and regulations of the SEC, based on their respective business
professional experience in the financial and accounting fields.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee, which consists of Steve Richards, MBA, CPA (Chair), Bette Jacobs and Chris H. Senanayake, assists our board of directors
in its oversight of the Company&#8217;s accounting and financial reporting processes and the audits of the Company&#8217;s financial
statements, including (a) the quality and integrity of the Company&#8217;s financial statements (b) the Company&#8217;s compliance with
legal and regulatory requirements, (c) the independent auditors&#8217; qualifications and independence and (d) the performance of the
Company&#8217;s internal audit functions and independent auditors, as well as other matters which may come before it as directed by the
board of directors. Further, the audit committee, to the extent it deems necessary or appropriate, among its several other responsibilities,
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    responsible for the appointment, compensation, retention, termination and oversight of the work of any independent auditor engaged
    for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discuss
    the annual audited financial statements and the quarterly unaudited financial statements with management and the independent auditor
    prior to their filing with the SEC in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    with the Company&#8217;s management on a periodic basis (i) issues regarding accounting principles and financial statement presentations,
    including any significant changes in our company&#8217;s selection or application of accounting principles; and (ii) the effect of
    any regulatory and accounting initiatives, as well as off-balance sheet structures, on the financial statements of the company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor
    the Company&#8217;s policies for compliance with federal, state, local and foreign laws and regulations and the Company&#8217;s policies
    on corporate conduct;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    open, continuing and direct communication between the board of directors, the audit committee and our independent auditors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitor
    our compliance with legal and regulatory requirements and will have the authority to initiate any special investigations of conflicts
    of interest, and compliance with federal, state and local laws and regulations, including the Foreign Corrupt Practices Act, as may
    be warranted.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee, which consists of Steve Richards (Chair) and Joshua Schafer, aids our board of directors in meeting its responsibilities
relating to the compensation of the Company&#8217;s executive officers and to administer all incentive compensation plans and equity-based
plans of the Company, including the plans under which Company securities may be acquired by directors, executive officers, employees
and consultants. Further, the compensation committee, to the extent it deems necessary or appropriate, among its several other responsibilities,
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    periodically our Company&#8217;s philosophy regarding executive compensation to (i) ensure the attraction and retention of corporate
    officers; (ii) ensure the motivation of corporate officers to achieve the Company&#8217;s business objectives; and (iii) align the
    interests of key management with the long-term interests of the Company&#8217;s stockholders;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 88; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    and approve corporate goals and objectives relating to chief executive officer compensation and other executive officers of Shuttle;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations to the board of directors regarding compensation for non-employee directors, and review periodically non- employee
    director compensation in relation to other comparable companies and in light of such factors as the compensation committee may deem
    appropriate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    periodically reports from management regarding funding the Company&#8217;s pension, retirement, long-term disability and other management
    welfare and benefit plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nominating and corporate governance committee, which consists of Joshua Schafer (Chair), Steve Richards and Bette Jacobs, recommends
to the board of directors individuals qualified to serve as directors and on committees of the board of directors to advise the board
of directors with respect to the board of directors composition, procedures and committees to develop and recommend to the board of directors
a set of corporate governance principles applicable to the Company, and to oversee the evaluation of the board of directors and Shuttle&#8217;s
management. In addition, the nominating and corporate governance committee will consider diversity of background including diversity
of race, ethnicity, international background, gender and age when evaluating candidates for board of directors membership.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the nominating and corporate governance committee, to the extent it deems necessary or appropriate, among its several other responsibilities
will:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    to the board of directors and for approval by a majority of independent directors for election by stockholders or appointment by
    the board of directors as the case may be, pursuant to our bylaws and consistent with the board of director&#8217;s evidence for
    selecting new directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    the suitability for continued service as a director of each member of the board of directors when his or her term expires or when
    he or she has a significant change in status;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    annually the composition of the board of directors and to review periodically the size of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations on the frequency and structure of board of directors meetings or any other aspect of procedures of the board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
    recommendations regarding the chairmanship and composition of standing committees and monitor their functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">review
    annually committee assignments and chairmanships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    the establishment of special committees as may be necessary or desirable from time to time; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    and periodically review corporate governance procedures and consider any other corporate governance issue.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the
business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge,
to any stockholder requesting a copy in writing from our secretary at our executive offices in Gaithersburg, Maryland. A copy of our
code of ethics is available on our website at <span style="text-decoration: underline">www.shuttlepharma.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 89; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insider
Trading Policies and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted an insider trading policy, as amended and restated on March 10, 2023 (the &#8220;Insider Trading Policy&#8221;),
overseen by the Company&#8217;s corporate secretary, that applies to all (i) directors, (ii) executive officers and (iii) employees who
are exposed to insider information (together, the &#8220;Covered Persons&#8221;). The Insider Trading Policy prohibits the use of material
non-public information obtained by Covered Persons through their involvement with the Company when making decisions to purchase, sell,
give away or otherwise trade in the Company&#8217;s securities or to provide such information to others outside the organization. Under
the Insider Trading Policy, material non-public information includes, among other things, significant changes in the Company&#8217;s
prospects, significant write-downs, liquidity problems, changes in management, extraordinary borrowings, changes in debt, planned public
offerings or any other information that may be deemed material to the Company or the Company&#8217;s prospects. Further, we have established
black-out periods to which all Covered Persons are subject, including quarterly black-out periods, which commence three weeks before
the end of each quarter and continue until the quarterly results are disclosed by filing the Company&#8217;s Quarterly Report on Form
10-Q or Annual Report on Form 10-K. The Company may impose black-out periods from time to time as other types of material non-public
information occur when material non-public events or disclosures are pending. If the Company imposes a special black-out period, the
Company will notify Covered Persons accordingly. Covered Persons are permitted to trade in the Company&#8217;s securities only when there
is no black-out period in effect and such trade has been pre-cleared by the Company&#8217;s corporate secretary, or when a qualified
10b5-1 plan has been established in accordance with federal securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clawback
Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company does not presently have in place any significant incentive compensation agreements or awards related to the Company&#8217;s
overall financial performance, the Company&#8217;s board of directors has adopted a clawback policy in order to comply with federal securities
laws. As such, we have adopted a clawback policy in which we may seek the recovery or forfeiture of incentive compensation paid by us,
including cash, equity or equity-based compensation, in the event we restate our financial statements under certain circumstances. The
clawback policy applies to our Section 16 officers, any employee who was eligible to receive incentive compensation and whose conduct
contributed to the need for a restatement, and any other former Section 16 officer or other employee who contributed to the need for
such restatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
of Directors Role in Risk Oversight</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
of the board of directors have periodic meetings with management and the Company&#8217;s independent auditors to perform risk oversight
with respect to the Company&#8217;s internal control processes. The Company believes that the board of directors&#8217; role in risk
oversight does not materially affect the leadership structure of the Company. The Company believes that its founders, leadership team
and members of the board of directors exemplify diversity and inclusivity with respect to race, sex and ethnic origin. The board of directors
presently has two diverse directors and is in the process of reviewing and vetting a female candidate to serve as a director. As such,
the Company anticipates being in full compliance with Nasdaq&#8217;s newly adopted diversity requirements by the end of its first year
of listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Section
16(A) Beneficial Ownership Reporting Compliance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our executive officers and directors, and persons who own more than 10% of our common stock, to file
reports regarding ownership of, and transactions in, our securities with the SEC and to provide us with copies of those filings. Based
solely on our review of the copies of such forms furnished to us and written representations by our officers and directors regarding
their compliance with applicable reporting requirements under Section 16(a) of the Exchange Act, we believe that all Section 16(a) filing
requirements for our executive officers, directors and 10% stockholders were met during the year ended December 31, 2023, except for
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delinquent
Section 16(a) Reports:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Late Reports</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Transactions Covered*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: justify">Milton Brown, M.D., Ph.D.</td><td style="width: 2%">&#160;</td>
    <td style="width: 20%; text-align: justify">Form 4</td><td style="width: 2%">&#160;</td>
    <td style="width: 22%; text-align: justify">common stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,921</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: justify">Form 4</td><td>&#160;</td>
    <td style="text-align: justify">common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">995</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Bette Jacobs, Ph.D.</td><td>&#160;</td>
    <td style="text-align: justify">Form 4</td><td>&#160;</td>
    <td style="text-align: justify">common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,157</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Anatoly Dritschilo, M.D.</td><td>&#160;</td>
    <td style="text-align: justify">Form 4</td><td>&#160;</td>
    <td style="text-align: justify">common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Steven Richards</td><td>&#160;</td>
    <td style="text-align: justify">Form 4</td><td>&#160;</td>
    <td style="text-align: justify">common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">995</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 90; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_021"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes all compensation awarded to, earned by, or paid to our Chief Executive Officer and Chief Financial Officer and
certain of our other executive officers for 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Aptos; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and principal position</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary
    <br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus
    <br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    Awards <br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Option
    Awards <br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Equity
    Incentive Plan Compensation ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonqualified
    Deferred Compensation Earnings<br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Other Compensation <br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    <br/> ($)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo M.D., CEO</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">287,175</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">399,175</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,253</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,668</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">268,921</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek, CFO, VP</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,530</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">302,530</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,792</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128,792</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Dritschilo, President and COO</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">242,012</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">314,012</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,333</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">178,641</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyvin
    Rich, Chief Medical Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">220,226</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">263,226</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,077</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,077</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our executive officers has entered into an employment agreement with us. The employees each will receive compensation on an annual
basis in cash, payable in monthly installments commencing at the completion of our IPO, as well as restricted stock units subject to
achieving certain key performance indicators. Certain of our executive officers are entitled to various target bonuses, upon achievement
of certain milestones. The terms of the employment agreements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 91; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Anatoly Dritschilo, MD</i></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 28, 2019, we entered into an employment agreement with our Chief Executive Officer and Chairman of the board of directors, Anatoly
Dritschilo, M.D. Under Dr. Dritschilo&#8217;s employment agreement, Dr. Dritschilo will receive base compensation of $274,000 per year.
Dr. Dritschilo also received an initial restricted stock unit grant of 45,495 restricted stock units (&#8220;RSUs&#8221;) (22,747 on
a post-reverse split basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vested over three years in substantially
equal one-third installments on each one year anniversary of the agreement. Under his employment agreement, if Dr. Dritschilo terminates
his employment for &#8220;Good Reason,&#8221; as defined in the agreement, Dr. Dritschilo will be entitled to his then applicable base
salary for period of 12 months, subject to his continued compliance with certain requirements of his employment agreement. Dr. Dritschilo
accepted a reduced salary prior to the Company&#8217;s completion of its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Michael Vander Hoek</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2019, we entered into an amended employment agreement with our Chief Financial Officer and Vice President for Operations
and Regulatory, Michael Vander Hoek. Under Mr. Vander Hoek&#8217;s employment agreement, he will receive base compensation of $227,000
and is entitled to a target bonus of $72,000 upon achievement of certain milestones. Mr. Vander Hoek also received an initial restricted
stock unit grant of 6,096 RSUs (on a post-reverse split basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs
vest over three years in substantially equal installments on each one year anniversary of the agreement. Under Mr. Vander Hoek&#8217;s
employment agreement, if he terminates his employment for &#8220;Good Reason,&#8221; as defined in the agreement, he will be entitled
to his then applicable base salary for period of 12 months, subject to his continued compliance with certain requirements of his employment
agreement. Mr. Vander Hoek accepted a reduced salary prior to the Company&#8217;s completion of its initial public offering in September
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Peter Dritschilo</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2019, we entered into an employment agreement with our President and Chief Operating Officer, Peter Dritschilo. Under Mr. Dritschilo&#8217;s
employment agreement, Mr. Dritschilo will receive base compensation of $236,000 and is entitled to a target bonus of $72,000 upon achievement
of certain milestones. Mr. Dritschilo also received an initial restricted stock unit grant of 20,760 RSUs (10,380 on a post-reverse split
basis) issuable under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments
on each one-year anniversary of the agreement. Under Mr. Dritschilo&#8217;s employment agreement, if Mr. Dritschilo terminates his employment
for &#8220;Good Reason,&#8221; as defined in the agreement, he will be entitled to his then applicable base salary for period of 12 months,
subject to his continued compliance with certain requirements of his employment agreement. Mr. Dritschilo accepted a reduced salary prior
to the Company&#8217;s completion of its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Tyvin Rich, M.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 31, 2019, we entered into an employment agreement with our Chief Clinical Officer, Tyvin Rich, M.D. Under Dr. Rich&#8217;s employment
agreement, Dr. Rich receives base compensation of $218,000 per year and is entitled to a target bonus of $43,000 upon achievement of
certain milestones. Dr. Rich also received an initial restricted stock unit grant of 3,843 RSUs (on a post-reverse split basis) issuable
under the Company&#8217;s 2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one
year anniversary of the agreement. Under Dr. Rich&#8217;s employment agreement, if Dr. Rich terminates his employment for &#8220;Good
Reason,&#8221; as defined in the agreement, he is entitled to his then applicable base salary for period of 12 months, subject to his
continued compliance with certain provisions of his employment agreement. Dr. Rich accepted a reduced salary prior to the Company&#8217;s
completion of its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
Agreement with Mira Jung, Ph.D.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, we entered into an employment agreement with Mira Jung, Ph.D., our Chief Scientific Officer, replacing the May 30, 2019
employment agreement. Under Dr. Jung&#8217;s current agreement, Dr. Jung receives a base salary of $46,000 (20%) per year and is entitled
to a target bonus of $15,620. She also received an additional grant worth $20,200 worth of Restricted Stock Units, vesting annually in
one-third increments commencing on the first anniversary date of the grant of Restricted Stock Units. Under Dr. Jung&#8217;s previous
agreement, Dr. Jung received base compensation of $46,800 and was entitled to a target bonus of $14,200 upon achievement of certain milestones.
Dr. Jung also received an initial restricted stock unit grant of 892 RSUs (on a post-reverse split basis) issuable under the Company&#8217;s
2018 Equity Incentive Plan, which RSUs vest over three years in substantially equal installments on each one-year anniversary of the
agreement. Under Dr. Jung&#8217;s employment agreement, if Dr. Jung terminates her employment for &#8220;Good Reason,&#8221; as defined
in the agreement, Dr. Jung is then entitled to her then applicable base salary for period of 12 months, subject to her continued compliance
with certain requirements of her employment agreement. Dr. Jung accepted a reduced salary prior to the Company&#8217;s completion of
its initial public offering in September 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 92; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, on a post-reverse split basis, a total of 259,326 RSUs have been granted to our executive officers and Directors
under our 2018 Equity Incentive Plan (the &#8220;Plan&#8221;), 99,273 RSUs were outstanding on December 31, 2022, 160,744 RSUs vested,
of which 197,855 remain subject to vesting. The Company has filed a registration statement on Form S-8 (SEC File No. 333-268758) to register
the shares granted under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the number of shares of common stock underlying outstanding equity incentive awards
for each of our executive officers as of December 31, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised
    Options Exercisable (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised
    Options Unexercisable (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Exercise Price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Expiration Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares or Units of Stock
    not yet Vested (#))</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Market Value of Shares or Units not
    yet Vested ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">Bette Jacobs</td><td style="width: 2%">&#160;</td>
    <td style="width: 7%">10/28/2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">11,863</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%; text-align: right">(1</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">5,457</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Milton Brown</td><td>&#160;</td>
    <td>02/15/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,667</td><td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,667</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    restricted stock units vest in two installments on the anniversary of the grant date.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018
Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan provides for equity incentives to be granted to our employees, executive officers or directors and to key
advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not less than the fair market
value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock awards, other stock- based
awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s compensation committee
or, alternatively, if there is no compensation committee, the Company&#8217;s board of directors. We have reserved 3,000,000 shares of
our common stock for issuance under the Plan, of which 678,180 shares have been granted under the Plan as of the date of this Annual
Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of our non-employee directors, pursuant to the terms of director agreements (the &#8220;Director Agreements&#8221;), between each of
the directors and the Company, receives compensation on an annual basis consisting of $25,000 in cash, payable in quarterly installments
commencing 90 days after completion of our initial public offering, and received $100,000 in restricted stock units (&#8220;RSUs&#8221;)
upon their respective dates of election. The RSUs vest over a two-year period in one third increments, with one-third vesting immediately
upon signing and one-third vesting on each of the first and second anniversary of election. In addition, non-employee directors will
also be reimbursed for out-of-pocket costs incurred in connection with attending meetings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 93; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_022"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRINCIPAL
STOCKHOLDERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of the date of this Annual Report, the beneficial ownership of our common stock by each director and executive
officer, by each person known by us to beneficially own 5% or more of our common stock and by directors and executive officers as a group.
Unless otherwise stated, the address of the persons set forth in the table is c/o Shuttle Pharmaceuticals Holdings, Inc., 401 Professional
Drive, Suite 260, Gaithersburg, MD 20879.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. Unless
otherwise indicated, the stockholders listed in the table below have sole voting and investment power with respect to the shares indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
share ownership figures include shares of our commons stock issuable upon securities convertible or exchangeable into shares of our common
stock, whether or not convertible or exchangeable within 60 days of the effective date of this Annual Report. Such shares are deemed
outstanding and beneficially owned by such person only for purposes of computing his or her percentage ownership, but not for purposes
of computing the percentage ownership for any other person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 20, 2024, there were issued and outstanding 16,794,893 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Names and addresses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>common
                                            stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>beneficially</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>owned
                                            (#)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>shares
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>common
                                            stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>beneficially</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>owned
                                            (%)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Named Executive Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly Dritschilo,
    M.D.<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">4,309,607</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">25.8</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton Brown, M.D., Ph.D.<sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Mira Jung, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,071,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Michael Vander Hoek</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Peter Dritschilo</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,560</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tyvin A. Rich, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Steve Richards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Joshua Schafer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,707</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chris H. Senanayake</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,791</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bette Jacobs<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,201</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">All directors and officers as a group (ten persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,609,852</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other 5% beneficial owners:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>None.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denotes
    the holder owns less than one percent of the outstanding common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#177;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    persons named above have full voting and investment power with respect to the shares indicated. Under the rules of the SEC, a person
    (or group of persons) is deemed to be a &#8220;beneficial owner&#8221; of a security if he or she, directly or indirectly, has or
    shares the power to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition of such
    security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 1,085,200 shares of common stock held of record by Dr. Anatoly Dritschilo, (ii) 1,104,407 shares of common stock and warrants
    to purchase 20,000 shares of commons stock, each held of record by Joy Dritschilo, his spouse, and (iii) 2,100,000 shares held by
    PAL Trust, a trust formed for the benefit of Dr. and Mrs. Dritschilo&#8217;s adult children and for which a third party serves as
    external trustee and two of their children serve as co-trustees . Dr. Dritschilo disclaims beneficial ownership over all securities
    held by Mrs. Dritschilo and PAL Trust.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(2)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consists of (i) 1,094,610 shares of common stock which includes 25,000
shares of common stock, which vest in three installments with 16,667 shares not yet vested.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">(3)</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Does not include 11,862 restricted stock units which remain subject to vesting.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
of Control</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 94; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
authorized for issuance under equity compensation plans </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2018
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers
or directors and to key advisers and consultants. Equity incentives may be in the form of stock options with an exercise price of not
less than the fair market value of the underlying shares as determined pursuant to the Plan, restricted stock awards, other stock- based
awards, or any combination of the foregoing. The Plan is administered by the Company&#8217;s compensation committee or, alternatively,
if there is no compensation committee, the Company&#8217;s board of directors. We have reserved 3,000,000 shares of our common stock
for issuance under the Plan, of which 678,180 shares have been granted under the Plan as of the date of this Annual Report, of which
197,855 remain subject to vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information as of December 31, 2023 about our equity compensation plans and arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Plan category</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of securities to be issued upon exercise of outstanding
    options, warrants and rights</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- average exercise price of outstanding options,
    warrants and rights</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of securities remaining available for future
    issuance under equity compensation plans</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">197,855</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1.47</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">2,321,820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">197,855</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
                                            </span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,321,820</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Outstanding
equity incentive grants consist entirely of restricted stock units which automatically vest over time into an equal number of shares
of common stock at no additional cost to the holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may find additional information regarding our equity compensation plans in Note 7 of the Notes to our Consolidated Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_023"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
described below, during the last two fiscal years, there were no transactions or series of similar transactions to which we were a party
or will be a party, in which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    amounts involved exceed or will exceed $120,000; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of any
    of the foregoing had, or will have, a direct or indirect material interest.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated two loans obtained in 2018 for a total of $350,000 from Joy Dritschilo, the wife our Chief
Executive Officer, which loans accrued interest at 7.5% since the date of inception,, into a single loan between Mrs. Dritschilo and
the Company (the &#8220;2018 Consolidated Loan&#8221;) such that, with accrued interest, the 2018 Consolidated Loan had a principal balance
of $424,005.65, bore interest at a rate of 7.5% per annum, and had a maturity date of December 31, 2021. The 2018 Consolidated Loan were
then extended until June 30, 2022, pursuant to an amendment to the 2018 Consolidated Loan agreement dated January 24, 2022. On July 29,
2022, the Company and Mrs. Dritschilo entered into an amendment to the 2018 Consolidated Loan, pursuant to which repayment was extended
through June 30, 2023. On January 15, 2023, following closing on the Convertible Note and Warrant offering to Ayrton Capital, the 2018
Consolidated Loan was paid off in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 95; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated the May 2018 Loan and the September 2019 Loan with our Chief Executive Officer (the &#8220;2019
Consolidated Loan&#8221;), such that, with accrued interest, the 2019 Consolidated Loan had a principal balance of $138,448.20, bears
interest at the rate of 7.5% per annum, and has a maturity date of December 31, 2021. The 2019 Consolidated Loan was extended until June
30, 2022, pursuant to an amendment to the 2019 Consolidated Loan agreement dated January 24, 2022. On July 29, 2022, the Company and
our Chief Executive Officer entered into an amendment to the 2019 Consolidated Loan, pursuant to which repayment was extended through
June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan agreement with Mrs. Dritschilo in the amount of $120,000 (principal), bearing interest
at the rate of 7.5% per annum, with a single balloon payment due at maturity on June 21, 2022 (the &#8220;June 2021 Loan Agreement&#8221;).
On July 29, 2022, the Company and Mrs. Dritschilo entered into an amendment to the June 2021 Loan Agreement, pursuant to which repayment
was extended through June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 1, 2022, in conjunction with our private placement of $125,000 of units consisting of 10% notes and warrants to purchase common
stock, which were sold to three accredited investors in total, Mrs. Dritschilo purchased a $50,000 note and received warrants to purchase
20,000 shares of common stock at $2.50 per share. The notes and warrants were sold pursuant to an exemption from registration pursuant
to Rule 506(b) of Regulation D of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR, The Company paid TCG GreenChem $450,000 during the year ended December
31, 2022 and a total of $1,096,370 during the year ended December 31, 2023, completing the contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval and Ratification of Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions are subject to the review, approval, or ratification of our board of directors or an appropriate committee
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_024"></span>Item
14. Principal Accountant Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table represents fees for professional audit services for the audit of the Company&#8217;s annual financial statements for
the fiscal years ended December 31, 2023 rendered by FORVIS LLP and the Company&#8217;s annual financial statements for the fiscal years
ended December 31, 2022, rendered by BF Borgers CPA PC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees <sup>1</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">429,555</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">56,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other Audit Fees<sup>2</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">27,500</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees <sup>3</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,588</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">441,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">88,588</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><sup>1.</sup></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
    fees consist of fees for professional services rendered by the principal accountant for the audit of the Company&#8217;s annual financial
    statements and review of the financial statements included in the Company&#8217;s Initial Public Offering, Form 10-K and Form 10-Q
    and for services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements.&#160;&#160;Fees
    include out of scope costs related to convertible notes and warrants.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><sup>2.</sup></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Other audit fees consist of transition costs from the
    prior audit firm.</i></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><sup>3.</sup></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Tax
    fees. Consists of professional services rendered by our principal accountant for tax compliance, tax advice and tax planning.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Pre-Approval Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is tasked with pre-approving any non-audit services proposed to be provided to the Company by the independent auditors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_025"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_026"></span>Item
15. Exhibit and Financial Statement Schedules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.75in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; width: 0.1in; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective March 30, 2022 (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex3-4.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Designation for Series A Convertible Preferred Stock, effective April 6, 2022 (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex3-5.htm" style="-sec-extract: exhibit">Certificate of Amendment to Amended and Restated Certificate of Incorporation, effective June 22, 2022 (incorporated by reference to Exhibit 3.5 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on June 23, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/ex3-1.htm" style="-sec-extract: exhibit">Second Amended and Restated By-Laws (incorporated by reference to Exhibit 3.1 to the current Report on Form 8-K filed on November 1, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex4-1.htm" style="-sec-extract: exhibit">Form of Convertible Note, dated February 2022 (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex4-2.htm" style="-sec-extract: exhibit">Form of 10% Promissory Note, dated August 2022 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex4-3.htm" style="-sec-extract: exhibit">Form of Warrant, dated August 2022 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex4-4.htm" style="-sec-extract: exhibit">Form of Public Offering Warrant (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex4-2.htm" style="-sec-extract: exhibit">Form of Underwriting Warrant issuable to Boustead Securities LLC (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-1.htm" style="-sec-extract: exhibit">Form of Subscription Agreement for Series A Convertible Preferred Stock (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-2.htm" style="-sec-extract: exhibit">2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-4.htm" style="-sec-extract: exhibit">Employment Agreement, dated July 30, 2014, between Shuttle Pharmaceuticals Holdings, Inc. and Tyvin Rich (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-5.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201400013C, dated September 19, 2014, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-6.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201400013C Amendment of Solicitation/Modification of Contract, dated August 3, 2015, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (Radiosensitizer Option Phase II) (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-7.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201600027C, dated September 19, 2016, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-8.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261600038C dated September 19, 2016 between Shuttle Pharmaceuticals, LLC. and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-9.htm" style="-sec-extract: exhibit">Material Transfer Agreement, dated April 25, 2017, between Shuttle Pharmaceuticals, Inc. and George Washington University (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-10.htm" style="-sec-extract: exhibit">Employment Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Peter Dritschilo (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-11.htm" style="-sec-extract: exhibit">Employment Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Mira Jung (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-12.htm" style="-sec-extract: exhibit">Employment Agreement, dated June 28, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-13.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement, dated September 1, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Michael Vander Hoek (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-14.htm" style="-sec-extract: exhibit">Form of Letter Agreement with Director (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-15.htm" style="-sec-extract: exhibit">Subaward Agreement dated October 28, 2014 between Shuttle Pharmaceuticals, LLC and LifeSpan/Rhode Island Hospital (incorporated by reference to Exhibit 10.15 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-16.htm" style="-sec-extract: exhibit">Sublicense Agreement, dated February 15, 2019, between Shuttle Pharmaceuticals Inc. and Propagenix, Inc. (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222017616/ex10-17.htm" style="-sec-extract: exhibit">SBIR Contract #HHSN261201800016C/75N91018C00016 Agreement between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-18.htm" style="-sec-extract: exhibit">Promissory Note, dated as of August 24, 2019, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-19.htm" style="-sec-extract: exhibit">SBIR Phase II Contract #75N9101C00031, dated September 6, 2019, between Shuttle Pharmaceuticals, Inc. and National Institute of Health National Cancer Institute (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-20.htm" style="-sec-extract: exhibit">Director
    Offer Letter, dated December 2, 2020, between Chris H. Senanayake and Shuttle Pharmaceuticals Holdings, Inc. (incorporated by
    reference to Exhibit 10.20 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-21.htm" style="-sec-extract: exhibit">Promissory Note, dated December 1, 2020, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.21 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-22.htm" style="-sec-extract: exhibit">Promissory Note, dated December 1, 2020, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-23.htm" style="-sec-extract: exhibit">Non-Disclosure, Evaluation and Option Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals, Inc. and University of Virginia Licensing &amp; Ventures Group (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-24.htm" style="-sec-extract: exhibit">First Amendment to Non-Disclosure, Evaluation and Option Agreement, dated November 30, 2019, between Shuttle Pharmaceutical, Inc. and University of Virginia Licensing &amp; Ventures Group (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-25.htm" style="-sec-extract: exhibit">Form of Note and Warrant Subscription Agreement, dated December 28, 2021 (incorporated by reference to Exhibit 10.25 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-26.htm" style="-sec-extract: exhibit">Form of Note, dated December 28, 2021 (incorporated by reference to Exhibit 10.26 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-27.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant, dated December 28, 2021 (incorporated by reference to Exhibit 10.27 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-28.htm" style="-sec-extract: exhibit">Consulting Agreement, dated January 1, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Steven Bayern (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-29.htm" style="-sec-extract: exhibit">Amendment to Promissory Note, dated January 25, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.29 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-30.htm" style="-sec-extract: exhibit">Amendment to Promissory Note, dated January 25, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.30 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-31.htm" style="-sec-extract: exhibit">Form of Convertible Note Subscription Agreement and Investor Rights Agreement (incorporated by reference to Exhibit 10.31 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex10-32.htm" style="-sec-extract: exhibit">Amendment No. 1 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals Holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.32 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex10-33.htm" style="-sec-extract: exhibit">Amendment No. 2 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals holdings, Inc. and Joy Dritschilo (incorporated by reference to Exhibit 10.33 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222023497/ex10-34.htm" style="-sec-extract: exhibit">Amendment No. 2 to Promissory Note, dated July 29, 2022, between Shuttle Pharmaceuticals Holdings, inc. and Anatoly Dritschilo (incorporated by reference to Exhibit 10.34 to the Registration Statement on Form S-1/A (File No. 333-265429) filed on August 18, 2022).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222026195/ex10-1.htm" style="-sec-extract: exhibit">Manufacturing Agreement, dated September 14, 2022, between Shuttle Pharmaceuticals, Inc. and TCG GreenChem, Inc. (incorporated by reference to Exhibit 10.1 to the Current report on Form 8-K filed September 19, 2022).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and the investors named therein (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-2.htm" style="-sec-extract: exhibit">Form of Note, dated January 11, 2023 (incorporated by reference to Exhibit 10.2 to the Current Report on form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-3.htm" style="-sec-extract: exhibit">Form of Warrant, dated January 11, 2023 (incorporated by reference to Exhibit 10.3 to the Current Report on form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-4.htm" style="-sec-extract: exhibit">Form of Security Agreement, dated January 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC &#8211; Segregated Portfolio B (incorporated by reference to Exhibit 10.4 to the Current Report on form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-5.htm" style="-sec-extract: exhibit">Form of Intellectual Property Security Agreement, dated January 11, 2023 (incorporated by reference to Exhibit 10.5 to the Current Report on form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-6.htm" style="-sec-extract: exhibit">Form of Subsidiary Guaranty (incorporated by reference to Exhibit 10.6 to the Current Report on form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223001308/ex10-7.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated January 11, 2023 (incorporated by reference to Exhibit 10.7 to the Current Report on form 8-K filed January 12, 2023).</a></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.42</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223005722/ex10-1.htm" style="-sec-extract: exhibit">Form of Director Offer Letter (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed February 22, 2023).</a></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.43</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223007073/ex10-1.htm" style="-sec-extract: exhibit">Proposal for Service Agreement, dated March 7, 2023, between Shuttle Pharmaceuticals, Inc. and University of Iowa Pharmaceuticals (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed March 9, 2023).</a></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223007686/ex10-44.htm" style="-sec-extract: exhibit">Amended and Restated Insider Trading Policy, effective March 10, 2023 (incorporated by reference to Exhibit 10.44 to the Annual Report on Form 10-K filed March 15, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223007686/ex10-45.htm" style="-sec-extract: exhibit">Form of Executive Compensation Clawback Policy, effective March 10, 2023 (incorporated by reference to Exhibit 10.45 to the Annual Report on Form 10-K filed March 15, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223007686/ex10-46.htm" style="-sec-extract: exhibit">Letter Agreement, dated March 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and Alto Opportunity Master Fund, SPC &#8211; Segregated Portfolio B, as Collateral Agent (incorporated by reference to Exhibit 10.46 to the Annual Report on Form 10-K filed March 15, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/ex10-1.htm" style="-sec-extract: exhibit">Research Agreement, dated March 16, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on March 22, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223008489/ex10-2.htm" style="-sec-extract: exhibit">Material Transfer Agreement, dated March 21, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on March 22, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223016290/ex10-1.htm" style="-sec-extract: exhibit">Amendment Agreement, dated May 10, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC &#8211; Segregated Master Portfolio B. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May 11, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223020084/ex10-1.htm" style="-sec-extract: exhibit">Amendment No. 1 to the Amendment Agreement, dated June 4, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC &#8211; Segregated Master Portfolio B. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 5, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223036358/ex10-1.htm" style="-sec-extract: exhibit">Consulting Agreement, dated October 1, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and Joseph Armstrong (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 5, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315223038736/ex10-1.htm" style="-sec-extract: exhibit">License Agreement, dated October 24, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc. and Georgetown University (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on October 30, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.53</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/ex10-1.htm" style="-sec-extract: exhibit">Asset Purchase Agreement, dated January 30, 2024, by and between Shuttle Pharmaceuticals Holdings, Inc., Alan Kozikowski and Werner Tueckmantel (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 5, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.54</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Diagnostics, Inc. and SRO LLC (incorporated herein by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on February 13, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.55</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/ex10-2.htm" style="-sec-extract: exhibit">Placement Agent and Advisory Services Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc. and Boustead Securities, LLC (incorporated herein by reference to Exhibit 10.2 to the Current Report on Form 8-K filed on February 13, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">10.56</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315224005970/ex10-3.htm" style="-sec-extract: exhibit">Offering Deposit Account Agency Agreement, dated February 7, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Boustead Securities, LLC and Sutter Securities Inc. (incorporated by reference to Exhibit 10.3 to the Current Report on Form 10-K filed on February 13, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1757499/000149315222015884/ex10-3.htm" style="-sec-extract: exhibit">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-265429) filed on June 3, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex21.htm">List of Subsidiaries.*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of FORVIS LLP*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of BF Borgers CPA PC*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded
    within the Inline XBRL document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Filed
herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Furnished herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_027"></span>Item
16. Form 10&#8211;K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99; Value: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ds_028"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this Annual Report to
be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
    Pharmaceuticals Holdings, Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Anatoly Dritschilo, M.D.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo, M.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman
    of the board of directors,</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
    Executive Officer and President</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 21, 2024 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Anatoly Dritschilo</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the board of directors,</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    executive officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Michael Vander Hoek</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    financial and accounting officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Chris H. Senanayake</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    H. Senanayake</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Steven Richards</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    Richards</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joshua Schafer</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
    Schafer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Milton Brown</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Milton
    Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bette Jacobs</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bette
    Jacobs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 21,
    2024</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>ex21.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>List
of Subsidiaries</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuttle
Pharmaceuticals, Inc., a Maryland corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shuttle Diagnostics, Inc., a Maryland corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
of Independent Registered Public Accounting Firm</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-268758) and Form S-1 (No. 333-269414) of
Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;Company&rdquo;) of our report dated March 21, 2024, with respect to the consolidated
financial statements of the Company, included in this Annual Report on Form 10-K for the year ended December 31, 2023. Our report contains
an explanatory paragraph describing conditions that raise substantial doubt about the Company&rsquo;s ability to continue as a going
concern as described in Note 1 to the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
FORVIS, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Atlanta,
Georgia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
21, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; color: Black; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Black; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Black; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (No. 333-268758) and Form S-1 (No. 333-269414), as amended of Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;Company&rdquo;)
of our report dated March 15, 2023, with respect to the consolidated financial statements of the Company, included in this Annual Report
on Form 10-K for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-2_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified
Public Accountants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lakewood,
CO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
21, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Black"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Anatoly Dritschilo, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2023 of Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 21, 2024</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Anatoly Dritschilo</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael Vander Hoek, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2023 of Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this Annual Report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this Annual Report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Annual Report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.
Disclosed in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.7in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 21, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Vander Hoek</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 5.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 5.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;Company&rdquo;) on Form 10-K pursuant for the
year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I,
Anatoly Dritschilo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 21, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/
    s/ Anatoly Dritschilo</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anatoly
    Dritschilo M.D.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Shuttle Pharmaceuticals Holdings, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended
December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Michael Vander
Hoek , Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 21, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Vander Hoek</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Vander Hoek </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" $G G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **YB[\:Q6/B";3[BUQ!%*(FF$H+ F(R[O+QG: ""<]>U74\6Z.\UI
M%]KVO=A3"'C9<AB0A.1QN(.,XSVH VJ*R-9\16VE17:KNFNK>V>X\I58@ *Q
M&Y@"%SM.,^E55\9Z?%'(;]C 4=EPBM)PJ(S,<+P '&?;F@#H:*Q;;Q/9S7DE
MJ^1.+AX42-6D)"[<N<#Y1\P&3QSUJ/\ X2RTGO[2VL<RM+=?9I@ZLC1?NW<'
M!'.=E &]1110 4444 %%,E?RHG<C(52<5QUG\0UN8[9Y+#R_.: D12^=A)4=
ME^ZN=XV8*X[CF@#M**QCXMT93!NO J3PF>.0HP1D"ECAL8SM!..O!H?Q;H\7
MV3S;LQF[ :(21LIP6V@G(^4$X )QF@#9HK-N-6:W\066FM;$K=Q2.LV\<%,9
M&W_@0YK2H **** "BBB@ HHKGO$_BH>')(%-JLX>&:=BTPCPL84D#(.YCNX'
M% '0T5S^G^+K.[N;JWG#P30R2!%\MSO5 I)!QC=AAE1DU8MO%>D7;0K#=%FF
M#D#RV^4(<,6X^4 \<XH V**S-.U^RUJVGETF5;IH<93E.2,KU'0CD&D\/ZT=
M<L99VMS \5Q);LH?>I9&P2K<97WP* -2BBB@ HHHH ***YW6?%HT?6X[%K3S
M4*0L[B4!OWDAC 5,?-@C)Y'% '145SNE^,[&]T]YKC?%-$I:2)8W;Y=[("OR
M_,,KU'2K2>+-&D1Y$O5,4=NMR\@1MBQGD$G& 3V'6@#8HK(/B*UGT2;4K"2*
M:.)BK>:YB",#@AB02N/I5C1-3&LZ-::@L+0BXC#B-B"5S[CK0!?HHHH *IWN
MJV>G36L5W.(GNY?)@!!.]\9QQTZ=ZN5CZYH9UFXLBTBK% 9"_P#>^9"JE?<$
M@_A0!H6M];7D"S6\JO&S,H/3)4D-U]"#1-?VMO+!%-<1(]PVR)689<X)P/P!
MKCK;P+?+>Z?=7=U#.]N,NJNR*KB5Y-RX!R&W $<=.XXI=-\"7-A]D:22RN6M
MKY;I?,0\*8RC1C.<!204^@SZT =9/J]E;ZI;:;-<*MY<JS118.6"]>>@_'WJ
M2YO[6RA,MS<111AE0LS #+$!1^)(KG=4\+:C?ZZ^J1:C'&\<T#P1&+(V1\D%
MNHSODZ>HK.;X>RBT>-&LF9HEW!XR5DD6X\T%N.?ERN>O)[4 =G#?V\\<CQR9
M6.1HVRI'S+U SUZ=J=;7<-W;Q30/N290Z9!4D$9Z'FN7@\(W<&JB[9[.9#).
MWER*2(?,?>&3_:'3MQCGM678>"M135(U=K>);-;8+=E"7<QPE"$_V23R#CIW
M[ '=2ZA:P2P1RW$2O<.8X@6'SL 20/? -2F5 C,77:IP3GH?2N'TSP'>V;02
MW$UE++%>K<8*':H\GRV*\##9PXP,9 ],TVR^']U9V449EMIY(YT>19V=XKD*
MCIN9<<-\^[OR!D]P =K8WL.HV,%Y;$F&=!(A(P2#TXJQ6?H6GOI.@V-A(ZN]
MM D3,HP"0,9%:% (**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#*;PY8/<ZG<-&3-J2>7-)QN"[ F%.,
M@8'YU"?">GG4+>\P_FPQ)"00K"14SMSD$]ST(SWK;HH PYO".G.9Q;^;:0W%
MN;::&W(2.1,,!D8ZC>V,8Z\YIK^#M.?[1EKC]^DR/A^TJ(C8X](UQ^-;U% &
M'%X2LH+[[7!-=13,SERD@^=6VY0\=/E!XYZ\U#I?@C3-)GBEMVN"\4JRKN<=
M51D&< 9^5S[GJ37144 %%%% !1110 V1!)&R-G# @XK*M?#.GV5AIUI;HT<5
MA(LD>W +,JE<M@<G!.:UZ* .9M_ 6EVMU;W$,ET'MT"1Y<'&$*9Y&?NL>.F>
M<4^W\#:7:RVLL1F$EOGYCL.\%R^""N ,DXV[<9Q71T4 9EUHD=WK=IJ;7=TD
MEJK+'$C+Y9#8W9&W/.!W[5IT44 %%%% !1110 50O-&L[_4[.^N8_,ELU<1!
M@"HW;<G!'7Y1@U?HH P;OP=IM[YOG-<?O7F=MLF.90 V./\ 9&/ZU#%X%TN.
M."-FN'CAF>?864!F?[V<*"![# ]17244 8UCX9M=.T>XTZUFN(XID\OS$*K(
M@Q@88*.0.YR?>K>CZ5'HNG1V4$TLL,0Q'YNW*KC  V@#%7J* "BBB@ HHHH
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M2=/N/,\^PM9/-8/)OA4[V P"<CD@=ZE^Q6N_?]FAW;M^[RQG=MVY^NWCZ<4
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M5/7&]S=$?DK_ +7_ 'T:/)4_WO\ OHU)12&,\I?]K_OHTGDJ/[W_ 'T:DHH
MC\E?]K_OHT>2O^U_WT:DHH C\E<8^;_OHTOE*#GYO^^C3Z* (_)3_:_[[/\
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M7(X&./:KL.EZ=:ZE&CP*=TLT4:23;A.@CRDGMD\#MSQTJ&J*6L"TZKVD2_\
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M&UPRYY8MC!Q[Y'< [:*:.9=T4BNO'*G/49_D13ZXYM'ULP.D<ES"(X',0BN
MH,@BB" X/(W*_!X]>#1X<OKF[\7:FES+=$Q!U6,R,8_O\$KG"$# ' W#)H Z
MR*Y@G+B&:.0HVQMC [6]#Z'VJ6N*MM!O$N+(K97,5I:7JO''YR)*%*.K%BC8
M=02N,G=C=U[R+;>(9(8EN(KSRXDACF6.Z59)BIDWLK;N,YC/)!(&* .NAFCN
M(EEAD62-N593D'\:?7):!::E976GZ=.9$BCMQ<3#S,[6&4V9'!!R&^JFNMH
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M2GO+M>#(2BGMSUKI0H5<*, 5I4K75D13I6=V(%"@ # %+116!L**GM/]>_\
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M]2?]\K_A4]%%PL0>1+_S]2?]\K_A1Y$O_/U)_P!\K_A4]%%PL0>1+_S]2?\
M?*_X4>1+_P _4G_?*_X5/11<+$'D2_\ /U)_WRO^%'D2_P#/U)_WRO\ A4]%
M%PL9]W#* N;ESU_A7_"J;1R?\]W_ .^5_P *TKWHGXU2:M8/0AK4K&.3_GNW
M_?*_X5&T<G_/=O\ OE?\*L-4;5JF18KF-_\ GLW_ 'RO^%,,<G_/9O\ OE?\
M*G:F&J3$1>6__/9O^^5_PH\M_P#GN_\ WRO^%2455Q#!')_SW?\ [Y7_  J:
MTCD\]_W[_<'\*^OTIHJ>T_U[_P"X/YU$GH-+4E,<G_/=_P#OE?\ "HS')_SW
M;_OE?\*L&F&H3*L5S')_SW;_ +Y7_"F&.3_GLW_?*_X5.:8:I,5B QR?\]F_
M[Y7_  IGER?\]F_[Y7_"IC3:M,1%Y;_\]F_[Y7_"CRW_ .>S_P#?*_X5)13N
M(C\M_P#GN_\ WRO^%*(Y/^>[_P#?*_X4^E%*X6)+*.3;-^_?[_\ =7^Z/:IV
MCD_Y[O\ ]\K_ (4VR^[-_O\ _LHJ8UFWJ6EH5S')_P ]V_[Y7_"F&.3_ )[M
M_P!\K_A5@U&U"8K%<QR?\]F_[Y7_  IAC?\ Y[-_WRO^%3M3#5H1$8W_ .>S
M?]\K_A2>6_\ SV?_ +Y7_"I**JXB/RW_ .>[_P#?*_X4OER?\]W_ .^5_P *
M?2BE<+"VD<GVIOW[_P"K_NKZ_2K31R?\]W_[Y7_"HK3_ (^F_P"N?]:M-6<G
MJ5%:%=HY/^>[?]\K_A4;1R?\]V_[Y7_"K#5&U"8-%=HY/^>S?]\K_A3#&_\
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MWQ(J6C?:[TB\_P!1B7)?\.W7O2?VAKQ9P-5<K&,O(+Q=B<XY;. <\8H^J/\
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MEI8]@?S$V$X#;A@GTS64MRX["-4;5!?ZG;:?)#'<._FS9\N..-G9@/O'"@G
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M_=/TH Z"S_X\8/\ KFO\JGJ"S_X\8/\ KFO\JGKC>YNBC_:5BVK2V+,OVN*
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MV7W9O]__ -E%3&LGN6MAAJ-JD-1M30$;4PT]J8:M$C:***8@I124HH FM/\
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MO\*/MD7_ $T_[]-_A3WGBC<(\B*Q&0"P!(R!G\R/S%24!J0?;(O^FG_?IO\
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M79H]@N]<TMPNW4+4X])15,ZQIW_/];?]_!7E>ZC=6BP<5U(>*EV/43J^G_\
M/];_ /?P5EZ]J5I-I,Z0W4+LRXVJX)-<%NHW5<<+%.]R7B&U:QU/A_Q!Y>VS
MO7^3I'(?X?8^U=0:\OW5TOA[Q#M*65XV5/$4A[>QI5J/VHCHU?LR.JHHHKE.
MD45/:?Z]_P#<'\Z@%3VG^O?_ '!_.IEL-;EDTPT\TPC)Q6:+(S3#6&GBV*?2
MVOX+*62(W"6T0\U SNS[,$9^3GLW:KMAJJZEIDEY#;S?NW>)X@ 6WH2K*"#@
M\C@YQ5)H31;--JII6IKK&CPZC##(B2J6$;8W#!(P>W:LY/$Z2%XDLIFNQ<"W
M6%9$8.VS?D.#MP%'/H>*JZ1-C;HK&B\2P3OIICMY3#J.!%)N7*L03@IG=@;2
M">@J>;7K.UU&XM+IO)\A(G,C_=8R%@JCOG*T[H+&E2BL5O%.FI?0PM.@@FMS
M,EQD[<[]FTC''/<XQ39/%=G:WJPW92*,O.IF$FX*8BH.0!U.[\,47069TME]
MV;_?_P#914QK!@\3V5M>?99V.Z>\^SQ-%F0$^4KY; ^7@^_KTZ:(UBSGTVXO
MK647$$",[% ?FVC/&>O3@]*R;U+2T+1J-JPF\68L;&Y.GMF^?9"GVJ+IL+Y9
MLX7@=#SFK]EK-KJ%O8RQET-]$988Y%PVT8SGTQD4TQ,M-3#63?\ B:&QUG^S
MWMI7(,(:177@RDA<+G+<CG'2I#XCTC$C#4(2(G,;[<G##.1P.V#GTQS5IH33
M-"BJ;ZQ81SB%[N-7*&09R%*@;B0W0\<]>E5T\1:?)?V=I%([O>(SQ,(VVD+C
M.<CCK_GBG="L:E**SDU<3:C/;6]M))':L$N)]RJL;%=V,$Y; (SCIF@^(-*6
M+S&O8POF>7RK [MN[&W&<XY''-%T%C7M/^/IO^N?]:M-619ZUIQO8U%Y$3/;
M^;&0<@IG.XGH!P>N.AI\GB?1DMQ.^HPK$9!&&.1EB,@8QGD<CU'2LY;E1V-!
MJC:J.H:RMK??8X+9[FX$0FD D2-8T)P"68@9)!P/:F2^(=+AFD@GO8HYXE#2
MQ$Y9,XP#CJ3N&,=<\4)@RZU,-46\0Z4(&F-_"(EC\TL21A=VS)_X%QCJ#5>Z
M\2Z?;WXLA(TEP5E.$4E0T8!*D]CR*NZ%8U**S]'UJUUNS2:V==YC1Y(L\Q[A
MD \<]^1QQ6A5$A2G[I^E)2G[I^E '06?_'C!_P!<U_E577K:6\T6Y@@3?(X&
MU<CGD>M6K/\ X\8/^N:_RJ>N-[FZV.);P_J,5V#!;9AN+J[GF&\#8Y654<<_
MQ!U!^@]ZO>&M-G@?SO[/.G1BRCMWB;8#+(,Y;"$CCIGJ<^U6(M>O9;>VO/LL
M"6=W,B0GS"9-K$\L,8&1SP32IXNLG15Q+YAA$F_RF\O<8O,"[L=2N3CVI#,3
M2]&U./1;*SC2_LVCW"X*^3"21$0H!CZKOQR>?6FWUAXEOY+F.2*8Q2V)C=/,
M78TFQ""/FP#NW#[H^IS71CQ-:>1-+Y=PT<$8>21(CLR0#M#'N-P_SFC3];;6
M$N7TU8G00QR6[2$J&W _>ZXQCM0!CIIVKNPE$=S@%EB%Q(K2HAEA.&.3G[LA
M')P,"J>JOK.BZ7+<W$]XZS8$@:X"[3YQP%8?<&SO].]:T'C&.TTZVN=<^SVS
M73'RD@<OA <%FR!T)[9ZU;D\56_G0QP6EW.)+PV99(^%8 DGZ#:?Y_4 SDL+
MG4]*\.W%O-<RR6^Z0RRN5);RF 9P3DC=@=^#Z&FZ?8:U-) EQ)J4-MYR--YM
MPID)$;[R"I/R%MF!]> *TK?Q982R0QR>:&D529!$WEJ2I8 MCN%-7=)UF#6$
MF>"*XC$3A3YT>PG*A@1[8(/XT :%%%% %/4_^/4?[PK*K5U/_CU'^\*RJWI_
M"93W$)P"3T%4;35M,UAY+>TN8+ME&7C W8QZ@CZ5?KC]2\/ZM/-?-"<P3ZDU
MPT2N,RQF%4!Y(&0PS@D>M6VR4CJ;UK:"UENKU8Q##&QDD=-P5/XNW3CD4L=G
M;>7'Y=M"$7#QA8@ "1U''!Q7+7'A_4I+74X)8WO)I[$0VUS)< &/]UM*,OJ6
MR<XQS[4H\,WGVY8BA_LT7 D,?V@_=-OM;OGF3G'XTK^06.J^QPDQ-]FBS#Q&
M?+'[O_=XX_"HK-[2^M8[BS6*2 EF1U3C.2&(XX.<YKE;70=<#6)NB6N(UM<7
M7VG_ (]PG^M7;_%N]><YYZ5'%X:UA+.W@V#>L(2%UN=HLY/.9F? ^]E2.F>F
M*+^06.U2W2/!CA1/E"@J@'RCH/H/2G8Q7F]M#<W+ZS<NEREY%%)/#+A_E9)B
MZAP?XB   /X:[7P[;SP:';F\W?:I]UQ,&.=KN=Q7Z#./PIIW!JQIUQ7C;=_:
M%L4#9"'D=N:[6I;.R@NKAC,@8A>_UJHS]F^8F4.=<IY:^L:E([NTC;W4J[B)
M0S XSD@9)X')I7UO4Y94DD<LZ,S*3 O#'!)QCKD YZUZ_P#V-9?\\11_8UE_
MSQ%'UJ/\@OJ\OYCQJXO[ZZ@\F=W:,OYC#8 6;U8@9)Y/6H[FXN;R8RW&]Y"H
M7<5QP!@?H*]I_L:R_P">(H_L:R_YXBJ6,2VB)X9O>1XAL;_GFW_?-7I-7U&2
M3S&;]YL,9<0J&*E=I!.,GCCFO8?[&LO^>(H_L:R_YXBAXQ/>(+"VVD>,/>7D
MA!9I"1 +?.WK&/X3ZBF0SW-NLRQ;U6:,QR +]Y3U'Z"O:O[&LO\ GB*/[&LO
M^>(H^N+;E#ZK_>/(9-<U67[\SD_-D^6H)W+M)/')*\9-3MXANQ8P00VWE/ L
M:I*,DIM[J".">_)R*]7_ +&LO^>(H_L:R_YXBI>)B_L%*A)?:/&QJ-Z/.V_*
MLRA7585"D Y' & 0>XYI[:QJ3R>8\LC,?,SE!SYGW^W>O8?[&LO^>(H_L:R_
MYXBG];C_ ""^KO\ F/(]8UF;6"A>T$95V?<,LW('RYQPHQP.>O6LW;)_<;\C
M7MW]C67_ #Q%']C67_/$41QBBK1C^(2PSD[MGB.'_N-^5&'_ +C?E7LMYI%F
M%3$([U2;2;3_ )Y"M5C&^A#POF>3X?\ NM^5)AQ_"WY5ZJVE6G_/(5E>(=/@
MAT>X:*/Y]O&*I8IMVL2\/9;GGP8D@#))Z 5UWAWP^8RMU=#Y^JJ>U)X;\->4
M%NKQ?WA^ZI_AKJL # Z45:U_=B.E2MJQ****P-A14]I_KW_W!_.H!4]I_KW_
M -P?SJ9;#6Y9-,-/-,-9HLYBY\'0WL]Q->7(DDN'A,FRW5%=8WW@,H^\3T+>
MG:M1M,MHRLEI%';S11F.%E7Y8P?]@$ ]:OFF&J20FS#TKP['INFVUM+/]HDM
M-WD3%-A3<<_=!P>3WJK'X4$,IN8;WRKSSQ.CQVZK$A"%,",''()R<\G%=$:;
M560KLP4\+0QMIJI<$0Z>5:,")1*Q&>LG7:222M37GAZ.\U5KXW#HS-;ML"C'
M[ERPY]]U:]%.R%<YUO!\3P747VR4?:8)82=@^422^:3^!XITOA+>\CPZA+"\
MC7.X^4K?+/MW#GT"\'WKH*44N5!=F7I_A>.%EDM;N2)K>]6XCR@8 "$1%3ZY
M7OZU;L/#JV&F7]D+IFCO-PVJFQ(05V_(F2!ZGMGL*TK+[LW^_P#^RBIC6;6I
M:>AS4?@^#[%86EY)!<063EA&MHL:R@QF/YADY/.=W7(I\'A6RCDTZ:ZQ=W-C
M$8EFE0;I!QM+>Z@#!K?-1M32%<Y[4_"T>I:Q)?/<[!*L(91"I<>6Q8;)#RN<
M\X%07'@^":TMH?M#;K>:>56:/(82L2RE01Z^O:ND:F&J44*[.=?PE&VI177V
MQRD((C@:,,B#R_+V@$XV]\8]:EL/#?\ 9\UE*E[(S6IE&TI\I23&449^4#:,
M<GO6W1560KF7_8TD=Y>2VE_);Q7IWS1K&"0^W;N1OX3@#UY%4M.\()8W,5P;
MZ262.X6X)*8W%8VCYY)Y#9SZUT-**+(+LQ-*\)1VGFVL=[)Y$]@+6Y4QC,JC
M< 0?X3\Y]>U6;'PA!8/9N+@-):SB;<L6TR8C9 &Y/9LY_05L6G_'TW_7/^M6
MFK.25RD[HPM9\.)JLTTJ7'D-<6_V:<-"LJR)DD'!Z,"3@^]5O^$4BCBF6*[E
M5VFMYXG* ^6\*!5R/X@<<].M=$U1M0D@;.7N?!5K=) )[F1RLDTEP=H N#(=
MQ!'8!@"![4ZW\*K:P6:)?2M+;I.DDK("9A+]\GG@\#GVKHFIAJE%"NS*TO1$
MTN;S%G>0_9(;7#*!Q&#AOQS6G115DA2G[I^E)2G[I^E '06?_'C!_P!<U_E4
M]06?_'C!_P!<U_E4]<;W.A&+;Z+IBW+Q0SR,8I!(+87!*PG.>$S\HR:D7PSI
MRP"$1OL!4X\P_P ,?E#_ ,=/]:YDZ)JT6LZK<VEO-'*_VDQRXB4?.HV%&'S%
ML@<-P.:O36&O6^NL;:>ZELXX"(59P5D^0\.Q;AB_?:>,<XS2 U7\+:>R2(#<
MK')L.Q9V"AEQAP.@;Y1S5G3M)LM$@;[*#'&$"L7<D!5SW/U-<UIMKXA5;);O
M[>P%T^5,H7$1"\N=Y.1\^!EL^W&+%MH]W#X0L+22VGF:UG5I[::4.9E5CD D
MX(Z$ D=,<4 :PT'3;FVLS"S[+<'RI(I3DJ3D@D=02!^5._X1RR-P\Y:X,SSK
M/YAF;<"N0 #_ '<,PQZ&L6YBUE]7L'TRQGL;%5^>$,@7!#YW*&P#G:> >O48
M-,2PUV"WBCFDU*X@/DO.([A1,7,9#!6)&%#[21GZ<9% &T?#%BML8H0\9^4J
MVXG:54JIQWQDTWPOH$GAW36M'NA.A?<H5-H3CZDG/7DUC_8?$<EYJ'F7-VJ2
M2*$$955">:N"C;S@B/<#\H[]>*U]'@OK?6-06X^U/:G;Y,D\@/3C"@$\8YW'
M!.>0>M &W1110!3U/_CU'^\*RJU=3_X]1_O"LJMZ?PF4]PHHHK0@**** "BB
MB@!=QXY/'2DHHH *9::H8/$UIIOE!A=6TLIDW<KL*#&/?=^E/K-3_DH6C_\
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M[/=0[)C(51T,I1@^1D<CT_QJ:'Q-<23"X;&UA&/+23*9 GRRG'*MY8(Z<8H
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MUQH-G-<S26GF&W1[G>8VRL>Q RC/^\2/?%7*E0C)IHA5*LE=,Z'_ (618?\
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M[364D6Z#CR+8181T:38CK(,EAR,Y&0>U2R>,O*A\PZ9-A+=KB8,^PHJR>6<
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M EP# 2(  A$! Q$!_\0
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M_P"Q\1[+7_H>G].__#TO]D'_ *&KQ?\ ^$#XD_\ D2C_ (>E_L@_]#5XO_\
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MC'#NM2]K*"J0D_Z)/^'I?[(/_0U>+_\ P@?$G_R)1_P]+_9!_P"AJ\7_ /A
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M^&/_ !,LH_\ F,_!2FNN]'0':65E#8SM)! ;!X.#S@\'&#7[V_\ #K7]FO\
MZ*;\8?S\.?\ S/4?\.M?V:_^BF_&'\_#G_S/4?\ $U/@PM?[>S33_JG\?_\
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M5*?/&53$?@I17[U_\.M?V:_^BF_&'\_#G_S/4?\ #K7]FO\ Z*;\8?S\.?\
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M+!@\9:8-;M-*CEUF/PWXGM+)=,U62RL[FYM?M%O)/:R0I/%7ZB_\.M?V:_\
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M(^+)-/U?X=>-O$%]=_&?XS^(=7\+:I#>:%>6VBPZ1'\/?#[>'/%-T-43X/\
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MW=I;0?2M<DH\LI1;3<6TVG=-K>SLKKSL<[7*VKIV=KK5?+^N@4444A!1110
M4444 %:)_P"00G_83?\ ])%K.K1/_((3_L)O_P"DBU=/_EY_UZJ?^XRH?;_P
M2_\ ;3XL\+_L;^'/"W[</Q0_;G@^+?Q>U/Q1\4OA#X?^#]]\%]3URUE^"7AK
M3_#Z>'8XO%?AGP^L(O+7Q9?#PW U]>2W#PL^HZH\4:-=.3Z3^U!\)_$?QS^
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M+4AXU^$^KW/PLN=2N_%NM1_#2]U3Q1%X/L/@_JQ\1:Q:+IOC%+(:])J3)?\
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MP73-8U#X>ZSX1B\+? NY^#WC^6'7=,\&^*]!TSQ9XG;5]=GFEU/P=XRT;7]
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M.!8OJ%S!XFN%\1VKPK!XSTO3M$T#7Y)-.T3219?PE_V3I?\ T#K'_P !8/\
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M:C&<*$ISE6IXBE+%\V'YHTI5*M"K%\S7Q1E'1N+W7[C_ -GW?_/-/^_]O_\
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M 4 8 %*L.J((PDLB"'=Y06]C41;\A_+ G 3<"0VW&[)SG->2S>)O#5OXKL_
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M[_V__P =H_L^[_YYI_W_ +?_ ..UQ.!Z#\A1@>@_(4?\0\P7_0SQG_A/A?\
MY(/]7Z'_ $$5O_ *9VW]GW?_ #S3_O\ V_\ \=K0-A=?V4B^6N?[2=O]=!C'
MV51G/FXZ\8SGVQS7G.!Z#\A6D0/[$7@?\AINP_Z!R4?\0_P<+6S+%OG?LG?#
MX;13O=JTMU[-63T=W?H-9!15_P#:*VJY?@I[/_\ 9.D_L^[_ .>:?]_[?_X[
M3A8WJAU50%D 5U%S  Z@A@K@2X8!@& .0" 1R*XLP2"-9C"XA9BBS&-A$SCJ
MBR%=A88.5#%AW%>:_$CXN_##X06F@7WQ-\8Z9X/@\5ZS-X<\+I>6FL:E?>(]
M>M]+O=<N=)T72M TS5]5U&]MM&TZ_P!5N8[:R=;>PL[BYF=(XV-3+P^P,4Y2
MS7%**W;H86R_\F>M^F_D+_5^A_T$5OG"DOS/H3RM6"NHFE"N '7[<FUP$$0#
MCS\,!&!& 00$ 3[H IVW6,AOM$^X*4!^WKD(<94'[1G:<#*]#@9'%>2^%?$7
MAWQSX;T7QEX+UK2_%7A/Q'81ZIH/B+0KJ+4-)U?3Y0=MS974)*R!&5X[F)@E
MQ9SQRVUY#!<0RQ)T/V2;G]RWR[]W ^7RBJR[O[HB+*)2<",L ^TD4_\ B'N!
M:NLTQ33U3]AA+/2^_/V=_1C_ -7Z/_016_\  *9VRPZJHB"RR*(01"%O8P(@
MP(818G'EA@2"$QD$@\5')9W\KEY?WCMC+R7,+N<  99IB3@  9/  '05YGXB
MUG1?".A:OXG\5ZKIOAKPWH%E+J6NZ[KEW!INE:/IT#>7+?:C>731PVEJDA$7
MG2LJ-*5B0M*RH<*V\?\ @B\UP^&+3Q)IUQXE5K,2>'HH[UM;MXM1U35]%TZ]
MO-+^R"]L=*U+5M UO3].UJ]AM]'O[C3+K[)?S1JCNO\ B'V 3M_:N)OV]C@[
M_=[2_P#PWD[+_5^C_P!!%;_P"F>S?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^
MW_\ CM<6T90@,H&0&' (922 RD9!!((R"1D$=0:;@>@_(57_ !#S!?\ 0TQ?
M_A/A?_DP_P!7Z'_016_\ IG;?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^W_\
MCM<3@>@_(48'H/R%'_$/,%_T,\9_X3X7_P"2#_5^A_T$5O\ P"F=M_9]W_SS
M3_O_ &__ ,=H_L^[_P">:?\ ?^W_ /CM<3@>@_(48'H/R%'_ !#S!?\ 0SQG
M_A/A?_D@_P!7Z'_016_\ IG;?V?=_P#/-/\ O_;_ /QVC^S[O_GFG_?^W_\
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MC ]!^0H_XAY@O^AGC/\ PGPO_P D'^K]#_H(K?\ @%,[;^S[O_GFG_?^W_\
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MPL^*_CJ^L/&MSX$\(ZA\1O'^K^,FU:?7]:O=>\*:UX?\(ZO;>&K+;:4O&O\
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M'@;QEH.;_P 0?M"_">[^*&JZ58?M&:\/V@/BWXVT'0_$WB+4;*[L'BT7X?\
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M8MIVKWG@VV\<?M/:C\8?B)K@\>Z1?>)O"OB+6?!5Q^S=X1?1==T:U\!Q^'/
MUM+KNE?#K7? OB+7$UOP]INHZM)9>'WFUBUN.:.-DW33P\_?M?EYFTOWEVDX
M*]G!;M73;6EKI2NXVB_>:7I=R7;5+EU>FCNM-_TS )( &22  .I).  .Y)X
M[FIFMYT4LT$RJ!DLT;A0,$Y)*@ 85CUZ GL:_#/2_B__ ,%!8/"4'B[7?$7Q
M#\275UX,^$7B/4?A_=_L_P#A33M,NM4^)WQU^-'PN\=^$I#IGA"#Q)#I7@KX
M7>'/ GB^"SCU!==T[4[X>)M=U2X\/Z]!I*> >!=>_;4\->,=.\<>'/AO\2/$
M7C'4]0LKFU\*>*?!GBO_ (0>;6-1F^%>K1:?9Z-?^1HW@^T.L6%UIUE?V+V
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M:(2.(G(+QAV$;D="R [6([$@XIE% $K33,XD:65G5=JNTC%PH!4*&)R%P2,
MXP2,8--,CLB1L[M&F=D98E$W?>V*3M7/? &>],HH D\Z;.?-DSECGS&SEE"L
M<YSEE 5CU*@ \ 4IFF((,LI# A@9&((.<@@G!!R<@]<GU-144 2M<3NVYII6
M;Y/F:1RW[LDQ\EB?W9)*?W"25P3474DGDDDD]R3R2?<GDT44 %%%% !1110
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M[_T!XK_P]\1?_1"'_$:?%/\ Z+7./_ L+_\ ,I^\3?\ !;GP:RE6_P""5?[
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M:KVEUJUH^FNUKRL=GKDX+'9BY)V<5C*K=U%S=K56G:*NVFTMFTW8^_?[1?\
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M?'2?_!9:_P#Q-']HO_SXZ3_X++7_ .)K/HH]A2_D7WS_ /E@?VQFW_0SQ_\
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M ,36?11["E_(OOG_ /+ _MC-O^AGC_\ PKK_ /R9H?VB_P#SXZ3_ ."RU_\
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MMM1N=.BMKB]N-3TQ5U3Q#9P*G-^"/V'_ /@G1XTA^*FOWWB3P3H6@^(_@O\
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M ?#WB77[Z?\ M?5[:6\E%C':V=@DUQ+,7"1/^BW_  XC_P""F/\ T2/X;_\
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M)(;O5O$MC'#<>%=2U?Q99_$#39)Y'\,ZWXFGAU.SL]5\2VGVS]#-,_X)G?\
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MC\Q0%UW7WK_,6BDR/4?F*,CU'YB@+KNOO7^8M%)D>H_,49'J/S% 77=?>O\
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M:YU#5/\ D=O&8XU34  !XIU<  "Y      KG_/N_^@AJG_@UU'_Y*K;\6_\
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M#5/_  :ZC_\ )51T5SW?=_\ @4O_ )(U^2^Z/_R)ZU\'/CU\:OV?/&-IX_\
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M7O[2OO\ GO\ ^0;?_P",T?VE??\ /?\ \@V__P 9JC11]=QO_0;C/_"O%?\
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MI-)0]QJ/*FTW&[?O-+\><*MJR]JGSW]E[O+[/W;:R3;EKK>RMZGPWXZ_:/\
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MO4C-?948J*6N^U]M$FV^^HVBBBL#H"BBB@ J^?\ D%+_ -A.3_TCCJA5\_\
M(*7_ +"<G_I''6E+_E[_ ->*O_N(SJ;TO^OT/RJGQ9X7_;.\)>*OVXOBA^PE
M;?"[XNZ?XT^%GPB\/?&'4?B[J>@6</P6\0Z5XA70'B\,^&O$:7CWUWXKL%\1
M6OVVRGL(;<-9ZFD,\C6<H&)^VG^T+\9OV>[O]FG4O@]X0TSX@VOB_P",7B6R
M^,'@9[2YN/&'B7X+>"?A%XW^(?CF'X536TT?D_$W1[+PZ/$OAG3KB*YM_%3Z
M+/X0(MKC7+>\@^N+?XB>"+[Q=J/PPM/'W@^]^(.AZ7;^(=7^'%KXLT.Y\;Z+
MH=[Y?V37M4\&PZ@_B#3='O/M$/V;5;O38;&X^T0F*=_.CW<+\1?%'P[T#XC_
M +.ND^,/#;ZQXT\8?$3Q=I'P<UQ--MKW_A"_&.E_"OQ=XA\0ZTU[/<P3Z*-1
M\":;X@T 7EG#>S7+:B-/D@CM[F6>/6$H*K3E]7;C&E>5.3E)5&J<^:K[R@U&
M7QI1NHJ-X2E;7&:G*E./MXJ4JK49Q]WD3FN6G>/-[T7:+NM7NEL?FCX#_P""
MLFC7F@>"M;N?#$/Q:\/>-_B1KND0_$+X97\MEINE^ _&OQY^)?PN^!FN7.B6
MVBZ[I]C;:KI'@_19-?U/QMXI\#W.M76H7+^#],\37^G:OIUAZQK'_!2:*TTK
M0]:TWX%>([G1[SX;? #XJ>+O%FK^,9+/P-\,O"_QY^&OBGXF:;-\0O$/AWP1
MXOO?#%CI-OX5N= A\6ZMH=IX&N=6NH;SQ#XD\':2$O)_06\ _P#!-70_B'8_
M#L>%?V9M#^(_@'Q1X>&G>";>TL-)N-!\;Z_\01XN\+P0Z-:FW\/77C!?B7\1
M1X@TNS:.^UWPQKWCP71AT6'Q+B[;I?PR_P"":T_A+Q%JNA>&_P!G.7P1#I6C
M>,/%FKZ+J!.BQ^&8M<\3_"S0;[7M2L-3S_PAD>N6?B_X=V6A7<Y\+@66L^'&
MTC^S+1[>/I?U1M/ZIB;/79VDIVY7[ME\-FFK*;>UCEYL2DTL5A]&U=RBVG&W
M,O>UU?,M6[:;Z'E]A_P5+\%:T_B&;PY\,=>U/2+O6-8T'X1Z^^NZS;:7\1M1
MT/XN67P?U&UU&>#P!>K8WNJZS>/XB\'Z)\-'^,GB#Q9X;L[H0:3::ZO]DU]L
M?LU_'2Q_:4^!O@+XTZ;X:UOP7;>,HO$,-QX0\0R>;JWAW5_"?BS7?!>O:9=2
M?9K%I%AUKP]?M:R3Z?IMXUH\!OM-T^]\^SA^3/C!XP_X)K_#2[@;QSH?P<O+
MCXM_&"\^&?B&;PS;1:A<>'OB#X$\0WUWXBU+4H-"O8K_ ,"OX*^(?A^VT_Q1
M=>!+;3];C^(-WHZW=E?:A++<P>A>"OVF_P!BSX.:EX3_ &?_  !XA^'W@#PJ
MWA?QWX]\(P>#IM,;X7:7X/T/P[X2^*WBCQ#<ZKHUS>6'A:/7+/XI:-KVDV&L
M?9-3\33ZM<:AIUG-#>6<EY%6E3E23H87$0DY74I7E%PA!*IIO?FDI/316M=.
MRTI5IQF_;XFC**C:T6E:4I/DU4;6Y4UJ[MWO9Z'W#17SC\0?VL/@7\./AEX+
M^,NK^,K?5?A?XY^)GA'X4Z9XQ\/12:AIUAXF\9:S>^'K)M:MI!;:K86^EZW8
M3Z9KMA_9TOB+3[[99?V)+=MY Q(_VU_V94U+Q3:ZI\5O#&@:+X;F^'$-CXUU
MC4K1/!WC8?%#P7<^/] N/!.I64M[<ZK9:7X;M+BZ\5ZA=6.GV/AGR99-7N;6
MUAFN(^98>NU=4:C5Y1T@W[T6E*-K7O%M)JU_+=KI>)PZ=G6IIM)I<W25G%[6
ML[KKU5['U317B=Y^TI^SUI^J>-=$OOC5\.;;5?AQ:)?>.+%O$,$DOAZU>\TS
M3=TKP)+#JD\6IZYH>E7%AH$NKZC:ZKK>CZ9=6D.H:I8VUQRO@[]KSX ^+_@E
M8_M$2>/--\)?"/5O&/C'P/H_BKQ@ZZ;!K&L^"_&?B3P/>MIEM:&_O+VVU34?
M"NL:GI*0V[7XT""34M5LM,6TU!+.?8UK7]E4LY1BGR2UE--Q2TNW))M))W2N
M5[>C=KVL-%)OWEHH.TGZ)[_A<^EJ*^;_ (A?M:? 7X=P>+TO/'ND>)?$7@8>
M$Y/$7@GPA=VNK^*[:W\9>)O!_A;3;B"VDFM--O!8W/COPSJ>NVMKJDU_HFB:
MG::AJ%I MY8I<W-$_:D^">H?"/X:?&SQ!XQLOAWX)^+;QV_@D^/I(M(U?4-0
MDU'4--&F'3[&35";N.33+JZNY())K'3M.V7^IWEG;;Y$/8U;)^RG:32C[KU;
MBY*RM=WBG)6BTTF[V3#ZQ0NU[6%U>_O;<K2>NVC:OKU/H2BO'(?VB/@-<>)]
M:\%P_&'X?2>+/#WB;1/!FL^'U\06_P#:%GXM\1^(;?PCHOAR-2H@U'5KSQ;=
MVOA5[?2I[\:?XDN8-#U5['4YDMFX3Q#^VC^RGX:374O/CO\ #Z^U/P]X8\2^
M+;WP]H>K-K'B"?2O"FG>*]3U2&QT^S@D%QJTT'@7QA#I&CO/#J&N7GAK6[;2
MH+M],O?(%1JMV5*HW9/X);.UG\.VJUVU6H>WHI7]K3M?E^);W:MWO=/I^&K^
MGJ*Y+P!XW\/_ !,\!^"?B3X2N)KOPK\0?"7AWQMX:NKFVFLKF?0O%&DVNLZ7
M)=6=PD<]I=&SO(A<VTJAH9Q)'E@H9NMJ&FFTU9IM-/=--II^:::?H:)J2333
M32::V:>J:\FB])_R#;;_ *_KK_TGMJHU>D_Y!MM_U_77_I/;51JZN\/^O-'_
M -(D12VG_P!?JO\ Z4@HHHK,T"BBB@!R %U#;MI90VT;FP2 =J_Q-CH.YXK\
MBK3]J[XX:3\;OVO_  =\:?BCH_PB\*?#KP!XZ^*_PEM/#_P<\,>.K.[^&/PF
MU&6_U;Q)\.?B6/$FJ>&O'OB"^\("PL_B?\/OB38Z!XN\)^-->T\>%K&VTO3;
MU;G]= 2"""00000<$$<@@CD$'H:\ A_94_9KM_$/Q2\5Q_ _X>?V_P#&W2Y-
M$^+-^^B"5?'.D7-S]MU+3M5L9)FTZVM=<OPFH^)(])M-._X2;4HH=0U\ZC>1
M1S+O0J4J;G[6'/S1BHVC&3BU.,FUSZ*\5)/1WNEHKWY\13J55%4Y\EG+F]Z4
M;IP<5K'71O\ &_2Z_/WP[^TM^V%X<;PV/BAXK^'$>L>#)?V,M)^)WAN_^&%A
MH%CXHU7]L_7O&"M-<ZSIVOB[\'K\#](7PKIE\V@+]A\3:GX;\9ZEJ"V]KJ=C
M!I/M>A_M3?$KX4_#+]M77_C;!I_Q1\2_LDVGA;Q;IMOX9T/1/ACJ7Q-\&>+_
M  +I^O:;JNF6MEK/B[PGI?A+Q!XL@\4Z;\-M=NM:NO$%WX6TF*Z\=:9I^K*L
MM[]B>)/@C\'?&/CG0OB9XL^&?@_Q'X^\-6$6EZ'XIUC24O=0LM/MTU..SM)(
M97.G:C'IR:WK*Z2=5LKZ32!J^I_V6]F;VX,E#1/V??@;X;\"^*/ACH7PH\%Z
M=\//&\7V;QCX.33&N-%\3V:V\%G!I^M17L]S<7NEV-E:VUAI6E27']FZ/I]O
M#8:3:V5F@@K>6(PLUKA[7]GS*$81M:IS5%&:?-[T>:*T6DDG;DBWS1PV*@_=
MK[<_+*4IM-.$8QO!N2TMUO9J_77X'\4_\%'/$?A^YG\/>)?@C<^!M9?XM^*?
M@UIFK:-\1_#GC^TO/&_PT^)_PC\"^.8I;"]\):"(?",UG\7M!U/2-<?RM;OO
M[-\0Z>FDZ1<0Z/JFH>2? ;_@II\2/$-SX6T#XA^$]*\:>.OB-J?@[PC\.=%\
M)QZ5X"\*:AXR\;^&OV84TJS\5:[>Q>(]6T+3U\4?&;Q)J<VLV-KJ,-IX?L(=
M*70]8UG^RQ+^JFK?L^? G7KJ.^UOX0^ -6O(O%.N^.([F^T"WGFC\9>)]5\.
M:[XC\4+(QR-;US6O"'A75-3O?OW-[X=TF=QNM$S@K^RI^S.FGWNDQ? CX90Z
M?J&EG1;JWM_#D%L6TS9X02.V@N+>2*[L7MQ\/_ KV5[83VNH6$WA#P_/97=O
M/IT,@%6P?+9X:6MKM25UM\,FW)=6UUV5MU3HXN[E[=.23Y=+*^MKQ247T]>I
M\C^'/^"B5_XU\72>#-"^"-QH[V?CWP'\#O$?BC5_B)H>IVOAKXZ?$W5_B_X,
M\.:%IGAZPTFU/C?P;I'CSX17UCK?BA/$/A>2YT+7M,U2PTW[5:ZOIMA]M? J
M3XWS?"GPG)^T?;> [/XTM#?#QM;?#)KE_ T=RFH7*:>= EO+JZNIH)=,6TEF
MDG:W<W$DB-9VS(4+-'_9_P#@9X>CTR/0OA'X"TA-&U#P)JVE"PT"V@:QU?X7
MOK$GPZU>)U^=M5\&S>(=?N-$U&9I;R&[UO5;R>:XN[ZXF?UZL*TZ,DHT:7(M
M')R?-)M:*S<GRIW?-'5.T-5RN^]&G74G*M54]+0C%<L4G9OF5DFU9<KZ7ET:
M"BBBL#H"BBB@ KE?'7_(D^+O^Q?U'_T2:ZJN5\=?\B3XN_[%_4?_ $2:VPW^
M\X?_ +"*'_IZD95_X%;_ *\U?_3=0^N5Z#Z#^5+2+T'T'\J6OUH_/ I&Z'Z'
M^5+7+>.=>N/"O@GQAXHM+>&[NO#?A;Q!KUM:W+.MO<W&CZ3=ZA#;SM'^\6&:
M2W6.5H_G",Q3Y@*4FE&3>R3;]$FW^"94(2J3A3CK*I.%.*;LG*<XPBFWHDY3
MBFWHDVWHF?Y??B[4=/'C'QJ#?V8(\;^-,@W4 (_XJG5^Q>N?_M+3O^?^R_\
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M.P%+_:6G?\_]E_X%0?\ QROTW_XB(?$__2-;]@G_ ,)74/\ Y3T?\1$/B?\
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MV\UXT4DGBGQAJ412.U@A9OM#_A*;#_H"W'_@U_\ N.C_ (2FP_Z MQ_X-?\
M[CK26&S*2Y77HV7)9*HDE[-IPM:AIRN,7OK;6^J>:RF:U6"G=N3NZM%N\[\V
MKK^;MV;NM=5^</P7_P""9'A'X->-/#7CJU^,?B_Q7K7AWXA?!SXEM)KGAS2$
M;4/$OP\\!>,O#WQ'OVFAOGDMK_X\_$'QK?\ Q>\:WZB6;2_$5K::5IRW-BBW
M$?GT'_!(WPC#X-3P8WQT\436;:<=.N[QO!UK:7$R6GA3X)Z3H<D/]E^)["2W
M^P^)_@/X0\1:A&+ECJ.CZCKOAJUETN>2PUZS_5__ (2FP_Z MQ_X-?\ [CH_
MX2FP_P"@+<?^#7_[CI_5\RYG+V]&[LF_:+IM_P P]M/3MV5C^R)VM]2GO?\
MC4K_ '_6+]7IMJ^Y\<VO[&MYHWP>\*?#_P +?%*S\.^-O#'[3NF?M8'QR?A]
M)K_A[4_B'8>);KQ#<:+=^#O$'C6_U^Y\.:FD\6F7FJZK\0M5\<.L)U5_$LFJ
M.DT/B>@?\$P['P1J>L^)_ 7QYU?1O&/B?PMXJ\$^)-7USX::!XBTF\\.?%'P
MK>:'\8)-.\.#7=,M=)UWQ+KETGBOP;>0W,VE^"VMD\-ZAH_BO1)[F.3],O\
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M_P"R\3_-0_\ !K_^4FGU3%_] T__  9A_P#Y<;E%8?\ PE-A_P! 6X_\&O\
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M%3^'4_Z]U/\ TW,Z,)_O6%_["L-_ZDX<_P ?NQ_X\[7_ *]X?_1:U:JK8_\
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MA/Q!9Q:->26&OVVH:>(KS3((;NTGE\1T?_@IW^SQX@MM2GT/PS\7];G\-?\
M">77CNTT/P]X0UV/X?Z!\-=.^'6M>+_%'B'6])\<W?AN_P!&T_1?BGX3U*&/
MPGK'B/5KPG6M-@TYM6T:YLC[U8_LS?LY^&?"^L^ &TJVA\._%7X->$/V:;W1
MM<\<WCS^,?AAX%TKQ3;^&?"FB2W>IPWVH:S::9XQ\07$VKZ(\VN7Z75O>7$C
MK:6[CR[3_P!CW]C[1;;XFZK>Z_>ZQ)X[T3QA\-/B=XI\7?'F;5+N>V\6^%_
M7@WQ-H.HZM/J]K8^&]='A?X8^!]*MK2TATNZT6#0A-9V-O+=7TLR7L=;JIO'
MEMVVE?SOM]W<TD\>E32GADU"I[64N5>\FI0M'HN7XFM+/F>MF=+\._VO='^*
M?QT7X:>$_!/B-/AO+\$_B-\7-&^+VMVT-CI7CP?#KXH:;\,]27P!96]_>7%]
MX=^W2:Q+)>^(;3P_K$KV>FW=CIEQHVK6]\> T[_@IC^S1<1^$;O71XZ\#Z7X
MM\)>#O';ZEXRT_PEITGA?PA\2H-<O/ACKGB3P_9^,M0\6-;^/=/\/7^I6$/A
MW0?$%QX<TZ;2KOQNGAJ+5;3=[%X#_9P_9X^$GC[Q-XS\*WUWI/B"S^'GB7PO
M=^']7^*MW?\ A?X;_#'Q[XH/C[Q-;>'O!.I:I_9_@#PUXB\7)<^)FU=H8H6N
MI[E+*^CTTPV<',V?[('[)L][X$M-/TZVNX]%^&/@;P7IGA*R^)5Q=Z5\1/AK
M\-M+U+3/AW<>-M#M-2>\^(FG>$]-U_4[?2?$,DPM+NUOU@U>?5K.&S@@/W-W
M>,^7E5FM[\K;O?N[6>VE[68O^%#EC:IAG4]K/G3LX\CJ)04;6:48)WC\;<FK
MN:1R^O\ [=FC^'-<^'#:Q\$?B_H/@7Q[\)/BM\7)?$GB2R\):7K-CHG@*_\
MA39^%9K+1$\7W-E>:-\08_BIIEQ!KUWK%C9^%_(=/%?]B)9:W-IECX/_ +>7
MPP^,NI?$_7=#ADTCX1?"OX'R_%OQ+XPU<B37=+U#PY\0OBGX%^(GAZ\TW1I]
M7T34=/\ #2?#*;5-(USPUK&KVGB6/4HWTV>>V>V=^KU_]AWX#^*?#?A7POXD
MD^*VN67@FTU33?"M_JOQ;\5W^NZ+H]_>^!M3L-!M-4NI)B- \*:K\,_ 6J^#
M](:W-GHNI>&K:[FCU%[W51?])\._V0?@-\,8OB/#H'AS7M7'Q>\/>)/"WQ,?
MQOXQU_QG+XQT7QCXF\6^,/%5MJDFK7+%9->\1>.?%5_?36OV<JFK-96:VEE:
M65O;C='ET4N:]EO:U]7J][:+I=;:W'&.8^TCSRHJG9N2]V_-RZ1]V/-RJ7Q6
M=VG=2323\]^(7[>WPB^$GA/P)XP^*O@SXO?#O3O'\ZR6%EXI\.>&+/5=-T"?
M5_#6CZ=XJN+:#QE=1Z]IVKR>+-)O['1_!DWB7Q=%I4.M7VI>'M/30M06.MIG
M_!0#X0:S-9Z?IG@7XU7?B+Q-J4FE_"SPK_PB7AZ#7OC1-:^.O&OPZU2?X>13
M^,([%+31_$GP\\5M?3>,K[PF7T:RM-9LDNK74K/?M>*?V#?V?_&VCZ5HOBZ;
MXO\ B&#2_"]_X$DO]2^,_C2;7-;\ 7NN>'O$EOX"U_61<+>7OA#1-:\*>'[S
M0=(LSIJV/]GM!<37T%_J<=[N77[%'[/L\/A<V>B^,-"U;P+IMWIO@;Q7X=\?
M^(]'\7^#3??$+Q!\4+O5?#NOPSR3V&O3>+?%?B5GU4Q32MH>LWGA\QG3C&D;
M_P!GM_R\OKMMOIOKMH^OS)MFEY-/#*/*N5-)R<O9VEK%**_>:J^FG\C9Y]XT
M_P""C/[.?@+6_'^@:\/'CZA\.+?7;?6[73=%\/WNKW7C/PMX>\/^*/%/PSL/
M"J^*E\76_C+0-*\26$=U<ZWH>D>#;S6+76="TGQ7?ZII4]N?N'2[NZO],TZ_
MO='U+P]>7ME;W5UH&LMI[ZOHL\T8>33-4;2;[4]*-_9L3#=?V=J5_9^:K""[
MG3#GY6UO]AW]G/Q%?^+;W5_#OBVZA\<PW4GB;1Q\0?%,6B:CX@U+2_#VB:WX
MZDLUNS/)X_\ $>D^%M&L]?\ %%Y>WDVH/%>:C]EAU?4K_4)_KJ21I7>1R"[L
M78@8!9CDG X&22<#@=JSG[/3DYO/F]%HOG=_<=&'6+O-XETK7:IJDM&N9N[;
MU2Y;))Z[N6MAE%%%0=(4444 %;#?\B['_P!AZ3_TV)6/6PW_ "+L?_8>D_\
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M?&X?$;P'K>L:7INEW'AGQ?I_BV.QEU"PT"\O?!6H^#-1\2ZM=W.O^,-(NHM
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MO5_$6B>*=;%YX.OEFN[G5]=U*ZU?3[#^SM#NA.(;32M/B#*_SAND_P">T_\
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M1U7X->#KWP+X ,$L'P_WV=GIF@:A=&\L8B8-2U0Q:K< 7,28XC=)_P ]I_\
MO_-_\<HW2?\ /:?_ +_S?_'*4N$<JFK2J9C)<O+9XZ5N5J2<;*@E9J<D]+M2
M:;:LEI3\;N,Z34J>&X9A)5%64ED%-R55.DU44I9E-\R=&E).]E*G&2C&7-*?
M'_\ $-#_ ,%"/^A__9,_\.OXG_\ G?4?\0T/_!0C_H?_ -DS_P .OXG_ /G?
M5V&Z3_GM/_W_ )O_ (Y1ND_Y[3_]_P";_P".5A_J1D7\N-_\+)?_ "D[/^(_
M^(/\^0_^&2G_ /-YS-K_ ,&R?_!16]+K9^-/V5KLQA3(+7XH>++@QAL[2XB^
M';E VT[2V,X.,X-?O=_P2M_X)U?M!?\ !.[]GCQ]\._CU>?#_5O$/Q&_:A\(
M^-_#W_"M=;UCQ'9IHUK\/1H$D=_)J>@:%/#??;=-N'$,%O<1_9BDAF#%D7\<
MOAU\4OB1\(O$MKXP^&/CCQ)X)\1VA 34=$U*>$7,(.6M-2LI6EL-5L).1+8Z
MC;7-M(I.8P3FOZ5/V+_VLOB-^U9\(=,USXF6&@VWBCP%\=/#OA.36O#L,^G0
M^(X)O!U_JR:I=Z6TDL&FW^;QX+B+3Y192A%DA@M@S1#KP7"N59?7^LX7ZU&L
MJ5:E&53$.K%1KTW3F^1TXIM1V]Y69XV>^,/%_$F7_P!EYM_9-3!/&8'&3AA<
MMCA*TZF7XE8JC%5XXJM*$745IVIRYHNVECZ>_LO4_P#H&ZA_X!7/_P :IR:=
MJT;!X[#4D=?NNEI=JR\8R&6,$'!(R"*]M\^?_GO/_P!_I?\ XNCSY_\ GO/_
M -_I?_BZ[?[)C_S_ )?^"X__ "9X/^N57_H7TO\ PIJ__*3Q1K'6')+V6J.2
MRL2UK>,2R A&):,DL@)"DG*@X&!3OLFM[G;[+J^Z3'F-]GO<R;1A=YV9?:.%
MW9P.F*]I\^?_ )[S_P#?Z7_XNCSY_P#GO/\ ]_I?_BZ/[)C_ ,_Y?^"X_P#R
M8?ZYU?\ H7TO_"FK_P#*3Q4V6LL,-9ZJPV&/#6UX1Y9P3'RA_=D@?)]W@<<4
M+9:TH0+9ZJHCW>6%MKU1&7!#%,(-A8$ABN"P.#FO:O/G_P">\_\ W^E_^+H\
M^?\ Y[S_ /?Z7_XNC^R8_P#/^7_@N/\ \F'^N57_ *%]+_PIJ_\ RD\4:QUE
MCEK+5&."N6M;PG:V-R\QGAMJY'0X&>@I39ZT2[&TU8M(NR0FWO29$P1L<E,N
M@!P%;*@< 5[5Y\__ #WG_P"_TO\ \71Y\_\ SWG_ ._TO_Q=']DQ_P"?\O\
MP7'_ .3#_7.K_P!"^E_X4U?_ )2>(MINJL=S:=J+$XR6L[HDX&!R8L\  #T
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M?_DP_P!<JO\ T+Z7_A35_P#E)XA_9>I_] W4/_ *Y_\ C5']EZG_ - W4/\
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M3YJDZG^\U=.=IV_@]+6OU/$/[+U/_H&ZA_X!7/\ \:H_LO4_^@;J'_@%<_\
MQJO;_/G_ .>\_P#W^E_^+H\^?_GO/_W^E_\ BZ7]DQ_Y_P O_!<?_DR_]<JO
M_0OI?^%-7_Y2>(?V7J?_ $#=0_\  *Y_^-4?V7J?_0-U#_P"N?\ XU7M_GS_
M //>?_O]+_\ %T>?/_SWG_[_ $O_ ,71_9,?^?\ +_P7'_Y,/]<JO_0OI?\
MA35_^4GB']EZG_T#=0_\ KG_ .-4?V7J?_0-U#_P"N?_ (U7M_GS_P#/>?\
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M"N?_ (U1_9>I_P#0-U#_ , KG_XU7M_GS_\ />?_ +_2_P#Q='GS_P#/>?\
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M%/PMI%Y-+9^#?&VNJVEP '#>)?V$_P!KCQ!?>$O&/A+PGJ/P_P!1\):)XO\
M#G@WPSK7[0K^(O%/@;Q#XN^$'@[PY\8_'>G_ ! 7Q#J9TG3_ -H'Q!X8UCPU
M!-HUUJ.O:+<ZO:?$34]%\/W6J:I#I_>:C^R9^V+<>+_"FO>$O#/B/P9\(M!\
M:>-O$.J? VZ_:8NFUC7OA+K]WHUM\)/@B-3LO$.J:+8ZE\#_ (D6GB+]I74;
MT^(CI/B#1-;M?@7:>(]5TRXO;33I(O\ @J)\7;RZ\;/)\/\ PAX6TV]\47WA
M;P;%XDTBVM]?^&%[#\==+^$WAN/XE:/>_%C2[MIO'OAV_E\76>H_%:W_ &=_
M#GAC55L]-N]3U?1;I-2D_2#]BSX\Z]^TW^S#\+?C?XITC0=#\3>+X_&-CK^G
M>%KQK_PXNJ>"_'WBGP-<WNBW+W-[NL-5_P"$<3588TO]0MX?MIBM-1U"S6WO
M)@#X!^'G[*W[6ND?#;6_"GCC2/$>N_&?5=4_9SEN_CL/VA[O^P[[X4^#_&'P
M&OO%WP:'AJ/Q(+UM6\-Z-X2^)YU3Q"VBVD7B:&^N5LO$&LS^.[^SASOV)OV<
M?C+\$OC3\'_@7)%K?A3X(?![X-:;\8_B=X4L_%.N:MH.C_M)6=OXK^"G@_PG
MH>K17MYH&I^ OB1X"U)?CS-X0TW4[B#1/$WANQO/$.AZ3J]_' _[8TXNY18R
M[&-"Q1"Q*(7(+E5)PI8@%B "Q SG% #:*** "BBB@ HHHH **** +3_\>5O_
M -?5Q_Z)AJK5I_\ CRM_^OJX_P#1,-5: "BBB@ HHHH *7!P3@X& 3C@$] 3
MT&>WKVI*_(K]HWXQ^,_ '_!2?]FWP\_QH\57?@+Q1%X-\)0_ ;X<>-+;0O$.
MAZSXMEU#3[OQ+\0?A!X@\.S:9\=?AAXR>[M+[6_&?A3Q"OC/X-6'A&^O;"'2
MX[6^FO #]=:*_!#QY\9/VK='MO&?@KQ)^T-=/I/AW]J3]M[1O$?Q@O=6B^!4
MD4/PF^'?PI\7_!/X1^";GPKI>L0Z89[CQ7XO3P;X1O+C5;;Q?=>&X1XJ?Q@B
MZEHFJ>_?L?\ QM^)GQ)_:0\#6OBCXC?$"]\1>/=7_:OM/C3\!_%NNZ?(GP7\
M'_#ZX^&3? &_NOA[8VEK:?#C7[S3-<MX[O5;.UL[3QYJ7BS7;I6U"WMK*'2P
M#]<:*_#'2?\ @H=^U1+X3M_'7B71O@9-X:O?!GP@\:W7AWPYX/\ B+I7B.+3
MOC?\>/C1\ [#P_8>)KKQS=PVVH>#U^&FD>.YO$O]CF74[S5[_P /1:3I=I:V
M&O/X!X*_;]_:/T;Q;9>,+ZZ\7?$W3-2O+:ZL?@ZNM>(UL9)=0F^%.L6?A[PW
M=6JOKVI7J)?ZOX:T6'Q#<ZY%?Q:_=/K5IJUWY94 _I-HK\/K_P#X*+?M$S+J
M6G>#[K]G;QM%X9^"OQ/^/&L?%+P_X.\>:CX%UR+X?_L^^'/C?>_!30]-M/'L
MBVOC7P]JFJ3^$?%GB)_$FHS6.EZIH.I7/A/2_$L5_P"'F_:W0=477= \/:^D
M#6B>(/#V@Z^MHS^:UH-<TBRU46K2E(S(;87?D&0QQE_+WE$)*@ U**** "BB
MB@ KD/B#_P B'XR_[%S4_P#T0:Z^N0^(/_(A^,O^Q<U/_P!$&@#Z67H/H/Y4
MM(O0?0?RI: "D;H?H?Y4M(W0_0_RH _@9\2?\C-XH_[&GQ/_ .G_ %&L:MGQ
M)_R,WBC_ +&GQ/\ ^G_4:QJ "F22QQ &61(P3@&1U0$]< L0"<=J?7O?P7\9
M>#?!>A?%._\ $CW"ZU=:;X&A\)Q:7IWA6_\ $-Q+;>,8+KQ#;Z0_C+0]?T.S
MAET5'36)9+-;F6P8Q6[.2T3 '@990-Q( .,$D ?-C;STYR,>N1CK7JWP?U?2
MM'\1>)1J6H6VB7>M?#/XA^&_#7B&\D,-KH'BG6= E@TR]FF )M1>VZ7^@1WR
MC?8S:S'<I\R5]@>"=9_93ETQ_&FMV/PKTCQ=XDN_$.J1>&[@:Y/9>$K7Q;H7
MQ+LKOPM>Z7=7<]I=W7AJ]F\%OI>L/8Z+I-M<W-C<:!:M'!J-U%B/%^QK;ZI%
M:0Z1X8FT:?4/".D6NIZAXO\ %6HW$G@S5/%>G6VN^)]2TW3(["30O'.C^%/[
M2N+];R^OGBGE6=M%26QM3> ?CY7M?575UJKJZNDVKW2=K.V?CS\&6^*VO?$:
M[\0^&_$OA[Q%I/B#3+KP4OAFZT+498=;C\-J^G^)=?O-?UG1M?MT;1YK6[D@
MTVPLYQ+]JEC;3HM02V2;XW_ B?PWKV@ZEK=AK^N:SIVCV*_$9O"'A32M>@N=
M/U>\O]>\06NCRZ9>PV6J^,/!M[:?"V:$>:=,T[P]9:_+!=:S<3Z?%Q"WO[/N
MN_%[6+[7+?P8WA*+X->"$\%Z=IM]=^&/"NH^/--TSPGIVOV_BR\9)/[-UY[2
M#Q1+-+=+%:7>M+9W4C2SSQ&;T30/"G[,^O:%JMQX8TSX3WGBO0/ WQ \4^(-
M/\7>./B"_A?1H=/U:SB^'5T=7C30SJCQZ#J$T?Q&FABAA/BQ?#R65G:65SJ<
M:<?L\?\ ]!F'_P#"#_[^/H_KO"O_ $3N</\ [N[\[<*]>MN[MM$[+4?VH_@)
M-8VNCVNK6TVE0RV\^M6K:+IT<7B:^L=*^*6B:;<:NLCSM<ZCIEAXR\/@ZE.R
MQS+HUQ%I]G8Z=<Z!%<^+_$SXN?#KQKX3^)6JVNK:!/>:KX:U;PQ;Z%90Z;I=
MWJ&K:A\;;CQK\,];M])TJRLK1++X9_#D7^BWVIO%&UO)J47AZ.>\3S!%V=_I
M7[*/BC7_  )X#\#VFGZS#XT\2-X'NO$D<GBZZ\3?#KPU=6GC8Z?XRL[)9;*V
MNXM UJX\-:KJTNJVVH7%QX<L9()S"LMS-%\LZ9)X>G^+NCOX8U'X<>"?"[^*
M=>M=!U_QO!>>(/#F@:/!<7MA8^(?&VF3_P!KRWLD5O$NK:):_99DN+R:P,D4
MD(WK=.&+4TZN)HU(*_-"&#]E)Z.UJGUNIRV=G\$KI6TO=<V+Q7#]3#U(8+)<
MSPF)?+[+$8CB-8ZE3:G%R<\)_J_@O:\T%.*2Q5+DE)33DH\DO$Q+$Q15DC9I
M%W1@.I,BCJR '+*/5<CWI?,CRJ[TRY8(-RY<K]X*,Y8K_$!DCO7WSXR\<?".
MY\'>/?('PKGD&@^.K2?P_9VFCS>(?'?C>W'PRMOA9XNM;SP_I5H+7^UH-)\4
MZIXLB\*ZMHVD:%/J.NZ;+!+-<QRW&7J_C/X2:CK?QHNX)?A'I?@KQ1X+TJUL
M=$T?PR+36=*\4-\']'@M+OP-8SZ3/-J.F:1X_@O-*.B6&MZ'?Z5KLTOC#5[_
M %FP@,-STGBGP[134W%5+#:VT;AG=AL#(W8&<'C.!GKBG4 %?O?_ ,$E_P#D
MBGC#_LY_PI_ZK>2OP0K]X/\ @E)JVDZ9\%O$ZZGJNF:8UY^U'X5AM!J.H6=A
M]JE7X<$&*V^US0B>4&1%\N+<^74!<L 0#]N*4$@Y'H0>X*L"K*0>"K*2K*05
M9258%200@@D$$$<$$8(/H0>E)0!1CTK1XK&WTN+1=#BTJTN([RTTF+1=+CTF
MTO(IS=17MIIB6BV%K>Q7+-<Q7D%O'<QW#-.DHE)<SO:V<LUO<RV-A+=6DMU<
M6EW)86<EW9W%\GEW]S9W3PM<6ES?Q_N[^XMY(YKV/*73RJ2*GHH CCA@B_U-
MM:P_(L1$-M;P@PH&5+=A'&H:WC5W6.W(,$:O(J1JLCAJT&EZ3:0K;V>C:+9V
MR1&!;:ST?3+2V6!CEK<6]M:Q0_9W/WX-GDO@;D.T8NT4 5TL[**>YNH;#3X+
MN\96O;R"PM(+V^98TA5KZ\BA2YO2L,44(-U+*1%%%&/DC1546MF)[.Z%C8"[
MTY)XM,NQ868N]+BNE5+F'2[H0^?IL-RB(EQ#8R6\4Z(J2HZJ )Z* ,_^R-%\
MC[*="T$VFZ\<69T32C9A]1$BZDXM39FW#ZDLTRZDXC#:@LLJWAG61P;5M:VE
MEM%C96-@$5$06%E:V(5(L>5&HM(80(XMJ^6@&V/ V 5-10!GC1]$6.UA70=
M$-C-<W%A"-#TD0V%Q>;_ +;<6$(L_+L;B]\R3[;/:K#+>;W^TO+O;,TMAIUQ
M!+:7&F:7<VDT)MY[.YTRPN+.:V,JSFVFM)K=[>6V-PJW)MY(VA-RJW)3SP)*
MM44 5S96!GDNVT[36NY[6*PGNVTZR:[N+""7SH-/N+IH#//I]O-^^@L9I'M(
M9@)8H4D 86*** "BBB@ HHHH *M'_CP7_K^;_P!)DJK5H_\ '@O_ %_-_P"D
MR4 ?-NB?M8_L\^)/VG?&_P"QEHGQ(LK_ /::^''P^TGXJ^-?A8NC>(XK[0_
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MOQ*U/QMJ?C[Q'%XSO-&N[6>3Q2?B-XRT^^LKC0I-/M]+U=;;3K:RDT[39[0
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M/[$'_1-=?_\ #C>._P#Y?5^D=% 'YN?\.F?V(/\ HFNO_P#AQO'?_P OJ/\
MATS^Q!_T377_ /PXWCO_ .7U?I'10!^;G_#IG]B#_HFNO_\ AQO'?_R^H_X=
M,_L0?]$UU_\ \.-X[_\ E]7Z1T4 ?FY_PZ9_8@_Z)KK_ /X<;QW_ /+ZE'_!
M)K]B$9Q\-_$*Y&#M^)'CU=P[JV-?&Y3QE3E20"1P*_2*B@#\WE_X).?L1H=T
M?PX\1QMAEWQ_$GQ]&^U@590Z:^K ,I*L <,I*L"I(+?^'3/[#XZ?#77_ /PX
MOCO_ .7U?I'10!^;G_#IG]B#_HFNO_\ AQO'?_R^H_X=,_L0?]$UU_\ \.-X
M[_\ E]7Z1T4 ?FY_PZ9_8@_Z)KK_ /X<;QW_ /+ZC_ATS^Q!_P!$UU__ ,.-
MX[_^7U?I'10!^;G_  Z9_8@_Z)KK_P#X<;QW_P#+ZF:1^Q'X0^ M[XSTWX'_
M  2\'>.?"'Q(\+V^D36'CSQ?>37G@?Q- -2M;G6XKSQ);:]=7.A:S9WVFRW\
M.AS6VMVMUH$7V0,MQ$]O^DU% 'A?A3X.ZOH?A;PUHFI?%#QGJ.H:-H&CZ3>Z
M@D/A/9>W6G:?;VD]TAO/"]U>%)I(6=#>75U=%"IN+B:7?(V__P *QNO^BA^-
M?^_'@K_YCZ]5HH \J_X5C=?]%#\:_P#?CP5_\Q]'_"L;K_HH?C7_ +\>"O\
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M8^O5:* /*O\ A6-U_P!%#\:_]^/!7_S'T?\ "L;K_HH?C7_OQX*_^8^O5:*
M/*O^%8W7_10_&O\ WX\%?_,?7D_Q*^#?B635O ?BK3(!\9+/P=JFLW.H?#7Q
MW=^&-)TW5&UG2O[-M-=TZ[A\-0:6VN>')0TME#KMO<6CVE]J#6DUEJ"VTS?5
MM% 'CGP+\$:UX!\"MI&NVVF:3=:AXE\4>)+;PMH=S)>Z'X*T[Q%K-SJECX/T
?>[>&U6>RT2&X$)DMK.SL3<O<BPM8;(0+7L=%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "Z D # 2(  A$! Q$!_\0
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M--S[T,WO1H,FCN)O.B_>O]\ _,?6GWUQ+]NG"RN%WG^(U#%_K4]V'\Z???\
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M7UC_ *!\E)_PBVL<_P#$NDQ1[2'</9R[&;Q2X%:7_"+ZQ_T#Y*3_ (1?6/\
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MCOM#_P#/5O\ OHT?:'_YZM_WT:;M'I1M'I1RH-1?M#_\]&_[Z-+]HD_YZO\
M]]&F[1Z4FT>E'*@U'_:)/^>C_P#?1H\Z3_GH_P#WT:9@#M2''-+E0:DGGR?\
M]'_[Z-'G2?\ /1_^^JB'K1Q1RH+LE\Z3_GH__?5'G/\ \]7_ .^J9@4;1Z4^
M5!=C_M#_ //5O^^C1]H?_GJ__?5-VCTHVCTI<J"['?:'_P">K_\ ?1H^T/\
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MSKN(S7I/PK^'-E\*_"</AZPO+G4K>V:287%XVZ60G)PQ[U*A%]#9UYGFVB_
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M!8>A.3G'7-+IGPP\':)JG]I:?X7TJRU#)87$5L P)&#CL,@G.*ZBBCD17,S
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M_NM^52_;)O\ GHWYT?;)O^>C?G1=@19?^ZWY4?-_=;\JE^V3?\]&_.C[7/\
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MT-1NFN8DF@BEM2L1D8'.W)X%?<D/AGX27'B"YT-=$\--K=M;"[N+(6B;HXR
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M]# C'&*^?_VA_C7X@^'VLW%GX8OXYM1L[$7\VF+9"4A >7D<_=7'IS6;X/\
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MYTG_ #T;\S1Y\G_/1OS-'.NPTFMF7/E_N^W04OR^F?PJEY\G_/1OS-'GR?\
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2:=#-(TT8,C$$X/)HO<7+J?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "Z D # 2(  A$! Q$!_\0
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M4****!!1110 4444 +:_\?$7^^O\ZLZO_P A&Y_WZK6O_'Q%_OK_ #JSJ_\
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M6QNGU*Y*VD[*6X(C//%1S1YMRU%\NQGT5-]@O/\ GSG_ ._9H_L^\_Y\Y_\
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MM[>?4='\%:'):2-$6;S)(0-\AS\P7.?PK#F7\IKR/N?=+:I<JI8W+*B\LS,
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M.S8'.1@D\5R\GC_QI\1_'/P;\4^)/%=AJ-EJ.L:C+!H5HJQRV B8JJ$*=Q!
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M]V6/[2N_^>[_ )T?VE=_\]W_ #J#\*/PHY8]@N^[)_[2N_\ GN_YT?VE=_\
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M*^P(?4L<_@*X#X>_"_Q!K$GB'5/&7P_\.^'0^D1:7;>'-.N!+;7TD;;Q/(0
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M^&\FL^"]-00Q^(7UKSIH#\\LC&U$GS?-D8V^E<QKGP=^(<?P7\,>%K?PHEU
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M\_0GE9]C;J-W%?+L?QZ^(.M>/;+PC87NBV4T5GJ<EWJ36AD$[VC$*\:[L!6
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MN?A>/!VIP:-X7^*$$?AK^PYO#^I:HDL>G2^89/,5FSD$':> >*Z-?!=]X?\
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ML _Y>D_[Y-/F%8J[J-U6OLT'_/TG_?)H^S0?\_2?]\FCF#E95W4;JM?9H/\
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M)D^M1-]X?6IKC_CXD^M'4?0AV4>6*=10(;LH\L4ZB@8W91LIU% #=E&RG44
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MX_.N@_L^U_Y]H?\ OV*/[/M?^?:'_OV*/:OL'LD<_N]Q^=&[W'YUT']GVO\
MS[0_]^Q1_9]K_P ^T/\ W[%'M7V%[)'/[O\ :'YTFX?WA^==#_9]K_S[0_\
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/\AE0 BIE5;5K#5-7/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_005.jpg
<TEXT>
begin 644 form10-k_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Y!'X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P"A\4?^2C:K
M_P!L?_1*5R%=?\4?^2C:K_VQ_P#1*5R%>[2_AQ]#R:GQL***[>TATA_ %UK3
MZ!8M=V]VEN,RW&UE*@DD"7K],#VJIRY5<48\SL<117H-OX+LM2@@EE,&F*-&
M-\?*FDE,QY^9LJ=@'&0,^V><5M3\&QSVFE2Z:L-O%_92WE]<RNY0')&[H3SV
M 'X5G[:-[/\ K?\ R+]E*UU_6W^9P]%:&LZ-=:'?"UNC&Q:-98Y(VRDB,,AA
MG!Q]0*SZU335T9M6T84444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !77^'O^2<^,_^W'_T<:Y"NO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"$C(!*(1T/K23F]FP:BM0_X1/PY_T+^E?^ <?^%'_")^'/\ H7]*_P# ./\
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MD.?[[*"J>OS$4_WFVHO<WT(_^$3\.?\ 0OZ5_P" <?\ A1_PB?AS_H7]*_\
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M=L9P%0$]C2O/S"T2M_PB?AS_ *%_2O\ P#C_ ,*/^$3\.?\ 0OZ5_P" <?\
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MIFH;CQ5HMJMV9KS:+2..2?\ =.=JR?</ YSGM1>?G^(6B+_PB?AS_H7]*_\
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MX.#AF4 G/8&F^=7WT%[GD1?\(GX<_P"A?TK_ , X_P#"C_A$_#G_ $+^E?\
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M*2,@(RH0W'H30N=[7!J*W'?\(GX<_P"A?TK_ , X_P#"C_A$_#G_ $+^E?\
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M\ X_\*V**.>7<.5=C'_X1/PY_P!"_I7_ (!Q_P"%'_")^'/^A?TK_P  X_\
M"MBBCGEW#E78Q_\ A$_#G_0OZ5_X!Q_X4?\ ")^'/^A?TK_P#C_PK8HHYY=P
MY5V,?_A$_#G_ $+^E?\ @''_ (4?\(GX<_Z%_2O_  #C_P *V**.>7<.5=C'
M_P"$3\.?]"_I7_@''_A1_P (GX<_Z%_2O_ ./_"MBBCGEW#E78Q_^$3\.?\
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M]"_I7_@''_A1_P (GX<_Z%_2O_ ./_"MBBCGEW%RKL8__")^'/\ H7]*_P#
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MR.".]366MZ??O-'#*Z20KNDCN(7A=5_O;7 ./?&*(SE%;;?YW_4)14KZ[_\
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MQ+7$;?ZE6.>?O-D'^X*N_P#" _\ 4V^*O_!E_P#8T?\ " _]3;XJ_P#!E_\
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M9H)4EB<95XV#*?H12+<0/))&LT;/$0)%# E">0".V: ):**C:>%)HX7E199
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M) K",>B@CC\*GG5K6_K_ (<KE=[G'V $_BBP_P"$<GBMK4:2XB-U \H*";'
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M.^><A&.#'@3_ #!NO3C'7M6K)X6LIK*XMYIKF66YDCEGN69?,D*$%>V ..@
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MZ6&RO;J&T8K<SP(I2(@9(Y8,Q Z[0V*:OB[2G\06FCI(S37=L+F"48\N13G
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MEN'V0H3R[8S@#Z"@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML1#8<\UZ%11[72UOZT_R#D\_ZU_S.4L6D\/:QK37-K>S17UP+FWDM[=Y=V4
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M?6MOJD%IIYB']M^=<*+)G6:T/W0 N/-4'.44^O'-=+_PJ[P;_P! ?_R9F_\
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M9:)8M>7\PCB' '5G;LJCN3Z5GMXLLO[/TRZBM[J:34DWVULBIYC +N).6"C
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MY=W<'33278\^MK6W@\4>()=3@UR-9IXV@>S2\".!& 3F'@\^M;&JV\UQXO\
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M7*WCM:2B5I)5Y?RRN\C=QG'I[UJ?\*N\&_\ 0'_\F9O_ (NC_A5W@W_H#_\
MDS-_\74*5-*WZ>5N_G]Y3C-O^O\ (YF:WUJT\-:/X6-M>VUO.C2:A=P6DLQC
M1G8^4-BGYB#S72^(M-5K/PX--LI3'%J%J3M@8,D2@X+C&0 /7I2_\*N\&_\
M0'_\F9O_ (NC_A5W@W_H#_\ DS-_\75.I!M/SOM_P1<D]?2QU]%0VEK#8V<%
MI;)L@@C6*-,D[548 R>3P*FKE-PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %I_7YF9HFMG6?$ADCDD2(Z<ADMF8XBE$K*P(_O#&,^U=565:^'[&RU^\UF
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M_A!#H?FV_P!J\S=OW-LQYV_KC/3VZU>73]5TR]O'TM;.:WO)?.9+F1HS#(0
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M: O)7M5N'3];TZZN;FR6PE-\$DGBFF=!%,%"LRL$.Y3@<$+TZ\UG[MO/^O\
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MII&^MPHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@EO)Y5=&0+S,X9MPP.0H&.,=Z.6%M_Z_K[@O+L;7AS5GUO2C>N(\&XFC38"
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M^*-2>*[U&&.VCL+*>*&:"6-C,=P0L0P; V[^FTYP:L:AI&L/>P0V\=K=:/
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MXKQ$_P!OCUK4[ K]CD^Q0I/C*32+-DL.FX ,HR#STSQ6U%]M3QM:KKMQ SK
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MFNL2@*G)"*C*00 1\P//(!XK(T^+5-(O=+UC4+6WMTNY'CNW2Y9G)G.Y-RE
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M/1K5-4L)8UAEM[PG[/$<Q0JRAE6,X'RXYZ#DG@5TU1)6=BT[A1114C"BBB@
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M1V&F!G@/F,TF]AC&"/NCKG<3D#@8IDGBR*U>2&>SN9WMK>.>[GM%5X8U89W
ME@6'!Z G':I[GQ-!:W"+)87WV5YD@%YY:B+>^-O5@Q&2!N"D<]:OW[D7C8VZ
M*YJ'Q5 'CMX;;4KZ>9[G8H2(-B*3:PZJ !GC/) YYZ[FG7\&J:=!?6Q8PSH'
M7<,'\1ZU#BTKEW5[%FBBBI&%%%% !1110 4444 %%%% !1110 4444 9EYX?
MTV^NFN+B!R[@+($F=%E Z!U4A7'^\#4*>%]+BO)KN%;R*:>3S9?*OIT5V]2H
M< _3&,<51\5W>I:5 ^H6VHR(J[5BMEM08B<_,9I"#M7'?* >]+J\VJZ?/;74
M6J>>UQ=QQ16*PH(VC8C=S@N6"Y;=N XZ5K%2LK,B5M;HU/[ TS[:;LVY,A8O
ML,CF/<>"WEYV;CSSC/--M/#VF61/DV[E=AC5))GD5$/545B0@]E Z"L'2O$+
MZA?"YDU:6WC-S+$MHUIF%D4LH EVC$AV[L;C_NU6T[Q*ZZ#/JMQJU[+=?8Y;
ME+2:U6.$X!(V-Y8+X&,X8^]'+*P75SIK3PYI=C',D%N^)8O(;S)Y)"(_[BEF
M)5>>@P*GFT>PGTV'3W@_T:$*(E5V5H]OW2K [@1Z@YK"M)-4_M.#3;C6KE_M
M=A]J$ZPPAXF5E#!?DV[2&[@GCK2:(=8U+3;V[77+C[-).5M99+:)Y!$APS *
MBC+$'&0P QP:'%[M_P!;?YB371?U:_\ D=%8Z=;:;"T=LC*';>[.[.[MTRS,
M22>!U/:K58/A74;G4+.[^TS-*8+IXHWEC$<I0 $&1 !M;GI@<8.!FMZHDFGJ
M5%JV@4445)04444 %%%% !1110!#=6L%[;/;W4*30N,,CC(-9R>&-)42;K>2
M9GC:(O<7$DK*C#!56=B5!'IBEUZ_N+*WM8;,HMU>7*6\;R+E4SDEB.^ #QZX
MK-_M8:/?S1S^(H-12&"22>UE>$7*,J[OD5 N1@'(;V.:N*=M"6]4:ESX=TR[
M>)I8'W11"$%)G3=&/X6VL-R^S9IL/AG2(+*XLXK3;;W$"V\J>:YW1J" N<Y&
M 3TYJN/$S/91W4>AZLZR1F55$<8/E@ [B2^T9SPN=WM5=O&^GF*2:*TOIK>*
MWBN99DC7;'$X)#'+ \8.0 3[&JM4V%>.YI3>'=+GDN))+8EK@(),2N 2GW6
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M4%"=UQ(5<I]UG7=AV&!RP)XJMXD.H6EE=ZC!J[6T<$.Z*W2!")).P8L"3DX
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M4W$SP;%7&<D+(6_2FV?B2"ZN+6.2RO+5+P$VLLZH%FXW<;6)4X&<,!3?/?\
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MM!TQ[ZZ261%8*$A4,[$G& "1]?PI+W6H+1+3RXIKN6\_X]X;<+ND&-Q.6(4
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M+ 8YSGY3V]*N5G)MVN:*VM@HHHJ1A1110 4444 %%%% !1110 4444 %%%%
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MZVE\3)>[D(\LPR.R[N/X\H/<+6AH$%UH<6EW]U9730OIB6TJQP,\D#JQ890
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MB;5(M2CD=(+:"W@NRIQ<(I<@YZ;@& /N/>NQHHJ)2YG=E*-M@HHHJ2@HHHH
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MA3Q8D>BV9TR;^RCO-U9NJE_,3)*$J6/JP//J<5WD\$5S;R03QK)%(I1T89#
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M%1CQA)>7&D0Z5813MJ4,DH-Q<&(1[,!E.U'YSD?A3]G+^OG_ ),GG6_]=/\
M-'5457M9+MK8O>P00S GY(9C*N/]XJI_2N9L/&=U<:5::Q=:5#!IEQ,(?,CN
MR[QDOL!92BC&?1CUZ4E!O8;DDKLZZBN<M=?U74K_ %*WL-+LVCL;@V[//?-&
M7. <@")O7UJ[IVM&^UW5-+:V$9L!%F02;M^]2>F!C&/Q]J.1_K_7WCYD:U%<
MG+XU\G4KFV?3\0VVHQ6,DWG=/,&0^-OK@8SWZTNN>-#I-[?6T&GBZ^QK!YCF
M?8-\K[57[I[<Y_2FJ<G:RW_X'^:)<XJ]^G]?H=716'>:OJFEZ1?ZC?Z=9JEK
M TJI!>LY<CG!S$N/KS]*J)XFOXY=.CN]+MT.I1L;7R;PR9<)O"OF-=N1W&:.
M1O;^NH^9'3T5R]GXR34/[+AM;(O?7<CI<6QEP;4)Q(6..<' ' SD=*U-5U@V
M%S:65O;_ &F^NRPAB+[% 499F;!P!QT!//2APDG8%),U**Y74?&+Z5I^I/=:
M>!J%@(W>V6?*2([;597VY(Z]5!R*W+";4Y2WV^SM(%P"A@NFE)/N#&N/UI.#
M2N',KV+U%8L/B#SM5UNQ^RX_LQ(WW^9_K=R%NF.,8QWK*OO'/V3PIINLQZ8T
M\]^-R6BS<@!2S'=MYP%/:FH2?X?B/F7]>7_#G7T5B7/B*.&ZT..&'SHM68A)
M-^-@V;P<8Y_2K&KZO_9KVEO#!]HO;R0QV\._8"0,DLV#A0!R<'Z&ERO87,MS
M3HKGV\4Q6/VZ/6(!:7%G +AUBD\U9(R< HQ"DG/&"!R15JTO]8DGA^TZ/'%;
MR\[X[L.\7&1O4JH'I\I;G\Z.5AS(UJ*YO1=?U;7+<7=OI5E':^>\1:2_??A6
M*D[1%CMTS5"+X@PR6OB!S8E9](9\1&7B=5.-P.WCGJ,'&1ZT_9R_K^O,.9?U
M_7D=G17+^(?&2:#;Z=+]A:X-TOFR*LF/)B !9SP<XW#CC-6/$6OWVB);SP:?
M:W5M/+'"KM=M&V]S@<"-AMZ<Y_"CV<M/N#G7ZG045SEWK^J6NJ:=I8TNS>]O
M(Y9#F^81H$Q_%Y63D'^Z*74->U/3IM,M'TRT>\OYGB55O6\M-J[LEO*SVZ;:
M.1Z>8<RU.BHK+TC6&U">\L[FW%M?6;JLT2R>8N&&596P,@CU Z&M2I:MN-.X
M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >=^*O"^M:AJFK7VFPXF8
M6WV63S%&["ND@Y/'RN>OX5!<^#]0AMGMX]*^U6J:Q!.(=\9\R!(@IX9@.V,$
MUZ77-0^(-8E\1R:,=)L5DBA6=Y!J#D;&8CC]SR>.G ]ZWA4ELNAE.,=V6M+M
MH(K2[AM/#IT@.OW=D""4X(_Y9.W3WQUKG9?#>IR?"^PT5K,->QM%YL!=","0
M%N<X/'O6N?%V-#UW4OL/_(*N)8?+\W_6[,<YV_+G/H:9-XUALS?I?VA@D@MT
MN;=!)N^U(V -O YW$+CGJ*%SWNEV?W:K\P:CLWW7WZ,HWW@J*7Q%<"QT^WLM
M.N=(EM7DMT1 )688RHP3QWQVJ>ZT_5M:TFQT6[T\VZPR0M<W1E1HW$9!_=@'
M=DD#[RKC)ZU-%XQD7Q58Z#>Z;]FFN;59F<3[A&Y#'9C:,_=//Z5GVWQ'6ZAF
ME32_W::C%8H?M'WU<G$GW>.F<>_6J2J:?UU:_,3<-?ZZ7_(9%I6M)IOB/21I
M,N=3O)WBNFFB\I4< !FP^_L>-M,\4^#8M6@ALSH<\SVULD-K?VMS&K# QB17
M*_+GTW'KTK3'B^]:'5+T:1$UAIMS)!.ZW9\TA,994V8/!SC=46K^/4TPZN8M
M/^T)I\5O*K"?;YPE/'\)QC/OGVI)SNK+M^22_"PVHZW\_P ]?Q-"2SUFR\!?
M88#]LU=+,0A@X&7(QG+$=.N3UQ6/#X:UO2=1T.:![6ZAMH&LIDMX?)(A*_>8
MM(=V& / !Y-:A\8P//9K;VQEBN;&6\#F3:5,>,H1CKG(/ICI5C1-9U75K&TU
M"33;*"RN(Q+N%Z[R*I&1\OE $_\  JEN2NVM]_Q7^8+E=DOZV?\ D<2/ ^M)
MX:T$16^R^@G"WL'F)\T0F,BG.<$KUZY^8UKQ:5K2:;XCTD:3+G4[R=XKIIHO
M*5'  9L/O['C;6MX?\6R>(I4EL[&)[%F=3*EVIEAQT\R,@;<]L%NU:NO:NNA
MZ-/?F$S-'@1PAL&1R0%4'!ZDBJG.=[26_P#F@C&.Z>WZ7_X)2UKP\;[PFND6
MSJ)(4B\EG/!:,@C/L=N/QJ21K_6;:XT^YTF6RMYH'CDEEGC)R1CY%0MD<]25
M^E9=[XZ6S\(V>N_V<\C3SBWDM1)\T;Y(89QR05/&!FI;[QK#;2W8M[47,,&E
M_P!I)*)<"0$X"XP<?7]*EQFT[KJ_O_JPTXJUOZU_S*MQI6KZEX9MO#5S8&((
M(HY[[S4,3(A!R@!W[B%Z%0!Z^N1J/@W5[O4YY8H=D5QJK><?,7Y[1A'N/7UC
MZ=:ZNR\0W376GPZEI\-LNHINMI(;DR@MMW;6RBX./3(XIWB;7;[P_:"\BT^W
MNK;<D9+W31N&9MHX\MACD<Y_"J4IJ7FW^)-HN'DE^!S-GX2U%KO1!=6TL<%O
M=7TD[0W7ELBR$E"&1@W/'3\:W]0\."U&F7.CVZF33[EIS"TAW3!U*OEVSEN<
MY8\XY-61KEW#KFG:3>V,,<UY'+(6AN3(J!,8ZHI.<^V/>L\^-?+GG,VG[+*W
MU(Z?/<>?GR^!M<C;T).#SQ[TKS=K?UK8?NJ]_P"NH]M/O]1UN;6IM,6,1V+6
ML%E<RKNE+-EMY3>H'  Z]3FN:L? ]S::G>WFE:?=Z9;SV,T4MG/<1N))&7"J
MA5C\H/.6(K<U3QXUAIE_J4&EFYM+>[6TA?S]OGMT8CY3@ \=\\]*GN?&\,?B
M#2=+@M//74(!.9A+CRP59E&,'.=I[BFN=+1:;?A?_@@^6^OK^*7YZ%-] U,^
M%O"=F+;_ $BPNK:2Y3S%^14!W'.<''MFDUKPK?ZOX@UMPHBM[K3XHH)V8$>:
MC[@" <XR!VJ:P\;W>JIHZV6DP^=J4<T@6:\*+&(VQU$9)S]!5B7QF(4M$>P(
MNI-273KB'SO]2Y&=P./F&,$<#.>U-^TYMM=?Q?\ FB?<MY*WX7?ZCKRSU+Q!
M=:5'=Z<]C%8W*W4TCRHXD90<+'M8G&3G+!>.U<GJ'@?6I_"=REO;[-2^VSD1
M>8G[Z"1P<$YQV5N3VK>B^(L,NBZU>_V>5GTR4J;<S?ZU-^T.&V^N>QQBM./Q
M#J5[KFH:;I^F6DGV(1%Y+B]:/=O7<, 1-T^M$7..J7G^3_R&U%[OR_-'.^+_
M  @^OW#NFB31:BBJ+?4+:ZC"-@<>:K$,,'^Z&/3GM6_XJTC4-1\"RZ7!F[OC
M'$I.X)YA5E+')( Z$]:O:_K4N@>&YM4EM4EEB5-T"RD+DL 0&V]!GKC\*S;S
MQ?<:6U]!J&FQ)=6]BU]&L%T9$E13@@L44J<X[&I4IM*W1E<L4[]U_P  GU7P
MNMQH-Q:64UP+AFCEC-U=RS+O1@P'SLV 2,'']*CNK/4-?U/2Y+G3I+&#3Y3<
M.9948ROM*J$V,?EYSEL'@<5:F\1B&[T& VO&JJS;O,QY6(]_I\WIVJK_ ,)9
M,=-?64TT-HJ$YG\_]Z4!P9!'MQM[_>SCM2M/K_70/=MI_2W.=T[PCJVFZ)HU
MPMO-/=6MPSW.F2W6Z)U+DAE!;8KJ,,,8_.NL\0:9<7<^EZC:1B6?3K@S>06"
MF12I5@">-W.1GCCK52\\7[==DTC3K6"[N8XDE*2W8A:4-R!$""'..>2HY'-2
MW7B+4!KTVE66E02R0VBW3M<79BX)(V@*C#/'KBG*4VU)^;$E%77]?UJ1:\==
MUGP]?6=KI36CW(6%#-<1EPK'#LP4E0 O3#$G/05EW7AW7;;4WD@^S74%SIDE
MC*MM%Y"IM4^42'D;<<DKD=,UL:3XOAUB_P!-MX+5ECO;)[H.[\H58*5QCGG/
M.>U1P^,5FMY=EB3='49-/MX!*/WK+_$6Q\HQDG@XQWHM-7C;^MAWB[._];G.
MIX-U:%_"=Q##M-N8!J,/F+\IC! ?K@D D<9[>E=#I-MJGARVGTVWTIKU#<22
MP3B=$CVNQ;#Y.X$9(^56[5)>>*I=,AU"/4+!([ZTM&O$BCG+QS(.#M<J""#C
M.5[CK1#XEOEN=,BOM,MXAJ:,;9H;MI/F";PKYC7&1W&:;E.2U7];_HR5&,7_
M %TT_4RY-#8>+M9O]0\+#5;>Z$/V=P+>3;M3#<2.I'..W.*==^%[O5?$5W=*
M+S2X)-+CA@D@N?+:*0,3M*QM@@ CCD>E7;;QH+N*QAAL"=3N+EK>:R,O-N4_
MUC,V.@&"..<BM7P]K/\ ;VE?;?L_D?OI(MF_=]QBN<X'7%)N:7II^@[1;_K^
MN@SPO#=VWA^VMKZPCLKB$%&CB*E&P?OK@]&Z\\Y)JGHFE7MI/XC:>'8+R\>6
M#Y@=ZE  >#QR.]'_  ET?_"9?V!]D;RL;/M>_P"7SMN_R\8Z[><YIESXN?\
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MO+QEV/!Z$+^%+_PL&'9X@;[ ^-*.(B9/^/GYBG'R\?,,=Z>WC.^.G:Q>PZ1
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MW=LEBTF^"T$)AFBC4>6!O60Y#,V<XSE?I5N[TJ6;XB1Z8A'V"9H]7N$S]V1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBLZZ\0:+8W#6]YJ^GV\ZXW1S
M7*(PSSR"<TTF]@V-&BF12QSPI+#(LD3J&1T.0P/0@CJ*?2 **** "BBB@ HH
MK.&OZ,;W[&-7L/M6_9Y'VE-^[TVYSGVII-[ W;<T:***0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKW[6=5MI)9(1&@%L5CW93 S@'Y3N)_#I6=!XLUNST;1M1-V=4EOK.>26W\I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJLN\X.,YQ[=:U+[3KV/5TU;3?(><P^1-!<.4610V5(8!BI!)['.:&XWT[O\
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M?MXD\QO-SN\S9MVX^_\ Q;NG:A<MM?Z_X(W?6Q:.I:Y9ZI96MXEA,UZ)=D<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4;%1=PHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M><?6KC'F_KR;_0ENW]>G^9Z%17-:1K6FC2(K6&*[LU19(^899(X"K,K9FP5
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MK)X<:YU$S/<V]LL\I"*#*&+ ; , \J5QQS56FU</=N17_A2ZO]8\TQV<5O\
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MM@*%4*/F7<0&SC&>:HSZOJEM<W&FQZB\RM?6]I%?M''O5G!,BX"A"5 '\/\
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M9M1?48FM&FN&>)$\A]P"XV@8#?-@-D_+UH]ZV_\ 2$[=OZ9T5%%%9&@4444
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M&L(EC@VQQ(KAL*FXGDCDECT'TIVH>$X;SQ+;ZU%<&"1(GCEC"Y$I*%58\C!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7=$TMPBB0>JY/(^E.BUK2I[.2\AU.SDM8CB29)U*(?=@<"ES2WM_6P[1VO\
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M]*7Q8MP^L>&EM98HIS>OM>6,R*/W+]5#*3^8K63PWH4<$L":+IRPRX\R-;5
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M]T_0'O7>1:7I\%D;**PM8[0G)@2%0A.<_=QCK4LMG:SS1S36T,DL88([H"R
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MNP">X3:VT=MWL*T_"KK'I>H.Y 5=0NB2>P\UJW5@A2=YUBC6:0!7D"@,P&<
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M\)[#]KV[?L/^A[^F_>?,V_[6-GOC/O6P-/LA;1VPL[<6\;!DB\I=JL#D$#&
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MI]I]K(P9_)7S",8QNQGI24TOZ_KT&XM_U_7J8$4%AK&IVLUG#!'HVEI*ID5
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MP1ACU!IJ4;IO^M"6G9I=C-N7GL[.TMK:+4].>_ODMW>]O/M#JFTL2A,D@4D
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MZL[BV1T1[<1G(?&00Z,/X13E-.=UMK^HH1:C9[G':O=7EIJ2:,D^HW-O%J,
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M9Y'D@AGD5EB9@0<';O/!. 6('Y5LUG+ETL6KZW"BBBH*"BBB@ HHHH ****
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M_)&I)^I/6K.G:=#ID,L4+.RRSR3G>03N=BQZ#IDU,I+7Y#29<HHHK,L****
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M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.2>@&4J>E[,'/7<[&BBBL30**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH B@MH;82"%-OF2&1^2<L>IYJ6BB@ J*.VABGFG1,2S$&1LDYP,
M#Z?_ *ZEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH CGA%Q;R0LSJ'4J6C<JPSW!'(/O6=I^AQV-XUY+>7=[=&(
J0K+<LI*1YSM&U5'7DD@D^M:M%--K835PHHHI#"BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex23-2_001.jpg
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B *,# 2(  A$! Q$!_\0
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E***  4444 %%%% !WHHHH .]%%% "=Z6BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>shph-20231231.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSPCbP9z5Z8iekhvWB1bZlKLywrDOx3CycSRpvGMeUG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:SHPH="http://shuttlepharma.com/20231231" elementFormDefault="qualified" targetNamespace="http://shuttlepharma.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://shuttlepharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" id="StatementsOfChangesInStockholdersEquityParenthetical">
          <link:definition>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
          <link:definition>00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" id="OrganizationAndLiquidity">
          <link:definition>00000009 - Disclosure - Organization and Liquidity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/Leases" id="Leases">
          <link:definition>00000011 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" id="NotesPayable-relatedParty">
          <link:definition>00000012 - Disclosure - Notes Payable-Related Party</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ConvertibleNotes" id="ConvertibleNotes">
          <link:definition>00000013 - Disclosure - Convertible Notes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>00000014 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
          <link:definition>00000015 - Disclosure - Derivative Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000016 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000017 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000018 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000021 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
          <link:definition>00000022 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" id="DerivativeLiabilitiesTables">
          <link:definition>00000023 - Disclosure - Derivative Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000024 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" id="OrganizationAndLiquidityDetailsNarrative">
          <link:definition>00000025 - Disclosure - Organization and Liquidity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" id="ScheduleOfErrorCorrectionDetails">
          <link:definition>00000026 - Disclosure - Schedule of the Error Correction (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" id="ScheduleOfCashAndCashEquivalentsDetails">
          <link:definition>00000027 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>00000028 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" id="ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails">
          <link:definition>00000029 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
          <link:definition>00000030 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" id="ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails">
          <link:definition>00000032 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" id="ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails">
          <link:definition>00000033 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000034 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" id="NotesPayable-relatedPartyDetailsNarrative">
          <link:definition>00000035 - Disclosure - Notes Payable-Related Party (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" id="ConvertibleNotesDetailsNarrative">
          <link:definition>00000036 - Disclosure - Convertible Notes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
          <link:definition>00000037 - Disclosure - Schedule of Warrants Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" id="ScheduleOfWarrantsActivityDetailsParenthetical">
          <link:definition>00000038 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" id="ScheduleOfRestrictedStockUnitsRsusDetails">
          <link:definition>00000039 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" id="ScheduleOfMonteCarloSimulationAssumptionDetails">
          <link:definition>00000041 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" id="ScheduleOfDerivativeLiabilitiesDetails">
          <link:definition>00000042 - Disclosure - Schedule of Derivative Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" id="DerivativeLiabilitiesDetailsNarrative">
          <link:definition>00000043 - Disclosure - Derivative Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000044 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" id="ScheduleOfReconciliationOfIncomeTaxBenefitDetails">
          <link:definition>00000045 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" id="ScheduleOfComponentsOfDeferredTaxAssetsDetails">
          <link:definition>00000046 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:definition>00000047 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000048 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000049 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="shph-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="SHPH_CommonStockToBeIssuedMember" name="CommonStockToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InstitutionalInvestorMember" name="InstitutionalInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AcceleratedFeatureMember" name="AcceleratedFeatureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NewLeaseAgreementMember" name="NewLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OfficersSpouseMember" name="OfficersSpouseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RelatedPartyOfficerMember" name="RelatedPartyOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_BousteadSecuritiesLLCMember" name="BousteadSecuritiesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNoteMember" name="ConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AltoConvertibleNoteMember" name="AltoConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TwoThousandEighteenEquityIncentivePlanMember" name="TwoThousandEighteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DirectorsAndOfficersMember" name="DirectorsAndOfficersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_BousteadMember" name="BousteadMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AyrtonMember" name="AyrtonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableMember" name="NotesPayableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableRelatedPartiesMember" name="NotesPayableRelatedPartiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" name="MeasurementInputVolumeWeightedAveragePriceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_MeasurementInputIlliquidityDiscountMember" name="MeasurementInputIlliquidityDiscountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_TCGGreenChemIncMember" name="TCGGreenChemIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_FederalTaxableIncomeMember" name="FederalTaxableIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StateTaxableIncomeMember" name="StateTaxableIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNotePayableCurrent" name="ConvertibleNotePayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_FinanceFee" name="FinanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_LossOnSettlementOfConvertibleDebt" name="LossOnSettlementOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_GainOnForgivenessOfNotePayable" name="GainOnForgivenessOfNotePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" name="StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" name="StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsIssuanceFees" name="WarrantsIssuanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccruedInterestSettledWithCommonStock" name="AccruedInterestSettledWithCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" name="IncreaseDecreaseInAccruedInterestPayableRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" name="ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForConversionOfAccruedInterest" name="CommonStockIssuedForConversionOfAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForSettlementOfDebt" name="CommonStockIssuedForSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" name="CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockIssuedForDividendPayable" name="CommonStockIssuedForDividendPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsIssuedForFinancingFees" name="WarrantsIssuedForFinancingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" name="InitialRecognitionOfRightOfUseAssetAndLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DisclosureNotesPayablerelatedPartyAbstract" name="DisclosureNotesPayablerelatedPartyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" name="NotesPayableRelatedPartyDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock" name="CorrectionOfPriorPeriodErrorsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ConvertibleNotePolicyTextBlock" name="ConvertibleNotePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" name="ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" name="ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OtherInformationAbstract" name="OtherInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RentVariableRate1" name="RentVariableRate1" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" name="EstimatedMonthlyCommonAreaMaintenanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonAreaMaintenanceCost" name="CommonAreaMaintenanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaymentForPlacementAgent" name="PaymentForPlacementAgent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InterestFeeAmount" name="InterestFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AccruedInterestValueToIssueShares" name="AccruedInterestValueToIssueShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" name="StockIssuedDuringPeriodSharesSettlementOfNotesPayable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_CommonStockVestingOfRestrictedStockUnit" name="CommonStockVestingOfRestrictedStockUnit" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable" name="StockIssuedDuringPeriodValueWarrantsNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" name="StockIssuedDuringPeriodSharesConversionOfPreferredShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" name="StockIssuedDuringPeriodSharesConversionOfDividends" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueDividendsPayable" name="StockIssuedDuringPeriodValueDividendsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeGainLossOnDerivativeWarrants" name="DerivativeGainLossOnDerivativeWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" name="AdditionOfNewDerivativesRecognizedAsDebtDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DerivativeDiscountPercentage" name="DerivativeDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_PaymentsToInvoicesInResearchAndDevelopment" name="PaymentsToInvoicesInResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationProvisionAdjustments" name="IncomeTaxReconciliationProvisionAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" name="IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ShortfallOfStockCompensationExpense" name="ShortfallOfStockCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsbasedCompensation" name="DeferredTaxAssetsbasedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxLiabilitiesFairMarketValue" name="DeferredTaxLiabilitiesFairMarketValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" name="DeferredTaxLiabilitiesFiniteLivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" name="EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" name="DeferredTaxAssetsOperatingLossCarriedForward" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" name="DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AdditionalEscrowDeposit" name="AdditionalEscrowDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_InitialPublicOfferingDescription" name="InitialPublicOfferingDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfTheErrorCorrectionTableTextBlock" name="ScheduleOfTheErrorCorrectionTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_OctoberTwoThousandTwentyThreeMember" name="OctoberTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ProceedsFromConvertibleNoteAndWarrantOffering" name="ProceedsFromConvertibleNoteAndWarrantOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_StockIssuedDuringPeriodValueSettlementNotesPayable" name="StockIssuedDuringPeriodValueSettlementNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_RoyaltyExpensePercentage" name="RoyaltyExpensePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_NetSales" name="NetSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ScheduleOfAnnualRoyaltyPaymentsTableTextBlock" name="ScheduleOfAnnualRoyaltyPaymentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPaymentsYearOne" name="AnnualRoyaltyPaymentsYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPaymentsYearTwo" name="AnnualRoyaltyPaymentsYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPaymentsYearThree" name="AnnualRoyaltyPaymentsYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPaymentsYearFour" name="AnnualRoyaltyPaymentsYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPaymentsYearFive" name="AnnualRoyaltyPaymentsYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPaymentsYearAfterFive" name="AnnualRoyaltyPaymentsYearAfterFive" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_AnnualRoyaltyPayments" name="AnnualRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SHPH_ReclassificationsPolicyTextBlock" name="ReclassificationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>shph-20231231_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="shph-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="shph-20231231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="shph-20231231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:href="shph-20231231.xsd#OrganizationAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/Leases" xlink:href="shph-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20231231.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotes" xlink:href="shph-20231231.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:href="shph-20231231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:href="shph-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxes" xlink:href="shph-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesTables" xlink:href="shph-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:href="shph-20231231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:href="shph-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:href="shph-20231231.xsd#OrganizationAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:href="shph-20231231.xsd#ScheduleOfErrorCorrectionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="shph-20231231.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="shph-20231231.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20231231.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20231231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:href="shph-20231231.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:href="shph-20231231.xsd#ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:href="shph-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20231231.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" xlink:href="shph-20231231.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20231231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20231231.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20231231.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:href="shph-20231231.xsd#ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:href="shph-20231231.xsd#ScheduleOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="shph-20231231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="shph-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="shph-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="shph-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="shph-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNotePayableCurrent" xlink:label="loc_SHPHConvertibleNotePayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_SHPHConvertibleNotePayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHFinanceFee" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_SHPHChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AccruedInterestSettledWithCommonStock" xlink:label="loc_SHPHAccruedInterestSettledWithCommonStock" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHAccruedInterestSettledWithCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDebtSecuritiesGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:label="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:title="00000009 - Disclosure - Organization and Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Leases" xlink:title="00000011 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000012 - Disclosure - Notes Payable-Related Party" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotes" xlink:title="00000013 - Disclosure - Convertible Notes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:title="00000015 - Disclosure - Derivative Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesTables" xlink:title="00000021 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:title="00000023 - Disclosure - Derivative Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:title="00000026 - Disclosure - Schedule of the Error Correction (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000027 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000028 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000029 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000030 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:title="00000032 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:title="00000033 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:title="00000034 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Payable-Related Party (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" xlink:title="00000036 - Disclosure - Convertible Notes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000037 - Disclosure - Schedule of Warrants Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000039 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:title="00000041 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:title="00000042 - Disclosure - Schedule of Derivative Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000043 - Disclosure - Derivative Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000044 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000045 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:label="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShortfallOfStockCompensationExpense" xlink:label="loc_SHPHShortfallOfStockCompensationExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_SHPHShortfallOfStockCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000046 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000047 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000048 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>shph-20231231_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="shph-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="shph-20231231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="shph-20231231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:href="shph-20231231.xsd#OrganizationAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/Leases" xlink:href="shph-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20231231.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotes" xlink:href="shph-20231231.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:href="shph-20231231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:href="shph-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxes" xlink:href="shph-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesTables" xlink:href="shph-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:href="shph-20231231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:href="shph-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:href="shph-20231231.xsd#OrganizationAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:href="shph-20231231.xsd#ScheduleOfErrorCorrectionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="shph-20231231.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="shph-20231231.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20231231.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20231231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:href="shph-20231231.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:href="shph-20231231.xsd#ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:href="shph-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20231231.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" xlink:href="shph-20231231.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20231231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20231231.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20231231.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:href="shph-20231231.xsd#ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:href="shph-20231231.xsd#ScheduleOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="shph-20231231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="shph-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="shph-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="shph-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="shph-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInterestReceivableCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssetsNoncurrent_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapInterestPayableCurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapNotesPayableCurrent_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNotePayableCurrent" xlink:label="loc_SHPHConvertibleNotePayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_SHPHConvertibleNotePayableCurrent_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRevenues_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapLegalFees_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_70" xlink:to="loc_us-gaapOperatingExpenses_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapInterestExpense_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapInvestmentIncomeInterest_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_SHPHFinanceFee_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_70" xlink:to="loc_us-gaapNonoperatingIncomeExpense_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_70" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_SHPHCommonStockToBeIssuedMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_70" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:title="00000009 - Disclosure - Organization and Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Leases" xlink:title="00000011 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000012 - Disclosure - Notes Payable-Related Party" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotes" xlink:title="00000013 - Disclosure - Convertible Notes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:title="00000015 - Disclosure - Derivative Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesTables" xlink:title="00000021 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:title="00000023 - Disclosure - Derivative Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InstitutionalInvestorMember" xlink:label="loc_SHPHInstitutionalInvestorMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHInstitutionalInvestorMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WorkingCapital" xlink:label="loc_SHPHWorkingCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SHPHWorkingCapital_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaapPartnersCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPartnersCapital_70" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:title="00000026 - Disclosure - Schedule of the Error Correction (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000027 - Disclosure - Schedule of Cash and Cash Equivalents (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000028 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_SHPHAcceleratedFeatureMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaapDerivativeAssetsCurrent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsCurrent_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_170" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000029 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000030 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustment_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:title="00000032 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:title="00000033 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:title="00000034 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NewLeaseAgreementMember" xlink:label="loc_SHPHNewLeaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SHPHNewLeaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapPaymentsForRent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapDeposits_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RentVariableRate1" xlink:label="loc_SHPHRentVariableRate1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHRentVariableRate1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:label="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapSecurityDeposit_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonAreaMaintenanceCost" xlink:label="loc_SHPHCommonAreaMaintenanceCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHCommonAreaMaintenanceCost_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Payable-Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_OfficersSpouseMember" xlink:label="loc_SHPHOfficersSpouseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHOfficersSpouseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="loc_SHPHRelatedPartyOfficerMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHRelatedPartyOfficerMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPaidNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" xlink:title="00000036 - Disclosure - Convertible Notes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNoteMember" xlink:label="loc_SHPHConvertibleNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHConvertibleNoteMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_130" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PaymentForPlacementAgent" xlink:label="loc_SHPHPaymentForPlacementAgent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHPaymentForPlacementAgent_130" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_130" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_130" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_130" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_130" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount_130" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_130" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLegalFees_130" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InterestFeeAmount" xlink:label="loc_SHPHInterestFeeAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHInterestFeeAmount_130" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_130" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_130" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_130" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest_130" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_130" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_130" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000037 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_BousteadMember" xlink:label="loc_SHPHBousteadMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AyrtonMember" xlink:label="loc_SHPHAyrtonMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHAyrtonMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableMember" xlink:label="loc_SHPHNotesPayableMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHNotesPayableMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableRelatedPartiesMember" xlink:label="loc_SHPHNotesPayableRelatedPartiesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHNotesPayableRelatedPartiesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_20" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000039 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DirectorsAndOfficersMember" xlink:label="loc_SHPHDirectorsAndOfficersMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsAndOfficersMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AccruedInterestValueToIssueShares" xlink:label="loc_SHPHAccruedInterestValueToIssueShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHAccruedInterestValueToIssueShares_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesSettlementOfNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesSettlementOfNotesPayable_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:label="loc_SHPHCommonStockVestingOfRestrictedStockUnit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHCommonStockVestingOfRestrictedStockUnit_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesExerciseOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesExerciseOfWarrants_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodValueWarrantsNotesPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueWarrantsNotesPayable_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_170" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_170" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_170" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_170" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_170" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_170" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:title="00000041 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="loc_us-gaapMeasurementInputDefaultRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDefaultRateMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputIlliquidityDiscountMember" xlink:label="loc_SHPHMeasurementInputIlliquidityDiscountMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIlliquidityDiscountMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_200" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:title="00000042 - Disclosure - Schedule of Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SHPHAcceleratedFeatureMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeGainLossOnDerivativeWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeGainLossOnDerivativeWarrants_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000043 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:label="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DerivativeDiscountPercentage" xlink:label="loc_SHPHDerivativeDiscountPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHDerivativeDiscountPercentage_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000044 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_TCGGreenChemIncMember" xlink:label="loc_SHPHTCGGreenChemIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHTCGGreenChemIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000045 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000046 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000047 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000048 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FederalTaxableIncomeMember" xlink:label="loc_SHPHFederalTaxableIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHFederalTaxableIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StateTaxableIncomeMember" xlink:label="loc_SHPHStateTaxableIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHStateTaxableIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaapTaxYear2016Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2016Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2017Member" xlink:label="loc_us-gaapTaxYear2017Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2017Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_80" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PurchaseAgreementMember" xlink:label="loc_SHPHPurchaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHPurchaseAgreementMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEscrowDeposit_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="loc_SHPHAdditionalEscrowDeposit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHAdditionalEscrowDeposit_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="loc_SHPHInitialPublicOfferingDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHInitialPublicOfferingDescription_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="10" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>shph-20231231_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="SHPH_CommonStockToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssuedMember" xlink:to="SHPH_CommonStockToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockToBeIssuedMember_lbl" xml:lang="en-US">Common Stock to be Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InstitutionalInvestorMember" xlink:label="SHPH_InstitutionalInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InstitutionalInvestorMember" xlink:to="SHPH_InstitutionalInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InstitutionalInvestorMember_lbl" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="SHPH_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SecuritiesPurchaseAgreementMember" xlink:to="SHPH_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US">US Treasury Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AcceleratedFeatureMember" xlink:label="SHPH_AcceleratedFeatureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AcceleratedFeatureMember" xlink:to="SHPH_AcceleratedFeatureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AcceleratedFeatureMember_lbl" xml:lang="en-US">Accelerated Feature [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NewLeaseAgreementMember" xlink:label="SHPH_NewLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NewLeaseAgreementMember" xlink:to="SHPH_NewLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NewLeaseAgreementMember_lbl" xml:lang="en-US">New Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_OfficersSpouseMember" xlink:label="SHPH_OfficersSpouseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficersSpouseMember" xlink:to="SHPH_OfficersSpouseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OfficersSpouseMember_lbl" xml:lang="en-US">Officers Spouse [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="SHPH_RelatedPartyOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyOfficerMember" xlink:to="SHPH_RelatedPartyOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_RelatedPartyOfficerMember_lbl" xml:lang="en-US">Related Party Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="SHPH_BousteadSecuritiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadSecuritiesLLCMember" xlink:to="SHPH_BousteadSecuritiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_BousteadSecuritiesLLCMember_lbl" xml:lang="en-US">Boustead Securities LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNoteMember" xlink:label="SHPH_ConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNoteMember" xlink:to="SHPH_ConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="SHPH_AltoConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoConvertibleNoteMember" xlink:to="SHPH_AltoConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AltoConvertibleNoteMember_lbl" xml:lang="en-US">Alto Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="SHPH_TwoThousandEighteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DirectorsAndOfficersMember" xlink:label="SHPH_DirectorsAndOfficersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsAndOfficersMember" xlink:to="SHPH_DirectorsAndOfficersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DirectorsAndOfficersMember_lbl" xml:lang="en-US">Directors and Officers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_BousteadMember" xlink:label="SHPH_BousteadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadMember" xlink:to="SHPH_BousteadMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_BousteadMember_lbl" xml:lang="en-US">Boustead [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AyrtonMember" xlink:label="SHPH_AyrtonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AyrtonMember" xlink:to="SHPH_AyrtonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AyrtonMember_lbl" xml:lang="en-US">Ayrton [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableMember" xlink:label="SHPH_NotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableMember" xlink:to="SHPH_NotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableMember_lbl" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableRelatedPartiesMember" xlink:label="SHPH_NotesPayableRelatedPartiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartiesMember" xlink:to="SHPH_NotesPayableRelatedPartiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableRelatedPartiesMember_lbl" xml:lang="en-US">Notes Payable Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:to="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_lbl" xml:lang="en-US">Measurement Input Volume Weighted Average Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="us-gaap_MeasurementInputDefaultRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDefaultRateMember" xlink:to="us-gaap_MeasurementInputDefaultRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDefaultRateMember_lbl" xml:lang="en-US">Measurement Input, Default Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputIlliquidityDiscountMember" xlink:label="SHPH_MeasurementInputIlliquidityDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputIlliquidityDiscountMember" xlink:to="SHPH_MeasurementInputIlliquidityDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_MeasurementInputIlliquidityDiscountMember_lbl" xml:lang="en-US">Illiquidity Discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_TCGGreenChemIncMember" xlink:label="SHPH_TCGGreenChemIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TCGGreenChemIncMember" xlink:to="SHPH_TCGGreenChemIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_TCGGreenChemIncMember_lbl" xml:lang="en-US">TCG Green Chem Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FederalTaxableIncomeMember" xlink:label="SHPH_FederalTaxableIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FederalTaxableIncomeMember" xlink:to="SHPH_FederalTaxableIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_FederalTaxableIncomeMember_lbl" xml:lang="en-US">Federal Taxable Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StateTaxableIncomeMember" xlink:label="SHPH_StateTaxableIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StateTaxableIncomeMember" xlink:to="SHPH_StateTaxableIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StateTaxableIncomeMember_lbl" xml:lang="en-US">State Taxable Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2016Member" xlink:label="us-gaap_TaxYear2016Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2016Member" xlink:to="us-gaap_TaxYear2016Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2016Member_lbl" xml:lang="en-US">Tax Year 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2017Member" xlink:label="us-gaap_TaxYear2017Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2017Member" xlink:to="us-gaap_TaxYear2017Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2017Member_lbl" xml:lang="en-US">Tax Year 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PurchaseAgreementMember" xlink:label="SHPH_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PurchaseAgreementMember" xlink:to="SHPH_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:to="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_lbl" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $121,685 and $114,875 respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNotePayableCurrent" xlink:label="SHPH_ConvertibleNotePayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePayableCurrent" xlink:to="SHPH_ConvertibleNotePayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ConvertibleNotePayableCurrent_lbl" xml:lang="en-US">Convertible notes payable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable non-current, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.00001 par value; 100,000,000 shares authorized; 16,069,320 and 13,603,129 shares issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US">Preferred stock, liquidation preference per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of contract expense reimbursements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal and professional</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FinanceFee" xlink:label="SHPH_FinanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_FinanceFee_lbl" xml:lang="en-US">Finance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="us-gaap_GainLossOnSaleOfInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfInvestments_lbl" xml:lang="en-US">Gain on sale of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Change in fair value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_lbl" xml:lang="en-US">Loss on settlement of convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="SHPH_GainOnForgivenessOfNotePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnForgivenessOfNotePayable" xlink:to="SHPH_GainOnForgivenessOfNotePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_GainOnForgivenessOfNotePayable_lbl" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Dividend on Series A Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per shares - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per shares - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Warrants exercised for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Warrants issued for financing costs, net of issuance fees of $8,727</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for conversion of convertible debt and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued for conversion of convertible debt and accrued interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Common stock issued for restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Common stock issued for restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends on Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan_lbl" xml:lang="en-US">Common shares issued for dividends on and conversion of Series A preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:label="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest and principal</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest and principal, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsIssuanceFees" xlink:label="SHPH_WarrantsIssuanceFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuanceFees" xlink:to="SHPH_WarrantsIssuanceFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsIssuanceFees_lbl" xml:lang="en-US">Warranst of issuance fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ChangeInFairValueOfDerivativeLiability" xlink:label="SHPH_ChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ChangeInFairValueOfDerivativeLiability" xlink:to="SHPH_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_ChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount and finance fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfInvestments" xlink:to="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfInvestments_2_lbl" xml:lang="en-US">Gain on marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_2_lbl" xml:lang="en-US">Change in fair value of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AccruedInterestSettledWithCommonStock" xlink:label="SHPH_AccruedInterestSettledWithCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestSettledWithCommonStock" xlink:to="SHPH_AccruedInterestSettledWithCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccruedInterestSettledWithCommonStock_lbl" xml:lang="en-US">Accrued interest settled with common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_2_lbl" xml:lang="en-US">Loss on settlement of convertible debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnForgivenessOfNotePayable" xlink:to="SHPH_GainOnForgivenessOfNotePayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_GainOnForgivenessOfNotePayable_2_lbl" xml:lang="en-US">Gain on forgiveness of Paycheck Protection Program note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="us-gaap_DebtSecuritiesGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesGainLoss_lbl" xml:lang="en-US">Gain on interest relief on conversion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xml:lang="en-US">Accrued interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:to="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_lbl" xml:lang="en-US">Accrued interest payable - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Change in operating lease asset and liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Investment in marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from disposition of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:to="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of common shares and exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from note payable-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of note payable-related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes payable and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment for finance costs related to convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment of convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Supplemental non-cash financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterest_lbl" xml:lang="en-US">Common stock issued for conversion of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForSettlementOfDebt" xlink:label="SHPH_CommonStockIssuedForSettlementOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForSettlementOfDebt" xlink:to="SHPH_CommonStockIssuedForSettlementOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForSettlementOfDebt_lbl" xml:lang="en-US">Common stock issued for settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_lbl" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForDividendPayable" xlink:label="SHPH_CommonStockIssuedForDividendPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForDividendPayable" xlink:to="SHPH_CommonStockIssuedForDividendPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForDividendPayable_lbl" xml:lang="en-US">Common stock issued for dividend payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsIssuedForFinancingFees" xlink:label="SHPH_WarrantsIssuedForFinancingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuedForFinancingFees" xlink:to="SHPH_WarrantsIssuedForFinancingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsIssuedForFinancingFees_lbl" xml:lang="en-US">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:label="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:to="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_lbl" xml:lang="en-US">Initial recognition of right of use asset and liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="SHPH_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureLeasesAbstract" xlink:to="SHPH_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:label="SHPH_DisclosureNotesPayablerelatedPartyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:to="SHPH_DisclosureNotesPayablerelatedPartyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DisclosureNotesPayablerelatedPartyAbstract_lbl" xml:lang="en-US">Notes Payable-related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:label="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:to="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable-Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock" xlink:label="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock" xlink:to="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock_lbl" xml:lang="en-US">Correction of an Immaterial Error in the Prior Period Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNotePolicyTextBlock" xlink:label="SHPH_ConvertibleNotePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePolicyTextBlock" xlink:to="SHPH_ConvertibleNotePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ConvertibleNotePolicyTextBlock_lbl" xml:lang="en-US">Convertible Note</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsPolicyTextBlock" xlink:label="SHPH_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsPolicyTextBlock" xlink:to="SHPH_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Schedule of the Error Correction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:to="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Lives for Property Plant Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Right-of Use Asset and Lease Information About Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units (RSUs)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Monte Carlo Simulation Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:to="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Income Tax Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Sale of stock membership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income loss</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WorkingCapital" xlink:label="SHPH_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WorkingCapital" xlink:to="SHPH_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance or sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument, face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Four year warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds from warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapital" xlink:label="us-gaap_PartnersCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapital" xlink:to="us-gaap_PartnersCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapital_lbl" xml:lang="en-US">Initiated a capital offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Total cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="us-gaap_DerivativeAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsCurrent" xlink:to="us-gaap_DerivativeAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsCurrent_lbl" xml:lang="en-US">United States Treasury Bonds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative Liability - Accelerated feature</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustment" xlink:to="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustment_lbl" xml:lang="en-US">Quarterly reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, uninsured amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Marketable securitie outstanding balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Marketable securities realized gain loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Marketable securities unrealized gain loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_3_lbl" xml:lang="en-US">Marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, net of contract expense reimbursements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureLeasesAbstract" xlink:to="SHPH_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Right-of Use Asset And Lease Information About Operating Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SubleaseIncome_lbl" xml:lang="en-US">Sublease income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_OtherInformationAbstract" xlink:label="SHPH_OtherInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OtherInformationAbstract" xlink:to="SHPH_OtherInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_OtherInformationAbstract_lbl" xml:lang="en-US">Other information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases (year)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DisclosureLeasesAbstract" xlink:to="SHPH_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="SHPH_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lessee, operating lease, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RentVariableRate1" xlink:label="SHPH_RentVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RentVariableRate1" xlink:to="SHPH_RentVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_RentVariableRate1_lbl" xml:lang="en-US">Rent variable rate</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:label="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:to="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_lbl" xml:lang="en-US">Estimated monthly common area maintenance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonAreaMaintenanceCost" xlink:label="SHPH_CommonAreaMaintenanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonAreaMaintenanceCost" xlink:to="SHPH_CommonAreaMaintenanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonAreaMaintenanceCost_lbl" xml:lang="en-US">Common area maintenance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="us-gaap_RelatedPartyTransactionRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionRate" xlink:to="us-gaap_RelatedPartyTransactionRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionRate_lbl" xml:lang="en-US">Related Party Transaction, Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="us-gaap_RelatedPartyTransactionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl" xml:lang="en-US">Related Party Transaction, Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaidNet_2_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Increase accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants exerciable shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Effective interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Warrant derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PaymentForPlacementAgent" xlink:label="SHPH_PaymentForPlacementAgent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentForPlacementAgent" xlink:to="SHPH_PaymentForPlacementAgent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaymentForPlacementAgent_lbl" xml:lang="en-US">Payment for placement agent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expected years</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Allocation of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Equity warrant as reduction in additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_2_lbl" xml:lang="en-US">Legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InterestFeeAmount" xlink:label="SHPH_InterestFeeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InterestFeeAmount" xlink:to="SHPH_InterestFeeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InterestFeeAmount_lbl" xml:lang="en-US">Interest fee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Debt principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Debt, principal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Life (Years), Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Life (Years), Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Number of shares warrant to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per RSU, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Stock Option Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per RSU, Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs, Outstanding, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Per RSU, Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Common stock issued for conversion of convertible debt, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AccruedInterestValueToIssueShares" xlink:label="SHPH_AccruedInterestValueToIssueShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestValueToIssueShares" xlink:to="SHPH_AccruedInterestValueToIssueShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_AccruedInterestValueToIssueShares_lbl" xml:lang="en-US">Accrued interest settled with common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" xlink:label="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" xlink:to="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable_lbl" xml:lang="en-US">[custom:StockIssuedDuringPeriodSharesSettlementOfNotesPayable]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Number of shares of common stock upon settlement of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:label="SHPH_CommonStockVestingOfRestrictedStockUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:to="SHPH_CommonStockVestingOfRestrictedStockUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockVestingOfRestrictedStockUnit_lbl" xml:lang="en-US">Common stock vesting of restricted stock unit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares of common stock issued for exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Exercise of warrants, value</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US">Common stock issued for exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable" xlink:label="SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable" xlink:to="SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable_lbl" xml:lang="en-US">Common stock issued for exercise of warrants notes payable, value</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_lbl" xml:lang="en-US">Number shares issued for conversion of note, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_lbl" xml:lang="en-US">Number shares issued for conversion dividends payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:label="SHPH_StockIssuedDuringPeriodValueDividendsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:to="SHPH_StockIssuedDuringPeriodValueDividendsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_StockIssuedDuringPeriodValueDividendsPayable_lbl" xml:lang="en-US">Common stock issued for dividends payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Number of warrants to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share granted under equity incentive plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares vested under plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted stock award granted shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Restricted stock award granted value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Life (Years), Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Time period (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:to="SHPH_DerivativeGainLossOnDerivativeWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants_lbl" xml:lang="en-US">Gain on change in fair value of the derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:to="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_lbl" xml:lang="en-US">Addition of new derivatives recognized as debt discounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:label="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:to="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_lbl" xml:lang="en-US">Warrants price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMeasurementInput_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DerivativeDiscountPercentage" xlink:label="SHPH_DerivativeDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeDiscountPercentage" xlink:to="SHPH_DerivativeDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeDiscountPercentage_lbl" xml:lang="en-US">Derivative discount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:to="SHPH_PaymentsToInvoicesInResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment_lbl" xml:lang="en-US">Payments to invoices in research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">R &amp; D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:label="SHPH_IncomeTaxReconciliationProvisionAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:to="SHPH_IncomeTaxReconciliationProvisionAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationProvisionAdjustments_lbl" xml:lang="en-US">Return to provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShortfallOfStockCompensationExpense" xlink:label="SHPH_ShortfallOfStockCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShortfallOfStockCompensationExpense" xlink:to="SHPH_ShortfallOfStockCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShortfallOfStockCompensationExpense_lbl" xml:lang="en-US">Shortfall of stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles (includes Section 174 capitalization)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsbasedCompensation" xlink:label="SHPH_DeferredTaxAssetsbasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsbasedCompensation" xlink:to="SHPH_DeferredTaxAssetsbasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsbasedCompensation_lbl" xml:lang="en-US">Equity based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Interest &amp; other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:label="SHPH_DeferredTaxAssetsLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:to="SHPH_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease asset/(liability)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:to="SHPH_DeferredTaxLiabilitiesFairMarketValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue_lbl" xml:lang="en-US">Change in fair market value of securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:to="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_lbl" xml:lang="en-US">Total deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Federal income tax benefit at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal tax effect</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_lbl" xml:lang="en-US">Change in tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xml:lang="en-US">Return to provision adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_lbl" xml:lang="en-US">Shortfall of stock compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operatiing loss</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_lbl" xml:lang="en-US">Carried forward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">state income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_lbl" xml:lang="en-US">Future taxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Federal Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_lbl" xml:lang="en-US">Carried forward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">R&amp;D tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Common stock trading price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of stock consideration received per transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Right offering</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="SHPH_AdditionalEscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionalEscrowDeposit" xlink:to="SHPH_AdditionalEscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SHPH_AdditionalEscrowDeposit_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="SHPH_InitialPublicOfferingDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialPublicOfferingDescription" xlink:to="SHPH_InitialPublicOfferingDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_InitialPublicOfferingDescription_lbl" xml:lang="en-US">Initial public offering description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Restricted stock units</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3_lbl" xml:lang="en-US">Restricted stock value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePayableCurrent" xlink:to="SHPH_ConvertibleNotePayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNotePayableCurrent_doc" xml:lang="en-US">Convertible note payable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_FinanceFee_doc" xml:lang="en-US">Finance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LossOnSettlementOfConvertibleDebt" xlink:to="SHPH_LossOnSettlementOfConvertibleDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_LossOnSettlementOfConvertibleDebt_doc" xml:lang="en-US">Loss on settlement of convertible debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_GainOnForgivenessOfNotePayable" xlink:to="SHPH_GainOnForgivenessOfNotePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_GainOnForgivenessOfNotePayable_doc" xml:lang="en-US">Gain on forgiveness of note payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockToBeIssuedMember" xlink:to="SHPH_CommonStockToBeIssuedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockToBeIssuedMember_doc" xml:lang="en-US">Common Stock To Be Issued [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal_doc" xml:lang="en-US">Stock Issued During Period Value Conversion O fAccruedInterest And Principal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal_doc" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Accrued Interest And Principal.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ChangeInFairValueOfDerivativeLiability" xlink:to="SHPH_ChangeInFairValueOfDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ChangeInFairValueOfDerivativeLiability_doc" xml:lang="en-US">Change in fair value of derivative liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestSettledWithCommonStock" xlink:to="SHPH_AccruedInterestSettledWithCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccruedInterestSettledWithCommonStock_doc" xml:lang="en-US">Accruedi nterest settled with common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:to="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_doc" xml:lang="en-US">Increase decrease in accrued interest payable - related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:to="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants_doc" xml:lang="en-US">Proceeds from issuance of common stock and exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:to="SHPH_CommonStockIssuedForConversionOfAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForConversionOfAccruedInterest_doc" xml:lang="en-US">Common Stock Issued For Conversion Of Accrued Interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForSettlementOfDebt" xlink:to="SHPH_CommonStockIssuedForSettlementOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForSettlementOfDebt_doc" xml:lang="en-US">Common stock issued for settlement of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForDividendPayable" xlink:to="SHPH_CommonStockIssuedForDividendPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForDividendPayable_doc" xml:lang="en-US">Common stock issued for dividend payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuedForFinancingFees" xlink:to="SHPH_WarrantsIssuedForFinancingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsIssuedForFinancingFees_doc" xml:lang="en-US">Warrants issued for financing fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:to="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InitialRecognitionOfRightOfUseAssetAndLiability_doc" xml:lang="en-US">Initial recognition of right of use asset and liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsIssuanceFees" xlink:to="SHPH_WarrantsIssuanceFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsIssuanceFees_doc" xml:lang="en-US">Warrants issuance fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_doc" xml:lang="en-US">Common stock issued for exercise of warrants with settlement of notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InstitutionalInvestorMember" xlink:to="SHPH_InstitutionalInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InstitutionalInvestorMember_doc" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SecuritiesPurchaseAgreementMember" xlink:to="SHPH_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WorkingCapital" xlink:to="SHPH_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock" xlink:to="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock_doc" xml:lang="en-US">Correction of prior period errors policytextblock</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ScheduleOfTheErrorCorrectionTableTextBlock" xlink:label="SHPH_ScheduleOfTheErrorCorrectionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfTheErrorCorrectionTableTextBlock" xlink:to="SHPH_ScheduleOfTheErrorCorrectionTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfTheErrorCorrectionTableTextBlock_doc" xml:lang="en-US">Schedule Of The Error Correction [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:to="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule of Useful Lives for Property Plant Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNotePolicyTextBlock" xlink:to="SHPH_ConvertibleNotePolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNotePolicyTextBlock_doc" xml:lang="en-US">Convertible Note [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WarrantsPolicyTextBlock" xlink:to="SHPH_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TCGGreenChemIncMember" xlink:to="SHPH_TCGGreenChemIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TCGGreenChemIncMember_doc" xml:lang="en-US">TCG Green Chem Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NewLeaseAgreementMember" xlink:to="SHPH_NewLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NewLeaseAgreementMember_doc" xml:lang="en-US">New Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RentVariableRate1" xlink:to="SHPH_RentVariableRate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RentVariableRate1_doc" xml:lang="en-US">Rent Variable Rate1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonAreaMaintenanceCost" xlink:to="SHPH_CommonAreaMaintenanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonAreaMaintenanceCost_doc" xml:lang="en-US">Common area maintenance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OtherInformationAbstract" xlink:to="SHPH_OtherInformationAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OtherInformationAbstract_doc" xml:lang="en-US">Other information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_OctoberTwoThousandTwentyThreeMember" xlink:label="SHPH_OctoberTwoThousandTwentyThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OctoberTwoThousandTwentyThreeMember" xlink:to="SHPH_OctoberTwoThousandTwentyThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OctoberTwoThousandTwentyThreeMember_doc" xml:lang="en-US">October 31, 2023 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_OfficersSpouseMember" xlink:to="SHPH_OfficersSpouseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_OfficersSpouseMember_doc" xml:lang="en-US">Officers Spouse [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RelatedPartyOfficerMember" xlink:to="SHPH_RelatedPartyOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RelatedPartyOfficerMember_doc" xml:lang="en-US">Related Party Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadSecuritiesLLCMember" xlink:to="SHPH_BousteadSecuritiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_BousteadSecuritiesLLCMember_doc" xml:lang="en-US">Boustead Securities LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ProceedsFromConvertibleNoteAndWarrantOffering" xlink:label="SHPH_ProceedsFromConvertibleNoteAndWarrantOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ProceedsFromConvertibleNoteAndWarrantOffering" xlink:to="SHPH_ProceedsFromConvertibleNoteAndWarrantOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ProceedsFromConvertibleNoteAndWarrantOffering_doc" xml:lang="en-US">Proceeds from convertible note and warrant offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ConvertibleNoteMember" xlink:to="SHPH_ConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ConvertibleNoteMember_doc" xml:lang="en-US">Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InterestFeeAmount" xlink:to="SHPH_InterestFeeAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InterestFeeAmount_doc" xml:lang="en-US">Interest fee amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestValueToIssueShares" xlink:to="SHPH_AccruedInterestValueToIssueShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AccruedInterestValueToIssueShares_doc" xml:lang="en-US">Accrued interest value to issue shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:to="SHPH_CommonStockVestingOfRestrictedStockUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_CommonStockVestingOfRestrictedStockUnit_doc" xml:lang="en-US">Common stock vesting of restricted stock unit.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueSettlementNotesPayable" xlink:label="SHPH_StockIssuedDuringPeriodValueSettlementNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueSettlementNotesPayable" xlink:to="SHPH_StockIssuedDuringPeriodValueSettlementNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodValueSettlementNotesPayable_doc" xml:lang="en-US">Stock issued during period value settlement notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants_doc" xml:lang="en-US">Stock issued during period shares exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares_doc" xml:lang="en-US">Stock issued during period shares conversion of preferred shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:to="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesConversionOfDividends_doc" xml:lang="en-US">Stock issued during period shares conversion of dividends.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:to="SHPH_StockIssuedDuringPeriodValueDividendsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodValueDividendsPayable_doc" xml:lang="en-US">Stock issued during period value dividends payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AltoConvertibleNoteMember" xlink:to="SHPH_AltoConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AltoConvertibleNoteMember_doc" xml:lang="en-US">Alto Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_BousteadMember" xlink:to="SHPH_BousteadMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_BousteadMember_doc" xml:lang="en-US">Boustead [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AyrtonMember" xlink:to="SHPH_AyrtonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AyrtonMember_doc" xml:lang="en-US">Ayrton [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding, Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted Average Remaining Life in Years Outstanding,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableMember" xlink:to="SHPH_NotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableMember_doc" xml:lang="en-US">Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartiesMember" xlink:to="SHPH_NotesPayableRelatedPartiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableRelatedPartiesMember_doc" xml:lang="en-US">Notes Payable Related Parties [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_doc" xml:lang="en-US">Share-based compensation arrangement by share-based payment award non-options outstanding intrinsic value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:to="SHPH_TwoThousandEighteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_TwoThousandEighteenEquityIncentivePlanMember_doc" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DirectorsAndOfficersMember" xlink:to="SHPH_DirectorsAndOfficersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DirectorsAndOfficersMember_doc" xml:lang="en-US">Directors and Officers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:to="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_doc" xml:lang="en-US">Class pf warrant or right number of securities called by warrants or rights value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeDiscountPercentage" xlink:to="SHPH_DerivativeDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeDiscountPercentage_doc" xml:lang="en-US">Derivative discount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:to="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputVolumeWeightedAveragePriceMember_doc" xml:lang="en-US">Measurement Input Volume Weighted Average Price [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:to="SHPH_DerivativeGainLossOnDerivativeWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants_doc" xml:lang="en-US">Derivative gain loss on derivative warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AcceleratedFeatureMember" xlink:to="SHPH_AcceleratedFeatureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AcceleratedFeatureMember_doc" xml:lang="en-US">Accelerated Feature [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:to="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts_doc" xml:lang="en-US">Addition of new derivatives recognized as debt discounts.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LicenseAgreementMember" xlink:label="SHPH_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_LicenseAgreementMember" xlink:to="SHPH_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RoyaltyExpensePercentage" xlink:label="SHPH_RoyaltyExpensePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_RoyaltyExpensePercentage" xlink:to="SHPH_RoyaltyExpensePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_RoyaltyExpensePercentage_doc" xml:lang="en-US">Royalty expense percentage.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NetSales" xlink:label="SHPH_NetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NetSales" xlink:to="SHPH_NetSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NetSales_doc" xml:lang="en-US">Net sales.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_UpfrontPayment" xlink:label="SHPH_UpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_UpfrontPayment" xlink:to="SHPH_UpfrontPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_UpfrontPayment_doc" xml:lang="en-US">Upfront payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:to="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_doc" xml:lang="en-US">Schedule Of Pretax Income From Continuing Operations [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:to="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_doc" xml:lang="en-US">Income tax reconciliation foreignIncome tax permanent differences.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsbasedCompensation" xlink:to="SHPH_DeferredTaxAssetsbasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsbasedCompensation_doc" xml:lang="en-US">Deferred tax assetsbased compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:to="SHPH_DeferredTaxAssetsLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsLeaseLiabilities_doc" xml:lang="en-US">Deferred tax assets lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_doc" xml:lang="en-US">Deferred tax assets liabilities net before valuation allowances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:to="SHPH_DeferredTaxLiabilitiesFairMarketValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue_doc" xml:lang="en-US">Deferred tax liabilities fair market value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate_doc" xml:lang="en-US">Effective income tax rate reconciliation change in tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_doc" xml:lang="en-US">Effective income tax rate reconciliation return to provision adjustments.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ScheduleOfAnnualRoyaltyPaymentsTableTextBlock" xlink:label="SHPH_ScheduleOfAnnualRoyaltyPaymentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ScheduleOfAnnualRoyaltyPaymentsTableTextBlock" xlink:to="SHPH_ScheduleOfAnnualRoyaltyPaymentsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ScheduleOfAnnualRoyaltyPaymentsTableTextBlock_doc" xml:lang="en-US">Schedule Of Annual Royalty Payments [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPaymentsYearOne" xlink:label="SHPH_AnnualRoyaltyPaymentsYearOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPaymentsYearOne" xlink:to="SHPH_AnnualRoyaltyPaymentsYearOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPaymentsYearOne_doc" xml:lang="en-US">Annual royalty payments year one.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPaymentsYearTwo" xlink:label="SHPH_AnnualRoyaltyPaymentsYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPaymentsYearTwo" xlink:to="SHPH_AnnualRoyaltyPaymentsYearTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPaymentsYearTwo_doc" xml:lang="en-US">Annual royalty payments year two.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPaymentsYearThree" xlink:label="SHPH_AnnualRoyaltyPaymentsYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPaymentsYearThree" xlink:to="SHPH_AnnualRoyaltyPaymentsYearThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPaymentsYearThree_doc" xml:lang="en-US">Annual royalty payments year three.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPaymentsYearFour" xlink:label="SHPH_AnnualRoyaltyPaymentsYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPaymentsYearFour" xlink:to="SHPH_AnnualRoyaltyPaymentsYearFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPaymentsYearFour_doc" xml:lang="en-US">Annual royalty payments year four.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPaymentsYearFive" xlink:label="SHPH_AnnualRoyaltyPaymentsYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPaymentsYearFive" xlink:to="SHPH_AnnualRoyaltyPaymentsYearFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPaymentsYearFive_doc" xml:lang="en-US">Annual royalty payments year five.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPaymentsYearAfterFive" xlink:label="SHPH_AnnualRoyaltyPaymentsYearAfterFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPaymentsYearAfterFive" xlink:to="SHPH_AnnualRoyaltyPaymentsYearAfterFive_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPaymentsYearAfterFive_doc" xml:lang="en-US">Annual royalty payments year after five.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AnnualRoyaltyPayments" xlink:label="SHPH_AnnualRoyaltyPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AnnualRoyaltyPayments" xlink:to="SHPH_AnnualRoyaltyPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AnnualRoyaltyPayments_doc" xml:lang="en-US">Annual royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:to="SHPH_PaymentsToInvoicesInResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaymentsToInvoicesInResearchAndDevelopment_doc" xml:lang="en-US">Payments to invoices in research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:to="SHPH_IncomeTaxReconciliationProvisionAdjustments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_IncomeTaxReconciliationProvisionAdjustments_doc" xml:lang="en-US">Income tax reconciliation provision adjustments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences_doc" xml:lang="en-US">Effective income tax rate reconciliation permanent differences.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PurchaseAgreementMember" xlink:to="SHPH_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionalEscrowDeposit" xlink:to="SHPH_AdditionalEscrowDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_AdditionalEscrowDeposit_doc" xml:lang="en-US">Additional escrow deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_InitialPublicOfferingDescription" xlink:to="SHPH_InitialPublicOfferingDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_InitialPublicOfferingDescription_doc" xml:lang="en-US">Initial public offering description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:to="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_doc" xml:lang="en-US">Deferred tax liabilities finite lived assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:to="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_NotesPayableRelatedPartyDisclosureTextBlock_doc" xml:lang="en-US">Notes Payable Related Party [Disclosure Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShortfallOfStockCompensationExpense" xlink:to="SHPH_ShortfallOfStockCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ShortfallOfStockCompensationExpense_doc" xml:lang="en-US">Shortfall of stock compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_doc" xml:lang="en-US">Effective income tax rate reconciliation short fall of stock compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForward_doc" xml:lang="en-US">Deferred tax assets operating loss carried forward</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_doc" xml:lang="en-US">Deferred tax assets operating loss carried forward future federal income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" xlink:to="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable_doc" xml:lang="en-US">Stock issued during period shares settlement of notes payable.</link:label>
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ReclassificationsPolicyTextBlock" xlink:label="SHPH_ReclassificationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ReclassificationsPolicyTextBlock" xlink:to="SHPH_ReclassificationsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_ReclassificationsPolicyTextBlock_doc" xml:lang="en-US">Reclassifications [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_MeasurementInputIlliquidityDiscountMember" xlink:to="SHPH_MeasurementInputIlliquidityDiscountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_MeasurementInputIlliquidityDiscountMember_doc" xml:lang="en-US">Illiquidity Discount [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FederalTaxableIncomeMember" xlink:to="SHPH_FederalTaxableIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_FederalTaxableIncomeMember_doc" xml:lang="en-US">Federal Taxable Income [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_StateTaxableIncomeMember" xlink:to="SHPH_StateTaxableIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_StateTaxableIncomeMember_doc" xml:lang="en-US">State Taxable Income [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:to="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_EstimatedMonthlyCommonAreaMaintenanceCost_doc" xml:lang="en-US">Estimated monthly common area maintenance cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_PaymentForPlacementAgent" xlink:to="SHPH_PaymentForPlacementAgent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SHPH_PaymentForPlacementAgent_doc" xml:lang="en-US">Payment for placement agent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_FinanceFee" xlink:to="SHPH_FinanceFee_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_FinanceFee_3_lbl" xml:lang="en-US">FinanceFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_2_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ChangeInFairValueOfDerivativeLiability" xlink:to="SHPH_ChangeInFairValueOfDerivativeLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ChangeInFairValueOfDerivativeLiability_3_lbl" xml:lang="en-US">ChangeInFairValueOfDerivativeLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesGainLoss" xlink:to="us-gaap_DebtSecuritiesGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:to="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedInterestPayableRelatedParties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_2_lbl" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of Related Party Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:to="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable_3_lbl" xml:lang="en-US">CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_WorkingCapital" xlink:to="SHPH_WorkingCapital_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_WorkingCapital_3_lbl" xml:lang="en-US">WorkingCapital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubleaseIncome_2_lbl" xml:lang="en-US">Sublease Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AccruedInterestValueToIssueShares" xlink:to="SHPH_AccruedInterestValueToIssueShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AccruedInterestValueToIssueShares_3_lbl" xml:lang="en-US">AccruedInterestValueToIssueShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:to="SHPH_DerivativeGainLossOnDerivativeWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DerivativeGainLossOnDerivativeWarrants_3_lbl" xml:lang="en-US">DerivativeGainLossOnDerivativeWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:to="SHPH_DeferredTaxLiabilitiesFairMarketValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxLiabilitiesFairMarketValue_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesFairMarketValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:to="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxLiabilitiesFiniteLivedAssets_3_lbl" xml:lang="en-US">DeferredTaxLiabilitiesFiniteLivedAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_3_lbl" xml:lang="en-US">DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationPermanentDifferences</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:to="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_3_lbl" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:to="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_3_lbl" xml:lang="en-US">DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SHPH_AdditionalEscrowDeposit" xlink:to="SHPH_AdditionalEscrowDeposit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SHPH_AdditionalEscrowDeposit_3_lbl" xml:lang="en-US">AdditionalEscrowDeposit</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>shph-20231231_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://shuttlepharma.com/role/Cover" xlink:href="shph-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheets" xlink:href="shph-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:href="shph-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfOperations" xlink:href="shph-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="shph-20231231.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:href="shph-20231231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:href="shph-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:href="shph-20231231.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:href="shph-20231231.xsd#OrganizationAndLiquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/Leases" xlink:href="shph-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:href="shph-20231231.xsd#NotesPayable-relatedParty" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotes" xlink:href="shph-20231231.xsd#ConvertibleNotes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquity" xlink:href="shph-20231231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:href="shph-20231231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:href="shph-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxes" xlink:href="shph-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEvents" xlink:href="shph-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesTables" xlink:href="shph-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:href="shph-20231231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:href="shph-20231231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:href="shph-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:href="shph-20231231.xsd#OrganizationAndLiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:href="shph-20231231.xsd#ScheduleOfErrorCorrectionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:href="shph-20231231.xsd#ScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="shph-20231231.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:href="shph-20231231.xsd#ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="shph-20231231.xsd#ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="shph-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:href="shph-20231231.xsd#ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:href="shph-20231231.xsd#ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:href="shph-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:href="shph-20231231.xsd#NotesPayable-relatedPartyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" xlink:href="shph-20231231.xsd#ConvertibleNotesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="shph-20231231.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:href="shph-20231231.xsd#ScheduleOfWarrantsActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:href="shph-20231231.xsd#ScheduleOfRestrictedStockUnitsRsusDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="shph-20231231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:href="shph-20231231.xsd#ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:href="shph-20231231.xsd#ScheduleOfDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="shph-20231231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="shph-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:href="shph-20231231.xsd#ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:href="shph-20231231.xsd#ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="shph-20231231.xsd#ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="shph-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="shph-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:label="loc_deiDocumentFinStmtRestatementRecoveryAnalysisFlag" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNotePayableCurrent" xlink:label="loc_SHPHConvertibleNotePayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SHPHConvertibleNotePayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaapConvertibleLongTermNotesPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapConvertibleLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaapPreferredStockLiquidationPreference" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FinanceFee" xlink:label="loc_SHPHFinanceFee" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHFinanceFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPreferredStockDividendsIncomeStatementImpact" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockToBeIssuedMember" xlink:label="loc_SHPHCommonStockToBeIssuedMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_SHPHCommonStockToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueDividendReinvestmentPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesDividendReinvestmentPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Changes in Stockholders&apos; Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsIssuanceFees" xlink:label="loc_SHPHWarrantsIssuanceFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_SHPHWarrantsIssuanceFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_SHPHChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHChangeInFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaapGainLossOnSaleOfInvestments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AccruedInterestSettledWithCommonStock" xlink:label="loc_SHPHAccruedInterestSettledWithCommonStock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHAccruedInterestSettledWithCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_GainOnForgivenessOfNotePayable" xlink:label="loc_SHPHGainOnForgivenessOfNotePayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHGainOnForgivenessOfNotePayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesGainLoss" xlink:label="loc_us-gaapDebtSecuritiesGainLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaapIncreaseDecreaseInInterestPayableNet" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInterestPayableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:label="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_SHPHIncreaseDecreaseInAccruedInterestPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaapPaymentsToAcquireMarketableSecurities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMarketableSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SHPHProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForConversionOfAccruedInterest" xlink:label="loc_SHPHCommonStockIssuedForConversionOfAccruedInterest" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SHPHCommonStockIssuedForConversionOfAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForSettlementOfDebt" xlink:label="loc_SHPHCommonStockIssuedForSettlementOfDebt" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SHPHCommonStockIssuedForSettlementOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:label="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SHPHCommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockIssuedForDividendPayable" xlink:label="loc_SHPHCommonStockIssuedForDividendPayable" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SHPHCommonStockIssuedForDividendPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsIssuedForFinancingFees" xlink:label="loc_SHPHWarrantsIssuedForFinancingFees" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SHPHWarrantsIssuedForFinancingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InitialRecognitionOfRightOfUseAssetAndLiability" xlink:label="loc_SHPHInitialRecognitionOfRightOfUseAssetAndLiability" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_SHPHInitialRecognitionOfRightOfUseAssetAndLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsIssuanceFees" xlink:label="loc_SHPHWarrantsIssuanceFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_SHPHWarrantsIssuanceFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidity" xlink:title="00000009 - Disclosure - Organization and Liquidity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/Leases" xlink:title="00000011 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedParty" xlink:title="00000012 - Disclosure - Notes Payable-Related Party">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:label="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableRelatedPartyDisclosureTextBlock" xlink:label="loc_SHPHNotesPayableRelatedPartyDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" xlink:to="loc_SHPHNotesPayableRelatedPartyDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotes" xlink:title="00000013 - Disclosure - Convertible Notes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquity" xlink:title="00000014 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilities" xlink:title="00000015 - Disclosure - Derivative Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactions" xlink:title="00000016 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock" xlink:label="loc_SHPHCorrectionOfPriorPeriodErrorsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHCorrectionOfPriorPeriodErrorsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaapDerivativesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNotePolicyTextBlock" xlink:label="loc_SHPHConvertibleNotePolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHConvertibleNotePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WarrantsPolicyTextBlock" xlink:label="loc_SHPHWarrantsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:label="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SHPHScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesTables" xlink:title="00000021 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesTables" xlink:title="00000023 - Disclosure - Derivative Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesTables" xlink:title="00000024 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:label="loc_SHPHScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative" xlink:title="00000025 - Disclosure - Organization and Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InstitutionalInvestorMember" xlink:label="loc_SHPHInstitutionalInvestorMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHInstitutionalInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_WorkingCapital" xlink:label="loc_SHPHWorkingCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_SHPHWorkingCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaapPartnersCapital" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPartnersCapital" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails" xlink:title="00000026 - Disclosure - Schedule of the Error Correction (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails" xlink:title="00000027 - Disclosure - Schedule of Cash and Cash Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="00000028 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaapUSTreasurySecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapUSTreasurySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_SHPHAcceleratedFeatureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaapDerivativeAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaapLiabilitiesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails" xlink:title="00000029 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000030 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails" xlink:title="00000032 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaapSubleaseIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapSubleaseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_OtherInformationAbstract" xlink:label="loc_SHPHOtherInformationAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_SHPHOtherInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails" xlink:title="00000033 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/LeasesDetailsNarrative" xlink:title="00000034 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureLeasesAbstract" xlink:label="loc_SHPHDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaapLesseeLeaseDescriptionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeLeaseDescriptionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaapLesseeLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLesseeLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NewLeaseAgreementMember" xlink:label="loc_SHPHNewLeaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_SHPHNewLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RentVariableRate1" xlink:label="loc_SHPHRentVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHRentVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EstimatedMonthlyCommonAreaMaintenanceCost" xlink:label="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHEstimatedMonthlyCommonAreaMaintenanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonAreaMaintenanceCost" xlink:label="loc_SHPHCommonAreaMaintenanceCost" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeLeaseDescriptionLineItems" xlink:to="loc_SHPHCommonAreaMaintenanceCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative" xlink:title="00000035 - Disclosure - Notes Payable-Related Party (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DisclosureNotesPayablerelatedPartyAbstract" xlink:label="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SHPHDisclosureNotesPayablerelatedPartyAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_OfficersSpouseMember" xlink:label="loc_SHPHOfficersSpouseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHOfficersSpouseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_RelatedPartyOfficerMember" xlink:label="loc_SHPHRelatedPartyOfficerMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_SHPHRelatedPartyOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionRate" xlink:label="loc_us-gaapRelatedPartyTransactionRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative" xlink:title="00000036 - Disclosure - Convertible Notes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SecuritiesPurchaseAgreementMember" xlink:label="loc_SHPHSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_BousteadSecuritiesLLCMember" xlink:label="loc_SHPHBousteadSecuritiesLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadSecuritiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ConvertibleNoteMember" xlink:label="loc_SHPHConvertibleNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaapDebtInstrumentDescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PaymentForPlacementAgent" xlink:label="loc_SHPHPaymentForPlacementAgent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHPaymentForPlacementAgent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaapDebtInstrumentFeeAmount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InterestFeeAmount" xlink:label="loc_SHPHInterestFeeAmount" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_SHPHInterestFeeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000037 - Disclosure - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_BousteadMember" xlink:label="loc_SHPHBousteadMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHBousteadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AyrtonMember" xlink:label="loc_SHPHAyrtonMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHAyrtonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableMember" xlink:label="loc_SHPHNotesPayableMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_NotesPayableRelatedPartiesMember" xlink:label="loc_SHPHNotesPayableRelatedPartiesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHNotesPayableRelatedPartiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical" xlink:title="00000038 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails" xlink:title="00000039 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000040 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AltoConvertibleNoteMember" xlink:label="loc_SHPHAltoConvertibleNoteMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_SHPHAltoConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_TwoThousandEighteenEquityIncentivePlanMember" xlink:label="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SHPHTwoThousandEighteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DirectorsAndOfficersMember" xlink:label="loc_SHPHDirectorsAndOfficersMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_SHPHDirectorsAndOfficersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AccruedInterestValueToIssueShares" xlink:label="loc_SHPHAccruedInterestValueToIssueShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHAccruedInterestValueToIssueShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_LossOnSettlementOfConvertibleDebt" xlink:label="loc_SHPHLossOnSettlementOfConvertibleDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHLossOnSettlementOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesSettlementOfNotesPayable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesSettlementOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_CommonStockVestingOfRestrictedStockUnit" xlink:label="loc_SHPHCommonStockVestingOfRestrictedStockUnit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHCommonStockVestingOfRestrictedStockUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesExerciseOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodValueWarrantsNotesPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueWarrantsNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfPreferredShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodSharesConversionOfDividends" xlink:label="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodSharesConversionOfDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StockIssuedDuringPeriodValueDividendsPayable" xlink:label="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHStockIssuedDuringPeriodValueDividendsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:label="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SHPHShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails" xlink:title="00000041 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDefaultRateMember" xlink:label="loc_us-gaapMeasurementInputDefaultRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputDefaultRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputIlliquidityDiscountMember" xlink:label="loc_SHPHMeasurementInputIlliquidityDiscountMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputIlliquidityDiscountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails" xlink:title="00000042 - Disclosure - Schedule of Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_srtStatementScenarioAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AcceleratedFeatureMember" xlink:label="loc_SHPHAcceleratedFeatureMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_SHPHAcceleratedFeatureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DerivativeGainLossOnDerivativeWarrants" xlink:label="loc_SHPHDerivativeGainLossOnDerivativeWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHDerivativeGainLossOnDerivativeWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:label="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_SHPHAdditionOfNewDerivativesRecognizedAsDebtDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000043 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_MeasurementInputVolumeWeightedAveragePriceMember" xlink:label="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_SHPHMeasurementInputVolumeWeightedAveragePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:label="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DerivativeDiscountPercentage" xlink:label="loc_SHPHDerivativeDiscountPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_SHPHDerivativeDiscountPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000044 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_TCGGreenChemIncMember" xlink:label="loc_SHPHTCGGreenChemIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SHPHTCGGreenChemIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PaymentsToInvoicesInResearchAndDevelopment" xlink:label="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SHPHPaymentsToInvoicesInResearchAndDevelopment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails" xlink:title="00000045 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncomeTaxReconciliationProvisionAdjustments" xlink:label="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationProvisionAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:label="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHIncomeTaxReconciliationForeignIncomeTaxPermanentDifferences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_ShortfallOfStockCompensationExpense" xlink:label="loc_SHPHShortfallOfStockCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHShortfallOfStockCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails" xlink:title="00000046 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsbasedCompensation" xlink:label="loc_SHPHDeferredTaxAssetsbasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHDeferredTaxAssetsbasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_SHPHDeferredTaxAssetsLeaseLiabilities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHDeferredTaxAssetsLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxLiabilitiesFairMarketValue" xlink:label="loc_SHPHDeferredTaxLiabilitiesFairMarketValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHDeferredTaxLiabilitiesFairMarketValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxLiabilitiesFiniteLivedAssets" xlink:label="loc_SHPHDeferredTaxLiabilitiesFiniteLivedAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHDeferredTaxLiabilitiesFiniteLivedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:label="loc_SHPHDeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHDeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000047 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationChangeInTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferences" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:label="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SHPHEffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000048 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_FederalTaxableIncomeMember" xlink:label="loc_SHPHFederalTaxableIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHFederalTaxableIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_StateTaxableIncomeMember" xlink:label="loc_SHPHStateTaxableIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SHPHStateTaxableIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2016Member" xlink:label="loc_us-gaapTaxYear2016Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxYear2017Member" xlink:label="loc_us-gaapTaxYear2017Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_us-gaapTaxYear2017Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForward" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:label="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_SHPHDeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000049 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_PurchaseAgreementMember" xlink:label="loc_SHPHPurchaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SHPHPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_AdditionalEscrowDeposit" xlink:label="loc_SHPHAdditionalEscrowDeposit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHAdditionalEscrowDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="shph-20231231.xsd#SHPH_InitialPublicOfferingDescription" xlink:label="loc_SHPHInitialPublicOfferingDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_SHPHInitialPublicOfferingDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555854495296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Shuttle
Pharmaceuticals Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001757499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5089826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">401
Professional Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">403-4212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SHPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,712,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,794,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag', window );">Document Financial Statement Restatement Recovery Analysis [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">FORVIS, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta,
GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtRestatementRecoveryAnalysisFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555878934624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,576,416<span></span>
</td>
<td class="nump">$ 8,417,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">114,473<span></span>
</td>
<td class="nump">161,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest income</a></td>
<td class="nump">14,901<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,593,005<span></span>
</td>
<td class="nump">8,578,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $121,685 and $114,875 respectively</a></td>
<td class="nump">24,827<span></span>
</td>
<td class="nump">12,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">333,904<span></span>
</td>
<td class="nump">56,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">5,951,736<span></span>
</td>
<td class="nump">8,653,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ConvertibleNotePayableCurrent', window );">Convertible notes payable, net</a></td>
<td class="nump">595,999<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">52,479<span></span>
</td>
<td class="nump">62,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,042,237<span></span>
</td>
<td class="nump">975,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable non-current, net</a></td>
<td class="nump">135,089<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">414,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability non-current</a></td>
<td class="nump">304,127<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">1,895,965<span></span>
</td>
<td class="nump">975,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value; 100,000,000 shares authorized; 16,069,320 and 13,603,129 shares issued and outstanding, respectively</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">19,543,222<span></span>
</td>
<td class="nump">16,572,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(15,487,612)<span></span>
</td>
<td class="num">(8,894,889)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">4,055,771<span></span>
</td>
<td class="nump">7,677,869<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">5,951,736<span></span>
</td>
<td class="nump">8,653,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses related party</a></td>
<td class="nump">282,860<span></span>
</td>
<td class="nump">116,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable - related parties</a></td>
<td class="nump">110,453<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses related party</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable - related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 685,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ConvertibleNotePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible note payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ConvertibleNotePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555854594032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 121,685<span></span>
</td>
<td class="nump">$ 114,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,069,320<span></span>
</td>
<td class="nump">13,603,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,069,320<span></span>
</td>
<td class="nump">13,603,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555854514800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="nump">3,517,093<span></span>
</td>
<td class="nump">1,148,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,046,854<span></span>
</td>
<td class="nump">538,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal and professional</a></td>
<td class="nump">1,328,435<span></span>
</td>
<td class="nump">866,770<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,892,382<span></span>
</td>
<td class="nump">2,554,278<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,892,382)<span></span>
</td>
<td class="num">(2,554,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">79,117<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_FinanceFee', window );">Finance fee</a></td>
<td class="num">(104,245)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">2,216,488<span></span>
</td>
<td class="nump">94,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of marketable securities</a></td>
<td class="nump">4,970<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Change in fair value of marketable securities</a></td>
<td class="nump">71,568<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="num">(477,221)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">328,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnForgivenessOfNotePayable', window );">Gain on forgiveness of Paycheck Protection Program note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73,007<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(700,341)<span></span>
</td>
<td class="num">(474,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss</a></td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="num">(3,028,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend on Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(71,009)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (6,592,723)<span></span>
</td>
<td class="num">$ (3,099,457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding basic</a></td>
<td class="nump">14,919,484<span></span>
</td>
<td class="nump">10,351,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding diluted</a></td>
<td class="nump">14,919,484<span></span>
</td>
<td class="nump">10,351,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per shares - basic</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per shares - diluted</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">$ (6,825)<span></span>
</td>
<td class="num">$ (52,010)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">$ (2,484,193)<span></span>
</td>
<td class="num">$ (917,879)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_FinanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_FinanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnForgivenessOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnForgivenessOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773044544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Stock to be Issued [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 4,150,867<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="num">$ (5,795,432)<span></span>
</td>
<td class="num">$ (1,628,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="nump">9,312,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">10,008,081<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,008,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Warrants exercised for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">14,084<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs, net of issuance fees of $8,727</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">412,241<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 412,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">604,863<span></span>
</td>
<td class="num">(16,340)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 588,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt and accrued interest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">576,467<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 576,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for exercise of warrants with settlement of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">403,956<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">403,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(71,009)<span></span>
</td>
<td class="num">(71,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">402,063<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">402,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan', window );">Common shares issued for dividends on and conversion of Series A preferred stock, shares</a></td>
<td class="num">(1,213)<span></span>
</td>
<td class="nump">437,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,028,448)<span></span>
</td>
<td class="num">(3,028,448)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">16,572,622<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,894,889)<span></span>
</td>
<td class="nump">$ 7,677,869<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,603,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,380,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Warrants issued for financing costs, net of issuance fees of $8,727</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,816<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 90,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt and accrued interest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,380,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock issued for restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock issued for restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
<td class="num">(6,592,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">2,697,825<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,697,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal', window );">Common stock issued for conversion of accrued interest and principal, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,380,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 19,543,222<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (15,487,612)<span></span>
</td>
<td class="nump">$ 4,055,771<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,069,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Conversion Of Accrued Interest And Principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Conversion O fAccruedInterest And Principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480348/946-230-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772849760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuanceFees', window );">Warranst of issuance fees</a></td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773041872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,592,723)<span></span>
</td>
<td class="num">$ (3,028,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6,811<span></span>
</td>
<td class="nump">5,972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(2,216,488)<span></span>
</td>
<td class="num">(94,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount and finance fees</a></td>
<td class="nump">2,123,049<span></span>
</td>
<td class="nump">885,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on marketable securities</a></td>
<td class="num">(4,970)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Change in fair value of marketable securities</a></td>
<td class="num">(71,568)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInterestSettledWithCommonStock', window );">Accrued interest settled with common stock</a></td>
<td class="nump">294,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="nump">477,221<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(328,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_GainOnForgivenessOfNotePayable', window );">Gain on forgiveness of Paycheck Protection Program note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(73,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesGainLoss', window );">Gain on interest relief on conversion of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">12,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">403,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest income</a></td>
<td class="num">(14,901)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">46,675<span></span>
</td>
<td class="num">(156,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">166,115<span></span>
</td>
<td class="num">(382,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses - related parties</a></td>
<td class="num">(12,054)<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="nump">110,453<span></span>
</td>
<td class="num">(13,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties', window );">Accrued interest payable - related parties</a></td>
<td class="num">(98,135)<span></span>
</td>
<td class="nump">51,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">6,480<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in operating lease asset and liability</a></td>
<td class="nump">16,001<span></span>
</td>
<td class="num">(5,693)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,581,147)<span></span>
</td>
<td class="num">(2,710,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Investment in marketable securities</a></td>
<td class="num">(2,998,572)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from disposition of marketable securities</a></td>
<td class="nump">187,895<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(19,046)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,829,723)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants', window );">Proceeds from issuance of common shares and exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,022,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable-related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of note payable-related party</a></td>
<td class="num">(685,473)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes payable and warrants</a></td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">600,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment for finance costs related to convertible note payable</a></td>
<td class="num">(345,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment of convertible note payable</a></td>
<td class="num">(334,444)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,570,083<span></span>
</td>
<td class="nump">10,622,908<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(5,840,787)<span></span>
</td>
<td class="nump">7,912,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">8,417,203<span></span>
</td>
<td class="nump">504,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">2,576,416<span></span>
</td>
<td class="nump">8,417,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">164,807<span></span>
</td>
<td class="nump">39,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Supplemental non-cash financing activities:</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForConversionOfAccruedInterest', window );">Common stock issued for conversion of accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForSettlementOfDebt', window );">Common stock issued for settlement of debt</a></td>
<td class="nump">2,697,849<span></span>
</td>
<td class="nump">588,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable', window );">Common stock issued for exercise of warrants with settlement of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">576,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockIssuedForDividendPayable', window );">Common stock issued for dividend payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">402,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuedForFinancingFees', window );">Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively</a></td>
<td class="nump">90,816<span></span>
</td>
<td class="nump">412,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InitialRecognitionOfRightOfUseAssetAndLiability', window );">Initial recognition of right of use asset and liability</a></td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AccruedInterestSettledWithCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accruedi nterest settled with common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AccruedInterestSettledWithCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued For Conversion Of Accrued Interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForDividendPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for dividend payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForDividendPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for exercise of warrants with settlement of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockIssuedForSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockIssuedForSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_GainOnForgivenessOfNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on forgiveness of note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_GainOnForgivenessOfNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued interest payable - related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InitialRecognitionOfRightOfUseAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right of use asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InitialRecognitionOfRightOfUseAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuedForFinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued for financing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuedForFinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772912096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsIssuanceFees', window );">Warranst of issuance fees</a></td>
<td class="nump">$ 8,727<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsIssuanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issuance fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsIssuanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555771057840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Liquidity</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLSnJOFJjx87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82A_zNQTfjOQsJoh">Organization and Liquidity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Organization
and Line of Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221;). In connection with the conversion the Company issued <span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuWYMCwBa1l" title="Conversion of stock, shares issued">45,000,000</span> shares of common
stock in exchange for <span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrFlg9kE6KXj" title="Sale of stock membership percentage">100</span>% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#8220;Company&#8221;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#8217;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#8217;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#8220;SBIR&#8221;) contract provided
by the National Cancer Institute (&#8220;NCI&#8221;), a unit of the National Institutes of Health (&#8220;NIH&#8221;). Ropidoxuridine
has been further developed though the Company&#8217;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#8217;s initial public offering, the Company
has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
production and marketing of the Company&#8217;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#8220;FDA&#8221;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay
or suspend clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and has a net loss of
approximately $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zvDIDv0jCj34" title="Net income loss">6.6</span> million and no revenues for the year ended December 31, 2023 and working capital of approximately $<span id="xdx_90D_ecustom--WorkingCapital_iN_pn5n6_di_c20230101__20231231_zpMi8peYTBP7" title="Working capital">4.6</span> million as
of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and certain cash
payment requirements. These conditions, and the Company&#8217;s ability to comply with such conditions, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2022, the Company completed its initial public offering of common stock, generating net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220901__20220930_zR49qYY8Cmnl" title="Proceeds from issuance or sale of equity">10.0</span>
million. Additionally, in January 2023, the Company entered into a securities purchase agreement with an institutional investor
through which the Company sold a convertible note with a principal value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLz2DBKNXBw9" title="Debt instrument, face amount">4.3</span>
million, along with a four-year warrant to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zl355kJKiw01" title="Four year warrant to purchase">1,018,079</span>
shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUpMqMf0Hl09" title="Exercisable price per share">2.35</span>
per share, providing the Company with approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zObOWFtvk5K9" title="Net proceeds from warrants">3.6</span>
million in net proceeds. To date, the warrant has not yet been exercised. However, the Company&#8217;s existing cash resources,
marketable securities and the cash received from the equity offering and convertible note are not expected to provide sufficient
funds to carry out the Company&#8217;s operations and clinical trials through the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital raise has supported operations leading up to the manufacture of drug product and FDA approval of the IND for the Phase II clinical
trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the company agreed to an expansion of the clinical
trial, necessitating additional capital to complete the trial. Management intends to initiate a rights offering for $<span id="xdx_90C_eus-gaap--PartnersCapital_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVMpPjuScNs2" title="Initiated a capital offering">4.5</span> million and has submitted
SBIR applications for non-dilutive NIH funding for pre-clinical project. The ability of the Company to continue as a going concern is
dependent upon its ability to successfully conduct clinical trials, bring a drug candidate to commercialization to generate revenues,
and to raise additional equity or debt financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements do not include any adjustments to reflect the future effects on the recoverability and
classification of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772890320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_ztutohW0DxZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_82D_zF1DC2RbvP0b">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zN9JmHykJAle">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zXzky5zRn35g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_84C_ecustom--CorrectionOfPriorPeriodErrorsPolicyTextBlock_zUNM6DMxDWG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zmSLE9UXGTZ4">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expense in accordance with ASC 730. As a <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">result,
c</span>ertain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the
materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting
Bulletin No. 99, &#8220;Materiality,&#8221; (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the
Company concluded that these error corrections in its <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations</span> are not material to any previously presented financial statements based upon overall considerations
of both quantitative and qualitative factors. The corrections had no impact on the</span> Consolidated <span style="background-color: white">Balance
Sheet, </span> Consolidated Statements of Cash Flows, or Consolidated Statement of Changes in Stockholders&#8217; <span style="background-color: white">Equity,
to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per
share, or working capital. The quarterly
corrections for 2023 include $<span id="xdx_902_eus-gaap--PriorPeriodReclassificationAdjustment_c20230101__20230331_zFakzIKd6fI5" title="Quarterly reclassifications">89,007</span>
(March 31), $<span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230401__20230630_zjgd06Zv936i" title="Quarterly reclassifications">93,708</span>
(June 30), and $<span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230701__20230930_z6t87eTcNI8l" title="Quarterly reclassifications">95,129</span>
(September 30). Accordingly, the Company corrected the previously reported immaterial errors for the years ended December 31, 2023
and 2022 in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of corrections reflecting the prior period impact to the Company&#8217;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zAUbI2M0uK5l" style="display: none">Schedule of the Error Correction</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As Corrected <br/>
December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">General and administrative expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">198,978</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">339,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">538,796</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,488,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(339,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,148,712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,687,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,687,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zyP3t9CJDzV" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the
accompanying consolidated financial statements for the valuation of derivatives and initial measurement of equity-based
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zJkXkj4AZTy2">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,550,098</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,411,378</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,026,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,005,825</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,576,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,417,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount">250,000</span> per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount">1,849,000</span>. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zcIP2rrvmXK8">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance">2,887,215</span>. During the year ended December 31, 2023, the Company recognized interest income of $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income">52,855</span>,
realized gains of $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss">4,970</span>, and unrealized gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss">71,568</span>. The were <span id="xdx_90E_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zVNP7VA0iPmh" title="Marketable securities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0679">no</span></span> marketable securities during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqfmU6VxYX7j">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">December 31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUfQ5IhZAVZ7">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine if an arrangement is a lease at inception. <span style="background-color: white">Operating leases are included in operating
lease right-of-use asset (&#8220;ROU&#8221;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with a lease term of 12 months or less at inception are not recorded on our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">balance </span>sheets <span style="background-color: white">and are expensed on a straight-line
basis over the lease term in our statement of operations. </span>We have lease agreements with lease and non-lease components, which
are generally accounted for separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#8220;incremental borrowing rate&#8221; or &#8220;IBR&#8221;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zhMEboul1fnf">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Furniture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life">5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life">10</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYSObLAWFqrd">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For
our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception
and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded
as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated
balance sheet sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zIShPO1DVFMg">Convertible
Note</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments
if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_860_zbFQsfTI6WN7">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;)
and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether
the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMKVdyEG0BI7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z4CSzyso8ih9">Stock-Based Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost for stock awards, which include restricted stock units (&#8220;RSUs&#8221;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z01OOEEOeht9">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#8217; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$<span id="xdx_901_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE8MCOpDGG97" title="Share based compensation">0.8</span> million and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyagly3uGnx8" title="Share based compensation">0.6</span> million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $<span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20231231_zQBcV79W2Tl3" title="Research and development, net of contract expense reimbursements">0</span> and $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20220101__20221231_z6jSzaNLWoj" title="Research and development, net of contract expense reimbursements">211,455</span> in Research and development, net of contract expense reimbursements, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zjUxdX9ZNGFl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwbvAlIY1l46">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all
entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share
computation. In the accompanying consolidated financial statements, basic loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by
the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to
reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and
warrants unless the result would be antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#8220;treasury
stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#8220;if-converted
method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)">959,513</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants">1,446,155</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants">356,810</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units">197,855</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities">2,603,523</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities">356,810</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zSWNCgOEheR1">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not expect the adoption of this standard to
have any material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.</p>

<p id="xdx_85E_zQNfopfWoCN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775896816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z08OzEyKAwJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_82E_zYhGzQEhHDX1">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had two lease agreements during the year which allowed for the use of laboratory facilities. <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zEya2wAH9aKc" title="Lessee, operating lease, description">The first was for a monthly payment
of $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20231231_z4j16dhXCej9" title="Payments for rent">6,480</span>, with a security deposit of $<span id="xdx_90A_eus-gaap--Deposits_iI_c20231231_zO8e4gkFsUJk" title="Deposits">6,480</span> held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019</span> and ended on <span id="xdx_90D_eus-gaap--LeaseExpirationDate1_c20230101__20231231_zI0l5Mds2Am4" title="Lease expiration date">October 31, 2023</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 16, 2023, the Company entered into a new lease agreement for new office and laboratory space, with base rent of $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zzwRNVzOdczf" title="Payments for rent">7,206</span> per month
for a period of 64 months, which increases at the rate of <span id="xdx_903_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIt1JZKcThLk" title="Rent variable rate">3</span>% per year, that <span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zj1i3ww8Qve3">commenced June 1, 2023</span>. The new lease included a six-month
50% rent abatement upon commencement. Additional common area maintenance (&#8220;CAM&#8221;) fees are charged monthly and revised annually.
The estimated monthly CAM fees are $<span id="xdx_908_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230215__20230216_zd0rmLCuEgvl" title="Estimated monthly common area maintenance cost">3,300</span> per month for the first year of the lease, which are being expensed as incurred. An irrevocable
letter of credit (&#8220;LOC&#8221;) for the security deposit of $<span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20230216_zE3n7U3fwQok" title="Security deposit">43,234</span> and base rent of $<span id="xdx_904_eus-gaap--PaymentsForRent_c20230215__20230216_zETIouZ8QDv6" title="Payments for rent">3,891</span>, including 50% abatement, and $<span id="xdx_909_ecustom--CommonAreaMaintenanceCost_c20230215__20230216_zRiqEIIYf8j8" title="Common area maintenance cost">3,315</span>
of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC,
and the expiry date of the LOC is February 15, 2024. Subsequent to December 31, 2023, the LOC was renewed with an updated expiry date
of March 1, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the right-of use asset and lease information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z3chxPAugTvb" style="display: none">Schedule of Right-of Use Asset and Lease Information About Operating Lease</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">112,022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">70,175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sublease income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,070</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,425</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,105</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">95,641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76,248</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">365,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term &#8212; operating leases (year)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_ziMEmd9Mt5Sc" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)">4.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)">0.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate &#8212; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zQzuTkcat7T6" style="text-align: right" title="Weighted-average discount rate - operating leases">10.48</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zFmXEc2OJ102" style="text-align: right" title="Weighted-average discount rate - operating leases">10</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A8_zAskMv6Jd9Ib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFdDGFDXJUZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zww5HoyzAXBk" style="display: none">Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Years ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzDPt_zsoBHIDG7oh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">91,502</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzDPt_z7eQTs5MmjR1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,247</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzDPt_zKCgLvy8lLQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,074</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzDPt_zDNVsoZEHARd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,986</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzDPt_zKj9Z36cUNyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzDPt_zB0xrbyBjUZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,044</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94,438</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,606</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zGZjjGq7mVc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772969776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable-Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureNotesPayablerelatedPartyAbstract', window );"><strong>Notes Payable-related Party</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_NotesPayableRelatedPartyDisclosureTextBlock', window );">Notes Payable-Related Party</a></td>
<td class="text"><p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zd061yowJNd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_825_zH1XaP0tjrW5">Notes Payable-Related Party</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z3NgxGTYg4V9">426,243</span>, bearing interest at the rate of <span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWqcEUtfPTu6">7.5</span>% per annum, with a maturity date of <span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zfFRy9Sub3Hc">December 31, 2021</span>; and (ii) a single loan
owed to an officer of the Company in the principal amount of $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z9TMMPLJqMKk">139,229</span>, bearing interest at the rate of <span id="xdx_90A_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zerWcgbpUGVj">7.5</span>% per annum, with a maturity
date of December 31, 2021. <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211231_zfxw96gGmmth">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zTHYCCtmQ77h">120,000</span> (principal) with
an interest rate of <span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z7JDA19McyJa">7.5</span>% per annum due June 21, 2022. In July of 2022, the loan was extended to June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023 principal payments of $<span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zSYaCBxemUD8">685,473</span> and interest of $<span id="xdx_902_eus-gaap--InterestPaidNet_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zffNQmXite2e">104,968</span> were paid. As of December 31, 2023, there were <span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_do_c20230101__20231231_z5bCjpTtB4u2" title="Increase accrued interest">no</span> outstanding
principal or interest balances for these related party notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureNotesPayablerelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureNotesPayablerelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_NotesPayableRelatedPartyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable Related Party [Disclosure Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_NotesPayableRelatedPartyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772410240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_z2GEya6C7Gm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5&#8211; <span><span id="xdx_821_z4YyPFusOaGd">Convertible Notes</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alto
Opportunity Master Fund, SPC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 11, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Alto Opportunity Master Fund,
SPC &#8211; Segregated Master Portfolio B, a Cayman entity (the &#8220;Investor&#8221;), pursuant to which the Company sold to the Investor
a $<span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1qYaf3PFxbb" title="Convertible debt">4,300,000</span> convertible note (the &#8220;Alto Convertible Note&#8221;) and warrant (the &#8220;Warrant&#8221;) to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSUnRPFxSwvf" title="Warrants to purchase common stock">1,018,079</span>
shares of common stock, exercisable at $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z64P6QuvGP1l" title="Warrants exerciable shares">2.35</span> per share, in exchange for gross proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230109__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXyVfotWMQH3" title="Proceeds from convertible note payable">3,935,000</span> million (the &#8220;Investment Amount&#8221;)
(See Note 7). The Company determined that the Warrant contains a net cash settlement feature at inception and categorized the Warrant
as a liability in the accompanying consolidated financial statements. The Alto Convertible Note matures on March 11, 2025, but may be
extended at the option of the noteholder. The Alto Convertible Note amortizes on a monthly basis and the Company can make such monthly
amortization payments in cash or, subject to certain equity conditions, in registered shares of common stock or a combination thereof.
Installments may be deferred by the noteholder, resulting in a variable interest rate. However, the effective interest rate is approximately
<span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYihioEmX1N1" title="Effective interest rate">346</span>% based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment,
<span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20230109__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zaxJ1y0qhQBi" title="Debt description">the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment
date. The noteholder may convert at any time at a fixed price of $2.35 per share.</span> The noteholder has an acceleration of installment amount
conversion option (the &#8220;Acceleration Option&#8221;), whereby the noteholder, with certain share percentage limitations, can convert
to common stock any outstanding installment amount at an amount equal to the installment amount plus five times (5x) the installment
amount at any time. The Company has determined the Acceleration Option is an embedded derivative within the host instrument and has bifurcated
it from the host instrument and recorded it as a derivative liability valued at $<span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zw9FmdP2k1rj" title="Derivative liability">1,442,000</span>, using a Monte Carlo simulation model (Note
7). The Convertible Note is repayable over 26 months and bears interest at the rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIDfdUAlNQL7" title="Debt interest rate">5</span>% per annum. Additionally, the note contains
certain redemption options and &#8220;Make Whole&#8221; provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the &#8220;Security
Agreement&#8221;), an intellectual property security agreement (the &#8220;IP Security Agreement&#8221;) and a subsidiary guaranty (the
&#8220;Subsidiary Guaranty&#8221;). The security agreements and guaranty allow, among other things, for the Investor to have a security
interest in and place a lien on all of the Company&#8217;s assets and intellectual property until such time as the Alto Convertible Note
is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the &#8220;Springing
DACA&#8221;), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume
control of the Company&#8217;s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such,
in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and
pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing
DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller
banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing
DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor
agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing
DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $<span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20231231_zhjUClDQimI" title="Convertible notes payable">10</span>
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Warrant, excluding the Springing
DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an opportunity to participate
in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company expects that such subsequent convertible notes and warrants would be issued on substantially similar
terms as the January 11, 2023 initial agreement, as amended, thus providing the Company the opportunity to negotiate certain aspects of
the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boustead
Securities, LLC (&#8220;Boustead&#8221;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_ziS9eEQtuv1f" title="Payment for placement agent">345,000</span> cash compensation and a warrant to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zAqlkvNNaDpd" title="Warrants to purchase common stock">71,266</span> shares of common stock, exercisable at $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zojy77XppzIe" title="Warrants exerciable shares">2.35</span> per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPC674AVJKXc" title="Expected years">five years</span>, volatility of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znMOWfqPGjYf" title="Warrants and rights outstanding measurement input">110</span>%, a risk-free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zILXwC7DhWBl">3.53</span>% for a value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zEonjOrQ2ZU" title="Fair value of warrants">99,543</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated the finance costs related to the Boustead placement agent fee of $<span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z1qEjzidygn" title="Payment for placement agent">345,000</span>, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $<span id="xdx_902_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGBEljeJa0Nb" title="Allocation of financing costs">232,027</span> to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $<span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmNk8FczQ6Wh" title="Warrant derivative liability">104,245</span> to the warrant derivative liability component,
expensed as a finance fee, and $<span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zSUixncCkJS1" title="Equity warrant as reduction in additional paid in capital">8,727</span> to the equity warrant as a reduction in additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company allocated to the debt component of the note an original discount of $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMx5hPAesnIi" title="Debt discount">300,000</span>, legal fees of $<span id="xdx_90D_eus-gaap--LegalFees_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zLBOZ1MJKbi8" title="Legal fees">65,000</span>, $<span id="xdx_900_ecustom--InterestFeeAmount_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zqJJyHoHEi83" title="Interest fee">215,000</span> for additional
interest fees on day one added to note principal, $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zayR1vJlE2s9" title="Debt principal amount">1,442,000</span> for the accelerated conversion feature, and $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxa2TC77bmFd" title="Fair value of warrants">1,288,543</span> for the fair value
of warrants, resulting in an additional $<span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_znnI28Rtm2fb" title="Interest expense debt">3,310,543</span> debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company recorded interest expense of $<span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_znhWETUYiYQb">2,484,193</span>, which included amortization of debt discount as
interest expense of $<span id="xdx_900_eus-gaap--InterestExpenseDebt_c20230101__20231231_zpTyEbkt4Xac">2,123,049</span>. During the year ended December 31, 2023, the Company settled $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJLs4MfXiOZ5" title="Debt, principal">1,925,700</span> of principal and settled $<span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIH04jwIMOkl" title="Accrued interest">294,927</span>
of accrued interest, which settlements were made in the form of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z61rjBMkQSyb">2,380,996</span> shares of common stock during the year ended December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the outstanding principal for the convertible note was $<span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20231231_zSRsEaMmQVQd">2,254,856</span> and the debt discount remaining was $<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20231231_zLkKrYZw6Y46">1,523,768</span>,
with a net convertible note carrying value of $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20231231_z90vWvRx7oy1" title="Convertible note payable">731,088</span>, which represents the current and non-current portions of the convertible note
as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773695744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRCb1RVFvgkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_825_zr458jZvyJC5">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231_zZds9nkiSPPl" title="Common stock issued for conversion of convertible debt, shares">2,380,996</span>
    shares of common stock to settle $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRAn1fkxWHy9" title="Debt, principal">1,925,700</span> of principal and $<span id="xdx_90B_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jBXJnIxDLa" title="Accrued interest settled with common stock">294,927</span> of interest on a Convertible Note and incurred $<span id="xdx_908_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMO1eJwiZXi" title="Loss on settlement of convertible debt">477,221</span> of
    loss on settlement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z96iryR5Kbn2" title="Common stock issued for conversion of convertible debt, shares">85,195</span>
    shares of common stock issued for vesting of restricted stock units.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20220101__20221231_zEEdlwiuK3mi" title="Common stock issued for conversion of convertible debt, shares">839</span>
    shares of common stock for conversion of $<span id="xdx_90F_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20220101__20221231_zCR0LvynQrpk" title="Accrued interest settled with common stock">16,340</span>
    of accrued interest and <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesSettlementOfNotesPayable_c20220101__20221231_zi3imVIifs4j">147,500</span> shares of common stock upon settlement of notes payable for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20221231_z32bqH7a2h3f" title="Number of shares of common stock upon settlement of notes payable">588,524</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_ecustom--CommonStockVestingOfRestrictedStockUnit_c20220101__20221231_zTGhXRDb9rbf" title="Common stock vesting of restricted stock unit">27,989</span>
    shares of common stock upon vesting of restricted stock units.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjeceiAKMQN6" title="Common stock issued for cash, shares">1,409,771</span>
    shares of common stock upon completion of the Company&#8217;s initial public offering for $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231_zReQhA0jXBO1" title="Common stock issued for cash">10,008,095</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_znddZycuNdzi" title="Number of shares of common stock issued for exercise of warrants">1,409,771</span> shares of common stock upon completion of the Company&#8217;s initial public offering for exercise of warrants
$<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20220101__20221231_zxa59QQ9BSid" title="Exercise of warrants, value">14,098</span>.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20220101__20221231_zaISTewlGzo4" title="Common stock issued for exercise of warrants, shares">857,780</span>
    shares of common stock upon exercise of warrants to settle notes payable for $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueWarrantsNotesPayable_c20220101__20221231_zPRvRgJIApw3" title="Common stock issued for exercise of warrants notes payable, value">576,476</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredShares_pp0p0_c20220101__20221231_zMXs1V3yATd" title="Number shares issued for conversion of note, shares">336,810</span>
    shares of common stock upon conversion of preferred shares and <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesConversionOfDividends_pp0p0_c20220101__20221231_zeGN8oiBf77k" title="Number shares issued for conversion dividends payable, shares">100,517</span> to settle dividends payable for $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueDividendsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxo9SNpEoe9d" title="Common stock issued for dividends payable">402,068</span>.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zam6FgbDoIvd" title="Number of warrants to purchase">71,266</span> shares of common stock, at an
exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_ziFSekf5Pqm7" title="Exercisable price per share">2.35</span> per share (Note 5). In addition, Alto was granted warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zxfR1IUHlnT6" title="Number of warrants to purchase">1,018,079</span> shares of common stock, at an
exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zCr58QMvgMwh" title="Exercise price per share">2.35</span> per share (Note 5, 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zQPSvyFjdRPc" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (years)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="width: 16%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">2,641,354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted Average Life (Years), Granted">4.75</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_z96MJfoqmzQl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">(2,284,544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_zAb8nlxLZFrd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">356,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">3.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted Average Life (Years), Outstanding Beginning">2.79</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted - Boustead</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">71,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">2.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted Average Life (Years), Granted">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Granted - Ayrton</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">1,018,079</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">2.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted Average Life (Years), Granted">4.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">1,446,155</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">2.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted Average Life (Years), Outstanding Ending">2.77</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
    warrants include those granted on conversion of Notes Payable - <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe" title="Number of shares warrant to purchase">677,500</span>, Notes Payable &#8211; Related Parties &#8211; <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk" title="Number of shares warrant to purchase">20,000</span>, Series
    A Preferred Shares - <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g" title="Converted shares issued">336,810</span> and issued during the IPO - <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k" title="Number of shares issued">1,607,044</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zV5jmENmows3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6" title="Warrants exercised">197,273</span> warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj" title="Number of shares issued">180,280</span> shares of common stock.</span></td></tr>
  </table>
<p id="xdx_8A4_z33AkX1pnRpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
intrinsic value of the warrants as of December 31, 2023 is $<span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20231231_zC4txtN2nCP9" title="Aggregate intrinsic value of warrants">0</span>. All of the outstanding warrants are exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equity
Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#8217;s
compensation committee. We have reserved <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zVWYrlzZ5Oq9" title="Common stock reserved for future issuance">3,000,000</span> shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
December 31, 2023, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zZqAzrExO8Pf" title="Share granted under equity incentive plan">678,180</span> shares have been granted under the 2018 Equity Incentive Plan, of which <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231_zdTmHNQqbfgf" title="Number of shares vested under plan">480,325</span> shares have vested.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Units</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may grant restricted stock units (&#8220;RSU&#8221;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2023 and 2022, pursuant to agreements with directors, officers and consultants, <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zFnLLrAAZDzd" title="Restricted stock award granted shares">259,326</span> and <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zYkx69bvfJxg" title="Restricted stock award granted shares">35,587</span> RSUs
with a value of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zce9Kpju1tFj" title="Restricted stock award granted value">352,400</span> and $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zxRxNN5a4Rs8" title="Restricted stock award granted value">100,000</span> were granted, respectively. Compensation expense for the vesting RSUs were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center">Year ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td>&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Recognized in general and administrative expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">115,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170,663</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recognized in research and development expense</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">233,293</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">181,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">403,956</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023 and 2022, there was $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEzBhMNnlrN8" title="Unrecognized compensation cost">231,550</span> and $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5mtOdUbbZX" title="Unrecognized compensation cost">61,111</span>, respectively, of unrecognized stock-based compensation expense
related to unvested RSUs, which is expected to be recognized over a weighted-average period of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuwnfeYO91d" title="Weighted Average Life (Years), Outstanding Ending">1.06</span> years
and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSrNXYP6sZG7" title="Weighted Average Life (Years), Outstanding Ending">1.83</span> years, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zXV9pKVawChd" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding, December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">63,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">23.87</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Granted">35,587</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">2.81</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">99,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">15.06</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="text-align: right" title="Number of Stock Option Outstanding, Granted">259,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.36</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Vested">(160,744</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">1.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Outstanding, Ending Balance">197,855</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance">1.47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A5_zV6HtUCMIcil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773487984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zM0LnaDFnXNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_82A_z4aTbusRJlK5">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Assumptions Used in Accounting for Derivative Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_z11cwYracUa3" title="Number of shares warrant to purchase">1,018,079</span>
shares of common stock, with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zIh20NrCUX41" title="Exercise price per share">2.35</span>
per share, valued at inception at $<span id="xdx_90C_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20230131_zRPJuOGDR5kl" title="Warrants price">1,189,000</span>
and as of December 31, 2023, at $<span id="xdx_90F_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20231231_zGXfDYMNMqJ7" title="Warrants price">410,660</span>. The Company determined our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy
the classification as equity instruments due to the existence of a certain net cash settlement provision that is not within the sole
control of the Company. In addition, there are certain down round provisions that could reduce the exercise price if the Company
issues securities at lower prices in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined our derivative liability from the noteholder&#8217;s Acceleration Option for the Alto Convertible Note is not clearly
and closely related to the host and should be thus accounted for as a bifurcated derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023, and for each reporting period. Key inputs for the simulation are summarized below. The Monte Carlo simulation
uses an implied VWAP for each valuation date. The implied VWAP was backsolved by setting the summation of the parts (e.g., derivatives
and debt without derivatives) equal to the cash proceeds. The simulation was then iterated and manipulated to solve for the implied share
price, which was approximately $<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TLyu8dorpa" title="Share price">1.58
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (or an approximate <span id="xdx_902_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjE6Jw38fbK2" title="Derivative discount percentage">14</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%
discount to the quoted market VWAP on January 11, 2023). Additionally, the Company estimates probability for various specific scenarios
impacting the warrant valuation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 80%">Annualized volatility</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zozFDVZAFK4e">77.51</span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0Ggii4jslye">92.33</span>%</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zoMIQofY4K5a">4.01</span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zwCcxH7FeOC5">5.23</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Quoted VWAP*</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_fKg_____zo7lD17gzxV2">0.59</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z4L0sAqFUTj8">2.35</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zrouVaColRqk">5</span>% - <span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zfcKKc9EOvb2">25</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmkmMVae8hSk">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9SRrpNLzopk" title="Time period (years)">0.53</span> - <span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zhXNFkwkLBCb" title="Time period (years)">3.03</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0F_z2LWif3ShStb">*</i></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F14_zMHZ22vWVnw6">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p style="margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Annualized volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____ze5I3bDWN1aj">34.23</span>% - <span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLIohlVjEEf3">59.15</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zCGZKKlOO9g1">4.68</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsa6ppLFMsB4">5.60</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Quoted VWAP*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">$<span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zYkXA6Tza4Ek">0.59</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zQDqXgqjbjIj">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zSr9igPhn80d" title="Time period (years)">0</span> - <span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLp7YOcr570g" title="Time period (years)">1.2</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F09_zHTgwsedsgfj">*</i></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F18_zw6xhmmh8TEf">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p id="xdx_8A5_z9FqO83Hz1gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zHuN5mIWCcld" style="display: none">Schedule of Derivative Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accelerated Feature</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance - December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdBqZ4p6AuHc" style="width: 14%; text-align: right" title="Beginning balance">94,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zyX1n8IWdRLe" style="width: 14%; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvHA7ssNPFdl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative">(94,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zJnad48mTEA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zipNXTFL6L3k" style="text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfiv9Plk69a" style="text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Addition of new derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoUz8eWIMtrb" style="text-align: right" title="Addition of new derivatives recognized as debt discounts">1,189,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_za5rszMeX5Sj" style="text-align: right" title="Addition of new derivatives recognized as debt discounts">1,442,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjV2cxH2Bmf9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative">(778,340</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zD45NbyyDdH3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative">(1,438,148</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3L6mkfzMUpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">410,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_znqHQDi2fG6g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">3,852</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AA_zjykzB9b6bda" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773485216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zysAiD3uWv96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_821_zqKZNps5qm1a">Related Party Transactions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#8220;TCG GreenChem&#8221;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. The Company paid TCG GreenChem $<span id="xdx_909_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20221231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zs0HwiZEVXj3" title="Payments to invoices in research and development">450,000</span> during the year ended December
31, 2022 and a total of $<span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20230101__20231231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zEZHhc9Bky7j" title="Payments to invoices in research and development">1,096,370</span> during the year ended December 31, 2023, completing the contract.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555771126160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zIzNnGyFJnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_82A_zYL3mUjUjp33">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no income tax expense or benefit for the years ended December 31, 2023 and 2022, since the Company has a full valuation allowance
for the net operating loss carryforwards in these periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination
by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated
based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain
tax positions to be reported for the tax years 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) amended IRC Section 174 to require capitalization of all research and development
(&#8220;R&amp;D&#8221;) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over
five years if the R&amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. For
tax reporting purposes, the Company capitalized $<span id="xdx_90F_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20231231_zXvHn7wdQpqg" title="Research and development expenses">3,517,485</span> and $<span id="xdx_904_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20221231_zCI5g925C8v7" title="Research and development expenses">1,488,530</span> of R&amp;D expenses incurred as of December 31, 2023 and
2022, respectively.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate">21</span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z2tRzaeOyVg3" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zjwy0KWXJK1e" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zSaqbByehmf1" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,384,472</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(635,974</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(452,682</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(249,847</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,710</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msITEBzspy_zIbOgxRjiMF1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">R &amp; D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(240,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(83,975</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_maITEBzspy_zKjunr4YTXDa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,355</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,535,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">924,937</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shortfall of stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zdVsqCFpXlch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zPU61r3hFOe7" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,727,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,173,451</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">7,801</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangibles (includes Section 174 capitalization)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,197,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,644</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">423,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,229</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest &amp; other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,574</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease asset/(liability)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,429,136</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,841,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Deferred tax Liabilities:</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Change in fair market value of securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(19,943</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,746</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,233</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,375,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,841,698</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,375,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,841,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zrwMVAPp8x91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zI3yIfzm5n7c" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zfaXBlkgHcyk" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_z5Nl7grKpMZf" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">R&amp;D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.3</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.2</td><td style="text-align: left">%)</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maDEF_zt6yAr9oJKm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.1</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23.2</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30.5</td><td style="text-align: left">%)</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shortfall of stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.4</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_ziTYp8KTsYlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalTaxableIncomeMember_zrG81Ug3Peyl" title="Net operatiing loss">6.4</span>
million and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateTaxableIncomeMember_zXVNaHVK7E06" title="Net operatiing loss">5.9</span> million of net operating losses (&#8220;NOL&#8221;) carried forward to offset federal and state taxable income, if
any, in the future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making
this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax
asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be
realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">NOLs created prior to 2018 could
be carried back two years and carried forward <span id="xdx_90E_ecustom--DeferredTaxAssetsOperatingLossCarriedForward_dtY_c20230101__20231231_ztKkx6mJrK2h" title="Carried forward">20</span> years. As amended by the Tax Cuts and Jobs Act of 2017 (TCJA), NOLs created after 2017
can no longer be carried back and are instead carried forward indefinitely. The Company has $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2016Member_zzagpmkbLOni" title="Operating loss carryforwards">139,813</span> and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2017Member_zflhOv8qsPn8" title="Operating loss carryforwards">238,380</span> of federal NOL carryforwards
from 2016 and 2017, respectively, which begin to expire in 2036. The Company has an additional $<span id="xdx_90B_eus-gaap--CurrentFederalTaxExpenseBenefit_c20230101__20231231_zxleUUsZJnK3" title="Federal income tax">6,036,599</span> and $<span id="xdx_907_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20230101__20231231_z3VTmnAMCrMh" title="state income tax">5,933,889</span> of federal and
state NOLs created after 2017, respectively, which can be carried forward indefinitely. The NOLs can be used to offset future income limited
to the lesser of the NOL or <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_pid_dp_uPure_c20230101__20231231_zA745rNSZcVk" title="Future taxable income">80</span>% of the year&#8217;s taxable income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of December 31, 2023, the Company has $<span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_zyM9U2Dualt9" title="Federal Research and Development">360,715</span>
of federal Research and Development (R&amp;D) tax credits. These can be carried forward <span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_dtY_c20230101__20231231_zE0Rx6zu1dBh" title="Carried forward">20</span> years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $<span id="xdx_900_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zgHvq6C4B1f" title="R&amp;D tax credits">80,000</span> of state R&amp;D tax credits which can be carried forward seven years.
These begin to expire in 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773480624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zvLsbfAmqZ93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_824_zs2tFHK7qGtg">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued
and determined that the following items are required to be disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Bid Price Requirement Extension Granted until August 26, 2024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 7.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2023, after the Company&#8217;s common stock had traded below $<span id="xdx_906_eus-gaap--SharePrice_iI_c20230831_zMaOM7ZhXbF7" title="Common stock trading price per share">1.00</span> per share for <span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uTradingDays_c20230831__20230831_zm1qjoOyB6m9">30</span> consecutive trading
days, the Company received notice from the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that it was not in compliance with Nasdaq Listing
Rule 5550(a)(2) (the &#8220;Bid Price Requirement&#8221;). In
accordance with Nasdaq Rules, the Company was provided with an initial period of 180 calendar days, or until February 27, 2024, to regain
compliance with the Bid Price Requirement. On February 19, 2024, the Company submitted a plan of compliance to Nasdaq seeking an additional
180-day grace period to regain compliance with the Bid Price Requirement. On February 29, 2024, the Company received formal approval
from Nasdaq granting it an additional 180 days, or until August 26, 2024, to regain compliance &#8211; whether organically through market forces or by effectuating a reverse stock split,
should such action be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FDA
Approval to Proceed with Phase II study of Ropidoxuridine (IPdR)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 8, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release announcing
that the Company had received the &#8220;Safe to Proceed&#8221; letter from the U.S. Food and Drug Administration for the Company&#8217;s
investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence
the Phase II study and, as a result, the Company is currently finalizing site enrollment with &#8220;first patient, first dose&#8221;
expected in the coming months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rights
Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase
agreement (the &#8220;Purchase Agreement&#8221;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed
to commit to purchasing from the Company $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJDnbJVClHRk" title="Sale of stock consideration received per transaction">2,250,000</span>
of units from the Company, with each Unit consisting of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp4MPskJvYJi" title="Share based compensation arrangement by share based payment award description">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $2.35
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.</span> Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90% of the VWAP of SHPH common
stock for the five trading days immediately preceding closing. The parties entered into the Purchase Agreement in anticipation of
the Company commencing a rights offering (the &#8220;Rights Offering&#8221;) pursuant to which the Company intends to offer a total
of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHARLaNGNfl" title="Proceeds from issuance of common stock">4,500,000</span>
Units to existing stockholders, which includes the $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEVUQW1Y2LFg" title="Sale of stock consideration received per transaction">2,250,000</span>
Units being sold to SRO LLC, an entity which is owned by Keith Moore, CEO of Boustead Securities, LLC
(&#8220;BSL&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Purchase Agreement allows SRO LLC up to 60 days to raise the initial $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeJXcEGJ6F95" title="Escrow deposit">2,250,000</span>, which funds will be placed in escrow with Sutter Securities,
Inc. (&#8220;SSI&#8221;), an affiliate of BSL, pursuant to the terms of an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI
on February 7, 2024 (the &#8220;Escrow Agreement&#8221;). The funds will remain in escrow up until closing on the Rights Offering. In
addition, in the event the Company fails to raise a full $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zAbw8U4vQqh" title="Right offering">4,500,000</span> in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant
to which it would have the right to purchase any remaining Units not purchased by existing SHPH stockholders in the Rights Offering,
up to an additional $<span id="xdx_905_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLidexbeXPOd" title="Escrow deposit">2,250,000</span> (the &#8220;Back-up Contingency&#8221;). <span id="xdx_902_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKBB7lm2dIQ" title="Initial public offering description">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#8217;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Stock Awarded to Chief Financial Officer</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 8, 2024, the CFO was awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zrFoglyhoPx1" title="Restricted stock units">100,000</span>
restricted stock units (&#8220;RSUs&#8221;), with a value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zz0X64iPXAvj" title="Restricted stock value">41,840</span>, with such RSUs vesting in full as of the date of issuance.
Each RSU represents the right to receive one share of SHPH common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775660176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_zN9JmHykJAle">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zXzky5zRn35g">Basis
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#8217;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_864_z51lIHBaxIod">Reclassifications</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock', window );">Correction of an Immaterial Error in the Prior Period Financial Statements</a></td>
<td class="text"><p id="xdx_84C_ecustom--CorrectionOfPriorPeriodErrorsPolicyTextBlock_zUNM6DMxDWG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zmSLE9UXGTZ4">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expense in accordance with ASC 730. As a <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">result,
c</span>ertain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the
materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting
Bulletin No. 99, &#8220;Materiality,&#8221; (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the
Company concluded that these error corrections in its <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations</span> are not material to any previously presented financial statements based upon overall considerations
of both quantitative and qualitative factors. The corrections had no impact on the</span> Consolidated <span style="background-color: white">Balance
Sheet, </span> Consolidated Statements of Cash Flows, or Consolidated Statement of Changes in Stockholders&#8217; <span style="background-color: white">Equity,
to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per
share, or working capital. The quarterly
corrections for 2023 include $<span id="xdx_902_eus-gaap--PriorPeriodReclassificationAdjustment_c20230101__20230331_zFakzIKd6fI5" title="Quarterly reclassifications">89,007</span>
(March 31), $<span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230401__20230630_zjgd06Zv936i" title="Quarterly reclassifications">93,708</span>
(June 30), and $<span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230701__20230930_z6t87eTcNI8l" title="Quarterly reclassifications">95,129</span>
(September 30). Accordingly, the Company corrected the previously reported immaterial errors for the years ended December 31, 2023
and 2022 in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of corrections reflecting the prior period impact to the Company&#8217;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zAUbI2M0uK5l" style="display: none">Schedule of the Error Correction</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As Corrected <br/>
December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">General and administrative expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">198,978</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">339,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">538,796</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,488,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(339,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,148,712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,687,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,687,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zyP3t9CJDzV" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_znBsmi9qpX7i">Use
of Estimates</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the
accompanying consolidated financial statements for the valuation of derivatives and initial measurement of equity-based
warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zJkXkj4AZTy2">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,550,098</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,411,378</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,026,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,005,825</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,576,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,417,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $<span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount">250,000</span> per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount">1,849,000</span>. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zcIP2rrvmXK8">Marketable
Securities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance">2,887,215</span>. During the year ended December 31, 2023, the Company recognized interest income of $<span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income">52,855</span>,
realized gains of $<span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss">4,970</span>, and unrealized gains of $<span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss">71,568</span>. The were <span id="xdx_90E_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zVNP7VA0iPmh" title="Marketable securities::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0679">no</span></span> marketable securities during the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqfmU6VxYX7j">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts of the Company&#8217;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">December 31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zUfQ5IhZAVZ7">Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
determine if an arrangement is a lease at inception. <span style="background-color: white">Operating leases are included in operating
lease right-of-use asset (&#8220;ROU&#8221;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Leases
with a lease term of 12 months or less at inception are not recorded on our </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">balance </span>sheets <span style="background-color: white">and are expensed on a straight-line
basis over the lease term in our statement of operations. </span>We have lease agreements with lease and non-lease components, which
are generally accounted for separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#8220;incremental borrowing rate&#8221; or &#8220;IBR&#8221;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zhMEboul1fnf">Property
and Equipment</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:</span></p>

<p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Furniture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life">5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life">10</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zYSObLAWFqrd">Derivative
Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For
our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception
and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded
as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated
balance sheet sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ConvertibleNotePolicyTextBlock', window );">Convertible Note</a></td>
<td class="text"><p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_868_zIShPO1DVFMg">Convertible
Note</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments
if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i><span id="xdx_860_zbFQsfTI6WN7">Warrants</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s
specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;)
and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares and whether
the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidated
<span style="background-color: white">statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zMKVdyEG0BI7">Impairment
of Long-Lived Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_z4CSzyso8ih9">Stock-Based Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
cost for stock awards, which include restricted stock units (&#8220;RSUs&#8221;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_z01OOEEOeht9">Research
and Development Expenses</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#8217; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$<span id="xdx_901_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE8MCOpDGG97" title="Share based compensation">0.8</span> million and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyagly3uGnx8" title="Share based compensation">0.6</span> million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, <i>Government Assistance</i>, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#8211; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $<span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20231231_zQBcV79W2Tl3" title="Research and development, net of contract expense reimbursements">0</span> and $<span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20220101__20221231_z6jSzaNLWoj" title="Research and development, net of contract expense reimbursements">211,455</span> in Research and development, net of contract expense reimbursements, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zjUxdX9ZNGFl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes in accordance with ASC Topic 740, <i>Income Taxes</i>. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#8220;more likely than not&#8221; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Stock</a></td>
<td class="text"><p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zwbvAlIY1l46">Net
Loss Per Common Stock</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all
entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share
computation. In the accompanying consolidated financial statements, basic loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by
the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to
reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and
warrants unless the result would be antidilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#8220;treasury
stock method,&#8221; which assumes that the &#8220;proceeds&#8221; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#8220;if-converted
method.&#8221; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)">959,513</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants">1,446,155</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants">356,810</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units">197,855</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities">2,603,523</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities">356,810</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zSWNCgOEheR1">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#8217;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not expect the adoption of this standard to
have any material impact on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ConvertibleNotePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Note [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ConvertibleNotePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Correction of prior period errors policytextblock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773145840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of the Error Correction</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of corrections reflecting the prior period impact to the Company&#8217;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BE_zAUbI2M0uK5l" style="display: none">Schedule of the Error Correction</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Correction</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As Corrected <br/>
December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">General and administrative expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">198,978</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">339,818</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">538,796</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,488,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(339,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,148,712</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,687,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,687,508</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_zAIRmxIIPtT9" style="display: none">Schedule of Cash and Cash Equivalents</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 64%">Cash</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,550,098</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,411,378</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Money market funds</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,026,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,005,825</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total cash
and cash equivalents</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,576,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,417,203</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below are the Company&#8217;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BA_zMDw775NrT6i" style="display: none">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">December 31, 2023</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Carrying Value</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable Securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-bottom: 1.5pt">United States Treasury Bonds</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0691">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">2,887,215</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0697">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,887,215</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Derivative Liability - Warrants</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">410,660</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative Liability - Accelerated feature</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">414,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock', window );">Schedule of Useful Lives for Property Plant Equipment</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zLo9hjhMywRk" style="display: none">Schedule of Useful Lives for Property Plant Equipment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Furniture</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life">5</span> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Computers and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life">10</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zz6N2TjW0PMb" style="display: none">Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible notes (Note 5)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)">959,513</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrant (Note 6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants">1,446,155</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants">356,810</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units (Note 6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units">197,855</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities">2,603,523</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities">356,810</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Useful Lives for Property Plant Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775846544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Right-of Use Asset and Lease Information About Operating Lease</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summarizes the right-of use asset and lease information for the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BD_z3chxPAugTvb" style="display: none">Schedule of Right-of Use Asset and Lease Information About Operating Lease</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Years Ended</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">112,022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">70,175</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,222</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sublease income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,819</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,070</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease cost</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,425</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,105</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other information</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">95,641</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">76,248</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">365,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term &#8212; operating leases (year)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_ziMEmd9Mt5Sc" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)">4.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)">0.80</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate &#8212; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zQzuTkcat7T6" style="text-align: right" title="Weighted-average discount rate - operating leases">10.48</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zFmXEc2OJ102" style="text-align: right" title="Weighted-average discount rate - operating leases">10</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability</a></td>
<td class="text"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFdDGFDXJUZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zww5HoyzAXBk" style="display: none">Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Years ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzDPt_zsoBHIDG7oh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">91,502</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzDPt_z7eQTs5MmjR1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,247</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzDPt_zKCgLvy8lLQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,074</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzDPt_zDNVsoZEHARd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,986</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzDPt_zKj9Z36cUNyd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2028</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68,235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzDPt_zB0xrbyBjUZi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">451,044</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94,438</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of payments</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">356,606</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773698032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Activity</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BF_zQPSvyFjdRPc" style="display: none">Schedule of Warrants Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Life (years)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted<sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="width: 16%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">2,641,354</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted Average Life (Years), Granted">4.75</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_z96MJfoqmzQl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">(2,284,544</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_zAb8nlxLZFrd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">0.26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">356,810</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">3.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted Average Life (Years), Outstanding Beginning">2.79</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Granted - Boustead</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance">71,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">2.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted Average Life (Years), Granted">5.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Granted - Ayrton</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">1,018,079</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">2.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted Average Life (Years), Granted">4.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Beginning Balance">1,446,155</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">2.74</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted Average Life (Years), Outstanding Ending">2.77</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
    warrants include those granted on conversion of Notes Payable - <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe" title="Number of shares warrant to purchase">677,500</span>, Notes Payable &#8211; Related Parties &#8211; <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk" title="Number of shares warrant to purchase">20,000</span>, Series
    A Preferred Shares - <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g" title="Converted shares issued">336,810</span> and issued during the IPO - <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k" title="Number of shares issued">1,607,044</span>.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zV5jmENmows3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6" title="Warrants exercised">197,273</span> warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj" title="Number of shares issued">180,280</span> shares of common stock.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units (RSUs)</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of activity regarding the Restricted Stock Units issued follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B2_zXV9pKVawChd" style="display: none">Schedule of Restricted Stock Units (RSUs)</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Outstanding, December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">63,686</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">23.87</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Granted">35,587</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">2.81</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="text-align: right" title="Number of RSUs, Outstanding, Beginning Balance">99,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance">15.06</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="text-align: right" title="Number of Stock Option Outstanding, Granted">259,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.36</td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Vested">(160,744</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested">1.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding, December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Outstanding, Ending Balance">197,855</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance">1.47</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555925507376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Monte Carlo Simulation Assumption</a></td>
<td class="text"><p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_znb7Uj9EztTl" style="display: none">Schedule of Monte Carlo Simulation Assumption</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Net cash settlement and down round key valuation inputs &#8211; warrants*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 80%">Annualized volatility</td><td style="width: 2%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 16%"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zozFDVZAFK4e">77.51</span>% - <span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0Ggii4jslye">92.33</span>%</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zoMIQofY4K5a">4.01</span>% - <span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zwCcxH7FeOC5">5.23</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Quoted VWAP*</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_fKg_____zo7lD17gzxV2">0.59</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z4L0sAqFUTj8">2.35</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Probability assessment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zrouVaColRqk">5</span>% - <span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zfcKKc9EOvb2">25</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmkmMVae8hSk">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9SRrpNLzopk" title="Time period (years)">0.53</span> - <span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zhXNFkwkLBCb" title="Time period (years)">3.03</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F0F_z2LWif3ShStb">*</i></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F14_zMHZ22vWVnw6">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<p style="margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Acceleration option key valuation inputs*</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Annualized volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____ze5I3bDWN1aj">34.23</span>% - <span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLIohlVjEEf3">59.15</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zCGZKKlOO9g1">4.68</span>% - <span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsa6ppLFMsB4">5.60</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Quoted VWAP*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">$<span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zYkXA6Tza4Ek">0.59</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Illiquidity discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-<span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zQDqXgqjbjIj">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Time period (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zSr9igPhn80d" title="Time period (years)">0</span> - <span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLp7YOcr570g" title="Time period (years)">1.2</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
  <td style="text-align: justify; width: 0.15in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F09_zHTgwsedsgfj">*</i></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F18_zw6xhmmh8TEf">Based on a Monte Carlo simulation analysis of 50,000 iterations</i></span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Derivative Liabilities</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the changes in the derivative liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B4_zHuN5mIWCcld" style="display: none">Schedule of Derivative Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Accelerated Feature</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Balance - December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdBqZ4p6AuHc" style="width: 14%; text-align: right" title="Beginning balance">94,025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zyX1n8IWdRLe" style="width: 14%; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvHA7ssNPFdl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative">(94,025</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zJnad48mTEA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"><span style="-sec-ix-hidden: xdx2ixbrl1126">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance - December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zipNXTFL6L3k" style="text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1128">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfiv9Plk69a" style="text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1130">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Addition of new derivatives</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoUz8eWIMtrb" style="text-align: right" title="Addition of new derivatives recognized as debt discounts">1,189,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_za5rszMeX5Sj" style="text-align: right" title="Addition of new derivatives recognized as debt discounts">1,442,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Gain on change in fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjV2cxH2Bmf9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative">(778,340</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zD45NbyyDdH3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative">(1,438,148</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance - December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3L6mkfzMUpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">410,660</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_znqHQDi2fG6g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">3,852</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555861322624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock', window );">Schedule of Reconciliation of Income Tax Benefit</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reconciliation of income tax benefit at the U.S. statutory rate of <span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate">21</span>% to the Company&#8217;s tax expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z2tRzaeOyVg3" style="display: none">Schedule
of Reconciliation of Income Tax Benefit</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20231231_zjwy0KWXJK1e" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_zSaqbByehmf1" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,384,472</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(635,974</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(452,682</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(249,847</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rate change</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,710</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msITEBzspy_zIbOgxRjiMF1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">R &amp; D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(240,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(83,975</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,015</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,214</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_maITEBzspy_zKjunr4YTXDa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">203,909</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,355</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,535,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">924,937</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shortfall of stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1185">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1188">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal components of deferred tax assets consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zPU61r3hFOe7" style="display: none">Schedule
of Components of Deferred Tax Assets</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,727,566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,173,451</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">7,801</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangibles (includes Section 174 capitalization)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,197,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">399,644</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">423,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,229</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,251</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest &amp; other accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,140</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,574</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Lease asset/(liability)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,326</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,429,136</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,841,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Deferred tax Liabilities:</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Change in fair market value of securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(19,943</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,544</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,746</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1223">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(53,233</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total deferred tax asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,375,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,841,698</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,375,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,841,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1235">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal income tax rate to the Company&#8217;s effective tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zI3yIfzm5n7c" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zfaXBlkgHcyk" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20220101__20221231_z5Nl7grKpMZf" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal income tax benefit at statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income tax benefit, net of federal tax effect</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">R&amp;D tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Return to provision adjustments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4.3</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.2</td><td style="text-align: left">%)</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maDEF_zt6yAr9oJKm2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3.1</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.7</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23.2</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30.5</td><td style="text-align: left">%)</td></tr>
  <tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shortfall of stock compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.4</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.1</td><td style="padding-bottom: 1.5pt; text-align: left">%)</td></tr>
  <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Pretax Income From Continuing Operations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772391680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 12, 2016</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592,723<span></span>
</td>
<td class="nump">$ 3,028,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=SHPH_InstitutionalInvestorMember', window );">Institutional Investor [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Initiated a capital offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock membership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Institutional Investor [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Four year warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of ownership interest of different classes of partners in limited partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_InstitutionalInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_InstitutionalInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555861261440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of the Error Correction (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">$ 1,046,854<span></span>
</td>
<td class="nump">$ 538,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 3,517,093<span></span>
</td>
<td class="nump">1,148,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,488,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Revision of Prior Period, Error Correction, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775782448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,550,098<span></span>
</td>
<td class="nump">$ 5,411,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">1,026,318<span></span>
</td>
<td class="nump">3,005,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 2,576,416<span></span>
</td>
<td class="nump">$ 8,417,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773241632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 2,887,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">414,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="nump">410,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=SHPH_AcceleratedFeatureMember', window );">Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="nump">3,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="nump">2,887,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">2,887,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="nump">2,887,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">414,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="nump">410,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability - Accelerated feature</a></td>
<td class="nump">3,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">United States Treasury Bonds</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=SHPH_AcceleratedFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=SHPH_AcceleratedFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775905104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Useful Lives for Property Plant Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775680144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">2,603,523<span></span>
</td>
<td class="nump">356,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">959,513<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,446,155<span></span>
</td>
<td class="nump">356,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">197,855<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555930352464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Quarterly reclassifications</a></td>
<td class="nump">$ 95,129<span></span>
</td>
<td class="nump">$ 93,708<span></span>
</td>
<td class="nump">$ 89,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securitie outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,887,215<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Marketable securities realized gain loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Marketable securities unrealized gain loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,568<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,960<span></span>
</td>
<td class="nump">403,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development, net of contract expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">211,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555854498992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 112,022<span></span>
</td>
<td class="nump">$ 70,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">24,222<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(7,819)<span></span>
</td>
<td class="num">(7,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">128,425<span></span>
</td>
<td class="nump">63,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_OtherInformationAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">95,641<span></span>
</td>
<td class="nump">76,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 365,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases (year)</a></td>
<td class="text">4 years 8 months 1 day<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">10.48%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773859072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 91,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">94,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">97,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">99,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">68,235<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">451,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(94,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of payments</a></td>
<td class="nump">$ 356,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555865816576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee, operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The first was for a monthly payment
of $6,480, with a security deposit of $6,480 held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 3,891<span></span>
</td>
<td class="nump">$ 6,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EstimatedMonthlyCommonAreaMaintenanceCost', window );">Estimated monthly common area maintenance cost</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">43,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonAreaMaintenanceCost', window );">Common area maintenance cost</a></td>
<td class="nump">$ 3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=SHPH_NewLeaseAgreementMember', window );">New Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lessee, operating lease, description</a></td>
<td class="text">commenced June 1, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="nump">$ 7,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_RentVariableRate1', window );">Rent variable rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonAreaMaintenanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common area maintenance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonAreaMaintenanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EstimatedMonthlyCommonAreaMaintenanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated monthly common area maintenance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EstimatedMonthlyCommonAreaMaintenanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_RentVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent Variable Rate1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_RentVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=SHPH_NewLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=SHPH_NewLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555861112048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable-Related Party (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2021</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt Instrument, Maturity Date, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,807<span></span>
</td>
<td class="nump">$ 39,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Increase accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember', window );">Officers Spouse [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 426,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related Party Transaction, Rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Related Party Transaction, Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from (Repayments of) Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 685,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Excluding Capitalized Interest, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember', window );">Related Party Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionRate', window );">Related Party Transaction, Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_OfficersSpouseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SHPH_RelatedPartyOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555765137968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,254,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exerciable shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,935,000<span></span>
</td>
<td class="nump">$ 600,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,512<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Allocation of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,435<span></span>
</td>
<td class="nump">$ 866,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,123,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,523,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">731,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,380,996<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember', window );">Boustead Securities LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exerciable shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentForPlacementAgent', window );">Payment for placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Allocation of financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Equity warrant as reduction in additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,484,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember', window );">Boustead Securities LLC [Member] | Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,288,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InterestFeeAmount', window );">Interest fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,310,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock | shares</a></td>
<td class="nump">1,018,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exerciable shares | $ / shares</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible note payable</a></td>
<td class="nump">$ 3,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">346.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt description</a></td>
<td class="text">the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment
date. The noteholder may convert at any time at a fixed price of $2.35 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Warrant derivative liability</a></td>
<td class="nump">$ 1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InterestFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InterestFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PaymentForPlacementAgent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for placement agent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PaymentForPlacementAgent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_BousteadSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555765112336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares warrant to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,018,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,607,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_NotesPayableMember', window );">Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares warrant to purchase</a></td>
<td class="nump">677,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_NotesPayableRelatedPartiesMember', window );">Notes Payable Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares warrant to purchase</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">356,810<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted Average Life (Years), Outstanding Ending</a></td>
<td class="text">2 years 9 months 7 days<span></span>
</td>
<td class="text">2 years 9 months 14 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">1,446,155<span></span>
</td>
<td class="nump">356,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Boustead [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">71,266<span></span>
</td>
<td class="nump">2,641,354<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Life (Years), Granted</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Ayrton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants Outstanding, Beginning Balance</a></td>
<td class="nump">1,018,079<span></span>
</td>
<td class="num">(2,284,544)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Life (Years), Granted</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">2,380,996<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares issued</a></td>
<td class="nump">336,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Granted
    warrants include those granted on conversion of Notes Payable - <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe" title="Number of shares warrant to purchase">677,500</span>, Notes Payable &#8211; Related Parties &#8211; <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk" title="Number of shares warrant to purchase">20,000</span>, Series
    A Preferred Shares - <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g" title="Converted shares issued">336,810</span> and issued during the IPO - <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k" title="Number of shares issued">1,607,044</span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes
    <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6" title="Warrants exercised">197,273</span> warrants exercised on a cashless basis for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj" title="Number of shares issued">180,280</span> shares of common stock.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life in Years Outstanding, Granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life in Years Outstanding,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_NotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_NotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_NotesPayableRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_NotesPayableRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_BousteadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_BousteadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_AyrtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_AyrtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555861125600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants Activity (Details) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,607,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">2,380,996<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="nump">197,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">180,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775728832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restricted Stock Units (RSUs) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Outstanding, Beginning Balance</a></td>
<td class="nump">99,273<span></span>
</td>
<td class="nump">63,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per RSU, Beginning Balance</a></td>
<td class="nump">$ 15.06<span></span>
</td>
<td class="nump">$ 23.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Option Outstanding, Granted</a></td>
<td class="nump">259,326<span></span>
</td>
<td class="nump">35,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="num">(160,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per RSU, Vested</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Outstanding, Ending Balance</a></td>
<td class="nump">197,855<span></span>
</td>
<td class="nump">99,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per RSU, Ending Balance</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 15.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555769508272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt, shares</a></td>
<td class="nump">2,380,996<span></span>
</td>
<td class="nump">839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInterestValueToIssueShares', window );">Accrued interest settled with common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="nump">$ 477,221<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable', window );">[custom:StockIssuedDuringPeriodSharesSettlementOfNotesPayable]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Number of shares of common stock upon settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 588,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_CommonStockVestingOfRestrictedStockUnit', window );">Common stock vesting of restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash, shares</a></td>
<td class="nump">1,607,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,008,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued for exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of warrants, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Common stock issued for exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable', window );">Common stock issued for exercise of warrants notes payable, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares', window );">Number shares issued for conversion of note, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodSharesConversionOfDividends', window );">Number shares issued for conversion dividends payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested under plan</a></td>
<td class="nump">480,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share granted under equity incentive plan</a></td>
<td class="nump">678,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember', window );">Alto Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt, shares</a></td>
<td class="nump">85,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 231,550<span></span>
</td>
<td class="nump">$ 61,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Life (Years), Outstanding Ending</a></td>
<td class="text">1 year 21 days<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Directors and Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock award granted shares</a></td>
<td class="nump">259,326<span></span>
</td>
<td class="nump">35,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="nump">$ 352,400<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued for conversion of convertible debt, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt, principal</a></td>
<td class="nump">1,925,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AccruedInterestValueToIssueShares', window );">Accrued interest settled with common stock</a></td>
<td class="nump">294,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_LossOnSettlementOfConvertibleDebt', window );">Loss on settlement of convertible debt</a></td>
<td class="nump">$ 477,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Number of shares of common stock upon settlement of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash, shares</a></td>
<td class="nump">2,380,996<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares of common stock issued for exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,409,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of warrants, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_StockIssuedDuringPeriodValueDividendsPayable', window );">Common stock issued for dividends payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock award granted shares</a></td>
<td class="nump">85,195<span></span>
</td>
<td class="nump">27,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock award granted value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AccruedInterestValueToIssueShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest value to issue shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AccruedInterestValueToIssueShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_CommonStockVestingOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock vesting of restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_CommonStockVestingOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_LossOnSettlementOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss on settlement of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_LossOnSettlementOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award non-options outstanding intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesConversionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesConversionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares settlement of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodValueDividendsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value dividends payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodValueDividendsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SHPH_TwoThousandEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=SHPH_AltoConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=SHPH_DirectorsAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555775224736">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Monte Carlo Simulation Assumption (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">77.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">59.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">92.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">5.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember', window );">Measurement Input, Default Rate [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember', window );">Illiquidity Discount [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember', window );">Illiquidity Discount [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member] | Equity Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Time period (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">3 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Based on a Monte Carlo simulation analysis of 50,000 iterations</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Based on a Monte Carlo simulation analysis of 50,000 iterations</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDefaultRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputIlliquidityDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555854586176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Derivative Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=SHPH_AcceleratedFeatureMember', window );">Accelerated Feature [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="num">$ (1,438,148)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives recognized as debt discounts</a></td>
<td class="nump">1,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">94,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeGainLossOnDerivativeWarrants', window );">Gain on change in fair value of the derivative</a></td>
<td class="num">(778,340)<span></span>
</td>
<td class="num">(94,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts', window );">Addition of new derivatives recognized as debt discounts</a></td>
<td class="nump">1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition of new derivatives recognized as debt discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeGainLossOnDerivativeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative gain loss on derivative warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeGainLossOnDerivativeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=SHPH_AcceleratedFeatureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=SHPH_AcceleratedFeatureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773646848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liabilities (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 11, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares warrant to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,018,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue', window );">Warrants price | $</a></td>
<td class="nump">$ 410,660<span></span>
</td>
<td class="nump">$ 1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember', window );">Measurement Input Volume Weighted Average Price [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DerivativeDiscountPercentage', window );">Derivative discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class pf warrant or right number of securities called by warrants or rights value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DerivativeDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DerivativeDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=SHPH_MeasurementInputVolumeWeightedAveragePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555878880944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember', window );">TCG Green Chem Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment', window );">Payments to invoices in research and development</a></td>
<td class="nump">$ 1,096,370<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_PaymentsToInvoicesInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to invoices in research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_PaymentsToInvoicesInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SHPH_TCGGreenChemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555772914448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Income Tax Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">$ (1,384,472)<span></span>
</td>
<td class="num">$ (635,974)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect</a></td>
<td class="num">(452,682)<span></span>
</td>
<td class="num">(249,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Rate change</a></td>
<td class="num">(5,710)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R &amp; D tax credits</a></td>
<td class="num">(240,000)<span></span>
</td>
<td class="num">(83,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationProvisionAdjustments', window );">Return to provision adjustments</a></td>
<td class="nump">286,015<span></span>
</td>
<td class="nump">66,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">203,909<span></span>
</td>
<td class="num">(21,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,535,466<span></span>
</td>
<td class="nump">924,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_ShortfallOfStockCompensationExpense', window );">Shortfall of stock compensation expense</a></td>
<td class="nump">40,674<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="nump">16,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation foreignIncome tax permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_IncomeTaxReconciliationProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_IncomeTaxReconciliationProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_ShortfallOfStockCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shortfall of stock compensation expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_ShortfallOfStockCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555861219744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Components of Deferred Tax Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,727,566<span></span>
</td>
<td class="nump">$ 1,173,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles (includes Section 174 capitalization)</a></td>
<td class="nump">1,197,938<span></span>
</td>
<td class="nump">399,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D tax credits</a></td>
<td class="nump">423,915<span></span>
</td>
<td class="nump">215,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsbasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">1,251<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Interest &amp; other accrued expenses</a></td>
<td class="nump">72,140<span></span>
</td>
<td class="nump">45,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsLeaseLiabilities', window );">Lease asset/(liability)</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">3,429,136<span></span>
</td>
<td class="nump">1,841,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxLiabilitiesFairMarketValue', window );">Change in fair market value of securities</a></td>
<td class="num">(19,943)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(30,544)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxLiabilitiesFiniteLivedAssets', window );">Fixed assets</a></td>
<td class="num">(2,746)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total</a></td>
<td class="num">(53,233)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Total deferred tax asset</a></td>
<td class="nump">3,375,903<span></span>
</td>
<td class="nump">1,841,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(3,375,903)<span></span>
</td>
<td class="num">(1,841,698)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities net before valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assetsbased compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxLiabilitiesFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fair market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxLiabilitiesFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxLiabilitiesFiniteLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities finite lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxLiabilitiesFiniteLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555880143824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal tax effect</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments', window );">Return to provision adjustments</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.20%)<span></span>
</td>
<td class="num">(30.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense', window );">Shortfall of stock compensation expense</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change in tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return to provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation short fall of stock compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555773327536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Research and development expenses</a></td>
<td class="nump">$ 3,517,485<span></span>
</td>
<td class="nump">$ 1,488,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForward', window );">Carried forward</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 1,727,566<span></span>
</td>
<td class="nump">$ 1,173,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal income tax</a></td>
<td class="nump">6,036,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">state income tax</a></td>
<td class="nump">$ 5,933,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases', window );">Future taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Federal Research and Development</a></td>
<td class="nump">$ 360,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome', window );">Carried forward</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member', window );">Tax Year 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">139,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member', window );">Tax Year 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">238,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_FederalTaxableIncomeMember', window );">Federal Taxable Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operatiing loss</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_StateTaxableIncomeMember', window );">State Taxable Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operatiing loss</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carried forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsOperatingLossCarriedForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carried forward future federal income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_FederalTaxableIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=SHPH_FederalTaxableIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=SHPH_StateTaxableIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=SHPH_StateTaxableIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140555880360656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 08, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>d </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock trading price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt Instrument, Convertible, Threshold Consecutive Trading Days | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock consideration received per transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation arrangement by share based payment award description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $2.35
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock units | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock value</a></td>
<td class="nump">$ 41,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Right offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_AdditionalEscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SHPH_InitialPublicOfferingDescription', window );">Initial public offering description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#8217;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_AdditionalEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional escrow deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_AdditionalEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SHPH_InitialPublicOfferingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial public offering description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SHPH_InitialPublicOfferingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SHPH_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SHPH_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MUWHV(SK4=ZVH(6Y1<Y6FF2X7F".:M7I6HH0O,I@SK(F:@@;'S*>$].=RFV7
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M;#1C0]N@%79F%W8S6ML8!T_#:S0;Q-MJ-;-K]2UDU9GH#9?ZD7SY"/D,I/$
MS^[HN378L;P=TFYEG$5'*CW9"]390OM(W@Z/<%LE=^U*WI2>%AFO71P&XI!U
M*S>3F<\<.J#A;JOA[G<T7!3RR8O2[NO9Q\K_Q\& VR8'+CO2HG1?D Y8:!_)
MVR'MO8L%>^;PI$5IT'R&,D1[)ZLFRX@&8= -E>.]VZ0<Y**Z9%.D*E*VMS3-
MU^8B[TUU?=7Y?DG/KK;7<:V;[>W@1XY%0J%(!G-TZ9P&B$IN+]RV+UJLJCNK
MF=!:Y-7C$CBF2*4!_CX76#O4+V4'S;7G]#]02P,$%     @ D8MU6(J@Z")A
M"   6$$  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R]7-]SHS@2_E=4
MWJV[W:KQ&(G?<TFJ9FQ@YV&O4I/;VX>M>R!&B:G!X 4EF?GO5\+$&$G(@>K;
ME]B8[J];ZE8C?1*Y>JGJK\V.4H:^[8NRN5[L&#M\6*V:[8[NT^9]=: EO_-0
MU?N4\<OZ<=4<:IIFK=*^6!'+\E;[-"\7-U?M;[?US57UQ(J\I+<U:I[V^[3^
M_HD6U<OU B]>?_B2/^Z8^&%U<W5('^D=9;\=;FM^M3JA9/F>EDU>E:BF#]>+
MC_A#8A.AT$K\-Z<OS=EW))IR7U5?Q<7G['IA"8]H0;=,0*3\XYFN:5$().['
MGQWHXF13*)Y_?T6/V\;SQMRG#5U7Q>]YQG;7BV"!,OJ0/A7L2_7R"^T:Y J\
M;54T[5_TTLE:"[1]:EBU[Y2Y!_N\/'ZFW[J..%-PPQ$%TBD028&0$06[4[ E
M!=L;47 Z!4=6<$<4W$[!E5WR1Q2\3L&3%+ ]HN!W"GX;K&/OMJ'9I"R]N:JK
M%U0+:8XFOK3Q;;5Y1/)2I.(=J_G=G.NQFW55-E619RFC&;IC_(/G&6M0]8#6
MN[1\I W*2WZCVG[=545&Z^:?*/KS*6??T1+]=K=!/_WX\]6*<4\$WFK;6?UT
MM$I&K-[R?*-UW9KDR.B/7^G^GM;_0W>TSKG)CVA,0F-K;;:UKO;[JKP,LS'#
M?,RR7 R>M$"W:9XM>:^LTT/.^+4!-)K@&ZO0/46?F^:)M]J &9LQOU#&*Q"'
MB-*ZS,O'QH25F+'^4_'V#=56/,%.649.649:'&<$YQ-]S$OA#"\;15INZ3OT
MG!9/%*4,;>CV/;+Q.T0L@G6I9(06I?I#<TBW]'K!:W%#ZV>ZN$&Z-#GBN"V.
MJ-#/-Z%]M7H^3P%5Q,&N%7C^4"Y2Y;!G.]90*E:EEJX?NHY-AH*)1A![),!G
M@H-NMT_=;D_M]F:7\EYZ4[\?L;WS1A(L]=A:%0IM+N9*3=P8'=4'\1\_8,_Z
MEVY008+%D& )$-@@VLXIVHXQVETQ:=IBDA_+")^KH&W:['3Q-:)-&%>..A@<
M*?J.FDJ69056@*6!!>13#(23C#D>NOJ1Z9YBY<Z.U>L@U<7,B#HQ6=>NVCC'
M"GU?"LH&TF@$"19#@B5 8(-\\$[YX!GSX?>TKE,Q[Z+?:+W-FPM#UP@V8>AZ
MEX>NITN20)**@!R*@7 27<.L,- /6O\4)']ND$QCU@@Z=<SZ;QRSD$8C2+ 8
M$BRYW!V#2 >G2 =OB_19:7[(2SZ%$I.I;=6PYATJ*1/+)"$BYE;H@=)VW?1C
M\,XGOBX3C$8G#%L@G$V@])Z#"7'DAS*0N1@()PDTL_2!VX.8AZ>8A_,>R57Y
MS)>]@C?AP3U>L?R^H"BC]PRE98;2[;86XGG)*'>=Z6)O-#XA]J%:V:2A'RI1
M]2PG\*29>Z2*+76+&""_$]5O-PA<XNB#AJV>O[#^KK"9BKC9BZE5O$,;UJW
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MZ/;$'C8S>Z]E_;@Y=E;7L_.PBS7C<%DY*1%F$%_Z1/#5V;1<YU5>S+&(I7
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MC-9"@-]_J"KV>B%>3#_],X6;OP!02P,$%     @ D8MU6-0@<W5K @  T@4
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M,CJ[H'Q,.R+:@]6-[[*%MM2S?EO15 7C'.B^U-IN#RY /Z>SWU!+ P04
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M<3;CMHLK8 T>K94#,(^DG=-A5P&3*1) =2=>'E YXPJ"MG&<'>16U$Y"/@[
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M8@Z$!M,"O%];"&[^0@<,O]Q>_1=02P,$%     @ D8MU6.834N\Z'   YE$
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M@_,$>A'>)5D.&?RU-U< /AJ3FPVZ,(![P2RD'@^]:!_]M8QF$EO+;F=48O
M, ],"L036][36CV"2?G'#VDYZ6/GF$$DB335I@W.#MA-KXKDU;;:?1GV[3F,
M,K%/'EZ)?_UT=7YQ]5I^1J+$Y)7\8V<:UZ+:.%A"%7^UY$7^;BW^0T?D. =
MH13SBP40!+6BK%.ZX/%@P>DK^=^]N7"D@^T!Y.X);I2UPF!$QY&VJ;I/*=F)
M9=B4*M?#54]?]4#3/MYUQL*U&Q]4@$$!N<&D&:Q=V2 =M'>4)\9SGL[]^O=
M^3P/E6D[7;*'LYK(![)&%A0=5!+C)Q1][9WA F0))*]9V<*6=DDF*N%9H_-5
M9?YN=4^;>S0@BQGC4*#E"8CX+C$J,6!4,@4H(0S =;UZ4_XM6C2QU^0,?$W?
M#O.AH;T H:EUP]%3$;)UL&E82;+J )%T2LQL,!\I<3Y/@2N)'=/8T]"(ZM%:
M.!> *X[N)F3CKKP):%DL:>UNG5T3C-NAN,]O1D1.IL@DQ-Y)6(4.&/U-D<1W
M;J-S)"8L&8U;M&2\+6\)0MS1].),F/G$UJ([KKX,$4JB5*SJ(I@N87K B%]3
MY@^D%3#7D!M=).(S +K(6&?)5X@ GX/'R(@$A"]S38J=<W;&GTAJ_U,>PHPK
M6P*[HE5.92\G3^'QB$_:^6B;E1<B1<[B'7,"/P2S";C?%P?N5VZ.4SAG=P")
M9YSW-UW FW61S$9M"312,(I!LAX$T)M-;1^)JRFGBU8'T7 KL%0C5.A!Z,.Y
MT]00RSO8/0;QE&LC=7S^3J.5\W)=Q)S# 6W?!S="_ N*FKS9^45U(.!Y44$H
M059L)_WWLA_.$,@@P)4!BHP8YG/"T]\20/0ETL<UGMVER7W(B?]WZO\]A7#)
MRPTM)G@MT<4!2<GLE?@&&A"2I0#X:J)@*]]9C(E2&,G9P5'ZG8^/_&:>>CG9
M*&PFA.UQ_UMX_4\?F2?CSR;C[/Q\W/UU:"RHORXQ,8%V02M*6HS@?Z> ?J?\
M7T]ORO%TH;-L-IDF?WW6E#+[4XOH%Z4AU$UD^IPEB@ZX G@5I2Q&[L<AY8S)
M=IZ(P2EE#\C%Q&R\X.$U-AN,[&*$MI/M:BCZ??GC6ZCY96D6G\:5"1>\0>$,
MW8]>!+$-QH>]FAA4_3B6H"8$%[RI/K05, 6PED<=J(4;SBYP<BPLE)@/3R ]
M+FVU9#.1O("Y!MO6PUIDGZH4X8::"(3-9%\I9F%[06!7-9U]0#._1-/O049_
M<UTV5F")P!VH$73)#H@Y__@F?%P"%I4+/40^G2G:(SK3BI.?)5MU.N&0U>(3
M(BY09-,[,)34_KQV7IHEN\[@N&F( +/MO7=M",+%]"$]WQ%+)/U@CI1L*K'J
M'S:B$ .O,8D8HXP^,/(4>JA#22Y<(M)D[_5PMYQ*@AT%YELZ11"H>\ =7"#<
M8 ,"'!^L!X&SQQ8M>N^<$0XH]=S6-<<U=21+V'Z2L^!GA-A@;<1P7-DML2VA
M]GF".%/&]*H$SL+I>"<\V-D^WK!\#K4\\ENJTMF@18[D=3#I6A7:YZ/]2_P"
M&IF*<I['F,A)N,G0*:0H;2B:6,X,PSG5(@!LG6SC8:41(J(MBXGZ;0RX.<S5
MG.S5C[K.#2Z'WUIOZ\A4QN(3,G6P%>-22;*5 *Y"C$L6#S,(W@GO%1"VPX)R
MJ"I5%#@*,-,^<4IK.M<SPDGJWF<"[*Y5$<&J$-*IXS9\6J)'ICA(IO3VRJ55
MQ[2$G^92HC]QJ=K(J#845+?KD'L?\!+9:X?.!<+! *?1MNQ*.H<G/E\A"%V#
M7,"DA)9(YD/W1U\=NAWW-2$C3\A(& PKZ*#'?4/50+;&D7 0E5U#_*"K>U/;
M"M\1+W"8=W6'E=I[0#QI_^ZG=U_Z#3T'&$Q8%6)9Y F,069Q0F"Q]=S2OCHB
MB&^4V. J$V<9$J#9H*T%KMH8&[$9[GR-[:*<J$/$DU$,GGJ5+_"NW@GTR>@W
M8F#+!'*<2QERWIH2G-TFXPQ]3(;P0)^ZBJ8S2D%-=NG6NVONF KNNO]U].*<
M=VC(?I*9H]#742:P7;>^HPN]$R!S-@<?4(,*TU#+%)?LD((JJAF%'?5.DC48
M$,H1$&HH7@M5%(8K]S"LT@]@-KGO1S=XR-[9Z=":@$)[+/]<Z4.HQ+NUAI
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M_\2V"CSD(!BJE]C9T>'-!?4.MT!K^E9]A:M; B#!V[=G8@P/S&:)IWP.)P7
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M>FF ;+N808]DBN8E68"J69C,YK0,%_@Z(;8%S_AI@QZQUM5!S:]:!M">*40
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MEFS!SR:#W5@DP3)C-"M#3O@S)W<; @J"PJU EK5B9KY\G=_MS+.G+7!.$;1
MSU:N*8J%R!ZL5H]L;P,6G??7.\:>^.T4*;^HA2&_3S!<A<,]^JU708X+YXN
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M(O.8:9YR\H\#.7=(MWR..N$H$M0P7AFX-6G+)PZ+7,Y8#@E=27NN8/4RE63
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MK<*]*$<P:M=.E23[E,!$H*?"#AXIIP#R!_0BID]RG-*#-.<  '&V95[N$+<
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M;H>"?;<9$3B98CV?<$EB:00,Z!^+)*BW.YTC,7[)8-R")>-M.4O@@\VVEUR
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M/"Z;LD@8(\@X X6F0#5:&G=?8X#F5*!]5UYO&=1FCB8G1Y+=W&,9X1H$'@#
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M7%Z= =]^B;,"JBI=J#>5\]DL.U\LQA1Z'N^ S<?O@'VB^T7R#_4PK+OCPX^
M0YI3T)S'4S9\LTFV]-21%V0P-R[/I_2.FT"H_(HAO*!7:.!O"F<!*;.<5.AW
MK% PL 00M<+K=#7>L%NYCAGG&[<&.S7*;YC5I+N;H.$^U@Z(LK="2*G9SO(-
M74%!.3ZD'Y3OS'>%G(/O821G#K7MMFR<G$/X(X*K%'4Q<*K0E(&/2  6S.NW
MQM?(+4B@QAX0WLEB^E]^9_ X+QMNII%:!:*<7B?;M"&,]+[G.0P#"C,!^"VE
MK8PMX_UNCXVR?"G#=:]W=6A=ZA'B7UL2,CW]VLMSD=\\WC";C]\P"R^B^*P;
M>H,7,(O0VJ"2?,>],EA #"X@\1>*57=8QMHH_^:%!/2$]$OZNB(Z87IM2OJN
M%#^#+R+F =D<"WN9V54E,#5%64C.:\.15?HAY"@PVY=S099]7+AV@D<-3J4*
M;06T7 VBWJ 3=*X6JP4U?0YEI6':R6IV_I5,GZ(%?OY->/\^F3VV4FJ*V@7(
M4),_P?DP]T:/.E1X3V].Q((A!H9KVLN27TSDTGW[!Y3>CTSB%/28)_+]P"MM
MGD&1,YC+1Y'2))]-$[(]33C2FW4(+"3$'AE[$&N!S1+N?3C\K9_836M<\R'G
M.;G 0<EL/RVO0^DANO.^:4RWWJ0O&&&.) W;<(R.N[%-*[R: $R'NWSOW[P0
MK32VHOC=<CM?V+N_+K,Z%D EU^@#B ^(+84KKFLN"60 _N6NG2?"=V="6W>#
M0/!:#.,S;T3=13:\"N2#BV0L@ F*IOW3H24H='@.71XA[$K%?&P>[ #S8J\?
M'X?P66M>QXN4OTE)P9=O=TX#N0$VIB\R2"XC/\&.<C5Q T'+F!DG?GM?P]M/
MTJ<\R_;O3C/3?/(D/NZVMM3KLJX9"2?;R9)7T*#L(&X\ID9[#?1<T3BP9OZ]
M57[7U&CH6,@WS+PF13#@'!@FJ[VU>+J%W5WB"O=5>\2F[S6@Q(KK1T[ZR!+K
MRC?1F.[ZT NIGG:%E_O$X?>(M6!ODZAL:4/73?I3<KL&7Y69$/6N3] ';R71
M4=Z20WC6FR(2.01X@N^MI-+_XI6\7EQGB]F9G A76'0_7>";J,[/+[(9H.NS
MQ45V-9MBU]A@7B6,N+ZD>^X3,<\NIF?9 @AP8T>12+P9,Q^_&?-%YWKO?;>-
MJ4WG^M6'4?MSIA1'IT0G&]@:7S- 54M7?;BY_4J_3*;76>CI32'ZRX#=7[V6
MG[884NG0 Q:?Q.*G?Z>I-W]BK\94E%:M =:N%1?0^4W/U!A)KS%2"1XDS)*\
M\(?L$HH;XDFJJ>^AD]Y]VS@SAA$<QG" @A4:MGFQCIM.[U7[\"J>Q2P JW(T
M/E3KD!_ULNFP:,@ZO7#Q@NNU*-C-H0)"%(J60:30.;3W<;Z8#;<?0\J)EVS1
MKX,_0G?--T7I=24.;;N7UIEZ[[)Y^JX_3LK&=VH"6F??U[!<]CHA4B'*1)*X
M/_J4-'XFO^5^=T7@]AZ*.FH60Z8.@5!R(QC?21!!2N^N<+^L>S*DM:?)^ZL!
MQJ[I+=U4Q:U;?I5U^#:\"?R&WW\='^?7B/\&41R^$:32*Q@Z/<'W;C?\9F[^
MT)H=O0U[:=K6;.G/C5;@ _$!^'UE8!ON RX0WH_^YO\ 4$L#!!0    ( )&+
M=5AG1HZL208  *00   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;+58
M6V_;-A1^UZ\@W*)H "76Q;*5- F0I.DVH.V"II>'80^T1,=<)-(EJ;C^]_L.
M)2O.XKC!AKU8O)TKOW.ACY?:W-JY$([]J"ME3P9SYQ9'PZ$MYJ+F]D OA,+.
M3)N:.TS-S= NC."E)ZJK81)%XV'-I1J<'ONU*W-ZK!M7226N#+--77.S.A>5
M7IX,XL%ZX9.\F3M:&)X>+_B-N!;NR^+*8#;LN92R%LI*K9@1LY/!67QTGM-Y
M?^"K%$N[,69DR53K6YK\5IX,(E)(5*)PQ('C<R<N1%41(ZCQO>,YZ$42X>9X
MS?V=MQVV3+D5%[KZ)DLW/QGD U:*&6\J]TDO?Q6=/1GQ*W1E_2];=F>C 2L:
MZW3=$4.#6JKVRW]T?G@.0=(1)%[O5I#7\BUW_/38Z"4S=!K<:.!-]=103BJZ
ME&MGL"M!YTZOV\M@>L:NY8V2,UEPY=A94>A&.:ENV)6N9"&%9:\_\VDE[-[Q
MT$$PD0^+3LAY*R1Y0DB<L ]:N;EEEZH4Y4,&0VC<JYVLU3Y/=G)\*XH#EL8A
M2Z(DW<$O[=V0>G[I$_RVV?O'V=0Z ]C\N<WBEM]H.S\*I2.[X(4X&2!6K#!W
M8G#ZZD4\CM[LT';4:SO:Q?WT&J%9-I6@6W-SP2Z-T89=:&-:K&_3=R?'[?J>
MK4.5Y!0]=TO!Z*,*WB+Q"R,A?B'P*9FLP<8QI_W6A<94K5Z]R)-X\L9BKBS\
M6W(G2G;M\$& .^+_.^BY9Q\&R#6>>B6X88(@PW#AHIX*L[[T)&3<"&;G>JG8
ME'++$?N96X)'3#8VV9E=ST09_"(4U*D85R7C)>).$A0H@3#Q PG1"O:2Q8=Y
M>#C),4K3PS"/:92E>3@Y' >?X$1NBKGG4(H[:+CPIJ[)XW"4YV&61NSUFGH/
MB_$(]'$2?$0^?J^M)3'A.)^$643L]Q_,=T IZZ&4/1M*%]RV^OK!Y?=&WO$*
M.MMM>-K)=CN>B&U _ OB+^[Y,ZF*JBE%NR%QH5S=(F'[F+1>I5HKL4+B,[=P
MS*Q1I46B='.LN,9(1_$*"Y">+*Z>*_P8(8B*LL[,Z)IDB 7==,B6<UE $^"'
MZIBL5D"WNA/&220X@NZM(ECQNI5/Z%^[QI.&I",A3"^ #& ')VJN4,3HBCMD
M-M._1!L(4$>BBMUG5R/MK5<7%QR %=S0B -"(!;_"=+4RVTAWZOQR(,PP *C
MB)0._#-=(2@0H@_CXLD[?A@<FY/ *T$*!)Z($)AE41@=>L"'HS@.TTD>?'A\
M17$8)>,P!;;3,(JR,$^RX+-V"*SB22R\9$F83<9@.\8XQW<2)E&Z"^SC'NSC
M9X/]'9>&?27'AW"\%1W.WDL^E54+J ^"V\:02Q7[)(K&&,IXYQR.WA81.V5O
MCPCT/ $ZI3:!>=AL2YHSJ;@J)+P&&#G3U-Y/@+EC+8;A/5(34)O2M%[KC0,S
M,M/CBZS@V%W;,24[O,V0*4VP<7(ND?R0O%:,/P')UPJ7S2A//\JI>P\!]]_\
M_"AEI^P])5,6=]^D^Z8 M#$K(O3"@E96\,'#D1H7=DVLO<2CX(N2?06R[+/Q
M&JS8N2;4$@)SI-@DSKJ4N[^YUB&X,^9GAS<,A3$&,/=59+V\PO%OT)RWT%_3
MC^(H'(^C^]%3M&A<T.$:7T]G@I*AP.H^XBW/DO:WTW?3XYN"1F&&_NQ^M"/.
M)GV<39X=9U^LF#4D_0YR"3!7!B\* ^6O*LJ%E()\9=P64CO%; \I]J^$!^\:
M TB0][* XJ]QPK1(%>LSV.FK>D_(XFB7Q_+>8_FS/7:&/G0?5:GQEWV/6G;Y
MPU?)LJUGK9:^92*J2PX#U(UE5PB6ZSD2PS:'[M1BNT/Q^ G6S9A]HAO;K%$/
MB@_J4HTBS/".*6X?I/FE,-1+;5I$E,5#J[P;L*^0**E:4I>)IH_2'K>> 'KB
M ;:N>IOD2TX7N.'+ _9_N/EYA7.COU":<L[KC_BP;(\=9H>(NY3M!UT>Z+;&
MU Z.1N,PSC*69F.TB!$!T!E)+6KGT@:HM1L4AQ.$? 9F23B.TC"# AWM5I@.
M-UZ.M3 W_GU,W00:G_81V:_V3_"S]N5Y?[Q]OR/3WJ ^H0>;@30ZF*!#-.V;
MN)TXO?#OT*EV>-7ZX1SMES!T /LS#2.Z"0GH_Y@X_1M02P,$%     @ D8MU
M6%\HTOP$!   Y D  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK59-
M;]LX$+WK5PS4;9$ LO5A2983VT#2;K$%DDW0)"WV2$MC2Z@D>DDJCO?7[Y"2
M52=QC!YZL8<2Y_'-\#V*TPT7/V2.J."I*FLYLW.EUF>N*],<*R:'?(TUO5ER
M43%%0[%RY5H@RTQ25;J!Y\5NQ8K:GD_-LULQG_)&E46-MP)D4U5,;"^QY)N9
M[=N[!U^+5:[T W<^7;,5WJ%Z6-\*&KD]2E946,N"UR!P.;,O_+/+2,\W$[X5
MN)%[,>A*%IS_T(,OV<SV-"$L,54:@='?(W[$LM1 1./?#M/NE]2)^_$._;.I
MG6I9,(D?>?F]R%0^LQ,;,ERRIE1?^>8O[.HQ!%->2O,+FVZN9T/:2,6K+ID8
M5$7=_K.GK@^_DA!T"8'AW2YD6'YBBLVG@F] Z-F$I@-3JLDF<D6M-^5."7I;
M4)Z:7R&5).'DGBU*E*=35Q&H?N6F'<!E"Q"\ > '<,UKE4OXL\XP>P[@$IN>
M4K"C=!D<1?R$Z1!&O@.!%XR.X(WZ$D<&;W2TQ$.5M7GAX3QMAS.Y9BG.;-*[
M1/&(]OS#.S_VSH^P"GM6X3'T^1W9*VM*!+X$8X4!!0\2X4)*\B*K,S#$X4O=
M6D]K^&)!OH*;-0H:UZMVQJ'*CJ]]GZ.UY"494H.T?BS^(QFH'$'LR#2T..O)
ME(9,L4>&(I/PD5=K5F\_O$L"?WPN@??T3(X\@]]7JZ4UH8416/\@$YWH+)(,
M5@L46C9[4VZ>,X&42P5_@.\'#KVF:.PY_CBROE'Y6O_[TX+0"6C.P+IK%KO:
M4UXAG(R=Q)_ J0Z\L0>GUCU7K'RQ1) X81!1%(\<WXNL&^J4V&_?'KF4R1R6
MM!L2EH)7KQI(*)/(B4-?,XZ=($RL71<'_291WQ>*#F',:!7 IS1G]0K-)M5T
M-K[ A)(*+LI"%09^%$=.%,44#:SOYB##;, >*84@!.K#_6>J0E&!V>W@_#77
MDRWMRRF$PW@,WC#Q7N-EA4QY4RN@1'P;R/>&80+OZ1_>'_%;U/LM^F6_?6Y4
M(Q#^YO4@976*I=G\:RJR:JI.BK=L2]\>:NL#*:P5^@LMPE77P^TA!QYE<_AL
M:6E9]7-:54>K;?YZ1ZOI:;VUM5L2AJYVWQSF3'6 ":T::,^ %P;]W<WIC(K:
MJ/#2J*'6MN]$7J!'$4S(=>%8QS%,M+]"'8]A,G$F2:SC!.+$"491Y[IER_:-
M)H61[WAA:%VAI"J+:MTHXP^2,))/3VBY<)20A6_U)I D'UG9F"[T$&2.*'9B
M+X9#(G3WOKP5BI6Y7T@P^FX_POW3_@IST7ZY?TYO[S_73*R*6E()2TKUAF-2
MD&CO%.U \;7YCB^XHEN!"7.ZAJ'0$^C]DG.U&^@%^HO=_']02P,$%     @
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M*RNT$%JZ/90]*/9Q(BI9KG3<I-]^DNRH&23N*/C%EF2=OW[G8HZF:ZF>] H
MR4;P4L^"%6)U%H8Z6X&@^EA64)HOA52"HIFJ9:@K!31W1H*'212-0T%9&:13
MMS97Z536R%D)<T5T+015K^? Y7H6Q,%VX8XM5V@7PG1:T27< SY4<V5FH5?)
MF8!2,UD2!<4L^!Z?G<>1-7 [?C%8ZYTQL:XLI'RRD^M\%D26"#AD:"6H>;W
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MM=#Q*^=]@^>?P--N=V'VTP\%C&XE9.)7D\T%BUXS"WU*7(HUCF%LJ6-  -^
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MF=2)Z:(>48BNT");DVR5)9@(=),DM"0B(VOT0/,LR8"C+Q$(G.4<_8X9PVI
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M!"VJS0W@%)AJ(,^O*!6O.RI ^U5H^C]02P,$%     @ D8MU6#I4?QZP P
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MN@8*<RXH*8-E!23)BG_\6 JQ$V![1P*<,L#9#^@<"7#+ %<3+2K3M"ZQP,&
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MU5LT[=G'LBSQ=.IU;G?4N!$6FDXZ5:33/Y<!]H1@/UB9I!63YSQ*QYUS<V,
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MF]>+-E]XL:G?GWE?<%ZLZX\K%L]9*4\0_U\4XAF__2(#[%[R>OD_4$L#!!0
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M&'30/*BN$*<RHR',+2P!$L0:+/_E"W?DO&VRWB4LZ BV([M?R>ZWT?W/>;(
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M]VU.(_R@ J$[X/T5YVK;T%OPZA/-_PU02P,$%     @ D8MU6*OJKR5Q @
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MQYB<1%<)=QW%MZ:87'.%I:EIEOCO 82>@,\+SM5+1R_0_Q])_P-02P,$%
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M[B7MJNF24F!*6$ )"REA$1&L)_#K3N#7[K>79\#DNAV*8YQ110)VVU1OO&/
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M*2TDI454M+YR.RO/<WMYKLGV]G$=_7:CH-ER..=94K>/E!:0TD)26D1%Z_>
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M!<D6 K,%T18"M079%@*W!>$6 KD%Z18"NP7Q%@*]%?56 KT5]58"O?7A9YM
M;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O0[V-0&]#O8U
M;T.]C4!O>]@L(=#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;46\G
MT-M1;R?0VU%O)]#;46\GT-L?-KL)]';4VPGT=M3;"?1VU-L)]';4VPGT=M3;
MGZEWRJ==3+>>ZQJ/;IY)=3Z_&V^?ORRO-Q'GX07G $>M[[]02P,$%     @
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M<' N>&UL4$L! A0#%     @ D8MU6-O V!;N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ D8MU6)E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " "1BW58X0HJ9P@(  "T-0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ D8MU6,,C5VBC
M!@  9!\  !@              ("!2Q   'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( )&+=5A$S0S'+@,  +P*   8              "
M@207  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "1BW58
M;N *>&@&   "'0  &               @(&(&@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ D8MU6(J@Z")A"   6$$  !@
M     ("!)B$  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M )&+=5C4('-U:P(  -(%   8              " @;TI  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " "1BW58G@+AI$$)  #]+   &
M            @(%>+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ D8MU6$&1.(=: @  LP4  !@              ("!U34  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )&+=5A0B!G/9 D  ,45
M   8              " @64X  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " "1BW58YA-2[SH<  #F40  &0              @('_00
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )&+=5@ZPG0Z
MH00  $(*   9              " @7!>  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ D8MU6)N8(#4M P  ?0<  !D
M ("!2&,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "1
MBW58[T^F$U0'  #5$0  &0              @(&L9@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( )&+=5B#O&E5K0<  )X1   9
M          " @3=N  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#
M%     @ D8MU6/<JD)UX!@  *P\  !D              ("!&W8  'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "1BW58M%Q#0R,#  #X
M!@  &0              @('*?   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM
M;%!+ 0(4 Q0    ( )&+=5AL#=6BT0<  % 2   9              " @22
M  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ D8MU6*G8
MSWQW!@  S0T  !D              ("!+(@  'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6Q02P$"% ,4    " "1BW58J$6Z;JX=   K70  &0
M    @(':C@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M )&+=5AG1HZL208  *00   9              " @;^L  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ D8MU6%\HTOP$!   Y D  !D
M             ("!/[,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " "1BW58$,$2OO #  !9"0  &0              @(%ZMP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )&+=5C])@F*/@0
M " *   9              " @:&[  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ D8MU6,$J&!V4!0  0@X  !D              ("!
M%L   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "1BW58
ML6QLFDL&  #A-0  &0              @('AQ0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( )&+=5BC4DIK60,  %4-   9
M      " @6/,  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ D8MU6#&NW\EX @  3P8  !D              ("!\\\  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "1BW58L=R06CT%  #()@
M&0              @(&BT@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( )&+=5B'$/#2?P(  !<)   9              " @1;8  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ D8MU6/HMRO%5
M P  YPX  !D              ("!S-H  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " "1BW581XH=&J0$   A&@  &0
M@(%8W@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( )&+
M=5@Z5'\>L ,  #<,   9              " @3/C  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ D8MU6*-;/&J\ @  =@<  !D
M         ("!&N<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " "1BW58,W) 60T$  #G#P  &0              @($-Z@  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( )&+=5C-'HR"A@4  ,<F
M   9              " @5'N  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ D8MU6,% Z%W&"@  -%L  !D              ("!#O0
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "1BW58W5]&
M':<&  #"+@  &0              @($+_P  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( )&+=5BHG/$:*@,  &<,   9
M  " @>D% 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
MD8MU6/84^BF- P  JPL  !D              ("!2@D! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " "1BW581M[=EP8*  #P50  &0
M            @($.#0$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( )&+=5A>CLG2S@<  &1)   9              " @4L7 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ D8MU6'?Y_HF] P
M.0\  !D              ("!4!\! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " "1BW58--P$M&4#  "N#0  &0              @(%$
M(P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( )&+=5BK
MZJ\E<0(  ,0%   9              " @> F 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ D8MU6"7#M"_S P  +0T  !D
M     ("!B"D! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )&+=5C"C[X1, ,  /(2   -              "
M ;A! 0!X;"]S='EL97,N>&UL4$L! A0#%     @ D8MU6)>*NQS     $P(
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9>&UL4$L%!@     Y #D A@\  'A. 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>159</ContextCount>
  <ElementCount>357</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Organization and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OrganizationAndLiquidity</Role>
      <ShortName>Organization and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Notes Payable-Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable-relatedParty</Role>
      <ShortName>Notes Payable-Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/DerivativeLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Organization and Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative</Role>
      <ShortName>Organization and Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/OrganizationAndLiquidity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of the Error Correction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails</Role>
      <ShortName>Schedule of the Error Correction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails</Role>
      <ShortName>Schedule of Useful Lives for Property Plant Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails</Role>
      <ShortName>Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails</Role>
      <ShortName>Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Notes Payable-Related Party (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative</Role>
      <ShortName>Notes Payable-Related Party (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/NotesPayable-relatedParty</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Convertible Notes (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative</Role>
      <ShortName>Convertible Notes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/ConvertibleNotes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>Schedule of Warrants Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical</Role>
      <ShortName>Schedule of Warrants Activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Schedule of Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails</Role>
      <ShortName>Schedule of Monte Carlo Simulation Assumption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails</Role>
      <ShortName>Schedule of Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Derivative Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative</Role>
      <ShortName>Derivative Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails</Role>
      <ShortName>Schedule of Reconciliation of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Schedule of Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://shuttlepharma.com/role/SubsequentEvents</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>shph-20231231.xsd</File>
    <File>shph-20231231_cal.xml</File>
    <File>shph-20231231_def.xml</File>
    <File>shph-20231231_lab.xml</File>
    <File>shph-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_005.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="631">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "SHPH",
   "nsuri": "http://shuttlepharma.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "shph-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "shph-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "shph-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "shph-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "shph-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 294,
   "keyCustom": 63,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 22,
   "hidden": {
    "total": 153,
    "http://fasb.org/us-gaap/2023": 127,
    "http://shuttlepharma.com/20231231": 23,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 159,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 542,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 631,
    "http://xbrl.sec.gov/dei/2023": 40
   },
   "report": {
    "R1": {
     "role": "http://shuttlepharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://shuttlepharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://shuttlepharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://shuttlepharma.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:WarrantsIssuanceFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://shuttlepharma.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical",
     "longName": "00000008 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:WarrantsIssuanceFees",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://shuttlepharma.com/role/OrganizationAndLiquidity",
     "longName": "00000009 - Disclosure - Organization and Liquidity",
     "shortName": "Organization and Liquidity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://shuttlepharma.com/role/Leases",
     "longName": "00000011 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://shuttlepharma.com/role/NotesPayable-relatedParty",
     "longName": "00000012 - Disclosure - Notes Payable-Related Party",
     "shortName": "Notes Payable-Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://shuttlepharma.com/role/ConvertibleNotes",
     "longName": "00000013 - Disclosure - Convertible Notes",
     "shortName": "Convertible Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://shuttlepharma.com/role/StockholdersEquity",
     "longName": "00000014 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://shuttlepharma.com/role/DerivativeLiabilities",
     "longName": "00000015 - Disclosure - Derivative Liabilities",
     "shortName": "Derivative Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://shuttlepharma.com/role/RelatedPartyTransactions",
     "longName": "00000016 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://shuttlepharma.com/role/IncomeTaxes",
     "longName": "00000017 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://shuttlepharma.com/role/SubsequentEvents",
     "longName": "00000018 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000019 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000020 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://shuttlepharma.com/role/LeasesTables",
     "longName": "00000021 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://shuttlepharma.com/role/StockholdersEquityTables",
     "longName": "00000022 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://shuttlepharma.com/role/DerivativeLiabilitiesTables",
     "longName": "00000023 - Disclosure - Derivative Liabilities (Tables)",
     "shortName": "Derivative Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://shuttlepharma.com/role/IncomeTaxesTables",
     "longName": "00000024 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
     "longName": "00000025 - Disclosure - Organization and Liquidity (Details Narrative)",
     "shortName": "Organization and Liquidity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "SHPH:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
     "longName": "00000026 - Disclosure - Schedule of the Error Correction (Details)",
     "shortName": "Schedule of the Error Correction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails",
     "longName": "00000027 - Disclosure - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "00000028 - Disclosure - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails",
     "longName": "00000029 - Disclosure - Schedule of Useful Lives for Property Plant Equipment (Details)",
     "shortName": "Schedule of Useful Lives for Property Plant Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "00000030 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000031 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:PriorPeriodReclassificationAdjustment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails",
     "longName": "00000032 - Disclosure - Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)",
     "shortName": "Schedule of Right-of Use Asset and Lease Information About Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails",
     "longName": "00000033 - Disclosure - Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)",
     "shortName": "Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://shuttlepharma.com/role/LeasesDetailsNarrative",
     "longName": "00000034 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
     "longName": "00000035 - Disclosure - Notes Payable-Related Party (Details Narrative)",
     "shortName": "Notes Payable-Related Party (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2021-12-012021-12-31",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-12-012021-12-31",
      "name": "us-gaap:DebtInstrumentMaturityDateDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:NotesPayableRelatedPartyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
     "longName": "00000036 - Disclosure - Convertible Notes (Details Narrative)",
     "shortName": "Convertible Notes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
     "longName": "00000037 - Disclosure - Schedule of Warrants Activity (Details)",
     "shortName": "Schedule of Warrants Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_NotesPayableMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
     "longName": "00000038 - Disclosure - Schedule of Warrants Activity (Details) (Parenthetical)",
     "shortName": "Schedule of Warrants Activity (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
     "longName": "00000039 - Disclosure - Schedule of Restricted Stock Units (RSUs) (Details)",
     "shortName": "Schedule of Restricted Stock Units (RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "00000040 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "SHPH:AccruedInterestValueToIssueShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
     "longName": "00000041 - Disclosure - Schedule of Monte Carlo Simulation Assumption (Details)",
     "shortName": "Schedule of Monte Carlo Simulation Assumption (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember",
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
     "longName": "00000042 - Disclosure - Schedule of Derivative Liabilities (Details)",
     "shortName": "Schedule of Derivative Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_AcceleratedFeatureMember",
      "name": "SHPH:DerivativeGainLossOnDerivativeWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_AcceleratedFeatureMember",
      "name": "SHPH:DerivativeGainLossOnDerivativeWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
     "longName": "00000043 - Disclosure - Derivative Liabilities (Details Narrative)",
     "shortName": "Derivative Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-01-31",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000044 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_TCGGreenChemIncMember",
      "name": "SHPH:PaymentsToInvoicesInResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_TCGGreenChemIncMember",
      "name": "SHPH:PaymentsToInvoicesInResearchAndDevelopment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails",
     "longName": "00000045 - Disclosure - Schedule of Reconciliation of Income Tax Benefit (Details)",
     "shortName": "Schedule of Reconciliation of Income Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails",
     "longName": "00000046 - Disclosure - Schedule of Components of Deferred Tax Assets (Details)",
     "shortName": "Schedule of Components of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "00000047 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000048 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000049 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-08-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "SHPH_AcceleratedFeatureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AcceleratedFeatureMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accelerated Feature [Member]",
        "documentation": "Accelerated Feature [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses related party",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "SHPH_AccruedInterestSettledWithCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AccruedInterestSettledWithCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest settled with common stock",
        "documentation": "Accruedi nterest settled with common stock."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AccruedInterestValueToIssueShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AccruedInterestValueToIssueShares",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest settled with common stock",
        "documentation": "Accrued interest value to issue shares.",
        "label": "AccruedInterestValueToIssueShares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r154",
      "r537"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "SHPH_AdditionOfNewDerivativesRecognizedAsDebtDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AdditionOfNewDerivativesRecognizedAsDebtDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition of new derivatives recognized as debt discounts",
        "documentation": "Addition of new derivatives recognized as debt discounts."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AdditionalEscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AdditionalEscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Escrow deposit",
        "documentation": "Additional escrow deposit.",
        "label": "AdditionalEscrowDeposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r687",
      "r838"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r572",
      "r757",
      "r758",
      "r759",
      "r815",
      "r840"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r354"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for financing costs, net of issuance fees of $8,727",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r124"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_AltoConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AltoConvertibleNoteMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alto Convertible Note [Member]",
        "documentation": "Alto Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount and finance fees",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r83",
      "r113",
      "r318"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r318",
      "r451",
      "r750"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r156",
      "r182",
      "r219",
      "r227",
      "r231",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r418",
      "r422",
      "r442",
      "r530",
      "r608",
      "r687",
      "r700",
      "r773",
      "r774",
      "r826"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r161",
      "r182",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r418",
      "r422",
      "r442",
      "r687",
      "r773",
      "r774",
      "r826"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Assets",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "SHPH_AyrtonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "AyrtonMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ayrton [Member]",
        "documentation": "Ayrton [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_BousteadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "BousteadMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boustead [Member]",
        "documentation": "Boustead [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_BousteadSecuritiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "BousteadSecuritiesLLCMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boustead Securities LLC [Member]",
        "documentation": "Boustead Securities LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r531",
      "r583",
      "r603",
      "r687",
      "r700",
      "r740"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r153",
      "r664"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r115",
      "r178"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r115"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ChangeInFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ChangeInFairValueOfDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative liabilities",
        "documentation": "Change in fair value of derivative liability.",
        "label": "ChangeInFairValueOfDerivativeLiability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r157",
      "r158",
      "r159",
      "r182",
      "r207",
      "r208",
      "r211",
      "r213",
      "r217",
      "r218",
      "r266",
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r326",
      "r327",
      "r329",
      "r332",
      "r339",
      "r442",
      "r562",
      "r563",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r595",
      "r617",
      "r638",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r722",
      "r751",
      "r762"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable price per share",
        "verboseLabel": "Warrants exerciable shares",
        "terseLabel": "Exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock",
        "verboseLabel": "Number of shares warrant to purchase",
        "terseLabel": "Number of warrants to purchase",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "SHPH_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants price",
        "documentation": "Class pf warrant or right number of securities called by warrants or rights value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four year warrant to purchase",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "SHPH_CommonAreaMaintenanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonAreaMaintenanceCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common area maintenance cost",
        "documentation": "Common area maintenance cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "SHPH_CommonStockIssuedForConversionOfAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonStockIssuedForConversionOfAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest",
        "documentation": "Common Stock Issued For Conversion Of Accrued Interest."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForDividendPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonStockIssuedForDividendPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for dividend payable",
        "documentation": "Common stock issued for dividend payable."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued for exercise of warrants with settlement of notes payable",
        "documentation": "Common stock issued for exercise of warrants with settlement of notes payable.",
        "label": "CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_CommonStockIssuedForSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonStockIssuedForSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for settlement of debt",
        "documentation": "Common stock issued for settlement of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r757",
      "r758",
      "r815",
      "r837",
      "r840"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r595"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r99",
      "r595",
      "r614",
      "r840",
      "r841"
     ]
    },
    "SHPH_CommonStockToBeIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonStockToBeIssuedMember",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock to be Issued [Member]",
        "documentation": "Common Stock To Be Issued [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.00001 par value; 100,000,000 shares authorized; 16,069,320 and 13,603,129 shares issued and outstanding, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r533",
      "r687"
     ]
    },
    "SHPH_CommonStockVestingOfRestrictedStockUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CommonStockVestingOfRestrictedStockUnit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock vesting of restricted stock unit",
        "documentation": "Common stock vesting of restricted stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r667"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Converted shares issued",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of stock, shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r132",
      "r836"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable non-current, net",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "SHPH_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note [Member]",
        "documentation": "Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ConvertibleNotePayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ConvertibleNotePayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable, net",
        "documentation": "Convertible note payable current."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ConvertibleNotePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ConvertibleNotePolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note",
        "documentation": "Convertible Note [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible notes payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r132",
      "r836"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note payable",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "SHPH_CorrectionOfPriorPeriodErrorsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "CorrectionOfPriorPeriodErrorsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Correction of an Immaterial Error in the Prior Period Financial Statements",
        "documentation": "Correction of prior period errors policytextblock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal income tax",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r754",
      "r812"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "state income tax",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r754",
      "r812"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r180",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r312",
      "r319",
      "r320",
      "r322"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r94",
      "r95",
      "r130",
      "r132",
      "r187",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r452",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r752"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r57",
      "r91",
      "r94",
      "r130",
      "r132"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, face amount",
        "verboseLabel": "Debt principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r86",
      "r297",
      "r452",
      "r675",
      "r676"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity warrant as reduction in additional paid in capital",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase accrued interest",
        "verboseLabel": "Accrued interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r84",
      "r323",
      "r452"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r298"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date, Description",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "verboseLabel": "Share price",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r187",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r452",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r752"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time period (years)",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r86",
      "r776"
     ]
    },
    "us-gaap_DebtSecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on interest relief on conversion of notes payable",
        "label": "Debt Securities, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r747",
      "r748"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r131",
      "r402"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangibles (includes Section 174 capitalization)",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r811"
     ]
    },
    "SHPH_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease asset/(liability)",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax asset",
        "documentation": "Deferred tax assets liabilities net before valuation allowances.",
        "label": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "SHPH_DeferredTaxAssetsOperatingLossCarriedForward": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLossCarriedForward",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carried forward",
        "documentation": "Deferred tax assets operating loss carried forward"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Carried forward",
        "documentation": "Deferred tax assets operating loss carried forward future federal income.",
        "label": "DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "verboseLabel": "Operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r811"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest &amp; other accrued expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r811"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "R&amp;D tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r811"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "SHPH_DeferredTaxAssetsbasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxAssetsbasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation",
        "documentation": "Deferred tax assetsbased compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r811"
     ]
    },
    "SHPH_DeferredTaxLiabilitiesFairMarketValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxLiabilitiesFairMarketValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair market value of securities",
        "documentation": "Deferred tax liabilities fair market value.",
        "label": "DeferredTaxLiabilitiesFairMarketValue"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DeferredTaxLiabilitiesFiniteLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DeferredTaxLiabilitiesFiniteLivedAssets",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets",
        "documentation": "Deferred tax liabilities finite lived assets.",
        "label": "DeferredTaxLiabilitiesFiniteLivedAssets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfComponentsOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53"
     ]
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States Treasury Bonds",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r587",
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r633",
      "r634",
      "r635",
      "r650",
      "r651",
      "r652",
      "r653",
      "r689",
      "r691"
     ]
    },
    "SHPH_DerivativeDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DerivativeDiscountPercentage",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative discount percentage",
        "documentation": "Derivative discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liabilities",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "SHPH_DerivativeGainLossOnDerivativeWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DerivativeGainLossOnDerivativeWarrants",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on change in fair value of the derivative",
        "documentation": "Derivative gain loss on derivative warrants.",
        "label": "DerivativeGainLossOnDerivativeWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r585",
      "r587",
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r633",
      "r634",
      "r635",
      "r650",
      "r651",
      "r652",
      "r653",
      "r666",
      "r689",
      "r691"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability - Accelerated feature",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "verboseLabel": "Warrant derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r74",
      "r75",
      "r80",
      "r186"
     ]
    },
    "SHPH_DirectorsAndOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DirectorsAndOfficersMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors and Officers [Member]",
        "documentation": "Directors and Officers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Right-of Use Asset And Lease Information About Operating Lease",
        "terseLabel": "Schedule Of Future Non-cancelable Minimum Lease Payments Under Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_DisclosureNotesPayablerelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "DisclosureNotesPayablerelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable-related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on Series A preferred stock",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r124"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715",
      "r717"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715",
      "r717"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per shares - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r193",
      "r194",
      "r196",
      "r197",
      "r199",
      "r204",
      "r207",
      "r211",
      "r212",
      "r213",
      "r215",
      "r434",
      "r435",
      "r527",
      "r543",
      "r669"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per shares - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r193",
      "r194",
      "r196",
      "r197",
      "r199",
      "r207",
      "r211",
      "r212",
      "r213",
      "r215",
      "r434",
      "r435",
      "r527",
      "r543",
      "r669"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Stock",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. statutory rate",
        "verboseLabel": "Federal income tax benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r398",
      "r412"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r813"
     ]
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationChangeInTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInTaxRate",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in tax rate",
        "documentation": "Effective income tax rate reconciliation change in tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Future taxable income",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to lease expense."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r813"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r813"
     ]
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Permanent differences",
        "documentation": "Effective income tax rate reconciliation permanent differences.",
        "label": "EffectiveIncomeTaxRateReconciliationPermanentDifferences"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Return to provision adjustments",
        "documentation": "Effective income tax rate reconciliation return to provision adjustments.",
        "label": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shortfall of stock compensation expense",
        "documentation": "Effective income tax rate reconciliation short fall of stock compensation expense.",
        "label": "EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income tax benefit, net of federal tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r813"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "R&amp;D tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r813"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation cost",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r148",
      "r166",
      "r167",
      "r168",
      "r188",
      "r189",
      "r190",
      "r192",
      "r200",
      "r202",
      "r216",
      "r267",
      "r270",
      "r341",
      "r385",
      "r386",
      "r387",
      "r408",
      "r409",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r471",
      "r547",
      "r548",
      "r549",
      "r572",
      "r638"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r661"
     ]
    },
    "SHPH_EstimatedMonthlyCommonAreaMaintenanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "EstimatedMonthlyCommonAreaMaintenanceCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated monthly common area maintenance cost",
        "documentation": "Estimated monthly common area maintenance cost."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r441"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r441"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Monte Carlo Simulation Assumption",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r438",
      "r486",
      "r487",
      "r488",
      "r675",
      "r676",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r343",
      "r348",
      "r438",
      "r486",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r343",
      "r348",
      "r438",
      "r487",
      "r675",
      "r676",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r438",
      "r488",
      "r675",
      "r676",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r486",
      "r487",
      "r488",
      "r675",
      "r676",
      "r680",
      "r681",
      "r682"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r21"
     ]
    },
    "SHPH_FederalTaxableIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "FederalTaxableIncomeMember",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Taxable Income [Member]",
        "documentation": "Federal Taxable Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_FinanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "FinanceFee",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance fee",
        "documentation": "Finance fee.",
        "label": "FinanceFee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r321",
      "r337",
      "r430",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r542",
      "r673",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on sale of marketable securities",
        "negatedLabel": "Gain on marketable securities",
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "SHPH_GainOnForgivenessOfNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "GainOnForgivenessOfNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on forgiveness of Paycheck Protection Program note payable",
        "negatedLabel": "Gain on forgiveness of Paycheck Protection Program note payable",
        "documentation": "Gain on forgiveness of note payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement of accounts payable",
        "negatedLabel": "Gain on settlement of accounts payable",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "verboseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r619"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r714",
      "r715"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r121"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r105",
      "r134",
      "r219",
      "r226",
      "r230",
      "r232",
      "r528",
      "r539",
      "r671"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r622"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r622"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r394",
      "r399",
      "r400",
      "r406",
      "r410",
      "r413",
      "r414",
      "r415",
      "r567"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r146",
      "r201",
      "r202",
      "r224",
      "r397",
      "r411",
      "r545"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r395",
      "r396",
      "r400",
      "r401",
      "r405",
      "r407",
      "r561"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "SHPH_IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Income tax reconciliation foreignIncome tax permanent differences."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rate change",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal tax benefit at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Research and Development",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "SHPH_IncomeTaxReconciliationProvisionAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "IncomeTaxReconciliationProvisionAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Return to provision adjustments",
        "documentation": "Income tax reconciliation provision adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income tax benefit, net of federal tax effect",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R &amp; D tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash financing activities:",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "SHPH_IncreaseDecreaseInAccruedInterestPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "IncreaseDecreaseInAccruedInterestPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued interest payable - related parties",
        "documentation": "Increase decrease in accrued interest payable - related parties.",
        "label": "IncreaseDecreaseInAccruedInterestPayableRelatedParties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued interest income",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses - related parties",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest payable",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating lease asset and liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r749"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "SHPH_InitialPublicOfferingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "InitialPublicOfferingDescription",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial public offering description",
        "documentation": "Initial public offering description."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_InitialRecognitionOfRightOfUseAssetAndLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "InitialRecognitionOfRightOfUseAssetAndLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial recognition of right of use asset and liability",
        "documentation": "Initial recognition of right of use asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_InstitutionalInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "InstitutionalInvestorMember",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Institutional Investor [Member]",
        "documentation": "Institutional Investor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r137",
      "r169",
      "r223",
      "r450",
      "r623",
      "r698",
      "r839"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r316",
      "r324",
      "r677",
      "r678"
     ]
    },
    "SHPH_InterestFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "InterestFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest fee",
        "documentation": "Interest fee amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest income",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "verboseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r176",
      "r177"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest payable - related parties",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest income",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r222"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r686"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right-of Use Asset and Lease Information About Operating Lease",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal and professional",
        "verboseLabel": "Legal fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, operating lease, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r182",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r419",
      "r422",
      "r423",
      "r442",
      "r594",
      "r670",
      "r700",
      "r773",
      "r826",
      "r827"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r133",
      "r535",
      "r687",
      "r753",
      "r769",
      "r819"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r152",
      "r182",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r419",
      "r422",
      "r423",
      "r442",
      "r687",
      "r773",
      "r826",
      "r827"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_LossOnSettlementOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "LossOnSettlementOfConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 7.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on settlement of convertible debt",
        "label": "Loss on settlement of convertible debt",
        "documentation": "Loss on settlement of convertible debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "verboseLabel": "Marketable securitie outstanding balance",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfOperations",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of marketable securities",
        "negatedLabel": "Change in fair value of marketable securities",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of realized and unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities realized gain loss",
        "documentation": "Amount of realized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities unrealized gain loss",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r350",
      "r513",
      "r546",
      "r586",
      "r587",
      "r646",
      "r647",
      "r648",
      "r649",
      "r654",
      "r662",
      "r663",
      "r672",
      "r679",
      "r683",
      "r688",
      "r775",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "us-gaap_MeasurementInputDefaultRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDefaultRateMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Default Rate [Member]",
        "documentation": "Measurement input using likelihood loan will not be repaid as proportion of outstanding loan."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "SHPH_MeasurementInputIlliquidityDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "MeasurementInputIlliquidityDiscountMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Illiquidity Discount [Member]",
        "documentation": "Illiquidity Discount [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_MeasurementInputVolumeWeightedAveragePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "MeasurementInputVolumeWeightedAveragePriceMember",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Volume Weighted Average Price [Member]",
        "documentation": "Measurement Input Volume Weighted Average Price [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r350",
      "r513",
      "r546",
      "r586",
      "r587",
      "r646",
      "r647",
      "r648",
      "r649",
      "r654",
      "r662",
      "r663",
      "r672",
      "r679",
      "r683",
      "r688",
      "r775",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails": {
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market funds",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "negatedLabel": "Net income loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117",
      "r135",
      "r150",
      "r163",
      "r164",
      "r168",
      "r182",
      "r191",
      "r193",
      "r194",
      "r196",
      "r197",
      "r201",
      "r202",
      "r209",
      "r219",
      "r226",
      "r230",
      "r232",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r435",
      "r442",
      "r541",
      "r616",
      "r636",
      "r637",
      "r671",
      "r698",
      "r773"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r193",
      "r194",
      "r196",
      "r197",
      "r204",
      "r205",
      "r210",
      "r213",
      "r219",
      "r226",
      "r230",
      "r232",
      "r671"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_NewLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "NewLeaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Lease Agreement [Member]",
        "documentation": "New Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r756"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable to related parties",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "SHPH_NotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "NotesPayableMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Member]",
        "documentation": "Notes Payable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_NotesPayableRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "NotesPayableRelatedPartiesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable Related Parties [Member]",
        "documentation": "Notes Payable Related Parties [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_NotesPayableRelatedPartyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "NotesPayableRelatedPartyDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable-Related Party",
        "documentation": "Notes Payable Related Party [Disclosure Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_OfficersSpouseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "OfficersSpouseMember",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officers Spouse [Member]",
        "documentation": "Officers Spouse [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r226",
      "r230",
      "r232",
      "r671"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r686"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFutureNon-cancelableMinimumLeasePaymentsUnderOperatingLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r686"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term - operating leases (year)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r686"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operatiing loss",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Liquidity",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r128",
      "r557",
      "r558"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "SHPH_OtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "OtherInformationAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other information",
        "documentation": "Other information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development, net of contract expense reimbursements",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_PartnersCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PartnersCapital",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initiated a capital offering",
        "documentation": "The amount of ownership interest of different classes of partners in limited partnership."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "SHPH_PaymentForPlacementAgent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "PaymentForPlacementAgent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for placement agent",
        "documentation": "Payment for placement agent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for finance costs related to convertible note payable",
        "label": "Allocation of financing costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "SHPH_PaymentsToInvoicesInResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "PaymentsToInvoicesInResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to invoices in research and development",
        "documentation": "Payments to invoices in research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividend on Series A Preferred Stock",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r98",
      "r751",
      "r777"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r694",
      "r695",
      "r696",
      "r697",
      "r837",
      "r840"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r326"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r595"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r595",
      "r614",
      "r840",
      "r841"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r532",
      "r687"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r279",
      "r280",
      "r665"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly reclassifications",
        "documentation": "The amount of a reclassification adjustment made to prior period financial statement amounts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes payable and warrants",
        "verboseLabel": "Proceeds from convertible note payable",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "SHPH_ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common shares and exercise of warrants",
        "documentation": "Proceeds from issuance of common stock and exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance or sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r562"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from note payable-related party",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from disposition of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r163",
      "r164",
      "r174",
      "r182",
      "r191",
      "r201",
      "r202",
      "r219",
      "r226",
      "r230",
      "r232",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r417",
      "r420",
      "r421",
      "r435",
      "r442",
      "r528",
      "r540",
      "r571",
      "r616",
      "r636",
      "r637",
      "r671",
      "r684",
      "r685",
      "r699",
      "r746",
      "r773"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net of accumulated depreciation of $121,685 and $114,875 respectively",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r529",
      "r538",
      "r687"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r142",
      "r145",
      "r536"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]",
        "documentation": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r342",
      "r350",
      "r381",
      "r382",
      "r383",
      "r489",
      "r513",
      "r546",
      "r586",
      "r587",
      "r646",
      "r647",
      "r648",
      "r649",
      "r654",
      "r662",
      "r663",
      "r672",
      "r679",
      "r683",
      "r688",
      "r691",
      "r772",
      "r775",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r342",
      "r350",
      "r381",
      "r382",
      "r383",
      "r489",
      "r513",
      "r546",
      "r586",
      "r587",
      "r646",
      "r647",
      "r648",
      "r649",
      "r654",
      "r662",
      "r663",
      "r672",
      "r679",
      "r683",
      "r688",
      "r691",
      "r772",
      "r775",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r475",
      "r476",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r615",
      "r645"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r475",
      "r476",
      "r477",
      "r478",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r615",
      "r645"
     ]
    },
    "SHPH_RelatedPartyOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "RelatedPartyOfficerMember",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Officer [Member]",
        "documentation": "Related Party Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r475"
     ]
    },
    "us-gaap_RelatedPartyTransactionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDate",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Date",
        "documentation": "Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionRate",
     "presentation": [
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Rate",
        "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r475",
      "r476",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r613",
      "r615",
      "r645",
      "r825"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r476",
      "r479",
      "r568",
      "r569",
      "r570",
      "r620",
      "r621",
      "r622",
      "r642",
      "r644"
     ]
    },
    "SHPH_RentVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "RentVariableRate1",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent variable rate",
        "documentation": "Rent Variable Rate1."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of convertible note payable",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of note payable-related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development, net of contract expense reimbursements",
        "verboseLabel": "Research and development expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r393",
      "r834"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r215",
      "r268",
      "r269",
      "r409",
      "r432",
      "r433",
      "r434",
      "r435",
      "r453",
      "r470",
      "r471",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails"
     ],
     "auth_ref": [
      "r149",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r215",
      "r268",
      "r269",
      "r409",
      "r432",
      "r433",
      "r434",
      "r435",
      "r453",
      "r470",
      "r471",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r124",
      "r534",
      "r551",
      "r556",
      "r566",
      "r596",
      "r687"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r188",
      "r189",
      "r190",
      "r192",
      "r200",
      "r202",
      "r267",
      "r270",
      "r385",
      "r386",
      "r387",
      "r408",
      "r409",
      "r424",
      "r426",
      "r427",
      "r429",
      "r433",
      "r547",
      "r549",
      "r572",
      "r840"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r182",
      "r220",
      "r221",
      "r225",
      "r228",
      "r229",
      "r233",
      "r234",
      "r235",
      "r266",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r442",
      "r528",
      "r773"
     ]
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r686"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock consideration received per transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock membership percentage",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r149",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r202",
      "r215",
      "r409",
      "r432",
      "r433",
      "r434",
      "r453",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r725",
      "r728",
      "r729",
      "r730",
      "r760",
      "r770",
      "r771",
      "r816",
      "r822",
      "r823"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "auth_ref": [
      "r203",
      "r351",
      "r723",
      "r761"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/NotesPayable-relatedPartyDetailsNarrative",
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59",
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Error Correction",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438"
     ]
    },
    "SHPH_ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Income Tax Benefit",
        "documentation": "Schedule Of Pretax Income From Continuing Operations [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfUsefulLivesForPropertyPlantEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restricted Stock Units (RSUs)",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants Activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "SHPH_ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Useful Lives for Property Plant Equipment",
        "documentation": "Schedule of Useful Lives for Property Plant Equipment [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r744",
      "r778"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Share based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation arrangement by share based payment award description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r65"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of RSUs, Outstanding, Beginning Balance",
        "periodEndLabel": "Number of RSUs, Outstanding, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per RSU, Beginning Balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per RSU, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Life (Years), Outstanding Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of RSUs, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value Per RSU, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Outstanding, Beginning Balance",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants Outstanding, Beginning Balance",
        "periodEndLabel": "Number of Warrants Outstanding, Beginning Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18"
     ]
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments outstanding in period weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value of warrants",
        "documentation": "Share-based compensation arrangement by share-based payment award non-options outstanding intrinsic value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share granted under equity incentive plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Stock Option Outstanding, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "SHPH_ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Outstanding Beginning Balance",
        "documentation": "Share based compensation arrangement by share based payment award non option grant in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r359",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock trading price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Life (Years), Granted",
        "documentation": "Weighted Average Remaining Life in Years Outstanding, Granted."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Life (Years), Outstanding Ending",
        "documentation": "Weighted Average Remaining Life in Years Outstanding,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares vested under plan",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_ShortfallOfStockCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "ShortfallOfStockCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfReconciliationOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shortfall of stock compensation expense",
        "documentation": "Shortfall of stock compensation expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r179"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "SHPH_StateTaxableIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StateTaxableIncomeMember",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Taxable Income [Member]",
        "documentation": "State Taxable Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r157",
      "r158",
      "r159",
      "r182",
      "r207",
      "r208",
      "r211",
      "r213",
      "r217",
      "r218",
      "r266",
      "r287",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r326",
      "r327",
      "r329",
      "r332",
      "r339",
      "r442",
      "r562",
      "r563",
      "r564",
      "r565",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r595",
      "r617",
      "r638",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r722",
      "r751",
      "r762"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r148",
      "r166",
      "r167",
      "r168",
      "r188",
      "r189",
      "r190",
      "r192",
      "r200",
      "r202",
      "r216",
      "r267",
      "r270",
      "r341",
      "r385",
      "r386",
      "r387",
      "r408",
      "r409",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r471",
      "r547",
      "r548",
      "r549",
      "r572",
      "r638"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r216",
      "r514",
      "r560",
      "r584",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r618",
      "r619",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r693"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r351",
      "r723",
      "r724",
      "r761"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfErrorCorrectionDetails",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r216",
      "r514",
      "r560",
      "r584",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r618",
      "r619",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r638",
      "r693"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest and principal, shares",
        "documentation": "Stock Issued During Period Shares Conversion Of Accrued Interest And Principal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of convertible debt and accrued interest, shares",
        "verboseLabel": "Common stock issued for conversion of convertible debt, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r57",
      "r124",
      "r313"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesConversionOfDividends": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfDividends",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number shares issued for conversion dividends payable, shares",
        "documentation": "Stock issued during period shares conversion of dividends."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_StockIssuedDuringPeriodSharesConversionOfPreferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredShares",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number shares issued for conversion of note, shares",
        "documentation": "Stock issued during period shares conversion of preferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for dividends on and conversion of Series A preferred stock, shares",
        "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r638",
      "r657"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for exercise of warrants, shares",
        "documentation": "Stock issued during period shares exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash, shares",
        "verboseLabel": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r98",
      "r99",
      "r124",
      "r562",
      "r638",
      "r656"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for exercise of warrants with settlement of notes payable, shares",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for restricted stock units, shares",
        "verboseLabel": "Restricted stock award granted shares",
        "terseLabel": "Restricted stock units",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r124"
     ]
    },
    "SHPH_StockIssuedDuringPeriodSharesSettlementOfNotesPayable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfNotesPayable",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StockIssuedDuringPeriodSharesSettlementOfNotesPayable]",
        "documentation": "Stock issued during period shares settlement of notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised for cash, shares",
        "verboseLabel": "Number of shares of common stock issued for exercise of warrants",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r98",
      "r99",
      "r124",
      "r365"
     ]
    },
    "SHPH_StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of accrued interest and principal",
        "documentation": "Stock Issued During Period Value Conversion O fAccruedInterest And Principal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for conversion of convertible debt and accrued interest",
        "verboseLabel": "Number of shares of common stock upon settlement of notes payable",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common shares issued for dividends on and conversion of Series A preferred stock",
        "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r572",
      "r638",
      "r657",
      "r692",
      "r699"
     ]
    },
    "SHPH_StockIssuedDuringPeriodValueDividendsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodValueDividendsPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for dividends payable",
        "documentation": "Stock issued during period value dividends payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for cash",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r98",
      "r99",
      "r124",
      "r572",
      "r638",
      "r656",
      "r699"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for exercise of warrants with settlement of notes payable",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for restricted stock units",
        "verboseLabel": "Restricted stock award granted value",
        "terseLabel": "Restricted stock value",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r98",
      "r99",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised for cash",
        "verboseLabel": "Exercise of warrants, value",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r34",
      "r124"
     ]
    },
    "SHPH_StockIssuedDuringPeriodValueWarrantsNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "StockIssuedDuringPeriodValueWarrantsNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for exercise of warrants notes payable, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://shuttlepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r102",
      "r103",
      "r119",
      "r597",
      "r614",
      "r639",
      "r640",
      "r687",
      "r700",
      "r753",
      "r769",
      "r819",
      "r840"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r181",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r341",
      "r431",
      "r641",
      "r643",
      "r660"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r686"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r481"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r482"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for:"
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_TCGGreenChemIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "TCGGreenChemIncMember",
     "presentation": [
      "http://shuttlepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TCG Green Chem Inc [Member]",
        "documentation": "TCG Green Chem Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxYear2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2016Member",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2016 [Member]",
        "documentation": "Identified as tax year 2016."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_TaxYear2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxYear2017Member",
     "presentation": [
      "http://shuttlepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2017 [Member]",
        "documentation": "Identified as tax year 2017."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r824"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r321",
      "r337",
      "r430",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r542",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "SHPH_TwoThousandEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "TwoThousandEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://shuttlepharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2018 Equity Incentive Plan [Member]",
        "documentation": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative",
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative",
      "http://shuttlepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r680",
      "r682",
      "r835"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r140",
      "r141",
      "r143",
      "r144"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://shuttlepharma.com/role/ScheduleOfRight-ofUseAssetAndLeaseInformationAboutOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r686"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://shuttlepharma.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://shuttlepharma.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://shuttlepharma.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://shuttlepharma.com/role/ScheduleOfMonteCarloSimulationAssumptionDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetails",
      "http://shuttlepharma.com/role/ScheduleOfWarrantsActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://shuttlepharma.com/role/ConvertibleNotesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected years",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "SHPH_WarrantsIssuanceFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "WarrantsIssuanceFees",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlowsParenthetical",
      "http://shuttlepharma.com/role/StatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranst of issuance fees",
        "documentation": "Warrants issuance fees."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsIssuedForFinancingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "WarrantsIssuedForFinancingFees",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for financing fees, net of issuance fees of $8,727 and $0, respectively",
        "documentation": "Warrants issued for financing fees."
       }
      }
     },
     "auth_ref": []
    },
    "SHPH_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://shuttlepharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Warrants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r213"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://shuttlepharma.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r213"
     ]
    },
    "SHPH_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://shuttlepharma.com/20231231",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://shuttlepharma.com/role/OrganizationAndLiquidityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Working capital",
        "documentation": "Working capital.",
        "label": "WorkingCapital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://shuttlepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480348/946-230-55-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001493152-24-010822-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-010822-xbrl.zip
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MZST_>_'L["D0$=6SW>/9EZ?=TZ<@8]?9)H4Q*8-U0E1&*"L,IR35<(F)Q1K
M*.:"MN")A7"21A\+.3R764[$_D25/6L&9*$0,>(W$"&R"-X211/H=9O0Z_1.
MF_")FP0E=,[H=<R6 IGR4L%U8BZ(H)RDH(^"BTO)@\>FI2DM(K1?DL(UC(4H
M4&53^:ZYZ':\-TB[*I7WC"BPY1[!E%&6A4Q!OP+6;\'J"W+$8P@7VG6( ':5
MIT00(]4><J+(3I$\@8AIJG 3P\6!TA&WR=#HA1A0A&L&N@@1/BX?!!7)(C1
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MI;>B\$'5Q\W;1MN^G*JGE'UQ?0902P,$%     @ E(MU6&V)#?M& P  U \
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MVVIE%VB+!> ; J'W UPR&PG600Z]RA5L.SCB]8/C7?'>SSTXCL-5N)3$T;,
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MVTMU[,/EW'(1'5_>V,QY+0;86ZHU->=J9]B]O:6Z\@O:O2FE[=[<+'_%=?+
MYU?T#O?G3_*:8QG/2];]N:W:>>![F3S=GYN\9X%U!C[<7\QQY//GQ<LCV\4$
M Z9?P0Q8/IC??:2T]>O Q_M/F*RR6B2G\G@5+/FCE,/%A%B62BF'\T<D7Y=2
M#@\70"D+/T9J1+)R-,%X80L_FMM"6^&JG]>V\V=FKF Y,S#8_&D1*]RF*0W0
MH_F2#*<]Z6N:IL0%Z037IF/=P-.FZ#/[M9CN>+Y<P=6M? 9*G3UIXI5V=4IJ
MG3][8G&Q]%60Z!H=5BV"+O?FOPRTBOV;CACWJFMT CQ%?N_>_"D0KQ+17CZ?
M[57S><XQAXVV-W_2R)HL>08I5%N-N;VZ[9Y28,V?:_-\9&D%W%I;0<QT'M::
M_QK4//"]*-BX5YO[)&066&?AV<7D'ST?@%D:V2XH#V3Z%<R Y=FOG+TLA+0\
M)!^O+MBXM$7,?U]L^90R_ZGO*U/*7G4!E++P^ZI[\U??>*W[JGNS%^R@H,-(
M,$%=7+7^%'XW09>S@C:SM;O,J[1[AW.KA*5=I=T[G-E;7.)5VKW#N>T51,HX
M8\P,T-$"RJ^8$LM2G''UWTMGA!/B,CI@:\U(:;,'.R>#23(D*JVAZNS,!M[^
M_ XX$%;HCIF@\"3/$H,S0C=_?O6-=$W.+0^G1$W1=*POS$>HAM?M14(Z_TWS
M43P"Z+#%_A!S8##"B^9$OS=6,V5Z$!?A'9TRKPN 8::.]6GXU4-F4;H7*1%>
M&LR%Q?FT17*SPQ,<U!B1$D,LZJNBU^T_F91LDM*=0@+MSY_?F 0X631I'OVQ
M/W^.74B*UVU5F02V]@67_<8 VIL;H%O>CT!:B &PO[\(L0R^]SU[Q$I/(OOF
M\33;-7^"PS20/(^1PYEC<[HB5\1ERGT!"^2)$ZO9T36?K9L%YKA(0-LW:71.
MKN?U LAG/YR?"'F8,CDW:/.=15]B )79B5CJ=?M6=+J .= 09)^ Y(VJ?\U(
MH/-?= 9QVQ;^"W+S/.E_N^4#H4CX1@I7JK#QN91(WN#JTCQQ5#K;YSV87P2^
MEG-Y,'_UC;@DG3)57U)*\ *@I\#\I=,/?.\S'W"[/A)\^'IWCX9Q((<Q:B;L
MP_'\=RP6O)C&'(N9/]N'EA"!=28\TW9A[B>+XDVS-^.PSE^E8.&P-B;!N@!7
M-Z,(X[R44ANA%*VLLA=Q.'N!S:4N8I1WGUG$_#=<EKD3.GH+I@VWT1D'G<S1
MN>03EE.;V]1;ZIZ\>#ES"]/$(A;)V+5) ,_-$TL">(+4/)S_0+/I^,(2=H D
M$RL493# _H(1@&?D@<^4U1:>8X.50Y'Y9@][(;SX5DC*0WM.CQT>+.) X#46
M.I(I]!76X-W>?9VTS*,%+/,/)@4:@51/%YWRV:RZH_G5PXB!?]U2F1"7#N <
M+- .!_]D0OG?&6%>0+4%Q/JGT<R0)JJ@#KEZGX;Q(SH*0OE?5T S5&I,G>E=
M.K#Q@0I(Q,=H5X':]RD*+SZI]HY3Y09?2BDJCW2I"_V3X]YSJPELSCH\])_!
M/S*S9> +ES]B?]W,RBR1J/U"%C4M'%W[KX[;\KBDR+Z2PNBZ.B80)^$)/X).
MA94"?H07T>WD:LWA E^F0FNUV5,3:)MC<R ^#XV_>S+ .?$BVO2PSZV<5K<_
MHY)[>G< UCGW$4D^UCE_W84H$)E>!B@"$!A._"O0UIEHMSE:K6)"QOISZJ!6
M.YC93=,BTI5^F]GV=9NT=U)0GC_BG[-5XZXMH#[Z!$2JMAIQ!N2L\,VM^R/X
M-*(^<8>WQ:Q!78!H;H_[)1!-@:$%M&%0B3  D0I<3'F:]V3_@5KM>+Y [1A4
M8UFR3TF546CJ<S;Q&(,F926.G2(^ \SLWN@H,"-.GHJ\OK130ZT^?X9G-DPW
MDO>9L#2AOPQ)LYO03R%)P(BP;P.P"#-R$9X#:>Z3\Q"J2 ;,2D+S6S1C)#V6
M./(T@]<74#-G6A F86'V8CA$(^>@V#$/@*?T?5J1D>Z]6(+NK1\DI< -Q60R
MH,<.7U%O-5P+Y2URQ^0>_8[],]][U!@5!C*HV^G[KL0QO6Z_6ZGK5H6[CYZU
MI7_&3I/PL^CU[>0TJ9'55)X;2#T3/(1PB_=ZL;2<)Q2G>B=ZBU,OL_#+Z&L\
M$_1%6W!IT")X9K_1T\O?TFW/1E^.)GN7-9N>JT_G86,@@*LH_3/8^)-X)>$X
M\6^C;W''BM^A%<=S6\DWPJ^3LX??:51.1&_$@=6#"MB\N4&I:J/KG\2P1^/K
M7Q:'G#ULEUK/)W(T[,M#3NZ8,44Y*;9:/'+J.49.?=G(&3T+N,IL-/@JJ(LE
M-^^@6Q)_KW^Q )+'OBU,H>-VAB7@0>I5GDC4BE=SCTVLE7W@?1HF?VD^"F_K
M),HJS$+"QW>9<R:@?9<);D[8HZ" =:6 E<N C&:9;VS[QS'P5KB_V/NUV?OE
M\?U$WS4W)E+*F:O/X,S5E^;,37%#OV"QUV2Q-0X$3)'?4=#.VM!.SN1.8=BO
M@V&?9^E34-#:4=!ZR:!%-_7-,6E%G9A5VAJ>)[D.IDBDJ2EKV<\2TTQPG-H,
M;]ZK6Z<I&)[8@5=R?6K+=GM'*72\DM/FD][8FM_*9C]=%FOS-_[)]6\Z$4Q1
MWVAS*6#TVN[HTC=]\Y\IDKBY&Q\;O%D+W_!MST]8<Y7(65CKALWGFL)(SZ+0
MI9]+/M_;:?-);UV,])5O=F&DKY^1OC(B*(ST]3/25RX!"B-]'8STU6<A%!9I
M89%NQG'(#-U*-Y]T7]6BS3.Q%!;QFEC$>22BPJ)>$XLZC\136.2O;I&O/]DL
MH=O3YA-68<=G4_A:)L:]I!'8YI/N^MCQ.2.6PHY?1SL^)T14V/'K:,?GA'@*
M.WZ][/CU(IM%=]G;?'(JK/=X&U=X9[FPOM<G+V3EFUU8SVMB/;\&$136[YI8
MOZ\I 0KK=1WR0I:W[<I]J1U4JD<5K \:_E7H^W6(MH6[\1*G9?2=I9Q9'8=G
M5O!7GHHHCI[L'+_\9(=6O$R/$-S46/MB!P;A!\H(49U67:G]0OU(W.[D)I!F
MEWF\V9&<R#R_'.M)__V]\%5O=PO[' ;,3JCF)_"R4*?P?M@'$!*=,Q(P/(OX
M5],61$++-!(4C4[4$6^=>I>N;PH6RBL+9<2+"X%?4.N<ILQLP>T4C2_W3*3:
MR-7=T$4@M[%LY.Y%R,U7)?-1Y.[-@-R#Y1CA,7(/(^3FV,/1ZW@I<I?DX4QQ
M5.IQ!H*U"7-BJRJ7.N3HCA#Y56WI)D613?C9-55;OI&XT[,XR)F6><4,VH*<
MUIF<UC*S=IR<P#+]=F=RA\&8-Y(/A!MX]O"6]UWIY_DD!"UN;&&KZ4?1#7[Y
MW&(+@GF>8&X!=1ZU&KZ!D>4-C7\NI2M/72DY53Z,6_EM(!'-@H""L)XZBGNJ
MU7D.*2?44-&R/@VC/W^%65!K#6F1:8WV!!HV[G1NAA[R;YP2Z@4E- I*2*#A
M+5-";22!].O=O:06U,,XDED0RTL4R(QP42=.2BM-@S)Y0]XRV=8+LEVPMBO(
M=G5ZMR#;A:GF@FP73+8;3Y+%UL]C'_[)\-@[Q]&HM3<)A<,<4V "@^?+((Z8
MA0^D=N MD^:H#5B0YK+-OH(T9[3S"M)<MFE7D&8&:6X.V17;^T)[3>>!-DV3
MV\">/K<N./,#N0%)#;FSW"@Q=-).O&5BK1?$NG:V7$&LS]AT!;&NCW7WIHEU
MDPFQV/"GI%,@'8'+;CK6A7C$OS8@1'LC7<"1/[RQ 7NP,KP/1YFHGX9XX69$
M\DQ$P5LA KPH&/A<1FAZ8Q0P8?UO9?O?ZK9O^G9/4=K6&0"V1,OF9[SE;](A
M71-&M80=^&+ XW6=/YIV8(&J!\PHIJ<[#-?ML.S*#9=W72;Q:"]S@%&Y\23^
M5DE0>;XX4Y#A9I+A>J6Y/RL--R;"O1*B>[4H>9XE74%B^2.QG$DQO!TEA>GK
M:K%?P;7U;N^^%B0W%<D]B;U"RDU]$;H@P0TCP765@C#'?O3701C'ON(/G_EF
M%"H*R8+6 Y:^+YGI!\R^Y[*7B&-/6/%KBBS<FA>*+-K$)=!+7$BNH))7II)T
MU;/D?B\E\I66#_FMJ[.VS)0?E*Z2\JJH^L@XTG^%,N>ZW18FE]Y=WPTVH2K,
M+;?Q[/0&*')X#]Z:QZC4@O=IF/PE(8*R$/!J6DIOSHL8:^2=Q5LU$VDGB5&-
MQC=(0!.Q4%!1DHIJ$175E!F>'T&=0FYM!N36ENUXU+ B8+T6_U6(]W44[WIS
M7D@[J7>67*84ZTH6M+..M#-C%=8E%0I-5D*OU3:Z,G/N*B./UO&N+3V7X[@@
MA?4DA0P)<OQ2"9(DH!5VG?T$,M?GS(KQ^?GS:7Y)Q^+B_6?>8?8Y 9L@F"<6
MFC-ELZ*"@ 6!O J!O&9&Z!<J7D%"E*YC8 %?/)'"<')^MSQ4)Z.K&\\,?7[]
M;Y42;B28Z'^X8+\+&Q;P%HDA$P5OE1YNA??] NRM2WA3<L^_!1WT%HEB,AXV
MG3*>-P_BUJY1GNJ5FV<R68[M\!("Q3S?S/MLF3C>.!*<PYDIB/$-$>,:.UDO
M3>3,+X%&V7,/3%KCFC1SG061/-&DM6G[[L:(KV>%R,35OF:,=P7M3O-S7KM"
MY-2.THK^_L&][X*:8XYU+CI=GW-']3Z]=$Q<PH#C3=#\<P>NXHKU>((O7K+T
MUV&5<+-6YH,4U+#&U/":%YV?S*D/J>=,8)\@5WI-QPJ/HO-/*]-972^\93 -
M ,]UV)V,[L+X6\ ]FX*J"ZI>QZL[$^+*FWMG;!F4FC<%K3?][5P4S,^FU]?4
M*JOM'=3W]O8;!1D4QL^+C1]%/ ='!?&\91NCMJG5-Z(FW,K%QTOGK@,?UZ5^
M1D*]U):M7J8LMC)Z,E@0P<PNT/,'CH4PFIM.FT/INQL0JEQ#*DVBMJ#1I_RS
M0F%NH#\VI2 B$_JHGFL3>MVW?8TEPLNJ)1;6U=NQKM8R3O!".BVLJ\VVKM:+
M1J?IJ*;4[?YQ08TY/^IXF4!2VWZX7VQ[(1FB-"9,<?1NV)"U[$U.[!Q?YL8)
M@^?W-U$*8R,*WD^UVUF+WKB]GZ+[1J_G.HFD]^B7.YB.>\T;R=M<RHVY #"E
MHAC#RT(LUC$@3FWF 7O2/&D GD!_H;?FI>VW%E-<+C6O;S/C-:;>"<?#13;2
MZV<C+>^X.+N"UN@U[C]<&YCH3TXI]%9SP"7K<+KPOZEB;/)5=S+;7HJ@Y>CJ
M-?4L5U+Y:Y["'-\\Z7_[(AS1"WIOCX 76\!C&I@P._P6BY0I /!C"OMOESO6
ML6R-X@[V6'#'ZW%'$OL%=[P2=TPN7E,HD 47^RFTR ;S2:%*7IU/"GVR^O.,
MQ3C1XZIF,YEE0]WJE2BVG//+Y/*J7)K">ZN!ILE55\?0LOY\L*$D>L;;++ +
MS^ 9DAU#TWK(S8(K5LH5A1_P6EQ1F/^O;_Y?VK8 )%D ^YGP3#>(+/PWQ J9
M5OY$S!2DNFA2?39#Y?D2_X6%DVV4O[@50F'BO)!#UCAW9F%\5=A(K\97;]9(
M6F.^6E*6!V5V7?>Q[^);9*H-R?0X X(:,"SB&J=YXMG*2-KRZ%YOG%&WI&2/
M@DDV(>&C8)+EYWR\<4[9I+R/@EV6G_I1L,O&I'\4[+*4#) WPB&OG_-1T.]B
MCS#>,N&NYABCH-A5G&2\$3I>@ZCK6[;DUSCPNMP#C8*]<G^H4;#7 NRMT;OV
M%TS(/Y@=<"(3[S,?<+N1?PZ)EO5I&/WY*\S"I-D=TB+35/,$&E[)CEGZ!?Q:
MVO)NFB:W 4$@)"XX\T%XY)<*4 Y%1Z!W)G<88"E9&G'"6C=NJY^M-%RP_SJQ
M__J7(1ZGI$)\O(KX6&-2F5##OA UZR1JUJ/Q6$$3ZT03:^R]3*2D0OV\OOI9
M+U+)/EB8A#2L^WS0R&=WC3P0RBHC\Q.-T_O37WZ1G#NGL&.7CIE?T3"YVG_F
M$@N#="KE49!'H3#&B.*"6R Z[7OVB(6R 6=N+\<V16AIJG7 HIJ!WW5EFD@F
M+WGC-$;VGI,R?4L[/FG!F[[?H?\)2_\79[)>K1WD?Z=A,3>$FK1S.;;&M[>Y
MAV]@<P\W?7.K1S#!ZVSAW,@AV)<:8,,)\HBF4;LPB:@I[<+4.XMW&_8J57!G
M#N._XIR2H.7Q'P$L]WS -^&R[,B"QM-*,E?\:FZ$WH\7D<O(.XMW(Z8BDM#@
MO FDV64>;W; .>L5-+281"&<\[K=Q+O-'<)JPN*=@/%74ILCU+AXS?!"X570
MY1NFRS66K3$UH[J/_WJ&FC$=]+0K>#OJSG/=;@N3RX*<YTSZO!>^#;1\Z5AB
M(*R V7$"Z!,(?TUJ1G)Y*34GWYF3F@-'*%+^>G<V2G<]E:Q[(CQWKUX[? ^/
MA$.%/Z7&Q[&R![_K,LF]2>/KQ=,S,TX H-UD3T*$,(Y0?/,JZ.$IE#M.9].O
M?12\C#$3,YYQQ^T!"3X]Y[/X&)TT8]CPY^3RGT<C2'O^]"[UX<\9]^A>,DLX
MG3,VG$@)@2_?3T=C'\7C>XE=(H'UO:[H&VT0Q;>\[8%09J8/ N_X\'C+\%W]
MG>OZCNMSD(/56GWKW91#'-7F'Z(Q_Q#[V4/4:],/<3CG$+7J<3USB%IUWTA^
MK!U,/V(V:N89<6_A(V;C?IX1#Q8^8O;FSC/BT<)'S&;&V4>L5:L+'W'1%%ZK
M+IH>:]4)U/.2(2:0RTN&F$ ?+QEB D&\8(C:! IXR1#9 OY%0TR08B\98H*0
MB89X1V-X+CACW(-OZ(LN9Q8:J1_?@9(_*95*'_N&YP]M\ /:8.F]-VK5OF_<
M@X'L&5?\P;AU>\PIJR_*!O:P;7\P>DQVA//>P$>K6R<?O3YSDJ-4VJPG[.'[
MY\:A9SWQ-U?3;IW\]W_6#JH?/K[# 4\^ONN?K!E\:<C^HU(Q+@2WK??&;6#S
MR@WK<*-2.?D(J VG>Q"6W\77JS]MI7YHN1(VHN*[_??&)YN9WXT]@-9S;6&E
M)^[['PS]<,OU?;<7/E_;W0_?B#&'NZK_G0#O70J^-4/J,C;]@X%.2X79H@-?
MF1QKA2P(YB,BA-;)UZO+^_.STMU]\_[\[N.[UDGN5G!W?OKU]O+^\ORNU+PZ
M,\[_>?IK\^J7<^/T^LN7R[N[R^NK7"VKKI?U)P.)Z71\URF7SG9/=XUZ=7_O
M.%=+R3-?7%S??BFI$=&!>[0>OQU7S[YQBXM*Y<PUZ:HKAGB^F7CBA5[-MV_X
M5PW^^?;WWZ>G?_]^*/XU^*,.PX'&<ER'_&-A&CH6 3IO- _.=^-SVRT595-.
M#+I,AL,PSH4)9<GYMTYJU<IOI!7C.6(:*<AE%.:_ L\7[>$B@=[^PN3WTK7#
M=]97Z6<AUL<D(]A$VX9O39 V/V^!78F?^\RRPL\O7D/"6HB4ONG:-NM[ $[X
M%P5"/OKRI>/K ,I'WWHY9 ,N?6$R.Z0%L%LRB2-:0W6WOB^<)>Z#;^5Y.7HV
M7S+':[L2C+J@W^?29+B]H]+S>$1Z-ATG8/8M[[O2SY:BCW=_-?>^_./B]+$U
MLQ1%L)C_\Y9X]-^W7-?FS/%EP$?$:R-+O"8!Q(T[/MP[^#!1TBYC0Y6IO&3Y
M]>0F-J^NOC8_TXINSV^N;^^-FZ^W=U^;5_?&_;4!MM<]&%A&K6%<WQJU_6UK
MQ[B^,.Y_/3=BLRPVR9JG]_AS[;BQE\07_$LJ7X\$TDFAI98!\X4K2WZ7&VWA
M 8490\ZDP1V+6\8HHYZ/,*K*<CM7IRW9G"HMV[[^^Z#QS]O9[9TDIUIXA0;>
MZUILB)!R9X1A][(8-@7HN  *S;?30,* _@4A G/UGEQ:[?.7O__ZU/O]]-Y:
M^-+&EK6?7-8D.+=.SKBIS@ QRRI3'I7'=O5T9%?C82_@&V^"'5L]=/_]]>[B
MW^<+LF,/LO9M!)0M2B*;*&B?EK^YX,4\R@]7Y@O>PN"=9"'FU[9=!S/V8#0(
M@&\)#'$_9<I>' ;?__S^Z_'GX5^+-&7;S/9&;=G#S%#!")3:GMU[:_;L_6WS
MZNX2C=;%V[1&8=2^EE'K1^1MJ/0?.FHROJ7^!S)DY)M\+3:/&W3J]GK"PRRU
M4EN [G4"M%O?CUFG%UJJJFNR%_#H5:#27[.DZ6>K^N^_VN?-J]\69)8>)67F
M* R81%BK[-7VCHX*Z_/U0O*IP6@VBYNNI--ED/'@RDI;.!D:.TU;M[PC/)07
M_A7L>#9]_5+=Z_SY(&M_. NBK^-Q^DK#L75RUPU\W^:EFRX#-6_R@#2G9_SJ
MVFB9 FXN'7/W.0+,6[Q_^_P1<%1"Y!ANVY 14@SF&5Z?FYBH:QD"]M/W#!-P
M P L.,Q>>")S&G3C'LK(47]K]*A?86FZ.<<W)UKGWO%/"TV,:(W)CO.4[, +
MV;*O90[=U#[%"N]R>.I:$T3)OZ_9O??KX<&]LY#P4<7C)B9+^[POW0&RS6@,
MJ5X=ES5/PHWA))L],,QN??X4<2Y_0--V1!=$$4_N<'VA&_R\@[HQA%M/$>X]
M>[S4UQY,(H*GK"N[T6)__?/TP#EB"]%^]=HX14X :.ODJ%[9KQX=']4/IJ3&
MR-%:ICR;9],7N='$NP2<*PT7/!\)_K,4GB5,<G[<]F(8=:4*<8TAW;[<O=V]
MVR7PSGM]VQUR^6:)3R2U2$2$LL,<\3=]EX<=S0_MI>4C0:F$Y$X19YH&9C"
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MM2ZRB?SL7P>_7_PN?Q&WA\LF\HPK0DD8"P7SVD _47T-+WRS3@>H&$VSGKH
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MQ5S2<(Y!+4AJ/4'-CU@,CVBHF).R\=![19'64ZU0F&GROJ\R$92X4^*/6Z'
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MH;!V&Z^(ZH+ON\9%=B^6=!^6$M"N:J22'(IB-;K+3=J#B7I%L)Z+-3YUGQ/
MD8>-:%R8P!9>W,D&YL'>0QZZ-FUAP_>8?#;2YZ>$JXI:^)RZ/5TRWMC&YW17
MC+OST["#T2[Z/+B(N*]-6.8>USE@6'@>J$JT06A3GQY:D (O;.OBTD7;OU2A
M9]7CI?1$DPRD$,"5ZKR!>QOVNMDUKMS)]&)@KR:C$S )@*CB+SJE)&'_[!I
MEH8F2\F95<)&,$:J>Q.U^3$LUPQT.QS<U0?$+S7!,7G8/R;]FCI:2+Q)^X@O
M=MD@W!+FP293:V(<%X:#A>(VE6B;SD_+\::1[PFK<[07R_QD<Y]T_QUUKBLD
M3.Q1E1NU/4]V\7G0RU)$M[L!$N>U1&?]</>(.JHM;"5?'9M['A$%=<%Y]!7_
M/PAD"74!R5-TJEK3:,[%+TY5[&*TU<U=-_!]FQLW70:L,-9*:*QG3N!%37>0
MN,*&.8$,G\MF F(29-_T?"8/R*SSC%]=VU(R[-(Q5T%U.>^9IT9_HBMIHVA
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M*540I%99(C</O%I% Y+GS2[.I7  EBQE7._3<1<8I"\L]S&0 HPS7C;.B=2
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M0&7>PD0ZP!O1!YAD0%&4"QQ;9M+U7=-5J7AAY0"%H;IQ!R1M\TH3$' 77DY
M2:1V/[ZM=I?P/YMTZ>),7;JX35RZ(#  /S<LF9]V11<OSE(7+_X,+U[0S8JO
MR;L6OR0Q^B7"Z&Y8Z.#9ZS<$Q>B=DR@I$6]0+.N>C#%R3X8@><V[,LFP@:*1
MU[PO U KC"SRSLQRC['6W:.8YGABOSB>6.3QQ'YQ/+%VQQ.%PUDXG(7#^3*'
M$\W%>]$7X#().W%+>L0%972-/VEO)^S.A(F/!@4/[V2/&?J4=$(^ $M=8PXM
M1H;_X'TOS%K@MDYD439W"%EJ8KHC2@OLN*F66DGS+70:)AA%"%(;C3=?^YO1
M+3D"-V6%) S_47\8+?46^IJJOP.Z6^N9[;6>W+R>4+WIM,#UW))"SC\OY\/J
M%6HQL20'09Z.+T1W^%.'.'&8D:*.Z<.<\H3CZ/@E?>J 8AOOD +(.(*6\7J4
M2$JJ6C.]P&<Z'LA\]BA8Q><V<SH"I;(GF+'=O/^R,Y;9O6M\]90+JTML4(1$
M!53();>$9^(5< R>J *=CADIG# A ) ^6O\#M2+,B'4],<T2OS)9G\P_/.9.
M+SMU?S!]G2],MH,'4ZGEI-$0V%#A:-1A?5"/RX%65N'-U_B.K;I0J/QWO"'I
M3<AFR*P)5(B9O$-5Z*.UVY)"'TVECZB&TJSZR&:>!^9W"T2<K>N?I26VKI(0
M_AI5 _<,4$$^'I=8G)D<($5#'M\]V"5@HNI.:+Y'5R+#TMV=T,_(RJ]70AQK
M9U"YC:BR61QD'DTGHXR*D8ONR@F37-WGQ-.YL,@:C<P]OQRUB(.O/#S1PI_<
MN)R-T>-8.EQX/5W$1H(+127 ?75$T..@1+&4FSDV/1X)40'SL*0_\S!7+.,4
M0B&76S'*F-+=3UH+&J!,QRPN=!2>V7%U]D@(%%'U+%+(OO$+=_%H"VO+?W6P
M]HJG.XV&1S>9;>S;X2ZPZ,:$=NS&;KVF/% 5HB9'CWQ1#%__" "B$,=X<H1G
M252H@$YHPC3!L2.:RZNS"E6P4Z71%62T<'(8DZ<6%M&"ZG E^4#PA_#T0)?
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MC!F+?$6!N3"S:*QN5Q);)94WIRM@MA'*[WQH] 6(,NF]-[9K5.Y7EZH,Z_K
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M)W5>G9Y>*>",[2NF<XCPEI#D79P;2P@K2^2*^P^N_+Y#LCXN#X>U[L$G[02
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M 1&,@:5L#_953M4 +Y9HGD+"P?(#M:-X#5JB-U5ZLV?<4G'_<BPE3UW;YEA
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M%[S/.B26B72S"1VD;1_CNMS[ )0J>0>%L2N'!G<&0KI M+ *6A*NPK%0*'2
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M,"4N'& E8]KM]1 +2;AQ\HADB.2RZ4H+\I+-@^\@=QW!RE2/'6#LT7JZ#&@
M2 UHO VO=P+X3O?K0U$-#GH/?G(0U?!J6[2DZPGXIL=[*+35F\)IHTC'_5/+
MY$X740-0">\[ FNAY';[@,D2 P!QB1'V'KK"[))H8_ X1R9!Q> %MA_9[",H
M>^!@@#CH>O5Z 1@>WA"LQEYH\IM#0#XX&6:2)5$6HAHAN>W*TD,7=DOI@Y9
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M('#B6"4LY;^.R]5JM5*KXW]*S#1=)5J CG'DW_C0N 9MA:-\!A7&TX&Y[5/
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M/D[BOQ=UF0N[I@-:O=0C[:*JBK'L0_[Z$P>C^K:4WO\JOK3T.?R-\S94+%V
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M>5K1]NH+"_<PZ,L<?!AM;2;ZOAIHN[C-Q"NL*(R;AG DBSW(XNOW8(O#G-R
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M72RK2 _LK(Q'BZ*8L$2+^S'Y(<NTJCB:I<BM&A>KC=ZT8ZM(Y$K'\[A@AL"
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MWA< /VH!\+PO /8%P+T8M$^'_OG<B<+(_;MY$_N,WWT-^A?R.)N$@LB,.)>
M)VA[8G_+++:]1GA,S$(]*]B'%*<)YSXY4.Q\1I<M7P2QXT_9U.!IOWXS+RCH
MN:P66(,_%I7 Z^)?0/]<%3)VNNJ/+RZ>T_#FV2B#9D^U1$EM62PH<$-KFQ*_
MB9>EPK/D2K>RW9']0677++EJWE/#8+>?]Q6>:W=/!@]P9C71MMHRX!.R^)F^
MVI_)(363Z'K-/U;Z!NGJ9RF><N.H#N@FB!%WX,<1\,K-?1QKQQ?&T+=&OB6Y
M!C-I*B5&6IG$PYGI5!!D>9@9<P&S?0('.I/NCUT<!Y@3(1NW;K$NR.V7&*7J
M)/(DMZ;64>/Y.4;I#MS(1\R-[(K(;=F%P$&6QQ$<9ZCEU?9R$TA%4GR\@!O.
MT@V"+9V5Q>UZGB@FE"TM6B)O8'C5W#9L[([^G-]A8@?1VS!2:KU;>P($W*#!
MD@Q'R7E\KVBJR(+P535J_ST]^LY[/SQZ])XA^^-!@3_Q.AW5V<(#;//8=V5;
M>17.,,(6:,*F?6;"BEY>3=Y8X QRI1IDVQ0/?V3_T;Z J]PM4^D@AS"<JKB7
M3&XC]*66MM2[#S@KD&->FV<]ZGW?1W7?%KE?*/O;'O&)5TJQW=D_,<LB%\HR
MY:(4MC]41-+Q':W121"*%KFD3R<&_B%Y?I*Z=6T_%;F66J 6EU9&H=RR#@_Y
M_8N+?AGO_:AZ>_?@IN1+M7<(,:4O7.'+K4JMM"0JW$'[R&'BX*GE!1!5=<E1
MK .SH S'P1[7VUQ^@.-]A[@J-#WH+*MP)ZIY+<K NI8=ET8*0DH^.3TI V.J
MH#5,0E]H;SE4=O.Q^JVQ]Z/J;>B#FY(OU8;>SD6I%>-30DHGC2X,-FRYI* N
M&(D 3M"&QC2!-2&*HMO+[)?HWH^JMV4/;DJ^5%OF(L\Q<.KLV04FS!NA50%^
MKE5:IDM$M )"ZJCBMNL?[J=>9BD!>'U%T;&6>>R_A!'5I.1A"H1J710+[8S3
M)&-O$1_80N\M8K]0/E.+"$S[Q#";VJ06V*#H,J'HK2DZRU\2<AGVBVSO1]5;
MHP<W)5^Z-5K3UQ8J$+=BM1,!K*,M:!OH4?E>D;Z"\#F,JK=(#VY*OE2+U)']
MLK(3W,$6*D"Y=A4M*?AD?0.QEZ :(;8+18??@5#K7K$?C=BM1XGU*+$O;7];
MC\-)/><*\F0XJX)D5\5:=)::<F_:#^H]DD3EXAFFFU7K,AMQWW&LDG "K0AZ
M#SV8E <1 $H==,(:BOZTVOM1]6[-@YN2+]7L62"8ZVO*8^BOI.RSK.:;*B.'
M1-O;5_17H>EPC"$C,I/3C#GE)LLLS]B^V9117=W1O-&OSKT?56_&'MR4?*EF
MS-7S%,]J-3 #A;6E)W-0>L\=WIR(['CFAW8#7;L="!P%QKJ*W2(^E>B5+,'Y
M!%*'HL K5.(HYF@):HJC8I+A6;7G7X/&)'::O?@ EUJKB(D.9;&);S*.K/SH
M;=L#-RTP/U? P"_J)TJ08SO$?L#87H87B*^<&MT!/-V3XV?C'UY>\7\.GQV&
MFG;]7MW[4?5&_<%-R9=JU#N:%'Z+PFLCK<9I.!>7]\MN[T?5VZ<'-R6]?7+V
MR8 C7IO=086U6+"<'%-1K0P+_3(55K^^]GY4O2%Z<%/2&R)GB-*;(ILTXE\T
MD2M!7SDU)5-MD6_D_CQ%K"<(U/$BS9:]C=K_4?4VZL%-R9=JHSS2GH>XF]0)
M+*#IU-CF<RG&LD)\:LL/RGBZ-!/.RR$HK',R?,_P4;\8]WU4O=5Z<%/RQ5HM
M@6,40A \L?U"2++_F\(Z.%MDPJ90+]]MT;RZEP6J=DO8]L*<]T#B^3+-'0=T
M.BINS-$B8VZ^IOI;B=KVIE#<#Q9 62P&\<5X7'#S/20*/$\@\P.(\-LV4>#(
M(P4MYUVDG'<-AGBF*MQ-2A=?@*U0^!!%5,T.%AQ_S&)H_S#)JG%=2?M9ETX=
MZ[5%(O+6INMK9EAWL[VHWOARE6Y?PZ1E'G+I.RT7\*J7("1G+1H&:Z<A*M+1
M8XX#HD!'SQTJQ+&"'KUF5>4M1EP,Z^#^0[O*'?1_4=<3@AH29#6T$C/P,S 5
MU\0LTHV\T@ESW%1%4W]/IGR$\AN%6%*0FZ?E$BH)OR@S1!HOLF46$,_GLXCF
M1WH)F0.=Z2)54B<80%->1])+*K'C2"L]65AS%;H7R*3L$(C7BRE/?03VY,H8
M7J7*NB@UQDV<\Q).Q_/,W(A@L2T\LMU;ZZSW!+/W2S#+@, M3EFLMG1LZK5U
MB[&'$A66TEY2$0X8>W&"K=9\-4$='*Z)%3/96L2Q7<1,D2\6 M80%"H&\BCI
MNKE_FQJ4@^B:_I_NCO.T^11V?X;8Z<S*?8(I=P6NTI2#!.;"7:?OK A(( [:
MD#UJ:83^8LU(F[<7%JCC/,]8P1NAS+;D!TQ'6'J"4?>LLEL;,=SAEMPUZB)W
ME9-#T <AU(I&R0H-V,XM,<V ]K\I:65I:NPLX@)EQHO"V2"\#<B]A-PU+%V^
M0_F 'KBDI<78 T?CM4OU<UHRUSO>,]T5U+M&221DS6;RDG/:$?3CJ$Q7V03?
MQ6PRJRUXSVF#(+&58?9!F:P4N=6NA605W;TQ9H9?/9$G/-GV6-XVQ6(Q(\#C
M4JQM"/EX6SPM5(:"/G<B8"?'PQ,AS"6OL5[6,CD3@U-QS22W'>IC\2U]\-7P
MW&MC\'A%K"84JX@ZUU#3L,?;AGT0?T>/B HI#@PUZPU3;E^D?)]7"Q\$Q3KT
M9"IZES2=T=9/L=%D=J%.E!637G3B#XE./.I%)SZJZ,2C7G2B%YW8BT%+O+JM
M)I"3]65:^)""7/I-]/SJO?'[]<:=-P&/R:LF;I$,<MZZKFS0BF_S3T,X*<]C
M,PM0-=PR_MF6ZQ)YO51$U1^X8B.O\+H9O#M>?OM=ZQ0)JWW5I8(5J;NZ%6I[
M6820(4==Q#N%"8*T1A><5N-;>"86($O.V=$B&\,79C=\S-QD37<F</;#<#F0
MK+1/ZSK);5K&3<8=SE6TZUUJ5-U^I8YXW+Z&HFQ_-:R,0)3#SD)+7"!0A>[0
M&6C.5B\TT+>0]BVD'W^=6LO/ VQ(M;B3( SK(?&JVYYE7W;M^R0V&=O!"9FS
M,=P -D"2. Z:SF^,DH91P#[/5CU^8_]'U5="']R4?*G&S50X<K-J+DBSL 6)
M6Z V^K>P<:AACB1WS(@T2=S9'B=RV+CB,*%8W+8W+<PL%4%5VZ34O'(QY6&,
MZL4[R5%K?A=-2IP^#:1ZM:%+!\N>HXRX7_=[/ZK>0#ZX*?E2#:24H-7WVY;Y
MY%"/#**YD5J/_X:*GVC1XU]DX*I)-A9>D%L6(K@UJJLME@PU[IV]3^(K\C!Z
M?W%?5GEO#ON%\IF9PT5:YV/O+#:3@KMS7$BN"7R C-Y.5(^T> +;T&W7X%_F
MINQ-VOZ/JC=I#VY*OE23%GAX8^!=4  5/(Y&KCZ]GRU'=5E)-Y56$L).K$TK
M/S_#Y7+^MGS8K\>]'U5ON![<E'RIADMQ7CP^#1\#X1.K$1]4:MFYZI?6WH^J
MMT$/;DJ^5!ODZ@>)FB'-QRL.?&U;4>YDS>C[.S^'4?56Z<%-R9=JE=+U&N2&
M8I/FF38^E89-$W=X3C,(P)FR*O+<](V;?\:@+_/(-Z^,S#A58F& \/)Z:<JB
MKG;VFJ1558PSADD*SZ6%XG0T%H4A.=>)NXLLD>V'T"X@EX1LH'M\UQS&Z;7_
M"B:G6] 8&,'6Q(@F5ENBSFVGQ:H$S8'0+:^S)5>_Z=I+M,U$W-VX"9A,6YG5
M!BQ8L9ZN7XCQA-K'F8]+@WXP;7J5?I-4BE#2+#(Q$ ;CYJ*R(?X:>>5$;IWD
M'IY28)%%:2!/W5WN2OCQ3$G?6M)"J2>9H#X5+IOYGB5N')T7E6]L])AH#^,<
M1$%OBP5C=0EOA./QS*@34XW+; 0\+?J"DU9+I;0"<>-GT' S+JKUUB*+)/EM
MV]#"W+=*@50>&-NWQ]P;EO[MW$0:_P8M31"76G'98*?49CQ*T4VMN.><5L>"
M->+3%7>7Q<MBPF0 KM//7MX!@+%+=6_J;HQ:".,R%O"RP%NZD-H]JO_^!@U+
M$CD>4;0/5EJ.TL;.='N&DLZ91Q.H-,LU8=\.EX\EX XC:0ZUC?Q5C790A@$P
M C3\*EIK:?56!9EO4#JSQ3/KC%<RS))HC.!WMUEE-.-C.0&,)H(&\=MY9R'.
M&EI8>C6?:%9G8@2[&7)ZG1.SH!O"D))!94L>;@Q^?70.T@4/UHQE\(:;WFA>
M"%)+*GYS>E+([WK,1%$& KK\LLITDO&_HLHPCX!T\Q\.XI>RL:4GE$PVSEH^
M\4-SG>73A31\%=+7[K)@+"UW2V>/2=<X)VAMX.VC3[,E@Q"D\B.;RG<> 5^0
MK<36B]DR#D$[Y;C(;S)Q)3IXC=JWU2(!\[SQ#2.56^#SEWV&X@:']32]*>0D
M;I4DBC+9U=VLDRW]N'7E7FSS7>WPC)AO0%H48F8F6!8P9R$[1=]]T'<?]-T'
MGT "@6.#D%PM4,W$7@]@%)V$*$Y%\Q.KR^VEP_&;>K4?][W:'[57^W'?J_W@
M>K7[H[4_6K^XH]64R\J>K$Q+Y@2G+1<IL]B4BN&6<";X4FE<\-B7)?9^5'W]
MZL%-R9=JF<"4O-XXE+4!Y6(ZWNR.T"U]HZ1U8-BR7+,KY(*:Q89S)IHBLKEZ
M1^CU_8N+?EGN_:AZ^_7@IN1+M5^K$NR0QK+"PX958!Q5F\.^UH3^78&-=6*4
M$'Z[JMMKS#ZP)=C;JGZA?&:VZC8M\RR?58X27HJ!C&'<Q(MT9!:^1TW*)^HS
M>2JK#B!$C[/>_U'U5NK!3<F7:J50239YUG"I&-G%)'&>.-HQX/=^TT-::+U%
MZA?*9V:1E"<^K$P[1$ULR/2(-2(S-"O37G;P,QA5;WP>W)1\J<8GO4FSA5+?
MN@J>[=</VNX[$79-U%R_WO9^5+UA>G!3\J4:IE69C5MX/=^ WQ"V22MMJ1%I
MGW2Q)J.52L."0ROWK;&?Q:AZ _7@IN1+-5"=GE-@>[PV<T,9H=&OL4/AN;1\
MEF+1V(KUG;5_PJ"=Q SW;6A#9T,KS^M*Q-,L3_.QJIPQ!I8;YNY2WMRU +8(
M 8,O1D$>,D[C*:U"=,WY6[&@:6Z04TC+#5UWE4$X]'9NT)%D)M*;%"CU,GQ/
M5#W)T5\L$FUZI>4Z-G'-?32L[IF()%Y";X)&8B(TTRA"IC'$9L^P5':\VI[V
MP+;0];1=BG+=-_'=YZ"OT5(5M<12@]4-YVJQ\.T2(JM4B=3.R-!ZFG KEHHJ
M2O>=<2W;=RD[X((_OKAX'E=+W&)9+"!3::+M=KE4-8;I.KSC.MH*WQ2K;%*\
MK\MLDN5&NKCMLL>*EQ6,1>I'OC1K$50$+'54R\KDQD/S/JM8>+9:%^-W\V)!
M.YE>(MH,#0TUK5P_._FH-[STR=2C\UEV[N75:_N$%3V44A?;Q[C^]O*-W#5%
M<S/T=E 8E3[X#E%:Z!AR1_JD87?\9.R6V\$V%^PMMWIK2:-S1K::O@W[TZQ$
M>H<0L'Q/M[5T?0;*2M+E?1?6SC60FHET_[56"0LAL?G0MLCH3@$@[1T<SPMN
MA2_HJZ4H@\AEN9FS4D50LMMT&54E%EX#T]VNWM0J"6U;1+.$0<"NARO?-NLW
M=H!E,! SC9]L'PH5OX;$ZD^6HFAENR"Y<02N08'MD:.Z'O"ZTAPDT;(A \!X
M(54?\,NWV>A4T5^MZ)07U&IKM+8D4F52ZMSW_T_TW=$$1&F95?2+;Y6* FNP
MJ-<L?ZJ3REVMX60KS0":7E6XUM%4A$+B(&$H0/VPB0UMTF6J! :I\"$)ZT-P
M^D6BZ+N;Z6"7[O4=PENM97O7BK14<3V'P?T(S34LJ3:#C_D N!4>@^Q&$"F8
M8=CI5,VJ*K)^=38XMKJR=(/%HKB%$>6:,05RV(:T"KW!3QI\S)&[0V[6_M:T
MH+XZ'3RRUZ4=OD#3K\/EV?/&'5G.MB=BG+07.A",9].F!XIWK")[+KUD8W5R
M?'+.=Z&]%_JI]C99/JTK*Z ;$'G8$P@G)TO9&O.NX>>JEJ_>+5K5HT4VQCZP
MYR'\Y#73ZD_,:.T=XT"SSCVA;2*W8T^5RRQXQR*O/*-[-*T=KC8KT<@>R59V
MA^HU+NK]<1P*]%+KQ9K5Z<EAMJ0IS2,^6ZZ**K-6@,<.(MN<>^7EB%RE&SF<
MZ)EG:G1I')&%+]%8K38!+T+<6A&:,,(<$S:$OK>UI_&3]CNW<^;X#VS?NMAR
M/H<R]U+"%Y8#%VI?F/'\+W:K6+'K8'5A@BM'>[DMO>=4S2.<0CU!RQ_2+W[2
M]\1^U)[8)WU/[(/KB?VLMO1'&S1%J9%:5'_R<X:)*Q:>)@3:7IMX6[:T9PK9
M>>^^G;EO9_Z?MS//!1I:C<G3201X19Y:HCZDS<]60E9HDP,VGO9D4!^,(^^0
M,A9_5G,+/)J=F37)*_0UJ[T?55_<?'!3\J6;0.;)0])XFPT)M4U5Y?N@5/V=
M^LV<YMQ*. 9^CAAC3J4C2])0LJ* 5M*X4V5674AFLYE(3OS/.PIQG+@&0=Q"
M,HJ+@ LJL?E1URPP08, 5PS4PG\@0XC >51G"\Z9(#]>KHI2"%.G94K7JL?\
M8B0LYUB<(GP*P9']?&>4#=6_;AZ(E2[\'*FH>I?P(5G WB5D::M:)$,5[\'%
M&"O8T!)[WI&L3$+Z6IL%3<LRS6<:[UFJ',U;PK-#81[F5Y*DY(7*5_LC?.]'
MU?MZ#VY*OE3;9GV]O%Z.C'A"XWF*2@K]@.XVKCS5A"M([*Z^J^<E!/^<SNI7
MX=Z/JC=7#VY*OE1S189(\V%B@1:9=<J<6[5(;ZLZ6U>BWRY5[+"!P"$0\S'4
M+&;DMU&86_=^U?Z/JC=4#VY*OE1#9?TJIR>DX&OT*(FL5BBF5;W+%HM02NL3
MIW;Z+$Z?Q?E2=V0WRG=D)$.K>#;N*>Q5?C^#4?4^P8.;DMX"P0)E^4VQ4$2R
MM%((ICA;\/]3N(*RE92A;(*9_S$Q4R,@7*:ORM&IQ3T(*70.X_$BS98A4HB"
MI+7"5>76KIK5PN9SHME_N>^:_BQ&U1O !S<E7[H!7+,:4^(TF&"+I'N'S9!J
M_W%W35ELT@4##;AYP@M%N@J[)X9HM]M\/E7Q!S_H"U<<B*2!()3QDUYY"@BY
M"_G6:'/)W"P3[E+D0B<W3# 8).A-+N*Z"GJ3!_%E0% D-W)M<NXN_*L(*!4L
M-  Z1FF55:Z]8N35>>F[/8ZV#[?[</OCKU/A#.#A-7@#X@9O0$??;-(&M_K4
M?J-_TT/0VLU*'=*;&,9OZ=7LW9B]'U7O[SZX*>EMX%TV4.DU.DD& C/WC'[5
M+[I]'U5OG1[<E/36Z4/6R:%=+36+A.@"?;6(^G&Z$BP&!^L.Y.K=--<2/S(!
M0Y5P='BV*W'5.EO/M]VV/M;_$P8MO&AOT@QPYJB#IX!I>)C\)61;:+!=-*D7
M+'-"B]*"\S]*NR9$9"549.@/U=P21<B%H[49S_-B4<QT\74NE9Y;[![96.XB
MLO!T'[3U1ZJQ"+NBU5<8EC:=B&792MJT(G=0A-!UHG2QR.B;:JX\##]$WP_B
MMT)@1F^%&5:4BZND-6[N>@#\!K808_>\)R%C# _6,X$ET8;7^&U."W^>K9CJ
M$<M?6%=&NF4L(Q:N+^DQO$[+4[7(Z%83?6G6T%(D36_(\)-*+JU-/,)WEFT3
MI?0ZPDW(Y%BX 1O=,3]0EF/PR@-VRZ2 GD>%O@HZ)O1L9>^1A=VF1M$^5OQ.
M:UVQDCIYJI0;$SF2%4\'P\>1M0'"UQ/T7O HPUG!,),/_$C1R'A?L@:$97.Q
M,$P>!8(SLCOT7;4KS-@6<A?2DMDF>)&G\V\Z6ZY2-6/!O?]_]MZUR6TCV1;]
MCE_!.'?'#2D"ZB/)GM?V_:*1[;'FC+=U)<V>SR )=F,$ AR Z!;GUY_,E9E5
M60#8DO=HVMT6(O9#9I- /;*R\KF6]O*.D5]V<R*FX5,3L-M$>_4IHBW5#0!O
M%^#D,@9"K=W,:=7KHA[X\LP2];KZN'H-<#RVO'T,[0Y-A*Q!<'8!C?E70&/^
ML(#&?%;0F#\LH#$+:,R#&+18WG^-ZI2AS_YWRUB,O0C79=VN88&S5R;U(73[
MM'M! U.4,%\;<KQBM$Q8ZX&4L6TN6VFV;G8UF^7K\GC#L*G\Q[^^[YC:$<]^
M,_1]562AE$1_]_*G_W[U[9-G?Z"#0"8$O=LPA05KC";7DCEOU+6,4J9G+ES<
M=DOFKA\RC%\+9P6-@P$;@\.PV/AW.&@R&#,5-Y&QDY<KL@YIMZ3W/VRAB"4]
M\XJ,/*Z,[BKIPJ"1,O#1BJQ$VDG83=IMWPT'-7C88E7[4PG75=ZR3Y13:VXC
MFX^L(\X<PX,5W-^/R&^<&!B8V=;;5N +O"JW:I S%#Q>H5-W$/'LM'!6J^2R
M+TC\L"_A*.RJ+2]!^H5P9B^[]N9XE0=K&W\=FG)_J%NQMSO-7KDO9!4MAW@'
M70!@"("JO+1K!H4,+V'5@5$*=O+LR=(#S-G\D5L1U<9E24Z-/ZA]IAN5BDGP
M;/3CB7R,4!&YZ .>P2W2$<S9.:W"M0 #+%3X4]X67@T'^N/-%4D 0$)K6H3O
M6PY4%(PFP0N[>O[TZ>_S^0%O6(1Z4Y\?E^*L4E!F]2.=N.C<P^)8^&LBC#@\
M^L:>#G>UHRN>OCAZJ]]P>NM?+]Y>X',XG.)QD[?A5CR1F1'+B@[[KTW%^_WV
M*%_!@D='D*MYFF,-EZ?F%$:/PHR>3R0]X%06'5YDWP]BFJ40G?&)T?62DLE'
M\1CR+0%_2/[TV(*7[C#FZA;=[A8">%CV(#-G^H9],O',X+_C'A7W7G=N)**3
MQ5E]7VYQ&-Z4=-]=E]@T/%$]>T"#7L(7YD_S$ C(Y,R*DWQ@*587DK:3U2#.
M;EBZN)Z]+)U&$W03Z0GE1K#<*\9Q&0YUA+66Y7(T7_TAUI5F3ISHP3,Z/'J0
M5\9WP3K#4+=U%_EQ0=,D2H@6X:ID+[-LQ!!AI!,Z3^_9006H+J-)SWO49P,S
M*J@2,):@1L##_2K0)= PW]*S:%CL2=7E:?7'HGF?&X9]WP\@>F 86?E%QMMW
M($=*Z!,D,+"OMK@020'2KWO95VX\/+0<1:J /U]T3T0,Z7)YPNZP+E5O^.SK
MJ@W>-2_UEF[J[A2?A6-8'0!T:_$17HUKVBL@ @+BNR*EI\?[FO8??X"(U7T[
M#T'K=#MPD#D6Q$&WS1CM.V@.T7Y94%1=&>]PWL&S:D_!E'6722C))0DAO\NR
M/;2<-4#!!T<P;$@(KAUI_G;?[_GA8+70"S^S"]]=\'KOTUW6T"%<=P/_X/G7
M.4O \YPY,X:Z?L)#< ^D52MZ'9 9#G2KR6-IG[JV/?1T^UT6=.)>U(RJK-$_
MMB6.5[CW3503XV0ZZ 3E_,"*9P/;/5>X?OM6$T;"PE=+[Y@:]NY*\5!)9ZX#
MF!S[?<M*4;:8BVRB@1;C]GJT'5R\ LB3V03PY/#:"SHY8L?3?&6=_M__Y_?/
MG_WNFSXK-$0&[: #[TE]1&G3D&79:&VG=-_0I5%%<V)TV;S@<T'6;"'K]-W
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M)==T3,(EP*!0N(3&NI;EK?+,;JMK0V99@K)W6W@!JZMI'=Z-R(++"= 6WD9
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M'NWM2 PN-0,@$9_0H7#N)>&3'M66T_3SV342EI)8N&6TT33\O>OY&AJE(V_
M.6I2(1%7]3O8D)SSLQ7V95)![SK$\OG^_848;P'T6  ]_GURVI27B D8E@8G
M OC,(5J5W#&(<4TQ/*8^7!]R$[V_0GTPLB>_JRXZS6:Q[UX6@1:*HXZ</JIZ
MS2NZ"(QOO$FH"V;OOYGA%FL:!5"$P %8[)>FZ@<_JJ7[_MYMR9>J3K4-(F!Q
M1C<%0=<GQE[@S;^D9GY]2F.>FB6?T61KU!56U]5VX$\&5!GP2X)Z-6TZGQI8
MY/G!CVI1?/=N2[Y4Q2>)'PP//O)Z7QTU0;AZA>IE;2 G'<9/_9934.KR(\+_
MB M-GS_]YM5_?8M_/?OFL90164+)0C.5SS,CQA]01T*J&>. U1J\T3YXG'!Q
MQWD'V(8:73"[<Y0N'?]FQ=7[D71F.28/?E2+/KUW6_*EZE/7;@>=NI?PHE;1
M:^!4<_H<5>+8' HK7+R4=%_1Q4SMICV4HE)1@F%E*POG_*]L5(L6NW=;\J5J
ML=0JE!(3Q=P18,R09N'^B$43_<I&M6BB>[<E7ZHFXHP]!K?MVL,3[K;NK )N
MHHP6@7KPHUHTS[W;DB]5\URB'U:#\>-B[U%$"97,BU0]^%$MZN?>;<F7JGX.
M;2NZ)ZD]O*51;*NM+8LW]BL;U:*4[MV6?*E*R6$'8XQ)(; O(+TL&S0Z,N*5
M0XF\KNA5<RDY[MA9)/#!CVI15?=N2[Y45658<3P^-9K0:?Z$R[1.@K"C:%,H
MG[52A]:U,)\,G&^VJ3C%.$+GIN$NR+,9QL,A\%LX/1!ATC2:LG.,FHM@/_A1
M+1KPWFW)EZH!71)/L98!M(QN_3,H"8QLM9&6M\NAVI; 0!ZWCJ.F(;1WNVI^
M]UB&,>T93G15=.W0;#&*2:F_8A37IP &T@$C]3AANC@)%(&!X"[L>[^&42VZ
M\MYMR9>J*Z^+[F1]3$#\.S"BB>)4[U;;XECX&BY@5V@OE%5PC=W?:B'$^T4&
M+6ALKW99BACIT4,%^FI,!C7+?@V$JY-Q'HZ"J_EJVTKO==GM&*6/L>"C\5^'
MZW6;9^AU!_3NL>IWI^2R[%9U>8D+-/4N]E4O72;2B%(66[V0>;B^CUA[XB)&
MH2$EX5*-2'&9M3$[V.N/,GSD9T@(!+>WQ86]D'W<,:X<=[ S""XZ)AL'HG8:
M 9J-A#R D(T[D[CC\TU[J+;MAZ&KMD;6<:B+1EG)3I,762]_XCWGBM\:<1M8
M>=*T"B%!(\&^+)KJGTZ*0,%1'PO%\9%"U]S&#5!U1@#M94C[MJF.[>QYS<ZG
M1X"PQ$@(VU:!V11:@(_W:#$8A4Z 2DE9V J0KK\L<:3'*U'IXU49,!* P"%-
M2>=FQCS7\,ID?ZRBP.  S#I%[^Y[PP:&B2T4&DQ]<IDG@!4*&BQG<XRJ82^>
MA;#C3#>]3Q@&!6) !U\"3FEO.J.]:0## >Z^F?T?;2PDEI<'4@C*E-*VQ:;'
MJ$[ !1O-L-@SBCB *>A@&)*K82LPF@%]BQ$-&8#C6+K>.=:*O0T3.Y;9C@7&
M!!^N09\?R^55=5"V/D7C:HY"&;GJVWT94?@4BEF !/>'\EC)&L2_;KOB9F;<
M66C.3H8Y@W,<"%%LH'0OL&?%BRD4E=6EHO%UY6ZHT0(C$2:AM^'-B[",,X=F
M(H"F\A4Z0YD8/D5R!3O> ?4-) &@]:"1W0V8EJGTAZ'+R5"Y 30.;V?88>R[
M1VP>VS(1@P,JB5%1/+1S""GBG]5."3W2QZB^(K'I3AF7UDW#E]M!A5ZM%K%3
M1)#G@Z(1FE,OG7G=,]OEGR&(>L[@F0,""H=G:OH$-3B"H#>$/"'6H M!4%&@
M9>56!=$+8T!G.Z!2]I)9AZ(I"SK6X9;Y-)U:]4Z%5D#B;KLM R\: FJD:ZI&
M/7=\^V1J:0$#+ZZP(B"^4Y]$=Z&?0R5=E[>/X+)MW; /O/O"2Q$C/_36+.H2
M5A#\"(,2[8!6;1$B9R]^\KW3DO$,IA=!IV&;(3ZXC!1SM$49V#)8VH$ONMD,
M@'T2O+]"$9# F"I$/I>=78M&\<78W8H&.$I$)DW<A="<'U5>A(]+6%[I#(X<
M#*,IME.EE]BV+85YB7_)B+R#(2SU3M:,J5VF'(^3 QB'F'KJOB(8]B.S_E^U
MZO^W@'\$P][I[ >@4.\7 N*S!0'QLR(@/EL0$!<$Q <Q:(E#J2.9*6?-V(7>
M)[#4 M8.V@S^<P-V#<>1XIL>X'!&0RC_)-S$S&Z,7AT71HD.?A?RX/1WYK&0
M_S1PNS4\'C$"D30_L;?)+A&B5^IY+C&@NXT!S0F42HK027C9,H%"#%*^)#P$
M)A#&N=4V9L?GH\>4(HQG13 [*X)B6P&^7'EC!#Q1;:7VIAF-EOYE)E$;Q-\\
M_AT^ M-0&*Z,5.<"I,U. $?7H%^ ;0F[#6;:YSQ3BMT3 3_#,#+$F_3\Z"'+
M_1'+ Q.8F.4&DN_HS,C-DB1$-W<"#3L^@$N*K:^(UVP@'S/G10K;'!R?F$L5
M2E>RLYE0,2"B-R?9+HND<7A;P<&]1'1L\;*6&,#R*C1( K/NZ>_(+B4K'GX,
M0)..51]9+6#7'K%A0$X-^B@BL6.J($)SXQ1!*-Q49C!+']BI?I"JB+FG1\JF
M:\'DJALTAX&O37LLL991F\ND!4(+*1Z]6+U-"#:]*/89R#L00W"@M.G(DEB%
M('V1Y7;9LL/8=@PQJZKG9/D-3.2:5F\KTB_T'X&"87V:&R^'U1CPALW"6\K)
M GYPOC(VT9?*-/PG=LE_3,;^6OWRU2-:UI=_^O'U8QQE?X@4-U<#%(&C*\-=
M[I9J9>DH/S ,89R#8AHLS6XQ ZJK9P-FKM:3J&:@3U0KY1J63HKD\DR"4:GZ
M=5H\U!+':TELE/Z<D;)SY<<*#:P::8WP_L:8.L/D>;V<'<0XEF5]S?+-SXJ<
M<K(/S&#6I@"_F^)0K-WM%$*ZN9"8!"!?[AD+Y),2T6L<F1TBT:<\OM)96X4R
MD-&[F01Z$M]SU&TD 0A);XJ>AX#($)?-2,CE/5U!RJ012FF"[*8+<X:*QA9S
M:"IRMI10[\#T=@S==)1L"LG\)<AJO)3E%MT/H?9 &W+*%8.T"YOEPHZ9)\CD
MUUU5ZPK1I4% 36F:=)OW.Q(#P'"SX,Y.%;LP)A"4HUTH[#??DK6R<%_'32@_
M5/T1A@1=54JB85D193!1:R@$A&0<R>T845!'9) DS^04\Z,Y#3#]H5<>2"C-
M3<-+]?SFD7CL8F S;KL4@XUU@F;#1-QPD P[W'[+4-5,V;$[Q5!;0Q=%,O8]
M4\PP8ZLWXX(VW0Z=1<N\\C%K)D*J2\:.3PV-88HRCI+:M%)-@J$*/48F7[L1
M>LP09<70#;DL4,4D@Q<CQN!U4_I*E]!3 W 69WY2XFOE;?27];"]+(\/S2RY
MPVC:0UB.!VFED<,HF94$C?Y,:C]5#)(&)E^H%'3I>4(VA9\?DP:\DQM"63OY
MW&>6\(6.52-!*VQ& 9&N8STEQLB4+2ZJ**WH$7*]2:++V3"2XO)5^3/'E=/6
M-+)P;?N,V"VYK[10MD5\7V!CHUT4\@*X@LPKO<BBFAX:N_SUKFBC1DU:&$8>
M\RQB=ZXF'-D1??OQO&$V;X4P2?LIJ+PQX]_YNX<3)O  G&@9+WG A63R@P_E
M9CB6FK?(;K'8/X5;&!L:?<<;N@P60H)/F=A"2+ 0$OR/QUHT6CSKC"0C*$]"
M5#.D S-.!]QR'V9;RK@?_*B6>O][MR5?JK:"CSB#>IW:M@9R+6:4V+_G69+G
M+;!%'!_\J!:]=>^VY$O56W7;]];2+E66H71+<35<\?\B40]^5(OJN7=;\J6J
M'DW86I?DF601)UQB1W@$ .K/)TH7Z7OPHUK4U+W;DB]53?EPL6"WMJL-LK7;
MBI/*Z^%H-$&<^MAP<G%='#=7Y2W@BM]PT'N1OH<^JD5-W;LM^5+55-4HL+35
M;K'W9ME4U.5T[[F.;9)KFRFGXSJ;-/".&KCXN]6VI#%MI<+#:;@%H.*7:PSX
M&Q>A:6%5[) 5NI7+XM)(ZX_<VG99;:3@J5!;6DK&;DF&SE2J3$5I6KN2,[A3
MH<_8%/W5RJ">\K3JB2L)&NW'/W#]-$FP+_C%76NCU7;L?8  6!H%[G#0WW?M
M/CO2=U"K1_\_5$BBS('3;/-2%FM28U!)/B\V9&.)7/16P5DT*,@H^IY4SV'H
M-E=<CRAE\</Q"7?W5LT3+7M#S<=LWL^7[U4SM>I6\%&2GARTZQ/ED&$.J&PH
MCB)^US3;OBS?H\J *S,SJ<R,+NIX;K&$0[%3_LZ<O57KB@HYSG]5=/MB4PZX
MG^,"A)+:\E@F30)2K,PZG1WHLX:F5';B'N".TW<(\0FL %NM.R12/;Q'U:,<
MELYBK@VP7)!WV7+>E7]A!<ST/=[[)T!DV&NS429#_2!=IES6";*Z9$D"PD$C
M-2):9&Q@#@=ZJM;_#'U2\#FJ(0DE+%PFQ%5W7"NK]3]9^L9J)\F4\D/!P\N3
MA>1Z$KLG$?&<K2[7)G!N7*_%L.=B7%W7F9](C:_O/R^.UG<A<=:XZ(%?%&6,
M9;I<KF$W^3R/M<VSIRW'FJGSDDFM*(DB"4G3-D_(3QFDU#4\A<Y7=ZDMVE$O
M-V71/<$NU&US^81'*KJ:Y!UUEU#87)KDM;4T21?F&%6\ZKS8^"2C-]5U">Q
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M#2(U@O$&%YQD>.$XA):%E2!%=5ULD-"V0Y9<'+Y*,Y3.Y0F3E2=_41-E7)8
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M@20Q!'2S3W#1'MC5]2#O6R6'O2TCW8YYRT1(QVFEJ6,4@^CG&#9CDL X7"S
MDL4<@018) (34IJQ_CD,"_7%*'^)=92A0.S, ,@MEIIE[RZ&EX2PH&03Y H[
MIL&P.,WZI 0+,:ZU!/GOF+AV-K_*$0Z.4Y6H1X^D+2@,G21W0]S&1Y1OC1U.
M"!]1@EK6%GLW/G2U-?>>>):K'<MIUMB'(.@FT1B:5&\6**Z_28K:00P:)AP/
M0)9T:_%!]%?73(QQ:) 0N"G39@"-RZ59.^&9T-AJR WR/7INZ4:ZA8,G='TV
M2H\@O$WT_=9%CT,2(_+'WK(9R&MP@31'H,\=TVSFF#XH27^0Q_,=RT3VT>.D
M.RAQ25@JA846UYUX0RZ]9*Z2.H.#Y,S4I!W1UMX$2M(L!CN=C/?E\2@,L;$N
M2>.S1D8R>;,E"HK.A_/G'FN) (UL-R)YF<^$<!PZ'.Q1UH;\-@X]2 ]-B#E:
MECOQ!,04KSP?55(1@*(QO$#C^U9U!<> N5$0''*A6@F4XH9UY=9.WR7Y$M"!
MGV3)ME5_&(Y@0 H9 *'H15 WE-SX7%L65X!\K$/;%5VE!&FT9$4CL)+T:M [
M6V>KUW(6M#_/L!Q 2^ '&F>PV:HL1$(K!T6B^9 R%WE<^UHA6G:QC&=>TK=!
M\"*]5$A9WJ8GPYG(+%OQ0J8CU5/8-9=%L(@)Q\K9::A/SH.R;(+1$$IUO:8-
M_";OJJ9HT-2K=86:3(CA^4CE-N+0<_D#NGC:8SFN?EHT[-W9\HB@6>82F9M3
M[+71 @*$'Z2$0+);FLU,"PB"*10K"<[I)W> -2_#IC/(CC[27*<',:8!46X0
MVUR4JEEK0,\=:,G;S!-K9Y;A%_(E<]ACP:T4_-%9,,M_L=OOVFY7YN[@>G$A
M+PLD.E]B'CW\_:9,S$7\Z;TJ/ONM57T[8SJ?UG;E]&QD?7-2^63\'MN&N=?:
M4X$0YI8<VDOA8PL"@DHR,CB$?"MW<9P0<70=BO+>&)OQ1Y!;-L+MR2F6S556
M>%7OOIRKMW"+#9Q6,<A-G'*JTX8T;!]_]!1G%M"S>I18EQMJ-;2[$ QUI?MR
MF98DQ'ZGH=>;/]I*NCEYXA:A58WFE\4^1M,3(^*C...DUD.BS$!8#:UY?- 1
MJ$L*168><+'ZL26/[9K7*:G(P1(HR"/JFMOZS$9@N%=%K_Y9V8RW!GBP3#2J
MJ^-WQ-67B;F8*[<KNV:9B$9%^T'GZ9@'$X,7QX?;O!FK'7#*$FSSL2J!4!*1
MEFD8\:I:TWI$@>@MFX[$_JK8<];"(JAZ;A(A#P;#C+31 6!\D3ZECL6>BQ/7
M:$9&7A-K\&);@X3;XS!<2^GL:-@'D%81:_)PLF/M5=,MO2EQ^"K7DAN6GI-"
M;190\T8EI*7-1 F9.86:&&^\=:/S,'V(6Y<H*O$<:3E/AH.J'?M):<]B@OTK
M%0E_6"H2/FM%PA^6BH2E(N%!#-I[56F8QS)G4BK7[*JME @C)ZG$%1VGCLDJ
M[$H#-0D-::KAI_'J<%ER?7:Y8(W<:?U);-VU8FF7?W>9VMTMJ=^?X9[B,D=8
MB8-U%=)7+#-9D)E8;>YE3*L%9%QD3KUOVILG5^V-ZX!4 Q?60-D(-7-:_NFE
M#H'3(-%>;#.ML_SHNQ'EDP0[L_3Q52$!6R4\WU;]ACQP,_#'1\:U*T@!AW7;
M74D5?18-=\06^;5UN;V$9\9Y=>EC*/>'NCV5)>KG.PX?'D>=!7P.C[S6JQZ5
MRVQ'CK_Q\LU/>( T+WKGA/Z:(;!:\RIS"G-[74D787#Q1MV6?],M=A[K9/*P
M.Y6C:Q4;U8N>+5UML$S6)TLF:RMJP](B)6T784'8"[.BFH9S[Y=WJ7?AJ!>U
M)/[;LC]4\BR!6.7"V#QU5VW/8)["G17C/0Y=$"X@""$K',JC71V.%_P93>J;
MR]ICY@*05JN_)9M"2MZE>U2P#%E09&"\,=_!0T>4:>5JNPJM)JMJJV.P$6\G
MW3S<DID<6:Z9";W/.2+J30^,?PO+^WXT\[*M6FA:UI,X96@N!VM(T@HNNR_:
M*)N''D&(!*D]FI4ZB$-C_^%O,[_04I[3S-]GH59GC?)\#QM6;C-D!6>(H,1W
M]YZY*]91**487G!M>GL)] ^]^+%<HS3J[XA%7!KY)$<U@RX9/GTF<:M9F'[&
M),[V]]Y8&4&XSQ_4E?@@[_'0?7LNIA)).[KTVM#@3E"DTL#5M<VE"/B@6B#*
MB950IB*E<A:>J]&6+'V\?LK*B5Q]^[9T>XDBWM1\1TG#2A\2B*'K'X4IB!MP
M!9W<(SN'E97D(NFSON7CEIT)_NW;1C2QC^4#"X35-;?6"][:;2%]2=3U7(U9
M+[;K'0Z:(26RL=B):F,URK%PD@']"P-*T07 %FE?6>'+NFI3G9J"=T6<D?'M
M[$L%VRX+W9+^#Q>K%S57!UY>L8:?9.XENAN"C KE<FM<-%2JLCWBSZ\"W&55
M@RJUHSPR"8E.C_'H^,ZU;_DK)L1AQT?W8O47UQ]5G%CS)TUN=E1UZD=WKL>)
M]!$DBX6#1]ET.KG\E?'A#6N'$MC_P>%=O0BEJN\!XJE-4N$;44O=M-W[Z/CH
M74Y;WXW* K-18-1UXEN7X2B3GY^M'?0Y!M2I<_Z'!794'OM=&FF-&C%+5GAN
M/W)?.7$+>INVR@&;E-,.6P ;;6R#8C)]N?SO,F03##TN6U&L=)SRIMB7$=71
M?(6(-L05:8RJ/BJS,Q]C/50D"?P0@TZTM@XI\ ,FNN$GDL <LS%LRZW@+,N5
M>9>Y9R<@;9?(AQE9CK,Q]._GJTW5;8:]%%#A)BE)9[ MA3;I:B.?::IL6F2$
M,G[<,'@W<.L^ E.<0(1Q(OB\:+<!&"K6*O7']A#<)_X]OIK''@Z&:4%'ST2R
MR=F)=WH '&!3EO:$?%(!NCHC_/-%<O0'^B>C-DW?QHWNF;8YG)_DN AVKIO>
MP&9_UOE[4")\K_)D7S]=\F2?,T_V]=,E3[;DR1[$H,GH>E/U[_OL#6-AR(WS
MIX@#^*:\'.I8@?Q:[?D7'$@EUZ1?+)Y?)C 6+V0-G".>+*A/""-WLG'<^EOH
M9LU4+\7'?$K?UV+CWK&-.Y>2[)*("K!FD:>(X)VTTUTXMKT'=L^YWHIM6$MW
M-9>H4I,  ?E.W&TL>'NQ]C*+633\K2]V)9=8EIPL*3;T+Q.P'.9@MWU?E@=\
MM2LYJXE_UL6Z%)QILCR[XA+UEYOWQ:7D4Q#O$8PRK1S>MXI43S:YE'F&'@9-
M1AV[:AT:Q;?=<-E?K-Y4EVW'U:. IJT:Q+]T6I)N"1]RCZYBM#=N'><.#A ,
M>BQ^YF.O"N!:E\<(A!T2.VB[:$YG,.45'+H@Z_T&@S? +9DF(XV]I6WK=QJ.
M"+FZD*[,W$A]=_\*./T11_&)RUL-34A^@U8@R!$I O(2-M4!=X TCAANLS52
M2-RN43P& 1>'?&9./@-NMM3#H6Q/592@I4Y6MQ\5D0\!WB$%4L-Z7W( I]3L
MUU6Y7\S^N\%A1#H%91 &[^MZCB0QS9)@IPR1,RM<'1^Y)*JJLC$G%SY:;1\:
M&OGWW[X0+#"6\"0?H@^D+[C,?I2U<:86U"G'TX$'R"F9XCTB"'1N3Z04>X<#
M(?5"=$LV4AS.,?O1U'('9CX<K$R57(7<L+@L::]8&Z.#%!6]3([CE-NBV\:0
M>9A7)31_K%DR!2!A![]'M>L-Q\#L#N"QN*!9?<,]80""9U:5L!(*R%!Q7+R6
M0;)&VEP5S64IG4RTJ?6IKW#(:?.!D\"JMS@6B %G7NDFRM:S)O9)1H +&BPV
M'T@2#DP\91$,+QHCM/D01X;"RD4V/4SLC%@%8BFM[3#@\Z%AB=Y$]2=9Y UW
MG99;C11O!QA+K+,=6+:[;5.@#FG0LR8(QLTW1A,2R2W0KP&DSV4&2LS")AS"
MZ5AWQ&=XRP_D96\"K@A$ADY?NP4>A0I/VC"12B8BF?R@Y-*XKLH;T_)HOU ]
MWYI<L"3A (7!7Y=A:-J6R57[$GH5!A]\GU\UM4:Q0MGE0"*.NJ9NM-WQF?(.
M>Z;*O@%I*$BXCB,6G(MMO%P)=S!H4@>9XO!U 82(8XE&^A5U<M2]M\.DI.S/
MM\!@]A'L)](836UEG,0(=,-VLY8%1E7PO3!S[5':STI_SOI#)@AH%$4X:]/<
M)G2/2'&FFE^>P*B_O18RA>'P[_6A7O]+8BX8RS&=R0'9+K(X^.(BNQ6NE'#"
ME.0I0Z.KM(\6*_;R5]\AG1B4[8\Q2_96@&E/JT=OOOOQ[6/ %["OR"O,)X[^
MZ[_D3*\K%$%N^MCL[ZAL'OWQ+R\>0[^!@B:X!EDD*)%&+V-%2VW7-IVJM7JD
MUK[T4\F@PAK#AG;#B^6%V!D!,"K[#3U&$3_-%#Y<T:5&GF\C\7=6?)P:1#"P
MMYZ@ZU(:+R_9_.7"4?&4$=F&P.?Q/4<&R-P;VQBMBU3_72E&E[V7':DG#+1)
M8\)94$H97H[P&&$^JPP.NFPZ,D@$.$*)6$Y68^(D4)_D%A()Y4 1T</)WVFE
M*8LA$@A>%.$8R9$D';Y?#W1&#1LZ16T^<97  ]-?]RO\_FP)OW_6\/NS)?R^
MA-\?Q*!]F\I<U"-IL%5T_;*[IHM72.N N3*'&G!5%O7Q:H/Z8:8B4K:RZ*?(
M"X'Q;#"-F0\LQBYH]4U&+M<\?)CK"Q:+25N"4_P]*T\,53]=>1CDZEIBS'<;
MV+$,>QIK&T69=^66X41S ="4\G=S[3XB:.RGFDO 3^J*0<I=B_6@T4RS;ZS4
MUD&]]V<>*H&A\C\?V'K/"4F\0OR5,;Y2?O;$$K5/BMW=(9_^D)G;YG_I+1$O
MF)\]IJ<7SW]3-?_&=:7;[7,,\G./\0^__=T?/M,@_\UR2K<"QH9<AAY^?]!)
MD5]VQ7[%.8,G[ZO-^S4;I'12[8HPF*=^/N,DE:CJQ[,%NZF.FC#:E-6U>KYR
MP;&SQF,A#W%H%*>?\3WHJUH=7#7V7[DRY@QT/9:5OA),EF7'4Q"7D;]/#^8Z
M6L%:=C,C1VSO+MG<//+#T&W(P;;!\%7-QIQ2=_)#QS^,[CYY2+A&-68 6&(%
M\;EM<<U]_1$.J: .RK_)X/=B!$ON7ASQ^WFF[^>H[OJR603ECD?UP-7]KJAC
MW]*GJ_:H7'L%!Y6T#U0]]_[2UX2CJ.>_B:9GOAE3K9)6U[^C8#<2M)DF79]\
M^H6!H)#*@M[L;U6<$9%(YH=T"YFD0VUP3QA$#%9R;/.DZ#_TVNNJ.RI/J6')
MFW6J0RXLWB:TT;'2MATU&"]'\\&/:M'A]VY+%AWN=/@/L"I7KPSS;O6:028<
M9]R+#=+?]M$+<O<?_?#J]8L7C_'G\/O8/_<N-AJR1OYNTS;MOMK@ZR\UYXR!
MZ&_I<>^^>_G#8W[V^ I9E1\ O(=&_GYS5>X52TNB!%.;F.\721XE22-7X:8I
MC.J:"],P#L;VZ\ MH7T(3;^O^C[P4=AUQ;0'6X&5@$<N;T^Q#6)^!L440#*S
M9C%K1$AN0+M/YFL8P-&FR2!#-Q#V%AGRSQW@HB@>_*B6&^7>;<F7?J/89?+3
MH6Q6K\4"[Y-HK 0S6//^%SZA+[^VG+K]8O6.-2^9OF6S.7$? 6(<R*L#:%-Y
M'>*C7DM4F+^JX$T8#6XM!K'90@F^Y-L!5PO7M>]+> ):(Z@W$+["/_MN.ZBZ
MM@?(K?>F9$(#^K?^<:.XKZA%,G4/OR')Q4@@:#=NMD<SL=8@, 8[UR5[^%/S
M2O+@D\C;7EY5]996)\![3B]O<W"DK!H4ZHI)8<[3#@!*=,E=EW6:MG=UW@*<
MW'MPVX-M*UWIE]7.L)RX6H2O)";*^(]G3X-3XRHF<*GRU<7W[U7+6$-T\7UC
M>[4HFH<^JN5&NG=;\J7>2 BY8'1("@+6I OMPXQ:IB5-Q9I45KBX^,NA&FS$
MI)=F,)#7',6]>BMOFS1*823 $R\3&#D&S;-W2W54GOHK.[1Y-UMQ""+<G?,2
MD,JOH/:C[P,V8QZ1<W@P",V@2B6V>C^:>A=/XF+V>&GQQP--G-[[02N21627
MEK@CJ/@,5L POL4;#00L"5OG/)8.66-D'XQ ?3;D*P+>9=-5C.]>NZ]E4Z 9
MM#0,[(#6>R4_1]'@H,U>AH85IY ':)F2UJV*A1^&WQ>*?4.-[O??OA">J \T
M2O:[I2I>2G>YX4@Q.%Q$UP <D1-T88"T$#$4Q[I?ND!!6)00!T;)JQE=AH"8
MU+0$6 &@D0=F%6F7]%!( :Q@[J2B<6)O-'B"N]^_5_I+[D6+G#Z99Q]@O1#D
MH8\M7Z+ Y-_\I-ZQ?W)   @Z95T)HO]6FS6D;\PA-2E?J^&> 5>QEY:'+(JA
M,N<R [R2SM!*TFHXZ'8E]A2,Q-(QA]Q.:[\*M/91.()DT6PSC_00D=:%6&V'
M2F,TCQ@.T*@.6J#4K0.)IF9E)VZ'8-4Z?3Y77))-0-J$DP',3[PI?(ZTM\Y"
M0LJTLU3!WAG7]&<MEG,2,2YU<DTL$!:H2-?,$DAJ4NW\;RV?2\ !68E88\6D
MFDY,AK(PTJN!,664O,PA"X<GJ^<L;[<*K)FY6 %6D@/LEW*LI1QK*<?Z_'*J
M9LDXDT#W^L%@S2LTG2XYY8<_JB7><N^VY$O5.S=%UUADN2Z/W XW+S>?+9"P
MW.[+[?ZEG;+KMN82C.YDE<4Q-&B]F%W)Z!0"\PLVP[3ZP'6MVB\$I(=\_;*3
MQM&TF&)7H@*",S7+1?#01[58#/=N2[Y47>9;SD6=-0H6+A5?$@67D*0%.<:L
MY _<Q/@,X_MXP_CSI6'\LS:,/U\:QN]=P_CB"RR^P')_WG9_*FF@^0#E!_>?
MNT^X4W]QR;R?HG@_1[58^?=N2[Y4+86R@::WDES2-0(E*,G1W= +:)I"<QDG
ME(<)D]SL0!]H253\^C;YWB*/#WY4B^*Z=UORI2JN6(*&8OF/E*$]T<;BF3ZT
M1=H>_*@6M73OMF112T$M^>I:0^8L;HH.@,\SE;)2W;FX?+^J42TJZMYMR9>J
MHL8N7X?"V6U'.JGV&/2A_G^1J@<_JD7]W+LM^5+5CQ$-\?CZLOKGT"WX2;^"
M42T:YMYMR9>J8:KF[T,CB;<%O.!7,ZI%P=R[+?E2%0Q:LP.$S;0_6\ 'N/=U
M:=;_!08M1 R@M0)BSTT9."RE'WC3[LN4,7-77+<"/Z$<I2G!@B?)21O7#^AM
MWY3(@B;M[:#4JYKJR%A$US3>C!LKR[50)5BEI/5(+UP)=SCH=U=EYD&O  @E
MD5A7R.K(*TTHI$/<[S^':IOR1K&AKAF2X:;:<A._4/\Q)*.P8^H_+U9O6?KD
MOTA79('6RSC*%/BD+U0:A1Y+2+&4:K8Z3BEF7RE';7AR;@"**L](ZRO5(-A7
M>R7V"E,6ND6)_@@AF%\'[M@'W)2^K>=Y6$.U/ -+!6*N W)P(SRM.)8]ESV-
MR"-I! ,/(F$_1E"\K05!0(8K9ZJ>'U= =;@I04@H^!S[EGXCH?>^3(^VQMD%
M[(%/[F;H.GIW?<J4Y[8L.MK._L@X&^#(C-R,@BU6"KR8HC@8N$S1]\PSG)(=
MRGYZV1/8^F;8KVEJ] U0E=(\'+4W-Z;OF4CC%H95?8[M'DC%(J.>"5\N%*E,
M*3I"()F,"V=":0'1G!^@<NJ"K.N S^,YQIKR$KJN/MF4!;)?J?Z4NL\6*' !
M!@0)B/SHN=B$XAB.SP-3-0]2/S)?N4,R2/GD6<=$]A\F7H7T"ULN;Y?0#.K9
M82YN2)@ )DR5IQS)A$X(D$B@XU/NO3XS+M'BNJAJ 7=@H7'9,X50]52LC)G@
M66:!IG1T:*L3N*>VNRR:ZI^%<C-^I[ E-Z7@-)3;#/"NI*5P?S? KF#&R3@!
MQ:T5?9B/I\?VA^H)AOMC& LEI'T28&@4W9:SA'L6^KAH6\5].67) X$^U _,
MX5[I:A?,=*R8+U/0"5X8@&:4C.C.L(U%7]%\_U@*5LQ$)\YKPBQAJ=73/338
M'M"\DF(^5@8$S)@K9.KP@ZH.4X[(.VP!!<+,ZCTKD)J?+>UPM(5;J4QSPL-7
M$ A] 4(/XVJ&RQ!,C>%WD7XQ-=8"HD@DFG22)23V(CI50'!D4DWZOMAZ2O.8
MB=($ SP#FC7L"^C#07$N$"5,R&O+P3@[/72;PBS5)+RBCI70WI&=!N"/<+/3
MES9TQRH&4)09-BL2H9G<Q"(*M(J[^+"QAI9'F]!%^8D&=2!5&5O%F/,63)18
M4OMM#G[BIMC2FLF"THQQM1DZ4'JYRKD$8W.N@"C'@<PT%/@P ).FSA6V):(^
M&8;S<F'<T86A=M.4_UR9H)NR-*PT4])0?A$FMA\.#/%C>-Y%Q":%QF(RX:/!
MXZG&^BM^'$TVA_X#]'2071@NM]CH@36"]?#0"QHWB<SN23*L1Q%TK&K83,)#
M\8C'IG6ELJ.6$P)<6&Z9P82@CP):V6N^$O\8Z("JW0*OLS3=+$TW_Q:@:^F]
M%ZME Y1]&$11F00,NUX Q9;LX\,?U9(<N'=;LJ@@N 9%WZI'A  )@_UQD- *
M0;=5<=FT9,O D YD\QH$(;O)7"-.:NKOQ)4&W2^L=6^V%)M-VVT=GK @!):\
M3HQ%TFT%]S)@C$CX^ILE1_IK&-6B!N_=EGSQ:C#R@H2N0(4F_?[;%T(?7I9'
M=?03;'5+A!R+XW LEU3JIP_ZXZ@C7RVH(Y\5=>2K!77DWJ&._*J.].=,?G>E
M :-[)'@D^P"/+FE&P5O7H);FN>O3DZ#%$0O+%3%>OV:\V)P281![I'&NBL:(
MMYGPKX]&+*)DB)=7_=SU<+'ZD9[$#\\G;53AG=N6'LG!O HHX!+?:T[R7$L<
MN7!XU0C=4M%+U49QS(I5)_#^2#1> W!\"&'G& DTVJ5\E:0^]A&J/)<D)B_*
MEM-0U1I\ )RM($U3[2,]4U(Y0"_9N>!E+GRUG%S3;%&:WL$8XQ#E%HVI)7 [
M'<J.QH5,R9LD.*][M"YX,3A);R-"TDB#]ORO[HFD:49QTZ(F1;5UA3#;/*:A
M @,*KS.#IW^@5>"E2^8ME[W%7\+PNW)7<T)Z/6PO06^1<9+LV)$P2LZ&=KCL
M=F4 +H\15J9+N:!3$'(G_!H9N([-(--)NO8!E3$F7X!WL$:X6HV0;<I-G,WT
M#@N>BZ2&-.$$SK 3!' WL$0@G?FA,"@7(,]C+95DN#ZM#"I&46"DR@!C=T4D
MG$NZP=F%YV<'N&4 ^J/LE\T=)TYS=@B#OYLFQMK=L>1* GK]<&C=2H9S=:![
M7KEGC*P91UJRHYP)[<NC4-<@I=?>-*,T$,M!?['Z:6#WU264:?GV!YZXUC.$
M5R+A9:FAF6?)>I#)<37M[<Y\GDXGF5;G8-5=,1BJ]((_S40$Y\LK#):?;-F"
MUI[/,I>@2+I)$YETF#Q+C.@+)AO)Q]P )-%,3%2 80V9$<F-I)GV)"F>LIC0
MN1"NC"6]=0>#_EN9K>GZ(;$1&4(NG'D'Y:A&450.O>EITPHGEBXHFI#$A8*E
M9SCE(CP/EU5?HYC&<YJ02'+JGVY1IN7A9%K7TGF1DZZU$2)DZ2-Q"VJ)51D9
M;O$SJT"THM6QA,WS(F;KJAU]&E+>%ZL7KJ#I_%0XO]QP*8&J*C?@_M0?RWVB
MPV(V>%_\/<G?9UI\YEQ-622Y[+N2S7PIK,J54&9S%380/RH_T-#Y$/;#F@-E
M7&#&54SIKXU%PUW^^GOET& .(%?^IB5[3;FKCG$=6JUHNBGZ5=D4(!J&V+3M
M>],D].(_DU'!D<+G3Y_^-I\I+?7/L\?0Q:/)S@R<)SK?*?_FW7!O9H_X]YQO
M>?[TFQ<O7^!?S[YYG#-']$U9'EA'TH6HE7J:'U:1+D",$O&.8^U%;@<(5J :
M"!CJ9=?>'*]2X<_Z %I$@R^;*Y1O<(QABU)M)542GFI<0'0B2FSUBL8L5I@>
M7JWFZ&.%'$Z6GJ98\Z'#20\(W9A;TDW=R8ERLJVUFDWX%C]F?1*.; Q>R9%P
MT,SFLP/$RV;'.%0D7_!^VV!EB%RC<N[4F@QCY+N6;4'Z^I*H7A+52Z+Z\\MI
M<$$P0O,\HM,"NQX>5"PDJ;:A@L21+4L57+F-98/R-!]+I>_W\G449*JFE3>1
MLA-B>[[LJO[]$W$,PROW(']C&KE.J]Z6^/^#']62*+IW6_*E:D+CIO_JZZ=_
M7'W+%O-K;1,Q9GE')"^,&6J1OK7X$9F:\QK.>FOF CZF:X.;+8@$K'?96].:
MP0T7C\/G$7,TT*+G7."X81/./DGJ584CGBDRN?9\.0@/?E2+QKQW6_*E:LR1
M6\G#C%Y<;$@0%=B2X]?Y.#<WL)"F>M*0FV^!T39V1G##Q([S(]RJH'YL6L?\
M;8S77A:''$'+MJG-DJ77Z:L+Z7Y3___;MAF.JQ_:NM0PP%)S]*L8U:(8[]V6
M+(KQ$Q3C@3.L' AM!L[!M,V38_%AM>7(XE&:.LK2NOF42=IWA87T:5F ")I?
M<PJEY<KYW%]Q )+'(;V_9')R()D>RWD?SA0C@0"%7&Z3)D(S0.W5,]G'V*UF
M"CH/;GN^^K;D#(15D_XW-YP5RD3Q8K<K*LU5IE_[5LC9+U9OJT;ZP9@97LFM
MPS#3"*),0S(<M*5<J\7QW3U?(IS.U!P"&O0P;YV25(>)*6]QC=&CK8N2DW:2
M"M?AH+=0MTX:K?>:&A^GZ*SWNOEX!FVI*[NS08>R#I"NTT:VR(=O.0E^PW'U
M6Z$T+/E=;-N#A,SEE"+??K'Z?NC@A=G10<J'TR&WI=62G$[161]J;BW^=@Z:
MRU9ZPN)H?):*)- B<DCP<XOQRE)!BG] IVM +S3/JW>IY8SUT3BEO.)L%%#-
MRVWLI1? \VFKG>6X>87.YKGYC^=SW9F58SA>>QA\=)[G\H.2,QGSWL\,;LE5
MWQGXS:B#7S?;"F[R46T%R0;74+!<!RR&F2O/BGR@424_>&C['I=E)_>FEN78
MCRWUMJ#;W.&@60]E,]M'#AL=77I4:)<E1X\[V5O&:)"$MZ\'#'G3N+?6<,L"
M\D<4::U>M@+0\D( 3IX_??9,@&?(Q*A)^67T(7WGLM-D+E+5I"2XFNT8'[W:
MD\ID*%!T_G*VO.B/J_]X=O%\=>RJNN:O6,\,<O'\IJ_H/SN@O3Q_^OP9?_'R
M4KI@AB,M%:E-FBO,J6S/=1:V*&9 63X?7[J!&K8D:'%)([Z4-$J0;!I^<(5#
M/9O4,PE^  ]^.,!JO&FY @^U P>^B\@!)]7*0\_Y,NJ.<HM@&GY97^QI6QG<
MYUWQ@=Y!G[[ATI.=6^#GN:ER5T'0QHH!V@!^:F[8,VU?.2.LIVLF71Y^#(H_
MT8U]K.K5CUSD:,^Y6+U46]0>,%Y?EXW:*PT08_&\PYU<CVTPRU1GYQY'IMW0
MJ/T+@(*Q.N%O:#E?GER/H7"0+&^R/#F.T<=22H=)$\MDLJZLR^O"G8]H5EN3
M@LK=?[WZP4$5P3G8*= DBZPUP .Y@HM@!(D!994; 31IHUIEP")-XK>*^Y^-
M*A69!ZX&MIPM9Y^(X^T36TTF!KDDW8&*0Z!!X>I6:B=8*%;@"AO@3(TK;4"N
M)9L!*HM1/!1E1413[ ]##YJ:!\88*\89(Y2,$2;H"6:4+8;#O]+J\?72ZO%9
M6SV^7EH]EE:/!S%H\05>[3+6K2F-J/<9N<11W>HQ]J%YOU:SWZ^X2*U; 5>!
M1HO<;%\)=";#6:G?2D8F(TF%&D(#?0]OG91$N^N Y)@==/5UHTLR,_0 _,,!
M./I>U0/Q9W$V[FK0KQKT\/!6'6/KS4=E;;;&?B)K/T/*,H"QI4RYN8TEJ6B,
M$99KV.\B0NV&S#<S7N0C*=ZWZ$[=]C#OO8=D$LH0LK#E,@L[UB?M94CAJ!3!
M"DT!&*UT"J! D_M&U#)>BBZ7HLNEZ/+?0<D=PKV QHC@D/!7C 9)^YG&@+RF
MS1C2KN3^'/?ADIY\\*-:\MCW;DN^5#UU(SGC$ Z*26LRGS@-,U)'T@:"3V^*
MQ.!&7[7'!W*E/HLH/OA1+3KKWFW)EZJS8G^:U@%*2WL(5*\U%2&IB@B1#2!M
M-; B7KU3;O)5%WSF/W(MMO;+C'2A4"#0FQCZ $,![4:[6Z3XP8]J47?W;DN^
M5'67FFB.20.T3_G*<="9$DLSL>"0@O$VH8^:%\#/5I&V1'Z6R,^7=EP_$OFQ
M/C%DT+<1]Z(N&/>#3 Z4#Z+>(U8'%-;9L$;&=-U^T,8&<L(ZH&>!DD?2^U7#
M=2/\W.5Z>?"C6NR0>[<E7ZIB.Q\JXB)D5.)+R1I4VI\&3IZUP[$6>#^@!53]
M>\ELL5Y+LFMHD74H=DOTZ%<UJD6-W;LM^<+56"CGZ <%Q;HJZ8.Z*HQEA_N#
M+.N_:*-?TZ@6;73OMN1+U48&26)A9<<:77,;@Z-.7)K8?Q6C6I3/O=N2+U7Y
MM$.G&;3#(%C+2X?R+U,[_88]X^R-L1&WJ-Y\";23U=MCNWF_>H!5QE(3;EMR
M9X72WZS6Q>;]9=<.S9:;%-KN/[G8]EC^6^K=;Z3]4"&UF14 Q+L"N"S=6ULP
M[4I[XY1SYK^*?EO\0W?Y1T4AJ(Z3RF"C1F]Y OS==<F/W);\\'*;9[Z@>%(-
M'+/@RK\+Z.>*AK/5'BY^?E]N!HU52[M80"(7L+&T8[S_MY6_W\$&WIFFN)/9
M_-1D+X9+>N'J*[12/O\*2!9: D_R0-;DD;LI0H>#BMU?5#+__X%&O=/@74_2
M2'+#4O%N7D)7?_G+R]4C34K(WPUQ&7#0$O$K N_ZZJNGP.P@^1(6<(,0WI*]
M>Z!)M=M5LAIGUVQ='F^X_?//0\V U3)9/GTV?_THTZWEE[\<0:8DQ^BJV.($
MB][=,P$$-Z 6*RYEVP_[U:866.0U0%'Y[-"Z_,>SBZ=/T6X+X!6 68>0J'"&
MZ.'/[/#3&]UJOE1$?EW/P]#U0R&X(J.M>3/4Y>HWO_G-TT?%XT?/'Z\\TO6/
M.L8_TMA>8VQOHHJQ';E8O=:G9^>>_OMG3Q]M'C_ZZO&C%X^EF5?7#&"'H'A@
M$(K:]HI6X-GO:4N+NF2F/]Y&DLY/V\&VRZ3U]_MRW0W '?\=]NQKW;)DACR.
MN@*0]FN\.R)[HTCQ4E@=PI>"]KUU:2Y6[]IL\F.9^>Q^?U2,]BQ\0B_6K<H/
M&Z:@'@D)Y"+*%:_AT\R?BF-7H.=85G-HX $*I[DL>]5'S,GU2;?R8O6B'VW9
M%@ V,C_&T_V4Y<G<\O##/VTSS^UA*D1\,LK>T.>Y"1Q-R?AO#S=.,O6$)I_I
M=&<W. %ZCS\]*R>\U:M_0+V=TE'=^#/+9Y]W+[FXLYF+&[NH5^DU-[L"< EH
MH:21$$3$;LL5RB6T<G?:";)'1I),?N!9S9!CRZ3SZ0/S:SJ,HUM%/,#)"-J
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M%K>KZ[8>]J42O&X"G"%S? +QV86%_)4_>8T"&Z)O32]^K3[_9QF"$OIP.,)
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M]Q?G,SA+[!5TV]!^@ ,<0$OGUD%Y#9E;]U!T=O>XK\;N+)&3#[K"AZ'CCG-
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M;FR<B!7G&3D+(A..K/4<&7"5A>,ZW#-1V$OY99)AV'*+^<%("I14((T\0QK
M/_JB&V/_2Q+2>9^B'8,%HG, "WX\'R0M$QV^]D8C<!U&22PX0#RD[S (0DD]
MO,5!?Q$6JFQO&"!0XCQH"IG-9HEPL$5<^(J?>.K8,>'(X+<17,DD8"/[B1/Y
M3X+/)BA: @LZM#ZQ38))8YJ<Q:E@+!&/$VUG&"270VVKE)221!G(0H:,3HFF
M^JQIEBQ59IY+7[#H=H64WOZA_3JK(L5DVWH<4GO2X3BJ;I;*YR94L4/3CI+>
MT&+B ]RAH ??<"1KM]N'&43(W^P.!D2N@)@ADB]ZII%EBSV>N%Z8QTKB75?+
MJQ95L@,&\(Z0JODS"SLUE4/[0X#5#GV/,99Z(*-=M/U]@8S1\K@1-&(XS@;(
M0.CP9*6=X>ER56%F\3#6[5ZYWD@CJN0^@^=FYB&T3W1&!OYRRU,>+5L[6DX'
MUC57BE--N MJB%!=!F_;2))6FM;!43SHJ ]]@1^9EO%!&(S57I//Q @Z/3=B
M+O&1!P_LHPB!-EB+_!*I;WWBYQ3ER;3=DZF'M8UP (!I!;V^"1+=$:"LL"HH
MIK8"W%XP[B W"9P,2H*B&#8:7$NR*U* ,F?9H7TZL UQQ%)EL*P$&DQV9UHJ
MTV>B294/98F,"GQ;>+C"I\N<)2Q<X#J+#*XG]DN%R"PAS3R=H+(3,W(L#8A7
M4L3/?'?99KCOP0Z71J:@O/-GO[3;_R1!+-U*= "*'+DR\[T?^UT&(?=CG\"]
M3WJB+[53^5*#M$6OU+E2Y_9BF_9'Y_@L[ M$!?5\-XT13%U7O,C&IMI:Y9>)
M\/T;Z8#2KZJ_*#!1\CKEQ0I#NM_0%U778TEOEGDJ$@;UAR+D>C-TMX.0D+K@
M"QBF"1-%SS@)HLCKCFXD*1K5QMC29-@CA(6FP+)\%Q))7J'Y4-A?F-7H(_BS
M^H0\YS.'.]><EL:F-#9[M$W[9FRTXSW&PC;)8@TZW@V2&"N[F>B:83MZ 6P&
MPMW IY(RY[\7NUQJXW[LDSKZ>Z%P,=^A[L!X(B844Z<,K9DDF8K+4_:!R1"F
M/T9HO]W8Z O.!L?*^H'M#QHSKQ]4?NPBW<?WLDC@=#P)P>92)^EQCZQS]>BH
MY4@'#YQ UQX(3+EA]8 ;)[% #D=QI=@VX&<QGB 5)!4G$#X3!<XEBS?Q:\,@
M,)5"J190;Q0?,VW%[\*\;2@&(@RYH,#5#BB="O!+(S^D_- 7HN<FD2AT7S&&
MBGT,O@RK.A8FPDQIUADXF .B3DV_QSX>Q4.=%I3S4U^3<X=O%,S85C.F6&TZ
M6RIBR"VIW0_0ZQV-@FOU#E1':O)%>A(3CLJC:@I*$\+>1$DT\7JR-W\0N@F>
MI7TG]RG02,ZORL^ D^W'EO*9J;#$-R>(Z38Y&X+,Z;IA9DK3"\7N>5I40ED2
MS&B&. P:#\;:<41^8(\"\/9#N4%6ND&YM9+W"PS<$^['U$O1=<#'TL>0"#GI
M_BT)XM5F2/1-X>+.X^S21 [" 6$^$M]J&7N^9RJ^3;NT&$7SJ$31W"B*YE&)
MHEFB:.[%H#D?+P]D"RTY? L6G7P+JARDDK^^%X$'RG R( )TKB21KA+T*8<>
M](3H1T16(R02%!VQ^-33\S,R_(, S\L#.OJXJL2AQ"ZF]"G7>PG'LT6YUR&<
MJ]?\&GC'6)=*ZA>I[W2%/'7QG&'*ZT$R&MV4Z?KMINL],)]^G_&]Q+1<T.^7
MD0C\Y"#!:&)(=1<:=EO_(\;T."7ZIMG('>MC,/'ZP7?P#, B<NK=AWE@":GV
M+N"KN8^1S'WR)EX(AG/DV&<'U0Z5$X#C2Z'(8(3P+D+6Z(9!#$/&,"7'8R/A
M(Q4GTP4[:1V"]?;E\8EMH(5/8 @X%-M@R0-O.@B_X5M,(BA9) S/"B?(=PRB
MG\!/D8A,5CRN>HBX&RJMF771A9PDW1%5X*$?>N-8+FHGN,'POY, *^RHRB"E
M$<WPP1L16G*J/Z%KBL<1>WR+[$1:\648"MAT2PL$!8S5/[1<@#O(Q0Y4EG-%
MTP9_@]X$GGT/5@/G/;IAPZ'<^E",;F0U(K[H[Z1_R6PV@_QH<:,M+C>>'F&4
M%5HNT-;O06M#-65<-PV[$A.*CT,K"GXT/N6&@6<UU@]<WF%YJ10<[T<1ECA?
M#P7AUV;L&=ZEN@(GD=!5?\)TB+ "8,OLTQBO!3+ +K$Q,U]7*Z%M(7GWUV D
MZ;-T6\$)W.#9BO<+]RH@1#['(B#?&RS"ACM_2HYXPG)3^M;;+(S+QFV,[@[&
M3(5]I%TDU8Z&F&@1;@@7(_AP*% B5906=[";@!J#P%&5*5\O;U3$R-?U1?"W
ML1>-!.=<P"SZ"&&515_.U\/*FCDZE&6R1J+NE"5S]QDW*LB<38594DLQ&"7<
M/-*](6.BI0GW58D3F0\MB$&8O<Q+L53R2+)GI=@O2@(/[2]"R2Y\.P3+2 TB
M5T(V+H$O)]"UE)%*/1*=7>C>Y*,(4\I!I7Q^@.\>B.N%JL1HXSV1RV X!?7"
M Q/*)HU=^ )Y:*^P$AL+JWM4$7[*1Q"%V^"\M>2,YH]&CT%51JLC4X_V>ACP
MA]"-6DZ'4P1U"Z=E[@?X,WTQ<B1*.APQX-T@L#MQ\,(E[R8#WF.VX"A;@G^,
M0;Y!RJ(8?!&1J>VGVEW, 4=IG:\0L<75_1J=DKP6-<5I\\(+/?*^X0HKDX*;
M'/@\Y2 T3NYT8S%8GMM5$@H>B94:3Y9P6*DDDM&G$#V+:V7&1M@6<07GMXR[
MJ^ X1\MAN63CEHZ]PM_Q".5OIV%.<U)8SR[!RJ3)A,5)[>5>F9R]M)-\UIXE
MH=4-T O$1B8O9!8?<F9)[Y)X&(3DW*''B">J4;S+WMD5MO#I',Q$!\*5F<4*
M8F)R)1-JW%>[X-H//!(@$$=5#SRK9X,BX+J[A45+^^_8!))O!S&KC!7(^E7
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MP/Y+/UD08WH(8B&QQ'NF\H*?%0H7VRO(-<'W8^/Z)37'6;&JDY7OA3^QCTX
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M1N-@.,Z\/9(VB.%S8&1XYR-+EMT--D'PEZ#G42N/KI^4! C<>_ W(31X8?\
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MF5A,@F$#"6?TC"S1%H)P]$N/@@F(DM3<-$K2'LK]M%'J9(U2X]!^C_S)%^Y
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MD\KZ.J$SF@0C$,3FO90S.+7,!<R\I)7>_MY8!SAR+&[$[Z<MCG8_H%HP10\
M9[53[6CQND3Q0]H00S5(S(=)'&/"#SXV!@%.R&&,+*RYY9JF4[]WR$>?[&^
M7V!N'%Y_/L+1&H9$&@8C<*11D9U<054&_Q9_<44G)+D2,.^@[_4L<B"*SC4<
M.<W(M'2*3(TBG"!CF.@$'8DT5,;=I+Q+.9V3Z>,V&:MLD]F%09=,:=M+<7^.
M*),EH05*$2]%_&$M]'3#937;<-DZM/_O1X$@6J+__Y7B?_]'<6Z[:MGM:F-_
MK,*IU4VQ"*&1$/ ;.5''OCNZ09<L,'$T3S(%[!]3:H<S3>U05C?OZFS^[=%U
M(KWWKR %T9"8%JCEP^T71BCPQI^V.E#AK61$DSZYJB:@0!OC&3&"'%YB^K88
M18(1!!6=QS'3>7PD.@\.OZTP9"3A0/0C#(O G;Q_, J";XS]K(9F4?10H@0I
M_B_L^O#EG28FQC*Z96!Q;3HGQ;D!MR+L!:%&$[@F478.,^*NI#G!IV%,T*=_
M<Q.+\1A\OZ50F;*/AP5 Y&JXH5&+!V$WS9[)H?UE2.326,*-BWT=("&4#+U*
M8*8\"PB.7OW.DK^CP?;SGX3KE]?S)E@YDOM+#+(MXOQOX7Y'N(]3OZ?%R?!^
M*$8Z6JM_!:'%/3X',(Q(* 9'!1.'-\DX3&0AVC/Y5&S8R;]I[-[D?T5D(?E?
MLF#KWXJX=XCU\J$5>:!E6/3Z'=&R(M[.E,=/WGDY !/-WYI/"SY!>VMT*VE!
MM#*":-+P]5P"T.O%S'<C[7#(Y0L4>NI[1+IBT/?(P@EDK9&3XA U\IMY:;7X
M''69H9@(FID;BMI9$ -9[2!'QL.?.[A4V%3-Q?3J6>;J9;F0(D$T4IK<1R/,
M.U0\A9HV@E%Q79,CW^E37SA'" N8AO)$0[P EEJ AT0F\^#.O"_"DO$RVM[8
M_2:X^[\[DF1PJ"Z256^.DE)OR&"$.BIE&8V3%_:2,38S(R$><VE2CF<0"\4.
M$,LXK1=9&<7!LP+[,U& -9T9*.'GPXM#>R#Z),51&H(>N=</B[?H@8E:]]>S
M*P02%M>E#[RKLWF-3Q=]"]3LC0C0=0FN??NS[U'&-;ZQWXL^^5P7O6$0T"$"
MQ\I-2@4Q(XANYX+H2$9'(7O$&+F90I(&@W$IK$GF&8I3SQ[1 7:I./5,GC:#
M @V/>'XBV#;X7VKM<R?:3T"?@IL6990>6=5Z:*=".+%##YY/=9&2L05LT(RI
M.93[@I.O!C=)ZGNV+P,D-(P,:&FT=%WABX''WBN_R(X1/U2&[#,3 [\<F3\D
MF3A_VN(9W/!U(DI@=T(D$'3[GC33_'?'[@W%.%"?)A=[/$Y\]1OTA3TJ&E6(
MJ<HE2)>H*W 4<@%-JE^<&D;S>M0H(4<&LT[Y<,9(;J>Y5!7).9P(#'A.S'::
M#!(Y:?+CMY]]_/1<X['*,="A84^\";CJ]"Y+\OE%F5U4A+'L-8,7XVI:'JH#
ME&C,*8MENA5J[AF>5R;Z,]@#>PC+@6<6M^=;@@EN$_8IX5N(F3.]NUKDD$\6
MUFL<4*YYY'%2DYLH7?N2\&1#.P+!HI?[FFIP]O##K83Y2F.Z>NF"#OI8LJ^
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M03^3B7 -U%=4)G)8+P1_K:8468EL%. #"'%R#'I).-3!E1>QX7-C*;R4Q)J
M)A.@.[5C$8@\OL; KE33!CWMLM%2"-#2^)D:E^AED8-QV+#!)DX22=PC(=U3
M &H:3= E"S]V_PY"S"'0PX=P^J*14&B["#:+:.\2K=?U39!4\+SU07:1=".*
M?<9DJ]@@&;_\HKQK;98;M<.F-H\&-K]5@.%-4I![@R)5R/U^QHOEI+NBV,'
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MB[+T8B\&_>_NKV>#P4$6GOP8#P4F=RE)';<TZ"_"DKPA%(QA#V1PT.6- 0<
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MRS5<,WU_-0<,&2 .K(CL8UM/D[DL]MZ17#8FT)B3LWML,8$%5GT535C+3*]
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M>7YNDM?H&VT<PG4EJ\J97I<'JBUK+OE?3G7M==3X^E1O+Y_^_%WOZ0!*20_
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M)^'O2B)^WWUU1]6(DI'!CM98>B105(J%%]%O\\%8&9XRI0I='OQ:%NKT3^;
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M0YGN3!\&3]ZG_.:87CT"@R<ZP/K5C NSN/-%-\FQB:I[;*+E8A-5]MA$&X)
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M,99)TN-M@,2^[<GZ+>D/#%,VAV?T(%43=4<TY4^_?A_FCJ23^FUOZJT O+7
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M+RWN4$>8NLUVSU ,S>AB:C$@TVW2[NGJ;X>$0A&A=8 *8/W/L A$3N*+D%W
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MC!<&:4B?R =INI\,\EX;(XL\G<:G5'*T,B8S,^2-C:W<_23-EB\9 N$>UEH
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MUE\(C1;G,\ 'IM&A'Z-?HVZ3.UX<@UKP*J?M![4R-KW_\!67*JH%Q\[+^MB
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MQQ"N3)C<]BS\[.@=?9BB,B):BA*L>DR=%!*B;1\4J>2GEX"NN#0.O)W]6(D
MW6;=150@:(AG0#EBXD3+\YRHY)VHM+H3'<I=;9AW3O6WRCI/5/).5%KX1$M+
M.='2K!,5 V@4VI!*-SD .<&+N,TXB:PXA)NXJIF1V[RB[<707CC"K.[B741_
M'[_"NR,@$F-2L4=_M!S(N!,$]N!FOM/RR@E]28PED89N.1H*4C!IK=TW/;=\
MR=>D*T-FO(M)KD QIFT2&=&N4".81.VW'-,BO+?BM%:[<I%(+$]9>Q44W+$*
M/ X>T@5/ W&^F,N%\(\$0U[4(:*?.( ,M6IG,/"HJ]#R<:;C4TSV7"S=A,*
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ML D-7?*>:3C='NH ^B;(HS"*!":,0BJ74=<?:Y/Q>J\<':=%\ 2QHP704F
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MF30_AU\[?D8%*]7R/G7C;+U'SD4@AD_;/X>+(1X0/LWM&["'U)CRUEH>ZXT
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M9JX70\L\H1]VG?6TU2SUM%EAG=ZY*V6NM6TP=*688UES*.$5,Q >2(+;3R5
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M(EH@HR?M,K,DPCUW/LI6?>T9*5_:#RV5S<9*R^N\B!*)U,MBS/&^6[&LR1$
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MU$JM.-H\A:2UQ]-12"4-A3#[['=-P8H.Z\Z6K@@<W^4%ZRPO:+S,CV]'GYK
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M+.LO 6,99ATE8+78((>J:(B!;Q$'WT\.&SVE?70QV'!]YRULA=GI,J8%?7K
MP0+<FCGB7*++;(-F2G\)QVX9LD)U.[.$:5\O,W2UD>/6X_B*M^V9N1A6LO9=
MK9.ZC. O*<79T3J;Q259Z&$\%0XNJ^[?3)?;ILJ4[WJ=S=7K.%9A*]3!<Q$:
M;'$^Y]0W03=755]T7WCQ95X\?#+>9&E2.:]L8)JAT\4Z1.<#!80.B#M:\7!H
M#39(X^-O035"7(=U*I@O8!-FSJ\R#;I1+NW^.,+4/E=,I\5R=1;UQ+4(/56
MS:=F^XUFL]1;\;UW\SJ>3LX;*QWE0%Z_KE!CPG2>5"!:@ .RYS2+="532G-+
MIGFQ;#'7^'DE43.("'["F?@A\*YR"+;W?'9;>A.&37:SX8.P$J*=#25ET"%^
M[*3G(7:!I&34' ZZ5LXQO/ 71'#3,G%I';' L-4]=ENH)Z1_<4MTT_Q,OWF^
M/;AFBK4-Q/5W/A284@F&X6 !OLT\HZA20A(WV?K;=G[-*1*X9%5E6DZONCD]
M6,>X++>O)9>]M6T.6W68Q5.K#OM?"/H!WD,=G+YC)FR.BHQ\_BQ7F>LL X-3
MNPU8!H?TGV:#=X!5E\UZIH/8 L(T<S:^1)=J%;I13):G^9+P-H$T- G"9O;-
MTB=!,C!B*2XQ&C*_S7+7'TKB0[\O/KQ];-;1.1,T[=^X:6X[:S2G#QVD&U 6
MQ^^ES*6MZ?E]V^VG[4==J%PI+='XEGMR-6Z09#5.TB 92_3YC:B7F,=*S^#Z
M&W"UH+<R6LGOI#V?TB OE;^'[RP"KE4-KDHW?*?S,E<_S^^;O6G]J\%L^427
MD$H&/'U'^,)]7'_^\W_V]JB.*$C\OU2/&PF_T9/>#1BD^R]5:_RF<!H(/8S:
MVS,IA1<_TF.97-7^1A67:2Q429&N/B)LJDNT)ZHKTS"22,A]>LHQ.GMNR%DP
M^TW=SJ;H!$T5&;"#W]0%4CT$KA<*0)"INW_UO];/X".'$BTR_,__(E"' %T5
MN+>]/C:*_T6R%'!F@AG=RX*Q'4GP5,A8U##U/-Q])#@K.8Z+2+9_A,\:9DRQ
MI5KTC*DTJW1C!TU50P=-+?[8E[EBO,KCJ_)YJ3/8<MG4#-G&;.]=MC9YN99]
MX07,$7M]!0M2SC=7M]YW31.I\GN2,]L**:]N:=8=SB<5N39(FFT%&+%IT+TU
M&"]N\M*A!> 5\?2J1,7W7*XEQU1U0M<>#[G' ^EM=#QP=6/\)66!26N/*Q=2
M;:2>3L^?ASM;0Y@K-6U3E=MW[=\VU/ZY6^W3V#A)RXZG(O_"3U^,GJ'"B/S#
M-E)STMM'HV]<%35F-:-CTBT]#NXJ7<ONX]B!2-F&%^6 ITP#PME2VN!]]Z*#
M,(W0"^$#UA5Q [* OO7]Y/[.6*C^\]^-J?CU&FPY;1/?NO"4.'$G#: BUQ^'
MR1SNM'9=&9=&5W=92I-W> WR\@29ZTIDMIPV,)] B]7]+',N_OF[H)W$]VG;
M 1-@7=_/DK>.XW77.)$T0+'6#\59%66I,KYN'QAU8;3VM5E69&,CU(4S]1F@
MF)%_TQ:4)=!4<3_+<)+-\&^N$$[BV;3M&HGPS3(R(XYGZPOJYY"]SEZ^U3#?
MMN]/WH\ZQN? 6*EFWK:!7-D@F)%GT]8M)=!4:3_+5KOMU[FYK'UFRWEY0_M9
M2IKB.+>ZF+8E*Y=OE=!MT&&J]ZQ79OG/FQ-])/U7;(6.Z[Q8%L#9.+R2ME+)
M3WO!7@U"A.5L)M^&UKJO#O()/%_)ZLU$P9W=9Y> >RCW-Q;C_M#MTF%<KU=G
M3;6AG)Q.LG1U;?66Z67)++<=TVPE[9"0M 16RF9W;V9T</X 3^+GW+R;+"MI
MXW1X:4'K>Y'MTV'<W3NIB9W:2;F2J>)PU[90)Y2FY@SPC*(@[03%U+JFM)2R
M^9N1D20FLCI4D5*YN)]E#G*LWB\NIO?QKN9._([K,$'Q4>:.+LOJ6>F!6VED
M?2MV72]K&*0 <C;A4,V:XHFBR&(V7W];!A]48^8G9N@':BRH?0/;LL,XA[GZ
M-)3SFWE'K7]OS5YKJTD6%&;DRZPIF&B^3)Y'DKK4_I^_OJDH-TPG6 35O/VT
M-/F1A?$<*ML.$V5;"X%#E WT*G,MEB)#G[%/J.FDN&>@W+VRD^+;XR8ZE4A#
MLBO_OM%%X2N?]AQ/Y6%HRRC%UIB42D_4WTB-0VJ2P,KJ3:X!I0MW?8FW3]/Z
MZ:WV).WBRO4M;WEH:@6\.MLI@*9 3M#N;@]JS/$4-YVJRA<B&UV09M3_>!L<
M&D7WQO;X_:%3N2)77P9VS?J+_3N;%9J&CEPI49\UOT3MY<5R=,W2.?0%H!SR
M[7-\[I>Y>E1G[D:EGC!#]*V+.@#&M3746AN:Q);9UG*:)WR)/J"//=,F$_<J
M-G=6 R/X0VU%3'H%1 L2CK#)?!!5Y36@"A<ZA2+J\?Z".[X_K;6+U<TA*NIX
M7C35TN;=XM!4"2UEPVBB+#0A#I0#&VYA[1_T6;'%WQ>79_A?S.]?>.^M*/"4
M>5W(DBK#H89^;E4? M(U7*JHDQN:)A--B<,"8F<:%S4A]AX:.I+R^U17QCW?
MF@:OA@]4@;.V"L+9@MWA2* @X<*-!#"I =Z:B-ZM49]C 7N;H@YM8!-%%2A)
M? .!H8\1#<J*7D#_ *V)++BIHI(WJ)09^8%WA[R,@L5W5-\ZE\#O4[?HFX:D
M8W&4XKAP&EY QB*/SELPI@H!P$B032V+JS<Q.'Q HWA#M<""T",JO ;@^QR+
M@S'ZHZ*A'P@3=!5.G;ES6.BXY.<";R"DHP?N4^<VR H.R.#!FMGWQ:.K('-:
MXZ3 /21G-@L-:?%79#T %82>&2@ ?C25.%F&TVLZ%+"-T(_A\!/N#?T180*W
MZ@'BX4S[U %>LV7"QOG @^LQIU&"!JI;U,8P;A$= 2$G)*A/<2-.E#4]"KD%
MC!IT8XG0/")D1.?0.:A2 (69"6^ )&<@.$<3%86)*I:(" W!=_M"P::CG5+5
M:[,N,!H&"$A 85.$ Q60PQ:9.F)U0^(+B!4M,01>'J5_*M1,X! U ^7Y)91?
M_[1CYF %Q#IZ4(<\YX77GX@N\C>]Z:=O7]7)B7K*CFV5TO(>PE8GB_8EN^0_
M!"3_1>( ;NI3%*4?L8.58FX%?4 ! ]A4#QBD^U03@74"H@M!>X;)&UI!6X9.
MP'VB]#6J.< %Z A'->KG;>ND^8NF/&CDACJ2R_!Y88"9!ND8>83^Y,<E/))3
M091HNL %L2FB@PSQJ%%I1N2P8R5J06,C=KMGO/419G>@G_:P5"#FAOOO3PA:
MZ'Y5R]"8<Z/IY*U_=BF+-E5<QNR07],*=^O,+X$C^V@J\VQ'IM2@ZTQ8A0\A
MJU"CL+5N/-4L/ VE\>5'_5WKR?4MQU,M%$^95]]!;+]4#W.P"9Y<#26(E;U
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MP!0I;$TPOWU2MLZ67^8:JW>.3VOO1_KHQQ_GWA2YN!WMZ__YCE6N]LBNZ+Q
MPMG@14B2VRT6,%(HS4&3:>SW.0G'O+6Q .-T<?)EK"K&:$SBT>0/ DZ50,4
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MESCX8/;>>/5[T_$O\0I8WT+-SIY)Q1_R$L:_)D+4'YA'[>;N43V"A:M ;UW
MAR-JU6ENA5^U!#.WHOI VY7!]98XL2@;T&>FMBV*$T4@3-;XLUKS2[CCU7KM
M[I?(NJD47T7IYVQAD_6@]RA0K()C+CFC="-O:$;56[(':GTY,4N*@C6!UR2/
MV<D1M ?6<)FII=?JL*K(2[4KS)4I0IM)H2:)]CD0+OQ\(\5GI"R9_^(_E[O7
MQDFJ=#X[?:^9WG?O%=>R^^9F ?Y S=$7IOK],-/J7@V]W>F17V A&F4Q>.#K
M1_L'1^WOM]<= /VA_5K(I.:B2F.X[TI\#]*0\)3-[:_(V0H":B^5Q>FL 0ML
M^,4E](AP-C:^,47LR/U DPC16"Z3,B> F<H;EML"F@..7^SA19ZG822TK@+L
MM,]?4B@]]:&0.6H ,]9ST,>GG,/671^G"89*%=Q4RPT,JO3)!]##?0E@.2?^
MNI1:_\$KIAM1,ZC1H&I0!.J@O$)%Q7@P8^)00S@YVO-!235J8S$EIX2(;Q $
M >OATSR/"&0)AM8_P]^QN5,Z5E"_0V!=W'#Y==6[&6,"<#S2QY1> KY#01%Q
MZA/E@]FZ(DZ\FB)*9S4E@[U$R*4H3_7K' K$V0"]P]]19>0R7&QVC1GEJ:J/
M$QADEB"14$Q5M#<6E&7V%VP?M9H ADTX'1RG$(6GU.G&I0%AA4LB1IZ:V=#^
M5#169_^M<3$R ;3*SKKU+%5VUI JK=R[1I9%58MXG<8E [!&*K!HPD$L1BFS
MP#-F )4[)DA.%!D:PHDH$?WA])U_^>KT(WZ1NW/1W@.#4&FO.JH;IERX@'J\
M\N6;UMFY0C/0'U%Y$*1P9=[IQ7E-F6 ]Q[I?^A1G&G<KVA<:F%N?-L904=V"
M_=*ZRX12(L,8V!_^M6I-+[E;&NB)^8(.9+KZAULF6=@R:T<^?TJ]-Q&W;"'H
M8W.,R.^NL8=77#,3"QF.$E!9KJ:JR7Q<F?UZ<TX__7IB:J,L1D#0R(I:0!#I
MZ]C@F8HA43A[FE,;&-"_M?[6GN[)RJ">B;'/<T-..+_&(:G<?<_[!FK>$@&T
MG\!A1>%INF<D Y)494!J#\:\\] [WV3.E38^J.18,4+?/.,:>^TA[AT64#@1
MK;K#51:D>ZC@'KEI1)XF<+934%@^HQ.!$BP:SP<:37GAS+UY,^_X5E<EJL,V
M66?X-190K$VIEDOM=FR[+=,PL^9N'^7%P/\EL\GK@W:0FS;G.@6;@R."Y6B9
MD:A6!7A:K:15$,NNL#'@[V!!*A&*#2XDWBB139VK9;7B'0>->,>KCG].AWQ:
M<6T7Z7B:27\ ;=B%_;[)-3AL7(.3FN_\HW$>OTTSB5[#WT#RY(,H5/@@*%<N
M,@;,.DTX!P)^<!?GJ2Y.X:GD'[1OUVSV+5N^N%JW^\(_)P2;_!?\S"53FRGA
MW>^Y&MYZ#>]#*GCW>T]5P;L&.US;3<NTG+L):U!I_/B<CFGQ<077D1%<%\<?
M/WFGIZ>/+726OZJUE#DS1]';KNL0W6W4(3)@SBD">,W$^MC6.E&-H:3_*]II
M:*1)IS8\U64Z._YP_.N;LS<?/CW1GC\OT_1I<E/+S!OH>\0^$7.54OLJZ5H7
MG8*,G<+4+X@LI%)=<A7AS7]9]@8]YZAL^]+N$:Z]^X?OY/-N*+/]667VWBO=
MZ?VT9.Z"*F6-K[3XUN\]S>7.LD%0+1-<YDXO4-0/E[WYQU=N[^^X]WO[R][\
M"P0!!IMT(]^D-2$39K4'_N*_ [N@>38MP:\ELXR[#O>T1[S>LWIBR^#9[=_C
MSNIYWJGC1!1I/*6IO,ZB(@]'49P&_EGG=6?USV15;]K!T?/=NV7.ZF0DH@P>
MI+FHM)E^BMT ,?>@9J;,R?%]_C?T+ I'0L8TE3\$I4&_2^7G53O*];F<^[O/
M=^^6>SFQ3@0GTI+X_L<%)06=ZUQ_OJ2J@CG-IL__7EX@F%Y#;J[:$:[/I=QS
ME_)N5&>*5K0E.*=PY?E?P+,H$S2/WTIL)7(Q<BKKUZBL[@+>4RI>4F(_%GU\
M/W?NT_0Z8FW](ZBESDS\RCNW_WSW[G'NW$D<80UT_/W<N+,H+E*^<J^R]";A
M.^?$W=?JFX?/=^^6BRC!3ICG?]$N"\PX-;)-9(-\U0YCC:[7WO/=NV7.ZK0"
MQV=7@KIN/J+"]38W=C:?_\7[+<U'I5 J]4@,ZU)]%6:X1O=NY_GNW=/<N^_D
MTIV,LBBGB;SKP$.)2,14?)9.K_S:X((SZ;Y:\#W_V_<*,3/9=RG"M)^[:_>U
MGA0G][Y>WYPC]W1M_LK7FWS#W-U'3M"]]V099&F9&][@R\MA!(]0.\%]8NV$
M$FH8@[@(W 7M^4L7T&'7]*@0O$(FV, C3;ZK$]M9UQ/[D(ZC1)B&FFT%6+<<
MY-+$"__?SCQP.5<L='^7J"P0C:H8^7V).+"(:()(GV$636R<O&HJ1 3],H\(
M4P51G+*("GT-%.CBTB,':+*2J\$*D(03A>TD82P[P&B4_SKK6%E03"=ANC5,
M&;:UT78.CQYQ@W)L&TK0_8OABCE'5(_R"O-#&9-<TU*%IS;3%Z2"5$XJ"*/>
M=K?7/NE,#")^/DUP,[%=*:+K%9GJNZ+G/I+QP!N7<8%]4/Q8"EAG/HHF"!X8
M<4(<?'$D10RW)Q29[/C'A?^KQ':K17J3^+\G$3821'#',SF@F.9E.$I31/CR
M_Q0P5G)5( ;<Z\Y))_ 1^):W2W5?$02?E,.B$'66H(]HI_QAEH[][M'A-F(-
M82^B%VI[L<.(6=XY+P^&*/#[EX7(MMIG]R[-)U$!TZ.!>]O;>]7 >N;&C$B'
MWEU&Z1X=[>(H\+\'+VA/3]$BC,;V2"Q?3DZWAB4A4+U/QWT$#J%#SN0(% 6D
ME1.4,9E_0C9E-4F/)KE]T/'?,5P6P7*K/50HMY1JG-=SC;'E[)WV@T&K/@B%
MT70B>'T?Y8C;'](/7O6T;KBF1H=I$6T8=+O3!.YS419 *0A^$J5E'D_IX&^H
M=R)=)L+ILK8(CW&,<%NG2=AAN"E_S$1NIU-[S25^D.ED)+#?+KWX#HB_M[?]
M?_V\RFGA!H>B2N[L]A@T#G&."X*BHNYI,'O$.1_!X5$#9@*SP@F_E00>K@]2
M;91W',)=&4_Q[Z<)8KS E&8NXRB-!SC&*Q'"3>.U4KY-B%#3U#D$KLG)2!(<
MI_\F 2XI)>&7$07@%ZTS@[<O9)+DT_A:))$(/-PE)ETUFGGK)(UCR6"B1-U1
M(GG#;OS?L/'G5".N8A9>:'$&,\([D5UC"OMO:904ABYA#=7M0Q W,9EV/-QX
MU1Q4;[7"U_,1(#I7 -((VGPKJGL+F_1M-NEDZTJN!@OG58K_1:>>X=]_R0PK
MG]=;>SXNN9%#AH$ 52&X'4'0P=TY+J]@D2@*CY@W_8&$9M)+ V]N:G=S="T.
ME1C&$3O^6[P-'Q"T3@G<(X4V>@SR*Z;>>(%_EM46;"D$FF@#U:> L7A?:<72
M1@$5-;%Z)R&AL3'?GYR<:&A, EM%9$6I."5!F"9PC$,88 N1?;T?X<G.D=4*
MECDV"P#&^*,IX64/^8OLZJQP6EDAXH%1ME'#!5RT?A[V&P$%R[$OL@R!'0WH
M-$PJ*Q'SV5-<.B\(5'58QD,$/<P+-+RNL"FM;C6A\#USF6 #.:6E$ $PHJ#^
M:F9#K!JH:W6**$75X=4.-/#FG]^QQK.N3M(_'H"I&-$L"=RV=G"&I/%,K+-0
M?7RQW1-!,@]3;43XPAH/NVI4]#JD+LN99!CDW>UM?RA"T-6F&BQZ.-1PF0.C
M/I&)HK2BP%($QTH*!"CV1DII0BLG2JF]%=! "-<;_M- LX;<WP#^!/\%,DKP
M(S449G&%__BQU]VO4=1<HJ)CP\UA00.R*:^TB "$S8C$2IDAF=O4[FEJ_^V3
M3>TXP58%I],"19GX-!1<W5QNW0"#\$.=B%<0:/^X@@!FG%@Z@VI\SQ+&.'Q]
M^A6A[2I"0YI;Q!_F,+X%-*5QNCV4JP6PY/JSLQ]+Y%5:,"2[P"\C#BZ0"&A!
MYK8@/[U2O2ZLOK1]6=P@-BN=EE;[</<9VDZCM7N*!)D%4,<VW&G@"M3=YBK!
M1C;8;DDS!'C>8JZP1=UJMW87[1:R]BU2$ +_(A:)L60:5]*KC($YIDJESBZ\
MH8:^ZW>T ?C=N+&(8.[O[FY[=$'ANHVF.=P\@8CW6BPIS'#2+//9.YS7U#9\
M] /<"+JS:M? XMBO=FV1#/(NF6M6K,S:+>1GMF2R\#W]2P9*#GS=*?9UC<><
M&7ZRV!KDVQMXE5C2+848EAXO').69FZA[3WE:TB-DV-9'4C5L5CR7MIXTAKB
M64^\VEC65*NCL^Z[Y>2!\V"K 4Q3T@@8TA=O#O,^F=<,O#.UB!-!L)#1N%^"
MAFU$Z GV):2MP-^/Q_"94'C:@-Q6!N2.5D^4'982;F^L=.[WHI_2>4V-;U(Y
MKM1X_@8\@C]M&M-T1XV\SX:1(6ZTZJBG1.'U4S3KFZM#CU:A-([6O;+PO.'K
M5Q*AK$3XKS)2/H- "ZBLV"HGU@7IS- I64A@QYP).+/, DW6AN4EVPYYXY+S
M*K&_(I.?Y6OP&TRZ;GX=8[,N&/Y55,G BWP:LDCD8WF'G;N5!>7,C95<37T=
MBX Q>PX#<[D8F#L. W/E,# =6UD>3!$51%M./'1@U/W\M;9KBZI7E2_A<E06
M1:SZ_'*KFUD__CM9\^WR9[QY%H+6_5"//FLX';&7@3$;>WO4SH=42A/1FJOW
M:'=BKJ4N-;L@.\RS#.IWEKNDH1M7@0.RV96%M/51#(RJ,C1Z/SNW]^;ID)67
M?GL?5'Z,&$CO3S0RQ;ARQ6O3Y*TH004AQ4+]4G>7X"@\6K>KM%VP5XR>04JC
M44 PA=M8H,:GK:?>[;)?OGO8@1_Q'\IPL8Z!&X*2 C@2$YS  5!P\CDK)T5(
M[;,+Y68><(<'UH&C&,'%J94['$Q.RJ Y-_0S8VO*QK<\L-X&):ED-,'VW53.
M%QE=DY\[]\]>'5?NWD5JE-.!5G(UY'+-A%<K'.^_#&:BELBO5%N2P)]E9<QC
M9NN B7BUGLR<K,:S6,WGL Y':SSUL1;P&R(T_&U^++/&U"Z5%Q9= AA5P44V
MYGZ1I4.X%:S75U$);9F2\^HL"K.T'YD@X5U"EQW_3V1=U")E9[MBGPU6F<82
M#%;@$I6337](NU8"/Q])CSJH\-L%,UGL=1/E8QJU>ALE"C!+;8RKZ!Y8@>RR
M>??Z^ 1>I^[PN*,TAP$0FS:(:R-19_F.V3K-V#SC]3&]=U1<LC^E?ER:F[X^
M?TV>5AH\10WG_\[&TA+T3^@P&C A<LQCG!GC5I<7G\YM;R';[%E>Z)[)WLRB
M_$%67G$C+9E;JS->Z#B>OU^:H\+S";?L*E1W***]ZKV!&(/TJ_;&4V$Z()UC
M'4ACP_%B]!JWN4Y$2%7F[/^(V"\S+U[W=VQX"'?XO;C)D'(<*UW)U0 K94R
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M^]^7=S$!3:XI>Y)0V4>1][8R'MXD@S*C& +JKJ:F1NCT0BW8?-;W8<!+4)?
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M:W,*GW\9HFVL$CD%I5X""5R50(75?89?,6>3L.Q@&$UM(@QC$2$(1*D'Q27
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MJ3\7@L^J\B&5I'[P]<*A>@TEGE\6C2G/2;]-N@^W"Z;<$9,<-AL8X50PS-[
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M2?%YJR^!,<#8$SHRM<FPJC7:X=INZANV:!/LK<,])8K\!A?QV]Q_O4/KSGQ
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M=^?O7[_Y>/G8^[_\I3POC7YQTG^PV 3VV01FX[Y?W<34OJDSMGI_RKI?90_
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M#KWFJS4*JC/&JDW@%466QFLV_[7<=+1T=??:B&\)HJ.2089_(^7J2J$+\LU
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MX@=NHJ%D8WH4R:$WTX= %^;Q]T089B5]CLD+G2X''2#\''U!M30L_ ,%]H-
M>7+PH2O0<W HT/&*&TSK:JDI]>R%V[F+M,*:T?\^M;(9":@ ;F(1J/3 QF1Y
MP>V#X U#I1,4WS":P.;U18RA>/0R_;C;VX5-W.OL[P6H+<G:\H6?J1731DRP
MA#9)RC';JSPL7$N.[^G-:28N=3G[;\[<4$G&34FH(AAL7LR"*Z(84<*EO\.]
M\7I!+5\14^/&\"PA6B@GV)SAQ54FN34X__$WD90BF_K8;@\'[OCG"7P*6%3O
M*/#X4_81M=0^^Y0)P7M_G[G4UZ#K^"9B2J_>B-SL .P'7,FK46T/=GBJ:O[=
M/?YCX%<I96&<YN1V2M02JE:9Y&C"M?S)*2C(\"4;0JE_/,T00O^$&7M%25[+
M:<$L)R(B'$.\EX@TXK(*5W(U=R^6VG/%4LLMEMIWQ5*N6.J9LI5[:G/PPYF8
MLD1D@9SP7R]!@>)1X+<C)5U0LS'ZVFS?J*;"=#0KH;3"%-Q=8SJZN\9$:F=W
MYS#8W3WLX,+[Z#+T;)6)X+(6*DWY_92FMNG9RH*E+GGW4I?:!KZ7NN2WJDO>
MH@.\B^K4,J^[JTZ^4IV\NNKT7&[?L^,E=$P]1?-U6JK3"EM6%7W2G6YJYJJL
MBMV(?%D5SM*&N<N;?&M1]]7WUKOEWC+_T"8>\((XQ2BN(K]!*?'BFRN=)KZ]
MJEZ-:_$OL%:^;\=Z/9IO=;Q;+]C][9%Y'UUXK;RV:^6[:[7ZJX%K=5Q>(:Y7
M5Y-0A+5PR5]E0F&J2M#"K;A&HI^ 2L_WBB\-P1GAOSFA1>6^*-#$[O9//F&^
MUA#.:NAFJEEI#?Z(PF' UP=,EHB!A#)9#J)":HQ*K*S$2YR2(=HD=#T\RN8?
ME?,GT99M!A(TPIA!VX2\.7!K57K-C[W.WC9=>GJ&Q6_+*JM5-$2L_"+'Y!-B
M?U0FKV#',I7PH1[UX-&/)?"0O>W]C?XFSN.CO"HY1<!_;1 VJ\J*X[!PMVPE
M5P.WK-)AN[OZIMW(IN""P<JA" L./#<DV*>37_U?X2_)R4B"I#E-PHZ_H61%
M[;=*L44*^;USV2&$FV@0@7Z&GCQ\^GTTE'D8H;69^Q?7A?^^&'30G7X5IWW*
M&DN ),."JEM%ADEJ0-OU"6+9:X3OATKDQ"GAP>*]/$W@<XR\=X*5J%47F0!A
M33T5(HA,_DIAAQO@A9,WY_3)D\MS7\W9K+#Y0^MB&J_<$"H@+TH!-DRR-,3(
MOUYBX _DM8S3"6TZE6C_>G9!JXLCO+[5\DGXGUX,/@9T^[7,)8=7_;L_[BKV
M8Z438/J S])2:_/>CM8!J"[3\ETCP-Q^L'-PVPBF^C/@&<M"/ZR7[=C#2JZ&
MTH:N(WD3>,=4#0,'3^E?P.N'B+"LZN1U.IC++5J?U1S',; 7/C?&-JWE "%
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M;-LLQLLL/!H[DV?&Q]'4O[>^_!]02P,$%     @ E(MU6.>4LE0.7@  OVD
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MS#X1,)=1:<-A4GOR/#9QNJMX09%GN,E."8\ N/(N<3S]63#UOPI=ZHE@<$
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MBXNKGQG!FYSF49NYJ[#3X.0B+T-?UL5"DE1+6]<&;0:-Y?%'K[2^9M/AQ6"
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M/2@E$+ 4> EWEA?;S3#X.MY\*]Z270,O!]\=$O!)X.5,A'+FPTL^Q7V*BL&
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M.0HSGONU* 7+GBG> -WV-&EPX</9LY^]BO5O+K+8,*3&JM_\TJ)[,_XPG+G
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M=?2>/\3OI-+04:YY<[L?:"'_SFP9G3KGS+7CJ=4O);I>4N[A8DH::I%P=9V
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M9Y3MWM_OI)*X%7.?7/5MI*8Y#KO..V E)9O3"+C4!SBKS<=A6BA&JRW%&#X
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M:/OZ"H:6".>7Q \.]O25D8-QPU(\R'>*!D"&I$V4(8NN7E,ISZS2J/26I5"
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M>=I5!<S@OIHE)FOHJ&M?#)1@^2G[SN9=OD80YXN%K:$NN B0A1)(I'\HEYU
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MH-(S',>6D:8Z:62.7K:O#-LZD:]ZNNXPCUIVJW7'B69W.#/!\LC:Z7G(28T
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M_H^2R8B-+B[D^OR5"8R<6*8/"]7!$GR\21^8W J7KA 0QAU&O$_SM9(1\:0
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ME4J585";FU102*SFH@KXRUROA[R-+,'!\+!Q:=N5SN- 3?0K0&OH_8\VKR.
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MSB2RC@]'I8:BR&[9GETH3C2IT?&8=H[<2$N%^<"A=IZ]U$G*;,UKST-L#&J
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MTE6 4D3C.;)X9] T3,OKQN/ ]E&7.MQ\'%I)N,LG1X%?U*:*,JH9]-='<]4
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M >?$!'P]X\@O#^25;ZOM=)GBM24S^-8Z_$/PC\>ZVD>[=EX(2$WKV#Q(>;R
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M)<RMIQ);K D6#);1K?8$&R S ^QGQ2\$#-1"4^O%*L+X;&#!%:2N.8/EI\'
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M]2U!=[==SIE;?H+]:OL%S?&]SS[ST^W.&?VLW%M+$L@F7!!+K M&\-<O?9S
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MV+ 40A 6KF)Y(R*8 WKQNN?Z@1_MW.T(?;RGT/PO$1&H.0'Z 5Y2)*U%4$K
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MPWAO"2ZV0Z5./3*)[F>=%<OWH2/YB8OH8HP\?.[@:OM&3D/-[>&*A05+O^$
M\0*6!IOP+$[M'KGA/=M6^R;'^WV._1.[N36,WY/O8\L-Z5[7,QG2(%J+$N/#
MI>CG*X$(3?Z3KV/V#U$#V$-+1M:U>;9SO!@;1TQCS(G%1G::,_OIRC+Q6W;7
ME>/1M^FU$HC=F\-/GJV/5+CZAZ2IZ>INN9KAVWTU _7]1XV]^7+SM5IQ?\<4
M96V4D$-$/GJ^7B"->X(B*1NMYD@@287_9?5]%MV7E1B/8GY((%_OKE?E$GNZ
MI8@>)Q71/X_:_'M+U7PK_'16;+O2+8%DR2RWA_XZ&$H4*TM[^=(%_7=[N[N
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M=K_+V-FFBMM65PD96(TGNLJWQXY4I-,+;Z^7>])]F^;J&LK%#_\=!_E*9<+
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M Q,J-9 [0*J?4":19BU_9H!PT+3IL47<;&0H(C.B/,!F<T-I36V#8X7CHU3
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M@7AMRI4F,(2\M@$<IR /V')@T#B,_AWI+)1R$=N" 5^MB+PCB1YY[)-EW/O
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MF_+,AQU$;FM60EPI<EW963'!!S$F0:C9_&-4TE2%#$2D&H.+P)_P!$@5?86
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M?HI!Y1G;"4#/QGON)=O> OW&S+L- KT#"5^'YK@<TO8!'SR@/8S[I=;(=16
M%%.3<<MA[#)^B4O;GXZ_*NR;'*H"T_V(GN//:^F--;QIC@MDKZ$,:V$CE;M=
MPANR,EKC/Y8MXXN&0/CF13MIZ5[%5@A T6ZF E!:I9ZZ?ON: +0K2P ZX_@A
M:E  ^FYF\%_;3/VOQ2NJ?9.W"DJ1S"M'AD/@%^&24I.G]))Y;7^_>*5VVWCN
M5^GO?23/_KX\\@8%(529KA@'UL]NV#'@^E+/I,1;H7<)0$<QWJS46 .D=!U#
M#J* N3IBM!^X@),&FJT.<T^.MKJ6HAQU]!ZD'-ML*=\,3[]!4>:///61")?%
M\/-WJ_1?O&&7CWA2DQBCUE ^DJ&J;I/G$Z)&";E<=:4S)T9ULLKR2):2;D2&
M:B?&J;IW]Z/GBDE=M@5JSQ?M2\MD./_8YIXRLG0)M,E^/LUI&,X-+ZTY8!G
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M_+];_?^P51_V,!16+\5=R^&84,,R]D](/\N]]['7QC(@?^S]KM>+OX25V@A
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MHG)=V?[Q1-'KJ^NW1D]2@U,/H1$6(PK\Q?!5X301FV],^_0GI2;M4O)-V:#
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M6!ED9YV-F=P(+VQP,5/QN]'4?T)'#3Q!:(*=*U%MH#RY)]?Q3D-C=,N'%P)
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M3UAS^>\,;QCW+F.H&&75;FHV)&54A[,6ZE80PK.3T*%FQ^%:70^;)\25U#3
M:B=MBU@[<@H>RY/WHA*_FU"&Z#5K(T"[]P7<H>[N\\"/!B3Z.)NL5R_N&[LX
M9/?7:AV7<J+;6T*GO+3[MCXG_W#9V/!_Y_R0=]_>7<I.?[QQS)_M.UQ1)\SW
M'S/QC&X_=RSYYH#U(0L4\?2HMI<,ADHM_;=)\4+I@2KIF]J_9E14_<]]^Y7&
MO7:\RIW[,E(NB%NV[-:?R-\0E/X@60;[MS*7E63\X1Y#-[>^E%&+GU7"_@AA
M_G'HZK';.2\&J*Q2&ML\Y."$GSM=8GKE_R3JRN4L_[^%#O'_EW7_GY)U_SF)
MV/R?F"2/M64X0L;M1P^DHW%&,53UO[F9?VUKNKS%<;ZL">70F+DO.9$;ZYJ0
M$K[]5I[/<+Z.;T7CN0JC^>:'PV_&G&:37^Z\XI;GT83NO^1G]..KJ;9U?L#;
MZO#]DPG-!H,BJW#X,^FEFI_N*#QK5UVS^E'L\E0LK]-#2]!&^J8G109;V34X
MUU?V/DH>[)M]$%T&N_9%KN;6DF=#5+%QCM+F01EL(,CD*&WI,D&TF4.=M=LM
M@R$;D=#W6AF,0:8NNPV5EGG*8%JWV2M+<&F26RWAO:[75_9^:K$#1)?J_'CQ
M//'00W-A-M6@Y0OGR\;-5[\[=F\Y-U5H-K:J^N-.Q_F/6RX-B?* )7O(*D*D
M0_FE%^U9[I.E<(=$O4KC>EI"V0)0@+VOGG9?K '>6A(@VTQI<4R6 80S2C%N
M9ZN)K[9%:3 !U8[T"C=?(V][8$)2^W3-.2=T]RCFH"1#!OO=S+TC"]E*@I.[
M.&QX(90GP,9/;H+,P3)GJ,0[A*^+VP(%M4YN 3,Y[&3VMF>D^%Q=+<NDRB--
MA*D%%^<A UI<E!:+!894YGA.253<@.!JFSET87[,J8&VJY]Z-M_Z]'3:VCK$
MR?@7?:+!0,@.5:N3IP<=HA^Y9>K\78GBM-;M3=71>S=3J@I>DE1L,;O@H6.Y
MR1&Q>:AP9N!^_D'S34?. H/Y!.7=AM8A^=:!.:CRJ+W] 5=B_AX_O>?6\=]>
M[]]:\/-O.L_^[K$GU&LI2++D8,XE**,1)1#/?FB9%BM=#VZ0\)*:# 7KH98=
MTD, *;9FB4LUAR@TN-C%3X!3'YM](YCKN7=LEG5T$'VL2'QTY.. P<(Y'-*X
MS2J&3HM320?BYA< 7/MQRGG@41;J]5)L^#)2-6I==\24&4[X,%N N&M C:5]
M8.]>9.V!^@_>0 ?R%T(]P 1 &C.5X_(;%%I$EL$\6%4@(3[8]K MOG^D?:%@
MQE&2[CY>>\/@\=GQ4X>#\&]JV7J/'C_=G15D^ZULH#C?+PE LG$;LAS(Q'.&
M0Y3#A7EA'=NK[1@UP06?U-\^O5YL?<S)X^5.UV'QM>=LSV#<Z)C0'ERL1B1J
M P=B .]6-[N7(H([Q'N-UY8\JTE 6_"5]G%H6RF*95%O_$JM@J:;G9<<087D
M%3^&RASB*&2W=+G?T-9C27PLY&;=FEZ!4M$T*IK]PHX1*9!+1LC[-RALRN<C
M:+Q0S\?!(0$V37IXD':ZG[5N%$(Z0NL$_=Q*=CD1$40YUSB"MBKR78OI2"F=
MR47U'Y&C_[ZE19)3OW?N KJTRK8!<BJ[:%>07G(M1_#4Y;!_\621-CVX_]/C
M,LF-%I&%[>\GO ]V;*_DQ] =3@:$O477ZMC5GA]Z>DG3<K=!V7>'FSFG;)WH
M"UB$S>''6]XJOKRT_H['O8S#S[Z]VZ'VZ[68]<L;<PB][^M%IE%OD5NC=HEO
M8#>CM0&2P+*-MIV"A9X :YU\XT26*3G(KI?BC;C+PE!^'D+_)&]<F^96D8@0
MN.IEVW((\[UCA'N[T4] B,MBM-&49C+7DG,5@>YD1+A3I\!E086_%)N['5H!
MXUKE'2^$!IV/4OFJA1T)9L=Q_QY\7Y?)TJC+. :+OG+L3$B7C6Y=T\"-VOR=
MTI&J:N9@Z%M]RLR)#J^5HS?O%SDGCX\EI9PZ=8L=5G'[\:#[0^?'1E,%626;
M;(H."(X8A;@KV\!C.GHO_5&D_E>I=58)<N+0)%+5J,CY<'KZHV/**42'K RD
MLC4MI<]"]74DS$5X0A[/U.&TT773TQLN=HM\R,@@V$\W*'L&[HQ;ZJR[^W3J
MYDG&=!;[)0,R5I!>$$WS)+EQ][ K%V>&EBFZ,MB^>.H'-7D'+$X6LSN0/_;J
M4C^(8K$K02I"CH"V$"G"BA'0BL@LZAU/6>P5F2?VEI0L4BR( %8NI':.A/CA
M5'OX3BFU[<TCRW-6-6E;]1@Y.U-6RI*<ZKV=[M0;CHM#H%+V!M;..2U,FIS#
M[F<[)KD"A/M-AOS/@RZ6=<.4JR"B(QQ^AZ+M5>*G1 J3/,BO8PM,-]6F6-U8
M.E [L*<APL\]B7$ L62(6D<V)PS7H-3FHC8#N8T"PD:S-I8JZ/R2GZ+B#"+O
M[V<1]!<)6_Q6A<;JS+C]S;B',\L170?J<1E_3"?RHTRZ@9PH52BC:_KNW:A=
MY'MSK=+MP^]FRDC2(3 T*1B[E7QBWMAD>XZWS;!+1T-F',U\)/B-WN*RTM4;
M(7\M'6E/O]*Y]O/' +7DAJ"RHG<_6&^M#!='7>L6<QMFQ%-#(;O-'UL331N4
M+#BC=%NJFL.M9)K9IW?/']IZ&)2+:6WL&ERB='./#/;+E\ZTG\P%\%V^"AV8
M/0"=.?^9R3H4UX95C-H->>) G39V?!8MKBFH^*L;\_X-EJ85)4L_OVC"=^U]
MOF!N+.=7Z/A;Z7?[;.N7WVC_G&UV5JH&T=&$H%(?_-[TLT!:VHHFPAUDWUL>
M'D$K3RW%N2VUN3/BJ!ODKD<&NSB$,LAQOT!-Y,94]V@]?N:SMIR[N]8UQ#;$
MH%OK1'@DZHHDF>T]-E-K17$L$UNPP6[)Q!I4)KC>"#:VF0MX\08X%<@+HS6+
MWPBBDK.DW$5J7.Y^H#*7I8'9>N\MQXKEYQJB9$J*EPZ48938\RDB]<N1^6TF
M;E^YJ#A]L6- KLY ,"FITPX*%$A"[<!KN1B@Z#XZB&XN]]:_SPFE&\%@!@."
MMQJGFQO'Y7#[3^HO/[R12JNOZR>YUV3AG5UNL[TCG1O\.S)^SUK]>F[3Z>+W
M@4_G^YUV?,[;@''Q?O?('3?N7\ C 6G")L@;3&K%'P<S'O-[$G*5!YI4@;%6
MWL[*9=YNLL,PI\UDI'5)@XC9.XP^-(V$SZAKU3+>A&ZL1MP7G_962PG3CF7[
M%Q,%NMW'?PE8T,EL"Z9"AWCSH$#1WSH2SL$B5NK%<GVSZ=-(ZH(!%DXV]TCC
M2^\"(W902 69W:ZU9WB9MGL""I#!S@TL$Q*C5 ;STEK#.^-7_%I#*HR43M7Z
MJW_^6S24-M\M.@5YMZ[UW-&PKHOCL%6CE,CF0F)S7VW/[DFT]!AT=<I#M]U(
MN@LH3-";+%(2YI5SB;G'P UM7%;\=[_,F1!26."^"GICFKY<GGGR/H@LZJ#L
MTLFYU8:V7-,^]%5@0!":2/$ /_L[+$:0U"#":[P2:!1=/#LP*ZS#:(Q8QDAW
M0DCKNIJ:.)N&OM][[P_?-OHV0; YCN]T+\WNS)BH>RQ>8DZ,]^.T'AL4Q=J>
M*:I]5._2E/5(3RLI4^!G@_&N>-(O-I4P@JF)5$T$O^B^6$5@ )%0+=AX'L*
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M#Q,\/_WWK/8&#5?Z3AVRV/]-67W!K349;&$T'PJZ MWD=K8@D];@=RD10+J
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M=DQ-VBZNC3]U:NE^ X^KAVHZ5N!3[?O6T./P\$"[;I';6EQ*%#IJ./P&8;U
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M$Z6-UVXX&=S>N>E:Z<YUWD.3$J.:2X32)!;CA]V2B.Z])086%FD"+^C(83%
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MBS2]+K^>_1%03[EG>J%'._?S7]X6\,,1(@-A4C,LP'OO(%R/?:^._ZVB"%O
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ME;P]PJ)PC0'.WD(P]O?A^9A-3"S!><  %FPXO4>"Y/DX+RJ%7_M&HG&;ELH
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M1C497J<P<:8=1 F*A@>12$&NI5FKM/BZBSB+T&I+O HM;'6HN"KBRV- ]#"
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M13Q@1C$9#R"&@_:LF2/_]>S?G?]?0Z^AA;$$/R9/^KIW% -N1\X[2 E.(V8
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M%9"D%.#!=Z!1@7'/ZK @[')I"PLT)T[C)D'QKP<[F2Y<W=;COO'1]N#+B8A
MH4.6O.\\B]'W\FIL_LUDQ4IS>]B4<3$)LJ'8845-;3QMV2K(%E;:5EE#&B<5
M5&7ESA;CZ=9U.^+U(Y7/6V:)6=XN^4F)FPOB7P\$O>?U!0R;@67(3Z+>#I,*
MIZU''F:V![H+:VNFX 6'J[:UP:U;D >$?K3(X=):K5DPHL)N\7U[T+:3D?2G
MIA]%?9?8RS.OMQEGWE$9RYX'CN/8M%4&RDT<VADD&!@6N@8WBUVZ'G.?"-TQ
MQA&7[VL$(/>FV:0>-8+U]UKEZ-RT;2KS[:JN7](I$MHR54"5;>$!=&!K#0J/
ML-9$/75/[L OB!.2P'OR IOVC[B6IL*/=_5A51*A@O85Y$80C%@^/_6CH;O3
MPUL<CI1[VTZ;^KZS<(!@$82?>:P<:;W?0'WPJA;U2YTJ>G["^P::W/M]Y4"A
MHH6]@;[=6NJG+:W5F3([7$#FY-JQ601#BWJ=UNA5PS6W+Z_L_WHMR*NDJ?2A
MB/$I)G>.W)N^.FBPG9TM9D8S(BX_,,HZ4O=)3UU(MY=&,R)8W.P*EILZN$!0
MP)7/^U6,N:/'1.;'SY^%=K2^,/:-CWY:1@I^\X81EW59H&]ZV/+GVHF.5%96
M+BH=OKM6%4[[1O:."QXPOJ$9;)S8>NP0]4S,)@ZV%>8K-=1Y8_7R1T%)-@VO
MQ3U^]V8IL^8IOG9V_D'&-A#?L)C:FIUHYX?H;7N9]H?I,K.;"B0W?=+3$1A?
M;\>3NY@B=7LU!&6OIZMS 250I8$GP7KLLKW!DX?HZAQ9=0'EHH"# :D-\'CJ
M^FAK[[PTE/G2?B>+XS#'P%;]0MT."(7PGBY:@P*P2G.G:KK#HCL?&/O7:^%D
M#;40'G+C4M0[^:J/=$EK.-9I%2L4>4O54Z'=>=2>%A?[D[GK32N%'HA G+!'
M\,,^'Y&"=9 P;H)Y)-[7-4?A[AW.M:UK\Q+/Y#Z"WP<,#4N]>?@L3\VB,/9
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MPE76J+WV950 5M0>*Y+;E-5]$.;R[*-40-W]V<6%&3HGT%RWQD\TF]5<>[0
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MP3@6#[/FVOKCK"BXT=KA+A^7.HU%N5 7Z84Y8:^M=D@F*V'EA@ZZG'NCI/:
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M?26,#%D>?,K8>_3TRO\W 5!+ P04    " "4BW58G&AY%*!%  !U3@  $
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M/F]GPL1( 08\8J0DPH *#8T! CE:M;_."U,X0&>;Z4[)7H$$ O/6"3*7/X9
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MIM[ UB.O<L65KQX",&:EG;/%-@N8;W?FS5N?].'B\CQY0 'OZ:6C*&%_O[8
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MT1T[:KPZ<*!*\7#A=(NM7VU@:RF*N^*TBUXO\',+IE B+%@-"7IW$,G6HXA
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MM6<_%5D(]8%D8&F?!>>@V6L#\,>1(F3,%RMKHD2_U[UJ!AS1]7L+'H*1P:_
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MKN1_LH1X=Y1EQ_R(PRJ(I?^L2E)M61Z&3Q:#%3S8/IK7J87%*DG5"RLQL!P
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M4/IZ/&K!FY4+,FJN#*\'J+V/,J+)/GW# =X:/MYM26%X-D4L>A9WYSYAMC0
M4Z DHA>G3LO+/96? :!\P+LZ:=:/\1<\V[4Y%0;N[<..OA9MUS*ZQKE*JM>M
MZ33VDF#.N/Y!S/AXN[LN=^8?A-OGA.B,C^)/.*XERJ3#?GT5#^J;)*D';K^Q
M'(#<M#W2&8"WU=1H'S>0"UB^K QB'4G.'Y\T6SKC >W$*DQ^Q@%@F3A HXJ,
MV3+O=H:'P=^R_IJX46;+EL8C/)*-<7_/Y83-+W_12GL1@<*7P=)N:3)0FQ/^
MGL1;I3P?9\*=;BL4^_07Z;&Q#"V-71\->@N:^C)]%B_9 O)^_PG\ZN0EB/?[
MJ3 CO@S-Q$0"+=] ]S-!K[/<[T6C!%L19.CN;;(&-UGX2'%:1#O+;AX%A[3:
MEQ]Y7X]5Z8S 7$C320%^A7?N!U75[^YSRD$9GV 7 RGD9R?6C*O^ J9XJ$=R
M80VR$RLW4"DN"0R6H1^V*D\=?E :Z"=I75X5K;D2Q="W3S)8YI8*5]J8/PIT
MSJY(<KZBQ\C_7-D[D;;XAFR<;* 8]R:%?<VI%&AOM_K$/6,327GL^RSU720!
M76GG\]>O2!YN*=86G<6S'2D>,ZG^*[V!6TMU/9CQ1O[;MD"K/UG.C2PNSDN]
MML@_B?+X1/7TQ^"A#6AU[=P1=US+LEU;UWE_/['3P',%#26(8]?RG/B?[_VX
MM?RP7R4[033M1=2ZF#:LK FRO/8;)7XX'J7J1W"6XXA3@>E?@OX6\$U 1WM&
M?AW^MZ!_:<72W/T?T?1WF(GK_R>"O_*T&PF/KLN52_.CTIJ*I6/[QX7.6^QU
MY1_S8BXS\"X_,5,MOD2"+'(N^]L8,CTDIO <MHXHRY';;A*K@5*@Q4B-3LW1
M?3]C6;72IJKJ1-<N@BZ2D0L$@%7B8KLDXH0B%>':H+=B4)$:N-O=U3NQ,;"G
M8],&39EOW#^Y#$'+\$D%I(Z5CQLXN",EMN /;#ZQ&:Z0EB"_VR4$N37SDHPM
M\P3F.]+'.U#YIJ$;BKZ<L?D%[S:\*897Z,+^UW#_=A@)W_]I5OQ7B[-D&:V&
M*:KV0#VP+XK]X_'=IJ<_1MRF6[ZD5/$^TXT JBNI/HH9I<LX+=F(PP$&Y"0=
M106/;0],SX@TUS0GB8Y>^ 3L^[BO\\D*U4G_G'Z6_CJT,C(]/NP%C5F&35;Z
M*_R'V;]]G'<R?_'<D.\WJ5CG <S49%A*A!&+63+SC*@1@FNE:CUH+[$O6N
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M2 4UK*7&4H&&/AG]EQ.Z?U&*9,_WQ_,[C"( !Z_1X*$Z0MH( '7X8]D9/4<
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M'G&QL YG0 #Z)*= L AXD.P&4\5U#@) 2ZJ. -2+WM(R198'&W9$9(4IA@4
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M81EZ+YF6+C]SOP^U8>40=T?^/(^Y*Y-:6<-_,2*Z^NIX^P']5A/^I >.3V;
M-FH^9LO]\P*%A^!H<X M?MW&H7O!H@&F07M"D(#'4WUS*G-9V%F9^TZ&.3QQ
M&!:<]VW#44)TR0/^YDKH)P+POUK#^QOR;\VGSVOK:QMYK8V:$W5_]^>!I66>
MN).1^4\3'2E.7J20DW_FK9;.]Q JC.<ST'#MML=_(AS&-#+(@@O^1Z"U(G2K
MO/C+%PO ?I1M5QKCXA$%B3FB 6)"\KDWA!RMG5'H6J'CN9>GDON45WX<@=0+
M2 IG9^@?%?\)X>K;H>^.,Q_/5H_:>3I,?(Y1%KP<>H36<B?J!.5UVME*\\^
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M:?V2XI0!C[A UKBR!T?^"9<O%$SCY79AL9+7"^6+8VD"J[*H.[J,I_Y[]HS
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M_7&6@G(S^,(&*=C3\+9UA';"-NI\&7-1SX"<W5"CQ36Q&@GK@YN]9AL__IX
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M#JD[0=GR1PT3D!=N/=7[1+TQWUWLA@9?Y9_W][.IR8XNRM:8AV/?A'5H;B,
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M&K!\L0TW5__QDRMEU[BNIB7<(WBCYR6SR:^=Z[L?LU6[>D,_[MVOS^!MY@C
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M"J0Q4I 6,HF!J7/IZXS(0B $MZ'C[K9\5-*V.E)I;V(W7I(=_E[!V-Y4W=4
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M[G!=Y@8Y_H8 3,ZO5=P3@RZY_IZL4^\=0EH1 +1MN'&L&:V-VX$93YZ/653
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ML?(@SBUTEM(W@7S%Q=PVILH'>\]YH>3_4/E,T:7%!8FV-5PJ7/&R59)8WBO
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M<".#.9%(Q0^^1(JT27\ L<YU3RX-F2]FAHG6X0G3KRXYW0K>J)<CNJ^CA66
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MWK/NE[N-#O;+Q#E(?M>POCXME"&Q(1BT/>182O'R%,A1$Z9>2,K[6M'-Z)+
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MAK=Y:JH6@I,O'SZX-*I)$:3\_QRMV3[#]<"N5H=Y:"#E%LK[EMDLIEZ%J^I
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M3/D31^!B3-AEM5G!B%2A*ERW[&))T'N'*(XZ2)7O&N V?5FX8)<:D$8*-[,
MVT>[#B'+!\4TO@SEJM__U[W\U=HM@!8**OXDO"4PT"Y';U3(+^[$,'*Q%> ^
M\_SY2(@>83XCK32W;N*BA9$N?DJI)NCYVCE!FHW75&ZJDNMMKU92LB;<]U)^
MY.+72=')_B+#^>*9/>!Z]D5#2:17B86;K];;LJ.CUH_=%D.7.8,6R>:ZM6\
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MW'M]DRMY=MBM4HNBC#^S!E2.$_8'-K+!0$5O"M0I&,F[I6;.EXG@7,RX2#(
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MS_X1^49:G$!^37JR;#-5$,PQBKZ#8J6;I87S6K43)Y"D<8#.FKZNX[)I:/F
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M#K&.4DY<S7*/KF7!0&VEKZ.E:P<?)>T\ (XB7Q/ZZ4E;8>&2_F;4:K? L*7
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M*\L %@H!$6C[^91]8<Y]TTM-8U1A=-W>*+;Q58A(!00Q[Y/V,B="?G%V1(S
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M$K;9DFQY&PR39C,/@&)61I!D^TJL3P>/X:R]$,_B_-[8+C;])C_-]E>B+0J
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M)6 +ZK13T%]625]MHIWQ3=K9J PLTS,I?6*H2M\54VXT;V)D]TBUQCCE73$
M#4E%(L@=6UF0<%T ?9%46I%<(4</:8L;:3==O=47ND^V;0@U/K=UV%E/7D5A
M\)[;)\9"X5OV&UQI#:@UTVPOQTLZK1!UC%<@2-S[YF_+Y]U-LR89[_S0^PDC
M4G7?:& -1A]%2J.9_#@6SB@VTY_;H0R;GQ/+&R4,TV.4Q7GD@N5K[4NQ$QEO
MCN6JEN86PN?6(8"4"'75[F0N7XDG2MU2?AZB1MY9R**?EF"3NCN<2@(0T9*O
MS0E<L6[*],)*GT )*"'CDY%?T_?(.9G36186Q=MM3&%6$P3Z)CL/ !NP."NE
M%Y+@+S;_FZ>,2IJ9^.7.QK[U/>SB5-]I&YN%89@(D5\Z> P4 U7>&GGFL:H@
M Q-5KY<2,V2DCE1HS';]]/!U&_);>Y-N28'@H\X:)Q#L_/J5T\HAOHF]%!LL
MJ?.PI+/@@_'BG)E1"X@ X7;Z.G'$%7/A;%?.[HH)VPB7[0_5?* _C8R58P^P
ME2#$>(T6GYN<?GZF%3/2N38@0DL%&'N<F#@] \M6<G$2Z']I[!=#;1UB\P93
M<2>AVUWCRD<7.O&)G8-4&(VA 7;SZ966<\R:N^X[WO@3\'.ID%;_2(V25;#9
MS-I/XHQ1OJS.I)=7+MTG@O5Y7'FM#2!?L$&\M58T(3F=\2N_CF'=F;,89?U;
MU5KUEF"Q@0[@'#;1AN("&3I8?"W?'TK,-AST.JR]S_GYWIV+Q\B!YT761TC@
M*UR=7_>##9'K2PJN*D3M;YBS3FU%14Q%-O/CU%HIR;X A7RH4!5O^"M_SGU_
M-DO4^9I;"KKT+RG)T=ON_>GR?_6G'/TDD[U+6?G]]BWDXL0I3?6K+#TK8=\>
M$RJMR2,Z2+"XJ&Z1H6D\&U;;"KMA7#4Q;NW")>HA>/V3E-Q=J7<P?DD0KOFQ
M1)SQ?^_V_B^E9]^-!\ W0;<5[)LH<>PLJ%* A);17\XV.\JW QUN">& T&U5
MGTS>V.N]3C=[B-"$"N=9_'P;VHOX3.-:@'?T$_[8\\EQU6EGN)'TR0. 5@-Z
M'QSS !@ZE33L-(2]8J@54R)PT'VB#^YKV:[)?AZ];\S/)=+KH._)J=S;O4AC
M5VXC!J)7NXI>703BP7'OD%WHH^Z@B>U"E$FYR^YP4,X%Z/IO</RFH5<^\O"S
M8XL(A\M*FS"@S[H.+!"!<3/H8OW"=_^YX.35#-4\B@^N4@VU']X88)A;**IF
M79B?1:^C1DOWJ4B-5,O?"/!J/[_$3PAN_J=V^S%&-RWP " &D<*]L7'+=SG7
M;9"I^F#UIKV6G-M>P!I)&A"OU/HHQ3&[NI$R^@8U0_\24_6D:D&>#X E6BF3
MDU1WT!R$KED_VKYV9[R\OSQU*[RJ6!#(3/K2_EZV('/4X]M7:^P@E*LBHT*Y
MSM%]5LD.Y?PNS-"-O;*T;@<' YIPHFE$O1S:?W]I>.; VE1>Z-66E75^PBC#
M&<<YYGEG7W>(8[^F%%AO&KB^X]>&L=2:2%S?L[7)&>VOI[/\O7*?P\4S[4;W
MV[X/!RV]6TR.2\J[1LT&G/AT[XJ<2(^2C7^:OXN'%((</ R]RO_X/@",&GT9
M]1F@,.V?OUYT.?=A_>JV\%5>G.F9_GB/ZT\U[L>.H7_X7I^/*"_LE>FS7EBY
M/PD)6W[=B<H!U>-D5K)3FX5S/0!JG+V*N!W/R1<#=>TMV0M'=OM<T9VUZ:G]
M9R3O4RIW=9L.BO&2H\2193/E A4));^#5*O];$4[@9L42-,4.<&/(SN@PA67
M$RRJ[8M_*<CP#]M,G'/J&<] C0+8HT#5()"'S>2[P102O.V_-!UL"JW<89Y[
M*%)<*IWFVE;]!T#M>EVFP)=4??(!$_W>D*[7Y@%ND6>IK#=Z("/UJ^!3LMH9
MU&-$#TY:]8-D9]).OWGE:)@QG>[?FFLH.%S2RPWA;TW1)/Z2N8['JWMF%& D
M*6O@I+9D&JDWM0'AKE7PI_=DL*@FF/48]B<A#C#A=-E3/\%3E]XS.Q55(4WH
M1/34P85@M7*!KEQ.ZS"8GX\U@,4[M"Y$.@H=J]+0YWM.4UO34=?QG#%N:H@*
M&_&"A4G,Y<4ZCBW%"'OQOSK#_ZLO_.MRA(-A832=HN?L 4=9^6NF7=UP8;#9
M3Y1Y3$,85G0PB<>)W1*B#;]V_%;&HJ37K7"4@= 4,2_0IF_6,(ON44Q.@7TK
M63K%4J)#J?1_MJUU]/,*3UM]AKH5$R3T\ZU'U$IX2*AO/GOB.H+//N+KK/ D
M<5_BO2<$KJ>HZ7.7YT50H'"CMK!_<EO)?9,.]&F'^H>1F,XM7C#/<5;^TY95
M$Y;3@.$,6 E_=AWI1:R+^<L8V["#+.;\)D8>UYXN669=R2K)PNQY^.8K/)$]
MDW,_Y%+([<NG^Q#O1<JFMH8PV2$('/\FV]^JKH3/;<SJ1K<N574A8A&! ^=T
MEB\M-Y8%!@N07=.&S$$6%6S<LA)K^,KC#LVSRIF_U;'73]ND.DF"[<Y .O60
M5?3O6\]CGU/S2 9$3M5?@9:;2^VV5(G>ZVET6*=Z6IQ_G,/,?P"$F2PO7:,_
M -:'EFY-0*,8C<X/@-*_?U-.!BXGKV%)\7' PH5NTG2G,F=.YQ7H3]!+%6S:
M]+]6YHVK6LT_9$1H>I4'QO>Y*SPE"6_%09+E)SNGV*4%WW/Z7A"$^JV,[!.&
M>-]X5L#N27Q"@[?Q'P )_,''GL%_*HY<[M > "<V+O=<<2#<X$'XJ),WGI+]
MG??)DNI(@-KD.<B)60,R,^*==,,CQUE4!9ZV3J-GJ$[P! .]#=[B[AF<V,':
MC_E"X.IM-SB3L_V4G%%O"W$CGKU%,P:"_0[4E?>#5_1\A>\_/P#^\C]N9C*#
MR2OZW_%YF[A$('B(58@^RC9ECN+[KO %%O.8#EOU9M,C%X)W!B%+\'5'7YL>
M5>FN(/H(3M/%[H((U)3\1S[E3]WB7GNQYRDY5Y:JLC?>G,I&5XX%T]8)^V$D
M]!GN>4+*+K1KM0 W/>E_?Z["+=LAY@-@[/4#@,GF ;"Z)^5;[GQA(OYI< ,R
MLQ<X$FQ8-<5TS-H4I]H8NTFC^P3<X7#8- O ]BL4H4[/^8$E2J,JQQ46"'(I
MD;$O3/YVL93AFM.?85,G[0EH.-6FWB"^/A[V;#\J;:%Z +P-ODUYK!*C<O]M
MN+V4RXA4SAX (<S/Q7?N0!N;%@@[O8^[8B\6#!?4S;F=T_,@\N0K,;F_3<*2
M2UZF8_8:6^;4C&UI']W"4K4K<3-+W?--IS-ROT-.[HU?UHK0GE%3;@?_UT[N
MW.A?!L.'U(@"I2L;]K9S(M?%_MNINY[I3PHNN4-RP_F'<V.LD!W+5]H!L9A*
MM)G!37CBJU%91$8(TS(R4I_JMY/E#<V^?[JLG#];'=">+1!7MGZ,^J?-QG J
M^QMI@@ZA'"?SNM94P>3?EYK=30P_<!(9:#I?+_8L'*?&J1YSB*5_7.@%^M!\
ME7_KPLC[;.2/#"T69RR^N-V&=X.):0^2) RXFBQ(\L-(WU1@E;@A$O-D>BLB
M%KW"C/P!X!LB*:;%^<F 9L*,>,)+FF]$)VQ-?^+=Q.N5C[&=L7Q* -L$=;!)
MV%!L2.2OO-V+Z^XZ\.\:^;&!L6'BS\XQ\))T(NDW<F;%]N7DDPV:_T&7[5^F
M8R*K43^QC]C=&>C)8P%8IT3\UL#ZJ-3#U@HI99R&SVU-0+&%V5L-/>7E7Q_2
M\V#-_K#/6\QQHE>.9,GCR2EM1=68*5A-TC;%XT20!EGF%E][Z+( <FK79SC7
MX+_&!U0N(K)!8>:8OTO>TJ9O25SKAHG_<[CM,TN)6'VE=8X^=./VC\@W@)>M
M\T!NHU1BYB)'S?WH)%<.K"E554EXWNA-8?)OKE4U?9;?EP4YB*:7]E13.I+<
M6M 9SSY!;&%N%[Z#C_+XOS#\0YZ5" 6Q3!Y^4O+Y]9Z)3'>P,>/GLWDJ=^(M
ML##.L7HBLM21>@ N5)03&1]&HJ[1+D0H/VCKY7TBU1T[ATY]#5;4>;7^Q2#K
M"#+;FE$W)NLA<4G4PFI/KBX@9NLK:I[KC*>V[]GCSEH$*WE\A3-=G#:..E)"
M,Z.Y)1/#%LR5S7!:(@$:'U):*_,->:/8G[ V[O']"H%MG$W[2@3OBW?"!)67
M)JUDYV>8I6 ]:-@03-CN_S@#BL][[)Q4^@#X(UOJT&3]\\3X3_T?3/WD0YP:
M^15%ZF419AI>5=@1<C/+GD_66C2RT["^X45UQD17?$DM[3W7G=@RO$C3B&V8
M(1HI@!P!RH<;M9/MIO[ID- %S\MBR/L:,GE_[(Z=0?M,0?.V+$/42Y5_!7KF
M.HL,MI. /\=YQ[24]//S;(];:/JU7H"<@K2*?>&R'K?9'HB:*;%@MPD_PC-Z
M9US!EC-KUD8(W+),3!6_Q%NQZ,X_:C@^QLEET7"L!%G4[[H<.29])]%],F4=
M*!_(7I*37B+*'-2^Y2;_0@B6M/*KP_<-E0H-O4KX)NYCO4\&4F#PR2&Q5-=0
M@&!)*_\"@7R\EHVR\#C#;GTNR=SQ%PT5OW^W0;8TLQ@[;86FG@VP91CU#RQ-
M'S"J]3,\9@/]30G;IZC-1/N\641K1W/#^^2,@2BBV^'6S^(ROREZ_;<J!9R<
M-UI4\JA(P@2?@2^6^KS!A&P_*"3^1*(Y9:^1[!!K]^1&3E[/WX8O9YWOW=OH
MQ-;!$A2<4X-R8F"7E8*U\O$$8J2.SF=_A8-TOE@#O2%! KK0#-7NKAX D'X8
MDQ;-S-1WM5F9S0]6LY!7[D(_>.@(C6'OE**>\D3Q;1J=32+^^.HR+7Z9W.!H
MZ$-T2LRTSL0'/MT*/PN4ZK"%3M()$]4=C+^?0*N6/XHYM:H%DBR,&XJ5GQU>
MW^O9.*0JPW=<]@XD+A"CVM]^F]*/;57]5'%D4M&),)A17'#6D6<37@:+T)0<
MM )]A))6B"-G?.RXRTW-J\% C1;(&?IBLR%K@%[ ?/D# !L_0<6_LG5AU;%[
M)F;E3D$V0;TE%;7><",NAR[@\9PB1>D';NEEE0_A1'7Y+7-1=XG*$_JH-$FF
M^7V8'#[$F5[TM_.W!OHQ>.'XNZ*9I1D(54A ND^HZD'B$<JJL:I!I>'K2>#/
MKD4+\=G/9!1;T;J"X4F5=GLKR'>JO-B][)QS(7H06X,1XR8_()41UB&U92M;
M9!!\T;U^U;4).DK=?K19(4$7[&9KX7%1S&T;"0IFA VC*U+H<_&Y_B8(?%Y1
M,6+OV4[B&ZFT+XAI5(3J;HP<T3-XT2-#%9)(_4/T37,DBY=SH^%]6?O@\5-L
M\<H]W0> 5@)T@NOL,!P_OR^.$;%SPAHC!6S]F9%+XR>RVJ!2B0O"'-F%WTBM
ME-/6QFXB23'[,V6(FK[$*B*V:.1!<]LY@NE6&\@%&H$)DSBI>B@LM/L5;9)6
MJ'&,3:;0E_V)(_HOY!B;K_"EH-4E\\-NJX\C;"+C(C[? WNZS@L[Z)3G;:=G
M4V\7G!I703ADN9Q4L1@(+JSA?8>WB<P<<-&WQZ+; R(5;2%/O=%J^**%@;&B
MW3:^MNIMXR@)R>*%663R2FWFS"H=MD 5),&]?LB9=HWZB1_)]I1&B4#Y/\)Q
MO U,A_^"QN%/LH5F9MUENT>SR+]Z_ 9Y/'\YK+UB3D: /<NB$H29^"2- K;Z
MQ[13$SW'^TYU?\T](9AAA;;TZSH)]MMBZ7@*C]2H@K '!>M6N8."]P(RK5=4
MGQS*'QOCYJB6<,6\:39!+,VWO'L9]_/);RS17O9,+*W47:ZU).7CJ-T3HP55
M:S>K*OX.;.5QL6IZMNSZ9\[9KQ0$)\;5=(PSEK(3!1(43TT4Y*8J-LEVGBY(
M.\.S,TCHAWYT%<.&K&G#SO]^H[:=:,4<0!CI*ZL&NOEVUVZJ58>C3Z[KD-^R
M#1/G"TVW5V2M?XS)&!5NFJS4ZZ1<^O8T<=YTT4R) :_^P-+*#QV3#ZWN$?D4
M)3QW/AP7?M.]U 6A)+VB.!V>)5ID(I"+[& L='=;"Q2$_2KRK(FUI%P ?IYC
M]HOK>:GTGE&F)R>S.DG^2"M>:<,.CP(#PM\89?]%/'Q;.GZU>1 S8I^.)S!W
M8#[LYNT/I2^]PYN?YJY/=>WR64^Y]T9O>\G='P"F6>NNI-=>N[=2QX+5M0UD
M+XU-R7-XA;9PU"9R*411L76#<?B#3D6^NB!?08H7<BP-ITRIUM^3>3#)?Z0?
M]TBRCQ7E(J3W)CKZVBN-TLE"Z.JJ)P0:G,WAOZ8(O>O<%?SI=!G.,?S,/<[*
MT@*I]$,[>22.S8QWUC3B*P42 #CC?_/"/W"=CE!1B+Z:WO74:1I->8R-_=H3
M<=SGT,=56U\?U2U%FZ4)@P-C_=;L*"?$N_7,.)X$>W1LQ?J5VU'4N1 Y&$;7
MP\!S#CR_QY5(ZL!-?*Q/*=YRB72L^V^E[FX7760E1FK\0W/Y8X*J35:9)E-$
M)J )4]C/+XL(H8]HCN&:8[:TL: Q1]1&?>@@Y"2@OE_*L0,]4$I.\UHGDE79
M67D)KG[RE$K\ ?!(-/]<=?A_KEO\/Q-O @7SOSUF@GIX./D(MF6/J^! +@Z%
MV=*4"3XG;HN*4)]7%#3B7^DLXCX LJ7O/PP_ +IG?KCI;;Y1:OU^;I=Z:@QK
MF:XK+3XKK&:GJ8;QDQ=RIM<P[?.:QHSY1_X.[41D=-560(&<4[F=FSPC8;UI
MK9$5?D]_S^]Z#'L&_Y<U[6.%5>-R\%C4*G"D-9O!%RR0]OZK.TU:AD8CMM-U
M5W5W,BE4G@S R[B=,#Z<S*N"7<2KO*;S==Z\8@(CSTG&;^KV"!(-M.=,Y_J-
MU <WG?!\E_\$)?_NU'2 OND#H/#VU=<;4<.EREO\W5YIJ0A?^FEN,K4&X<%5
M#,CS]YSM@P/.UFL'\>GQ';V2K'!#ZOH'P/RQ;+XR<Y(>+%,H<FIE9?$;W><.
MP &#;:Q2^>&_/V+\ ?"BN:/]#.L!T)_2?M6D7*:G=^GO]Q?C%W.@=/FGEJ'2
M86$-/RC)#36JLK_H.8?+5PY=$6$NZ8!Q;19SC?A,7]&2)$K&657=8X'Y4'^)
M=^ .EC#8]YJT%-^;/%L&5[=1Y>W_!9ILQRARM7\KS$K:%'VG]L\U8F[^RIQ(
M]I\+_U%BZ1];;[$9#08*I>%E%"GY-C/6QK_A1._/%"907O8A DCR&_C4+(&"
M^&'U4ZC*\K,,H?>>A',?!GU$[M]T*#[#+^X]FVV^<EL1W^L_./ L/QVE5Z&_
MR]%L3%Y/Q_R]/B7][]->\5V-T S^-WF /S[1NM#AVJ:,%FITZHHH2_@0%%RK
M9/?7,KBQ.1U_=10J?_UDT9BS_5M=6@;32Z '[G8F:50 3Y=Y==^/@_X%;(#X
MS.A_]O<_T:^4KT^PSRW!1N+%/8S%;LSLD8XOBJJ;HF>W5>R 8$Q=OZGUDA I
MBU[-'^Z\J?"QKZGX(664JP,7]NN:C!.RKZSU?AQXLV?T8IQ&9SE4_J?9_$]#
M_[[PN<M?_[]_(WE_.KGLO6_V([VEL1?,K\^6B+"H">@%C]O*&R@3\(TV;S+4
M!UT.QT(G=*7"5@*I.LWL[OMJ;X010G_;6WV0,)&;KK7#5XG5^L.%[+GZ!9!?
M<L3:Q/\1-LQ]:]4:VZIK4Z<I#3@J+9MYB@%]17Z:F?RA\6=EN,Z'!E,'%3F3
M>KH)JN">-13!@O[W1..>=VS.<MZB9\Q03\1AV)D+T5W6C>DH2MH6N1%T/NF\
M;WL0G]4D-O/?D:V=\G.#>WGWCZWP\ZGN0(KLH\-P%)7<&PHZI/^@S433X :@
M>:WG^2A5.D$#2N>,!N]BYU;R57FA\<"/';CF!QA/_;3XO8[C\62VU.?([?;_
M!48KZ')=M[I<__U[C^F0GMC2ONSG1ST2G[/+@J 9:OK4[RM0&N6["9F+DA,!
M;AR*#*SXOXQE4Z57F.D.ZX/>R$$?I]:HFX64TYDA_8R37O%3/Q\>C1[U.0U[
MSG]:%*__?3T6['8OW;8OAWQ-;*\<&SZZR(SW;5;)'%5LKH/%*=MM^7%F,I[Z
M<,GT43BW7)X+;@N.V <].9J)*NHNLK]V2? B]5;:ZIOM8_/E4'@'RBUS&%;:
MMG_64/XNDJ4LYH58RY,UI29- K ,]E^@LQHJS^UP1)IR%2_ML11Y=OGUX\G
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MDEBGIR8_8OX;ZK73(W91KO2)W=8-Y$;2W3TU:2SAPCE9\S=FH\J:FD4#C09
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M2.S$[6KS2-H25\!Z4\_9PH_;;%BZM+A@9,@#"K!/>2&O@-VG,1P[GSR]7==
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M]ZY[L$IFZN-FMK*I,4R?5I8Q&8VO2V!$N;.!/8+0EV3BP?P<]O:,"*'7!J&
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M>[J2FEWD;7*M7]N>M+>GNK84)/G-H(=6LP&6PO1*#9Q.N$J(WVJSU' 2^"0
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M&4GG.<'R3.W.BU''0SR);+'9"C@?=IR)U8U^JE-!!L\L K05Q[O15B*A%4Q
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M7^1H>9>?4EG6(WX,>F>GXEE:\LT^J2*DP7*\2U-SMN_-SH62^&$+'Z+G;/\
MAG"F3KZ#@"-N3.2N@Q*$MW[X82M=3:7K=S,*\8;V^J2SLR*I/<N,+*>:-83$
M(WB<DX=O?'SO :;C#6]O92IVY$[/\DJWD$GCQEQ1:&,3KFI9LL8OG+2X\\K8
MB#S//P(#/>K6)7/&%_'':DF3LMC"6Z^L$9"CW4914:RU?KH EU]:87VFTHS0
M:TR ^+*@:WU#L\?12REE=;:U_FTO/T+"#34N<:M#J9%\0\D4&--'-E;/M?>L
M]7S'Q*?B8).N:6VU_WQ]P68OWI.9]$?)?<(G(8D4*'ST;C@HX0>[)#Y"YHF=
M*Y@@R%7.9\=1][N'1]QG_-)/CEH@NM<[AIDO6NLJ#WG"]WFXS>L_T7RT2GT=
MB2>+4*<(+Q;!' C1O>^FKMW<J+1\)>\ZM*9LI&0<L$@>%+<9P&D@*UAQ"[44
M Y5@KL8R)A; ?8$44:"H%$L[4N%,767LC8)#DI'L&I3@K9Q$(Y<C=I0=DX(8
MOF*O24[<Z*2+<7Y%>2=W;5-FW"O](;N"H2?>M.+4N=[==G&](#H.3@+P O$"
M<]VN\*_. +-?[VF2DOT/BV!]; VO"*XVR!NY:$Z1EW<AZ^=E$W<TIS8N=AY$
MI^DBGJ-M>+] -&;1@XJRG>N%LQ<AZK5M\0-WT\S=;TNWG*P%,?(VU&R?"!=1
M3B$>&=Q_$RT%%T],3X;:4-F2>? _?&)%@2NIHSEC#+F8,.+=]O($F]?W(PT0
M^PSE)TX3%&IXJCV[Y6\S%E,7Y+/K)F%.+$E4$'AEL>#GPVH*0OY&0ES1/4RK
M7DBWD>[P<%FM?N3[)C(J\A+NVW B.**OSHH[QR;[HD0?IK4M8;!O$;28Y/FX
M>D^K]($D)6[E1ISQ7'X42XYT'$%8?0NEB+Y>^4Y8F+QS*5SIUY$4'KDBWO8_
MK2":!".N>\!2^\^#5=3)IM;>:I,.&(2M3:DEW @(I755-I^0LL<^I$\#NC;1
MU-M&1KR@U/8IR?S45_.!F$2TQ_G*8_5<W\W^'!6#;P0UK[#H=&*+<J&_$R]T
M=-L:]JP7KT\KAO('VO11C"$(I;.)4;()W>9]V@M8!;Y:X1P'MXQ:S30D4;5V
MNYFG+(V412B;ZI2G!S@=S !6EU[<DQ*1U+,,2U=8?JIBBHY *2^()ZD@.R#2
M,\8M<GGT)A[K'@!I/]M&.@AQ2A%H3BU-E3/5)?G52/+PH5GEBA_]^'!(A:EU
MZU.S:^""3=SA7@8G3%QM3V\Z1#N]@PY)Z+9$Y[?"AQS(5]_F4#.>'.SH<1V4
M[><WAE&+@&","//:Z+):8;&=3CK.$:Y:=J=3 BK#Y^,KN]/)GA*]SV?3/MD>
M23C[T'^*W/0G\1.Z23WM&6Y$-HAT6G].W_.(%'+PLZ+UT^2P4ZB[A=[Z=X+F
M%U"]<P6?W4OV^#>TD"WZM?7<-:"ZL!\Y7+&*WKG23.,]T67+LX)QD/(=#\0S
M'R!]-CFE3#+%!OH=<5*]D9:B:GU]KZ$R+0G[[X&L\R\O[SQ*EDH^NW\]\;N5
M4P@;A# S(I;E/Z\XKR9RC7D];!B%U,X)W09"NE+^ LNT944,9,(ZF#I^E3S)
MW/%;SB,R^L]#\*(S1HNL(BBED7K<&?*+4-?79>5O/H88[$6.A[X/H9\G'<U@
MD-/LEPIYH")#G :W>C'\1W.,K-$-'"+N$O8'$:<P_K.#KG-*]%ZMAI+_T@%C
M)@LI _-5TFS.(=T6AQ?TIYIGXT1^HQDJ :(\@>DD%FF=JHWUV/JX+7#Q_KLI
MV98B>MLS4SD))2-LG3JO/*=]C:&6)]W',5N8!1L;&AIC=I2,@X<T(OWR%2,5
MHWE? ]_D?'2>A?\)8/>7#;1<)A+0KA];BM%LN!O]$E"^ "VVP59J\7)L5BJ0
M*EPUG5:-7+?1]BHR,OB*T]U,U$4>M<;J@F]P0NN<>[RE>C=9+2YSALRX"UF]
MS1E&!TZMB/4*3-0+&)>7%!M"DY^+VR63SM82 <\?"@\$^8>;I@?B#3T("4D-
M)K)1:;@P<3"?+%UMAE"%!;%J,[[DEM5PZV%5GVO7@%< FS-4*SX[\-!1,K?A
M[S2 N#X=]L%MF&<>!L5H*V1]=A^Z_A0\[[7 QL($)%.L#IK,X?]XU\XNJ2^3
MM_W<TLZEVU_MJD0H13N_CZO*ZU),]W%Q]XJDS8Z&G9<F2TX.Q@Y=ZMM:&=!N
MW1CQ?+E'CB'-]:-&3',8M5BO?8:09WMYF^D?R7YM1_:_'X5,^9V282%4V,BX
M4L%U(L5F;JV/J"5! -;KK< *CT2H!JI'HB0B3);Y.+\@1.H2K5W%0^'EQQ?X
M/Z?+UAH/34)I]1/0,LFN_K_E*#?3_;>[3O+G2+]?( ;/M9OC562J!IS.ACX6
MD\EM+XAI4+@^$O@H;>PAA,^>=\Q5GU)X]W(\0359 YI$^:<!H3XG?6+Q&E^;
M)FC56=&GP'"G_METH%5$ 6+E_2%%3VVE )LH$(_<BL1^N>7-/< IQFAR%_\6
MH5XEE[#"+A@EK$*<]I$PA_%X0E)OTA2F3F-4WNR")=YQ#Y@Y@.%%BN'U?:5Q
MXYL'4%'W\G](["\+W(%&#"Q<[;O'+6!4"E7-XM?7R0V!J@5K>B,3Z987JGHQ
MIA/,253CFXXI^6\&>;&[75B!9I9T]P#\'Y1N<S>OISX]3YQ*PG ZI'E\WE]7
M:QYK?Z>'$UGJ9L?.K^Y=(EQ*IT/"K]FP 3"SNK;\D_LM]3(PZY)H8&'CSG3=
MBW(>.%Z^2MHEF9>BTM<TK_ 4P.]?K8,GNK$VS(_I>6X]MU7SR90FE(..1KT!
MDM;DR S0"%##<6N"3((*-\_0GB7T%0X,3C..%HH-51KAZ[/?R)GVE\+47%*G
M)J:R>NY8=6#EOS XTN&6VE_(VG-N9"J.F$'M78>")!'N<<[F(JH?[PS3!@*!
MTBZU0]$?-^ V948ANM5-D]R[+QKTFFHQ&SW!^([4=+Z'6\9PHVBX"=9=Y]='
M4WH_T?59]P"N3&-8OTGNTY']KQM":@OJS=63'A"3.?\]=;5XBA0E\.>V48:O
M628B)"X'\L'30X?')W?-,2DGXEW+94S"RV*.+-#/\+%22K>W;VUH*@N5J5=2
MQY!M8>L_Y]A27@(2-EX?\F)5#':(;)G8?(> E=RR55S*,EXP*#J\,Z&8NSYH
MOIXR/^B3U/_6Z>+DMG29B=&"@+ =I<?IA6>=?;\\\#XC+^Z4M;MU%%5)U=M4
MLEF.9KG<0U$7:+KBQAZC5?!5XN+J,EX#$:]Q4V67H_G6DD1#3WK9G[/:NN]$
MD(NGDS9JA(0<&->UY5D673#(CSMP+S9.1J(MJ*R(_WQA,_Q*TD2.-4W_Q5;_
MC')\6\5M>:Q ='(?K]:N[(NES^XF.*MBO-8]'N9Y#Y"1(\=$!HR@(7J]1&H8
MU21G9#+'*+F"F@%QRPK6X8D0Q5ESP=;$Y=.A%U^XSY3-?%*>7?\D51OK7%W4
MIRZ,5M>,OP=TZ^DE'2E G2M@?(WF+Q /Y7%4/_$Z]$O_&5'*L]]JZLW(VVYJ
M[<WV(L<+!'KI30QB]+SA;P%:WL"_3.;XP/#(+G#GJLH8G29PD:P29O#RJ:K$
M*$D655U]4L#8!DV[9T&D]72DX!"GK(<KS_>/\.0 \46<#0:1@:/CG<C5^:-^
M[\P?GJU.1."!?+%H\,#GV/?]5''*U->_.V3*H-ZIR_,;2W/7&'N5(D:-_PB^
M%R(/8"(5JE]CY',/R&C%&3F]:S*>JYMVX-Y?J5/,%%O5<T<LHPQ4<'J5YW-$
M^_-4O53C_Q@QCVS!]QP!BIUQ^C[&*[0/=O90-9(PW!OMIPL]3/(^!46-]2E\
MC;0D'[JM2!>$E+0BN[HFO'6!F:)<YHVQ+1/]Y)2\;89?#^/5U^TMJ=J'3FD2
M3%,FMGTS,F/,SI''GV&_/H[HI%LM.C^04F4^*[$I4"!/)JMGEK P6+&CEX??
M%']+Z)/$7Z^#3AX*%]A8YZ01J:'GC)8W;GE(5X,_Y\699AI6Q2R5;G*;0034
M:J<J' 7WY%525<P+WPR._1@$:.RN4+ESP@M'J[*U)TRWL)*:Z, 7:2#$"&>.
M"Q,P(2!#DVO53O*GC3F<>]%9G%1OUT-4B.[NC9==#?6U0FZEC73:I$V!_?'.
MS@30TW76%*/P$ I"ZB.C7SXE =YL.+,I7S<WXE)@;+V2O#CYP=ZA'F%:! S"
ME'PA$[=:%::^KL&:[:<30\<X+'/MY3DQGT]"XT71A[JY35"A6?B#KQ[&*Z>;
M]BJM;JI52;;ECIZ2G#3*PGP=<9$%LK/!,AG.2FK(J0JFJD8MBS335ES:)_[Y
MC#%RQ(^O=%7E_';"IF%U@+%Y=)^Y$W#P$;![->*9]+>04?_(PG&UA6FGXYM/
MZU/W@/)[P*IO "K/SD;2>5:E&D2Z*EN;7@PP^"/QD"/$NP1$KS? _?[8#)QX
M]"H_^1R64>J9W>OLNUQ9E\89I>K9/5H,F=^O;NEH, A;B/-U4+AU,[A2[2EK
M[<TZRWH2:!GV"P8(Y*<XEKX',+1H3V H^/)3VT\G"UC:*^2;[P&?0MY9(_EF
MJ3^,$:@_#F.-;>(6>4+^-"ZNS]2^[%F4>P1\R>0/0<"\FW"6^.?*YL\6VH"5
M= 8GH_4;468(N(N3 \9IZ5WL"9L/?H->]:WL^B!D';A*MS)ZM<-SEY!']DGW
M[_;J'R-9DE/%03>R^9B\9L%QL0:X"KES)[":WV.NBKR2]O1EV"%Q?-5,OU/.
MC ]/')9;6$+6E\/.13BM6Y_1AJ#*$(QRSU$(M%(??*!62WG^E-?@[HU$@LLB
M;?I*6T )Q\Z[<,.I;T_EM@JVQ4M' 8Q%C&#2=1Z7)$C'-=9\R4PYU/TOXY[X
M\T*U8>%J)C#K9%1>9<>'9ZW*4,"-',J4/_&CBI'VY.[II6[D<@N[2P!/E(>W
M$+!G+2^OA4Q97"4L-IQ!0_9JO=EHT&7-=IS[_/]X%%_\RQ1C/ <!RW-OE1GJ
M6:,5QQ67!FC_^.FFKI2^<N2^T5W6"]=MJ2:09"PEP".ZSEL]4)1)XHAOO<6>
M0^0/GBUHUD3NH]3Y\10US^+B3B2G(H]N60Y?3KS*GA*22*,1FI"?J=6N-7'
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MU6-O$ .>=4K\](F[EU;QFB&>KXLVD*/C?T9N]-EA^?;BT3_UA$66V8VXWH"
M)3^+N15U]GKG^JB9OK%2U-KEUP7(C-[ UUC:[@%']P"!\154[9;[Y0%J2R$7
MYU-"=:)Z<A$V0JFAO]#17RD/G4L$W)]W-_%]I0%B\@E<X"A^6]'845KE9EER
MP;U:EOKZS!E$@TZDKD_4B&XX&\7]%:+K**EBE[=II)9\UFS+4[YKR7;.CXT
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M43 7?5? MI)#R.'8$+9U0BXU75'UC2YK'LT*28_,5U]N$?WY;7ZN3>!H<'#
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ML_@AF&P>*7-?^$UI%$B&[F+65&9K.Z];G*^!0V/"G.+B:E2X&W.6F%(5NUR
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M2W/YQ+ZO'A]?(B%7WX^6+%(+T>*3.4S25=HZ!J%GD6>L$2"ZQHKSK\/AUI5
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M8VO9R%?!F>(2N38/9QZXO1*M,SS\)[#TQ!-2; ,?8BFX2YSK[+YFE?G@?/;
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M\B%7M,;D.\.\^-R]'](,_@G*F_F<O@FZI9C?>46E+K+W*\O8EUV$_\B@Q\4
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M;QZY%MD)OTO9+:&2AG[X-[3.2(VH)[-*?96MS+$U4=9HS*N[!2,%VAFP\%^
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MLW2F=\7B'Q8N[(NT63^V18Z3*9TT<QK*.[I8>!L"4?DNG-J#S3Y^ARNKH%O
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M7[N:C%9'ONZ=X15$>Y594>UU8TI"G+5<^I892$A?V[+V^\*:US[4@:U&C@7
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M3E.ZQ^#VK,8XI_MS:ZRTZX[R-;SP=K:IM-.S:F3ZE,'SLS?]ZG ]>6/M#BZ
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MNV>O*S/Q[M'<T_@=CKUU@R&O*E#5<#7X[72:%FA38BEQMO<56<[KUN 64LU
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MUY V#J;/ &W>-*IF87\,(2+M(M_=FX>FM\?S\_] ^^?F*3&,?$^@?1Z[9M9
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MF*YSQ?/^0DO\9<M>D"E>!W]WLH;#),I.1/>BF \45V4L[PH4*'-NG453Z9(
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MD(=DP=^@#.H.K#/%@<5 8\3JR%RF,J&:3MK_H6Z(1F]R!Y6E[5[G$FLK4[1
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MU2=RIUU8LJXD1[T$M<@CA73[WA67)1A8,5[N 9,N]VZ"XJY37/<>:,?-B!S
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M9L8.$.6W.'W1OWE>OOD#N,75=>U<JK4XT<M'*A25#.<C6<CI/1J 6[8^L6(
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M9/\3:4/87L^34[50*?2;F<&$ .AUZ#,B71P0E03T<4MW;QIC+D$HQ]-3XDA
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M07?N29DZ;M,GJGN%"((XQX0G!,:@#_UWF$AO F6!P'<J[I&AH2XTX#4516V
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MK<I'RH%6"K#AUT;AL?>XRN!LC?WXK]J:']44=;9H^TPPUCJ+#J&OA91)"T5
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MV8OO%OX[F/WV:>7')+*&A@NE%?;%EHHJCD5@[I2DE"Z\!B$J*1 V.L>Q\K&
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M(@WH_N6KV:=C?2\__/PG4$L#!!0    ( )2+=5AO6_5;510  ,4' 0 5
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M.C_DNMDE\2'7[9#K=LAU.^2Z'7+=+ %F%%$$>YKKME/*U1@3KFR\W\K*>J!
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M3[(M>N$.)ZQ($GD]*1+]"L7"Y1=43B8,H65D 00P%STU,!NP'HF8%%005 M
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M&2L4'"V,>Q0@,*)52[<L[K\5$*9VWNX^2^/SK(CTIRP#&L\5\V3U1L7R.@)
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M*BZ?>@QY#Q7^>%(0@F.1$]-3_8R0@I1FYS>#WV.-@NEF]8H5N#,'Q]U<C>5
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M(+W[$Z4^VQS*7NG7X(?A(MJJY!&!/,!41)+605@XT;W2[<#G/X3.P0PYBL[
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MJVXB#(>L\;OD>BJ@"#*\ZWV7;GA86%HDZ.M7OIL(#I,E?/JAMPEO=$]PT W
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ML/K!K*3\O,PSXN1 ]HXW5($?(Y+RJ(FHPN^D3I H8#6_3CTYH8>V=$.(.&7
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M%3$0T=$)RD4Q+3D61TX'SIRO8'FYH=XC#>4^DL^QTG-Q&8<<XD3,M^G&;#J
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M\C9DW;@4E;Z;1L\VNQ__27F?^6%T<R..HOH )6C]\9%H*2!ZZ/FN=\4Z)*_
MZUTVA:1;-N/&/&JGQ2J&81)CQ[+O>B8S+292NG>F #-M)>PS2RO-59&H1@7]
M"-/4Q_=MF'N/?O$P,'/O1\#<AS;,?;!D;K" AJ&8^^ J<V<;N=1+-TSPEJ9:
MY37L8JHR#9-?H@U%^;FZ99+ALF#@/4[O7W1N.]2L]/J$XCWB@;U9^GS_P*0T
MFWUHLVG>UM7!#DT9>JQ4%,,,'_X$O\UHN ^G,4SOJ@KCG=Q5$J$GR) ^U@O"
MA'GVGNLC]47&ZD5#AQ.12R)I_I-I.N_W*XY,X7JUKB9(Z14![$F[B(TPS=.5
M8MAA"$/H>H7F1F"ZSL"*,.VI[Y-03$,DN"+B'3BBS8^B+@ZU+@QVU!F2&+WH
MCBR1Q0V9^<:G4@[+Q0!L/F\<),W2HI.P?ZLJ[^ YWZX1?7RTH@*FJW '7@P
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M!Z_HB_C)>+&GJX/M V6AEM7;'R,2Z,<-\71)EA*V$PKP"$MS!6R'I_8T&3!
MYPC,35M.!K/OM^?$52Z4$FT/? O-*0!4&3EZ$+XYAJY-=63<.ZY/^5GG34##
M3%B']@X5ER]^F/%&\W>=Q2Q1/-9XZ?&9/7I*YH3)'.VZH_R'[W5'^8,O3_:?
MGFR_/1$434I?%[6VWY_P#DQD#TXG_7Y/^H*7#@H!M@?T\QTW-K8=K ;]P(!O
M6^@H!\ "T=\7W%":889<]?*L-]#P;1X=93G;-#>@MY4,^M&3(O:#([H%I[ES
MM][*:+XQUW1#28XP^$ :4T8&V^"3/UN44J[U(GD^W)W;6!';] /5Y\9WG(R
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MAP+ZDK [&Q=!VW+?#S31U*NX,>WT:9ZIRXB>X:O<)=,*T536#9*,BM><5.!
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MU'K5%K6#7?$7\3_BH5K^F_\/4$L! A0#%     @ E(MU6-4G5/7X 0  +PD
M  @              ( !     &5X,C$N:'1M4$L! A0#%     @ E(MU6%WU
M_&1N P  > T   H              ( !'@(  &5X,C,M,2YH=&U02P$"% ,4
M    " "4BW58;8D-^T8#  #4#P  "@              @ &T!0  97@R,RTR
M+FAT;5!+ 0(4 Q0    ( )2+=5BO# MNA0<   LN   *              "
M 2()  !E>#,Q+3$N:'1M4$L! A0#%     @ E(MU6$]'J]6@!P  M3    H
M             ( !SQ   &5X,S$M,BYH=&U02P$"% ,4    " "4BW58O?6M
M.G4$  !Z&@  "@              @ &7&   97@S,BTQ+FAT;5!+ 0(4 Q0
M   ( )2+=5C$[*JH8P0  -D:   *              "  30=  !E>#,R+3(N
M:'1M4$L! A0#%     @ E(MU6+17937Z&@, M,P<  P              ( !
MOR$  &9O<FTQ,"UK+FAT;5!+ 0(4 Q0    ( )2+=5CGE+)4#EX  +]I   0
M              "  >,\ P!F;W)M,3 M:U\P,#$N:G!G4$L! A0#%     @
ME(MU6$$(]<R_>P$ YJ ! !               ( !'YL# &9O<FTQ,"UK7S P
M,BYJ<&=02P$"% ,4    " "4BW58^JGYM"9(   Z4   $
M@ $,%P4 9F]R;3$P+6M?,# S+FIP9U!+ 0(4 Q0    ( )2+=5B<:'D4H$4
M '5.   0              "  6!?!0!F;W)M,3 M:U\P,#0N:G!G4$L! A0#
M%     @ E(MU6)XX"-SX1 ( /V$" !               ( !+J4% &9O<FTQ
M,"UK7S P-2YJ<&=02P$"% ,4    " "4BW58$;'IJ^(1  #KPP  $0
M        @ %4Z@< <VAP:"TR,#(S,3(S,2YX<V102P$"% ,4    " "4BW58
M;UOU6U44  #%!P$ %0              @ %E_ < <VAP:"TR,#(S,3(S,5]C
M86PN>&UL4$L! A0#%     @ E(MU6+R:[[U:-@  IJ$# !4
M ( ![1 ( '-H<&@M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( )2+=5CW
M1IK=H'<  (/)!@ 5              "  7I'" !S:'!H+3(P,C,Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " "4BW58N$S3+01-  "/* 4 %0
M@ %-OP@ <VAP:"TR,#(S,3(S,5]P<F4N>&UL4$L%!@     2 !( 000  (0,
$"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SHPH="http://shuttlepharma.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="shph-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CommonStockToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">SHPH:CommonStockToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2016-08-122016-08-12_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-12</startDate>
            <endDate>2016-08-12</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:InstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-02-152023-02-16_custom_NewLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16_custom_NewLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">SHPH:NewLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2023-02-152023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-02-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-02-16</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-01_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:RelatedPartyOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-06-212021-06-21_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-21</startDate>
            <endDate>2021-06-21</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-06-30_custom_OfficersSpouseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">SHPH:OfficersSpouseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="From2023-01-092023-01-11_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-31_custom_AltoConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:AltoConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SHPH:TwoThousandEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">SHPH:DirectorsAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_AyrtonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:AyrtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember14624828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:BousteadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:AyrtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_WarrantMember14624859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember14624875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_NotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_NotesPayableRelatedPartiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">SHPH:NotesPayableRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-11</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDefaultRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputVolumeWeightedAveragePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">SHPH:MeasurementInputIlliquidityDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AcceleratedFeatureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AcceleratedFeatureMember14626328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">SHPH:AcceleratedFeatureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TCGGreenChemIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TCGGreenChemIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SHPH:TCGGreenChemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_FederalTaxableIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:FederalTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_StateTaxableIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SHPH:StateTaxableIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TaxYear2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TaxYear2017Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="From2023-08-312023-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-07</instant>
        </period>
    </context>
    <context id="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SHPH:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <context id="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001757499</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-08</startDate>
            <endDate>2024-03-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="TradingDays">
        <measure>utr:D</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000005">0001757499</dei:EntityCentralIndexKey>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0063"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0066"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0078"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl0100"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ConvertibleNotePayableCurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0109"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0121"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:FinanceFee
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0222"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0366"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0377"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0429"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_custom_CommonStockToBeIssuedMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      id="xdx2ixbrl0440"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:AccruedInterestSettledWithCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtSecuritiesGainLoss
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForConversionOfAccruedInterest
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:CommonStockIssuedForDividendPayable
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:InitialRecognitionOfRightOfUseAssetAndLiability
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_USTreasurySecuritiesMember"
      id="xdx2ixbrl0692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_WarrantMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0715"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      id="xdx2ixbrl0760"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl0768"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:VariableLeaseCost
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0975"
      unitRef="Shares"
      xsi:nil="true"/>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl0977"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_custom_AcceleratedFeatureMember"
      id="xdx2ixbrl1126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1128"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1167"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:ShortfallOfStockCompensationExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1195"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeferredTaxAssetsbasedCompensation
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1205"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeferredTaxAssetsLeaseLiabilities
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1211"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeferredTaxLiabilitiesFairMarketValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1220"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:DeferredTaxLiabilitiesFiniteLivedAssets
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1223"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1234"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1235"
      unitRef="USD"
      xsi:nil="true"/>
    <SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1261"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000014">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000016">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018">001-41488</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019">Shuttle Pharmaceuticals Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021">82-5089826</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022">401 Professional Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="Fact000023">Suite 260</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000024">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000025">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000026">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000027">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000028">403-4212</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000029">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000030">SHPH</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000038">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-12-31" id="Fact000039">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000040">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000041">true</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentFinStmtRestatementRecoveryAnalysisFlag contextRef="From2023-01-01to2023-12-31" id="Fact000042">false</dei:DocumentFinStmtRestatementRecoveryAnalysisFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000043">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000044"
      unitRef="USD">11712797</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-03-20"
      decimals="INF"
      id="Fact000045"
      unitRef="Shares">16794893</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="Fact000046">686</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000047">FORVIS, LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000048">Atlanta, GA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">2576416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">8417203</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">114473</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">161148</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">2887215</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">14901</us-gaap:InterestReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">5593005</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">8578351</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">121685</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">114875</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">24827</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">12592</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">6480</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">333904</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">56122</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">5951736</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">8653545</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000093"
      unitRef="USD">282860</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000094"
      unitRef="USD">116745</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000096"
      unitRef="USD">446</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000097"
      unitRef="USD">12500</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000099"
      unitRef="USD">110453</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000103"
      unitRef="USD">98135</us-gaap:InterestPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000106"
      unitRef="USD">685473</us-gaap:NotesPayableCurrent>
    <SHPH:ConvertibleNotePayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000108"
      unitRef="USD">595999</SHPH:ConvertibleNotePayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">52479</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000112"
      unitRef="USD">62823</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">1042237</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000115"
      unitRef="USD">975676</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">135089</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">414512</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">304127</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">1895965</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000127"
      unitRef="USD">975676</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000137"
      unitRef="USDPShares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000139"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000141"
      unitRef="USDPShares">1000</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000149"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000154"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000156"
      unitRef="USDPShares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">16069320</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">16069320</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">13603129</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">13603129</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000151"
      unitRef="USD">161</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">136</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000170"
      unitRef="USD">19543222</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">16572622</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000173"
      unitRef="USD">-15487612</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-8894889</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000176"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000179"
      unitRef="USD">5951736</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">8653545</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000188"
      unitRef="USD">3517093</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000189"
      unitRef="USD">1148712</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000191"
      unitRef="USD">1046854</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000192"
      unitRef="USD">538796</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LegalFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000194"
      unitRef="USD">1328435</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000195"
      unitRef="USD">866770</us-gaap:LegalFees>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">5892382</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000198"
      unitRef="USD">2554278</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000200"
      unitRef="USD">-5892382</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-2554278</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000206"
      unitRef="USD">6825</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000207"
      unitRef="USD">52010</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000209"
      unitRef="USD">2484193</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000210"
      unitRef="USD">917879</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000212"
      unitRef="USD">79117</us-gaap:InvestmentIncomeInterest>
    <SHPH:FinanceFee
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">104245</SHPH:FinanceFee>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">2216488</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">94025</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">4970</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">71568</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">328687</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">73007</SHPH:GainOnForgivenessOfNotePayable>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">-700341</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-474170</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-6592723</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">-3028448</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">71009</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">-6592723</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-3099457</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">14919484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000250"
      unitRef="Shares">14919484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000252"
      unitRef="Shares">10351046</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000254"
      unitRef="Shares">10351046</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000258"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000260"
      unitRef="USDPShares">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000262"
      unitRef="USDPShares">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">1213</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000273"
      unitRef="Shares">9312152</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">93</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">4150867</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact000267"
      unitRef="USD">16340</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-5795432</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">-1628132</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000276"
      unitRef="USD">14</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">10008081</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000280"
      unitRef="USD">10008095</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000285"
      unitRef="USD">14</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000286"
      unitRef="USD">14084</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000289"
      unitRef="USD">14098</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000295"
      unitRef="USD">412241</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">412241</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000307"
      unitRef="Shares">148339</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">604863</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_custom_CommonStockToBeIssuedMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">-16340</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000305"
      unitRef="USD">588524</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000316"
      unitRef="Shares">857780</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000310"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000311"
      unitRef="USD">576467</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000314"
      unitRef="USD">576476</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">27989</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000329"
      unitRef="USD">403956</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">403956</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000338"
      unitRef="USD">71009</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">71009</us-gaap:DividendsPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">-1213</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">437327</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">5</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">402063</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">402068</us-gaap:StockIssuedDuringPeriodValueDividendReinvestmentPlan>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-3028448</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-3028448</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">13603129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">16572622</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-8894889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000364"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000379"
      unitRef="Shares">13603129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">136</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000372"
      unitRef="USD">16572622</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000374"
      unitRef="USD">-8894889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">7677869</us-gaap:StockholdersEquity>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000383"
      unitRef="USD">90816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000386"
      unitRef="USD">90816</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">2380996</SHPH:StockIssuedDuringPeriodSharesConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000391"
      unitRef="USD">24</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000392"
      unitRef="USD">2697825</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000395"
      unitRef="USD">2697849</SHPH:StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000406"
      unitRef="Shares">85195</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000400"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000401"
      unitRef="USD">-1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000410"
      unitRef="USD">181960</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">181960</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">-6592723</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">-6592723</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000431"
      unitRef="Shares">16069320</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000423"
      unitRef="USD">161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">19543222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-15487612</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000427"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">16069320</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000434"
      unitRef="USD">161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000435"
      unitRef="USD">19543222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000437"
      unitRef="USD">-15487612</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">4055771</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">-6592723</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-3028448</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">6811</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000454"
      unitRef="USD">5972</us-gaap:Depreciation>
    <SHPH:ChangeInFairValueOfDerivativeLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000456"
      unitRef="USD">2216488</SHPH:ChangeInFairValueOfDerivativeLiability>
    <SHPH:ChangeInFairValueOfDerivativeLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000457"
      unitRef="USD">94025</SHPH:ChangeInFairValueOfDerivativeLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000459"
      unitRef="USD">2123049</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000460"
      unitRef="USD">885505</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">4970</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">71568</us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments>
    <SHPH:AccruedInterestSettledWithCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">294927</SHPH:AccruedInterestSettledWithCommonStock>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000471"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000475"
      unitRef="USD">328687</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <SHPH:GainOnForgivenessOfNotePayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000478"
      unitRef="USD">73007</SHPH:GainOnForgivenessOfNotePayable>
    <us-gaap:DebtSecuritiesGainLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000481"
      unitRef="USD">-12625</us-gaap:DebtSecuritiesGainLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">181960</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">403956</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">14901</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-46675</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000493"
      unitRef="USD">156282</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">166115</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000496"
      unitRef="USD">-382881</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000498"
      unitRef="USD">-12054</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000499"
      unitRef="USD">12500</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">110453</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000502"
      unitRef="USD">-13177</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">-98135</SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties>
    <SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000505"
      unitRef="USD">51188</SHPH:IncreaseDecreaseInAccruedInterestPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-6480</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000510"
      unitRef="USD">16001</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-5693</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000513"
      unitRef="USD">-5581147</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000514"
      unitRef="USD">-2710454</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000519"
      unitRef="USD">2998572</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">187895</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">19046</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">-2829723</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000535"
      unitRef="USD">10022193</SHPH:ProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">50000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">685473</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000541"
      unitRef="USD">50000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">3935000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000544"
      unitRef="USD">600715</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000546"
      unitRef="USD">345000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">334444</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000552"
      unitRef="USD">2570083</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000553"
      unitRef="USD">10622908</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000555"
      unitRef="USD">-5840787</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000556"
      unitRef="USD">7912454</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">8417203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000559"
      unitRef="USD">504749</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">2576416</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000562"
      unitRef="USD">8417203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">164807</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000568"
      unitRef="USD">39201</us-gaap:InterestPaidNet>
    <SHPH:CommonStockIssuedForConversionOfAccruedInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000577"
      unitRef="USD">16340</SHPH:CommonStockIssuedForConversionOfAccruedInterest>
    <SHPH:CommonStockIssuedForSettlementOfDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000579"
      unitRef="USD">2697849</SHPH:CommonStockIssuedForSettlementOfDebt>
    <SHPH:CommonStockIssuedForSettlementOfDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000580"
      unitRef="USD">588524</SHPH:CommonStockIssuedForSettlementOfDebt>
    <SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000583"
      unitRef="USD">576476</SHPH:CommonStockIssuedForExerciseOfWarrantsWithSettlementOfNotesPayable>
    <SHPH:CommonStockIssuedForDividendPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000586"
      unitRef="USD">402068</SHPH:CommonStockIssuedForDividendPayable>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000591"
      unitRef="USD">8727</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuanceFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000593"
      unitRef="USD">0</SHPH:WarrantsIssuanceFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000588"
      unitRef="USD">90816</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:WarrantsIssuedForFinancingFees
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000589"
      unitRef="USD">412241</SHPH:WarrantsIssuedForFinancingFees>
    <SHPH:InitialRecognitionOfRightOfUseAssetAndLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000595"
      unitRef="USD">365556</SHPH:InitialRecognitionOfRightOfUseAssetAndLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000598">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zLSnJOFJjx87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
1 &#x2013; &lt;span id="xdx_82A_zNQTfjOQsJoh"&gt;Organization and Liquidity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Organization
and Line of Business&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company was formed as Shuttle Pharmaceuticals, LLC, in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed
articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name
to Shuttle Pharmaceuticals, Inc. (&#x201c;Shuttle&#x201d;). In connection with the conversion the Company issued &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesIssued1_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQuWYMCwBa1l" title="Conversion of stock, shares issued"&gt;45,000,000&lt;/span&gt; shares of common
stock in exchange for &lt;span id="xdx_905_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20160812__20160812__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrFlg9kE6KXj" title="Sale of stock membership percentage"&gt;100&lt;/span&gt;% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed
a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation
(the &#x201c;Company&#x201d;), pursuant to which Shuttle, our operating entity, became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal
tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy. Shuttle has deployed its proprietary technology
to develop novel cancer immunotherapies, producing a pipeline of selective HDAC inhibitors for cancer and immunotherapy applications.
The Company&#x2019;s HDAC platform is designed to target candidate molecules with potential roles in therapeutics beyond cancer, including
autoimmune, inflammatory, metabolic, neurological and infectious diseases. The Company&#x2019;s Ropidoxuridine product, which is used
with radiation therapy to sensitize cancer cells, was funded by a Small Business Innovation Research (&#x201c;SBIR&#x201d;) contract provided
by the National Cancer Institute (&#x201c;NCI&#x201d;), a unit of the National Institutes of Health (&#x201c;NIH&#x201d;). Ropidoxuridine
has been further developed though the Company&#x2019;s collaborations with scientists at the University of Virginia for use in combination
with proton therapy to improve patient survival. Historically, and prior to the Company&#x2019;s initial public offering, the Company
has obtained funding to develop products through NIH grants, including a product to predict late effects of radiation with metabolite
biomarkers and develop prostate cancer cell lines in health disparities research.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
production and marketing of the Company&#x2019;s products and its ongoing research and development activities will be and are subject
to extensive regulation by numerous governmental authorities in the United States. Prior to marketing in the United States, any products
or combination of products developed by the Company must undergo rigorous preclinical (animal) and clinical (human) testing and an extensive
regulatory approval process implemented by the Food and Drug Administration (&#x201c;FDA&#x201d;) under the Food, Drug and Cosmetic Act.
There can be no assurance that the Company will not encounter problems in clinical trials that will cause the Company or the FDA to delay
or suspend clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s success will depend in part on its ability to obtain patents and product license rights, maintain trade secrets, and
operate without infringing on the proprietary rights of others, both in the United States and in other countries. There can be no assurance
that patents issued to or licensed by the Company will not be challenged, invalidated or circumvented, or that the rights granted thereunder
will provide proprietary protection or competitive advantages to the Company now or in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
consolidated financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities and commitments in the normal course of business. The Company has incurred losses since inception and has a net loss of
approximately $&lt;span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn5n6_di_c20230101__20231231_zvDIDv0jCj34" title="Net income loss"&gt;6.6&lt;/span&gt; million and no revenues for the year ended December 31, 2023 and working capital of approximately $&lt;span id="xdx_90D_ecustom--WorkingCapital_iN_pn5n6_di_c20230101__20231231_zpMi8peYTBP7" title="Working capital"&gt;4.6&lt;/span&gt; million as
of December 31, 2023. In addition, the convertible note payable outstanding at December 31, 2023 includes covenants and certain cash
payment requirements. These conditions, and the Company&#x2019;s ability to comply with such conditions, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within
one year after the date that the consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
September 2022, the Company completed its initial public offering of common stock, generating net proceeds of approximately $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20220901__20220930_zR49qYY8Cmnl" title="Proceeds from issuance or sale of equity"&gt;10.0&lt;/span&gt;
million. Additionally, in January 2023, the Company entered into a securities purchase agreement with an institutional investor
through which the Company sold a convertible note with a principal value of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zLz2DBKNXBw9" title="Debt instrument, face amount"&gt;4.3&lt;/span&gt;
million, along with a four-year warrant to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zl355kJKiw01" title="Four year warrant to purchase"&gt;1,018,079&lt;/span&gt;
shares of common stock, exercisable at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUpMqMf0Hl09" title="Exercisable price per share"&gt;2.35&lt;/span&gt;
per share, providing the Company with approximately $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20230101__20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zObOWFtvk5K9" title="Net proceeds from warrants"&gt;3.6&lt;/span&gt;
million in net proceeds. To date, the warrant has not yet been exercised. However, the Company&#x2019;s existing cash resources,
marketable securities and the cash received from the equity offering and convertible note are not expected to provide sufficient
funds to carry out the Company&#x2019;s operations and clinical trials through the next twelve months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
capital raise has supported operations leading up to the manufacture of drug product and FDA approval of the IND for the Phase II clinical
trial of Ropidoxuridine and radiation therapy in glioblastoma. The FDA recommended and the company agreed to an expansion of the clinical
trial, necessitating additional capital to complete the trial. Management intends to initiate a rights offering for $&lt;span id="xdx_90C_eus-gaap--PartnersCapital_iI_pn5n6_c20230131__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zVMpPjuScNs2" title="Initiated a capital offering"&gt;4.5&lt;/span&gt; million and has submitted
SBIR applications for non-dilutive NIH funding for pre-clinical project. The ability of the Company to continue as a going concern is
dependent upon its ability to successfully conduct clinical trials, bring a drug candidate to commercialization to generate revenues,
and to raise additional equity or debt financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statements do not include any adjustments to reflect the future effects on the recoverability and
classification of assets or the amounts and classification of liabilities if the Company is unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">45000000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2016-08-122016-08-12_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Pure">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="Fact000604"
      unitRef="USD">-6600000</us-gaap:NetIncomeLoss>
    <SHPH:WorkingCapital
      contextRef="From2023-01-01to2023-12-31"
      decimals="-5"
      id="Fact000606"
      unitRef="USD">-4600000</SHPH:WorkingCapital>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2022-09-012022-09-30"
      decimals="-5"
      id="Fact000608"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000610"
      unitRef="USD">4300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000612"
      unitRef="Shares">1018079</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31_us-gaap_CommonStockMember_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000614"
      unitRef="USDPShares">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-012023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000616"
      unitRef="USD">3600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PartnersCapital
      contextRef="AsOf2023-01-31_custom_InstitutionalInvestorMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-5"
      id="Fact000618"
      unitRef="USD">4500000</us-gaap:PartnersCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000620">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_ztutohW0DxZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
2 &#x2013; &lt;span id="xdx_82D_zF1DC2RbvP0b"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zN9JmHykJAle"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zXzky5zRn35g"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z51lIHBaxIod"&gt;Reclassifications&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--CorrectionOfPriorPeriodErrorsPolicyTextBlock_zUNM6DMxDWG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zmSLE9UXGTZ4"&gt;Correction of an Immaterial Error in the Prior Period Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expense in accordance with ASC 730. As a &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;result,
c&lt;/span&gt;ertain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the
materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting
Bulletin No. 99, &#x201c;Materiality,&#x201d; (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the
Company concluded that these error corrections in its &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated
Statements of Operations&lt;/span&gt; are not material to any previously presented financial statements based upon overall considerations
of both quantitative and qualitative factors. The corrections had no impact on the&lt;/span&gt; Consolidated &lt;span style="background-color: white"&gt;Balance
Sheet, &lt;/span&gt; Consolidated Statements of Cash Flows, or Consolidated Statement of Changes in Stockholders&#x2019; &lt;span style="background-color: white"&gt;Equity,
to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per
share, or working capital. The quarterly
corrections for 2023 include $&lt;span id="xdx_902_eus-gaap--PriorPeriodReclassificationAdjustment_c20230101__20230331_zFakzIKd6fI5" title="Quarterly reclassifications"&gt;89,007&lt;/span&gt;
(March 31), $&lt;span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230401__20230630_zjgd06Zv936i" title="Quarterly reclassifications"&gt;93,708&lt;/span&gt;
(June 30), and $&lt;span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230701__20230930_z6t87eTcNI8l" title="Quarterly reclassifications"&gt;95,129&lt;/span&gt;
(September 30). Accordingly, the Company corrected the previously reported immaterial errors for the years ended December 31, 2023
and 2022 in this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A summary of corrections reflecting the prior period impact to the Company&#x2019;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zAUbI2M0uK5l" style="display: none"&gt;Schedule of the Error Correction&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Correction&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As Corrected &lt;br/&gt;
December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;General and administrative expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;198,978&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;339,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;538,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,488,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(339,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,148,712&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,687,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,687,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zyP3t9CJDzV" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_znBsmi9qpX7i"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the
accompanying consolidated financial statements for the valuation of derivatives and initial measurement of equity-based
warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zJkXkj4AZTy2"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zAIRmxIIPtT9" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,411,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,005,825&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,417,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $&lt;span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount"&gt;1,849,000&lt;/span&gt;. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zcIP2rrvmXK8"&gt;Marketable
Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance"&gt;2,887,215&lt;/span&gt;. During the year ended December 31, 2023, the Company recognized interest income of $&lt;span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income"&gt;52,855&lt;/span&gt;,
realized gains of $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss"&gt;4,970&lt;/span&gt;, and unrealized gains of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss"&gt;71,568&lt;/span&gt;. The were &lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zVNP7VA0iPmh" title="Marketable securities::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0679"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zqfmU6VxYX7j"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zMDw775NrT6i" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zUfQ5IhZAVZ7"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine if an arrangement is a lease at inception. &lt;span style="background-color: white"&gt;Operating leases are included in operating
lease right-of-use asset (&#x201c;ROU&#x201d;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Leases
with a lease term of 12 months or less at inception are not recorded on our &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;balance &lt;/span&gt;sheets &lt;span style="background-color: white"&gt;and are expensed on a straight-line
basis over the lease term in our statement of operations. &lt;/span&gt;We have lease agreements with lease and non-lease components, which
are generally accounted for separately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#x201c;incremental borrowing rate&#x201d; or &#x201c;IBR&#x201d;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zhMEboul1fnf"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zLo9hjhMywRk" style="display: none"&gt;Schedule of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Furniture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computers and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zYSObLAWFqrd"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For
our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception
and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded
as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated
balance sheet sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zIShPO1DVFMg"&gt;Convertible
Note&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments
if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zbFQsfTI6WN7"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;)
and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether
the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zMKVdyEG0BI7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z4CSzyso8ih9"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost for stock awards, which include restricted stock units (&#x201c;RSUs&#x201d;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z01OOEEOeht9"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#x2019; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE8MCOpDGG97" title="Share based compensation"&gt;0.8&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyagly3uGnx8" title="Share based compensation"&gt;0.6&lt;/span&gt; million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, &lt;i&gt;Government Assistance&lt;/i&gt;, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#x2013; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $&lt;span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20231231_zQBcV79W2Tl3" title="Research and development, net of contract expense reimbursements"&gt;0&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20220101__20221231_z6jSzaNLWoj" title="Research and development, net of contract expense reimbursements"&gt;211,455&lt;/span&gt; in Research and development, net of contract expense reimbursements, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zjUxdX9ZNGFl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zwbvAlIY1l46"&gt;Net
Loss Per Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all
entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share
computation. In the accompanying consolidated financial statements, basic loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by
the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to
reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and
warrants unless the result would be antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#x201c;treasury
stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted
method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zz6N2TjW0PMb" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Convertible notes (Note 5)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"&gt;959,513&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant (Note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"&gt;1,446,155&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"&gt;356,810&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"&gt;197,855&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"&gt;2,603,523&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"&gt;356,810&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zSWNCgOEheR1"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#x2019;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;does not expect the adoption of this standard to
have any material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.&lt;/p&gt;

&lt;p id="xdx_85E_zQNfopfWoCN" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000622">&lt;p id="xdx_84B_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zJYURIS0DRR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zN9JmHykJAle"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities
and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements and disclosures have been prepared using the accrual
basis of accounting in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000624">&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zkcl5kN2tnbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zXzky5zRn35g"&gt;Basis
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a consolidated basis with those of the Company&#x2019;s wholly-owned subsidiaries,
Shuttle Pharmaceuticals, Inc. and Shuttle Diagnostics, Inc. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2023-01-01to2023-12-31" id="Fact000626">&lt;p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zBWpZS1NGOtd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z51lIHBaxIod"&gt;Reclassifications&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000628">&lt;p id="xdx_84C_ecustom--CorrectionOfPriorPeriodErrorsPolicyTextBlock_zUNM6DMxDWG" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zmSLE9UXGTZ4"&gt;Correction of an Immaterial Error in the Prior Period Financial Statements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;During
the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused
by an immaterial classification error of certain research and development expense in accordance with ASC 730. As a &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;result,
c&lt;/span&gt;ertain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the
materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting
Bulletin No. 99, &#x201c;Materiality,&#x201d; (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the
Company concluded that these error corrections in its &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Consolidated
Statements of Operations&lt;/span&gt; are not material to any previously presented financial statements based upon overall considerations
of both quantitative and qualitative factors. The corrections had no impact on the&lt;/span&gt; Consolidated &lt;span style="background-color: white"&gt;Balance
Sheet, &lt;/span&gt; Consolidated Statements of Cash Flows, or Consolidated Statement of Changes in Stockholders&#x2019; &lt;span style="background-color: white"&gt;Equity,
to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per
share, or working capital. The quarterly
corrections for 2023 include $&lt;span id="xdx_902_eus-gaap--PriorPeriodReclassificationAdjustment_c20230101__20230331_zFakzIKd6fI5" title="Quarterly reclassifications"&gt;89,007&lt;/span&gt;
(March 31), $&lt;span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230401__20230630_zjgd06Zv936i" title="Quarterly reclassifications"&gt;93,708&lt;/span&gt;
(June 30), and $&lt;span id="xdx_90B_eus-gaap--PriorPeriodReclassificationAdjustment_c20230701__20230930_z6t87eTcNI8l" title="Quarterly reclassifications"&gt;95,129&lt;/span&gt;
(September 30). Accordingly, the Company corrected the previously reported immaterial errors for the years ended December 31, 2023
and 2022 in this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A summary of corrections reflecting the prior period impact to the Company&#x2019;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zAUbI2M0uK5l" style="display: none"&gt;Schedule of the Error Correction&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Correction&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As Corrected &lt;br/&gt;
December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;General and administrative expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;198,978&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;339,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;538,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,488,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(339,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,148,712&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,687,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,687,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zyP3t9CJDzV" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</SHPH:CorrectionOfPriorPeriodErrorsPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">89007</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      id="Fact000632"
      unitRef="USD">93708</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:PriorPeriodReclassificationAdjustment
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact000634"
      unitRef="USD">95129</us-gaap:PriorPeriodReclassificationAdjustment>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000636">&lt;p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zpQW9hgZ2frd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A summary of corrections reflecting the prior period impact to the Company&#x2019;s Consolidated Statement of Operations,
for the year ended December 31, 2022, are shown below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BE_zAUbI2M0uK5l" style="display: none"&gt;Schedule of the Error Correction&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20220101__20221231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zSiUN2fdx1Vb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220101__20221231__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zkZcVedOl2gd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Correction&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220101__20221231_zZTkSEIRjpfk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As Corrected &lt;br/&gt;
December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--GeneralAndAdministrativeExpense_zMgEcfiCdPFc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;General and administrative expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;198,978&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;339,818&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;538,796&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ResearchAndDevelopmentExpense_zYPbxXp6R8mi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,488,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(339,818&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,148,712&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProfitLoss_zcsFhs8E7YEd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net Loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,687,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,687,508&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000638"
      unitRef="USD">198978</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="0"
      id="Fact000639"
      unitRef="USD">339818</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000640"
      unitRef="USD">538796</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">1488530</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"
      decimals="0"
      id="Fact000643"
      unitRef="USD">-339818</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">1148712</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact000646"
      unitRef="USD">1687508</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000648"
      unitRef="USD">1687508</us-gaap:ProfitLoss>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000650">&lt;p id="xdx_848_eus-gaap--UseOfEstimates_zMBrFPqjRAp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_znBsmi9qpX7i"&gt;Use
of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and
assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that
it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results
experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent there are material differences
between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the
accompanying consolidated financial statements for the valuation of derivatives and initial measurement of equity-based
warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000652">&lt;p id="xdx_84E_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_ziARHajJdpgc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zJkXkj4AZTy2"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zAIRmxIIPtT9" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,411,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,005,825&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,417,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zqd2jMS4buMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Periodically,
the Company may carry cash balances at financial institutions in excess of the federally insured limit of $&lt;span id="xdx_90A_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zogCujVNNT5b" title="Cash FDIC insured amount"&gt;250,000&lt;/span&gt; per institution. The
amount in excess of the FDIC insurance as of December 31, 2023 was approximately $&lt;span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20231231_zqP3IFhQi8Tb" title="Cash, uninsured amount"&gt;1,849,000&lt;/span&gt;. The Company has not experienced losses on
these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these
deposits is not significant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000654">&lt;p id="xdx_89B_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_zJ7zINkvCYB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents include cash in bank accounts and money market funds with maturities of less than three months from inception, which
are readily convertible to known amounts of cash and which, in the opinion of management, are subject to an insignificant risk of loss
in value. As of December 31, 2023 and 2022, cash and cash equivalents consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_zAIRmxIIPtT9" style="display: none"&gt;Schedule of Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231_zghCZpzWecVa" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zxvrrxMWcL77" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Cash_iI_maCACEAzwWH_zm97DCiMXigg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 64%"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,550,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,411,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--MoneyMarketFundsAtCarryingValue_iI_maCACEAzwWH_zcm4W1anTTq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Money market funds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,026,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,005,825&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iTI_mtCACEAzwWH_zb13RN4S5oT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,576,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,417,203&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000656"
      unitRef="USD">1550098</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000657"
      unitRef="USD">5411378</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000659"
      unitRef="USD">1026318</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">3005825</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">2576416</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000663"
      unitRef="USD">8417203</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000665"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000667"
      unitRef="USD">1849000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000669">&lt;p id="xdx_845_eus-gaap--MarketableSecuritiesPolicy_zKSKiZlFX8Je" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zcIP2rrvmXK8"&gt;Marketable
Securities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
investments in debt securities are carried at fair value. Investments in debt securities that are not classified as held-to-maturity
are carried at fair value and classified as either trading or available-for-sale. Realized and unrealized gains and losses on trading
of debt securities are charged to income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the marketable securities held by the Company, which are classified as trading marketable securities, consisted
of an outstanding balance of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesCurrent_iI_c20231231_zL1JtFLIX3Vf" title="Marketable securitie outstanding balance"&gt;2,887,215&lt;/span&gt;. During the year ended December 31, 2023, the Company recognized interest income of $&lt;span id="xdx_90D_eus-gaap--InterestIncomeExpenseNet_c20230101__20231231_zh1VKYEMYToh" title="Interest income"&gt;52,855&lt;/span&gt;,
realized gains of $&lt;span id="xdx_908_eus-gaap--MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments_c20230101__20231231_zGHKy1D2FCTh" title="Marketable securities realized gain loss"&gt;4,970&lt;/span&gt;, and unrealized gains of $&lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20230101__20231231_zPnZKVRtdKne" title="Marketable securities unrealized gain loss"&gt;71,568&lt;/span&gt;. The were &lt;span id="xdx_90E_eus-gaap--MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments_dxL_c20220101__20221231_zVNP7VA0iPmh" title="Marketable securities::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0679"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000671"
      unitRef="USD">2887215</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000673"
      unitRef="USD">52855</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000675"
      unitRef="USD">4970</us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000677"
      unitRef="USD">71568</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000681">&lt;p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zYnEeim8mj1a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zqfmU6VxYX7j"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows accounting guidelines on fair value measurements for financial instruments measured on a recurring basis, as well as
for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price,
or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
as of the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes
the use of unobservable inputs to value its financial instruments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
    3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values
    are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which
    the determination of fair value requires a significant judgment or estimation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair
value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety
requires the Company to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or
estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed, or initial
amounts recorded, may not be indicative of the amount that the Company or holders of the instruments could realize in a current market
exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
carrying amounts of the Company&#x2019;s financial instruments including cash and cash equivalents, prepaid expenses, accounts payable
and accrued liabilities approximate fair value due to the short-term maturities of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zMDw775NrT6i" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z0BMFzUNZAHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000683">&lt;p id="xdx_897_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zSIonfwaYqH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below are the Company&#x2019;s financial instruments that are required to be remeasured at fair value on a recurring basis and their
fair value hierarchy as of December 31, 2023 (none for December 31, 2022):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BA_zMDw775NrT6i" style="display: none"&gt;Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxM1bBFsBuza" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxC3dbHjmq03" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5STlZhRRiw1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231_z8T6OxMWRiDd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsAbstract_iB_zyUtFVLtCxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DerivativeAssetsCurrent_iI_hus-gaap--FairValueByAssetClassAxis__us-gaap--USTreasurySecuritiesMember_zLm87oIK62o6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-bottom: 1.5pt"&gt;United States Treasury Bonds&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0692"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosure_iI_zEOKYh11hRef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0697"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,887,215&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LiabilitiesAbstract_iB_zncvoYtwNRSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_ztYAFhXlbef9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Derivative Liability - Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;410,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DerivativeLiabilitiesCurrent_iI_hus-gaap--FinancialInstrumentAxis__custom--AcceleratedFeatureMember_zatoxTiQyVD9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative Liability - Accelerated feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LiabilitiesFairValueDisclosure_iI_zsXTKOqHXeFj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;414,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000690"
      unitRef="USD">2887215</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="AsOf2023-12-31_us-gaap_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact000693"
      unitRef="USD">2887215</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000695"
      unitRef="USD">2887215</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000698"
      unitRef="USD">2887215</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000707"
      unitRef="USD">410660</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember"
      decimals="0"
      id="Fact000708"
      unitRef="USD">410660</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000712"
      unitRef="USD">3852</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact000713"
      unitRef="USD">3852</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000717"
      unitRef="USD">414512</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000718"
      unitRef="USD">414512</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000720">&lt;p id="xdx_842_eus-gaap--LesseeLeasesPolicyTextBlock_z3ZBtWwyvkHa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zUfQ5IhZAVZ7"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
determine if an arrangement is a lease at inception. &lt;span style="background-color: white"&gt;Operating leases are included in operating
lease right-of-use asset (&#x201c;ROU&#x201d;), operating lease liability - current, and operating lease liability - noncurrent on the
consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities
in our consolidated balance sheets. The Company did not utilize any financing that required recognition of finance leases during the
years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ROU
assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease
payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present
value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based
on the estimated rate of interest for collateralized borrowing, over a similar term of the lease payments at commencement date. The operating
lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or
terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on
a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Leases
with a lease term of 12 months or less at inception are not recorded on our &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;balance &lt;/span&gt;sheets &lt;span style="background-color: white"&gt;and are expensed on a straight-line
basis over the lease term in our statement of operations. &lt;/span&gt;We have lease agreements with lease and non-lease components, which
are generally accounted for separately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determines the present value of minimum future lease payments for operating leases by estimating a rate of interest that it would
have to pay to borrow on a collateralized basis over a similar term, an amount equal to the lease payments and a similar economic environment
(the &#x201c;incremental borrowing rate&#x201d; or &#x201c;IBR&#x201d;). The Company determines the appropriate IBR by identifying a reference
rate and making adjustments that take into consideration financing options and certain lease-specific circumstances. For the reference
rate, the Company used an equity built up, risk adjusted rate, as the implicit interest rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000722">&lt;p id="xdx_84E_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z8MmAaVMdZR3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zhMEboul1fnf"&gt;Property
and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to expense as incurred;
additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost
and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of
property and equipment is provided using the straight-line method for substantially all assets with estimated lives as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zLo9hjhMywRk" style="display: none"&gt;Schedule of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Furniture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computers and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zxD6isOTvgRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000724">&lt;p id="xdx_892_ecustom--ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock_zWSpQ5dHOcsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zLo9hjhMywRk" style="display: none"&gt;Schedule of Useful Lives for Property Plant Equipment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;Furniture&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zUZwleHokYf9" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Computers and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zExjBP60vsi4" title="Property plant and equipment useful life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zLYzitJLiVob" title="Property plant and equipment useful life"&gt;10&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfUsefulLivesForPropertyPlantEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000726">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000728">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_EquipmentMember"
      id="Fact000730">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DerivativesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000732">&lt;p id="xdx_84F_eus-gaap--DerivativesPolicyTextBlock_zBMVAu3vuLLj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zYSObLAWFqrd"&gt;Derivative
Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For
derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value
and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For
our derivative financial instruments, the Company used a Monte Carlo valuation model to value the derivative instruments at inception
and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded
as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated
balance sheet sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within twelve (12) months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesPolicyTextBlock>
    <SHPH:ConvertibleNotePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000734">&lt;p id="xdx_840_ecustom--ConvertibleNotePolicyTextBlock_zMEKxrz3nfQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zIShPO1DVFMg"&gt;Convertible
Note&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments
if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative
instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument
that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable
generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument
with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</SHPH:ConvertibleNotePolicyTextBlock>
    <SHPH:WarrantsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000736">&lt;p id="xdx_84E_ecustom--WarrantsPolicyTextBlock_z1qgekWaZ22h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zbFQsfTI6WN7"&gt;Warrants&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;)
and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial
instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements
for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares and whether
the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control,
among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the
time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;For
issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component
of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification,
the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter.
Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;consolidated
&lt;span style="background-color: white"&gt;statements of operations. The fair value of the warrants is estimated using a Black-Scholes pricing
model or a Monte Carlo simulation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SHPH:WarrantsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000738">&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zieP66ou2jog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zMKVdyEG0BI7"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying
amount of the asset may not be fully recoverable. Recoverability of assets is measured by a comparison of the carrying amount of an asset
to the estimated undiscounted cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated
future cash flows, an impairment charge will be recognized in the amount by which the carrying amount of the asset exceeds the fair value
of the asset. There were no impairments of long-lived assets during the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000740">&lt;p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zH6lgVCffzOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_z4CSzyso8ih9"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Compensation
cost for stock awards, which include restricted stock units (&#x201c;RSUs&#x201d;), is measured at the fair value on the grant date and
recognized as expense, over the related service or performance period. The fair value of stock awards is based on the quoted price of
our common stock on the grant date. Compensation expense related to the RSUs is reduced by the fair value of the units that are forfeited
by employees that leave the Company prior to vesting as they occur. Compensation cost for RSUs are recognized using the straight-line
method over the requisite service period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000742">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zvRlhX5DOMC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_z01OOEEOeht9"&gt;Research
and Development Expenses&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product
development, clinical and regulatory expenses, payroll and other personnel expenses, which include a certain portion of our chief executive officer, chief operating officer, chief financial officer and directors&#x2019; compensation. For the year
ended December 31, 2023 and 2022, a portion of personnel-related expenses and stock-based compensation expense for these individuals totaling
$&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_pn5n6_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zE8MCOpDGG97" title="Share based compensation"&gt;0.8&lt;/span&gt; million and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zyagly3uGnx8" title="Share based compensation"&gt;0.6&lt;/span&gt; million, respectively, was included within research and development due to their
active involvement in the research and development activities, materials, supplies, related subcontract expenses, and consulting costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
the accounting treatment for reimbursements, GAAP provides limited guidance on the accounting for government grants received by for-profit
companies. In accordance with ASC Topic 832, &lt;i&gt;Government Assistance&lt;/i&gt;, as adopted January 1, 2022, we disclose certain types of
government assistance received in the notes to the consolidated financial statements that includes: a) the nature of the transaction
including the nature of the assistance being given, b) the accounting policies being used to account for the transaction and c) other
provisions of relevance, where required. Depending on the type of grant or contract, we understand there is more than one acceptable
alternative for the accounting treatment &#x2013; a reduction of costs, a deferred credit to be amortized, revenue or other income. The
Company has concluded that reimbursements received for R&amp;amp;D expenses incurred, are more akin to a reduction of costs and applies reimbursements
against incurred research costs. For the years ended December 31, 2023 and 2022, we recorded $&lt;span id="xdx_90C_eus-gaap--OtherResearchAndDevelopmentExpense_c20230101__20231231_zQBcV79W2Tl3" title="Research and development, net of contract expense reimbursements"&gt;0&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OtherResearchAndDevelopmentExpense_c20220101__20221231_z6jSzaNLWoj" title="Research and development, net of contract expense reimbursements"&gt;211,455&lt;/span&gt; in Research and development, net of contract expense reimbursements, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000744"
      unitRef="USD">800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-5"
      id="Fact000746"
      unitRef="USD">600000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000748"
      unitRef="USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000750"
      unitRef="USD">211455</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000752">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zDAunLdGAjX" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zjUxdX9ZNGFl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes in accordance with ASC Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;. ASC 740 requires a company to use the asset
and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences,
and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the
reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the
opinion of management, the Company does not foresee generating taxable income in the near future and utilizing its deferred tax asset,
therefore, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets
and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d; that the tax position would be sustained
in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that
is greater than 50% likely of being realized on examination. For tax positions not meeting the &#x201c;more likely than not&#x201d; test,
no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000754">&lt;p id="xdx_841_eus-gaap--EarningsPerSharePolicyTextBlock_zsQXKiX1zFa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zwbvAlIY1l46"&gt;Net
Loss Per Common Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
loss per share of common stock requires presentation of basic earnings per share on the face of the statements of operations for all
entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share
computation. In the accompanying consolidated financial statements, basic loss per share is computed by dividing net loss by the weighted
average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by
the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to
reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and
warrants unless the result would be antidilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dilutive effect of restricted stock units subject to vesting and other stock-based payment awards is calculated using the &#x201c;treasury
stock method,&#x201d; which assumes that the &#x201c;proceeds&#x201d; from the exercise of these instruments are used to purchase common
shares at the average market price for the period. The dilutive effect of convertible securities is calculated using the &#x201c;if-converted
method.&#x201d; Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting
shares of common stock are included in the denominator of the diluted calculation for the entire period being presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zz6N2TjW0PMb" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Convertible notes (Note 5)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"&gt;959,513&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant (Note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"&gt;1,446,155&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"&gt;356,810&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"&gt;197,855&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"&gt;2,603,523&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"&gt;356,810&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z9ZYST80qrw2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000756">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zMFSoz5znW06" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the following common stock equivalents were excluded from the computation of diluted net
loss per share as the result of the computation was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zz6N2TjW0PMb" style="display: none"&gt;Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Convertible notes (Note 5)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zpHdqZ0f48q" title="Convertible notes (Note 6)"&gt;959,513&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zkOcSbFRRQE3" title="Convertible notes (Note 6)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0760"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrant (Note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zTBnTL30YwS6" title="Warrants"&gt;1,446,155&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqNikXfwpzn3" title="Warrants"&gt;356,810&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted stock units (Note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zdGWy7MsXoId" title="Restricted stock units"&gt;197,855&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z0jPrngUZSA1" title="Restricted stock units"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231_z4DV2UOZ7Bo9" title="Anti-dilutive securities"&gt;2,603,523&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231_zRKiCEjITY92" title="Anti-dilutive securities"&gt;356,810&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000758"
      unitRef="Shares">959513</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000762"
      unitRef="Shares">1446155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000764"
      unitRef="Shares">356810</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000766"
      unitRef="Shares">197855</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000770"
      unitRef="Shares">2603523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000772"
      unitRef="Shares">356810</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000774">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zhkioRiMnfDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zSWNCgOEheR1"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income
taxes paid. The guidance is effective for the Company&#x2019;s fiscal years beginning after February 1, 2025, with early adoption permitted.
The Company &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;does not expect the adoption of this standard to
have any material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;There have been no other recent accounting pronouncements,
changes in accounting pronouncements or recently adopted accounting guidance during the year ended December 31, 2023 that are of significance
or potential significance to the Company.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000776">&lt;p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z08OzEyKAwJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
3 &#x2013; &lt;span id="xdx_82E_zYhGzQEhHDX1"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had two lease agreements during the year which allowed for the use of laboratory facilities. &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zEya2wAH9aKc" title="Lessee, operating lease, description"&gt;The first was for a monthly payment
of $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_c20230101__20231231_z4j16dhXCej9" title="Payments for rent"&gt;6,480&lt;/span&gt;, with a security deposit of $&lt;span id="xdx_90A_eus-gaap--Deposits_iI_c20231231_zO8e4gkFsUJk" title="Deposits"&gt;6,480&lt;/span&gt; held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019&lt;/span&gt; and ended on &lt;span id="xdx_90D_eus-gaap--LeaseExpirationDate1_c20230101__20231231_zI0l5Mds2Am4" title="Lease expiration date"&gt;October 31, 2023&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 16, 2023, the Company entered into a new lease agreement for new office and laboratory space, with base rent of $&lt;span id="xdx_90C_eus-gaap--PaymentsForRent_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zzwRNVzOdczf" title="Payments for rent"&gt;7,206&lt;/span&gt; per month
for a period of 64 months, which increases at the rate of &lt;span id="xdx_903_ecustom--RentVariableRate1_iI_dp_uPure_c20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zIt1JZKcThLk" title="Rent variable rate"&gt;3&lt;/span&gt;% per year, that &lt;span id="xdx_908_eus-gaap--LesseeOperatingLeaseDescription_c20230215__20230216__us-gaap--LeaseContractualTermAxis__custom--NewLeaseAgreementMember_zj1i3ww8Qve3"&gt;commenced June 1, 2023&lt;/span&gt;. The new lease included a six-month
50% rent abatement upon commencement. Additional common area maintenance (&#x201c;CAM&#x201d;) fees are charged monthly and revised annually.
The estimated monthly CAM fees are $&lt;span id="xdx_908_ecustom--EstimatedMonthlyCommonAreaMaintenanceCost_c20230215__20230216_zd0rmLCuEgvl" title="Estimated monthly common area maintenance cost"&gt;3,300&lt;/span&gt; per month for the first year of the lease, which are being expensed as incurred. An irrevocable
letter of credit (&#x201c;LOC&#x201d;) for the security deposit of $&lt;span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20230216_zE3n7U3fwQok" title="Security deposit"&gt;43,234&lt;/span&gt; and base rent of $&lt;span id="xdx_904_eus-gaap--PaymentsForRent_c20230215__20230216_zETIouZ8QDv6" title="Payments for rent"&gt;3,891&lt;/span&gt;, including 50% abatement, and $&lt;span id="xdx_909_ecustom--CommonAreaMaintenanceCost_c20230215__20230216_zRiqEIIYf8j8" title="Common area maintenance cost"&gt;3,315&lt;/span&gt;
of CAM cost, was due and paid on execution of the lease agreement. Alexandria Real Estate (ARE-QRS-CORP) is the beneficiary of the LOC,
and the expiry date of the LOC is February 15, 2024. Subsequent to December 31, 2023, the LOC was renewed with an updated expiry date
of March 1, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the right-of use asset and lease information for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z3chxPAugTvb" style="display: none"&gt;Schedule of Right-of Use Asset and Lease Information About Operating Lease&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;112,022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;70,175&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Sublease income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,070&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;128,425&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;63,105&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;95,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;76,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;365,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term &#x2014; operating leases (year)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_ziMEmd9Mt5Sc" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)"&gt;4.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zQzuTkcat7T6" style="text-align: right" title="Weighted-average discount rate - operating leases"&gt;10.48&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zFmXEc2OJ102" style="text-align: right" title="Weighted-average discount rate - operating leases"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zAskMv6Jd9Ib" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFdDGFDXJUZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zww5HoyzAXBk" style="display: none"&gt;Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzDPt_zsoBHIDG7oh5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;91,502&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzDPt_z7eQTs5MmjR1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzDPt_zKCgLvy8lLQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzDPt_zDNVsoZEHARd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzDPt_zKj9Z36cUNyd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzDPt_zB0xrbyBjUZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(94,438&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zGZjjGq7mVc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-01-01to2023-12-31" id="Fact000778">The first was for a monthly payment
of $6,480, with a security deposit of $6,480 held for the duration of the lease, that commenced on October 1, 2018, with the first payment
made on January 1, 2019</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:PaymentsForRent
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000780"
      unitRef="USD">6480</us-gaap:PaymentsForRent>
    <us-gaap:Deposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">6480</us-gaap:Deposits>
    <us-gaap:LeaseExpirationDate1 contextRef="From2023-01-01to2023-12-31" id="Fact000784">2023-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember"
      decimals="0"
      id="Fact000786"
      unitRef="USD">7206</us-gaap:PaymentsForRent>
    <SHPH:RentVariableRate1
      contextRef="AsOf2023-02-16_custom_NewLeaseAgreementMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Pure">0.03</SHPH:RentVariableRate1>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="From2023-02-152023-02-16_custom_NewLeaseAgreementMember"
      id="Fact000789">commenced June 1, 2023</us-gaap:LesseeOperatingLeaseDescription>
    <SHPH:EstimatedMonthlyCommonAreaMaintenanceCost
      contextRef="From2023-02-152023-02-16"
      decimals="0"
      id="Fact000791"
      unitRef="USD">3300</SHPH:EstimatedMonthlyCommonAreaMaintenanceCost>
    <us-gaap:SecurityDeposit
      contextRef="AsOf2023-02-16"
      decimals="0"
      id="Fact000793"
      unitRef="USD">43234</us-gaap:SecurityDeposit>
    <us-gaap:PaymentsForRent
      contextRef="From2023-02-152023-02-16"
      decimals="0"
      id="Fact000795"
      unitRef="USD">3891</us-gaap:PaymentsForRent>
    <SHPH:CommonAreaMaintenanceCost
      contextRef="From2023-02-152023-02-16"
      decimals="0"
      id="Fact000797"
      unitRef="USD">3315</SHPH:CommonAreaMaintenanceCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000799">&lt;p id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_zcDz6E02IYI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following summarizes the right-of use asset and lease information for the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BD_z3chxPAugTvb" style="display: none"&gt;Schedule of Right-of Use Asset and Lease Information About Operating Lease&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zTtQP76cjIu4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220101__20221231_zYMfadYPMD7l" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Years Ended&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_zPUvDVqluFD3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;112,022&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;70,175&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--VariableLeaseCost_zrMHMcdo18R6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--SubleaseIncome_iN_di_zTymURVOeYFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Sublease income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,819&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,070&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LeaseCost_z9kSj7uST6n1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease cost&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;128,425&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;63,105&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--OtherInformationAbstract_iB_ztfZxHw4hnC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingLeasePayments_z2gpGKdvQlnj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;95,641&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;76,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_zZpVYGOUEDz5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;365,556&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term &#x2014; operating leases (year)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_ziMEmd9Mt5Sc" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)"&gt;4.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zIFqiVyLA0t1" style="text-align: right" title="Weighted-average remaining lease term - operating leases (year)"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate &#x2014; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zQzuTkcat7T6" style="text-align: right" title="Weighted-average discount rate - operating leases"&gt;10.48&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zFmXEc2OJ102" style="text-align: right" title="Weighted-average discount rate - operating leases"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000801"
      unitRef="USD">112022</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000802"
      unitRef="USD">70175</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000804"
      unitRef="USD">24222</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000807"
      unitRef="USD">7819</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000808"
      unitRef="USD">7070</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000810"
      unitRef="USD">128425</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000811"
      unitRef="USD">63105</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000816"
      unitRef="USD">95641</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000817"
      unitRef="USD">76248</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000819"
      unitRef="USD">365556</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact000822">P4Y8M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31" id="Fact000824">P0Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000826"
      unitRef="Pure">0.1048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000828"
      unitRef="Pure">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000830">&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFdDGFDXJUZd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
non-cancelable minimum lease payments under the operating lease liability as of December 31, 2023, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zww5HoyzAXBk" style="display: none"&gt;Schedule of Future Non-cancelable Minimum Lease Payments Under the Operating Lease Liability&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zgaXA26D0Fqb" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzDPt_zsoBHIDG7oh5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;91,502&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzDPt_z7eQTs5MmjR1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzDPt_zKCgLvy8lLQl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,074&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzDPt_zDNVsoZEHARd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99,986&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzDPt_zKj9Z36cUNyd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzDPt_zB0xrbyBjUZi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;451,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z22eMN2z7f7i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(94,438&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_zeK2VG8PSnK4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of payments&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;356,606&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000832"
      unitRef="USD">91502</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000834"
      unitRef="USD">94247</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000836"
      unitRef="USD">97074</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000838"
      unitRef="USD">99986</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000840"
      unitRef="USD">68235</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000842"
      unitRef="USD">451044</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000844"
      unitRef="USD">94438</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000846"
      unitRef="USD">356606</us-gaap:OperatingLeaseLiability>
    <SHPH:NotesPayableRelatedPartyDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000848">&lt;p id="xdx_80C_ecustom--NotesPayableRelatedPartyDisclosureTextBlock_zd061yowJNd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
4 &#x2013; &lt;span id="xdx_825_zH1XaP0tjrW5"&gt;Notes Payable-Related Party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 1, 2020, the Company consolidated all of the outstanding loans owed to an officer of the Company and to his spouse, resulting
in the following two loans: (i) a single loan from the spouse of an officer of the Company, dated December 1, 2020, with a principal
balance of $&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z3NgxGTYg4V9"&gt;426,243&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_900_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zWqcEUtfPTu6"&gt;7.5&lt;/span&gt;% per annum, with a maturity date of &lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionDate_dd_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zfFRy9Sub3Hc"&gt;December 31, 2021&lt;/span&gt;; and (ii) a single loan
owed to an officer of the Company in the principal amount of $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_z9TMMPLJqMKk"&gt;139,229&lt;/span&gt;, bearing interest at the rate of &lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20201201__20201201__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RelatedPartyOfficerMember_zerWcgbpUGVj"&gt;7.5&lt;/span&gt;% per annum, with a maturity
date of December 31, 2021. &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateDescription_c20211201__20211231_zfxw96gGmmth"&gt;In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2021, the Company entered into a loan from the spouse of an officer of the Company in the amount of $&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zTHYCCtmQ77h"&gt;120,000&lt;/span&gt; (principal) with
an interest rate of &lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionRate_pid_dp_uPure_c20210621__20210621__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_z7JDA19McyJa"&gt;7.5&lt;/span&gt;% per annum due June 21, 2022. In July of 2022, the loan was extended to June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023 principal payments of $&lt;span id="xdx_908_eus-gaap--ProceedsFromRepaymentsOfRelatedPartyDebt_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zSYaCBxemUD8"&gt;685,473&lt;/span&gt; and interest of $&lt;span id="xdx_902_eus-gaap--InterestPaidNet_c20230101__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OfficersSpouseMember_zffNQmXite2e"&gt;104,968&lt;/span&gt; were paid. As of December 31, 2023, there were &lt;span id="xdx_90E_eus-gaap--DebtInstrumentIncreaseAccruedInterest_do_c20230101__20231231_z5bCjpTtB4u2" title="Increase accrued interest"&gt;no&lt;/span&gt; outstanding
principal or interest balances for these related party notes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</SHPH:NotesPayableRelatedPartyDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000849"
      unitRef="USD">426243</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:RelatedPartyTransactionDate
      contextRef="From2020-12-012020-12-01_custom_OfficersSpouseMember"
      id="Fact000851">2021-12-31</us-gaap:RelatedPartyTransactionDate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember"
      decimals="0"
      id="Fact000852"
      unitRef="USD">139229</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2020-12-012020-12-01_custom_RelatedPartyOfficerMember"
      decimals="INF"
      id="Fact000853"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:DebtInstrumentMaturityDateDescription contextRef="From2021-12-012021-12-31" id="Fact000854">In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of
2022, the notes were extended to June 30, 2023.</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000855"
      unitRef="USD">120000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionRate
      contextRef="From2021-06-212021-06-21_custom_OfficersSpouseMember"
      decimals="INF"
      id="Fact000856"
      unitRef="Pure">0.075</us-gaap:RelatedPartyTransactionRate>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000857"
      unitRef="USD">685473</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-06-30_custom_OfficersSpouseMember"
      decimals="0"
      id="Fact000858"
      unitRef="USD">104968</us-gaap:InterestPaidNet>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000860"
      unitRef="USD">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000862">&lt;p id="xdx_802_eus-gaap--DebtDisclosureTextBlock_z2GEya6C7Gm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
5&#x2013; &lt;span&gt;&lt;span id="xdx_821_z4YyPFusOaGd"&gt;Convertible Notes&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Alto
Opportunity Master Fund, SPC&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 11, 2023, the Company entered into a securities purchase agreement (the &#x201c;SPA&#x201d;) with Alto Opportunity Master Fund,
SPC &#x2013; Segregated Master Portfolio B, a Cayman entity (the &#x201c;Investor&#x201d;), pursuant to which the Company sold to the Investor
a $&lt;span id="xdx_909_eus-gaap--ConvertibleDebt_iI_pp0p0_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z1qYaf3PFxbb" title="Convertible debt"&gt;4,300,000&lt;/span&gt; convertible note (the &#x201c;Alto Convertible Note&#x201d;) and warrant (the &#x201c;Warrant&#x201d;) to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSUnRPFxSwvf" title="Warrants to purchase common stock"&gt;1,018,079&lt;/span&gt;
shares of common stock, exercisable at $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z64P6QuvGP1l" title="Warrants exerciable shares"&gt;2.35&lt;/span&gt; per share, in exchange for gross proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20230109__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zXyVfotWMQH3" title="Proceeds from convertible note payable"&gt;3,935,000&lt;/span&gt; million (the &#x201c;Investment Amount&#x201d;)
(See Note 7). The Company determined that the Warrant contains a net cash settlement feature at inception and categorized the Warrant
as a liability in the accompanying consolidated financial statements. The Alto Convertible Note matures on March 11, 2025, but may be
extended at the option of the noteholder. The Alto Convertible Note amortizes on a monthly basis and the Company can make such monthly
amortization payments in cash or, subject to certain equity conditions, in registered shares of common stock or a combination thereof.
Installments may be deferred by the noteholder, resulting in a variable interest rate. However, the effective interest rate is approximately
&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYihioEmX1N1" title="Effective interest rate"&gt;346&lt;/span&gt;% based on the internal rate of return calculated on a series of cash flows that occur at regular intervals. For equity repayment,
&lt;span id="xdx_909_eus-gaap--DebtInstrumentDescription_c20230109__20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zaxJ1y0qhQBi" title="Debt description"&gt;the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment
date. The noteholder may convert at any time at a fixed price of $2.35 per share.&lt;/span&gt; The noteholder has an acceleration of installment amount
conversion option (the &#x201c;Acceleration Option&#x201d;), whereby the noteholder, with certain share percentage limitations, can convert
to common stock any outstanding installment amount at an amount equal to the installment amount plus five times (5x) the installment
amount at any time. The Company has determined the Acceleration Option is an embedded derivative within the host instrument and has bifurcated
it from the host instrument and recorded it as a derivative liability valued at $&lt;span id="xdx_904_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zw9FmdP2k1rj" title="Derivative liability"&gt;1,442,000&lt;/span&gt;, using a Monte Carlo simulation model (Note
7). The Convertible Note is repayable over 26 months and bears interest at the rate of &lt;span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230111__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zIDfdUAlNQL7" title="Debt interest rate"&gt;5&lt;/span&gt;% per annum. Additionally, the note contains
certain redemption options and &#x201c;Make Whole&#x201d; provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with entry into the SPA, the Company entered into a series of related agreements, including a security agreement (the &#x201c;Security
Agreement&#x201d;), an intellectual property security agreement (the &#x201c;IP Security Agreement&#x201d;) and a subsidiary guaranty (the
&#x201c;Subsidiary Guaranty&#x201d;). The security agreements and guaranty allow, among other things, for the Investor to have a security
interest in and place a lien on all of the Company&#x2019;s assets and intellectual property until such time as the Alto Convertible Note
is paid off. In addition, the SPA called for the Company to enter into a springing deposit account control agreement (the &#x201c;Springing
DACA&#x201d;), which, in the event the Company defaults on its repayment of the Alto Convertible Note, would allow the Investor to assume
control of the Company&#x2019;s bank account only with regard to any funds remaining outstanding under the Alto Convertible Note. As such,
in conjunction with entry into the SPA, the Company established a separate bank account in which it deposited the Investment Amount and
pursuant to which the Company, the Investor and the bank holding the Investment Amount, First Republic Bank, entered into the Springing
DACA agreement. As the Investment Amount had been held at First Republic Bank, in light of certain banking crises then affecting smaller
banks, on March 12, 2023, the Company and the Investor moved the Investment Amount from First Republic Bank, after which time the Springing
DACA was no longer in effect. Further, pursuant to amendments to the SPA entered into in May and June of 2023, the Company and the Investor
agreed that all of the Investment Amount would be released to the Company and the relevant provision of the SPA which required the Springing
DACA would no longer be deemed applicable. In addition, the Company granted the Investor the option to purchase up to an additional $&lt;span id="xdx_905_eus-gaap--ConvertibleNotesPayable_iI_pn6n6_c20231231_zhjUClDQimI" title="Convertible notes payable"&gt;10&lt;/span&gt;
million in convertible notes and warrants on substantially the same terms as the Alto Convertible Note and Warrant, excluding the Springing
DACA requirement, with such option to be effective through December 31, 2025. The agreement offers the investor an opportunity to participate
in future capital raises at substantially similar terms as the January 11, 2023 agreement. The Company expects that such subsequent convertible notes and warrants would be issued on substantially similar
terms as the January 11, 2023 initial agreement, as amended, thus providing the Company the opportunity to negotiate certain aspects of
the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Boustead
Securities, LLC (&#x201c;Boustead&#x201d;) served as a placement agent for the Alto Convertible Note and Warrant offering and received
$&lt;span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_ziS9eEQtuv1f" title="Payment for placement agent"&gt;345,000&lt;/span&gt; cash compensation and a warrant to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zAqlkvNNaDpd" title="Warrants to purchase common stock"&gt;71,266&lt;/span&gt; shares of common stock, exercisable at $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zojy77XppzIe" title="Warrants exerciable shares"&gt;2.35&lt;/span&gt; per share. The Boustead warrant
was determined to be an equity instrument valued on a non-recurring basis. The Company used the Black Scholes valuation model using a
term of &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zPC674AVJKXc" title="Expected years"&gt;five years&lt;/span&gt;, volatility of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znMOWfqPGjYf" title="Warrants and rights outstanding measurement input"&gt;110&lt;/span&gt;%, a risk-free rate of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zILXwC7DhWBl"&gt;3.53&lt;/span&gt;% for a value of $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_uUSD_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zEonjOrQ2ZU" title="Fair value of warrants"&gt;99,543&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated the finance costs related to the Boustead placement agent fee of $&lt;span id="xdx_902_ecustom--PaymentForPlacementAgent_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_z1qEjzidygn" title="Payment for placement agent"&gt;345,000&lt;/span&gt;, based on the relative fair market values
of the Convertible Note and warrants issued. The allocation of the financing costs applied $&lt;span id="xdx_902_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zGBEljeJa0Nb" title="Allocation of financing costs"&gt;232,027&lt;/span&gt; to the debt component as a debt discount
that is being amortized to interest expense over the term of the Convertible Note, $&lt;span id="xdx_90A_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zmNk8FczQ6Wh" title="Warrant derivative liability"&gt;104,245&lt;/span&gt; to the warrant derivative liability component,
expensed as a finance fee, and $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFeeAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zSUixncCkJS1" title="Equity warrant as reduction in additional paid in capital"&gt;8,727&lt;/span&gt; to the equity warrant as a reduction in additional paid in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company allocated to the debt component of the note an original discount of $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zMx5hPAesnIi" title="Debt discount"&gt;300,000&lt;/span&gt;, legal fees of $&lt;span id="xdx_90D_eus-gaap--LegalFees_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zLBOZ1MJKbi8" title="Legal fees"&gt;65,000&lt;/span&gt;, $&lt;span id="xdx_900_ecustom--InterestFeeAmount_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zqJJyHoHEi83" title="Interest fee"&gt;215,000&lt;/span&gt; for additional
interest fees on day one added to note principal, $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zayR1vJlE2s9" title="Debt principal amount"&gt;1,442,000&lt;/span&gt; for the accelerated conversion feature, and $&lt;span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zxa2TC77bmFd" title="Fair value of warrants"&gt;1,288,543&lt;/span&gt; for the fair value
of warrants, resulting in an additional $&lt;span id="xdx_908_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_znnI28Rtm2fb" title="Interest expense debt"&gt;3,310,543&lt;/span&gt; debt discount that is being amortized to interest expense over the term of the Alto
Convertible Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company recorded interest expense of $&lt;span id="xdx_903_eus-gaap--InterestExpenseDebt_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_znhWETUYiYQb"&gt;2,484,193&lt;/span&gt;, which included amortization of debt discount as
interest expense of $&lt;span id="xdx_900_eus-gaap--InterestExpenseDebt_c20230101__20231231_zpTyEbkt4Xac"&gt;2,123,049&lt;/span&gt;. During the year ended December 31, 2023, the Company settled $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zJLs4MfXiOZ5" title="Debt, principal"&gt;1,925,700&lt;/span&gt; of principal and settled $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIncreaseAccruedInterest_c20230101__20231231__dei--LegalEntityAxis__custom--BousteadSecuritiesLLCMember_zIH04jwIMOkl" title="Accrued interest"&gt;294,927&lt;/span&gt;
of accrued interest, which settlements were made in the form of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z61rjBMkQSyb"&gt;2,380,996&lt;/span&gt; shares of common stock during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the outstanding principal for the convertible note was $&lt;span id="xdx_902_eus-gaap--ConvertibleDebt_iI_c20231231_zSRsEaMmQVQd"&gt;2,254,856&lt;/span&gt; and the debt discount remaining was $&lt;span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20230101__20231231_zLkKrYZw6Y46"&gt;1,523,768&lt;/span&gt;,
with a net convertible note carrying value of $&lt;span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20231231_z90vWvRx7oy1" title="Convertible note payable"&gt;731,088&lt;/span&gt;, which represents the current and non-current portions of the convertible note
as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">4300000</us-gaap:ConvertibleDebt>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Shares">1018079</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000868"
      unitRef="USDPShares">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-092023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">3935000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000872"
      unitRef="Pure">3.46</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="From2023-01-092023-01-11_custom_SecuritiesPurchaseAgreementMember"
      id="Fact000874">the Alto Convertible Note is convertible into shares of common stock at a price per share equal to the lower of (i) $2.35, (ii) 90% of
the three lowest daily VWAPs of the 15 trading days prior to the payment date, or (iii) 90% of the VWAP of the trading day prior to payment
date. The noteholder may convert at any time at a fixed price of $2.35 per share.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">1442000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-01-11_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-12-31"
      decimals="-6"
      id="Fact000880"
      unitRef="USD">10000000</us-gaap:ConvertibleNotesPayable>
    <SHPH:PaymentForPlacementAgent
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000882"
      unitRef="USD">345000</SHPH:PaymentForPlacementAgent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">71266</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="INF"
      id="Fact000886"
      unitRef="USDPShares">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact000888">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Pure">110</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact000891"
      unitRef="Pure">3.53</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000893"
      unitRef="USD">99543</us-gaap:FairValueAdjustmentOfWarrants>
    <SHPH:PaymentForPlacementAgent
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000895"
      unitRef="USD">345000</SHPH:PaymentForPlacementAgent>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000897"
      unitRef="USD">232027</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000899"
      unitRef="USD">104245</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000901"
      unitRef="USD">8727</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact000903"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LegalFees
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">65000</us-gaap:LegalFees>
    <SHPH:InterestFeeAmount
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">215000</SHPH:InterestFeeAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact000909"
      unitRef="USD">1442000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact000911"
      unitRef="USD">1288543</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember_custom_ConvertibleNoteMember"
      decimals="0"
      id="Fact000913"
      unitRef="USD">3310543</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000914"
      unitRef="USD">2484193</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000915"
      unitRef="USD">2123049</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000917"
      unitRef="USD">1925700</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2023-01-012023-12-31_custom_BousteadSecuritiesLLCMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">294927</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000920"
      unitRef="Shares">2380996</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000921"
      unitRef="USD">2254856</us-gaap:ConvertibleDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000922"
      unitRef="USD">1523768</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000924"
      unitRef="USD">731088</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000926">&lt;p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRCb1RVFvgkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
6 &#x2013; &lt;span id="xdx_825_zr458jZvyJC5"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2023, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231_zZds9nkiSPPl" title="Common stock issued for conversion of convertible debt, shares"&gt;2,380,996&lt;/span&gt;
    shares of common stock to settle $&lt;span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRAn1fkxWHy9" title="Debt, principal"&gt;1,925,700&lt;/span&gt; of principal and $&lt;span id="xdx_90B_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8jBXJnIxDLa" title="Accrued interest settled with common stock"&gt;294,927&lt;/span&gt; of interest on a Convertible Note and incurred $&lt;span id="xdx_908_ecustom--LossOnSettlementOfConvertibleDebt_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBMO1eJwiZXi" title="Loss on settlement of convertible debt"&gt;477,221&lt;/span&gt; of
    loss on settlement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z96iryR5Kbn2" title="Common stock issued for conversion of convertible debt, shares"&gt;85,195&lt;/span&gt;
    shares of common stock issued for vesting of restricted stock units.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20220101__20221231_zEEdlwiuK3mi" title="Common stock issued for conversion of convertible debt, shares"&gt;839&lt;/span&gt;
    shares of common stock for conversion of $&lt;span id="xdx_90F_ecustom--AccruedInterestValueToIssueShares_pp0p0_c20220101__20221231_zCR0LvynQrpk" title="Accrued interest settled with common stock"&gt;16,340&lt;/span&gt;
    of accrued interest and &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesSettlementOfNotesPayable_c20220101__20221231_zi3imVIifs4j"&gt;147,500&lt;/span&gt; shares of common stock upon settlement of notes payable for $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20220101__20221231_z32bqH7a2h3f" title="Number of shares of common stock upon settlement of notes payable"&gt;588,524&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_ecustom--CommonStockVestingOfRestrictedStockUnit_c20220101__20221231_zTGhXRDb9rbf" title="Common stock vesting of restricted stock unit"&gt;27,989&lt;/span&gt;
    shares of common stock upon vesting of restricted stock units.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjeceiAKMQN6" title="Common stock issued for cash, shares"&gt;1,409,771&lt;/span&gt;
    shares of common stock upon completion of the Company&#x2019;s initial public offering for $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231_zReQhA0jXBO1" title="Common stock issued for cash"&gt;10,008,095&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_znddZycuNdzi" title="Number of shares of common stock issued for exercise of warrants"&gt;1,409,771&lt;/span&gt; shares of common stock upon completion of the Company&#x2019;s initial public offering for exercise of warrants
$&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20220101__20221231_zxa59QQ9BSid" title="Exercise of warrants, value"&gt;14,098&lt;/span&gt;.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesExerciseOfWarrants_c20220101__20221231_zaISTewlGzo4" title="Common stock issued for exercise of warrants, shares"&gt;857,780&lt;/span&gt;
    shares of common stock upon exercise of warrants to settle notes payable for $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueWarrantsNotesPayable_c20220101__20221231_zPRvRgJIApw3" title="Common stock issued for exercise of warrants notes payable, value"&gt;576,476&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesConversionOfPreferredShares_pp0p0_c20220101__20221231_zMXs1V3yATd" title="Number shares issued for conversion of note, shares"&gt;336,810&lt;/span&gt;
    shares of common stock upon conversion of preferred shares and &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesConversionOfDividends_pp0p0_c20220101__20221231_zeGN8oiBf77k" title="Number shares issued for conversion dividends payable, shares"&gt;100,517&lt;/span&gt; to settle dividends payable for $&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueDividendsPayable_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxo9SNpEoe9d" title="Common stock issued for dividends payable"&gt;402,068&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the January 2023 Alto Convertible Note, Boustead was granted warrants to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_zam6FgbDoIvd" title="Number of warrants to purchase"&gt;71,266&lt;/span&gt; shares of common stock, at an
exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131__us-gaap--DebtInstrumentAxis__custom--AltoConvertibleNoteMember_ziFSekf5Pqm7" title="Exercisable price per share"&gt;2.35&lt;/span&gt; per share (Note 5). In addition, Alto was granted warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230131_zxfR1IUHlnT6" title="Number of warrants to purchase"&gt;1,018,079&lt;/span&gt; shares of common stock, at an
exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zCr58QMvgMwh" title="Exercise price per share"&gt;2.35&lt;/span&gt; per share (Note 5, 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zQPSvyFjdRPc" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="width: 16%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;2,641,354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;0.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted Average Life (Years), Granted"&gt;4.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_z96MJfoqmzQl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;(2,284,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_zAb8nlxLZFrd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;0.26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;356,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;3.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted Average Life (Years), Outstanding Beginning"&gt;2.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Granted - Boustead&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;71,266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;2.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted Average Life (Years), Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Granted - Ayrton&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;1,018,079&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;2.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted Average Life (Years), Granted"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;1,446,155&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;2.74&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted Average Life (Years), Outstanding Ending"&gt;2.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted
    warrants include those granted on conversion of Notes Payable - &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe" title="Number of shares warrant to purchase"&gt;677,500&lt;/span&gt;, Notes Payable &#x2013; Related Parties &#x2013; &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk" title="Number of shares warrant to purchase"&gt;20,000&lt;/span&gt;, Series
    A Preferred Shares - &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g" title="Converted shares issued"&gt;336,810&lt;/span&gt; and issued during the IPO - &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k" title="Number of shares issued"&gt;1,607,044&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zV5jmENmows3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
    &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6" title="Warrants exercised"&gt;197,273&lt;/span&gt; warrants exercised on a cashless basis for &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj" title="Number of shares issued"&gt;180,280&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_z33AkX1pnRpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
intrinsic value of the warrants as of December 31, 2023 is $&lt;span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue_iI_c20231231_zC4txtN2nCP9" title="Aggregate intrinsic value of warrants"&gt;0&lt;/span&gt;. All of the outstanding warrants are exercisable as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Equity
Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) provides for equity incentives to be granted to our employees, executive officers,
directors and key advisers and consultants. Equity incentive grants may be made in the form of stock options with an exercise price of
not less than the fair market value of the underlying shares as determined pursuant to the 2018 Equity Incentive Plan, restricted stock
awards, other stock-based awards, or any combination of the foregoing. The 2018 Equity Incentive Plan is administered by the Company&#x2019;s
compensation committee. We have reserved &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20181231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zVWYrlzZ5Oq9" title="Common stock reserved for future issuance"&gt;3,000,000&lt;/span&gt; shares of our common stock for issuance under the 2018 Equity Incentive Plan. As of
December 31, 2023, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandEighteenEquityIncentivePlanMember_zZqAzrExO8Pf" title="Share granted under equity incentive plan"&gt;678,180&lt;/span&gt; shares have been granted under the 2018 Equity Incentive Plan, of which &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231_zdTmHNQqbfgf" title="Number of shares vested under plan"&gt;480,325&lt;/span&gt; shares have vested.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
may grant restricted stock units (&#x201c;RSU&#x201d;) under our 2018 Plan. RSUs are bookkeeping entries representing an amount equal to
the fair market value of one share of our common stock. Subject to the provisions of our 2018 Plan, the administrator determines the
terms and conditions of RSUs, including the vesting criteria and the form and timing of payment. Notwithstanding the foregoing, the administrator,
in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. RSUs granted typically vest annually
in one third increments from the date of appointment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2023 and 2022, pursuant to agreements with directors, officers and consultants, &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zFnLLrAAZDzd" title="Restricted stock award granted shares"&gt;259,326&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zYkx69bvfJxg" title="Restricted stock award granted shares"&gt;35,587&lt;/span&gt; RSUs
with a value of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zce9Kpju1tFj" title="Restricted stock award granted value"&gt;352,400&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--DirectorsAndOfficersMember_zxRxNN5a4Rs8" title="Restricted stock award granted value"&gt;100,000&lt;/span&gt; were granted, respectively. Compensation expense for the vesting RSUs were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Recognized in general and administrative expense&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;115,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;170,663&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recognized in research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;233,293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;181,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;403,956&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023 and 2022, there was $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zEzBhMNnlrN8" title="Unrecognized compensation cost"&gt;231,550&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5mtOdUbbZX" title="Unrecognized compensation cost"&gt;61,111&lt;/span&gt;, respectively, of unrecognized stock-based compensation expense
related to unvested RSUs, which is expected to be recognized over a weighted-average period of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXuwnfeYO91d" title="Weighted Average Life (Years), Outstanding Ending"&gt;1.06&lt;/span&gt; years
and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSrNXYP6sZG7" title="Weighted Average Life (Years), Outstanding Ending"&gt;1.83&lt;/span&gt; years, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding the Restricted Stock Units issued follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zXV9pKVawChd" style="display: none"&gt;Schedule of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;63,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;23.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;35,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.81&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;99,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;15.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;259,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Vested"&gt;(160,744&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;1.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Outstanding, Ending Balance"&gt;197,855&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance"&gt;1.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_zV6HtUCMIcil" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000928"
      unitRef="Shares">2380996</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">1925700</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">294927</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:LossOnSettlementOfConvertibleDebt
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">477221</SHPH:LossOnSettlementOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Shares">85195</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000938"
      unitRef="Shares">839</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <SHPH:AccruedInterestValueToIssueShares
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000940"
      unitRef="USD">16340</SHPH:AccruedInterestValueToIssueShares>
    <SHPH:StockIssuedDuringPeriodSharesSettlementOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000941"
      unitRef="Shares">147500</SHPH:StockIssuedDuringPeriodSharesSettlementOfNotesPayable>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000943"
      unitRef="USD">588524</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <SHPH:CommonStockVestingOfRestrictedStockUnit
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000945"
      unitRef="Shares">27989</SHPH:CommonStockVestingOfRestrictedStockUnit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000947"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000949"
      unitRef="USD">10008095</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">1409771</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000953"
      unitRef="USD">14098</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <SHPH:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000955"
      unitRef="Shares">857780</SHPH:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <SHPH:StockIssuedDuringPeriodValueWarrantsNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000957"
      unitRef="USD">576476</SHPH:StockIssuedDuringPeriodValueWarrantsNotesPayable>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfPreferredShares
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000959"
      unitRef="Shares">336810</SHPH:StockIssuedDuringPeriodSharesConversionOfPreferredShares>
    <SHPH:StockIssuedDuringPeriodSharesConversionOfDividends
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000961"
      unitRef="Shares">100517</SHPH:StockIssuedDuringPeriodSharesConversionOfDividends>
    <SHPH:StockIssuedDuringPeriodValueDividendsPayable
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">402068</SHPH:StockIssuedDuringPeriodValueDividendsPayable>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact000965"
      unitRef="Shares">71266</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31_custom_AltoConvertibleNoteMember"
      decimals="INF"
      id="Fact000967"
      unitRef="USDPShares">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">1018079</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact000971"
      unitRef="USDPShares">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000973">&lt;p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zYUyrflizBO8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding all warrants issued for the year ended December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BF_zQPSvyFjdRPc" style="display: none"&gt;Schedule of Warrants Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjuYcgvRHal" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0975"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4xGXCAwN6Tj" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; width: 40%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zPxXrFtitK4i" style="width: 16%; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;2,641,354&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_zlyZQ5q1wWaf" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;0.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_fKDEp_z9kvRoBzdLNh" title="Weighted Average Life (Years), Granted"&gt;4.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercised&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_z96MJfoqmzQl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;(2,284,544&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_fKDIp_zAb8nlxLZFrd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;0.26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9UI044YgV5" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;356,810&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbRi84hzFj9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;3.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVK2h47ttkBl" title="Weighted Average Life (Years), Outstanding Beginning"&gt;2.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Granted - Boustead&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zRVWl16AVagj" style="text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;71,266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zP4pVamBEbW6" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;2.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--BousteadMember_zbAwWgoJ4z0d" title="Weighted Average Life (Years), Granted"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Granted - Ayrton&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zKe68UzemyL1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;1,018,079&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_zISN0tLiSKz7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;2.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--AyrtonMember_z6X298lHDXuk" title="Weighted Average Life (Years), Granted"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3ZA5GLGhimk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Beginning Balance"&gt;1,446,155&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziOT5Z7k8vIk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;2.74&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhtZKqpxzGS6" title="Weighted Average Life (Years), Outstanding Ending"&gt;2.77&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0D_zaWFFkv4rp8l" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zMCl4UNl52H5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Granted
    warrants include those granted on conversion of Notes Payable - &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe" title="Number of shares warrant to purchase"&gt;677,500&lt;/span&gt;, Notes Payable &#x2013; Related Parties &#x2013; &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk" title="Number of shares warrant to purchase"&gt;20,000&lt;/span&gt;, Series
    A Preferred Shares - &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g" title="Converted shares issued"&gt;336,810&lt;/span&gt; and issued during the IPO - &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k" title="Number of shares issued"&gt;1,607,044&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F05_zGy4OpA2kYd4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zV5jmENmows3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Includes
    &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6" title="Warrants exercised"&gt;197,273&lt;/span&gt; warrants exercised on a cashless basis for &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj" title="Number of shares issued"&gt;180,280&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Shares">2641354</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact000981"
      unitRef="USDPShares">0.75</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      id="Fact000983">P4Y9M</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      decimals="INF"
      id="Fact000985"
      unitRef="Shares">-2284544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      decimals="INF"
      id="Fact000987"
      unitRef="USDPShares">0.26</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000989"
      unitRef="Shares">356810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">3.92</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember14624828"
      id="Fact000993">P2Y9M14D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact000995"
      unitRef="Shares">71266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      decimals="INF"
      id="Fact000997"
      unitRef="USDPShares">2.35</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_BousteadMember"
      id="Fact000999">P5Y</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      decimals="INF"
      id="Fact001001"
      unitRef="Shares">1018079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      decimals="INF"
      id="Fact001003"
      unitRef="USDPShares">2.35</SHPH:ShareBasedCompensationArrangementByShareBasedPaymetAwardNonOptionGrandInPeriodWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember_custom_AyrtonMember"
      id="Fact001005">P4Y</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember14624859"
      decimals="INF"
      id="Fact001007"
      unitRef="Shares">1446155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_WarrantMember14624859"
      decimals="INF"
      id="Fact001009"
      unitRef="USDPShares">2.74</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember14624875"
      id="Fact001011">P2Y9M7D</SHPH:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_NotesPayableMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">677500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_NotesPayableRelatedPartiesMember"
      decimals="INF"
      id="Fact001016"
      unitRef="Shares">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001018"
      unitRef="Shares">336810</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001020"
      unitRef="Shares">1607044</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001023"
      unitRef="Shares">197273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001025"
      unitRef="Shares">180280</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001027"
      unitRef="USD">0</SHPH:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001029"
      unitRef="Shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2023-12-31_custom_TwoThousandEighteenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact001031"
      unitRef="Shares">678180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001033"
      unitRef="Shares">480325</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Shares">259326</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Shares">35587</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="0"
      id="Fact001039"
      unitRef="USD">352400</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_DirectorsAndOfficersMember"
      decimals="0"
      id="Fact001041"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001043"
      unitRef="USD">231550</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001045"
      unitRef="USD">61111</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453"
      id="Fact001047">P1Y21D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468"
      id="Fact001049">P1Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001051">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zQ3F4taCBjJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of activity regarding the Restricted Stock Units issued follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B2_zXV9pKVawChd" style="display: none"&gt;Schedule of Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQp0K0rXX4Gc" style="width: 16%; text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;63,686&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqe67dBYRjOe" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;23.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxFG8KzbDVpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;35,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zq4SzMGLzOvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;2.81&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJJLlR2oM68k" style="text-align: right" title="Number of RSUs, Outstanding, Beginning Balance"&gt;99,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zbGSPCWzvNQ3" style="text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Beginning Balance"&gt;15.06&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb8H48qjFDX2" style="text-align: right" title="Number of Stock Option Outstanding, Granted"&gt;259,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zm2rFXcHGT6f" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDOZ0v9rffxd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs, Vested"&gt;(160,744&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqiZ4bcJQMo6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Vested"&gt;1.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding, December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zB3h4SMKiWMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs, Outstanding, Ending Balance"&gt;197,855&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zeElVTFzf1u8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Grant Date Fair Value Per RSU, Ending Balance"&gt;1.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">63686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001055"
      unitRef="USDPShares">23.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468"
      decimals="INF"
      id="Fact001057"
      unitRef="Shares">35587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockUnitsRSUMember14624468"
      decimals="INF"
      id="Fact001059"
      unitRef="USDPShares">2.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Shares">99273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001063"
      unitRef="USDPShares">15.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453"
      decimals="INF"
      id="Fact001065"
      unitRef="Shares">259326</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453"
      decimals="INF"
      id="Fact001067"
      unitRef="USDPShares">1.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453"
      decimals="INF"
      id="Fact001069"
      unitRef="Shares">160744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember14624453"
      decimals="INF"
      id="Fact001071"
      unitRef="USDPShares">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001073"
      unitRef="Shares">197855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001075"
      unitRef="USDPShares">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001077">&lt;p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zM0LnaDFnXNf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
7 &#x2013; &lt;span id="xdx_82A_z4aTbusRJlK5"&gt;Derivative Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Assumptions Used in Accounting for Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
815 requires us to assess the fair market value of derivative liabilities at the end of each reporting period and recognize any change
in the fair market value as other income or expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
January 2023, in connection with the Alto Convertible Note, the Company issued warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230131_z11cwYracUa3" title="Number of shares warrant to purchase"&gt;1,018,079&lt;/span&gt;
shares of common stock, with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230131_zIh20NrCUX41" title="Exercise price per share"&gt;2.35&lt;/span&gt;
per share, valued at inception at $&lt;span id="xdx_90C_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20230131_zRPJuOGDR5kl" title="Warrants price"&gt;1,189,000&lt;/span&gt;
and as of December 31, 2023, at $&lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue_iI_pid_c20231231_zGXfDYMNMqJ7" title="Warrants price"&gt;410,660&lt;/span&gt;. The Company determined our derivative liabilities from the warrants issued in relation to the Alto Convertible Note do not satisfy
the classification as equity instruments due to the existence of a certain net cash settlement provision that is not within the sole
control of the Company. In addition, there are certain down round provisions that could reduce the exercise price if the Company
issues securities at lower prices in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company determined our derivative liability from the noteholder&#x2019;s Acceleration Option for the Alto Convertible Note is not clearly
and closely related to the host and should be thus accounted for as a bifurcated derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
classified these derivative liabilities as a Level 3 fair value measurement and used the Monte Carlo pricing model to calculate the fair
value as of January 11, 2023, and for each reporting period. Key inputs for the simulation are summarized below. The Monte Carlo simulation
uses an implied VWAP for each valuation date. The implied VWAP was backsolved by setting the summation of the parts (e.g., derivatives
and debt without derivatives) equal to the cash proceeds. The simulation was then iterated and manipulated to solve for the implied share
price, which was approximately $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1TLyu8dorpa" title="Share price"&gt;1.58
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (or an approximate &lt;span id="xdx_902_ecustom--DerivativeDiscountPercentage_iI_pid_dp_uPure_c20230111__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjE6Jw38fbK2" title="Derivative discount percentage"&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%
discount to the quoted market VWAP on January 11, 2023). Additionally, the Company estimates probability for various specific scenarios
impacting the warrant valuation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_znb7Uj9EztTl" style="display: none"&gt;Schedule of Monte Carlo Simulation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Net cash settlement and down round key valuation inputs &#x2013; warrants*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 80%"&gt;Annualized volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 16%"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zozFDVZAFK4e"&gt;77.51&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0Ggii4jslye"&gt;92.33&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zoMIQofY4K5a"&gt;4.01&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zwCcxH7FeOC5"&gt;5.23&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_fKg_____zo7lD17gzxV2"&gt;0.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z4L0sAqFUTj8"&gt;2.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Probability assessment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zrouVaColRqk"&gt;5&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zfcKKc9EOvb2"&gt;25&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmkmMVae8hSk"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9SRrpNLzopk" title="Time period (years)"&gt;0.53&lt;/span&gt; - &lt;span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zhXNFkwkLBCb" title="Time period (years)"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F0F_z2LWif3ShStb"&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F14_zMHZ22vWVnw6"&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Acceleration option key valuation inputs*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____ze5I3bDWN1aj"&gt;34.23&lt;/span&gt;% - &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLIohlVjEEf3"&gt;59.15&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zCGZKKlOO9g1"&gt;4.68&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsa6ppLFMsB4"&gt;5.60&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;$&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zYkXA6Tza4Ek"&gt;0.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zQDqXgqjbjIj"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zSr9igPhn80d" title="Time period (years)"&gt;0&lt;/span&gt; - &lt;span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLp7YOcr570g" title="Time period (years)"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F09_zHTgwsedsgfj"&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F18_zw6xhmmh8TEf"&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A5_z9FqO83Hz1gf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes in the derivative liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zHuN5mIWCcld" style="display: none"&gt;Schedule of Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Accelerated Feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance - December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdBqZ4p6AuHc" style="width: 14%; text-align: right" title="Beginning balance"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zyX1n8IWdRLe" style="width: 14%; text-align: right" title="Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvHA7ssNPFdl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(94,025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zJnad48mTEA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance - December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zipNXTFL6L3k" style="text-align: right" title="Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfiv9Plk69a" style="text-align: right" title="Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Addition of new derivatives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoUz8eWIMtrb" style="text-align: right" title="Addition of new derivatives recognized as debt discounts"&gt;1,189,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_za5rszMeX5Sj" style="text-align: right" title="Addition of new derivatives recognized as debt discounts"&gt;1,442,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjV2cxH2Bmf9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(778,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zD45NbyyDdH3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(1,438,148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3L6mkfzMUpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;410,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_znqHQDi2fG6g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AA_zjykzB9b6bda" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001079"
      unitRef="Shares">1018079</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001081"
      unitRef="USDPShares">2.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue
      contextRef="AsOf2023-01-31"
      decimals="INF"
      id="Fact001083"
      unitRef="USD">1189000</SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue>
    <SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001085"
      unitRef="USD">410660</SHPH:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsValue>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001087"
      unitRef="USDPShares">1.58</us-gaap:DebtInstrumentMeasurementInput>
    <SHPH:DerivativeDiscountPercentage
      contextRef="AsOf2023-01-11_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001089"
      unitRef="Pure">0.14</SHPH:DerivativeDiscountPercentage>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001091">&lt;p id="xdx_896_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zK9vn2FRSjzh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
range of key inputs for the Monte Carlo simulation for the year ended December 31, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_znb7Uj9EztTl" style="display: none"&gt;Schedule of Monte Carlo Simulation Assumption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Net cash settlement and down round key valuation inputs &#x2013; warrants*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 80%"&gt;Annualized volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 16%"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zozFDVZAFK4e"&gt;77.51&lt;/span&gt;% - &lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z0Ggii4jslye"&gt;92.33&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zoMIQofY4K5a"&gt;4.01&lt;/span&gt;% - &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zwCcxH7FeOC5"&gt;5.23&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_fKg_____zo7lD17gzxV2"&gt;0.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z4L0sAqFUTj8"&gt;2.35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Probability assessment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zrouVaColRqk"&gt;5&lt;/span&gt;% - &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDefaultRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zfcKKc9EOvb2"&gt;25&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zmkmMVae8hSk"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____z9SRrpNLzopk" title="Time period (years)"&gt;0.53&lt;/span&gt; - &lt;span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_fKg_____zhXNFkwkLBCb" title="Time period (years)"&gt;3.03&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F0F_z2LWif3ShStb"&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F14_zMHZ22vWVnw6"&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Acceleration option key valuation inputs*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____ze5I3bDWN1aj"&gt;34.23&lt;/span&gt;% - &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLIohlVjEEf3"&gt;59.15&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--DebtInstrumentMeasurementInput_iI_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zCGZKKlOO9g1"&gt;4.68&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zsa6ppLFMsB4"&gt;5.60&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Quoted VWAP*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;$&lt;span id="xdx_903_eus-gaap--DebtInstrumentMeasurementInput_iI_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputVolumeWeightedAveragePriceMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zYkXA6Tza4Ek"&gt;0.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Illiquidity discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;span id="xdx_900_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIlliquidityDiscountMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zQDqXgqjbjIj"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Time period (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zSr9igPhn80d" title="Time period (years)"&gt;0&lt;/span&gt; - &lt;span id="xdx_90F_eus-gaap--DebtInstrumentTerm_dtY_c20230101__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_fKg_____zLp7YOcr570g" title="Time period (years)"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td style="text-align: justify; width: 0.15in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F09_zHTgwsedsgfj"&gt;*&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i id="xdx_F18_zw6xhmmh8TEf"&gt;Based on a Monte Carlo simulation analysis of 50,000 iterations&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001092"
      unitRef="Pure">77.51</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001093"
      unitRef="Pure">92.33</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001094"
      unitRef="Pure">4.01</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001095"
      unitRef="Pure">5.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001096"
      unitRef="USDPShares">0.59</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001097"
      unitRef="USDPShares">2.35</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MinimumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001098"
      unitRef="Pure">5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputDefaultRateMember_srt_MaximumMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001099"
      unitRef="Pure">25</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Pure">17</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_WarrantMember"
      id="Fact001102">P0Y6M10D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_WarrantMember"
      id="Fact001104">P3Y10D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Pure">34.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001107"
      unitRef="Pure">59.15</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001108"
      unitRef="Pure">4.68</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001109"
      unitRef="Pure">5.60</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputVolumeWeightedAveragePriceMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001110"
      unitRef="USDPShares">0.59</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2023-12-31_custom_MeasurementInputIlliquidityDiscountMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001111"
      unitRef="Pure">17</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember_us-gaap_StockOptionMember"
      id="Fact001113">P0Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2023-01-012023-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember_us-gaap_StockOptionMember"
      id="Fact001115">P1Y2M12D</us-gaap:DebtInstrumentTerm>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001118">&lt;p id="xdx_89C_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zp40o5VqGrmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the changes in the derivative liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B4_zHuN5mIWCcld" style="display: none"&gt;Schedule of Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements Using Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Accelerated Feature&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Balance - December 31, 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdBqZ4p6AuHc" style="width: 14%; text-align: right" title="Beginning balance"&gt;94,025&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zyX1n8IWdRLe" style="width: 14%; text-align: right" title="Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvHA7ssNPFdl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(94,025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20220101__20221231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zJnad48mTEA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance - December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zipNXTFL6L3k" style="text-align: right" title="Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAfiv9Plk69a" style="text-align: right" title="Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1130"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Addition of new derivatives&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoUz8eWIMtrb" style="text-align: right" title="Addition of new derivatives recognized as debt discounts"&gt;1,189,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionOfNewDerivativesRecognizedAsDebtDiscounts_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_za5rszMeX5Sj" style="text-align: right" title="Addition of new derivatives recognized as debt discounts"&gt;1,442,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Gain on change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zjV2cxH2Bmf9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(778,340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DerivativeGainLossOnDerivativeWarrants_iN_di_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_zD45NbyyDdH3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gain on change in fair value of the derivative"&gt;(1,438,148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance - December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3L6mkfzMUpd" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;410,660&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20230101__20231231__srt--StatementScenarioAxis__custom--AcceleratedFeatureMember_znqHQDi2fG6g" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;3,852&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001120"
      unitRef="USD">94025</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001124"
      unitRef="USD">94025</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001132"
      unitRef="USD">1189000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts
      contextRef="From2023-01-012023-12-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact001134"
      unitRef="USD">1442000</SHPH:AdditionOfNewDerivativesRecognizedAsDebtDiscounts>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001136"
      unitRef="USD">778340</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <SHPH:DerivativeGainLossOnDerivativeWarrants
      contextRef="From2023-01-012023-12-31_custom_AcceleratedFeatureMember"
      decimals="0"
      id="Fact001138"
      unitRef="USD">1438148</SHPH:DerivativeGainLossOnDerivativeWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001140"
      unitRef="USD">410660</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_AcceleratedFeatureMember14626328"
      decimals="0"
      id="Fact001142"
      unitRef="USD">3852</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001144">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zysAiD3uWv96" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
8 &#x2013; &lt;span id="xdx_821_zqKZNps5qm1a"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 14, 2022, we entered into a manufacturing agreement with TCG GreenChem, Inc. (&#x201c;TCG GreenChem&#x201d;), the U.S. subsidiary
of TCG Lifesciences Pvt Ltd., a global contract research and manufacturing services company located in India. Dr. Chis Senanayake, one
of our independent directors, is CEO and CSO of TCG GreenChem and CSO of TCG Lifesciences Pvt Ltd. TCG GreenChem was contracted for process
research, development and cGMP compliant manufacture of IPdR. The Company paid TCG GreenChem $&lt;span id="xdx_909_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20220101__20221231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zs0HwiZEVXj3" title="Payments to invoices in research and development"&gt;450,000&lt;/span&gt; during the year ended December
31, 2022 and a total of $&lt;span id="xdx_90A_ecustom--PaymentsToInvoicesInResearchAndDevelopment_c20230101__20231231__dei--LegalEntityAxis__custom--TCGGreenChemIncMember_zEZHhc9Bky7j" title="Payments to invoices in research and development"&gt;1,096,370&lt;/span&gt; during the year ended December 31, 2023, completing the contract.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2022-01-012022-12-31_custom_TCGGreenChemIncMember"
      decimals="0"
      id="Fact001146"
      unitRef="USD">450000</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <SHPH:PaymentsToInvoicesInResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_custom_TCGGreenChemIncMember"
      decimals="0"
      id="Fact001148"
      unitRef="USD">1096370</SHPH:PaymentsToInvoicesInResearchAndDevelopment>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001150">&lt;p id="xdx_809_eus-gaap--IncomeTaxDisclosureTextBlock_zIzNnGyFJnD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
9 &#x2013; &lt;span id="xdx_82A_zYL3mUjUjp33"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has no income tax expense or benefit for the years ended December 31, 2023 and 2022, since the Company has a full valuation allowance
for the net operating loss carryforwards in these periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
recognize tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained upon examination
by the taxing authorities based on the technical merits of the position. The tax benefits recognized from such positions are estimated
based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. There are no uncertain
tax positions to be reported for the tax years 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;) amended IRC Section 174 to require capitalization of all research and development
(&#x201c;R&amp;amp;D&#x201d;) costs incurred in tax years beginning after December 31, 2021. These costs are required to be amortized over
five years if the R&amp;amp;D activities are performed in the U.S., or over 15 years if the activities were performed outside the U.S. For
tax reporting purposes, the Company capitalized $&lt;span id="xdx_90F_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20231231_zXvHn7wdQpqg" title="Research and development expenses"&gt;3,517,485&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_iI_c20221231_zCI5g925C8v7" title="Research and development expenses"&gt;1,488,530&lt;/span&gt; of R&amp;amp;D expenses incurred as of December 31, 2023 and
2022, respectively.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income tax benefit at the U.S. statutory rate of &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate"&gt;21&lt;/span&gt;% to the Company&#x2019;s tax expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z2tRzaeOyVg3" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zjwy0KWXJK1e" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zSaqbByehmf1" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(1,384,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(635,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(452,682&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(249,847&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rate change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,710&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msITEBzspy_zIbOgxRjiMF1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;R &amp;amp; D tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(240,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(83,975&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_maITEBzspy_zKjunr4YTXDa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,355&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,535,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;924,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zdVsqCFpXlch" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of deferred tax assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zPU61r3hFOe7" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,727,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,173,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1195"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;7,801&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Intangibles (includes Section 174 capitalization)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,197,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;399,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,915&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;215,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Equity based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest &amp;amp; other accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease asset/(liability)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,326&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,429,136&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,841,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Deferred tax Liabilities:&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Change in fair market value of securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(19,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1223"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,375,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,841,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,375,903&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,841,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zrwMVAPp8x91" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zI3yIfzm5n7c" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zfaXBlkgHcyk" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_z5Nl7grKpMZf" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maDEF_zt6yAr9oJKm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_ziTYp8KTsYlh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the Company had approximately $&lt;span id="xdx_905_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--FederalTaxableIncomeMember_zrG81Ug3Peyl" title="Net operatiing loss"&gt;6.4&lt;/span&gt;
million and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--StateTaxableIncomeMember_zXVNaHVK7E06" title="Net operatiing loss"&gt;5.9&lt;/span&gt; million of net operating losses (&#x201c;NOL&#x201d;) carried forward to offset federal and state taxable income, if
any, in the future. In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management
considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making
this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax
asset relating to NOLs for every period because it is more likely than not that all of the deferred tax asset will not be
realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;NOLs created prior to 2018 could
be carried back two years and carried forward &lt;span id="xdx_90E_ecustom--DeferredTaxAssetsOperatingLossCarriedForward_dtY_c20230101__20231231_ztKkx6mJrK2h" title="Carried forward"&gt;20&lt;/span&gt; years. As amended by the Tax Cuts and Jobs Act of 2017 (TCJA), NOLs created after 2017
can no longer be carried back and are instead carried forward indefinitely. The Company has $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2016Member_zzagpmkbLOni" title="Operating loss carryforwards"&gt;139,813&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_c20231231__us-gaap--TaxPeriodAxis__us-gaap--TaxYear2017Member_zflhOv8qsPn8" title="Operating loss carryforwards"&gt;238,380&lt;/span&gt; of federal NOL carryforwards
from 2016 and 2017, respectively, which begin to expire in 2036. The Company has an additional $&lt;span id="xdx_90B_eus-gaap--CurrentFederalTaxExpenseBenefit_c20230101__20231231_zxleUUsZJnK3" title="Federal income tax"&gt;6,036,599&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20230101__20231231_z3VTmnAMCrMh" title="state income tax"&gt;5,933,889&lt;/span&gt; of federal and
state NOLs created after 2017, respectively, which can be carried forward indefinitely. The NOLs can be used to offset future income limited
to the lesser of the NOL or &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases_pid_dp_uPure_c20230101__20231231_zA745rNSZcVk" title="Future taxable income"&gt;80&lt;/span&gt;% of the year&#x2019;s taxable income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;As of December 31, 2023, the Company has $&lt;span id="xdx_904_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_c20230101__20231231_zyM9U2Dualt9" title="Federal Research and Development"&gt;360,715&lt;/span&gt;
of federal Research and Development (R&amp;amp;D) tax credits. These can be carried forward &lt;span id="xdx_900_ecustom--DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome_dtY_c20230101__20231231_zE0Rx6zu1dBh" title="Carried forward"&gt;20&lt;/span&gt; years to offset future federal income tax.
These begin to expire in 2037. Additionally, the Company has $&lt;span id="xdx_900_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zgHvq6C4B1f" title="R&amp;amp;D tax credits"&gt;80,000&lt;/span&gt; of state R&amp;amp;D tax credits which can be carried forward seven years.
These begin to expire in 2030.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001152"
      unitRef="USD">3517485</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001154"
      unitRef="USD">1488530</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001156">&lt;p id="xdx_894_ecustom--ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock_z1wDH33OnKVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reconciliation of income tax benefit at the U.S. statutory rate of &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_zYThPGwVZlU2" title="U.S. statutory rate"&gt;21&lt;/span&gt;% to the Company&#x2019;s tax expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_z2tRzaeOyVg3" style="display: none"&gt;Schedule
of Reconciliation of Income Tax Benefit&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20231231_zjwy0KWXJK1e" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_zSaqbByehmf1" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzspy_zAF6OgnC6TQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(1,384,472&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(635,974&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzspy_znBDCKmu4f26" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(452,682&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(249,847&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzspy_z4DUuMrOJo4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rate change&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,710&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1167"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_msITEBzspy_zIbOgxRjiMF1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;R &amp;amp; D tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(240,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(83,975&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--IncomeTaxReconciliationProvisionAdjustments_maITEBzspy_zWnl78dBtDW1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;286,015&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences_maITEBzspy_zKjunr4YTXDa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;203,909&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,355&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzspy_zWwiNAPMh4Qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,535,466&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;924,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ShortfallOfStockCompensationExpense_maITEBzspy_z59VNiUxFTu1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1182"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzspy_zuhFzLWieGih" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1185"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzspy_zSU60B2SLD8h" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1188"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</SHPH:ScheduleOfPretaxIncomeFromContinuingOperationsTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001158"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001160"
      unitRef="USD">-1384472</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001161"
      unitRef="USD">-635974</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001163"
      unitRef="USD">-452682</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001164"
      unitRef="USD">-249847</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001166"
      unitRef="USD">-5710</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001169"
      unitRef="USD">-240000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001170"
      unitRef="USD">-83975</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <SHPH:IncomeTaxReconciliationProvisionAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001172"
      unitRef="USD">286015</SHPH:IncomeTaxReconciliationProvisionAdjustments>
    <SHPH:IncomeTaxReconciliationProvisionAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001173"
      unitRef="USD">66214</SHPH:IncomeTaxReconciliationProvisionAdjustments>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001175"
      unitRef="USD">203909</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences>
    <SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001176"
      unitRef="USD">-21355</SHPH:IncomeTaxReconciliationForeignIncomeTaxPermanentDifferences>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001178"
      unitRef="USD">1535466</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001179"
      unitRef="USD">924937</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <SHPH:ShortfallOfStockCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001181"
      unitRef="USD">40674</SHPH:ShortfallOfStockCompensationExpense>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001184"
      unitRef="USD">16800</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001190">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zXbvXpbotbjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal components of deferred tax assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B4_zPU61r3hFOe7" style="display: none"&gt;Schedule
of Components of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_ztZC3rNAtHqa" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_zVpK3NguAVYd" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax asset:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_zPVNDFdUH3B6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,727,566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,173,451&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_zqf9ceVKiF3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1195"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;7,801&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_zDgTVazHhjac" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Intangibles (includes Section 174 capitalization)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,197,938&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;399,644&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_zJV7cFNAYVGf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;423,915&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;215,229&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--DeferredTaxAssetsbasedCompensation_iI_zSxrvUxCF8Rf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Equity based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOther_iI_zXK4WJadIk76" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest &amp;amp; other accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,140&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,574&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiabilities_iI_zOos3L44Yiyk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Lease asset/(liability)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,326&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_zVmD9PoEGNch" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,429,136&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,841,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Deferred tax Liabilities:&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesFairMarketValue_iNI_di_z0DYuknlm5M5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Change in fair market value of securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;(19,943&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_di_zk0qPSjhpmM9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,544&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxLiabilitiesFiniteLivedAssets_iI_z2PZLT3kefA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Fixed assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,746&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1223"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_zzLtSZTBR107" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(53,233&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1226"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_iTI_zG01nMZn61Re" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total deferred tax asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3,375,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,841,698&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zW3iWbbiWkv" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,375,903&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,841,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_zSit31X5Puab" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1234"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1235"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001192"
      unitRef="USD">1727566</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001193"
      unitRef="USD">1173451</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001196"
      unitRef="USD">7801</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001198"
      unitRef="USD">1197938</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001199"
      unitRef="USD">399644</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001201"
      unitRef="USD">423915</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001202"
      unitRef="USD">215229</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <SHPH:DeferredTaxAssetsbasedCompensation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001204"
      unitRef="USD">1251</SHPH:DeferredTaxAssetsbasedCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001207"
      unitRef="USD">72140</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001208"
      unitRef="USD">45574</us-gaap:DeferredTaxAssetsOther>
    <SHPH:DeferredTaxAssetsLeaseLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001210"
      unitRef="USD">6326</SHPH:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001213"
      unitRef="USD">3429136</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001214"
      unitRef="USD">1841698</us-gaap:DeferredTaxAssetsGross>
    <SHPH:DeferredTaxLiabilitiesFairMarketValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001216"
      unitRef="USD">19943</SHPH:DeferredTaxLiabilitiesFairMarketValue>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001219"
      unitRef="USD">30544</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <SHPH:DeferredTaxLiabilitiesFiniteLivedAssets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001222"
      unitRef="USD">-2746</SHPH:DeferredTaxLiabilitiesFiniteLivedAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001225"
      unitRef="USD">53233</us-gaap:DeferredIncomeTaxLiabilities>
    <SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001228"
      unitRef="USD">3375903</SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001229"
      unitRef="USD">1841698</SHPH:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001231"
      unitRef="USD">3375903</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001232"
      unitRef="USD">1841698</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001237">&lt;p id="xdx_896_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zoujnhQ4M3Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BF_zI3yIfzm5n7c" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zfaXBlkgHcyk" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220101__20221231_z5Nl7grKpMZf" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zlkv9buQ0s1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal income tax benefit at statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zaK7R5h3gQU5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income tax benefit, net of federal tax effect&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.9&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EffectiveIncomeTaxRateReconciliationChangeInTaxRate_pid_dp_uPure_maDEF_z4l5hREBu8eg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_pid_dp_uPure_msDEF_zEVJqGFuwcu5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_pid_dp_uPure_maDEF_zLP42dwSJtgl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Return to provision adjustments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationPermanentDifferences_pid_dp_uPure_maDEF_zt6yAr9oJKm2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zPJ7iF7J45ab" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense_pid_dp_uPure_maDEF_zv4aGO4rL3Wa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shortfall of stock compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maDEF_z1QwuoMSzFr8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_zlcoUj2m0kXb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001239"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001240"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001242"
      unitRef="Pure">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001243"
      unitRef="Pure">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001245"
      unitRef="Pure">0.001</SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate>
    <SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001246"
      unitRef="Pure">0.000</SHPH:EffectiveIncomeTaxRateReconciliationChangeInTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001248"
      unitRef="Pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001249"
      unitRef="Pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001251"
      unitRef="Pure">-0.043</SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001252"
      unitRef="Pure">-0.022</SHPH:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001254"
      unitRef="Pure">-0.031</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001255"
      unitRef="Pure">0.007</SHPH:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001257"
      unitRef="Pure">-0.232</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001258"
      unitRef="Pure">-0.305</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001260"
      unitRef="Pure">-0.006</SHPH:EffectiveIncomeTaxRateReconciliationShortFallOfStockCompensationExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001263"
      unitRef="Pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001264"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001266"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001267"
      unitRef="Pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_FederalTaxableIncomeMember"
      decimals="-5"
      id="Fact001269"
      unitRef="USD">6400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_StateTaxableIncomeMember"
      decimals="-5"
      id="Fact001271"
      unitRef="USD">5900000</us-gaap:OperatingLossCarryforwards>
    <SHPH:DeferredTaxAssetsOperatingLossCarriedForward contextRef="From2023-01-01to2023-12-31" id="Fact001273">P20Y</SHPH:DeferredTaxAssetsOperatingLossCarriedForward>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_TaxYear2016Member"
      decimals="0"
      id="Fact001275"
      unitRef="USD">139813</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31_us-gaap_TaxYear2017Member"
      decimals="0"
      id="Fact001277"
      unitRef="USD">238380</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">6036599</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001281"
      unitRef="USD">5933889</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001283"
      unitRef="Pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLeases>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001285"
      unitRef="USD">360715</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <SHPH:DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome contextRef="From2023-01-01to2023-12-31" id="Fact001287">P20Y</SHPH:DeferredTaxAssetsOperatingLossCarriedForwardFutureFederalIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001289"
      unitRef="USD">80000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001291">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zvLsbfAmqZ93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
10 &#x2013; &lt;span id="xdx_824_zs2tFHK7qGtg"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued
and determined that the following items are required to be disclosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Nasdaq
Bid Price Requirement Extension Granted until August 26, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 7.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 31, 2023, after the Company&#x2019;s common stock had traded below $&lt;span id="xdx_906_eus-gaap--SharePrice_iI_c20230831_zMaOM7ZhXbF7" title="Common stock trading price per share"&gt;1.00&lt;/span&gt; per share for &lt;span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_uTradingDays_c20230831__20230831_zm1qjoOyB6m9"&gt;30&lt;/span&gt; consecutive trading
days, the Company received notice from the Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) that it was not in compliance with Nasdaq Listing
Rule 5550(a)(2) (the &#x201c;Bid Price Requirement&#x201d;). In
accordance with Nasdaq Rules, the Company was provided with an initial period of 180 calendar days, or until February 27, 2024, to regain
compliance with the Bid Price Requirement. On February 19, 2024, the Company submitted a plan of compliance to Nasdaq seeking an additional
180-day grace period to regain compliance with the Bid Price Requirement. On February 29, 2024, the Company received formal approval
from Nasdaq granting it an additional 180 days, or until August 26, 2024, to regain compliance &#x2013; whether organically through market forces or by effectuating a reverse stock split,
should such action be required.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;FDA
Approval to Proceed with Phase II study of Ropidoxuridine (IPdR)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 8, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), issued a press release announcing
that the Company had received the &#x201c;Safe to Proceed&#x201d; letter from the U.S. Food and Drug Administration for the Company&#x2019;s
investigational new drug (IND) application for its Phase II study of Ropidoxuridine (IPdR) as a radiation sensitizing agent during radiotherapy
in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. Receipt of the letter allows Shuttle to commence
the Phase II study and, as a result, the Company is currently finalizing site enrollment with &#x201c;first patient, first dose&#x201d;
expected in the coming months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Rights
Offering&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
February 7, 2024, the Company and its wholly-owned subsidiary, Shuttle Diagnostics, Inc., entered into a securities purchase
agreement (the &#x201c;Purchase Agreement&#x201d;) with SRO, LLC, a Nevada limited liability company, pursuant to which SRO LLC agreed
to commit to purchasing from the Company $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJDnbJVClHRk" title="Sale of stock consideration received per transaction"&gt;2,250,000&lt;/span&gt;
of units from the Company, with each Unit consisting of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zp4MPskJvYJi" title="Share based compensation arrangement by share based payment award description"&gt;(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $2.35
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.&lt;/span&gt; Pursuant to the terms of the Purchase Agreement, the Units will be sold at a per Unit price equal to 90% of the VWAP of SHPH common
stock for the five trading days immediately preceding closing. The parties entered into the Purchase Agreement in anticipation of
the Company commencing a rights offering (the &#x201c;Rights Offering&#x201d;) pursuant to which the Company intends to offer a total
of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHARLaNGNfl" title="Proceeds from issuance of common stock"&gt;4,500,000&lt;/span&gt;
Units to existing stockholders, which includes the $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEVUQW1Y2LFg" title="Sale of stock consideration received per transaction"&gt;2,250,000&lt;/span&gt;
Units being sold to SRO LLC, an entity which is owned by Keith Moore, CEO of Boustead Securities, LLC
(&#x201c;BSL&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Purchase Agreement allows SRO LLC up to 60 days to raise the initial $&lt;span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zeJXcEGJ6F95" title="Escrow deposit"&gt;2,250,000&lt;/span&gt;, which funds will be placed in escrow with Sutter Securities,
Inc. (&#x201c;SSI&#x201d;), an affiliate of BSL, pursuant to the terms of an escrow agreement entered into between the Company, Shuttle Diagnostics, Inc., BSL and SSI
on February 7, 2024 (the &#x201c;Escrow Agreement&#x201d;). The funds will remain in escrow up until closing on the Rights Offering. In
addition, in the event the Company fails to raise a full $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zAbw8U4vQqh" title="Right offering"&gt;4,500,000&lt;/span&gt; in the Rights Offering, SRO LLC agreed to a backstop commitment pursuant
to which it would have the right to purchase any remaining Units not purchased by existing SHPH stockholders in the Rights Offering,
up to an additional $&lt;span id="xdx_905_ecustom--AdditionalEscrowDeposit_iI_c20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zLidexbeXPOd" title="Escrow deposit"&gt;2,250,000&lt;/span&gt; (the &#x201c;Back-up Contingency&#x201d;). &lt;span id="xdx_902_ecustom--InitialPublicOfferingDescription_c20240207__20240207__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zKBB7lm2dIQ" title="Initial public offering description"&gt;Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#x2019;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Restricted Stock Awarded to Chief Financial Officer&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 8, 2024, the CFO was awarded &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zrFoglyhoPx1" title="Restricted stock units"&gt;100,000&lt;/span&gt;
restricted stock units (&#x201c;RSUs&#x201d;), with a value of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20240308__20240308__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zz0X64iPXAvj" title="Restricted stock value"&gt;41,840&lt;/span&gt;, with such RSUs vesting in full as of the date of issuance.
Each RSU represents the right to receive one share of SHPH common stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2023-08-31"
      decimals="INF"
      id="Fact001293"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="From2023-08-312023-08-31"
      decimals="INF"
      id="Fact001294"
      unitRef="TradingDays">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001296"
      unitRef="USD">2250000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      id="Fact001298">(i)
one share of SHPH common stock, (ii) a warrant to purchase one share of SHPH common stock exercisable at a purchase price of $2.35
per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC
will own a 22% interest in Diagnostics.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001300"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001302"
      unitRef="USD">2250000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001304"
      unitRef="USD">2250000</us-gaap:EscrowDeposit>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001306"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <SHPH:AdditionalEscrowDeposit
      contextRef="AsOf2024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      decimals="0"
      id="Fact001308"
      unitRef="USD">2250000</SHPH:AdditionalEscrowDeposit>
    <SHPH:InitialPublicOfferingDescription
      contextRef="From2024-02-072024-02-07_us-gaap_SubsequentEventMember_custom_PurchaseAgreementMember"
      id="Fact001310">Unless the parties waive the conditions to closing, in the event
the full $4,500,000 is not raised, whether through SRO LLC or through SHPH&#x2019;s existing stockholders, the Company will not close
on the offering and any funds raised and held in escrow will be returned to investors.</SHPH:InitialPublicOfferingDescription>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      id="Fact001312"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-03-082024-03-08_us-gaap_SubsequentEventMember_srt_ChiefFinancialOfficerMember"
      decimals="0"
      id="Fact001314"
      unitRef="USD">41840</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000979"
          xlink:label="Fact000979"
          xlink:type="locator"/>
        <link:footnote id="Footnote001012" xlink:label="Footnote001012" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Granted
    warrants include those granted on conversion of Notes Payable - <xhtml:span
  id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember_zh6vjTe0CSMe"
  title="Number of shares warrant to purchase">677,500</xhtml:span>, Notes Payable &#x2013; Related Parties &#x2013; <xhtml:span
  id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--NotesPayableRelatedPartiesMember_zk1SVGn7glwk"
  title="Number of shares warrant to purchase">20,000</xhtml:span>, Series
    A Preferred Shares - <xhtml:span
  id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzcSM9GhQf2g"
  title="Converted shares issued">336,810</xhtml:span> and issued during the IPO - <xhtml:span
  id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231_zMbYwRm9rO3k"
  title="Number of shares issued">1,607,044</xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000979"
          xlink:to="Footnote001012"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000981"
          xlink:label="Fact000981"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000981"
          xlink:to="Footnote001012"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000983"
          xlink:label="Fact000983"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000983"
          xlink:to="Footnote001012"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000985"
          xlink:label="Fact000985"
          xlink:type="locator"/>
        <link:footnote id="Footnote001021" xlink:label="Footnote001021" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes
    <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zEuPYmKnfrI6"
  title="Warrants exercised">197,273</xhtml:span> warrants exercised on a cashless basis for <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFdhcnJhbnRzIEFjdGl2aXR5IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zV3eQtrViwHj"
  title="Number of shares issued">180,280</xhtml:span> shares of common stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000985"
          xlink:to="Footnote001021"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000987"
          xlink:label="Fact000987"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000987"
          xlink:to="Footnote001021"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001092"
          xlink:label="Fact001092"
          xlink:type="locator"/>
        <link:footnote id="Footnote001105" xlink:label="Footnote001105" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 50,000 iterations</link:footnote>
        <link:footnote id="Footnote001116" xlink:label="Footnote001116" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Based on a Monte Carlo simulation analysis of 50,000 iterations</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001092"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001092"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001093"
          xlink:label="Fact001093"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001093"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001093"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001094"
          xlink:label="Fact001094"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001094"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001094"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001095"
          xlink:label="Fact001095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001095"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001095"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001096"
          xlink:label="Fact001096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001096"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001096"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001097"
          xlink:label="Fact001097"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001097"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001097"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001098"
          xlink:label="Fact001098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001098"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001098"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001099"
          xlink:label="Fact001099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001099"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001099"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001100"
          xlink:label="Fact001100"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001100"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001100"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001102"
          xlink:label="Fact001102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001102"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001102"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001104"
          xlink:label="Fact001104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001104"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001104"
          xlink:to="Footnote001105"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001106"
          xlink:label="Fact001106"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001106"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001107"
          xlink:label="Fact001107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001107"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001108"
          xlink:label="Fact001108"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001108"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001109"
          xlink:label="Fact001109"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001109"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001110"
          xlink:label="Fact001110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001110"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001111"
          xlink:label="Fact001111"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001111"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001113"
          xlink:label="Fact001113"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001113"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001115"
          xlink:label="Fact001115"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001115"
          xlink:to="Footnote001116"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
